drug_name	ind_name	ind_id	NCT	status	phase	DetailedStatus	DrugCUI	DrugString
Lepirudin	Heparin-induced thrombocytopenia with thrombosis	C0272275		Approved			C0772394	Hirudin variant-1
Cetuximab	Squamous cell carcinoma of mouth	C0585362		Approved			C0995188	Cétuximab
Cetuximab	Squamous cell carcinoma of nose	C3163899		Approved			C0995188	Cétuximab
Cetuximab	Squamous cell carcinoma of pharynx	C1319317		Approved			C0995188	Cétuximab
Cetuximab	Laryngeal Squamous Cell Carcinoma	C0280324		Approved			C0995188	Cétuximab
Cetuximab	Malignant tumor of colon	C0007102		Approved			C0995188	Cétuximab
Dornase alfa	Cystic Fibrosis	C0010674		Approved			C1135662	Dornasa alfa
Denileukin diftitox	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0717670	Interleukin-2/diptheria toxin fusion protein
Etanercept	Rheumatoid Arthritis	C0003873		Approved			C4291381	etanercept-szzs
Etanercept	Juvenile arthritis	C3495559		Approved			C4291381	etanercept-szzs
Etanercept	Arthritis, Psoriatic	C0003872		Approved			C4291381	etanercept-szzs
Etanercept	Ankylosing spondylitis	C0038013		Approved			C4291381	etanercept-szzs
Etanercept	Chronic small plaque psoriasis	C0406317		Approved			C4291381	etanercept-szzs
Leuprolide	Precocious Puberty	C0034013		Approved			C0085272	Leuprorelinum
Leuprolide	Endometriosis	C0014175		Approved			C0085272	Leuprorelinum
Peginterferon alfa-2a	Hepatitis C, Chronic	C0524910		Approved			C0391001	Pegylated interferon alpha-2a
Peginterferon alfa-2a	Hepatitis B, Chronic	C0524909		Approved			C0391001	Pegylated interferon alpha-2a
Alteplase	Ischemic stroke	C0948008		Approved			C0032143	Alteplasa
Alteplase	Acute myocardial infarction	C0155626		Approved			C0032143	Alteplasa
Alteplase	Pulmonary Embolism	C0034065		Approved			C0032143	Alteplasa
Sermorelin	Pituitary dwarfism	C0013338		Approved			C0142046	Sermorelin
Urokinase	Pulmonary Embolism	C0034065		Approved			C0042071	TCUK
Goserelin	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0120107	Goserelina
Goserelin	Endometriosis	C0014175		Approved			C0120107	Goserelina
Reteplase	Acute myocardial infarction	C0155626		Approved			C0256103	Reteplasa
Erythropoietin	Anemia in chronic kidney disease	C1561828		Approved			C0357126	Epoetina alfa
Erythropoietin	Anemia due to chemotherapy	C1998329		Approved			C0357126	Epoetina alfa
Salmon Calcitonin	Osteoporosis, Postmenopausal	C0029458		Approved			C0073994	Calcitonina salmón sintética
Salmon Calcitonin	Osteitis Deformans	C0029401		Approved			C0073994	Calcitonina salmón sintética
Pegfilgrastim	Chemotherapy-induced neutropenia	C1827687		Approved			C4735048	pegfilgrastim-cbqv
Sargramostim	Chemotherapy-induced neutropenia	C1827687		Approved			C0216231	Recombinant human granulocyte-macrophage colony stimulating factor
Peginterferon alfa-2b	Hepatitis C, Chronic	C0524910		Approved			C0796545	Peginterferon alfa-2b
Asparaginase	Acute lymphocytic leukemia	C0023449		Approved			C0003993	Colaspase
Anakinra	Rheumatoid Arthritis	C0003873		Approved			C0245109	IL-1RA
Anakinra	Cryopyrin-Associated Periodic Syndromes	C2316212		Approved			C0245109	IL-1RA
Anakinra	Chronic Infantile Neurological, Cutaneous, and Articular Syndrome	C0409818		Approved			C0245109	IL-1RA
Gramicidin D	Bacterial conjunctivitis	C0009768		Approved			C0018165	Gramicidina
Gramicidin D	Infective blepharitis	C0729587		Approved			C0018165	Gramicidina
Gramicidin D	Blepharoconjunctivitis	C0005743		Approved			C0018165	Gramicidina
Gramicidin D	Bacterial keratitis	C0854211		Approved			C0018165	Gramicidina
Insulin Human	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			C0795635	Insulina regular
Insulin Human	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0795635	Insulina regular
Insulin Human	Diabetes Mellitus	C0011849		Approved			C0795635	Insulina regular
Tenecteplase	Acute myocardial infarction	C0155626		Approved			C0872913	Tenecteplasa
Desmopressin	Hemophilia A	C0019069		Approved			C0011701	1-desamino-8-D-arginine vasopressin
Desmopressin	von Willebrand Disease	C0042974		Approved			C0011701	1-desamino-8-D-arginine vasopressin
Desmopressin	Bedwetting	C0270327		Approved			C0011701	1-desamino-8-D-arginine vasopressin
Coagulation factor VIIa Recombinant Human	Hemophilia A	C0019069		Approved			C0534191	rFVIIa
Coagulation factor VIIa Recombinant Human	Hemophilia B	C0008533		Approved			C0534191	rFVIIa
Coagulation factor VIIa Recombinant Human	Thrombasthenia	C0040015		Approved			C0534191	rFVIIa
Coagulation factor VIIa Recombinant Human	Factor VII Deficiency	C0015503		Approved			C0534191	rFVIIa
Oprelvekin	Thrombocytopenia	C0040034		Approved			C0537670	Recombinant interleukin-11
Palifermin	Mucositis following radiation therapy	C0392190		Approved			C0677829	Palifermina
Palifermin	Drug-induced mucositis	C1274988		Approved			C0677829	Palifermina
Glucagon recombinant	Hypoglycemia	C0020615		Approved			C0017687	Glucagon
Aldesleukin	Leukemia, Myelocytic, Acute	C0023467		Approved			C0218986	Aldesleukina
Aldesleukin	Metastatic Renal Cell Cancer	C0278678		Approved			C0218986	Aldesleukina
Aldesleukin	Malignant melanoma, metastatic	C0860594		Approved			C0218986	Aldesleukina
Omalizumab	Asthma	C0004096		Approved			C0966225	Omalizumab
Omalizumab	Chronic idiopathic urticaria	C0578870		Approved			C0966225	Omalizumab
Insulin Lispro	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			C0293359	Insulina lispro
Insulin Lispro	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0293359	Insulina lispro
Insulin Glargine	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			C0907402	Insulin glargine
Insulin Glargine	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0907402	Insulin glargine
Collagenase clostridium histolyticum	Dupuytren's disease of finger, with contracture	C0410065		Approved			C0162745	Collagenase
Collagenase clostridium histolyticum	Peyronie Disease	C0030848		Approved			C0162745	Collagenase
Rasburicase	Hyperuricemia	C0740394		Approved			C0937932	Rasburicasa
Adalimumab	Rheumatoid Arthritis	C0003873		Approved			C5195654	adalimumab-bwwd
Adalimumab	Juvenile arthritis	C3495559		Approved			C5195654	adalimumab-bwwd
Adalimumab	Arthritis, Psoriatic	C0003872		Approved			C5195654	adalimumab-bwwd
Adalimumab	Ankylosing spondylitis	C0038013		Approved			C5195654	adalimumab-bwwd
Adalimumab	Crohn Disease	C0010346		Approved			C5195654	adalimumab-bwwd
Adalimumab	Ulcerative Colitis	C0009324		Approved			C5195654	adalimumab-bwwd
Adalimumab	Chronic small plaque psoriasis	C0406317		Approved			C5195654	adalimumab-bwwd
Adalimumab	Hidradenitis Suppurativa	C0162836		Approved			C5195654	adalimumab-bwwd
Somatropin recombinant	Growth retardation	C0151686		Approved			C0169964	Somatropina
Somatropin recombinant	Prader-Willi Syndrome	C0032897		Approved			C0169964	Somatropina
Somatropin recombinant	Pituitary dwarfism	C0013338		Approved			C0169964	Somatropina
Somatropin recombinant	Turner Syndrome	C0041408		Approved			C0169964	Somatropina
Imiglucerase	Gaucher Disease	C0017205		Approved			C0291140	Imiglucerasa
Gemtuzumab ozogamicin	Leukemia, Myelocytic, Acute	C0023467		Approved			C1533699	Gemtuzumab ozogamicin
Pegaspargase	Acute lymphocytic leukemia	C0023449		Approved			C0071568	Pegaspargasa
Interferon beta-1a	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C0254119	Interferon-beta-1a
Eptifibatide	Acute Coronary Syndrome	C0948089		Approved			C0253563	Eptifibatida
Infliximab	Crohn Disease	C0010346		Approved			C4490035	Infliximab-abda
Infliximab	Ulcerative Colitis	C0009324		Approved			C4490035	Infliximab-abda
Infliximab	Rheumatoid Arthritis	C0003873		Approved			C4490035	Infliximab-abda
Infliximab	Ankylosing spondylitis	C0038013		Approved			C4490035	Infliximab-abda
Infliximab	Arthritis, Psoriatic	C0003872		Approved			C4490035	Infliximab-abda
Infliximab	Chronic small plaque psoriasis	C0406317		Approved			C4490035	Infliximab-abda
Vasopressin	Bedwetting	C0270327		Approved			C1705480	Vasopressina
Vasopressin	von Willebrand Disease	C0042974		Approved			C1705480	Vasopressina
Vasopressin	Hemophilia A	C0019069		Approved			C1705480	Vasopressina
Interferon beta-1b	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C0244714	Recombinant interferon beta-1b
Trastuzumab	HER2-positive carcinoma of breast	C1960398		Approved			C5187552	trastuzumab-anns
Trastuzumab	Secondary malignant neoplasm of female breast	C0346993		Approved			C5187552	trastuzumab-anns
Trastuzumab	Secondary malignant neoplasm of stomach	C0686068		Approved			C5187552	trastuzumab-anns
Rituximab	Lymphoma, Non-Hodgkin	C0024305		Approved			C5195655	rituximab-pvvr
Rituximab	Chronic Lymphocytic Leukemia	C0023434		Approved			C5195655	rituximab-pvvr
Rituximab	Rheumatoid Arthritis	C0003873		Approved			C5195655	rituximab-pvvr
Basiliximab	Renal transplant rejection	C0238217		Approved			C0676831	Basiliximab
Ibritumomab tiuxetan	Lymphoma, Follicular	C0024301		Approved			C4256155	mAb Murine (IGG1) Anti P19437 (CD20_MOUSE)
Daptomycin	Right-sided Staphylococcus aureus endocarditis	C1960924		Approved			C0057144	daptomicina
Daptomycin	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0057144	daptomicina
Pegvisomant	Acromegaly	C0001206		Approved			C0913469	Pegvisomant
Pancrelipase	Exocrine pancreatic insufficiency	C0267963		Approved			C0770343	Pancreatic extract pancrelipase
Alemtuzumab	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C0383429	Alemtuzumab
Alglucerase	Gaucher Disease, Type 1	C1961835		Approved			C0102139	Alglucerase
Laronidase	Mucopolysaccharidosis I	C0023786		Approved			C1302054	Laronidase (genetical recombination)
Cyclosporine	Rheumatoid Arthritis	C0003873		Approved			C0010592	Cyclosporine
Cyclosporine	Dry Eye Syndromes	C0013238		Approved			C0010592	Cyclosporine
Cyclosporine	Keratoconjunctivitis Sicca	C0022575		Approved			C0010592	Cyclosporine
Alefacept	Chronic small plaque psoriasis	C0406317		Approved			C0962603	Alefacept
Efalizumab	Chronic small plaque psoriasis	C0406317		Approved			C1174995	anti-CD11a
Filgrastim	Chemotherapy-induced neutropenia	C1827687		Approved			C4721554	Filgrastim-aafi
Filgrastim	Congenital neutropenia	C0340970		Approved			C4721554	Filgrastim-aafi
Filgrastim	Cyclic neutropenia	C0221023		Approved			C4721554	Filgrastim-aafi
Filgrastim	Chronic idiopathic neutropenia	C2267231		Approved			C4721554	Filgrastim-aafi
Coagulation Factor IX	Hemophilia B	C0008533		Approved			C4512069	nonacog gamma
Becaplermin	Neuropathic diabetic ulcer - foot	C0406526		Approved			C0379135	rhPDGF-BB
Agalsidase beta	Fabry Disease	C0002986		Approved			C0002268	Alpha-galactosidase A
Octreotide	Acromegaly	C0001206		Approved			C0028833	Octreotida
Octreotide	Malignant Carcinoid Syndrome	C0024586		Approved			C0028833	Octreotida
Abarelix	Ischemic priapism	C2711256		Approved			C0965390	Abarelix
Oxytocin	Unspecified Abortion	C0156543		Approved			C0030095	Oxitocina
Oxytocin	Postpartum Hemorrhage	C0032797		Approved			C0030095	Oxitocina
Oxytocin	Incomplete spontaneous abortion	C0000810		Approved			C0030095	Oxitocina
Natalizumab	Multiple Sclerosis	C0026769		Approved			C1172734	Anti-VLA4
Natalizumab	Crohn Disease	C0010346		Approved			C1172734	Anti-VLA4
Enfuvirtide	HIV Infections	C0019693		Approved			C0537439	Enfuvirtida
Palivizumab	Respiratory Syncytial Virus Infections	C0035235		Approved			C0672596	Palivizumab
Daclizumab	Renal transplant rejection	C0238217		Approved			C0663182	Daclizumab beta
Daclizumab	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C0663182	Daclizumab beta
Bevacizumab	Secondary malignant neoplasm of colon	C0346974		Approved			C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Nonsquamous nonsmall cell neoplasm of lung	C2585890		Approved			C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Glioblastoma Multiforme	C1621958		Approved			C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Metastatic Renal Cell Cancer	C0278678		Approved			C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Cervix carcinoma	C0302592		Approved			C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Malignant tumor of peritoneum	C0153467		Approved			C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Malignant epithelial tumor of ovary	C0346161		Approved			C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Malignant neoplasm of fallopian tube	C0153579		Approved			C0796392	Anti-VEGF monoclonal antibody
Cyanocobalamin	Megaloblastic anemia due to folate deficiency	C0151482		Approved			C0042845	Cianocobalamina
Cyanocobalamin	Anemia, Pernicious	C0002892		Approved			C0042845	Cianocobalamina
Cyanocobalamin	Iron deficiency anemia	C0162316		Approved			C0042845	Cianocobalamina
Cyanocobalamin	Vitamin Deficiency	C1510471		Approved			C0042845	Cianocobalamina
Cyanocobalamin	Vitamin B 12 Deficiency	C0042847		Approved			C0042845	Cianocobalamina
Biotin	Biotin deficiency disease	C2937225		Approved			C0982111	D-(+)-biotin
Choline	Sleeplessness	C0917801		Approved			C0008405	Vitamin J
Vitamin C	Breastfeeding (mother)	C1623040		Approved			C0003968	Acidum ascorbicum
Vitamin C	Vitamin Deficiency	C1510471		Approved			C0003968	Acidum ascorbicum
L-Aspartic Acid	Hypokalemia	C0020621		Approved			C0004015	Acidum asparticum
L-Glutamine	Short Bowel Syndrome	C0036992		Approved			C0017797	Glutamina
Adenosine monophosphate	Pulmonary Cystic Fibrosis	C0392164		Approved			C0001465	Ado5'P
L-Serine	Glaucoma, Open-Angle	C0017612		Approved			C0036720	Serine
L-Serine	Bacterial urinary infection	C0729524		Approved			C0036720	Serine
L-Serine	Tuberculosis, Pulmonary	C0041327		Approved			C0036720	Serine
L-Serine	Acute tuberculosis	C0275959		Approved			C0036720	Serine
L-Serine	Escherichia coli urinary tract infection	C0577708		Approved			C0036720	Serine
Calcitriol	Chronic small plaque psoriasis	C0406317		Approved			C0006674	Calcitriolum
Calcitriol	Hypocalcemia	C0020598		Approved			C0006674	Calcitriolum
Calcitriol	Hypophosphatemia	C0085682		Approved			C0006674	Calcitriolum
Calcitriol	Renal Osteodystrophy	C0035086		Approved			C0006674	Calcitriolum
Calcitriol	Hypoparathyroidism	C0020626		Approved			C0006674	Calcitriolum
Xanthophyll	Age related macular degeneration	C0242383		Approved			C0043328	Lutein
Xanthophyll	Dry Eye Syndromes	C0013238		Approved			C0043328	Lutein
Xanthophyll	Meibomian gland dysfunction	C1275684		Approved			C0043328	Lutein
Succinic acid	Iron deficiency anemia	C0162316		Approved			C0075429	Acidum succinicum
Riboflavin	Mineral deficiency	C0687148		Approved			C4550958	Vitamin Bi
Riboflavin	Vitamin Deficiency	C1510471		Approved			C4550958	Vitamin Bi
Glycine	Rhinorrhea	C1260880		Approved			C0017890	Glicina
Glycine	Coughing	C0010200		Approved			C0017890	Glicina
Glycine	Nasal congestion (finding)	C0027424		Approved			C0017890	Glicina
Glycine	Allergic rhinitis (disorder)	C2607914		Approved			C0017890	Glicina
Glycine	Rhinitis	C0035455		Approved			C0017890	Glicina
Glycine	Common Cold	C0009443		Approved			C0017890	Glicina
Calcidiol	Hypocalcemia	C0020598		Approved			C0006657	Calcifediol
Calcidiol	Renal Osteodystrophy	C0035086		Approved			C0006657	Calcifediol
Calcidiol	Rickets	C0035579		Approved			C0006657	Calcifediol
Calcidiol	Hypophosphatemia	C0085682		Approved			C0006657	Calcifediol
L-Cysteine	Bronchitis	C0006277		Approved			C0010654	L-Cystein
L-Cysteine	Poisoning by acetaminophen	C0237963		Approved			C0010654	L-Cystein
L-Cysteine	Amyloidosis	C0002726		Approved			C0010654	L-Cystein
L-Cysteine	Pulmonary Cystic Fibrosis	C0392164		Approved			C0010654	L-Cystein
L-Cysteine	Bronchiectasis	C0006267		Approved			C0010654	L-Cystein
Thiamine	Vitamin B 12 Deficiency	C0042847		Approved			C0039840	thiamine
Thiamine	Wernicke-Korsakoff Syndrome	C0349464		Approved			C0039840	thiamine
Thiamine	Vitamin Deficiency	C1510471		Approved			C0039840	thiamine
Thiamine	Anemia, Pernicious	C0002892		Approved			C0039840	thiamine
Thiamine	Thiamine Deficiency	C0039841		Approved			C0039840	thiamine
Thiamine	Mineral deficiency	C0687148		Approved			C0039840	thiamine
Ergocalciferol	Vitamin D Deficiency	C0042870		Approved			C0014695	Vitamina D2
Ergocalciferol	Osteomalacia	C0029442		Approved			C0014695	Vitamina D2
Ergocalciferol	Rickets	C0035579		Approved			C0014695	Vitamina D2
Ergocalciferol	Vitamin D-dependent rickets	C0221468		Approved			C0014695	Vitamina D2
Ergocalciferol	Vitamin Deficiency	C1510471		Approved			C0014695	Vitamina D2
Ergocalciferol	Osteoporosis	C0029456		Approved			C0014695	Vitamina D2
Ergocalciferol	Hypocalcemia	C0020598		Approved			C0014695	Vitamina D2
Ergocalciferol	Osteoporosis, Postmenopausal	C0029458		Approved			C0014695	Vitamina D2
Ergocalciferol	Vitamin D-Resistant Rickets, X-Linked	C3536984		Approved			C0014695	Vitamina D2
Ergocalciferol	Hypoparathyroidism	C0020626		Approved			C0014695	Vitamina D2
Folic Acid	Megaloblastic anemia due to folate deficiency	C0151482		Approved			C0016410	Folic acid
Folic Acid	Mineral deficiency	C0687148		Approved			C0016410	Folic acid
Folic Acid	Breastfeeding (mother)	C1623040		Approved			C0016410	Folic acid
Folic Acid	Iron deficiency anemia	C0162316		Approved			C0016410	Folic acid
Folic Acid	Folic Acid Deficiency	C0016412		Approved			C0016410	Folic acid
Folic Acid	Vitamin Deficiency	C1510471		Approved			C0016410	Folic acid
Icosapent	Breastfeeding (mother)	C1623040		Approved			C0000545	(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid
Icosapent	Hypertriglyceridemia	C0020557		Approved			C0000545	(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid
Vitamin A	Mineral deficiency	C0687148		Approved			C0087161	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
Vitamin A	Vitamin Deficiency	C1510471		Approved			C0087161	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
Vitamin A	Vitamin A Deficiency	C0042842		Approved			C0087161	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
Vitamin E	Vitamin E Deficiency	C0042875		Approved			C0969677	alpha-tocopherol
Pyridoxine	Breastfeeding (mother)	C1623040		Approved			C0034272	5-hydroxy-6-methyl-3,4-pyridinedimethanol
Pyridoxine	EPILEPSY, PYRIDOXINE-DEPENDENT	C1849508		Approved			C0034272	5-hydroxy-6-methyl-3,4-pyridinedimethanol
Pyridoxine	Vitamin B 6 Deficiency	C0936215		Approved			C0034272	5-hydroxy-6-methyl-3,4-pyridinedimethanol
Lipoic Acid	Diabetic peripheral neuropathy	C0740447		Approved			C0023791	Alpha lipoic acid
Cholecalciferol	Osteoporosis, Postmenopausal	C0029458		Approved			C0008318	Colecalciferolum
Cholecalciferol	Hypoparathyroidism	C0020626		Approved			C0008318	Colecalciferolum
Cholecalciferol	Rickets	C0035579		Approved			C0008318	Colecalciferolum
Cholecalciferol	Hypocalcemia	C0020598		Approved			C0008318	Colecalciferolum
Cholecalciferol	Vitamin Deficiency	C1510471		Approved			C0008318	Colecalciferolum
Cholecalciferol	Osteomalacia	C0029442		Approved			C0008318	Colecalciferolum
Cholecalciferol	Vitamin D-dependent rickets	C0221468		Approved			C0008318	Colecalciferolum
Cholecalciferol	Osteoporosis	C0029456		Approved			C0008318	Colecalciferolum
Pravastatin	Cerebrovascular accident	C0038454		Approved			C0085542	Pravastatine
Pravastatin	Hyperlipoproteinemia Type III	C0020479		Approved			C0085542	Pravastatine
Pravastatin	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0085542	Pravastatine
Pravastatin	Hypercholesterolemia	C0020443		Approved			C0085542	Pravastatine
Pravastatin	Hypertriglyceridemia	C0020557		Approved			C0085542	Pravastatine
Pravastatin	Hyperlipidemia, Familial Combined	C0020474		Approved			C0085542	Pravastatine
Pravastatin	Arteriosclerosis	C0003850		Approved			C0085542	Pravastatine
Fluvoxamine	Obsessive-Compulsive Disorder	C0028768		Approved			C0085228	Fluvoxaminum
Fluvoxamine	Phobia, Social	C0031572		Approved			C0085228	Fluvoxaminum
Valsartan	Chronic heart failure	C0264716		Approved			C0216784	N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Valsartan	Hypertensive disease	C0020538		Approved			C0216784	N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Ramipril	Cerebrovascular accident	C0038454		Approved			C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Ramipril	Chronic heart failure	C0264716		Approved			C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Ramipril	Hypertensive disease	C0020538		Approved			C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Masoprocol	Actinic keratosis	C0022602		Approved			C0733397	masoprocol
Flunisolide	Allergic rhinitis (disorder)	C2607914		Approved			C0060501	Flunisolidum
Flunisolide	Asthma	C0004096		Approved			C0060501	Flunisolidum
Baclofen	Muscle spasticity of spinal origin	C1562430		Approved			C0004609	beta-(p-Chlorophenyl)-gamma-aminobutyric acid
Amphetamine	Obesity	C0028754		Approved			C0002658	Amfetaminum
Amphetamine	Attention deficit hyperactivity disorder	C1263846		Approved			C0002658	Amfetaminum
Amphetamine	Narcolepsy	C0027404		Approved			C0002658	Amfetaminum
Nicotine	Pellagra	C0030783		Approved			C0028040	Nikotin
Nicotine	Nicotine Dependence	C0028043		Approved			C0028040	Nikotin
Lorazepam	Lennox-Gastaut syndrome	C0238111		Approved			C0024002	Loracepam
Lorazepam	Absence Epilepsy	C0014553		Approved			C0024002	Loracepam
Lorazepam	Epilepsies, Myoclonic	C0014550		Approved			C0024002	Loracepam
Lorazepam	Epileptic drop attack	C0270846		Approved			C0024002	Loracepam
Lorazepam	Anxiety	C0003467		Approved			C0024002	Loracepam
Lorazepam	Status Epilepticus	C0038220		Approved			C0024002	Loracepam
Lorazepam	Panic Disorder	C0030319		Approved			C0024002	Loracepam
Esmolol	Atrial Fibrillation	C0004238		Approved			C0116569	(±)-esmolol
Esmolol	Supraventricular tachycardia	C0039240		Approved			C0116569	(±)-esmolol
Esmolol	Perioperative hypertension	C3661921		Approved			C0116569	(±)-esmolol
Bortezomib	Multiple Myeloma	C0026764		Approved			C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634		Approved			C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Ethchlorvynol	Sleeplessness	C0917801		Approved			C0014987	etclorvinol
Carbidopa	Parkinson Disease	C0030567		Approved			C1881339	Carbidopa (anhydrous)
Carbidopa	Parkinsonian Disorders	C0242422		Approved			C1881339	Carbidopa (anhydrous)
Carbidopa	Parkinson Disease, Postencephalitic	C0030568		Approved			C1881339	Carbidopa (anhydrous)
Phentermine	Hypotension	C0020649		Approved			C0031447	Fentermina
Phentermine	Obesity	C0028754		Approved			C0031447	Fentermina
Tramadol	Chronic pain	C0150055		Approved			C0040610	Tramadolum
Tramadol	Degenerative polyarthritis	C0029408		Approved			C0040610	Tramadolum
Tramadol	Pain	C0030193		Approved			C0040610	Tramadolum
Vidarabine	Keratitis, Dendritic	C0022570		Approved			C0042646	Vidarabinum
Vidarabine	Keratitis, Herpetic	C0019357		Approved			C0042646	Vidarabinum
Betaxolol	Hypertensive disease	C0020538		Approved			C0005320	1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
Betaxolol	Ocular Hypertension	C0028840		Approved			C0005320	1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
Betaxolol	Glaucoma, Open-Angle	C0017612		Approved			C0005320	1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
Fluconazole	Oropharyngeal candidiasis	C0919659		Approved			C0016277	Fluconazol
Fluconazole	Septicemia candida	C0349009		Approved			C0016277	Fluconazol
Fluconazole	Candidiasis, Vulvovaginal	C0700345		Approved			C0016277	Fluconazol
Fluconazole	Oral candidiasis	C0006849		Approved			C0016277	Fluconazol
Fluconazole	Mucocutaneous candidiasis	C0006848		Approved			C0016277	Fluconazol
Fluconazole	Candidiasis of the esophagus	C0239295		Approved			C0016277	Fluconazol
Fluconazole	Meningitis, Cryptococcal	C0085436		Approved			C0016277	Fluconazol
Fluconazole	Candidemia	C0877445		Approved			C0016277	Fluconazol
Fluconazole	Systemic candidiasis	C0153252		Approved			C0016277	Fluconazol
Oseltamivir	Influenza	C0021400		Approved			C0874161	Oséltamivir
Erythromycin	Diphtheria	C0012546		Approved			C0014806	Erythromycinum
Erythromycin	Ophthalmia Neonatorum	C0029076		Approved			C0014806	Erythromycinum
Erythromycin	Infective otitis media	C0729586		Approved			C0014806	Erythromycinum
Erythromycin	Acute bacterial sinusitis	C0275556		Approved			C0014806	Erythromycinum
Erythromycin	Acute gonococcal endometritis	C0153196		Approved			C0014806	Erythromycinum
Erythromycin	Neonatal pneumonia	C0339968		Approved			C0014806	Erythromycinum
Erythromycin	Pneumonia, Bacterial	C0004626		Approved			C0014806	Erythromycinum
Erythromycin	Chlamydial urethritis	C1278807		Approved			C0014806	Erythromycinum
Erythromycin	Gonorrhea of rectum	C0275665		Approved			C0014806	Erythromycinum
Erythromycin	Pneumococcal pharyngitis	C0275761		Approved			C0014806	Erythromycinum
Erythromycin	Acute gonococcal urethritis	C0275652		Approved			C0014806	Erythromycinum
Erythromycin	Staphylococcus aureus infection	C1318973		Approved			C0014806	Erythromycinum
Erythromycin	Legionnaires' Disease	C0023241		Approved			C0014806	Erythromycinum
Erythromycin	non-gonococcal urethritis (NGU)	C1112709		Approved			C0014806	Erythromycinum
Erythromycin	Streptococcus pyogenes infection	C0554628		Approved			C0014806	Erythromycinum
Erythromycin	Listeriosis	C0023860		Approved			C0014806	Erythromycinum
Erythromycin	Inclusion conjunctivitis	C0009770		Approved			C0014806	Erythromycinum
Erythromycin	Chlamydial cervicitis	C0341834		Approved			C0014806	Erythromycinum
Erythromycin	Pertussis	C0043167		Approved			C0014806	Erythromycinum
Erythromycin	Erythrasma	C0014752		Approved			C0014806	Erythromycinum
Erythromycin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0014806	Erythromycinum
Erythromycin	Streptococcal pneumonia	C0155862		Approved			C0014806	Erythromycinum
Erythromycin	Syphilis	C0039128		Approved			C0014806	Erythromycinum
Erythromycin	Chlamydial pneumonia	C0339959		Approved			C0014806	Erythromycinum
Erythromycin	Acute gonococcal cervicitis	C0153195		Approved			C0014806	Erythromycinum
Erythromycin	Acne Vulgaris	C0001144		Approved			C0014806	Erythromycinum
Erythromycin	Acute otitis media	C0271429		Approved			C0014806	Erythromycinum
Erythromycin	Mycoplasma pneumonia	C0032302		Approved			C0014806	Erythromycinum
Erythromycin	Gonorrhea	C0018081		Approved			C0014806	Erythromycinum
Erythromycin	Intraabdominal Infections	C1112209		Approved			C0014806	Erythromycinum
Erythromycin	Meningitis	C0025289		Approved			C0014806	Erythromycinum
Erythromycin	Cholangitis	C0008311		Approved			C0014806	Erythromycinum
Erythromycin	Bacterial sepsis	C0684256		Approved			C0014806	Erythromycinum
Erythromycin	Hepatic Coma	C0019147		Approved			C0014806	Erythromycinum
Erythromycin	Infection of bone	C2242472		Approved			C0014806	Erythromycinum
Erythromycin	Urinary tract infection	C0042029		Approved			C0014806	Erythromycinum
Erythromycin	Arthropathy associated with infection	C0157749		Approved			C0014806	Erythromycinum
Hydroxocobalamin	Vitamin B 12 Deficiency	C0042847		Approved			C0020316	OH-Cbl
Hydroxocobalamin	Toxic effect of cyanide	C0238080		Approved			C0020316	OH-Cbl
Hydroxocobalamin	Anemia, Pernicious	C0002892		Approved			C0020316	OH-Cbl
Caffeine	Headache Disorders	C0393735		Approved			C0006644	Teína
Caffeine	Allergic rhinitis (disorder)	C2607914		Approved			C0006644	Teína
Caffeine	Pain	C0030193		Approved			C0006644	Teína
Caffeine	Vascular Headaches	C0042376		Approved			C0006644	Teína
Caffeine	Back Pain	C0004604		Approved			C0006644	Teína
Caffeine	Cluster Headache	C0009088		Approved			C0006644	Teína
Caffeine	Arthralgia	C0003862		Approved			C0006644	Teína
Caffeine	Influenza-like symptoms	C0392171		Approved			C0006644	Teína
Caffeine	Common Cold	C0009443		Approved			C0006644	Teína
Caffeine	Muscle Spasticity	C0026838		Approved			C0006644	Teína
Caffeine	Rhinorrhea	C1260880		Approved			C0006644	Teína
Caffeine	Nasal congestion (finding)	C0027424		Approved			C0006644	Teína
Caffeine	Sinus headache	C0037195		Approved			C0006644	Teína
Caffeine	Dysmenorrhea	C0013390		Approved			C0006644	Teína
Caffeine	Tension Headache	C0033893		Approved			C0006644	Teína
Caffeine	Migraine Disorders	C0149931		Approved			C0006644	Teína
Caffeine	Apnea in the newborn	C0232058		Approved			C0006644	Teína
Sildenafil	Pulmonary arterial hypertension	C2973725		Approved			C0529793	Sildenafilo
Sildenafil	Erectile dysfunction	C0242350		Approved			C0529793	Sildenafilo
Pyrimethamine	Malaria	C0024530		Approved			C0034283	Pyrimethaminum
Pyrimethamine	Toxoplasmosis associated with AIDS	C1720498		Approved			C0034283	Pyrimethaminum
Pyrimethamine	Toxoplasmosis	C0040558		Approved			C0034283	Pyrimethaminum
Reserpine	Psychotic Disorders	C0033975		Approved			C0035179	Reserpin
Reserpine	Hypertensive disease	C0020538		Approved			C0035179	Reserpin
Azithromycin	Pulmonary Mycobacterium avium complex infection	C2733595		Approved			C0052796	Azithromycine
Azithromycin	Streptococcal tonsillitis	C0275804		Approved			C0052796	Azithromycine
Azithromycin	Pneumonia due to Staphylococcus aureus	C2349530		Approved			C0052796	Azithromycine
Azithromycin	Acute bacterial bronchitis	C0339933		Approved			C0052796	Azithromycine
Azithromycin	Infective otitis media	C0729586		Approved			C0052796	Azithromycine
Azithromycin	Chlamydial pneumonia	C0339959		Approved			C0052796	Azithromycine
Azithromycin	Chlamydial urethritis	C1278807		Approved			C0052796	Azithromycine
Azithromycin	Streptococcus pyogenes infection	C0554628		Approved			C0052796	Azithromycine
Azithromycin	Acute gonococcal cervicitis	C0153195		Approved			C0052796	Azithromycine
Azithromycin	Legionella pneumophila pneumonia	C0857846		Approved			C0052796	Azithromycine
Azithromycin	Acute gonococcal urethritis	C0275652		Approved			C0052796	Azithromycine
Azithromycin	Chancroids	C0007947		Approved			C0052796	Azithromycine
Azithromycin	Bacterial conjunctivitis	C0009768		Approved			C0052796	Azithromycine
Azithromycin	Pneumonia, Bacterial	C0004626		Approved			C0052796	Azithromycine
Azithromycin	Chlamydial pelvic inflammatory disease	C0520777		Approved			C0052796	Azithromycine
Azithromycin	Chlamydial cervicitis	C0341834		Approved			C0052796	Azithromycine
Azithromycin	Streptococcal pneumonia	C0155862		Approved			C0052796	Azithromycine
Azithromycin	Mycoplasma pneumonia	C0032302		Approved			C0052796	Azithromycine
Azithromycin	Staphylococcus aureus infection	C1318973		Approved			C0052796	Azithromycine
Azithromycin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0052796	Azithromycine
Azithromycin	Acute bacterial sinusitis	C0275556		Approved			C0052796	Azithromycine
Azithromycin	Pelvic inflammatory disease due to Mycoplasma hominis	C1261256		Approved			C0052796	Azithromycine
Azithromycin	Haemophilus influenzae pneumonia	C0276026		Approved			C0052796	Azithromycine
Azithromycin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0052796	Azithromycine
Ticlopidine	Cerebrovascular Occlusion	C0596298		Approved			C0040207	Ticlopidina
Trospium	Urge Incontinence	C0150045		Approved			C0772089	Trospium
Trospium	Bladder muscle dysfunction - overactive	C0403643		Approved			C0772089	Trospium
Trospium	Increased frequency of micturition	C0042023		Approved			C0772089	Trospium
Trospium	Urgency of micturition	C0085606		Approved			C0772089	Trospium
Adapalene	Acne Vulgaris	C0001144		Approved			C0165631	Adapalène
Midodrine	Hypotension, Orthostatic	C0020651		Approved			C0026078	(±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
Pantoprazole	Erosive esophagitis	C0267055		Approved			C0081876	Pantoprazolum
Pantoprazole	Zollinger-Ellison syndrome	C0043515		Approved			C0081876	Pantoprazolum
Pantoprazole	Gastroesophageal reflux disease	C0017168		Approved			C0081876	Pantoprazolum
Pantoprazole	Multiple Endocrine Neoplasia	C0027662		Approved			C0081876	Pantoprazolum
Pantoprazole	Peptic Ulcer	C0030920		Approved			C0081876	Pantoprazolum
Torasemide	Hypertensive disease	C0020538		Approved			C0076840	Torasémide
Torasemide	Edema	C0013604		Approved			C0076840	Torasémide
Torasemide	Decompensated cardiac failure	C0581377		Approved			C0076840	Torasémide
Torasemide	Renal disease with edema NOS	C0866125		Approved			C0076840	Torasémide
Citalopram	Generalized Anxiety Disorder	C0270549		Approved			C0008845	Citalopramum
Citalopram	Major Depressive Disorder	C1269683		Approved			C0008845	Citalopramum
Citalopram	Depressive disorder	C0011581		Approved			C0008845	Citalopramum
Eletriptan	Migraine Disorders	C0149931		Approved			C0759933	Eletriptán
Moxifloxacin	Chlamydial pneumonia	C0339959		Approved			C0536495	Moxifloxacino
Moxifloxacin	Acute bacterial sinusitis	C0275556		Approved			C0536495	Moxifloxacino
Moxifloxacin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0536495	Moxifloxacino
Moxifloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0536495	Moxifloxacino
Moxifloxacin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0536495	Moxifloxacino
Moxifloxacin	Mycoplasma pneumonia	C0032302		Approved			C0536495	Moxifloxacino
Moxifloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0536495	Moxifloxacino
Moxifloxacin	Enterobacteriaceae Infections	C0014347		Approved			C0536495	Moxifloxacino
Moxifloxacin	Abdominal Abscess	C0243001		Approved			C0536495	Moxifloxacino
Moxifloxacin	Staphylococcus aureus infection	C1318973		Approved			C0536495	Moxifloxacino
Moxifloxacin	Streptococcus pyogenes infection	C0554628		Approved			C0536495	Moxifloxacino
Moxifloxacin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0536495	Moxifloxacino
Moxifloxacin	Staphylococcal Pneumonia	C0032308		Approved			C0536495	Moxifloxacino
Moxifloxacin	Peritonitis	C0031154		Approved			C0536495	Moxifloxacino
Moxifloxacin	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			C0536495	Moxifloxacino
Moxifloxacin	Pneumonia, Bacterial	C0004626		Approved			C0536495	Moxifloxacino
Moxifloxacin	Streptococcal pneumonia	C0155862		Approved			C0536495	Moxifloxacino
Moxifloxacin	Intraabdominal Infections	C1112209		Approved			C0536495	Moxifloxacino
Moxifloxacin	Bacterial conjunctivitis	C0009768		Approved			C0536495	Moxifloxacino
Moxifloxacin	Rhinoscleroma	C0035468		Approved			C0536495	Moxifloxacino
Moxifloxacin	Pneumonic Plague	C0524688		Approved			C0536495	Moxifloxacino
Moxifloxacin	Plague, Septicemic	C0152936		Approved			C0536495	Moxifloxacino
Nelfinavir	HIV Infections	C0019693		Approved			C0525005	Nelfinavir
Glimepiride	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0061323	Glimepirida
Diflorasone	Pruritus Ani	C0033775		Approved			C0304612	Diflorasonum
Diflorasone	Granuloma Annulare	C0085074		Approved			C0304612	Diflorasonum
Diflorasone	Chronic small plaque psoriasis	C0406317		Approved			C0304612	Diflorasonum
Diflorasone	Exanthema	C0015230		Approved			C0304612	Diflorasonum
Diflorasone	Pruritus of genital organs	C0033777		Approved			C0304612	Diflorasonum
Diflorasone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0304612	Diflorasonum
Diflorasone	Lupus Erythematosus, Discoid	C0024138		Approved			C0304612	Diflorasonum
Diflorasone	Lichen Simplex Chronicus	C0149922		Approved			C0304612	Diflorasonum
Diflorasone	Contact Dermatitis	C0011616		Approved			C0304612	Diflorasonum
Diflorasone	Scalp psoriasis	C0406326		Approved			C0304612	Diflorasonum
Diflorasone	Seborrheic dermatitis	C0036508		Approved			C0304612	Diflorasonum
Diflorasone	Dermatitis, Atopic	C0011615		Approved			C0304612	Diflorasonum
Indinavir	HIV Infections	C0019693		Approved			C0376637	(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
Guanadrel	Hypertensive disease	C0020538		Approved			C0061938	Guanadrelum
Lovastatin	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Lovastatin	Hyperlipidemia	C0020473		Approved			C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Lovastatin	Hypercholesterolemia	C0020443		Approved			C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Lovastatin	Hypoalphalipoproteinemias	C0473527		Approved			C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Lovastatin	Hyperlipidemia, Familial Combined	C0020474		Approved			C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Lovastatin	Hypertriglyceridemia	C0020557		Approved			C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Lovastatin	Arteriosclerosis	C0003850		Approved			C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Pregabalin	Diabetic peripheral neuropathy	C0740447		Approved			C0657912	(S)-3-Isobutyl GABA
Pregabalin	Fibromyalgia	C0016053		Approved			C0657912	(S)-3-Isobutyl GABA
Pregabalin	Postherpetic neuralgia	C0032768		Approved			C0657912	(S)-3-Isobutyl GABA
Pregabalin	Generalized Anxiety Disorder	C0270549		Approved			C0657912	(S)-3-Isobutyl GABA
Temazepam	Sleeplessness	C0917801		Approved			C0039468	Temazepam
Methyclothiazide	Hypertensive disease	C0020538		Approved			C0025696	Methyclothiazide
Methyclothiazide	Renal disease with edema NOS	C0866125		Approved			C0025696	Methyclothiazide
Methyclothiazide	Edema	C0013604		Approved			C0025696	Methyclothiazide
Aminosalicylic Acid	Acute tuberculosis	C0275959		Approved			C0030125	4-amino-2-hydroxybenzoic acid
Aminosalicylic Acid	Tuberculosis, Pulmonary	C0041327		Approved			C0030125	4-amino-2-hydroxybenzoic acid
Reboxetine	Major Depressive Disorder	C1269683		Approved			C0168388	Reboxetina
Milrinone	Decompensated cardiac failure	C0581377		Approved			C0128513	Milrinonum
Butabarbital	Severe anxiety (panic)	C0231403		Approved			C0006464	Secbutabarbitale
Butabarbital	Dysuria	C0013428		Approved			C0006464	Secbutabarbitale
Butabarbital	Sleeplessness	C0917801		Approved			C0006464	Secbutabarbitale
Nevirapine	HIV Infections	C0019693		Approved			C0132326	Nevirapina
Oxiconazole	Tinea corporis (disorder)	C0040252		Approved			C0069765	2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]
Oxiconazole	Tinea Versicolor	C0040262		Approved			C0069765	2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]
Oxiconazole	Tinea cruris	C1384589		Approved			C0069765	2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]
Oxiconazole	Tinea Pedis	C0040259		Approved			C0069765	2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]
Alclometasone	Contact Dermatitis	C0011616		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Exanthema	C0015230		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Chronic small plaque psoriasis	C0406317		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Pruritus Ani	C0033775		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Lichen Simplex Chronicus	C0149922		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Dermatitis, Atopic	C0011615		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Granuloma Annulare	C0085074		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Seborrheic dermatitis	C0036508		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Scalp psoriasis	C0406326		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Lupus Erythematosus, Discoid	C0024138		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Alclometasone	Pruritus of genital organs	C0033777		Approved			C0360534	(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Butalbital	Tension Headache	C0033893		Approved			C0054234	Allylbarbitone
Cladribine	Hairy Cell Leukemia	C0023443		Approved			C0092801	Cladribina
Ranolazine	Angina Pectoris	C0002962		Approved			C0073633	Ranolazina
Mesalazine	Chronic ulcerative proctitis	C2937222		Approved			C0253787	p-Aminosalicylsaeure
Mesalazine	Ulcerative Colitis	C0009324		Approved			C0253787	p-Aminosalicylsaeure
Mesalazine	Ulcerative colitis in remission	C3697010		Approved			C0253787	p-Aminosalicylsaeure
Mesalazine	Chronic ulcerative rectosigmoiditis	C0267390		Approved			C0253787	p-Aminosalicylsaeure
Benzatropine	Extrapyramidal Disorders	C0015371		Approved			C0005098	Tropine benzohydryl ether
Benzatropine	Parkinson Disease, Postencephalitic	C0030568		Approved			C0005098	Tropine benzohydryl ether
Benzatropine	Parkinson Disease	C0030567		Approved			C0005098	Tropine benzohydryl ether
Benzatropine	Parkinsonian Disorders	C0242422		Approved			C0005098	Tropine benzohydryl ether
Ziprasidone	Bipolar disorder in remission	C0270425		Approved			C0380393	Ziprasidonum
Ziprasidone	Schizophrenia	C0036341		Approved			C0380393	Ziprasidonum
Ziprasidone	Mixed bipolar I disorder	C0236780		Approved			C0380393	Ziprasidonum
Ziprasidone	Bipolar affective disorder, current episode manic	C0338873		Approved			C0380393	Ziprasidonum
Cabergoline	Hyperprolactinemia	C0020514		Approved			C0107994	1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea
Idoxuridine	Keratitis, Herpetic	C0019357		Approved			C0020811	Idoxuridinum
Dapsone	Acne Vulgaris	C0001144		Approved			C0010980	4-aminophenyl sulfone
Dapsone	Leprosy	C0023343		Approved			C0010980	4-aminophenyl sulfone
Dapsone	Dermatitis Herpetiformis	C0011608		Approved			C0010980	4-aminophenyl sulfone
Terconazole	Candidiasis, Vulvovaginal	C0700345		Approved			C0076115	Terconazole
Phenytoin	Status Epilepticus	C0038220		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Epilepsy	C0014544		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Motor cortex epilepsy	C0234978		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Epilepsies, Partial	C0014547		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Tonic - clonic seizures	C0494475		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Lennox-Gastaut syndrome	C0238111		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Tonic-Clonic Epilepsy	C0014549		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Bipolar disorder in remission	C0270425		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Phenytoin	Simple Partial Seizures	C0234974		Approved			C0031507	5,5-diphenyltetrahydro-1H-2,4-imidazoledione
Medrysone	Rosacea	C0035854		Approved			C0065865	Medrysonum
Medrysone	Iritis	C0022081		Approved			C0065865	Medrysonum
Medrysone	Punctate keratopathy	C0423234		Approved			C0065865	Medrysonum
Medrysone	Iridocyclitis	C0022073		Approved			C0065865	Medrysonum
Medrysone	Corneal abrasion	C0010032		Approved			C0065865	Medrysonum
Medrysone	Uveitis	C0042164		Approved			C0065865	Medrysonum
Medrysone	Herpes zoster keratitis	C1275687		Approved			C0065865	Medrysonum
Medrysone	Corneal Ulcer	C0010043		Approved			C0065865	Medrysonum
Medrysone	Cyclitis	C0010543		Approved			C0065865	Medrysonum
Medrysone	Allergic Conjunctivitis	C0009766		Approved			C0065865	Medrysonum
Doxycycline	Acne Vulgaris	C0001144		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Brucellosis	C0006309		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Scrub Typhus	C0036472		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Lymphogranuloma Venereum	C0024286		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Rocky Mountain Spotted Fever	C0035793		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Acute gonococcal cervicitis	C0153195		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Chlamydia trachomatis infection of genital structure	C1997322		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Cutaneous anthrax	C0003177		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Q Fever	C0034362		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Acute gonococcal urethritis	C0275652		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Actinomycosis	C0001261		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Endemic Flea-Borne Typhus	C0041472		Approved			C2699808	Doxycycline anhydrous
Doxycycline	TYPHUS	C0041471		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Anthrax disease	C0003175		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Cholera	C0008354		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Tularemia	C0041351		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Chancroids	C0007947		Approved			C2699808	Doxycycline anhydrous
Doxycycline	GONOCOCCAL INFECTION DISSEMINATED	C0744451		Approved			C2699808	Doxycycline anhydrous
Doxycycline	non-gonococcal urethritis (NGU)	C1112709		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Pharyngitis	C0031350		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Sinusitis	C0037199		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Trachoma	C0040592		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Boutonneuse Fever	C0006060		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Gonorrhea of rectum	C0275665		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Yaws	C0043388		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Q fever endocarditis	C0340354		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Gonorrhea	C0018081		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Brill-Zinsser Disease	C0006181		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Listeriosis	C0023860		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Rickettsia Infections	C0035585		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Gonorrhea of pharynx	C0149966		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Typhus, Epidemic Louse-Borne	C0041473		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Rickettsialpox	C0035597		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Acute gonococcal endometritis	C0153196		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Acute gonococcal epididymo-orchitis	C0153193		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Inhalational anthrax	C0155866		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Gastrointestinal anthrax	C0152945		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Syphilis	C0039128		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Granuloma Inguinale	C0018190		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Mycoplasma pneumonia	C0032302		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Bronchitis	C0006277		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Bartonella Infections	C0004771		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Psittacosis	C0029291		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Relapsing Fever	C0035021		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Pneumonia, Bacterial	C0004626		Approved			C2699808	Doxycycline anhydrous
Doxycycline	Chlamydia Infections	C0008149		Approved			C2699808	Doxycycline anhydrous
Clotrimazole	Candidiasis, Vulvovaginal	C0700345		Approved			C0009074	Clotrimazol
Clotrimazole	Diaper Rash	C0011974		Approved			C0009074	Clotrimazol
Clotrimazole	Oropharyngeal candidiasis	C0919659		Approved			C0009074	Clotrimazol
Clotrimazole	Tinea corporis (disorder)	C0040252		Approved			C0009074	Clotrimazol
Clotrimazole	Cutaneous Candidiasis	C0006846		Approved			C0009074	Clotrimazol
Clotrimazole	Oral candidiasis	C0006849		Approved			C0009074	Clotrimazol
Clotrimazole	Tinea cruris	C1384589		Approved			C0009074	Clotrimazol
Clotrimazole	Tinea Pedis	C0040259		Approved			C0009074	Clotrimazol
Clotrimazole	Tinea Versicolor	C0040262		Approved			C0009074	Clotrimazol
Calcium Acetate	Disorder of electrolytes	C1704431		Approved			C0717537	Calcium acetate
Calcium Acetate	Hypermagnesemia	C0151714		Approved			C0717537	Calcium acetate
Calcium Acetate	Cardiac Arrest	C0018790		Approved			C0717537	Calcium acetate
Calcium Acetate	Hypocalcemia	C0020598		Approved			C0717537	Calcium acetate
Calcium Acetate	Hyperkalemia	C0020461		Approved			C0717537	Calcium acetate
Calcium Acetate	Hypocalcemic tetany	C0151940		Approved			C0717537	Calcium acetate
Sulfanilamide	Vulvovaginitis	C0042998		Approved			C0038702	para-aminobenzenesulfonamide
Sulfanilamide	Candidiasis, Vulvovaginal	C0700345		Approved			C0038702	para-aminobenzenesulfonamide
Cycloserine	Escherichia coli urinary tract infection	C0577708		Approved			C0010590	(+)-4-amino-3-isoxazolidinone
Cycloserine	Tuberculosis, Pulmonary	C0041327		Approved			C0010590	(+)-4-amino-3-isoxazolidinone
Cycloserine	Acute tuberculosis	C0275959		Approved			C0010590	(+)-4-amino-3-isoxazolidinone
Cycloserine	Bacterial urinary infection	C0729524		Approved			C0010590	(+)-4-amino-3-isoxazolidinone
Anagrelide	Thrombocythemia, Essential	C0040028		Approved			C0051809	Anagrelida
Carmustine	Malignant neoplasm of brain	C0153633		Approved			C1516302	Carmustinum
Carmustine	Multiple Myeloma	C0026764		Approved			C1516302	Carmustinum
Carmustine	Hodgkin Disease	C0019829		Approved			C1516302	Carmustinum
Carmustine	Diffuse Large B-Cell Lymphoma	C0079744		Approved			C1516302	Carmustinum
Carmustine	Lymphoma, Non-Hodgkin	C0024305		Approved			C1516302	Carmustinum
Carmustine	Malignant Glioma	C0555198		Approved			C1516302	Carmustinum
Carmustine	Glioblastoma multiforme of brain	C0349543		Approved			C1516302	Carmustinum
Sulfisoxazole	Chlamydial cervicitis	C0341834		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Infective otitis media	C0729586		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Chancroids	C0007947		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Meningococcal meningitis	C0025294		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Acute otitis media	C0271429		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Nocardia Infections	C0028242		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Malaria, Falciparum	C0024535		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Trachoma	C0040592		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Inclusion conjunctivitis	C0009770		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Chlamydial urethritis	C1278807		Approved			C0038745	Sulfafurazolum
Sulfisoxazole	Urinary tract infection	C0042029		Approved			C0038745	Sulfafurazolum
Metoprolol	Hypertensive disease	C0020538		Approved			C0025859	DL-metoprolol
Metoprolol	Myocardial Infarction	C0027051		Approved			C0025859	DL-metoprolol
Metoprolol	Acute Coronary Syndrome	C0948089		Approved			C0025859	DL-metoprolol
Metoprolol	Angina Pectoris	C0002962		Approved			C0025859	DL-metoprolol
Metoprolol	Chronic heart failure	C0264716		Approved			C0025859	DL-metoprolol
Crotamiton	Scabies <infestation>	C0036262		Approved			C0056519	Crotamiton
Crotamiton	Pruritus	C0033774		Approved			C0056519	Crotamiton
Dicoumarol	Myocardial Infarction	C0027051		Approved			C0005640	bis(4-hydroxycoumarin-3-yl)methane
Dicoumarol	Thromboembolism	C0040038		Approved			C0005640	bis(4-hydroxycoumarin-3-yl)methane
Dicoumarol	Thrombosis	C0040053		Approved			C0005640	bis(4-hydroxycoumarin-3-yl)methane
Dicoumarol	Cerebral Embolism	C0007780		Approved			C0005640	bis(4-hydroxycoumarin-3-yl)methane
Ropinirole	Parkinson Disease	C0030567		Approved			C0244821	Ropinirolum
Ropinirole	Restless Legs Syndrome	C0035258		Approved			C0244821	Ropinirolum
Isradipine	Hypertensive disease	C0020538		Approved			C0071304	Isradipinum
Topiramate	Tonic-Clonic Epilepsy	C0014549		Approved			C0076829	Topiramato
Topiramate	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0076829	Topiramato
Topiramate	Lennox-Gastaut syndrome	C0238111		Approved			C0076829	Topiramato
Topiramate	Simple Partial Seizures	C0234974		Approved			C0076829	Topiramato
Cefmetazole	Pneumonia	C0032285		Approved			C0007550	Cefmetazolo
Cefmetazole	Staphylococcal Pneumonia	C0032308		Approved			C0007550	Cefmetazolo
Cefmetazole	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007550	Cefmetazolo
Cefmetazole	Pneumonia due to Escherichia coli	C0276089		Approved			C0007550	Cefmetazolo
Cefmetazole	Urinary tract infection	C0042029		Approved			C0007550	Cefmetazolo
Cefmetazole	Intraabdominal Infections	C1112209		Approved			C0007550	Cefmetazolo
Cefmetazole	Haemophilus influenzae pneumonia	C0276026		Approved			C0007550	Cefmetazolo
Cefmetazole	Lower respiratory tract infection	C0149725		Approved			C0007550	Cefmetazolo
Olmesartan	Hypertensive disease	C0020538		Approved			C1098320	4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
Theophylline	Lung diseases	C0024115		Approved			C0039771	Teofilina
Theophylline	Status Asthmaticus	C0038218		Approved			C0039771	Teofilina
Theophylline	Asthma night-time symptoms	C1273489		Approved			C0039771	Teofilina
Theophylline	Asthma	C0004096		Approved			C0039771	Teofilina
Theophylline	Bronchitis	C0006277		Approved			C0039771	Teofilina
Theophylline	Pulmonary Emphysema	C0034067		Approved			C0039771	Teofilina
Theophylline	Asthma-chronic obstructive pulmonary disease overlap syndrome	C4038730		Approved			C0039771	Teofilina
Theophylline	Bronchial Spasm	C0006266		Approved			C0039771	Teofilina
Theophylline	Asthma attack	C0347950		Approved			C0039771	Teofilina
Argatroban	Heparin-induced thrombocytopenia with thrombosis	C0272275		Approved			C2698183	Argatroban anhydrous
Liothyronine	Malignant neoplasm of thyroid	C0007115		Approved			C0041014	4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Liothyronine	Endemic goiter	C0018022		Approved			C0041014	4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Liothyronine	Myxedema	C0027145		Approved			C0041014	4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Liothyronine	Congenital Hypothyroidism	C0010308		Approved			C0041014	4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Liothyronine	Goiter	C0018021		Approved			C0041014	4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Liothyronine	Hypothyroidism	C0020676		Approved			C0041014	4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Liothyronine	Myxedema coma	C0238298		Approved			C0041014	4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
Disopyramide	Ventricular arrhythmia	C0085612		Approved			C0012702	Disopyramidum
Lidocaine	Ventricular arrhythmia	C0085612		Approved			C0023660	Lidocaína
Lidocaine	Scabies <infestation>	C0036262		Approved			C0023660	Lidocaína
Lidocaine	Infestation by Phthirus pubis	C0030759		Approved			C0023660	Lidocaína
Lidocaine	Pruritus Ani	C0033775		Approved			C0023660	Lidocaína
Lidocaine	Pruritus	C0033774		Approved			C0023660	Lidocaína
Lidocaine	Postherpetic neuralgia	C0032768		Approved			C0023660	Lidocaína
Lidocaine	Skin irritation	C0152030		Approved			C0023660	Lidocaína
Lidocaine	Hemorrhoids	C0019112		Approved			C0023660	Lidocaína
Lidocaine	Urethritis	C0041976		Approved			C0023660	Lidocaína
Lidocaine	Pediculus capitis infestation	C0030757		Approved			C0023660	Lidocaína
Lidocaine	Neuralgia	C0027796		Approved			C0023660	Lidocaína
Lidocaine	Mouth irritation	C0235339		Approved			C0023660	Lidocaína
Lidocaine	Premature Ejaculation	C0033038		Approved			C0023660	Lidocaína
Pamidronate	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C3714572	Pamidronic acid
Pamidronate	Osteolytic Lesions of Multiple Myeloma	C3898069		Approved			C3714572	Pamidronic acid
Pamidronate	Osteitis Deformans	C0029401		Approved			C3714572	Pamidronic acid
Clemastine	Nasal congestion (finding)	C0027424		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Symptomatic dermographism	C0343065		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Sneezing	C0037383		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Urticaria	C0042109		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Allergic rhinitis (disorder)	C2607914		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Pruritus	C0033774		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Allergic Conjunctivitis	C0009766		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Rhinorrhea	C1260880		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastine	Rhinitis, Vasomotor	C0035460		Approved			C0008929	(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Acarbose	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0050393	Acarbosum
Venlafaxine	Phobia, Social	C0031572		Approved			C0078569	Venlafaxinum
Venlafaxine	Major Depressive Disorder	C1269683		Approved			C0078569	Venlafaxinum
Venlafaxine	Generalized Anxiety Disorder	C0270549		Approved			C0078569	Venlafaxinum
Venlafaxine	Panic Disorder	C0030319		Approved			C0078569	Venlafaxinum
Conjugated Estrogens	Hot flushes	C0600142		Approved			C0014938	Conjugated estrogens
Conjugated Estrogens	Dyspareunia	C1384606		Approved			C0014938	Conjugated estrogens
Travoprost	Ocular Hypertension	C0028840		Approved			C0937916	Travoprostum
Travoprost	Glaucoma, Open-Angle	C0017612		Approved			C0937916	Travoprostum
Amcinonide	Granuloma Annulare	C0085074		Approved			C0051556	Amcinonidum
Amcinonide	Contact Dermatitis	C0011616		Approved			C0051556	Amcinonidum
Amcinonide	Pruritus Ani	C0033775		Approved			C0051556	Amcinonidum
Amcinonide	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0051556	Amcinonidum
Amcinonide	Scalp psoriasis	C0406326		Approved			C0051556	Amcinonidum
Amcinonide	Lichen Simplex Chronicus	C0149922		Approved			C0051556	Amcinonidum
Amcinonide	Chronic small plaque psoriasis	C0406317		Approved			C0051556	Amcinonidum
Amcinonide	Pruritus of genital organs	C0033777		Approved			C0051556	Amcinonidum
Amcinonide	Dermatitis, Atopic	C0011615		Approved			C0051556	Amcinonidum
Amcinonide	Exanthema	C0015230		Approved			C0051556	Amcinonidum
Amcinonide	Lupus Erythematosus, Discoid	C0024138		Approved			C0051556	Amcinonidum
Amcinonide	Seborrheic dermatitis	C0036508		Approved			C0051556	Amcinonidum
Atomoxetine	Attention deficit hyperactivity disorder	C1263846		Approved			C0076823	Atomoxetina
Bleomycin	Squamous cell carcinoma	C0007137		Approved			C0005740	Bleomycinum
Bleomycin	Lymphoma, Non-Hodgkin	C0024305		Approved			C0005740	Bleomycinum
Bleomycin	Malignant tumor of cervix	C0007847		Approved			C0005740	Bleomycinum
Bleomycin	Diffuse Large B-Cell Lymphoma	C0079744		Approved			C0005740	Bleomycinum
Bleomycin	Lymphoma, Follicular	C0024301		Approved			C0005740	Bleomycinum
Bleomycin	Pleural Effusion, Malignant	C0080032		Approved			C0005740	Bleomycinum
Bleomycin	Cancer of Head and Neck	C0278996		Approved			C0005740	Bleomycinum
Bleomycin	Testicular Germ Cell Tumor	C1336708		Approved			C0005740	Bleomycinum
Bleomycin	Malignant neoplasm of penis	C0153601		Approved			C0005740	Bleomycinum
Bleomycin	FIGO stage finding for vulvar carcinoma	C1272826		Approved			C0005740	Bleomycinum
Bleomycin	Hodgkin Disease	C0019829		Approved			C0005740	Bleomycinum
Chlorambucil	Lymphoma, Follicular	C0024301		Approved			C0008163	Phenylbutyric acid nitrogen mustard
Chlorambucil	Hodgkin Disease	C0019829		Approved			C0008163	Phenylbutyric acid nitrogen mustard
Chlorambucil	Chronic Lymphocytic Leukemia	C0023434		Approved			C0008163	Phenylbutyric acid nitrogen mustard
Morphine	Chronic pain	C0150055		Approved			C0026549	Morfina
Morphine	Acute postoperative pain	C2215257		Approved			C0026549	Morfina
Morphine	Pain	C0030193		Approved			C0026549	Morfina
Morphine	Severe pain	C0278140		Approved			C0026549	Morfina
Morphine	Diarrhea	C0011991		Approved			C0026549	Morfina
Bupivacaine	Skin irritation	C0152030		Approved			C0006400	Bupivacaina
Bupivacaine	Pruritus	C0033774		Approved			C0006400	Bupivacaina
Penciclovir	Herpes zoster disease	C0019360		Approved			C0164815	Penciclovirum
Penciclovir	Recurrent genital herpes simplex	C1274323		Approved			C0164815	Penciclovirum
Penciclovir	Recurrent herpes simplex labialis	C1274321		Approved			C0164815	Penciclovirum
Penciclovir	Herpes Labialis	C0019345		Approved			C0164815	Penciclovirum
Tenofovir	Hepatitis B, Chronic	C0524909		Approved			C0673857	Bis(POC)PMPA
Tenofovir	HIV Infections	C0019693		Approved			C0673857	Bis(POC)PMPA
Tranexamic Acid	Female hypogonadism syndrome	C0271578		Approved			C0040613	Tranexamic acid
Tranexamic Acid	Menorrhagia	C0025323		Approved			C0040613	Tranexamic acid
Tranexamic Acid	Endometriosis	C0014175		Approved			C0040613	Tranexamic acid
Ertapenem	Miscarriage with sepsis	C0269398		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Acute bacterial peritonitis	C0275550		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Diabetic foot infection	C0744130		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Haemophilus influenzae pneumonia	C0276026		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Peptostreptococcus infection	C1096562		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Abdominal Abscess	C0243001		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	PYELONEPHRITIS E COLI	C0748196		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Streptococcal pneumonia	C0155862		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Intraabdominal Infections	C1112209		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Female genital tract infection	C1263758		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Moraxella catarrhalis pneumonia	C0857831		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Ertapenem	Pneumonia, Bacterial	C0004626		Approved			C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Mitomycin	Adenocarcinoma of pancreas	C0281361		Approved			C0702050	Ametycine
Mitomycin	Malignant neoplasm of stomach stage IV	C0278498		Approved			C0702050	Ametycine
Talbutal	Sleeplessness	C0917801		Approved			C0301407	Talbutale
Bexarotene	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0765273	p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
Vindesine	Malignant neoplasm of lung	C0242379		Approved			C0042682	3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
Vindesine	Myeloid Leukemia, Chronic	C0023473		Approved			C0042682	3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
Vindesine	melanoma	C0025202		Approved			C0042682	3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
Vindesine	Acute lymphocytic leukemia	C0023449		Approved			C0042682	3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
Chlorthalidone	Edema	C0013604		Approved			C0008294	Chlortalidonum
Chlorthalidone	Hypertensive disease	C0020538		Approved			C0008294	Chlortalidonum
Pentobarbital	Epilepsy	C0014544		Approved			C0030883	5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione
Pentobarbital	Status Epilepticus	C0038220		Approved			C0030883	5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione
Pentobarbital	Cerebral Ischemia	C0917798		Approved			C0030883	5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione
Pentobarbital	Sleeplessness	C0917801		Approved			C0030883	5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione
Pentobarbital	Severe anxiety (panic)	C0231403		Approved			C0030883	5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione
Valproic Acid	Bipolar affective disorder, current episode manic	C0338873		Approved			C0042291	acidum valproicum
Valproic Acid	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0042291	acidum valproicum
Valproic Acid	Epilepsy	C0014544		Approved			C0042291	acidum valproicum
Valproic Acid	Absence Epilepsy	C0014553		Approved			C0042291	acidum valproicum
Capreomycin	Acute tuberculosis	C0275959		Approved			C0262964	Capreomicina
Capreomycin	Tuberculosis, Pulmonary	C0041327		Approved			C0262964	Capreomicina
Zolmitriptan	Migraine Disorders	C0149931		Approved			C0528166	Zolmitriptán
Acetaminophen	Pain	C0030193		Approved			C0000970	Acetaminofén
Acetaminophen	Tension Headache	C0033893		Approved			C0000970	Acetaminofén
Acetaminophen	Back Pain	C0004604		Approved			C0000970	Acetaminofén
Acetaminophen	Migraine Disorders	C0149931		Approved			C0000970	Acetaminofén
Acetaminophen	Headache Disorders	C0393735		Approved			C0000970	Acetaminofén
Acetaminophen	Arthritic pains	C0857177		Approved			C0000970	Acetaminofén
Acetaminophen	Arthralgia	C0003862		Approved			C0000970	Acetaminofén
Acetaminophen	Fever	C0015967		Approved			C0000970	Acetaminofén
Acetaminophen	Allergic rhinitis (disorder)	C2607914		Approved			C0000970	Acetaminofén
Acetaminophen	Sinus headache	C0037195		Approved			C0000970	Acetaminofén
Acetaminophen	Influenza-like symptoms	C0392171		Approved			C0000970	Acetaminofén
Acetaminophen	Toothache	C0040460		Approved			C0000970	Acetaminofén
Acetaminophen	Common Cold	C0009443		Approved			C0000970	Acetaminofén
Gefitinib	Non-Small Cell Lung Carcinoma	C0007131		Approved			C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Gefitinib	Epidermal growth factor receptor positive non-small cell lung cancer	C1960925		Approved			C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Codeine	Sneezing	C0037383		Approved			C0009214	O3-Methylmorphine
Codeine	Coughing	C0010200		Approved			C0009214	O3-Methylmorphine
Codeine	Common Cold	C0009443		Approved			C0009214	O3-Methylmorphine
Codeine	Fever	C0015967		Approved			C0009214	O3-Methylmorphine
Codeine	Nasal congestion (finding)	C0027424		Approved			C0009214	O3-Methylmorphine
Codeine	Sore Throat	C0242429		Approved			C0009214	O3-Methylmorphine
Codeine	Rhinitis	C0035455		Approved			C0009214	O3-Methylmorphine
Codeine	Headache Disorders	C0393735		Approved			C0009214	O3-Methylmorphine
Codeine	Rhinorrhea	C1260880		Approved			C0009214	O3-Methylmorphine
Codeine	Pain	C0030193		Approved			C0009214	O3-Methylmorphine
Codeine	Influenza-like symptoms	C0392171		Approved			C0009214	O3-Methylmorphine
Codeine	Tension Headache	C0033893		Approved			C0009214	O3-Methylmorphine
Codeine	Allergic rhinitis (disorder)	C2607914		Approved			C0009214	O3-Methylmorphine
Piperacillin	Enterobacter pneumonia	C1096258		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Infection due to Pseudomonas aeruginosa	C0276075		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Proteus septicemia	C0577690		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Acute gonococcal endometritis	C0153196		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Staphylococcus aureus infection	C1318973		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Bacterial sepsis	C0684256		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Proteus urinary tract infection	C0577709		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Acute gonococcal cervicitis	C0153195		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Abdominal Abscess	C0243001		Approved			C1882383	Piperacillin anhydrous
Piperacillin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Escherichia coli septicemia	C0276088		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Nosocomial pneumonia	C0949083		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Lower respiratory tract infection	C0149725		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Pneumonia due to Escherichia coli	C0276089		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Infection of bone	C2242472		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Arthropathy associated with infection	C0157749		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Escherichia coli Infections	C0014836		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Streptococcal sepsis	C0152964		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Pelvic Inflammatory Disease	C0242172		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Septicemia due to enterococcus	C0588233		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Appendicitis	C0003615		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Enterobacteriaceae Infections	C0014347		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Sepsis due to Pseudomonas	C2887096		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Postoperative infection	C0392618		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Acute gonococcal urethritis	C0275652		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Peritonitis	C0031154		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Intraabdominal Infections	C1112209		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Sepsis due to Gram negative bacteria	C3163829		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Pneumonia due to Pseudomonas	C0155860		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Rhinoscleroma	C0035468		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Diabetic foot infection	C0744130		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Gonorrhea	C0018081		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Serratia Infections	C0085394		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Septicemia due to Bacteroides	C0276064		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Serratia sepsis	C0152973		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Urinary tract infection	C0042029		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Escherichia coli urinary tract infection	C0577708		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Haemophilus influenzae pneumonia	C0276026		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Pneumonia, Bacterial	C0004626		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Klebsiella cystitis	C0520775		Approved			C1882383	Piperacillin anhydrous
Piperacillin	Female genital tract infection	C1263758		Approved			C1882383	Piperacillin anhydrous
Dihydroergotamine	Cluster Headache	C0009088		Approved			C0012291	9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
Dihydroergotamine	Vascular Headaches	C0042376		Approved			C0012291	9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
Dihydroergotamine	Migraine Disorders	C0149931		Approved			C0012291	9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
Amitriptyline	Mixed anxiety and depressive disorder	C0338908		Approved			C0002600	5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
Amitriptyline	Depressive disorder	C0011581		Approved			C0002600	5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
Floxuridine	Malignant neoplasm of liver	C0345904		Approved			C0016343	Fluoruridine deoxyribose
Floxuridine	Primary malignant neoplasm of gastrointestinal tract	C1306632		Approved			C0016343	Fluoruridine deoxyribose
Tolcapone	Parkinson Disease	C0030567		Approved			C0246330	3,4-dihydroxy-4'-methyl-5-nitrobenzophenone
Fluorometholone	Uveitis	C0042164		Approved			C0016351	Fluorométholone
Fluorometholone	Herpes zoster keratitis	C1275687		Approved			C0016351	Fluorométholone
Fluorometholone	Cyclitis	C0010543		Approved			C0016351	Fluorométholone
Fluorometholone	Iridocyclitis	C0022073		Approved			C0016351	Fluorométholone
Fluorometholone	Punctate keratopathy	C0423234		Approved			C0016351	Fluorométholone
Fluorometholone	Corneal Ulcer	C0010043		Approved			C0016351	Fluorométholone
Fluorometholone	Corneal abrasion	C0010032		Approved			C0016351	Fluorométholone
Fluorometholone	Rosacea	C0035854		Approved			C0016351	Fluorométholone
Fluorometholone	Allergic Conjunctivitis	C0009766		Approved			C0016351	Fluorométholone
Fluorometholone	Iritis	C0022081		Approved			C0016351	Fluorométholone
Nitroprusside	Hypertensive urgency	C0745138		Approved			C0028193	Nitroprusside
Nitroprusside	Decompensated cardiac failure	C0581377		Approved			C0028193	Nitroprusside
Nitroprusside	Hypertensive disease	C0020538		Approved			C0028193	Nitroprusside
Nitroprusside	Malignant essential hypertension	C0024588		Approved			C0028193	Nitroprusside
Calcium Gluceptate	Hypermagnesemia	C0151714		Approved			C0108111	Calcium gluceptate
Calcium Gluceptate	Hyperkalemia	C0020461		Approved			C0108111	Calcium gluceptate
Calcium Gluceptate	Hypocalcemia	C0020598		Approved			C0108111	Calcium gluceptate
Calcium Gluceptate	Disorder of electrolytes	C1704431		Approved			C0108111	Calcium gluceptate
Calcium Gluceptate	Hypocalcemic tetany	C0151940		Approved			C0108111	Calcium gluceptate
Calcium Gluceptate	Cardiac Arrest	C0018790		Approved			C0108111	Calcium gluceptate
Hydromorphone	Common Cold	C0009443		Approved			C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Hydromorphone	Coughing	C0010200		Approved			C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Hydromorphone	Acute postoperative pain	C2215257		Approved			C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Hydromorphone	Pain	C0030193		Approved			C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Hydromorphone	Severe pain	C0278140		Approved			C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Indomethacin	Tenosynovitis	C0039520		Approved			C0021246	Indometacina
Indomethacin	Bursitis	C0006444		Approved			C0021246	Indometacina
Indomethacin	shoulder bursitis	C0262399		Approved			C0021246	Indometacina
Indomethacin	Rheumatoid Arthritis	C0003873		Approved			C0021246	Indometacina
Indomethacin	Ankylosing spondylitis	C0038013		Approved			C0021246	Indometacina
Indomethacin	Patent ductus arteriosus	C0013274		Approved			C0021246	Indometacina
Indomethacin	Shoulder tendinitis	C0262633		Approved			C0021246	Indometacina
Indomethacin	Synovitis	C0039103		Approved			C0021246	Indometacina
Indomethacin	Degenerative polyarthritis	C0029408		Approved			C0021246	Indometacina
Indomethacin	Tendinitis	C0039503		Approved			C0021246	Indometacina
Indomethacin	Gout	C0018099		Approved			C0021246	Indometacina
Indomethacin	Rheumatism	C0035435		Approved			C0021246	Indometacina
Ethambutol	Acute tuberculosis	C0275959		Approved			C0014964	(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol
Ethambutol	Tuberculosis, Pulmonary	C0041327		Approved			C0014964	(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol
Metformin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0025598	Metformina
Ipratropium bromide	Bronchial Spasm	C0006266		Approved			C0700580	bromuro de ipratropio
Ipratropium bromide	Rhinorrhea	C1260880		Approved			C0700580	bromuro de ipratropio
Ipratropium bromide	Allergic rhinitis (disorder)	C2607914		Approved			C0700580	bromuro de ipratropio
Ipratropium bromide	Chronic Obstructive Airway Disease	C0024117		Approved			C0700580	bromuro de ipratropio
Ipratropium bromide	Pulmonary Emphysema	C0034067		Approved			C0700580	bromuro de ipratropio
Ipratropium bromide	Bronchitis	C0006277		Approved			C0700580	bromuro de ipratropio
Methadone	Opioid withdrawal	C0029104		Approved			C0025605	Methadonum
Methadone	Severe pain	C0278140		Approved			C0025605	Methadonum
Olanzapine	Depression, Bipolar	C0005587		Approved			C0171023	Olanzapinum
Olanzapine	Bipolar disorder in remission	C0270425		Approved			C0171023	Olanzapinum
Olanzapine	Major Depressive Disorder	C1269683		Approved			C0171023	Olanzapinum
Olanzapine	Mixed bipolar I disorder	C0236780		Approved			C0171023	Olanzapinum
Olanzapine	Bipolar affective disorder, current episode manic	C0338873		Approved			C0171023	Olanzapinum
Olanzapine	Schizophrenia	C0036341		Approved			C0171023	Olanzapinum
Atenolol	Myocardial Infarction	C0027051		Approved			C0004147	Atenololum
Atenolol	Angina Pectoris	C0002962		Approved			C0004147	Atenololum
Atenolol	Hypertensive disease	C0020538		Approved			C0004147	Atenololum
Nitrofural	Escherichia coli urinary tract infection	C0577708		Approved			C0740138	Furacilin
Nitrofural	Klebsiella cystitis	C0520775		Approved			C0740138	Furacilin
Nitrofural	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0740138	Furacilin
Omeprazole	Erosive esophagitis	C0267055		Approved			C0028978	Omeprazolum
Omeprazole	Zollinger-Ellison syndrome	C0043515		Approved			C0028978	Omeprazolum
Omeprazole	Peptic Esophagitis	C0014869		Approved			C0028978	Omeprazolum
Omeprazole	Gastroesophageal reflux disease	C0017168		Approved			C0028978	Omeprazolum
Omeprazole	Peptic Ulcer	C0030920		Approved			C0028978	Omeprazolum
Omeprazole	Gastric ulcer	C0038358		Approved			C0028978	Omeprazolum
Omeprazole	Duodenal Ulcer	C0013295		Approved			C0028978	Omeprazolum
Pyrazinamide	Acute tuberculosis	C0275959		Approved			C0034239	Pyrazinamidum
Pyrazinamide	Tuberculosis, Pulmonary	C0041327		Approved			C0034239	Pyrazinamidum
Pyrazinamide	Tuberculosis, Meningeal	C0041318		Approved			C0034239	Pyrazinamidum
Metixene	Parkinsonian Disorders	C0242422		Approved			C0066139	Métixène
Cetirizine	Allergic Conjunctivitis	C0009766		Approved			C0055147	Cetirizinum
Cetirizine	Hay fever	C0018621		Approved			C0055147	Cetirizinum
Cetirizine	Rhinorrhea	C1260880		Approved			C0055147	Cetirizinum
Cetirizine	Common Cold	C0009443		Approved			C0055147	Cetirizinum
Cetirizine	Chronic idiopathic urticaria	C0578870		Approved			C0055147	Cetirizinum
Cetirizine	Allergic rhinitis (disorder)	C2607914		Approved			C0055147	Cetirizinum
Cetirizine	Nasal congestion (finding)	C0027424		Approved			C0055147	Cetirizinum
Cetirizine	Rhinitis, Vasomotor	C0035460		Approved			C0055147	Cetirizinum
Cetirizine	Sneezing	C0037383		Approved			C0055147	Cetirizinum
Diltiazem	Angina Pectoris, Variant	C0002963		Approved			C0012373	d-cis-diltiazem
Diltiazem	Hypertensive disease	C0020538		Approved			C0012373	d-cis-diltiazem
Diltiazem	Paroxysmal supraventricular tachycardia	C0030590		Approved			C0012373	d-cis-diltiazem
Diltiazem	Angina Pectoris	C0002962		Approved			C0012373	d-cis-diltiazem
Diltiazem	Atrial Fibrillation	C0004238		Approved			C0012373	d-cis-diltiazem
Protriptyline	Depressive disorder	C0011581		Approved			C0033743	5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene
Alfuzosin	Prostatic Hypertrophy	C1739363		Approved			C0051150	Alfuzosina
Trimethadione	Epilepsy	C0014544		Approved			C0041038	Triméthadione
Trimethadione	Absence Epilepsy	C0014553		Approved			C0041038	Triméthadione
Nitisinone	Tyrosinemia, Type I	C0268490		Approved			C0173083	2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
Clobazam	Lennox-Gastaut syndrome	C0238111		Approved			C0055891	Clobazamum
Minoxidil	Hypertensive disease	C0020538		Approved			C0026196	Minossidile
Minoxidil	Alopecia	C0002170		Approved			C0026196	Minossidile
Megestrol acetate	Nutritional deficiency associated with AIDS	C0276587		Approved			C0065879	17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
Megestrol acetate	Endometrial Carcinoma	C0476089		Approved			C0065879	17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
Megestrol acetate	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0065879	17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
Tioguanine	Leukemia, Myelocytic, Acute	C0023467		Approved			C1883309	Thioguanine, anhydrous
Methylergometrine	Postpartum Hemorrhage	C0032797		Approved			C0025760	Metilergometrinio
Buclizine	Motion Sickness	C0026603		Approved			C0164386	1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine
Aztreonam	Intraabdominal Infections	C1112209		Approved			C0004521	Aztréonam
Aztreonam	Serratia Infections	C0085394		Approved			C0004521	Aztréonam
Aztreonam	Enterobacter pneumonia	C1096258		Approved			C0004521	Aztréonam
Aztreonam	URINARY TRACT INFECTION CITROBACTER	C0749955		Approved			C0004521	Aztréonam
Aztreonam	Bacterial urinary infection	C0729524		Approved			C0004521	Aztréonam
Aztreonam	Klebsiella cystitis	C0520775		Approved			C0004521	Aztréonam
Aztreonam	Sepsis due to Pseudomonas	C2887096		Approved			C0004521	Aztréonam
Aztreonam	Pelvic Inflammatory Disease	C0242172		Approved			C0004521	Aztréonam
Aztreonam	Rhinoscleroma	C0035468		Approved			C0004521	Aztréonam
Aztreonam	Infection due to Pseudomonas aeruginosa	C0276075		Approved			C0004521	Aztréonam
Aztreonam	Haemophilus influenzae pneumonia	C0276026		Approved			C0004521	Aztréonam
Aztreonam	Proteus urinary tract infection	C0577709		Approved			C0004521	Aztréonam
Aztreonam	Enterobacteriaceae Infections	C0014347		Approved			C0004521	Aztréonam
Aztreonam	Bacterial peritonitis	C0341503		Approved			C0004521	Aztréonam
Aztreonam	Pneumonia due to Escherichia coli	C0276089		Approved			C0004521	Aztréonam
Aztreonam	Escherichia coli Infections	C0014836		Approved			C0004521	Aztréonam
Aztreonam	Peritonitis	C0031154		Approved			C0004521	Aztréonam
Aztreonam	Endometritis	C0014179		Approved			C0004521	Aztréonam
Aztreonam	Escherichia coli urinary tract infection	C0577708		Approved			C0004521	Aztréonam
Aztreonam	Escherichia coli septicemia	C0276088		Approved			C0004521	Aztréonam
Aztreonam	Female genital tract infection	C1263758		Approved			C0004521	Aztréonam
Aztreonam	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0004521	Aztréonam
Aztreonam	Serratia sepsis	C0152973		Approved			C0004521	Aztréonam
Aztreonam	Pneumonia due to Pseudomonas	C0155860		Approved			C0004521	Aztréonam
Aztreonam	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0004521	Aztréonam
Aztreonam	Proteus septicemia	C0577690		Approved			C0004521	Aztréonam
Aztreonam	Lower respiratory tract infection	C0149725		Approved			C0004521	Aztréonam
Aztreonam	Sepsis due to Gram negative bacteria	C3163829		Approved			C0004521	Aztréonam
Aztreonam	Urinary tract infection	C0042029		Approved			C0004521	Aztréonam
Aztreonam	Proteus pneumonia	C1260917		Approved			C0004521	Aztréonam
Chlorzoxazone	Muscle Spasticity	C0026838		Approved			C0008296	Chlorzoxazona
Aminoglutethimide	Secondary malignant neoplasm of female breast	C0346993		Approved			C0002555	DL-Aminoglutethimide
Mefloquine	Malaria, Vivax	C0024537		Approved			C0025153	Mefloquinum
Sulfadiazine	Toxoplasmosis	C0040558		Approved			C0038675	Sulfadiazinum
Sulfadiazine	Chorioretinitis	C0008513		Approved			C0038675	Sulfadiazinum
Sulfadiazine	Ulcerative Colitis	C0009324		Approved			C0038675	Sulfadiazinum
Sulfadiazine	Toxoplasmosis associated with AIDS	C1720498		Approved			C0038675	Sulfadiazinum
Sulfadiazine	Skin Ulcer	C0037299		Approved			C0038675	Sulfadiazinum
Sulfadiazine	Toxoplasmosis, Congenital	C0040560		Approved			C0038675	Sulfadiazinum
Sapropterin	Classical phenylketonuria	C0751434		Approved			C0048897	(-)-(6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinone
Vinorelbine	Non-Small Cell Lung Carcinoma	C0007131		Approved			C0078257	Vinorelbinum
Anidulafungin	Candidiasis of the esophagus	C0239295		Approved			C1142738	Anidulafungina
Anidulafungin	candidal peritonitis	C2062982		Approved			C1142738	Anidulafungina
Anidulafungin	Candidemia	C0877445		Approved			C1142738	Anidulafungina
Clozapine	Treatment-resistant schizophrenia	C3544321		Approved			C0009079	Clozapina
Sucralfate	Duodenal Ulcer	C0013295		Approved			C0038633	Sucralfatum
Doxylamine	Pruritus	C0033774		Approved			C0013092	Doxilamina
Doxylamine	Influenza-like symptoms	C0392171		Approved			C0013092	Doxilamina
Doxylamine	Allergic Conjunctivitis	C0009766		Approved			C0013092	Doxilamina
Doxylamine	Rhinitis, Vasomotor	C0035460		Approved			C0013092	Doxilamina
Doxylamine	Common Cold	C0009443		Approved			C0013092	Doxilamina
Doxylamine	Hay fever	C0018621		Approved			C0013092	Doxilamina
Doxylamine	Sneezing	C0037383		Approved			C0013092	Doxilamina
Doxylamine	Nasal congestion (finding)	C0027424		Approved			C0013092	Doxilamina
Doxylamine	Urticaria	C0042109		Approved			C0013092	Doxilamina
Doxylamine	Allergic rhinitis (disorder)	C2607914		Approved			C0013092	Doxilamina
Doxylamine	Rhinorrhea	C1260880		Approved			C0013092	Doxilamina
Doxylamine	Symptomatic dermographism	C0343065		Approved			C0013092	Doxilamina
Levonorgestrel	Menorrhagia	C0025323		Approved			C0023566	Lèvonorgestrel
Levonorgestrel	Hot flushes	C0600142		Approved			C0023566	Lèvonorgestrel
Norepinephrine	Asthma attack	C0347950		Approved			C0028351	(-)-noradrenaline
Norepinephrine	Bronchitis	C0006277		Approved			C0028351	(-)-noradrenaline
Norepinephrine	Asthma	C0004096		Approved			C0028351	(-)-noradrenaline
Norepinephrine	Hypotension	C0020649		Approved			C0028351	(-)-noradrenaline
Norepinephrine	Bronchiectasis	C0006267		Approved			C0028351	(-)-noradrenaline
Norepinephrine	Pulmonary Emphysema	C0034067		Approved			C0028351	(-)-noradrenaline
Norepinephrine	Parkinson Disease	C0030567		Approved			C0028351	(-)-noradrenaline
Mirtazapine	Major Depressive Disorder	C1269683		Approved			C0049506	Mirtazapin
Meprobamate	Anxiety	C0003467		Approved			C0025386	Meprobamato
Timolol	Ocular Hypertension	C0028840		Approved			C0040233	Timololo
Timolol	Glaucoma, Open-Angle	C0017612		Approved			C0040233	Timololo
Timolol	Hypertensive disease	C0020538		Approved			C0040233	Timololo
Treprostinil	Pulmonary arterial hypertension	C2973725		Approved			C1145760	Tréprostinil
Colestipol	Hypercholesterolemia	C0020443		Approved			C0009279	Colestipolum
Colestipol	Hyperlipidemia	C0020473		Approved			C0009279	Colestipolum
Trihexyphenidyl	Extrapyramidal Disorders	C0015371		Approved			C0041009	Trihexyphenidylum
Trihexyphenidyl	Parkinsonian Disorders	C0242422		Approved			C0041009	Trihexyphenidylum
Trihexyphenidyl	Parkinson Disease	C0030567		Approved			C0041009	Trihexyphenidylum
Trihexyphenidyl	Parkinson Disease, Postencephalitic	C0030568		Approved			C0041009	Trihexyphenidylum
Palonosetron	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C0220578	(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one
Mexiletine	Ventricular arrhythmia	C0085612		Approved			C0025887	(±)-1-(2,6-dimethylphenoxy)propan-2-amine
Amlodipine	Angina Pectoris, Variant	C0002963		Approved			C0051696	Amlodipinum
Amlodipine	Cerebrovascular accident	C0038454		Approved			C0051696	Amlodipinum
Amlodipine	Hypertensive disease	C0020538		Approved			C0051696	Amlodipinum
Amlodipine	Angina Pectoris	C0002962		Approved			C0051696	Amlodipinum
Oxyphencyclimine	Peptic Ulcer	C0030920		Approved			C0069833	Oxyphencycliminum
Triamterene	Hypertensive disease	C0020538		Approved			C0040869	Triamterena
Triamterene	Edema	C0013604		Approved			C0040869	Triamterena
Valrubicin	Malignant neoplasm of urinary bladder	C0005684		Approved			C0068314	Valrubicinum
Procyclidine	Parkinson Disease	C0030567		Approved			C0033254	Prociclidina
Procyclidine	Parkinsonian Disorders	C0242422		Approved			C0033254	Prociclidina
Procyclidine	Extrapyramidal Disorders	C0015371		Approved			C0033254	Prociclidina
Procyclidine	Parkinson Disease, Postencephalitic	C0030568		Approved			C0033254	Prociclidina
Phenylephrine	Coughing	C0010200		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Sneezing	C0037383		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Rhinorrhea	C1260880		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Fever	C0015967		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Redness of eye	C0235267		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Rectal pain	C0034886		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Allergic Conjunctivitis	C0009766		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Headache Disorders	C0393735		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Rhinitis	C0035455		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Sinus headache	C0037195		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Proctitis	C0033246		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Nasal congestion (finding)	C0027424		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Allergic rhinitis (disorder)	C2607914		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Hemorrhoids	C0019112		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Hay fever	C0018621		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Rhinitis, Vasomotor	C0035460		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Influenza-like symptoms	C0392171		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Mydriasis	C0026961		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Common Cold	C0009443		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Phenylephrine	Pruritus Ani	C0033775		Approved			C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Carbimazole	Hyperthyroidism	C0020550		Approved			C0006983	Carbimazolo
Carbimazole	Graves Disease	C0018213		Approved			C0006983	Carbimazolo
Digoxin	Atrial Fibrillation	C0004238		Approved			C0012265	Digossina
Digoxin	Poisoning by digitalis glycoside	C0274726		Approved			C0012265	Digossina
Digoxin	Chronic heart failure	C0264716		Approved			C0012265	Digossina
Sulpiride	Schizophrenia	C0036341		Approved			C0038803	N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide
Nimodipine	Subarachnoid Hemorrhage	C0038525		Approved			C0028094	2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-methoxyethyl ester 5-isopropyl ester
Beclomethasone dipropionate	Rhinitis	C0035455		Approved			C0004906	Beclometasone dipropionato
Beclomethasone dipropionate	Nasal Polyps	C0027430		Approved			C0004906	Beclometasone dipropionato
Beclomethasone dipropionate	Asthma	C0004096		Approved			C0004906	Beclometasone dipropionato
Beclomethasone dipropionate	Allergic rhinitis (disorder)	C2607914		Approved			C0004906	Beclometasone dipropionato
Beclomethasone dipropionate	Rhinitis, Vasomotor	C0035460		Approved			C0004906	Beclometasone dipropionato
Carisoprodol	Back Pain	C0004604		Approved			C0007248	2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
Carisoprodol	Muscle Spasticity	C0026838		Approved			C0007248	2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
Progesterone	Hot flushes	C0600142		Approved			C0033308	Gelbkörperhormon
Progesterone	Endometrial Carcinoma	C0476089		Approved			C0033308	Gelbkörperhormon
Progesterone	Secondary malignant neoplasm of kidney	C0153685		Approved			C0033308	Gelbkörperhormon
Progesterone	Endometriosis	C0014175		Approved			C0033308	Gelbkörperhormon
Progesterone	Metrorrhagia	C0025874		Approved			C0033308	Gelbkörperhormon
Progesterone	Atrophic Vaginitis	C0221392		Approved			C0033308	Gelbkörperhormon
Progesterone	Secondary physiologic amenorrhea	C0232940		Approved			C0033308	Gelbkörperhormon
Phenylpropanolamine	Influenza-like symptoms	C0392171		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Allergic rhinitis (disorder)	C2607914		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Rhinitis, Vasomotor	C0035460		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Nasal congestion (finding)	C0027424		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Coughing	C0010200		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Hay fever	C0018621		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Rhinorrhea	C1260880		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Common Cold	C0009443		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Sneezing	C0037383		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Allergic Conjunctivitis	C0009766		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Sinus headache	C0037195		Approved			C0031495	(+-)-Phenylpropanolamine
Phenylpropanolamine	Rhinitis	C0035455		Approved			C0031495	(+-)-Phenylpropanolamine
Sorafenib	Renal Cell Carcinoma	C0007134		Approved			C1516119	Sorafenibum
Sorafenib	Liver carcinoma	C2239176		Approved			C1516119	Sorafenibum
Sorafenib	Malignant epithelial neoplasm of thyroid	C3163939		Approved			C1516119	Sorafenibum
Zoledronic acid	Osteoporosis	C0029456		Approved			C0257685	ácido zoledrónico
Zoledronic acid	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0257685	ácido zoledrónico
Zoledronic acid	Osteitis Deformans	C0029401		Approved			C0257685	ácido zoledrónico
Zoledronic acid	Osteolytic Lesions of Multiple Myeloma	C3898069		Approved			C0257685	ácido zoledrónico
Zoledronic acid	Osteoporosis, Postmenopausal	C0029458		Approved			C0257685	ácido zoledrónico
Griseofulvin	Tinea corporis (disorder)	C0040252		Approved			C0018242	Griséofulvine
Griseofulvin	Tinea cruris	C1384589		Approved			C0018242	Griséofulvine
Griseofulvin	Tinea Capitis	C0040250		Approved			C0018242	Griséofulvine
Griseofulvin	Onychomycosis	C0040261		Approved			C0018242	Griséofulvine
Griseofulvin	Tinea barbae	C2349994		Approved			C0018242	Griséofulvine
Griseofulvin	Tinea Pedis	C0040259		Approved			C0018242	Griséofulvine
Nisoldipine	Hypertensive disease	C0020538		Approved			C0028116	Nisoldipina
Eszopiclone	Sleeplessness	C0917801		Approved			C1436328	(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate
Alprazolam	Anxiety	C0003467		Approved			C0002333	8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
Alprazolam	Mixed anxiety and depressive disorder	C0338908		Approved			C0002333	8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
Alprazolam	Generalized Anxiety Disorder	C0270549		Approved			C0002333	8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
Alprazolam	Panic Disorder	C0030319		Approved			C0002333	8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
Dexbrompheniramine	Symptomatic dermographism	C0343065		Approved			C0057605	d-brompheniramine
Dexbrompheniramine	Rhinitis, Vasomotor	C0035460		Approved			C0057605	d-brompheniramine
Dexbrompheniramine	Influenza-like symptoms	C0392171		Approved			C0057605	d-brompheniramine
Dexbrompheniramine	Hay fever	C0018621		Approved			C0057605	d-brompheniramine
Dexbrompheniramine	Allergic Conjunctivitis	C0009766		Approved			C0057605	d-brompheniramine
Dexbrompheniramine	Pruritus	C0033774		Approved			C0057605	d-brompheniramine
Dexbrompheniramine	Urticaria	C0042109		Approved			C0057605	d-brompheniramine
Dexbrompheniramine	Allergic rhinitis (disorder)	C2607914		Approved			C0057605	d-brompheniramine
Gentian Violet	Candidiasis, Vulvovaginal	C0700345		Approved			C3848552	Gentian violet cation
Loxapine	Schizophrenia	C0036341		Approved			C0024056	Oxilapine
Loxapine	Bipolar Disorder	C0005586		Approved			C0024056	Oxilapine
Mupirocin	Impetigo	C0021099		Approved			C0085259	Mupirocina
Carbachol	Glaucoma, Open-Angle	C0017612		Approved			C0006945	carbacol
Pramipexole	Restless Legs Syndrome	C0035258		Approved			C0074710	Pramipexolum
Pramipexole	Parkinson Disease	C0030567		Approved			C0074710	Pramipexolum
Ampicillin	Acute otitis media	C0271429		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Acute bacterial epiglottitis	C0275555		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Escherichia coli septicemia	C0276088		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Cholangitis	C0008311		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Pneumonia, Bacterial	C0004626		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Meningitis, Escherichia coli	C0338395		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Acute epiglottitis	C0155814		Approved			C0724526	Ampicillin anhydrous
Ampicillin	pharyngitis due to Haemophilus influenzae	C2062475		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Septicemia due to enterococcus	C0588233		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Streptococcal pneumonia	C0155862		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Acute gonococcal cervicitis	C0153195		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Gonorrhea of rectum	C0275665		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Bacterial peritonitis	C0341503		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Female genital tract infection	C1263758		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Bacterial Endocarditis	C0014121		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Staphylococcus aureus infection	C1318973		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Infective otitis media	C0729586		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Salmonella sepsis	C0152486		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Staphylococcal endocarditis	C0520767		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Streptococcal endocarditis	C3665800		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Bacterial sepsis	C0684256		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Streptococcal sepsis	C0152964		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Sinusitis	C0037199		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Staphylococcal Pneumonia	C0032308		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Acute gonococcal urethritis	C0275652		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Meningitis, Bacterial	C0085437		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Dysentery	C0013369		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Gonorrhea	C0018081		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Acute gonococcal endometritis	C0153196		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Meningitis, Pneumococcal	C0025295		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Shigella Infections	C0013371		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Meningococcal meningitis	C0025294		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Acute bacterial sinusitis	C0275556		Approved			C0724526	Ampicillin anhydrous
Ampicillin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Pharyngitis	C0031350		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Urinary tract infection	C0042029		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Proteus septicemia	C0577690		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Pneumococcal pharyngitis	C0275761		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Escherichia coli Infections	C0014836		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Proteus urinary tract infection	C0577709		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Streptococcal tonsillitis	C0275804		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Genitourinary tract infection	C1279247		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Intraabdominal Infections	C1112209		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Pelvic Inflammatory Disease	C0242172		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Enterobacteriaceae Infections	C0014347		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Paratyphoid Fever	C0030528		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Rhinoscleroma	C0035468		Approved			C0724526	Ampicillin anhydrous
Ampicillin	Haemophilus influenzae pneumonia	C0276026		Approved			C0724526	Ampicillin anhydrous
Phenoxymethylpenicillin	Pharyngitis	C0031350		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Staphylococcus aureus infection	C1318973		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Fusospirochetal pharyngitis	C1318559		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Acute otitis media	C0271429		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Erysipelas	C0014733		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Infective otitis media	C0729586		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Upper Respiratory Infections	C0041912		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Gingivostomatitis	C0149704		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Streptococcal tonsillitis	C0275804		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Scarlet Fever	C0036285		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Phenoxymethylpenicillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0030840	(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
Secobarbital	Epilepsy	C0014544		Approved			C0036516	5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
Secobarbital	Status Epilepticus	C0038220		Approved			C0036516	5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
Secobarbital	Severe anxiety (panic)	C0231403		Approved			C0036516	5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
Secobarbital	Sleeplessness	C0917801		Approved			C0036516	5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
Miglustat	Gaucher Disease	C0017205		Approved			C1321596	N-(n-Butyl)deoxynojirimycin
Miglustat	Niemann-Pick Disease, Type C	C0220756		Approved			C1321596	N-(n-Butyl)deoxynojirimycin
Promazine	Bipolar affective disorder, current episode manic	C0338873		Approved			C0033399	Promazina
Promazine	Angioedema	C0002994		Approved			C0033399	Promazina
Promazine	Vomiting	C0042963		Approved			C0033399	Promazina
Promazine	Symptomatic dermographism	C0343065		Approved			C0033399	Promazina
Promazine	Allergic rhinitis (disorder)	C2607914		Approved			C0033399	Promazina
Promazine	Pruritus	C0033774		Approved			C0033399	Promazina
Promazine	Urticaria	C0042109		Approved			C0033399	Promazina
Promazine	Nausea and vomiting	C0027498		Approved			C0033399	Promazina
Promazine	Intractable hiccups	C0744896		Approved			C0033399	Promazina
Promazine	Acute intermittent porphyria	C0162565		Approved			C0033399	Promazina
Promazine	Sneezing	C0037383		Approved			C0033399	Promazina
Promazine	Disruptive Behavior Disorder	C0012734		Approved			C0033399	Promazina
Promazine	Psychotic Disorders	C0033975		Approved			C0033399	Promazina
Promazine	Rhinorrhea	C1260880		Approved			C0033399	Promazina
Promazine	Nasal congestion (finding)	C0027424		Approved			C0033399	Promazina
Promazine	Allergic Conjunctivitis	C0009766		Approved			C0033399	Promazina
Promazine	Nausea	C0027497		Approved			C0033399	Promazina
Promazine	Schizophrenia	C0036341		Approved			C0033399	Promazina
Spironolactone	Hypertensive disease	C0020538		Approved			C0037982	Espironolactona
Spironolactone	Ascites	C0003962		Approved			C0037982	Espironolactona
Spironolactone	Edema	C0013604		Approved			C0037982	Espironolactona
Spironolactone	Chronic heart failure	C0264716		Approved			C0037982	Espironolactona
Spironolactone	Hyperaldosteronism	C0020428		Approved			C0037982	Espironolactona
Methylphenidate	Attention deficit hyperactivity disorder	C1263846		Approved			C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Methylphenidate	Narcolepsy	C0027404		Approved			C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Methocarbamol	Muscle Spasticity	C0026838		Approved			C0025659	Metocarbamolo
Hyoscyamine	Sinus bradycardia	C0085610		Approved			C0596004	L-Tropine tropate
Hyoscyamine	Sialorrhea	C0037036		Approved			C0596004	L-Tropine tropate
Hyoscyamine	Dysuria	C0013428		Approved			C0596004	L-Tropine tropate
Hyoscyamine	Peptic Ulcer	C0030920		Approved			C0596004	L-Tropine tropate
Zolpidem	Sleeplessness	C0917801		Approved			C0078839	Zolpidemum
Zolpidem	Initial insomnia	C0393760		Approved			C0078839	Zolpidemum
Famciclovir	Herpes zoster disease	C0019360		Approved			C0209227	9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
Famciclovir	Recurrent genital herpes simplex	C1274323		Approved			C0209227	9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
Famciclovir	Recurrent herpes simplex labialis	C1274321		Approved			C0209227	9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
Triprolidine	Hay fever	C0018621		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Rhinorrhea	C1260880		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Rhinitis, Vasomotor	C0035460		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Common Cold	C0009443		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Urticaria	C0042109		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Pruritus	C0033774		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Allergic Conjunctivitis	C0009766		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Symptomatic dermographism	C0343065		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Triprolidine	Allergic rhinitis (disorder)	C2607914		Approved			C0041098	(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine
Carboprost Tromethamine	Postpartum Hemorrhage	C0032797		Approved			C0054721	1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9α,11β,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate
Carboprost Tromethamine	Unspecified Abortion	C0156543		Approved			C0054721	1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9α,11β,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate
Lindane	Scabies <infestation>	C0036262		Approved			C0005038	Lindanum
Lindane	Pediculus capitis infestation	C0030757		Approved			C0005038	Lindanum
Lindane	Infestation by Phthirus pubis	C0030759		Approved			C0005038	Lindanum
Trifluridine	Herpes simplex keratoconjunctivitis	C0276228		Approved			C0040987	Trifluridina
Trifluridine	Keratitis, Herpetic	C0019357		Approved			C0040987	Trifluridina
Trifluridine	Malignant tumor of colon	C0007102		Approved			C0040987	Trifluridina
Prochlorperazine	Schizophrenia	C0036341		Approved			C0033229	Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
Prochlorperazine	Nausea and vomiting	C0027498		Approved			C0033229	Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
Cyproheptadine	Rhinorrhea	C1260880		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Allergic Conjunctivitis	C0009766		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Nasal congestion (finding)	C0027424		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Urticaria	C0042109		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Sneezing	C0037383		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Symptomatic dermographism	C0343065		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Allergic rhinitis (disorder)	C2607914		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Pruritus	C0033774		Approved			C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Nitric Oxide	Persistent Fetal Circulation Syndrome	C0031190		Approved			C0028128	óxido nítrico
Nitric Oxide	Pulmonary Hypertension	C0020542		Approved			C0028128	óxido nítrico
Bendroflumethiazide	Hypertensive disease	C0020538		Approved			C0004975	6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
Allopurinol	Calcium renal calculus	C1959799		Approved			C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Allopurinol	Gout	C0018099		Approved			C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Allopurinol	Arthritis, Gouty	C0003868		Approved			C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Allopurinol	Hyperuricemia	C0740394		Approved			C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Allopurinol	Uric acid renal calculus	C0558595		Approved			C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Ceftazidime	Sepsis due to Pseudomonas	C2887096		Approved			C0007559	Ceftazidima
Ceftazidime	Infection of bone	C2242472		Approved			C0007559	Ceftazidima
Ceftazidime	Meningococcal meningitis	C0025294		Approved			C0007559	Ceftazidima
Ceftazidime	Pneumonia due to Pseudomonas	C0155860		Approved			C0007559	Ceftazidima
Ceftazidime	Proteus urinary tract infection	C0577709		Approved			C0007559	Ceftazidima
Ceftazidime	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007559	Ceftazidima
Ceftazidime	Escherichia coli Infections	C0014836		Approved			C0007559	Ceftazidima
Ceftazidime	Escherichia coli septicemia	C0276088		Approved			C0007559	Ceftazidima
Ceftazidime	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007559	Ceftazidima
Ceftazidime	Peritonitis	C0031154		Approved			C0007559	Ceftazidima
Ceftazidime	Arthropathy associated with infection	C0157749		Approved			C0007559	Ceftazidima
Ceftazidime	Proteus pneumonia	C1260917		Approved			C0007559	Ceftazidima
Ceftazidime	Ecthyma gangrenosum	C0276085		Approved			C0007559	Ceftazidima
Ceftazidime	Staphylococcus aureus infection	C1318973		Approved			C0007559	Ceftazidima
Ceftazidime	Enterobacter pneumonia	C1096258		Approved			C0007559	Ceftazidima
Ceftazidime	Staphylococcal Pneumonia	C0032308		Approved			C0007559	Ceftazidima
Ceftazidime	Bacterial urinary infection	C0729524		Approved			C0007559	Ceftazidima
Ceftazidime	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0007559	Ceftazidima
Ceftazidime	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007559	Ceftazidima
Ceftazidime	Pneumonia, Bacterial	C0004626		Approved			C0007559	Ceftazidima
Ceftazidime	Neonatal meningitis	C0456107		Approved			C0007559	Ceftazidima
Ceftazidime	Meningitis, Bacterial	C0085437		Approved			C0007559	Ceftazidima
Ceftazidime	Haemophilus influenzae pneumonia	C0276026		Approved			C0007559	Ceftazidima
Ceftazidime	Escherichia coli urinary tract infection	C0577708		Approved			C0007559	Ceftazidima
Ceftazidime	Bacterial sepsis	C0684256		Approved			C0007559	Ceftazidima
Ceftazidime	Lower respiratory tract infection	C0149725		Approved			C0007559	Ceftazidima
Ceftazidime	Endometritis	C0014179		Approved			C0007559	Ceftazidima
Ceftazidime	Intraabdominal Infections	C1112209		Approved			C0007559	Ceftazidima
Ceftazidime	Serratia sepsis	C0152973		Approved			C0007559	Ceftazidima
Ceftazidime	Rhinoscleroma	C0035468		Approved			C0007559	Ceftazidima
Ceftazidime	Streptococcus pyogenes infection	C0554628		Approved			C0007559	Ceftazidima
Ceftazidime	Pneumonia due to Escherichia coli	C0276089		Approved			C0007559	Ceftazidima
Ceftazidime	Enterobacteriaceae Infections	C0014347		Approved			C0007559	Ceftazidima
Ceftazidime	Klebsiella cystitis	C0520775		Approved			C0007559	Ceftazidima
Ceftazidime	Haemophilus sepsis	C0854324		Approved			C0007559	Ceftazidima
Ceftazidime	Gonococcal meningitis	C0153225		Approved			C0007559	Ceftazidima
Ceftazidime	Pelvic Inflammatory Disease	C0242172		Approved			C0007559	Ceftazidima
Ceftazidime	Streptococcal sepsis	C0152964		Approved			C0007559	Ceftazidima
Trimethoprim	Urinary tract infection	C0042029		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Bacterial conjunctivitis	C0009768		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Proteus urinary tract infection	C0577709		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Shigella Infections	C0013371		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Blepharoconjunctivitis	C0005743		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Escherichia coli urinary tract infection	C0577708		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Klebsiella cystitis	C0520775		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Bacterial urinary infection	C0729524		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Infective otitis media	C0729586		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Trimethoprim	Acute otitis media	C0271429		Approved			C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Gemcitabine	Non-Small Cell Lung Carcinoma	C0007131		Approved			C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Adenocarcinoma of pancreas	C0281361		Approved			C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Malignant neoplasm of ovary	C1140680		Approved			C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Carcinoma breast stage IV	C0278488		Approved			C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Entecavir	Hepatitis B, Chronic	C0524909		Approved			C0971023	Entecavirum
Betamethasone	Transplanted organ rejection	C0345468		Approved			C0005308	Bétaméthasone
Betamethasone	Chronic small plaque psoriasis	C0406317		Approved			C0005308	Bétaméthasone
Betamethasone	Disorder of eye	C0015397		Approved			C0005308	Bétaméthasone
Betamethasone	Nephrotic Syndrome	C0027726		Approved			C0005308	Bétaméthasone
Betamethasone	Lupus Erythematosus, Systemic	C0024141		Approved			C0005308	Bétaméthasone
Betamethasone	Sarcoidosis	C0036202		Approved			C0005308	Bétaméthasone
Betamethasone	Inflammatory Bowel Diseases	C0021390		Approved			C0005308	Bétaméthasone
Betamethasone	Cerebral Edema	C0006114		Approved			C0005308	Bétaméthasone
Betamethasone	Serum Sickness	C0036830		Approved			C0005308	Bétaméthasone
Betamethasone	Seborrheic dermatitis	C0036508		Approved			C0005308	Bétaméthasone
Betamethasone	Hodgkin Disease	C0019829		Approved			C0005308	Bétaméthasone
Betamethasone	Congenital adrenal hyperplasia	C0001627		Approved			C0005308	Bétaméthasone
Betamethasone	Bursitis	C0006444		Approved			C0005308	Bétaméthasone
Betamethasone	Asthma	C0004096		Approved			C0005308	Bétaméthasone
Betamethasone	Erythema Multiforme	C0014742		Approved			C0005308	Bétaméthasone
Betamethasone	Dermatologic disorders	C0037274		Approved			C0005308	Bétaméthasone
Betamethasone	Angioedema	C0002994		Approved			C0005308	Bétaméthasone
Betamethasone	Crohn Disease	C0010346		Approved			C0005308	Bétaméthasone
Betamethasone	Rheumatoid Arthritis	C0003873		Approved			C0005308	Bétaméthasone
Betamethasone	Status Asthmaticus	C0038218		Approved			C0005308	Bétaméthasone
Betamethasone	Adrenal cortical hypofunction	C0405580		Approved			C0005308	Bétaméthasone
Betamethasone	Acquired thrombocytopenia	C0154301		Approved			C0005308	Bétaméthasone
Betamethasone	Lymphoma, Follicular	C0024301		Approved			C0005308	Bétaméthasone
Betamethasone	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0005308	Bétaméthasone
Betamethasone	Tendinitis	C0039503		Approved			C0005308	Bétaméthasone
Betamethasone	Exfoliative dermatitis	C0011606		Approved			C0005308	Bétaméthasone
Betamethasone	Synovitis	C0039103		Approved			C0005308	Bétaméthasone
Betamethasone	Laryngeal Edema	C0023052		Approved			C0005308	Bétaméthasone
Betamethasone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0005308	Bétaméthasone
Betamethasone	Cooley's anemia	C0002875		Approved			C0005308	Bétaméthasone
Betamethasone	Scalp psoriasis	C0406326		Approved			C0005308	Bétaméthasone
Betamethasone	Allergic rhinitis (disorder)	C2607914		Approved			C0005308	Bétaméthasone
Betamethasone	Tinea Pedis	C0040259		Approved			C0005308	Bétaméthasone
Betamethasone	Lichen Simplex Chronicus	C0149922		Approved			C0005308	Bétaméthasone
Betamethasone	Pemphigus	C0030807		Approved			C0005308	Bétaméthasone
Betamethasone	Contact Dermatitis	C0011616		Approved			C0005308	Bétaméthasone
Betamethasone	Mycosis Fungoides	C0026948		Approved			C0005308	Bétaméthasone
Betamethasone	Autoimmune Diseases	C0004364		Approved			C0005308	Bétaméthasone
Betamethasone	Dermatitis, Atopic	C0011615		Approved			C0005308	Bétaméthasone
Betamethasone	Multiple Sclerosis	C0026769		Approved			C0005308	Bétaméthasone
Betamethasone	Simple Pulmonary Eosinophilia	C0242459		Approved			C0005308	Bétaméthasone
Betamethasone	Lupus Erythematosus, Discoid	C0024138		Approved			C0005308	Bétaméthasone
Betamethasone	Epicondylitis	C0014488		Approved			C0005308	Bétaméthasone
Betamethasone	Trichinellosis	C0040896		Approved			C0005308	Bétaméthasone
Betamethasone	Autoimmune hemolytic anemia	C0002880		Approved			C0005308	Bétaméthasone
Betamethasone	Acute lymphocytic leukemia	C0023449		Approved			C0005308	Bétaméthasone
Betamethasone	Addisonian crisis	C0151467		Approved			C0005308	Bétaméthasone
Betamethasone	Pruritus Ani	C0033775		Approved			C0005308	Bétaméthasone
Betamethasone	Tuberculosis, Miliary	C0041321		Approved			C0005308	Bétaméthasone
Betamethasone	Scalp Dermatoses	C0036271		Approved			C0005308	Bétaméthasone
Betamethasone	Addison Disease	C0001403		Approved			C0005308	Bétaméthasone
Betamethasone	Arthritis, Psoriatic	C0003872		Approved			C0005308	Bétaméthasone
Betamethasone	Tinea cruris	C1384589		Approved			C0005308	Bétaméthasone
Betamethasone	Rheumatic Heart Disease	C0035439		Approved			C0005308	Bétaméthasone
Betamethasone	Anemia, Diamond-Blackfan	C1260899		Approved			C0005308	Bétaméthasone
Betamethasone	Aspiration pneumonitis	C1761609		Approved			C0005308	Bétaméthasone
Betamethasone	Psoriasis	C0033860		Approved			C0005308	Bétaméthasone
Betamethasone	Dermatitis Herpetiformis	C0011608		Approved			C0005308	Bétaméthasone
Betamethasone	Post traumatic osteoarthritis	C2894027		Approved			C0005308	Bétaméthasone
Betamethasone	Arthritis, Gouty	C0003868		Approved			C0005308	Bétaméthasone
Betamethasone	Tinea corporis (disorder)	C0040252		Approved			C0005308	Bétaméthasone
Betamethasone	Granuloma Annulare	C0085074		Approved			C0005308	Bétaméthasone
Betamethasone	Berylliosis	C0005138		Approved			C0005308	Bétaméthasone
Betamethasone	Ankylosing spondylitis	C0038013		Approved			C0005308	Bétaméthasone
Betamethasone	Adrenogenital disorder	C0701163		Approved			C0005308	Bétaméthasone
Betamethasone	Musculoskeletal Diseases	C0026857		Approved			C0005308	Bétaméthasone
Betamethasone	Thyroiditis	C0040147		Approved			C0005308	Bétaméthasone
Betamethasone	Lymphoma, Non-Hodgkin	C0024305		Approved			C0005308	Bétaméthasone
Betamethasone	Exanthema	C0015230		Approved			C0005308	Bétaméthasone
Betamethasone	Tenosynovitis	C0039520		Approved			C0005308	Bétaméthasone
Betamethasone	Pruritus of genital organs	C0033777		Approved			C0005308	Bétaméthasone
Teniposide	Acute lymphocytic leukemia	C0023449		Approved			C0039512	Téniposide
Epirubicin	Breast Carcinoma	C0678222		Approved			C0014582	Epirubicinum
Chloramphenicol	Meningococcal meningitis	C0025294		Approved			C0008168	Cloranfenicol
Chloramphenicol	Streptococcal meningitis	C0154639		Approved			C0008168	Cloranfenicol
Chloramphenicol	Rickettsia Infections	C0035585		Approved			C0008168	Cloranfenicol
Chloramphenicol	Boutonneuse Fever	C0006060		Approved			C0008168	Cloranfenicol
Chloramphenicol	Typhoid Fever	C0041466		Approved			C0008168	Cloranfenicol
Chloramphenicol	Otitis Externa	C0029878		Approved			C0008168	Cloranfenicol
Chloramphenicol	Paratyphoid Fever	C0030528		Approved			C0008168	Cloranfenicol
Chloramphenicol	Salmonella infections	C0036117		Approved			C0008168	Cloranfenicol
Lansoprazole	Duodenal Ulcer	C0013295		Approved			C0050940	Lansoprazolum
Lansoprazole	Gastric ulcer	C0038358		Approved			C0050940	Lansoprazolum
Lansoprazole	Zollinger-Ellison syndrome	C0043515		Approved			C0050940	Lansoprazolum
Lansoprazole	Erosive esophagitis	C0267055		Approved			C0050940	Lansoprazolum
Lansoprazole	Gastroesophageal reflux disease	C0017168		Approved			C0050940	Lansoprazolum
Lansoprazole	Peptic Ulcer	C0030920		Approved			C0050940	Lansoprazolum
Dipivefrin	Glaucoma, Open-Angle	C0017612		Approved			C0058415	1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol
Levothyroxine	Myxedema	C0027145		Approved			C0040165	3,5,3',5'-Tetraiodo-L-thyronine
Levothyroxine	Malignant neoplasm of thyroid	C0007115		Approved			C0040165	3,5,3',5'-Tetraiodo-L-thyronine
Levothyroxine	Hyperlipidemia	C0020473		Approved			C0040165	3,5,3',5'-Tetraiodo-L-thyronine
Levothyroxine	Congenital Hypothyroidism	C0010308		Approved			C0040165	3,5,3',5'-Tetraiodo-L-thyronine
Levothyroxine	Hypothyroidism	C0020676		Approved			C0040165	3,5,3',5'-Tetraiodo-L-thyronine
Levothyroxine	Hashimoto Disease	C0677607		Approved			C0040165	3,5,3',5'-Tetraiodo-L-thyronine
Levothyroxine	Goiter	C0018021		Approved			C0040165	3,5,3',5'-Tetraiodo-L-thyronine
Pethidine	Severe pain	C0278140		Approved			C0025376	Meperidina
Pethidine	Pain	C0030193		Approved			C0025376	Meperidina
Pethidine	Labor Pain	C0474368		Approved			C0025376	Meperidina
Loratadine	Sneezing	C0037383		Approved			C0065180	Loratadina
Loratadine	Rhinorrhea	C1260880		Approved			C0065180	Loratadina
Loratadine	Rhinitis, Vasomotor	C0035460		Approved			C0065180	Loratadina
Loratadine	Hay fever	C0018621		Approved			C0065180	Loratadina
Loratadine	Nasal congestion (finding)	C0027424		Approved			C0065180	Loratadina
Loratadine	Common Cold	C0009443		Approved			C0065180	Loratadina
Loratadine	Allergic Conjunctivitis	C0009766		Approved			C0065180	Loratadina
Loratadine	Allergic rhinitis (disorder)	C2607914		Approved			C0065180	Loratadina
Loratadine	Chronic idiopathic urticaria	C0578870		Approved			C0065180	Loratadina
Cefalotin	Haemophilus influenzae pneumonia	C0276026		Approved			C0007735	Céfalotine
Cefalotin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007735	Céfalotine
Cefalotin	Infection of bone	C2242472		Approved			C0007735	Céfalotine
Cefalotin	Arthropathy associated with infection	C0157749		Approved			C0007735	Céfalotine
Cefalotin	Female genital tract infection	C1263758		Approved			C0007735	Céfalotine
Cefalotin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007735	Céfalotine
Cefalotin	Genitourinary tract infection	C1279247		Approved			C0007735	Céfalotine
Cefalotin	Pneumonia	C0032285		Approved			C0007735	Céfalotine
Cefalotin	Urinary tract infection	C0042029		Approved			C0007735	Céfalotine
Cefalotin	Lower respiratory tract infection	C0149725		Approved			C0007735	Céfalotine
Cefalotin	Bacterial sepsis	C0684256		Approved			C0007735	Céfalotine
Prazosin	Hypertensive disease	C0020538		Approved			C0032912	Prazosine
Imipramine	Depressive disorder	C0011581		Approved			C0020934	10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine
Imipramine	Bedwetting	C0270327		Approved			C0020934	10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine
Acitretin	Psoriasis	C0033860		Approved			C0050559	Acitretinum
Verteporfin	Choroidal retinal neovascularization	C0271066		Approved			C0387288	Verteporfinum
Verteporfin	Choroidal Neovascularization	C0600518		Approved			C0387288	Verteporfinum
Verteporfin	Ocular histoplasmosis syndrome	C1562543		Approved			C0387288	Verteporfinum
Verteporfin	Exudative age-related macular degeneration	C0271084		Approved			C0387288	Verteporfinum
Nabumetone	Degenerative polyarthritis	C0029408		Approved			C0068334	Nabumétone
Nabumetone	Rheumatoid Arthritis	C0003873		Approved			C0068334	Nabumétone
Methylscopolamine bromide	Coughing	C0010200		Approved			C0141756	Hyoscine methobromide
Methylscopolamine bromide	Peptic Ulcer	C0030920		Approved			C0141756	Hyoscine methobromide
Methylscopolamine bromide	Nasal congestion (finding)	C0027424		Approved			C0141756	Hyoscine methobromide
Methylscopolamine bromide	Common Cold	C0009443		Approved			C0141756	Hyoscine methobromide
Methylscopolamine bromide	Rhinorrhea	C1260880		Approved			C0141756	Hyoscine methobromide
Methylscopolamine bromide	Irritable Bowel Syndrome	C0022104		Approved			C0141756	Hyoscine methobromide
Methylscopolamine bromide	Allergic rhinitis (disorder)	C2607914		Approved			C0141756	Hyoscine methobromide
Methylscopolamine bromide	Rhinitis, Vasomotor	C0035460		Approved			C0141756	Hyoscine methobromide
Sodium Tetradecyl Sulfate	Varicosity	C0042345		Approved			C0037556	Tetradecilsulfato sodico
Ketorolac	Acute postoperative pain	C2215257		Approved			C0073631	Kétorolac
Ketorolac	Allergic Conjunctivitis	C0009766		Approved			C0073631	Kétorolac
Ketorolac	Severe pain	C0278140		Approved			C0073631	Kétorolac
Enoxacin	Acute gonococcal cervicitis	C0153195		Approved			C0014310	Enoxacina
Enoxacin	Gonorrhea	C0018081		Approved			C0014310	Enoxacina
Enoxacin	Acute gonococcal urethritis	C0275652		Approved			C0014310	Enoxacina
Enoxacin	Gonorrhea of rectum	C0275665		Approved			C0014310	Enoxacina
Enoxacin	Gonorrhea of pharynx	C0149966		Approved			C0014310	Enoxacina
Enoxacin	Urinary tract infection	C0042029		Approved			C0014310	Enoxacina
Quinine	Malaria, Falciparum	C0024535		Approved			C0034417	(R)-(-)-quinine
Tenoxicam	Arthritis	C0003864		Approved			C0076096	Tenoxicamum
Montelukast	Allergic rhinitis (disorder)	C2607914		Approved			C0298130	1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
Montelukast	Allergic asthma	C0155877		Approved			C0298130	1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
Montelukast	Intrinsic asthma	C0155880		Approved			C0298130	1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
Fluoxetine	Depressive disorder	C0011581		Approved			C0016365	Fluoxetina
Fluoxetine	Bulimia Nervosa	C2267227		Approved			C0016365	Fluoxetina
Fluoxetine	Obsessive-Compulsive Disorder	C0028768		Approved			C0016365	Fluoxetina
Fluoxetine	Major Depressive Disorder	C1269683		Approved			C0016365	Fluoxetina
Fluoxetine	Premenstrual Dysphoric Disorder	C0520676		Approved			C0016365	Fluoxetina
Fluoxetine	Panic Disorder	C0030319		Approved			C0016365	Fluoxetina
Fluoxetine	Depression, Bipolar	C0005587		Approved			C0016365	Fluoxetina
Chlordiazepoxide	Anxiety	C0003467		Approved			C0008188	Clordiazepóxido
Chlordiazepoxide	Severe anxiety (panic)	C0231403		Approved			C0008188	Clordiazepóxido
Chlordiazepoxide	Alcohol Withdrawal Delirium	C0001957		Approved			C0008188	Clordiazepóxido
Chlordiazepoxide	Peptic Ulcer	C0030920		Approved			C0008188	Clordiazepóxido
Chlordiazepoxide	Irritable Bowel Syndrome	C0022104		Approved			C0008188	Clordiazepóxido
Chlordiazepoxide	Mixed anxiety and depressive disorder	C0338908		Approved			C0008188	Clordiazepóxido
Chlordiazepoxide	Alcohol withdrawal syndrome	C0236663		Approved			C0008188	Clordiazepóxido
Duloxetine	Generalized Anxiety Disorder	C0270549		Approved			C0245561	Duloxetina
Duloxetine	Diabetic peripheral neuropathy	C0740447		Approved			C0245561	Duloxetina
Duloxetine	MUSCULOSKELETAL PAIN CHRONIC	C0746683		Approved			C0245561	Duloxetina
Duloxetine	Fibromyalgia	C0016053		Approved			C0245561	Duloxetina
Duloxetine	Major Depressive Disorder	C1269683		Approved			C0245561	Duloxetina
Duloxetine	Female stress incontinence	C0038437		Approved			C0245561	Duloxetina
Chlorpromazine	Schizophrenia	C0036341		Approved			C0008286	3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Chlorpromazine	Bipolar affective disorder, current episode manic	C0338873		Approved			C0008286	3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Chlorpromazine	Nausea and vomiting	C0027498		Approved			C0008286	3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Chlorpromazine	Acute intermittent porphyria	C0162565		Approved			C0008286	3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Chlorpromazine	Intractable hiccups	C0744896		Approved			C0008286	3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Chlorpromazine	Psychotic Disorders	C0033975		Approved			C0008286	3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Chlorpromazine	Disruptive Behavior Disorder	C0012734		Approved			C0008286	3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Rimantadine	Influenza due to Influenza A virus	C2711180		Approved			C0035629	alpha-Methyladamantanemethylamine
Amikacin	Enterobacteriaceae Infections	C0014347		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Diverticulitis of gastrointestinal tract	C0349774		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Infection due to Pseudomonas aeruginosa	C0276075		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Proteus septicemia	C0577690		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Escherichia coli septicemia	C0276088		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Neonatal pneumonia	C0339968		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Klebsiella sepsis	C0745528		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Nosocomial pneumonia	C0949083		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Meningitis, Bacterial	C0085437		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Infection of bone	C2242472		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Staphylococcal Pneumonia	C0032308		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Pseudomonas aeruginosa meningitis	C3665869		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Neonatal meningitis	C0456107		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Arthropathy associated with infection	C0157749		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Pneumonia, Bacterial	C0004626		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Rhinoscleroma	C0035468		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Cholangitis	C0008311		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Staphylococcal bacteraemia	C0152965		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Osteomyelitis	C0029443		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Pneumonia due to Pseudomonas	C0155860		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Intraabdominal Infections	C1112209		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Sepsis due to Pseudomonas	C2887096		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Meningitis due to Klebsiella mobilis	C1719906		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Pneumonia due to Escherichia coli	C0276089		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Staphylococcal meningitis	C0154640		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Serratia Infections	C0085394		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Escherichia coli Infections	C0014836		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Sepsis due to Gram negative bacteria	C3163829		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Proteus pneumonia	C1260917		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Proteus meningitis	C0338396		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Meningitis, Escherichia coli	C0338395		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Serratia sepsis	C0152973		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Sepsis of the newborn	C0456103		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Bacterial meningitis due to Gram-negative bacteria	C0854215		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Pneumonia due to Gram negative bacteria	C0854248		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Enterobacter pneumonia	C1096258		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Amikacin	Bacterial sepsis	C0684256		Approved			C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Lenalidomide	Multiple Myeloma	C0026764		Approved			C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Lenalidomide	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634		Approved			C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Raloxifene	Osteoporosis, Postmenopausal	C0029458		Approved			C0244404	Raloxifène
Celecoxib	Acute postoperative pain	C2215257		Approved			C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Celecoxib	Dysmenorrhea	C0013390		Approved			C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Celecoxib	Rheumatoid Arthritis	C0003873		Approved			C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Celecoxib	Ankylosing spondylitis	C0038013		Approved			C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Celecoxib	Degenerative polyarthritis	C0029408		Approved			C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Brimonidine	Glaucoma, Open-Angle	C0017612		Approved			C0525227	Brimonidina
Brimonidine	Ocular Hypertension	C0028840		Approved			C0525227	Brimonidina
Dicloxacillin	Staphylococcal Pneumonia	C0032308		Approved			C0012093	Dicloxacillina
Dicloxacillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0012093	Dicloxacillina
Dicloxacillin	Staphylococcus aureus infection	C1318973		Approved			C0012093	Dicloxacillina
Altretamine	Malignant neoplasm of ovary	C1140680		Approved			C0019453	2,4,6-tris(dimethylamino)-s-triazine
Buspirone	Generalized Anxiety Disorder	C0270549		Approved			C0006462	Buspirona
Miglitol	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0066535	Miglitolum
Fosinopril	Chronic heart failure	C0264716		Approved			C0118168	Fosenopril
Fosinopril	Hypertensive disease	C0020538		Approved			C0118168	Fosenopril
Cefotaxime	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Ophthalmia Neonatorum	C0029076		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Neonatal meningitis	C0456107		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Streptococcal meningitis	C0154639		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Infection of bone	C2242472		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Intraabdominal Infections	C1112209		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Haemophilus influenzae type b infection	C2028293		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Haemophilus influenzae pneumonia	C0276026		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Pneumonia due to Pseudomonas	C0155860		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Proteus urinary tract infection	C0577709		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Klebsiella cystitis	C0520775		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Serratia sepsis	C0152973		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Sepsis of the newborn	C0456103		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Meningitis, Bacterial	C0085437		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Serratia Infections	C0085394		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Bacterial urinary infection	C0729524		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Escherichia coli septicemia	C0276088		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Female genital tract infection	C1263758		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Peritonitis	C0031154		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Staphylococcal Pneumonia	C0032308		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Bacterial sepsis	C0684256		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Proteus pneumonia	C1260917		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Meningitis due to Klebsiella mobilis	C1719906		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Escherichia coli urinary tract infection	C0577708		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Enterobacter pneumonia	C1096258		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Arthritis, Bacterial	C1692886		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Lower respiratory tract infection	C0149725		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	URINARY TRACT INFECTION CITROBACTER	C0749955		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Meningitis, Escherichia coli	C0338395		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Pneumonia, Bacterial	C0004626		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Neonatal pneumonia	C0339968		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Streptococcal sepsis	C0152964		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Meningococcal meningitis	C0025294		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxime	Pneumonia due to Escherichia coli	C0276089		Approved			C0007554	(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Entacapone	Parkinson Disease	C0030567		Approved			C0165921	(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
Zidovudine	HIV Infections	C0019693		Approved			C0043474	Zidovudinum
Darifenacin	Bladder muscle dysfunction - overactive	C0403643		Approved			C0529351	(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamide
Darifenacin	Urge Incontinence	C0150045		Approved			C0529351	(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamide
Darifenacin	Urgency of micturition	C0085606		Approved			C0529351	(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamide
Darifenacin	Increased frequency of micturition	C0042023		Approved			C0529351	(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamide
Oxycodone	Acute postoperative pain	C2215257		Approved			C0030049	Oxycodonum
Oxycodone	Severe pain	C0278140		Approved			C0030049	Oxycodonum
Flutamide	Prostatic Neoplasms	C0033578		Approved			C0016384	4'-nitro-3'-trifluoromethylisobutyranilide
Tolmetin	Degenerative polyarthritis	C0029408		Approved			C0040377	Tolmetina
Tolmetin	Rheumatoid Arthritis	C0003873		Approved			C0040377	Tolmetina
Cimetidine	Duodenal Ulcer	C0013295		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Upper gastrointestinal hemorrhage	C0041909		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Dyspepsia	C0013395		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Gastroesophageal reflux disease	C0017168		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Zollinger-Ellison syndrome	C0043515		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Heartburn	C0018834		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Mastocytosis, Systemic	C0221013		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Multiple Endocrine Neoplasia	C0027662		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Cimetidine	Gastric ulcer	C0038358		Approved			C0008783	N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
Haloperidol	Chronic schizophrenia	C0221765		Approved			C0018546	4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
Haloperidol	Gilles de la Tourette syndrome	C0040517		Approved			C0018546	4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
Haloperidol	Schizophrenia	C0036341		Approved			C0018546	4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
Haloperidol	Psychotic Disorders	C0033975		Approved			C0018546	4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
Ritonavir	HIV Infections	C0019693		Approved			C0292818	Ritonavirum
Ritonavir	Hepatitis C, Chronic	C0524910		Approved			C0292818	Ritonavirum
Nitazoxanide	Giardiasis	C0017536		Approved			C0068788	Nitazoxanida
Nitazoxanide	Cryptosporidiosis	C0010418		Approved			C0068788	Nitazoxanida
Triflupromazine	Psychotic Disorders	C0033975		Approved			C0040989	Triflupromazin
Triflupromazine	Nausea	C0027497		Approved			C0040989	Triflupromazin
Triflupromazine	Vomiting	C0042963		Approved			C0040989	Triflupromazin
Triflupromazine	Nausea and vomiting	C0027498		Approved			C0040989	Triflupromazin
Dextrothyroxine	Hyperlipidemia	C0020473		Approved			C0011824	O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine
Vancomycin	Bacterial Endocarditis	C0014121		Approved			C0042313	Vancomycine
Vancomycin	Neonatal pneumonia	C0339968		Approved			C0042313	Vancomycine
Vancomycin	Bacterial sepsis	C0684256		Approved			C0042313	Vancomycine
Vancomycin	Staphylococcal Pneumonia	C0032308		Approved			C0042313	Vancomycine
Vancomycin	Sepsis of the newborn	C0456103		Approved			C0042313	Vancomycine
Vancomycin	Staphylococcus aureus infection	C1318973		Approved			C0042313	Vancomycine
Vancomycin	Streptococcal endocarditis	C3665800		Approved			C0042313	Vancomycine
Vancomycin	Staphylococcal bacteraemia	C0152965		Approved			C0042313	Vancomycine
Vancomycin	Staphylococcal Infections	C0038160		Approved			C0042313	Vancomycine
Vancomycin	Enterocolitis, Pseudomembranous	C0014358		Approved			C0042313	Vancomycine
Vancomycin	Staphylococcal enterocolitis	C0038157		Approved			C0042313	Vancomycine
Vancomycin	Infection of bone	C2242472		Approved			C0042313	Vancomycine
Vancomycin	Arthropathy associated with infection	C0157749		Approved			C0042313	Vancomycine
Vancomycin	Staphylococcal endocarditis	C0520767		Approved			C0042313	Vancomycine
Vancomycin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0042313	Vancomycine
Dextromethorphan	Sneezing	C0037383		Approved			C0011816	Dextromethorfan
Dextromethorphan	Mouth irritation	C0235339		Approved			C0011816	Dextromethorfan
Dextromethorphan	Headache Disorders	C0393735		Approved			C0011816	Dextromethorfan
Dextromethorphan	Influenza-like symptoms	C0392171		Approved			C0011816	Dextromethorfan
Dextromethorphan	Pseudobulbar affect	C2316460		Approved			C0011816	Dextromethorfan
Dextromethorphan	Allergic rhinitis (disorder)	C2607914		Approved			C0011816	Dextromethorfan
Dextromethorphan	Rhinitis, Vasomotor	C0035460		Approved			C0011816	Dextromethorfan
Dextromethorphan	Coughing	C0010200		Approved			C0011816	Dextromethorfan
Dextromethorphan	Common Cold	C0009443		Approved			C0011816	Dextromethorfan
Dextromethorphan	Fever	C0015967		Approved			C0011816	Dextromethorfan
Dextromethorphan	Sore Throat	C0242429		Approved			C0011816	Dextromethorfan
Dextromethorphan	Rhinorrhea	C1260880		Approved			C0011816	Dextromethorfan
Dextromethorphan	Nasal congestion (finding)	C0027424		Approved			C0011816	Dextromethorfan
Dextromethorphan	Rhinitis	C0035455		Approved			C0011816	Dextromethorfan
Cisplatin	Malignant neoplasm of ovary	C1140680		Approved			C0008838	cisplatino
Cisplatin	Testicular Germ Cell Tumor	C1336708		Approved			C0008838	cisplatino
Anisotropine Methylbromide	Gastric ulcer	C0038358		Approved			C0051923	Metilbromuro de octatropina
Anisotropine Methylbromide	Peptic Ulcer	C0030920		Approved			C0051923	Metilbromuro de octatropina
Albendazole	Echinococcus granulosus infection of liver	C0153289		Approved			C0001911	5-(propylthio)-2-carbomethoxyaminobenzimidazole
Albendazole	Echinococcus granulosus infection of lung	C0153290		Approved			C0001911	5-(propylthio)-2-carbomethoxyaminobenzimidazole
Albendazole	Neurocysticercosis	C0338437		Approved			C0001911	5-(propylthio)-2-carbomethoxyaminobenzimidazole
Albendazole	Echinococcus granulosus infection	C0152068		Approved			C0001911	5-(propylthio)-2-carbomethoxyaminobenzimidazole
Trandolapril	Chronic heart failure	C0264716		Approved			C0076891	Trandolaprilum
Trandolapril	Hypertensive disease	C0020538		Approved			C0076891	Trandolaprilum
Caspofungin	candidal peritonitis	C2062982		Approved			C0537894	(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
Caspofungin	Candidiasis of the esophagus	C0239295		Approved			C0537894	(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
Caspofungin	Candidemia	C0877445		Approved			C0537894	(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
Carteolol	Glaucoma, Open-Angle	C0017612		Approved			C0007299	Cartéolol
Carteolol	Hypertensive disease	C0020538		Approved			C0007299	Cartéolol
Carteolol	Ocular Hypertension	C0028840		Approved			C0007299	Cartéolol
Metolazone	Hypertensive disease	C0020538		Approved			C0025854	2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
Metolazone	Renal disease with edema NOS	C0866125		Approved			C0025854	2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
Tolnaftate	Tinea cruris	C1384589		Approved			C0040379	N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
Tolnaftate	Tinea manus	C0153246		Approved			C0040379	N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
Tolnaftate	Tinea Versicolor	C0040262		Approved			C0040379	N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
Tolnaftate	Tinea corporis (disorder)	C0040252		Approved			C0040379	N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
Tolnaftate	Tinea Capitis	C0040250		Approved			C0040379	N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
Tolnaftate	Tinea Pedis	C0040259		Approved			C0040379	N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
Tolnaftate	Tinea barbae	C2349994		Approved			C0040379	N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
Oxaliplatin	Metastasis from malignant tumor of colon	C1282500		Approved			C0069717	oxaliplatine
Cinchocaine	Skin irritation	C0152030		Approved			C0012050	2-butoxy-N-(α-diethylaminoethyl)cinchoninamide
Cinchocaine	Pruritus	C0033774		Approved			C0012050	2-butoxy-N-(α-diethylaminoethyl)cinchoninamide
Lercanidipine	Hypertensive disease	C0020538		Approved			C0526399	Lercanidipino
Erlotinib	Non-Small Cell Lung Carcinoma	C0007131		Approved			C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	Adenocarcinoma of pancreas	C0281361		Approved			C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Cyclophosphamide	Lymphoma	C0024299		Approved			C0010583	Cyclophosphamidum
Cyclophosphamide	Multiple Myeloma	C0026764		Approved			C0010583	Cyclophosphamidum
Cyclophosphamide	Mycosis Fungoides	C0026948		Approved			C0010583	Cyclophosphamidum
Cyclophosphamide	Neuroblastoma	C0027819		Approved			C0010583	Cyclophosphamidum
Cyclophosphamide	Retinoblastoma	C0035335		Approved			C0010583	Cyclophosphamidum
Cefdinir	Moraxella catarrhalis pneumonia	C0857831		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir	Streptococcus pyogenes infection	C0554628		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir	Haemophilus influenzae pneumonia	C0276026		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir	Streptococcal tonsillitis	C0275804		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir	Staphylococcus aureus infection	C1318973		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefdinir	Infective otitis media	C0729586		Approved			C0060405	(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Guanidine	Lambert-Eaton Myasthenic Syndrome	C0022972		Approved			C0120446	Iminourea
Ciprofloxacin	Acute gonococcal urethritis	C0275652		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Infective otitis externa	C0021355		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Enterobacteriaceae Infections	C0014347		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Escherichia coli septicemia	C0276088		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Typhoid Fever	C0041466		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Bacterial conjunctivitis	C0009768		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Streptococcus pyogenes infection	C0554628		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Pneumonia due to Pseudomonas	C0155860		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Staphylococcus aureus infection	C1318973		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Infection of bone	C2242472		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Anthrax disease	C0003175		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Pneumonia, Bacterial	C0004626		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Infective cystitis	C0600041		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Enterobacter pneumonia	C1096258		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Rhinoscleroma	C0035468		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Nosocomial pneumonia	C0949083		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Arthropathy associated with infection	C0157749		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	URINARY TRACT INFECTION CITROBACTER	C0749955		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Acute gonococcal cervicitis	C0153195		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Chancroids	C0007947		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Escherichia coli urinary tract infection	C0577708		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Cystitis	C0010692		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Traveler's diarrhea	C0277528		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Acute osteomyelitis	C0158371		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	prostatitis	C0033581		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Proteus urinary tract infection	C0577709		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Lower respiratory tract infection	C0149725		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Bacterial urinary infection	C0729524		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Cystitis escherichia	C0853852		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Klebsiella cystitis	C0520775		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Escherichia coli Infections	C0014836		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Intraabdominal Infections	C1112209		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Abdominal Abscess	C0243001		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Chronic Bacterial Prostatitis	C1720797		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Shigella Infections	C0013371		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Acute maxillary sinusitis	C0155804		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Pneumonia due to Escherichia coli	C0276089		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Otitis Externa	C0029878		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	PYELONEPHRITIS E COLI	C0748196		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Proteus pneumonia	C1260917		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacin	Enteric campylobacteriosis	C0275982		Approved			C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Toremifene	Carcinoma breast stage IV	C0278488		Approved			C0076836	Toremifeno
Nortriptyline	Depressive disorder	C0011581		Approved			C0028420	10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine
Vincristine	Rhabdomyosarcoma	C0035412		Approved			C0042679	Vincristina
Vincristine	Nephroblastoma	C0027708		Approved			C0042679	Vincristina
Vincristine	Lymphoma, Follicular	C0024301		Approved			C0042679	Vincristina
Vincristine	Acute lymphocytic leukemia	C0023449		Approved			C0042679	Vincristina
Vincristine	Diffuse Large B-Cell Lymphoma	C0079744		Approved			C0042679	Vincristina
Vincristine	Burkitt Lymphoma	C0006413		Approved			C0042679	Vincristina
Vincristine	Hodgkin Disease	C0019829		Approved			C0042679	Vincristina
Vincristine	Neuroblastoma	C0027819		Approved			C0042679	Vincristina
Vincristine	Lymphoma, Non-Hodgkin	C0024305		Approved			C0042679	Vincristina
Benazepril	Hypertensive disease	C0020538		Approved			C0053091	Bénazépril
Amoxapine	Depressive disorder	C0011581		Approved			C0002644	2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine
Fluorouracil	Adenocarcinoma of pancreas	C0281361		Approved			C0016360	Fluorouracilum
Fluorouracil	Malignant tumor of colon	C0007102		Approved			C0016360	Fluorouracilum
Fluorouracil	Superficial basal cell carcinoma	C0862889		Approved			C0016360	Fluorouracilum
Fluorouracil	Metastasis from malignant tumor of colon	C1282500		Approved			C0016360	Fluorouracilum
Fluorouracil	Actinic keratosis	C0022602		Approved			C0016360	Fluorouracilum
Fluorouracil	Carcinoma breast stage IV	C0278488		Approved			C0016360	Fluorouracilum
Fluorouracil	Malignant neoplasm of stomach	C0024623		Approved			C0016360	Fluorouracilum
Pyridostigmine	Myasthenia Gravis	C0026896		Approved			C0034261	Piridostigmina
Desoximetasone	Chronic small plaque psoriasis	C0406317		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Pruritus of genital organs	C0033777		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Contact Dermatitis	C0011616		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Granuloma Annulare	C0085074		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Exanthema	C0015230		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Seborrheic dermatitis	C0036508		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Pruritus Ani	C0033775		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Scalp psoriasis	C0406326		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Lupus Erythematosus, Discoid	C0024138		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Dermatitis, Atopic	C0011615		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetasone	Lichen Simplex Chronicus	C0149922		Approved			C0011707	9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
Azelaic Acid	Acne Vulgaris	C0001144		Approved			C0052761	Nonandisäure
Zafirlukast	Asthma	C0004096		Approved			C0378466	4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide
Propylthiouracil	Thyroid Crisis	C0040127		Approved			C0033511	6-propyl-2-thiouracil
Propylthiouracil	Hyperthyroidism	C0020550		Approved			C0033511	6-propyl-2-thiouracil
Acetohydroxamic Acid	Urinary tract infection	C0042029		Approved			C0050451	Acetyl hydroxyamino
Pentostatin	Hairy Cell Leukemia	C0023443		Approved			C0030896	Pentostatine
Methoxsalen	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0025684	9-methoxy-7H-furo[3,2-g][1]benzopyran-7-one
Methoxsalen	Vitiligo	C0042900		Approved			C0025684	9-methoxy-7H-furo[3,2-g][1]benzopyran-7-one
Piroxicam	Degenerative polyarthritis	C0029408		Approved			C0031990	4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
Piroxicam	Rheumatoid Arthritis	C0003873		Approved			C0031990	4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
Lamotrigine	Epilepsy	C0014544		Approved			C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Lamotrigine	Lennox-Gastaut syndrome	C0238111		Approved			C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Lamotrigine	Simple Partial Seizures	C0234974		Approved			C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Lamotrigine	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Lamotrigine	Tonic - clonic seizures	C0494475		Approved			C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Lamotrigine	Bipolar disorder in remission	C0270425		Approved			C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Hydroxyzine	Allergic Conjunctivitis	C0009766		Approved			C0020404	Idrossizina
Hydroxyzine	Rhinorrhea	C1260880		Approved			C0020404	Idrossizina
Hydroxyzine	Urticaria	C0042109		Approved			C0020404	Idrossizina
Hydroxyzine	Symptomatic dermographism	C0343065		Approved			C0020404	Idrossizina
Hydroxyzine	Pruritus	C0033774		Approved			C0020404	Idrossizina
Hydroxyzine	Dermatitis, Atopic	C0011615		Approved			C0020404	Idrossizina
Hydroxyzine	Allergic rhinitis (disorder)	C2607914		Approved			C0020404	Idrossizina
Zanamivir	Influenza	C0021400		Approved			C0216660	5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Bosentan	Pulmonary arterial hypertension	C2973725		Approved			C2825457	bosentan anhydrous
Bosentan	Pulmonary Hypertension	C0020542		Approved			C2825457	bosentan anhydrous
Bosentan	Scleroderma	C0011644		Approved			C2825457	bosentan anhydrous
Tigecycline	Complicated appendicitis	C1632842		Approved			C1260298	(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Tigecycline	Haemophilus influenzae pneumonia	C0276026		Approved			C1260298	(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Tigecycline	Abdominal Abscess	C0243001		Approved			C1260298	(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Tigecycline	Intraabdominal Infections	C1112209		Approved			C1260298	(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Tigecycline	Legionella pneumophila pneumonia	C0857846		Approved			C1260298	(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Doxapram	Respiratory Depression	C0235063		Approved			C0013084	1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone
Methotrexate	Psoriasis	C0033860		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Malignant epithelial neoplasm of female breast	C3163805		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Cancer of Head and Neck	C0278996		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Gestational Trophoblastic Neoplasms	C1135868		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Mycosis Fungoides	C0026948		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Lymphoma, Non-Hodgkin	C0024305		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Meningeal Leukemia	C0948840		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Acute lymphocytic leukemia	C0023449		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Malignant neoplasm of lung	C0242379		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Burkitt Lymphoma	C0006413		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Rheumatoid Arthritis	C0003873		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Osteosarcoma of bone	C0585442		Approved			C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Carbamazepine	Epilepsy	C0014544		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Tonic - clonic seizures	C0494475		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Simple Partial Seizures	C0234974		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Lennox-Gastaut syndrome	C0238111		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Glossopharyngeal Neuralgia	C0154731		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Mixed bipolar I disorder	C0236780		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Tonic-Clonic Epilepsy	C0014549		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Bipolar affective disorder, current episode manic	C0338873		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Bipolar disorder in remission	C0270425		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Epilepsies, Partial	C0014547		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	mixed; epileptic	C1398376		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Carbamazepine	Trigeminal Neuralgia	C0040997		Approved			C0006949	5-carbamoyl-5H-dibenz[b,f]azepine
Succimer	Accidental poisoning by lead and its compounds and fumes	C0261486		Approved			C0012384	succimero
Cephalexin	Infective otitis media	C0729586		Approved			C0007716	Cefalexina
Cephalexin	prostatitis	C0033581		Approved			C0007716	Cefalexina
Cephalexin	Klebsiella cystitis	C0520775		Approved			C0007716	Cefalexina
Cephalexin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007716	Cefalexina
Cephalexin	Arthropathy associated with infection	C0157749		Approved			C0007716	Cefalexina
Cephalexin	Acute otitis media	C0271429		Approved			C0007716	Cefalexina
Cephalexin	Streptococcus pyogenes infection	C0554628		Approved			C0007716	Cefalexina
Cephalexin	Proteus urinary tract infection	C0577709		Approved			C0007716	Cefalexina
Cephalexin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007716	Cefalexina
Cephalexin	Streptococcal tonsillitis	C0275804		Approved			C0007716	Cefalexina
Cephalexin	Infection of bone	C2242472		Approved			C0007716	Cefalexina
Cephalexin	Escherichia coli urinary tract infection	C0577708		Approved			C0007716	Cefalexina
Cephalexin	Staphylococcus aureus infection	C1318973		Approved			C0007716	Cefalexina
Cinnarizine	Vertigo	C0042571		Approved			C0008803	Cinarizina
Cinnarizine	Nausea	C0027497		Approved			C0008803	Cinarizina
Cinnarizine	Motion Sickness	C0026603		Approved			C0008803	Cinarizina
Fondaparinux sodium	Pulmonary Thromboembolisms	C0524702		Approved			C1098510	Natural heparin pentasaccharide
Fondaparinux sodium	Deep Vein Thrombosis	C0149871		Approved			C1098510	Natural heparin pentasaccharide
Vinblastine	Gestational Trophoblastic Neoplasms	C1135868		Approved			C0042670	Vinblastina
Vinblastine	Hodgkin Disease	C0019829		Approved			C0042670	Vinblastina
Vinblastine	Carcinoma breast stage IV	C0278488		Approved			C0042670	Vinblastina
Vinblastine	Letterer-Siwe Disease	C0023381		Approved			C0042670	Vinblastina
Vinblastine	Malignant neoplasm of testis	C0153594		Approved			C0042670	Vinblastina
Vinblastine	Lymphoma, Non-Hodgkin	C0024305		Approved			C0042670	Vinblastina
Vinblastine	Mycosis Fungoides	C0026948		Approved			C0042670	Vinblastina
Vinblastine	Kaposi Sarcoma	C0036220		Approved			C0042670	Vinblastina
Vinblastine	Malignant epithelial neoplasm of female breast	C3163805		Approved			C0042670	Vinblastina
Propranolol	Idiopathic hypertrophic subaortic stenosis	C0700053		Approved			C0033497	Propranololum
Propranolol	Atrial Fibrillation	C0004238		Approved			C0033497	Propranololum
Propranolol	Supraventricular tachycardia	C0039240		Approved			C0033497	Propranololum
Propranolol	Angina Pectoris	C0002962		Approved			C0033497	Propranololum
Propranolol	Hypertrophic Cardiomyopathy	C0007194		Approved			C0033497	Propranololum
Propranolol	Hypertensive disease	C0020538		Approved			C0033497	Propranololum
Propranolol	Hemangioma	C0018916		Approved			C0033497	Propranololum
Fenoprofen	Rheumatoid Arthritis	C0003873		Approved			C0015837	α-methyl-3-phenoxybenzeneacetic acid
Fenoprofen	Degenerative polyarthritis	C0029408		Approved			C0015837	α-methyl-3-phenoxybenzeneacetic acid
Fenoprofen	Pain	C0030193		Approved			C0015837	α-methyl-3-phenoxybenzeneacetic acid
Clonidine	Glaucoma, Open-Angle	C0017612		Approved			C0009014	2-((2,6-Dichlorophenyl)imino)imidazolidine
Clonidine	Attention deficit hyperactivity disorder	C1263846		Approved			C0009014	2-((2,6-Dichlorophenyl)imino)imidazolidine
Clonidine	Hypertensive disease	C0020538		Approved			C0009014	2-((2,6-Dichlorophenyl)imino)imidazolidine
Clonidine	Severe pain	C0278140		Approved			C0009014	2-((2,6-Dichlorophenyl)imino)imidazolidine
Sulfamethizole	Proteus urinary tract infection	C0577709		Approved			C0038687	Sulfametizol
Sulfamethizole	Klebsiella cystitis	C0520775		Approved			C0038687	Sulfametizol
Sulfamethizole	Escherichia coli urinary tract infection	C0577708		Approved			C0038687	Sulfametizol
Sulfamethizole	Bacterial urinary infection	C0729524		Approved			C0038687	Sulfametizol
Sulfamethizole	Infective otitis media	C0729586		Approved			C0038687	Sulfametizol
Sulfamethizole	Acute otitis media	C0271429		Approved			C0038687	Sulfametizol
Sulfamethizole	Shigella Infections	C0013371		Approved			C0038687	Sulfametizol
Valaciclovir	Herpes zoster disease	C0019360		Approved			C0249458	Valaciclovirum
Valaciclovir	Recurrent genital herpes simplex	C1274323		Approved			C0249458	Valaciclovirum
Valaciclovir	Herpes Labialis	C0019345		Approved			C0249458	Valaciclovirum
Valaciclovir	Chickenpox	C0008049		Approved			C0249458	Valaciclovirum
Valaciclovir	Genital Herpes	C0019342		Approved			C0249458	Valaciclovirum
Carbenicillin	prostatitis	C0033581		Approved			C0006976	α-carboxybenzylpencillin
Carbenicillin	Escherichia coli urinary tract infection	C0577708		Approved			C0006976	α-carboxybenzylpencillin
Carbenicillin	Proteus urinary tract infection	C0577709		Approved			C0006976	α-carboxybenzylpencillin
Carbenicillin	Urinary tract infection	C0042029		Approved			C0006976	α-carboxybenzylpencillin
Carbenicillin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0006976	α-carboxybenzylpencillin
Carbenicillin	Bacterial urinary infection	C0729524		Approved			C0006976	α-carboxybenzylpencillin
Mazindol	Obesity	C0028754		Approved			C0024977	Mazindolum
Lactulose	Hepatic Encephalopathy	C0019151		Approved			C0022957	Lactulosum
Lactulose	Hyperammonemia	C0220994		Approved			C0022957	Lactulosum
Lactulose	Constipation	C0009806		Approved			C0022957	Lactulosum
Voriconazole	Fusariosis	C0276758		Approved			C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Voriconazole	Systemic candidiasis	C0153252		Approved			C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Voriconazole	Candidiasis of the esophagus	C0239295		Approved			C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Voriconazole	Invasive Pulmonary Aspergillosis	C0276653		Approved			C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Voriconazole	Candidemia	C0877445		Approved			C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
L-Carnitine	Carnitine deficiency	C1142132		Approved			C0087163	Levocarnitine
Enalapril	Asymptomatic left ventricular systolic dysfunction	C3698411		Approved			C0014025	1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Enalapril	Hypertensive disease	C0020538		Approved			C0014025	1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Enalapril	Congestive heart failure	C0018802		Approved			C0014025	1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Nizatidine	Erosive esophagitis	C0267055		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Nizatidine	Peptic Esophagitis	C0014869		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Nizatidine	Dyspepsia	C0013395		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Nizatidine	Duodenal Ulcer	C0013295		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Nizatidine	Peptic Ulcer	C0030920		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Nizatidine	Heartburn	C0018834		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Nizatidine	Gastroesophageal reflux disease	C0017168		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Nizatidine	Gastric ulcer	C0038358		Approved			C0085154	N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine
Diclofenac	Degenerative polyarthritis	C0029408		Approved			C0012091	Diclofenac acid
Diclofenac	Actinic keratosis	C0022602		Approved			C0012091	Diclofenac acid
Diclofenac	Osteoarthritis, Knee	C0409959		Approved			C0012091	Diclofenac acid
Diclofenac	Rheumatoid Arthritis	C0003873		Approved			C0012091	Diclofenac acid
Diclofenac	Dysmenorrhea	C0013390		Approved			C0012091	Diclofenac acid
Diclofenac	Sprains and Strains	C0038048		Approved			C0012091	Diclofenac acid
Diclofenac	Ankylosing spondylitis	C0038013		Approved			C0012091	Diclofenac acid
Diclofenac	Pain	C0030193		Approved			C0012091	Diclofenac acid
Fluticasone Propionate	Seborrheic dermatitis	C0036508		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Pruritus of genital organs	C0033777		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Exanthema	C0015230		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Allergic rhinitis (disorder)	C2607914		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Allergic asthma	C0155877		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Granuloma Annulare	C0085074		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Chronic small plaque psoriasis	C0406317		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Lichen Simplex Chronicus	C0149922		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Intrinsic asthma	C0155880		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Scalp psoriasis	C0406326		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Lupus Erythematosus, Discoid	C0024138		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Pruritus Ani	C0033775		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Contact Dermatitis	C0011616		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Pulmonary Emphysema	C0034067		Approved			C0117996	Fluticasone propionate
Fluticasone Propionate	Dermatitis, Atopic	C0011615		Approved			C0117996	Fluticasone propionate
Lisuride	Migraine Disorders	C0149931		Approved			C0023863	N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea
Lisuride	Amenorrhea	C0002453		Approved			C0023863	N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea
Lisuride	Acromegaly	C0001206		Approved			C0023863	N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea
Doxazosin	Hypertensive disease	C0020538		Approved			C0114873	Doxazosine
Doxazosin	Prostatic Hypertrophy	C1739363		Approved			C0114873	Doxazosine
Fluocinolone Acetonide	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Exanthema	C0015230		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Pruritus Ani	C0033775		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Lupus Erythematosus, Discoid	C0024138		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Contact Dermatitis	C0011616		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Lichen Simplex Chronicus	C0149922		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Granuloma Annulare	C0085074		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Chloasma	C0025218		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Dermatitis, Atopic	C0011615		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Chronic small plaque psoriasis	C0406317		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Scalp psoriasis	C0406326		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Choroiditis	C0008526		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Seborrheic dermatitis	C0036508		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Pruritus of genital organs	C0033777		Approved			C0016298	Fluocinolone acetonide
Fluocinolone Acetonide	Scurfiness of scalp	C0423775		Approved			C0016298	Fluocinolone acetonide
Piperazine	Enterobiasis	C0086227		Approved			C0031957	Piperazina
Piperazine	Ascariasis	C0003950		Approved			C0031957	Piperazina
Ethosuximide	Absence Epilepsy	C0014553		Approved			C0015043	α-ethyl-α-methylsuccinimide
Amiloride	Edema	C0013604		Approved			C0002502	3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
Amiloride	Hypertensive disease	C0020538		Approved			C0002502	3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
Oxytetracycline	Bacterial keratitis	C0854211		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Rocky Mountain Spotted Fever	C0035793		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Lymphogranuloma Venereum	C0024286		Approved			C0030092	Ossitetraciclina
Oxytetracycline	TYPHUS	C0041471		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Acute gonococcal urethritis	C0275652		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Bacterial conjunctivitis	C0009768		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Brucellosis	C0006309		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Relapsing Fever	C0035021		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Actinomycosis	C0001261		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Chlamydia trachomatis infection of genital structure	C1997322		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Syphilis	C0039128		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Acute gonococcal cervicitis	C0153195		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Infective otitis media	C0729586		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Pharyngitis	C0031350		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Psittacosis	C0029291		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Trachoma	C0040592		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Gingivostomatitis	C0149704		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Bronchitis	C0006277		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Granuloma Inguinale	C0018190		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Sinusitis	C0037199		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Acute gonococcal epididymo-orchitis	C0153193		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Gonorrhea of rectum	C0275665		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Gonorrhea of pharynx	C0149966		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Acute gonococcal endometritis	C0153196		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Rickettsialpox	C0035597		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Pneumonia	C0032285		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Urinary tract infection	C0042029		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Q Fever	C0034362		Approved			C0030092	Ossitetraciclina
Oxytetracycline	Yaws	C0043388		Approved			C0030092	Ossitetraciclina
Ulobetasol	Granuloma Annulare	C0085074		Approved			C0082787	Ulobetasolum
Ulobetasol	Seborrheic dermatitis	C0036508		Approved			C0082787	Ulobetasolum
Ulobetasol	Lichen Simplex Chronicus	C0149922		Approved			C0082787	Ulobetasolum
Ulobetasol	Chronic small plaque psoriasis	C0406317		Approved			C0082787	Ulobetasolum
Ulobetasol	Scalp psoriasis	C0406326		Approved			C0082787	Ulobetasolum
Ulobetasol	Lupus Erythematosus, Discoid	C0024138		Approved			C0082787	Ulobetasolum
Ulobetasol	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0082787	Ulobetasolum
Ulobetasol	Pruritus of genital organs	C0033777		Approved			C0082787	Ulobetasolum
Ulobetasol	Contact Dermatitis	C0011616		Approved			C0082787	Ulobetasolum
Ulobetasol	Exanthema	C0015230		Approved			C0082787	Ulobetasolum
Ulobetasol	Pruritus Ani	C0033775		Approved			C0082787	Ulobetasolum
Labetalol	Hypertensive disease	C0020538		Approved			C0022860	Labétalol
Thiopental	Epilepsy	C0014544		Approved			C0039925	(±)-thiopental
Thiopental	Pseudotumor Cerebri	C0033845		Approved			C0039925	(±)-thiopental
Linezolid	Streptococcus pyogenes infection	C0554628		Approved			C0663241	Linezolidum
Linezolid	Staphylococcus aureus infection	C1318973		Approved			C0663241	Linezolidum
Linezolid	Staphylococcal Pneumonia	C0032308		Approved			C0663241	Linezolidum
Ivermectin	Onchocerciasis	C0029001		Approved			C0022322	Ivermectine
Ivermectin	Strongyloidiasis	C0038463		Approved			C0022322	Ivermectine
Medroxyprogesterone acetate	Secondary malignant neoplasm of kidney	C0153685		Approved			C0065864	6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
Medroxyprogesterone acetate	Metrorrhagia	C0025874		Approved			C0065864	6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
Medroxyprogesterone acetate	Endometriosis	C0014175		Approved			C0065864	6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
Medroxyprogesterone acetate	Endometrial Carcinoma	C0476089		Approved			C0065864	6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
Medroxyprogesterone acetate	Hot flushes	C0600142		Approved			C0065864	6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
Medroxyprogesterone acetate	Secondary physiologic amenorrhea	C0232940		Approved			C0065864	6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
Medroxyprogesterone acetate	Atrophic Vaginitis	C0221392		Approved			C0065864	6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
Cisapride	Gastroesophageal reflux disease	C0017168		Approved			C0072916	Cisaprid
Sulindac	Ankylosing spondylitis	C0038013		Approved			C0038792	Sulindacum
Sulindac	Rheumatoid Arthritis	C0003873		Approved			C0038792	Sulindacum
Sulindac	Degenerative polyarthritis	C0029408		Approved			C0038792	Sulindacum
Sulindac	Arthritis, Gouty	C0003868		Approved			C0038792	Sulindacum
Sulindac	Bursitis	C0006444		Approved			C0038792	Sulindacum
Sulindac	Tendinitis	C0039503		Approved			C0038792	Sulindacum
Nafcillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Staphylococcal meningitis	C0154640		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Staphylococcus aureus infection	C1318973		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Staphylococcal Pneumonia	C0032308		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Staphylococcal Infections	C0038160		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Infection of bone	C2242472		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Nafcillin	Staphylococcal endocarditis	C0520767		Approved			C0027324	(2-ethoxy-1-naphthyl)penicillin
Chloroquine	Quartan malaria	C0024536		Approved			C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Chloroquine	Rheumatoid Arthritis	C0003873		Approved			C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Chloroquine	Malaria, Falciparum	C0024535		Approved			C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Chloroquine	Lupus Erythematosus, Systemic	C0024141		Approved			C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Chloroquine	Lupus Erythematosus, Discoid	C0024138		Approved			C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Chloroquine	Ovale malaria	C0152072		Approved			C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Chloroquine	Malaria, Vivax	C0024537		Approved			C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Ethionamide	Acute tuberculosis	C0275959		Approved			C0015021	Etionamide
Ethionamide	Tuberculosis, Pulmonary	C0041327		Approved			C0015021	Etionamide
Butorphanol	Pain	C0030193		Approved			C0006491	(-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan
Butorphanol	Labor Pain	C0474368		Approved			C0006491	(-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan
Bisoprolol	Hypertensive disease	C0020538		Approved			C0053799	(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
Rifabutin	Pulmonary Mycobacterium avium complex infection	C2733595		Approved			C0140575	4-N-isobutylspiropiperidylrifamycin S
Paramethadione	Epilepsy	C0014544		Approved			C0070072	Parametadiona
Paramethadione	Absence Epilepsy	C0014553		Approved			C0070072	Parametadiona
Demeclocycline	Trachoma	C0040592		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Gonorrhea	C0018081		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Chancroids	C0007947		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Acute gonococcal urethritis	C0275652		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Sinusitis	C0037199		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Urinary tract infection	C0042029		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Infective otitis media	C0729586		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Acute gonococcal endometritis	C0153196		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Actinomycosis	C0001261		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Q Fever	C0034362		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Gonorrhea of pharynx	C0149966		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Yaws	C0043388		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Lymphogranuloma Venereum	C0024286		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Pharyngitis	C0031350		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Rocky Mountain Spotted Fever	C0035793		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Rickettsialpox	C0035597		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Brucellosis	C0006309		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Psittacosis	C0029291		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	TYPHUS	C0041471		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Gingivostomatitis	C0149704		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Gonorrhea of rectum	C0275665		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Syphilis	C0039128		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Acute gonococcal cervicitis	C0153195		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Klebsiella cystitis	C0520775		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Pneumonia	C0032285		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Staphylococcus aureus infection	C1318973		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Bronchitis	C0006277		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	pharyngitis due to Haemophilus influenzae	C2062475		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Relapsing Fever	C0035021		Approved			C0011276	7-chloro-6-demethyltetracycline
Demeclocycline	Granuloma Inguinale	C0018190		Approved			C0011276	7-chloro-6-demethyltetracycline
Imatinib	Leukemia, Myeloid, Accelerated Phase	C0023472		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Mastocytosis, Systemic	C0221013		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Leukemia, Myeloid, Chronic-Phase	C0023474		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Blast Phase	C0005699		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Chronic eosinophilic leukemia	C0346421		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Philadelphia chromosome-positive acute lymphoblastic leukemia	C1960397		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Dermatofibrosarcoma Protuberans	C0392784		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Idiopathic Hypereosinophilic Syndrome	C0206141		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Gastrointestinal Stromal Tumors	C0238198		Approved			C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Triamcinolone	Scalp psoriasis	C0406326		Approved			C0040864	Triamcinolonum
Triamcinolone	Tendinitis	C0039503		Approved			C0040864	Triamcinolonum
Triamcinolone	Lymphoma, Non-Hodgkin	C0024305		Approved			C0040864	Triamcinolonum
Triamcinolone	Inflammatory Bowel Diseases	C0021390		Approved			C0040864	Triamcinolonum
Triamcinolone	Giant Cell Arteritis	C0039483		Approved			C0040864	Triamcinolonum
Triamcinolone	Granuloma Annulare	C0085074		Approved			C0040864	Triamcinolonum
Triamcinolone	Uveitis	C0042164		Approved			C0040864	Triamcinolonum
Triamcinolone	Aphthous Stomatitis	C0038363		Approved			C0040864	Triamcinolonum
Triamcinolone	Keloid	C0022548		Approved			C0040864	Triamcinolonum
Triamcinolone	Cooley's anemia	C0002875		Approved			C0040864	Triamcinolonum
Triamcinolone	Gingival Diseases	C0017563		Approved			C0040864	Triamcinolonum
Triamcinolone	Status Asthmaticus	C0038218		Approved			C0040864	Triamcinolonum
Triamcinolone	Simple Pulmonary Eosinophilia	C0242459		Approved			C0040864	Triamcinolonum
Triamcinolone	Exanthema	C0015230		Approved			C0040864	Triamcinolonum
Triamcinolone	Erythema Multiforme	C0014742		Approved			C0040864	Triamcinolonum
Triamcinolone	Contact Dermatitis	C0011616		Approved			C0040864	Triamcinolonum
Triamcinolone	Arthritis, Gouty	C0003868		Approved			C0040864	Triamcinolonum
Triamcinolone	Autoimmune Diseases	C0004364		Approved			C0040864	Triamcinolonum
Triamcinolone	Post traumatic osteoarthritis	C2894027		Approved			C0040864	Triamcinolonum
Triamcinolone	Lichen Simplex Chronicus	C0149922		Approved			C0040864	Triamcinolonum
Triamcinolone	Laryngeal Edema	C0023052		Approved			C0040864	Triamcinolonum
Triamcinolone	Autoimmune hemolytic anemia	C0002880		Approved			C0040864	Triamcinolonum
Triamcinolone	Bursitis	C0006444		Approved			C0040864	Triamcinolonum
Triamcinolone	Exfoliative dermatitis	C0011606		Approved			C0040864	Triamcinolonum
Triamcinolone	Chronic small plaque psoriasis	C0406317		Approved			C0040864	Triamcinolonum
Triamcinolone	Crohn Disease	C0010346		Approved			C0040864	Triamcinolonum
Triamcinolone	Asthma	C0004096		Approved			C0040864	Triamcinolonum
Triamcinolone	Acute lymphocytic leukemia	C0023449		Approved			C0040864	Triamcinolonum
Triamcinolone	Adrenogenital disorder	C0701163		Approved			C0040864	Triamcinolonum
Triamcinolone	Disorder of eye	C0015397		Approved			C0040864	Triamcinolonum
Triamcinolone	Thyroiditis	C0040147		Approved			C0040864	Triamcinolonum
Triamcinolone	Pemphigus	C0030807		Approved			C0040864	Triamcinolonum
Triamcinolone	Aspiration pneumonitis	C1761609		Approved			C0040864	Triamcinolonum
Triamcinolone	Sarcoidosis	C0036202		Approved			C0040864	Triamcinolonum
Triamcinolone	Pruritus Ani	C0033775		Approved			C0040864	Triamcinolonum
Triamcinolone	Multiple Sclerosis	C0026769		Approved			C0040864	Triamcinolonum
Triamcinolone	Alopecia Areata	C0002171		Approved			C0040864	Triamcinolonum
Triamcinolone	Arthritis, Psoriatic	C0003872		Approved			C0040864	Triamcinolonum
Triamcinolone	Cutaneous Candidiasis	C0006846		Approved			C0040864	Triamcinolonum
Triamcinolone	Epicondylitis	C0014488		Approved			C0040864	Triamcinolonum
Triamcinolone	Trichinellosis	C0040896		Approved			C0040864	Triamcinolonum
Triamcinolone	Addisonian crisis	C0151467		Approved			C0040864	Triamcinolonum
Triamcinolone	Berylliosis	C0005138		Approved			C0040864	Triamcinolonum
Triamcinolone	Lichen Planus	C0023646		Approved			C0040864	Triamcinolonum
Triamcinolone	Ophthalmia, Sympathetic	C0029077		Approved			C0040864	Triamcinolonum
Triamcinolone	Acquired thrombocytopenia	C0154301		Approved			C0040864	Triamcinolonum
Triamcinolone	Mycosis Fungoides	C0026948		Approved			C0040864	Triamcinolonum
Triamcinolone	Synovitis	C0039103		Approved			C0040864	Triamcinolonum
Triamcinolone	Serum Sickness	C0036830		Approved			C0040864	Triamcinolonum
Triamcinolone	Dermatitis, Atopic	C0011615		Approved			C0040864	Triamcinolonum
Triamcinolone	Lupus Erythematosus, Systemic	C0024141		Approved			C0040864	Triamcinolonum
Triamcinolone	Allergic rhinitis (disorder)	C2607914		Approved			C0040864	Triamcinolonum
Triamcinolone	Nephrotic Syndrome	C0027726		Approved			C0040864	Triamcinolonum
Triamcinolone	Rheumatic Heart Disease	C0035439		Approved			C0040864	Triamcinolonum
Triamcinolone	Pruritus of genital organs	C0033777		Approved			C0040864	Triamcinolonum
Triamcinolone	Seborrheic dermatitis	C0036508		Approved			C0040864	Triamcinolonum
Triamcinolone	Tenosynovitis	C0039520		Approved			C0040864	Triamcinolonum
Triamcinolone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0040864	Triamcinolonum
Triamcinolone	Transplanted organ rejection	C0345468		Approved			C0040864	Triamcinolonum
Triamcinolone	Rheumatoid Arthritis	C0003873		Approved			C0040864	Triamcinolonum
Triamcinolone	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0040864	Triamcinolonum
Triamcinolone	Hodgkin Disease	C0019829		Approved			C0040864	Triamcinolonum
Triamcinolone	Dermatitis Herpetiformis	C0011608		Approved			C0040864	Triamcinolonum
Triamcinolone	Psoriasis	C0033860		Approved			C0040864	Triamcinolonum
Triamcinolone	Angioedema	C0002994		Approved			C0040864	Triamcinolonum
Triamcinolone	Lupus Erythematosus, Discoid	C0024138		Approved			C0040864	Triamcinolonum
Triamcinolone	Adrenal cortical hypofunction	C0405580		Approved			C0040864	Triamcinolonum
Triamcinolone	Ankylosing spondylitis	C0038013		Approved			C0040864	Triamcinolonum
Triamcinolone	Cerebral Edema	C0006114		Approved			C0040864	Triamcinolonum
Triamcinolone	Subacute bursitis	C1290159		Approved			C0040864	Triamcinolonum
Triamcinolone	Hay fever	C0018621		Approved			C0040864	Triamcinolonum
Triamcinolone	Tuberculosis, Miliary	C0041321		Approved			C0040864	Triamcinolonum
Triamcinolone	Dermatologic disorders	C0037274		Approved			C0040864	Triamcinolonum
Triamcinolone	Anemia, Diamond-Blackfan	C1260899		Approved			C0040864	Triamcinolonum
Triamcinolone	Addison Disease	C0001403		Approved			C0040864	Triamcinolonum
Triamcinolone	Congenital adrenal hyperplasia	C0001627		Approved			C0040864	Triamcinolonum
Triamcinolone	Musculoskeletal Diseases	C0026857		Approved			C0040864	Triamcinolonum
Triamcinolone	Lymphoma, Follicular	C0024301		Approved			C0040864	Triamcinolonum
Triamcinolone	Necrobiosis Lipoidica Diabeticorum	C0392445		Approved			C0040864	Triamcinolonum
Nicardipine	Hypertensive disease	C0020538		Approved			C0028005	Nicardipinum
Fluphenazine	Schizophrenia	C0036341		Approved			C0016368	10-(3'-(4''-(β-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
Fluphenazine	Psychotic Disorders	C0033975		Approved			C0016368	10-(3'-(4''-(β-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
Testosterone	Primary hypogonadism	C0948896		Approved			C0039601	Testostérone
Testosterone	Hypogonadotropic hypogonadism	C0271623		Approved			C0039601	Testostérone
Testosterone	Cryptorchidism	C0010417		Approved			C0039601	Testostérone
Testosterone	Klinefelter Syndrome	C0022735		Approved			C0039601	Testostérone
Testosterone	Delayed Puberty	C0034012		Approved			C0039601	Testostérone
Testosterone	Testicular hypogonadism	C0151721		Approved			C0039601	Testostérone
Testosterone	Deficiency of testosterone biosynthesis	C0342527		Approved			C0039601	Testostérone
Testosterone	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0039601	Testostérone
Testosterone	Hot flushes	C0600142		Approved			C0039601	Testostérone
Testosterone	Hypopituitarism	C0020635		Approved			C0039601	Testostérone
Efavirenz	HIV Infections	C0019693		Approved			C0674428	(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
Bacitracin	Corneal abrasion	C0010032		Approved			C0052882	Bacitracin A
Bacitracin	Bacterial keratitis	C0854211		Approved			C0052882	Bacitracin A
Bacitracin	Keratitis	C0022568		Approved			C0052882	Bacitracin A
Bacitracin	Blepharoconjunctivitis	C0005743		Approved			C0052882	Bacitracin A
Bacitracin	Infective blepharitis	C0729587		Approved			C0052882	Bacitracin A
Niacin	Hypercholesterolemia	C0020443		Approved			C0027996	anti-pellagra vitamin
Niacin	Hypertriglyceridemia	C0020557		Approved			C0027996	anti-pellagra vitamin
Niacin	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0027996	anti-pellagra vitamin
Niacin	Hyperlipidemia, Familial Combined	C0020474		Approved			C0027996	anti-pellagra vitamin
Niacin	Vitamin Deficiency	C1510471		Approved			C0027996	anti-pellagra vitamin
Niacin	Hyperlipidemia	C0020473		Approved			C0027996	anti-pellagra vitamin
Clorazepate	Anxiety	C0003467		Approved			C0770393	Clorazepic acid
Clorazepate	Alcohol withdrawal syndrome	C0236663		Approved			C0770393	Clorazepic acid
Guanabenz	Hypertensive disease	C0020538		Approved			C0018312	Guanabenzum
Alendronic acid	Osteoporosis, Postmenopausal	C0029458		Approved			C0771311	Acide Alendronique
Alendronic acid	Osteitis Deformans	C0029401		Approved			C0771311	Acide Alendronique
Clofarabine	Acute lymphocytic leukemia	C0023449		Approved			C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Docosanol	Herpes Labialis	C0019345		Approved			C0075770	1-Docosanol
Sulfacetamide	Trachoma	C0040592		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Blepharoconjunctivitis	C0005743		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Infective blepharitis	C0729587		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Acne Vulgaris	C0001144		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Inclusion conjunctivitis	C0009770		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Bacterial conjunctivitis	C0009768		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Amebiasis	C0002438		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Iridocyclitis	C0022073		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Vulvovaginitis	C0042998		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Seborrheic dermatitis	C0036508		Approved			C0038670	Sulphacetamidum
Sulfacetamide	Scurfiness of scalp	C0423775		Approved			C0038670	Sulphacetamidum
Prednisone	Exfoliative dermatitis	C0011606		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Acute lymphocytic leukemia	C0023449		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Crohn Disease	C0010346		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Lymphoma, Non-Hodgkin	C0024305		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Mycosis Fungoides	C0026948		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Contact Dermatitis	C0011616		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Simple Pulmonary Eosinophilia	C0242459		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Pemphigus	C0030807		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Nephrotic Syndrome	C0027726		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Trichinellosis	C0040896		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Allergic rhinitis (disorder)	C2607914		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Autoimmune hemolytic anemia	C0002880		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Lymphoma, Follicular	C0024301		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Asthma	C0004096		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Berylliosis	C0005138		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Laryngeal Edema	C0023052		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Chronic Lymphocytic Leukemia	C0023434		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Thyroiditis	C0040147		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Hodgkin Disease	C0019829		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Lupus Erythematosus, Systemic	C0024141		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Erythema Multiforme	C0014742		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Adrenogenital disorder	C0701163		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Transplanted organ rejection	C0345468		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Adrenal cortical hypofunction	C0405580		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Dermatologic disorders	C0037274		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Angioedema	C0002994		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Musculoskeletal Diseases	C0026857		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Dermatitis Herpetiformis	C0011608		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Rheumatic Heart Disease	C0035439		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Psoriasis	C0033860		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Multiple Sclerosis	C0026769		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Anemia, Diamond-Blackfan	C1260899		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Cooley's anemia	C0002875		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Addison Disease	C0001403		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Exacerbation of asthma	C0349790		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Diffuse Large B-Cell Lymphoma	C0079744		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Arthritis, Psoriatic	C0003872		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Serum Sickness	C0036830		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Acquired thrombocytopenia	C0154301		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Sarcoidosis	C0036202		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Rheumatoid Arthritis	C0003873		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Ankylosing spondylitis	C0038013		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Arthritis, Gouty	C0003868		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Epicondylitis	C0014488		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Autoimmune Diseases	C0004364		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Inflammatory Bowel Diseases	C0021390		Approved			C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Clofibrate	Hyperlipidemia	C0020473		Approved			C0009002	Ethyl 2-(p-chlorophenoxy)isobutyrate
Astemizole	Sneezing	C0037383		Approved			C0085170	1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole
Astemizole	Allergic Conjunctivitis	C0009766		Approved			C0085170	1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole
Astemizole	Chronic idiopathic urticaria	C0578870		Approved			C0085170	1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole
Astemizole	Allergic rhinitis (disorder)	C2607914		Approved			C0085170	1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole
Butoconazole	Candidiasis, Vulvovaginal	C0700345		Approved			C0054259	1-[4-(4-Chloro-phenyl)-2-(2,6-dichloro-phenylsulfanyl)-butyl]-1H-imidazole
Adenosine	Pulmonary Cystic Fibrosis	C0392164		Approved			C0001443	Adenogesic
Adenosine	Paroxysmal supraventricular tachycardia	C0030590		Approved			C0001443	Adenogesic
Simvastatin	Hypoalphalipoproteinemias	C0473527		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Hyperlipoproteinemia Type III	C0020479		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Cerebrovascular accident	C0038454		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Arteriosclerosis	C0003850		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Hypercholesterolemia	C0020443		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Familial hypercholesterolemia - homozygous	C0342881		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Hypertriglyceridemia	C0020557		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Hyperlipidemia, Familial Combined	C0020474		Approved			C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Pemetrexed	Malignant Pleural Mesothelioma	C0812413		Approved			C0210657	Pemetrexed
Pemetrexed	Non-Small Cell Lung Carcinoma	C0007131		Approved			C0210657	Pemetrexed
Mebendazole	Enterobiasis	C0086227		Approved			C0025023	Mebendazol
Mebendazole	Ascariasis	C0003950		Approved			C0025023	Mebendazol
Mebendazole	Infection by Trichuris trichiura	C0040954		Approved			C0025023	Mebendazol
Gonadorelin	Amenorrhea	C0002453		Approved			C0023610	Gonadorelina
Dyclonine	Skin irritation	C0152030		Approved			C0058831	4'-butoxy-3-piperidinopropiophenone
Dyclonine	Pruritus	C0033774		Approved			C0058831	4'-butoxy-3-piperidinopropiophenone
Dyclonine	Mouth irritation	C0235339		Approved			C0058831	4'-butoxy-3-piperidinopropiophenone
Nystatin	Candidiasis, Vulvovaginal	C0700345		Approved			C0028741	Nystatine
Nystatin	Mucocutaneous candidiasis	C0006848		Approved			C0028741	Nystatine
Nystatin	Gastrointestinal candidiasis	C0343886		Approved			C0028741	Nystatine
Nystatin	Oral candidiasis	C0006849		Approved			C0028741	Nystatine
Nystatin	Cutaneous Candidiasis	C0006846		Approved			C0028741	Nystatine
Dextropropoxyphene	Pain	C0030193		Approved			C0033493	Dextroproxifeno
Mitotane	Carcinoma in situ of adrenal cortex	C0686510		Approved			C0026256	Mitotanum
Stavudine	HIV Infections	C0019693		Approved			C0164662	Estavudina
Leucovorin	Poisoning by pyrimethamine	C0274478		Approved			C0023413	Folinate
Leucovorin	Methotrexate poisoning	C0568062		Approved			C0023413	Folinate
Leucovorin	Anemia, Megaloblastic	C0002888		Approved			C0023413	Folinate
Leucovorin	Folic Acid Deficiency	C0016412		Approved			C0023413	Folinate
Leucovorin	Poisoning by sulfadiazine	C0274462		Approved			C0023413	Folinate
Dyphylline	Pulmonary Emphysema	C0034067		Approved			C0013360	Diprophyllinum
Dyphylline	Asthma	C0004096		Approved			C0013360	Diprophyllinum
Dyphylline	Bronchial Spasm	C0006266		Approved			C0013360	Diprophyllinum
Dyphylline	Asthma night-time symptoms	C1273489		Approved			C0013360	Diprophyllinum
Dyphylline	Bronchitis, Chronic	C0008677		Approved			C0013360	Diprophyllinum
Dyphylline	Asthma-chronic obstructive pulmonary disease overlap syndrome	C4038730		Approved			C0013360	Diprophyllinum
Pentazocine	Labor Pain	C0474368		Approved			C0030873	Pentazocin
Pentazocine	Pain	C0030193		Approved			C0030873	Pentazocin
Magnesium Sulfate	Eclampsia in pregnancy	C0156677		Approved			C0024480	Magnesium sulfate
Magnesium Sulfate	Hypomagnesemia	C0151723		Approved			C0024480	Magnesium sulfate
Magnesium Sulfate	Mild pre-eclampsia	C0269658		Approved			C0024480	Magnesium sulfate
Magnesium Sulfate	Severe pre-eclampsia	C0341950		Approved			C0024480	Magnesium sulfate
Magnesium Sulfate	Incomplete passage of stool	C0426639		Approved			C0024480	Magnesium sulfate
Magnesium Sulfate	Constipation	C0009806		Approved			C0024480	Magnesium sulfate
Latanoprost	Ocular Hypertension	C0028840		Approved			C0090306	propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Latanoprost	Glaucoma, Open-Angle	C0017612		Approved			C0090306	propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Estrone	Acne Vulgaris	C0001144		Approved			C0014942	Follicular hormone
Estrone	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C0014942	Follicular hormone
Estrone	Atrophic Vaginitis	C0221392		Approved			C0014942	Follicular hormone
Trazodone	Major Depressive Disorder	C1269683		Approved			C0040805	2-(3-[4-(3-chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
Mecamylamine	Hypertensive disease	C0020538		Approved			C0025029	Mecamylamine
Acamprosate	Alcoholic Intoxication, Chronic	C0001973		Approved			C0284941	Acamprosatum
Metaxalone	Muscle Spasticity	C0026838		Approved			C0163055	Metaxalonum
Verapamil	Atrial Fibrillation	C0004238		Approved			C0042523	Vérapamil
Verapamil	Hypertensive disease	C0020538		Approved			C0042523	Vérapamil
Verapamil	Angina Pectoris, Variant	C0002963		Approved			C0042523	Vérapamil
Verapamil	Paroxysmal supraventricular tachycardia	C0030590		Approved			C0042523	Vérapamil
Verapamil	Angina Pectoris	C0002962		Approved			C0042523	Vérapamil
Trimethobenzamide	Vomiting	C0042963		Approved			C0077163	N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
Trimethobenzamide	Nausea	C0027497		Approved			C0077163	N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
Trimethobenzamide	Nausea and vomiting	C0027498		Approved			C0077163	N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
Flumethasone	Seborrheic dermatitis	C0036508		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Chronic small plaque psoriasis	C0406317		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Lupus Erythematosus, Discoid	C0024138		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Pruritus of genital organs	C0033777		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Exanthema	C0015230		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Granuloma Annulare	C0085074		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Scalp psoriasis	C0406326		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Contact Dermatitis	C0011616		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Lichen Simplex Chronicus	C0149922		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Pruritus Ani	C0033775		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Flumethasone	Dermatitis, Atopic	C0011615		Approved			C0016294	6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Nilutamide	Metastatic Prostate Carcinoma	C0936223		Approved			C0068771	5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin
Nafarelin	Precocious Puberty	C0034013		Approved			C0064906	Nafarelinum
Nafarelin	Endometriosis	C0014175		Approved			C0064906	Nafarelinum
Histamine Phosphate	Degenerative polyarthritis	C0029408		Approved			C0062740	Histamine Phosphate
Epinephrine	anaphylaxis	C0002792		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Hypotension	C0020649		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Bronchiectasis	C0006267		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Asthma attack	C0347950		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Glaucoma, Open-Angle	C0017612		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Dyspnea	C0013404		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Bronchitis	C0006277		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Wheezing	C0043144		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Exacerbation of asthma	C0349790		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Asthma	C0004096		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Epinephrine	Pulmonary Emphysema	C0034067		Approved			C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Sumatriptan	Migraine Disorders	C0149931		Approved			C0075632	(3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
Sumatriptan	Cluster Headache	C0009088		Approved			C0075632	(3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
Pirenzepine	Peptic Ulcer	C0030920		Approved			C0031978	Pirenzépine
Cefixime	Acute otitis media	C0271429		Approved			C0060400	(-)-cefixim
Cefixime	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0060400	(-)-cefixim
Cefixime	Upper Respiratory Infections	C0041912		Approved			C0060400	(-)-cefixim
Cefixime	Acute gonococcal urethritis	C0275652		Approved			C0060400	(-)-cefixim
Cefixime	Streptococcal tonsillitis	C0275804		Approved			C0060400	(-)-cefixim
Cefixime	Pharyngitis	C0031350		Approved			C0060400	(-)-cefixim
Cefixime	Proteus urinary tract infection	C0577709		Approved			C0060400	(-)-cefixim
Cefixime	Acute gonococcal cervicitis	C0153195		Approved			C0060400	(-)-cefixim
Cefixime	Escherichia coli urinary tract infection	C0577708		Approved			C0060400	(-)-cefixim
Cefixime	Infective otitis media	C0729586		Approved			C0060400	(-)-cefixim
Cefixime	Bronchitis	C0006277		Approved			C0060400	(-)-cefixim
Cefixime	Urinary tract infection	C0042029		Approved			C0060400	(-)-cefixim
Cefixime	Tonsillitis	C0040425		Approved			C0060400	(-)-cefixim
Cefixime	Gonorrhea	C0018081		Approved			C0060400	(-)-cefixim
Chlorpropamide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0008287	4-chloro-N-((propylamino)carbonyl)benzenesulfonamide
Aprepitant	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C1176306	Aprépitant
Galantamine	Alzheimer's Disease	C0002395		Approved			C0016967	Galantamina
Tamoxifen	Malignant epithelial neoplasm of female breast	C3163805		Approved			C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Tamoxifen	Invasive Ductal Breast Carcinoma	C1134719		Approved			C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Losartan	Diabetic Nephropathy	C0011881		Approved			C0126174	2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Losartan	Hypertensive urgency	C0745138		Approved			C0126174	2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Losartan	Hypertensive disease	C0020538		Approved			C0126174	2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Thioridazine	Treatment-resistant schizophrenia	C3544321		Approved			C0039943	Thioridazinum
Moricizine	Ventricular arrhythmia	C0085612		Approved			C0079856	ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate
Amphotericin B	Aspergillosis	C0004030		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Candidiasis of the esophagus	C0239295		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Yaws	C0043388		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Brucellosis	C0006309		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Rhinocerebral phycomycosis	C1636205		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Invasive Pulmonary Aspergillosis	C0276653		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Coccidioidomycosis	C0009186		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Infective otitis media	C0729586		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Fungal infection of lung	C0151874		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Meningitis, Fungal	C0085438		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Acute gonococcal cervicitis	C0153195		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Gonorrhea of rectum	C0275665		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Histoplasmosis	C0019655		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Mucormycosis	C0026718		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Relapsing Fever	C0035021		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Granuloma Inguinale	C0018190		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Gonorrhea of pharynx	C0149966		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Bronchitis	C0006277		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Psittacosis	C0029291		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Rocky Mountain Spotted Fever	C0035793		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Pulmonary cryptococcosis	C0276688		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Sinusitis	C0037199		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Leishmaniasis, Visceral	C0023290		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Intraabdominal Infections	C1112209		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Q Fever	C0034362		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Gonorrhea	C0018081		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Chlamydia trachomatis infection of genital structure	C1997322		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Syphilis	C0039128		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Septicemia candida	C0349009		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Fungal septicemia	C2960008		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Cutaneous Candidiasis	C0006846		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Infection by Cryptococcus neoformans	C0010414		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Blastomycosis	C0005716		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Lymphogranuloma Venereum	C0024286		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Systemic candidiasis	C0153252		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Candidal meningitis	C0153256		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Candidal endocarditis	C0153254		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Candidiasis	C0006840		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Disseminated sporotrichosis	C0276725		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Acne Vulgaris	C0001144		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Mycotic endocarditis	C0276648		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Urinary tract infection	C0042029		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Pharyngitis	C0031350		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Pelvic Inflammatory Disease	C0242172		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Pneumonia	C0032285		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Acute gonococcal urethritis	C0275652		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Candidemia	C0877445		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Diaper Rash	C0011974		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Actinomycosis	C0001261		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Leishmaniasis	C0023281		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	candidal peritonitis	C2062982		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Urinary tract infection fungal	C0877131		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	TYPHUS	C0041471		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Oral candidiasis	C0006849		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Trachoma	C0040592		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Gingivostomatitis	C0149704		Approved			C1145701	Liposomal amphotericin B
Amphotericin B	Rickettsialpox	C0035597		Approved			C1145701	Liposomal amphotericin B
Warfarin	Thrombosis	C0040053		Approved			C0043031	Warfarina
Warfarin	Thromboembolism	C0040038		Approved			C0043031	Warfarina
Warfarin	Cerebral Embolism	C0007780		Approved			C0043031	Warfarina
Warfarin	Deep Vein Thrombosis	C0149871		Approved			C0043031	Warfarina
Midazolam	Agitation	C0085631		Approved			C0026056	Midazolamum
Midazolam	Anxiety	C0003467		Approved			C0026056	Midazolamum
Tobramycin	Enterobacteriaceae Infections	C0014347		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Pneumonia due to Pseudomonas	C0155860		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Bacterial sepsis	C0684256		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Punctate keratitis	C0259799		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Serratia Infections	C0085394		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Dacryocystitis	C0010930		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Anterior uveitis	C0042165		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Bacterial conjunctivitis	C0009768		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Sepsis due to Pseudomonas	C2887096		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Escherichia coli septicemia	C0276088		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Neonatal meningitis	C0456107		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Corneal Perforation	C0339293		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Bacterial peritonitis	C0341503		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Meningitis, Bacterial	C0085437		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Allergic Conjunctivitis	C0009766		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Rhinoscleroma	C0035468		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Staphylococcus aureus infection	C1318973		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Herpes zoster keratitis	C1275687		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Blepharoconjunctivitis	C0005743		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Infection of bone	C2242472		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Sepsis of the newborn	C0456103		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Rosacea	C0035854		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Meibomianitis	C0549398		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Pneumonia due to Escherichia coli	C0276089		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Enterobacter pneumonia	C1096258		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Escherichia coli Infections	C0014836		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Keratoconjunctivitis	C0022573		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Corneal abrasion	C0010032		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Staphylococcal Pneumonia	C0032308		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Nosocomial pneumonia	C0949083		Approved			C0040341	3'-Deoxykanamycin B
Tobramycin	Infective blepharitis	C0729587		Approved			C0040341	3'-Deoxykanamycin B
Trovafloxacin	Female genital tract infection	C1263758		Approved			C0379881	trovafloxacino
Trovafloxacin	Postoperative infection	C0392618		Approved			C0379881	trovafloxacino
Trovafloxacin	Urinary tract infection	C0042029		Approved			C0379881	trovafloxacino
Trovafloxacin	Intraabdominal Infections	C1112209		Approved			C0379881	trovafloxacino
Trovafloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0379881	trovafloxacino
Trovafloxacin	Pneumonia due to Pseudomonas	C0155860		Approved			C0379881	trovafloxacino
Trovafloxacin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0379881	trovafloxacino
Trovafloxacin	Mycoplasma pneumonia	C0032302		Approved			C0379881	trovafloxacino
Trovafloxacin	Acute gonococcal cervicitis	C0153195		Approved			C0379881	trovafloxacino
Trovafloxacin	Gonorrhea of rectum	C0275665		Approved			C0379881	trovafloxacino
Trovafloxacin	Acute gonococcal urethritis	C0275652		Approved			C0379881	trovafloxacino
Trovafloxacin	Chronic Bacterial Prostatitis	C1720797		Approved			C0379881	trovafloxacino
Trovafloxacin	Staphylococcal Pneumonia	C0032308		Approved			C0379881	trovafloxacino
Trovafloxacin	Acute gonococcal endometritis	C0153196		Approved			C0379881	trovafloxacino
Trovafloxacin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0379881	trovafloxacino
Trovafloxacin	Legionella pneumophila pneumonia	C0857846		Approved			C0379881	trovafloxacino
Trovafloxacin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0379881	trovafloxacino
Trovafloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0379881	trovafloxacino
Trovafloxacin	Acute bacterial sinusitis	C0275556		Approved			C0379881	trovafloxacino
Trovafloxacin	Pneumonia due to Escherichia coli	C0276089		Approved			C0379881	trovafloxacino
Trovafloxacin	Chlamydial pneumonia	C0339959		Approved			C0379881	trovafloxacino
Trovafloxacin	Chlamydial cervicitis	C0341834		Approved			C0379881	trovafloxacino
Trovafloxacin	Chlamydial pelvic inflammatory disease	C0520777		Approved			C0379881	trovafloxacino
Trovafloxacin	Endomyometritis	C0269050		Approved			C0379881	trovafloxacino
Trovafloxacin	Female pelvic cellulitis	C0349734		Approved			C0379881	trovafloxacino
Trovafloxacin	Miscarriage with sepsis	C0269398		Approved			C0379881	trovafloxacino
Trovafloxacin	Postnatal infection	C1278797		Approved			C0379881	trovafloxacino
Pentosan Polysulfate	Bladder pain	C0232849		Approved			C0600296	Pentosano polisulfato
Pentosan Polysulfate	Interstitial Cystitis	C0282488		Approved			C0600296	Pentosano polisulfato
Fludrocortisone	Adrenogenital disorder	C0701163		Approved			C0016280	9alpha-Fluorocortisol
Fludrocortisone	Addison Disease	C0001403		Approved			C0016280	9alpha-Fluorocortisol
Flurazepam	Sleeplessness	C0917801		Approved			C0016375	Flurazépam
Moexipril	Hypertensive disease	C0020538		Approved			C0066685	Moexiprilum
Phentolamine	Peripheral Vascular Diseases	C0085096		Approved			C0031448	2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
Phentolamine	Hypertensive emergency	C0745136		Approved			C0031448	2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
Phentolamine	Pheochromocytoma	C0031511		Approved			C0031448	2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
Phentolamine	Cerebral Ischemia	C0917798		Approved			C0031448	2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
Phentolamine	Paroxysmal hypertension	C0221154		Approved			C0031448	2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
Daunorubicin	Acute lymphocytic leukemia	C0023449		Approved			C0011015	(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Daunorubicin	Acute Promyelocytic Leukemia	C0023487		Approved			C0011015	(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Daunorubicin	Acute monocytic leukemia	C0023465		Approved			C0011015	(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Daunorubicin	Leukemia, Myelocytic, Acute	C0023467		Approved			C0011015	(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Daunorubicin	Acute Erythroblastic Leukemia	C0023440		Approved			C0011015	(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Daunorubicin	Kaposi Sarcoma	C0036220		Approved			C0011015	(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Furosemide	Decompensated cardiac failure	C0581377		Approved			C0016860	Furosemidu
Furosemide	Edema	C0013604		Approved			C0016860	Furosemidu
Furosemide	Acute pulmonary edema	C0155919		Approved			C0016860	Furosemidu
Furosemide	Hypertensive disease	C0020538		Approved			C0016860	Furosemidu
Ergotamine	Migraine Disorders	C0149931		Approved			C0014710	12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
Ergotamine	Vascular Headaches	C0042376		Approved			C0014710	12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
Ergotamine	Cluster Headache	C0009088		Approved			C0014710	12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
Tizanidine	Muscle spasticity of spinal origin	C1562430		Approved			C0146011	Tizanidin
Tizanidine	Muscle Spasticity	C0026838		Approved			C0146011	Tizanidin
Nitrofurantoin	Escherichia coli urinary tract infection	C0577708		Approved			C0028156	nitrofurantoina
Nitrofurantoin	Klebsiella cystitis	C0520775		Approved			C0028156	nitrofurantoina
Nitrofurantoin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0028156	nitrofurantoina
Eplerenone	Hypertensive disease	C0020538		Approved			C0961485	Eplerenona
Amprenavir	HIV Infections	C0019693		Approved			C0754188	Amprénavir
Methazolamide	Angle Closure Glaucoma	C0017605		Approved			C0025631	Méthazolamide
Methazolamide	Secondary glaucoma	C0149893		Approved			C0025631	Méthazolamide
Methazolamide	Glaucoma, Open-Angle	C0017612		Approved			C0025631	Méthazolamide
Naltrexone	Drug-induced constipation	C0267511		Approved			C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Naltrexone	Chronic pain	C0150055		Approved			C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Naltrexone	Alcoholic Intoxication, Chronic	C0001973		Approved			C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Naltrexone	Severe pain	C0278140		Approved			C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Naltrexone	Obesity	C0028754		Approved			C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Delavirdine	HIV Infections	C0019693		Approved			C0288165	N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide
Tamsulosin	Prostatic Hypertrophy	C1739363		Approved			C0257343	(-)-tamsulosin
Porfimer	Non-Small Cell Lung Carcinoma	C0007131		Approved			C1130428	Porfimer sodium
Porfimer	Malignant neoplasm of esophagus	C0546837		Approved			C1130428	Porfimer sodium
Sufentanil	Pain, Postoperative	C0030201		Approved			C0143993	Sufentanilum
Lamivudine	HIV Infections	C0019693		Approved			C0209738	Lamivudina
Lamivudine	Hepatitis B, Chronic	C0524909		Approved			C0209738	Lamivudina
Ibandronate	Osteoporosis, Postmenopausal	C0029458		Approved			C0379200	ácido ibandrónico
Ibandronate	Hypercalcemia	C0020437		Approved			C0379200	ácido ibandrónico
Diethylcarbamazine	Eosinophilic Pneumonia	C1527407		Approved			C0012191	Dietilcarbamazina
Diethylcarbamazine	Loiasis	C0023968		Approved			C0012191	Dietilcarbamazina
Diethylcarbamazine	Onchocerciasis	C0029001		Approved			C0012191	Dietilcarbamazina
Diethylcarbamazine	Elephantiasis	C0013882		Approved			C0012191	Dietilcarbamazina
Flurbiprofen	Degenerative polyarthritis	C0029408		Approved			C0016377	2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid
Flurbiprofen	Rheumatoid Arthritis	C0003873		Approved			C0016377	2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid
Oxacillin	Staphylococcal Pneumonia	C0032308		Approved			C0029983	Ossacillina
Oxacillin	Staphylococcal Infections	C0038160		Approved			C0029983	Ossacillina
Oxacillin	Infection of bone	C2242472		Approved			C0029983	Ossacillina
Oxacillin	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0029983	Ossacillina
Oxacillin	Lower respiratory tract infection	C0149725		Approved			C0029983	Ossacillina
Oxacillin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0029983	Ossacillina
Oxacillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0029983	Ossacillina
Oxacillin	Staphylococcus aureus infection	C1318973		Approved			C0029983	Ossacillina
Oxacillin	Staphylococcal endocarditis	C0520767		Approved			C0029983	Ossacillina
Oxacillin	Sinusitis	C0037199		Approved			C0029983	Ossacillina
Oxacillin	Staphylococcal meningitis	C0154640		Approved			C0029983	Ossacillina
Oxacillin	Pharyngitis	C0031350		Approved			C0029983	Ossacillina
Oxacillin	Staphylococcal bacteraemia	C0152965		Approved			C0029983	Ossacillina
Apomorphine	Parkinson Disease	C0030567		Approved			C0003596	(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Paroxetine	Major Depressive Disorder	C1269683		Approved			C0070122	Paroxetina
Paroxetine	Obsessive-Compulsive Disorder	C0028768		Approved			C0070122	Paroxetina
Paroxetine	Panic Disorder	C0030319		Approved			C0070122	Paroxetina
Paroxetine	Phobia, Social	C0031572		Approved			C0070122	Paroxetina
Paroxetine	Post-Traumatic Stress Disorder	C0038436		Approved			C0070122	Paroxetina
Paroxetine	Premenstrual Dysphoric Disorder	C0520676		Approved			C0070122	Paroxetina
Paroxetine	Generalized Anxiety Disorder	C0270549		Approved			C0070122	Paroxetina
Paroxetine	Depressive disorder	C0011581		Approved			C0070122	Paroxetina
Paroxetine	Hot flushes	C0600142		Approved			C0070122	Paroxetina
Nedocromil	Allergic Conjunctivitis	C0009766		Approved			C0068483	9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsäure
Nedocromil	Asthma	C0004096		Approved			C0068483	9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsäure
Nedocromil	Itching of eye	C0022281		Approved			C0068483	9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsäure
Norethisterone	Atrophic Vaginitis	C0221392		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Secondary physiologic amenorrhea	C0232940		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Menorrhagia	C0025323		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Female hypogonadism syndrome	C0271578		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Hot flushes	C0600142		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Atrophy of vulva	C0156393		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Metrorrhagia	C0025874		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Acne Vulgaris	C0001144		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Norethisterone	Endometriosis	C0014175		Approved			C0028356	19-nor-17-α-ethynyltestosterone
Adefovir Dipivoxil	Hepatitis B, Chronic	C0524909		Approved			C0540694	Adefovir pivoxil
Azatadine	Pruritus	C0033774		Approved			C0052759	Azatadinum
Azatadine	Nasal congestion (finding)	C0027424		Approved			C0052759	Azatadinum
Azatadine	Sneezing	C0037383		Approved			C0052759	Azatadinum
Azatadine	Common Cold	C0009443		Approved			C0052759	Azatadinum
Azatadine	Urticaria	C0042109		Approved			C0052759	Azatadinum
Azatadine	Rhinitis, Vasomotor	C0035460		Approved			C0052759	Azatadinum
Azatadine	Allergic rhinitis (disorder)	C2607914		Approved			C0052759	Azatadinum
Azatadine	Allergic Conjunctivitis	C0009766		Approved			C0052759	Azatadinum
Azatadine	Rhinorrhea	C1260880		Approved			C0052759	Azatadinum
Azatadine	Hay fever	C0018621		Approved			C0052759	Azatadinum
Azatadine	Symptomatic dermographism	C0343065		Approved			C0052759	Azatadinum
Lisinopril	Myocardial Infarction	C0027051		Approved			C0065374	[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
Lisinopril	Chronic heart failure	C0264716		Approved			C0065374	[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
Lisinopril	Hypertensive disease	C0020538		Approved			C0065374	[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
Methoxamine	Paroxysmal supraventricular tachycardia	C0030590		Approved			C0025681	Méthoxamédrine
Imiquimod	Condylomata Acuminata	C0009663		Approved			C0165032	1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
Imiquimod	Superficial basal cell carcinoma	C0862889		Approved			C0165032	1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
Imiquimod	Actinic keratosis	C0022602		Approved			C0165032	1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
Imiquimod	Common wart	C0043037		Approved			C0165032	1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
Homatropine Methylbromide	Coughing	C0010200		Approved			C0062923	Méthylbromure d'homatropine
Homatropine Methylbromide	Irritable Bowel Syndrome	C0022104		Approved			C0062923	Méthylbromure d'homatropine
Homatropine Methylbromide	Peptic Ulcer	C0030920		Approved			C0062923	Méthylbromure d'homatropine
Trimipramine	Depressive disorder	C0011581		Approved			C0041056	β-methylimipramine
Nitroglycerin	Perioperative hypertension	C3661921		Approved			C0017887	1,2,3-propanetrioltrinitrate
Thiabendazole	Larva Migrans, Cutaneous	C0546999		Approved			C0039832	Tiabendazolum
Thiabendazole	Infection by Uncinaria	C0041648		Approved			C0039832	Tiabendazolum
Thiabendazole	Toxocariasis	C0040553		Approved			C0039832	Tiabendazolum
Thiabendazole	Enterobiasis	C0086227		Approved			C0039832	Tiabendazolum
Thiabendazole	Trichinellosis	C0040896		Approved			C0039832	Tiabendazolum
Thiabendazole	Ascariasis	C0003950		Approved			C0039832	Tiabendazolum
Thiabendazole	Infection by Trichuris trichiura	C0040954		Approved			C0039832	Tiabendazolum
Thiabendazole	Strongyloidiasis	C0038463		Approved			C0039832	Tiabendazolum
Nateglinide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0903898	nateglinida
Pralidoxime	Organophosphate poisoning	C0700359		Approved			C0071808	Pralidoximum
Risperidone	Schizophrenia	C0036341		Approved			C0073393	Rispéridone
Risperidone	Bipolar disorder in remission	C0270425		Approved			C0073393	Rispéridone
Risperidone	Autistic Disorder	C0004352		Approved			C0073393	Rispéridone
Risperidone	Mixed bipolar I disorder	C0236780		Approved			C0073393	Rispéridone
Risperidone	Bipolar affective disorder, current episode manic	C0338873		Approved			C0073393	Rispéridone
Naftifine	Tinea Pedis	C0040259		Approved			C0068367	Naftifinum
Naftifine	Tinea corporis (disorder)	C0040252		Approved			C0068367	Naftifinum
Naftifine	Tinea cruris	C1384589		Approved			C0068367	Naftifinum
Esomeprazole	Erosive esophagitis	C0267055		Approved			C0937846	Ésoméprazole
Esomeprazole	Zollinger-Ellison syndrome	C0043515		Approved			C0937846	Ésoméprazole
Esomeprazole	Peptic Esophagitis	C0014869		Approved			C0937846	Ésoméprazole
Esomeprazole	Gastroesophageal reflux disease	C0017168		Approved			C0937846	Ésoméprazole
Esomeprazole	Peptic Ulcer	C0030920		Approved			C0937846	Ésoméprazole
Meclizine	Vertigo	C0042571		Approved			C0025039	Meclozina
Meclizine	Motion Sickness	C0026603		Approved			C0025039	Meclozina
Pentamidine	African Trypanosomiasis	C0041228		Approved			C0030863	1,5-bis(4-amidinophenoxy)pentane
Riluzole	Amyotrophic Lateral Sclerosis	C0002736		Approved			C0073379	Riluzolum
Hydrocortisone	Blepharoconjunctivitis	C0005743		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Bacterial keratitis	C0854211		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Cerebral Edema	C0006114		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Rheumatic Heart Disease	C0035439		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Laryngeal Edema	C0023052		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Nephrotic Syndrome	C0027726		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Recurrent herpes simplex labialis	C1274321		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Corneal abrasion	C0010032		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Crohn Disease	C0010346		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Proctitis	C0033246		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Lichen Simplex Chronicus	C0149922		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Lupus Erythematosus, Systemic	C0024141		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Rheumatoid Arthritis	C0003873		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Transplanted organ rejection	C0345468		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Uveitis	C0042164		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Inflammatory Bowel Diseases	C0021390		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Keratitis	C0022568		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Infective blepharitis	C0729587		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Exanthema	C0015230		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Synovitis	C0039103		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Herpes zoster keratitis	C1275687		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Aphthous Stomatitis	C0038363		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Angioedema	C0002994		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Corneal Ulcer	C0010043		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Anemia, Diamond-Blackfan	C1260899		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Cooley's anemia	C0002875		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Multiple Sclerosis	C0026769		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Psoriasis	C0033860		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Aspiration pneumonitis	C1761609		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Adrenogenital disorder	C0701163		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Iridocyclitis	C0022073		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Lupus Erythematosus, Discoid	C0024138		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Pemphigus	C0030807		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Dermatitis Herpetiformis	C0011608		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Tenosynovitis	C0039520		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Acne Vulgaris	C0001144		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Trichinellosis	C0040896		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Acute lymphocytic leukemia	C0023449		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Tinea Pedis	C0040259		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Allergic Conjunctivitis	C0009766		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Seborrheic dermatitis	C0036508		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Rosacea	C0035854		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Granuloma Annulare	C0085074		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Serum Sickness	C0036830		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Hodgkin Disease	C0019829		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Infective otitis externa	C0021355		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Exfoliative dermatitis	C0011606		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Lymphoma, Non-Hodgkin	C0024305		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Acquired thrombocytopenia	C0154301		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Simple Pulmonary Eosinophilia	C0242459		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Thyroiditis	C0040147		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Dermatitis, Atopic	C0011615		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Bursitis	C0006444		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Chronic small plaque psoriasis	C0406317		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Asthma	C0004096		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Erythema Multiforme	C0014742		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Arthritis, Gouty	C0003868		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Tinea cruris	C1384589		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Itching of ear	C0849907		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Hemorrhoids	C0019112		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Arthritis, Psoriatic	C0003872		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Addisonian crisis	C0151467		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Pruritus of genital organs	C0033777		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Adrenal cortical hypofunction	C0405580		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Iritis	C0022081		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Tinea corporis (disorder)	C0040252		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Post traumatic osteoarthritis	C2894027		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Cyclitis	C0010543		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Scalp psoriasis	C0406326		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Addison Disease	C0001403		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Mycosis Fungoides	C0026948		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Inflammatory dermatosis	C3875321		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Status Asthmaticus	C0038218		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Allergic rhinitis (disorder)	C2607914		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Autoimmune Diseases	C0004364		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Chronic ulcerative proctitis	C2937222		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Contact Dermatitis	C0011616		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Otitis Externa	C0029878		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Gingival Diseases	C0017563		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Ulcerative Colitis	C0009324		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Tendinitis	C0039503		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Autoimmune hemolytic anemia	C0002880		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Disorder of eye	C0015397		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Sarcoidosis	C0036202		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Berylliosis	C0005138		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Musculoskeletal Diseases	C0026857		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Ankylosing spondylitis	C0038013		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Punctate keratopathy	C0423234		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Hydrocortisone	Pruritus Ani	C0033775		Approved			C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Mannitol	Ocular Hypertension	C0028840		Approved			C0024730	(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Mannitol	Edema	C0013604		Approved			C0024730	(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Mannitol	Pseudotumor Cerebri	C0033845		Approved			C0024730	(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Mannitol	Cerebral Edema	C0006114		Approved			C0024730	(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Mannitol	Cystic Fibrosis	C0010674		Approved			C0024730	(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Zileuton	Allergic asthma	C0155877		Approved			C0081408	N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea
Zileuton	Intrinsic asthma	C0155880		Approved			C0081408	N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea
Modafinil	Narcolepsy	C0027404		Approved			C0066677	2-((diphenylmethyl)sulfinyl)acetamide
Deferoxamine	Chronic iron overload	C1739382		Approved			C0011145	Deferrioxamine B
Deferoxamine	Poisoning by iron AND/OR its compounds	C0412842		Approved			C0011145	Deferrioxamine B
Scopolamine	Rhinorrhea	C1260880		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Posterior synechiae	C0152253		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Rhinitis, Vasomotor	C0035460		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Uveitis	C0042164		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Peptic Ulcer	C0030920		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Mydriasis	C0026961		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Irritable Bowel Syndrome	C0022104		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Nasal congestion (finding)	C0027424		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Cycloplegia	C0235238		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Allergic rhinitis (disorder)	C2607914		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Coughing	C0010200		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Iridocyclitis	C0022073		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Motion Sickness	C0026603		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Scopolamine	Common Cold	C0009443		Approved			C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Carbinoxamine	Symptomatic dermographism	C0343065		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Hay fever	C0018621		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Pruritus	C0033774		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Urticaria	C0042109		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Rhinitis, Vasomotor	C0035460		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Allergic rhinitis (disorder)	C2607914		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Common Cold	C0009443		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Allergic Conjunctivitis	C0009766		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Carbinoxamine	Rhinorrhea	C1260880		Approved			C0054672	2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine
Etodolac	Pain	C0030193		Approved			C0059865	1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
Etodolac	Degenerative polyarthritis	C0029408		Approved			C0059865	1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
Etodolac	Rheumatoid Arthritis	C0003873		Approved			C0059865	1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
Prilocaine	Premature Ejaculation	C0033038		Approved			C0033124	2-(Propylamino)-o-propionotoluidide
Epinastine	Itching of eye	C0022281		Approved			C0078442	épinastine
Epinastine	Allergic Conjunctivitis	C0009766		Approved			C0078442	épinastine
Tranylcypromine	Major Depressive Disorder	C1269683		Approved			C0040778	dl-tranylcypromine
Ethotoin	Tonic-Clonic Epilepsy	C0014549		Approved			C0098350	3-ethyl-5-phenylhydantoin
Ethotoin	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0098350	3-ethyl-5-phenylhydantoin
Tretinoin	Acute Promyelocytic Leukemia	C0023487		Approved			C0040845	Tretin M
Tretinoin	Acne Vulgaris	C0001144		Approved			C0040845	Tretin M
Tretinoin	Hyperkeratosis	C0870082		Approved			C0040845	Tretin M
Tretinoin	Senile lentigo	C0036651		Approved			C0040845	Tretin M
Tretinoin	Chloasma	C0025218		Approved			C0040845	Tretin M
Dolasetron	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C0209210	Dolasétron
Clopidogrel	Acute ST segment elevation myocardial infarction (disorder)	C1303258		Approved			C0070166	Clopidogrelum
Clopidogrel	Acute Coronary Syndrome	C0948089		Approved			C0070166	Clopidogrelum
Clopidogrel	Non-Q wave myocardial infarction	C0542269		Approved			C0070166	Clopidogrelum
Clopidogrel	Cerebral Embolism	C0007780		Approved			C0070166	Clopidogrelum
Tetracycline	Lymphogranuloma Venereum	C0024286		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Relapsing Fever	C0035021		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Acute gonococcal urethritis	C0275652		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Gonorrhea	C0018081		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Sinusitis	C0037199		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Rickettsialpox	C0035597		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Pelvic Inflammatory Disease	C0242172		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Actinomycosis	C0001261		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Gonorrhea of pharynx	C0149966		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Pneumonia	C0032285		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Rocky Mountain Spotted Fever	C0035793		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Chlamydia trachomatis infection of genital structure	C1997322		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Ophthalmia Neonatorum	C0029076		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Bacterial keratitis	C0854211		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Psittacosis	C0029291		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	TYPHUS	C0041471		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Acute gonococcal epididymo-orchitis	C0153193		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Brucellosis	C0006309		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Trachoma	C0040592		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Bacterial conjunctivitis	C0009768		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Urinary tract infection	C0042029		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Syphilis	C0039128		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Infective otitis media	C0729586		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Pharyngitis	C0031350		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Q Fever	C0034362		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Acute gonococcal endometritis	C0153196		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Granuloma Inguinale	C0018190		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Gonorrhea of rectum	C0275665		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Bronchitis	C0006277		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Yaws	C0043388		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Gingivostomatitis	C0149704		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Acne Vulgaris	C0001144		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Tetracycline	Acute gonococcal cervicitis	C0153195		Approved			C0039644	(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Meropenem	Infection due to Pseudomonas aeruginosa	C0276075		Approved			C0066005	Meropenemum
Meropenem	Complicated appendicitis	C1632842		Approved			C0066005	Meropenemum
Meropenem	Meningococcal meningitis	C0025294		Approved			C0066005	Meropenemum
Meropenem	Peritonitis	C0031154		Approved			C0066005	Meropenemum
Meropenem	Meningitis, Bacterial	C0085437		Approved			C0066005	Meropenemum
Meropenem	Meningitis, Pneumococcal	C0025295		Approved			C0066005	Meropenemum
Meropenem	Streptococcal meningitis	C0154639		Approved			C0066005	Meropenemum
Meropenem	Intraabdominal Infections	C1112209		Approved			C0066005	Meropenemum
Meropenem	Abdominal Abscess	C0243001		Approved			C0066005	Meropenemum
Potassium Chloride	Constipation	C0009806		Approved			C0032825	Potassium chloride
Potassium Chloride	Incomplete passage of stool	C0426639		Approved			C0032825	Potassium chloride
Potassium Chloride	Hypokalemia	C0020621		Approved			C0032825	Potassium chloride
Irinotecan	Metastasis from malignant tumor of colon	C1282500		Approved			C0123931	(+)-Irinotecan
Irinotecan	Secondary malignant neoplasm of pancreas	C0346976		Approved			C0123931	(+)-Irinotecan
Methimazole	Hyperthyroidism	C0020550		Approved			C0025644	Thiamazol
Mometasone	Pruritus of genital organs	C0033777		Approved			C0360564	Mometason
Mometasone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0360564	Mometason
Mometasone	Lichen Simplex Chronicus	C0149922		Approved			C0360564	Mometason
Mometasone	Seborrheic dermatitis	C0036508		Approved			C0360564	Mometason
Mometasone	Asthma	C0004096		Approved			C0360564	Mometason
Mometasone	Scalp psoriasis	C0406326		Approved			C0360564	Mometason
Mometasone	Chronic small plaque psoriasis	C0406317		Approved			C0360564	Mometason
Mometasone	Pruritus Ani	C0033775		Approved			C0360564	Mometason
Mometasone	Allergic rhinitis (disorder)	C2607914		Approved			C0360564	Mometason
Mometasone	Exanthema	C0015230		Approved			C0360564	Mometason
Mometasone	Contact Dermatitis	C0011616		Approved			C0360564	Mometason
Mometasone	Allergic asthma	C0155877		Approved			C0360564	Mometason
Mometasone	Granuloma Annulare	C0085074		Approved			C0360564	Mometason
Mometasone	Intrinsic asthma	C0155880		Approved			C0360564	Mometason
Mometasone	Lupus Erythematosus, Discoid	C0024138		Approved			C0360564	Mometason
Metyrosine	Pheochromocytoma	C0031511		Approved			C0886584	α-MPT
Clavulanate	Escherichia coli urinary tract infection	C0577708		Approved			C0110038	Clavulanate
Clavulanate	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			C0110038	Clavulanate
Clavulanate	Klebsiella cystitis	C0520775		Approved			C0110038	Clavulanate
Clavulanate	Bacterial sepsis	C0684256		Approved			C0110038	Clavulanate
Clavulanate	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0110038	Clavulanate
Clavulanate	Rhinoscleroma	C0035468		Approved			C0110038	Clavulanate
Clavulanate	Streptococcal pneumonia	C0155862		Approved			C0110038	Clavulanate
Clavulanate	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0110038	Clavulanate
Clavulanate	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0110038	Clavulanate
Clavulanate	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0110038	Clavulanate
Clavulanate	Bacterial urinary infection	C0729524		Approved			C0110038	Clavulanate
Clavulanate	Acute bacterial sinusitis	C0275556		Approved			C0110038	Clavulanate
Clavulanate	Pneumonia due to Staphylococcus aureus	C2349530		Approved			C0110038	Clavulanate
Clavulanate	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0110038	Clavulanate
Clavulanate	Infective otitis media	C0729586		Approved			C0110038	Clavulanate
Clavulanate	Moraxella catarrhalis pneumonia	C0857831		Approved			C0110038	Clavulanate
Clavulanate	Sepsis due to Pseudomonas	C2887096		Approved			C0110038	Clavulanate
Clavulanate	Escherichia coli septicemia	C0276088		Approved			C0110038	Clavulanate
Clavulanate	Escherichia coli Infections	C0014836		Approved			C0110038	Clavulanate
Clavulanate	Haemophilus influenzae pneumonia	C0276026		Approved			C0110038	Clavulanate
Clavulanate	Staphylococcus aureus infection	C1318973		Approved			C0110038	Clavulanate
Clavulanate	URINARY TRACT INFECTION CITROBACTER	C0749955		Approved			C0110038	Clavulanate
Clavulanate	Urinary tract infection	C0042029		Approved			C0110038	Clavulanate
Clavulanate	Pneumonia, Bacterial	C0004626		Approved			C0110038	Clavulanate
Clavulanate	Staphylococcal Pneumonia	C0032308		Approved			C0110038	Clavulanate
Olopatadine	Allergic rhinitis (disorder)	C2607914		Approved			C0527189	Olopatadinum
Olopatadine	Hay fever	C0018621		Approved			C0527189	Olopatadinum
Olopatadine	Allergic Conjunctivitis	C0009766		Approved			C0527189	Olopatadinum
Alprostadil	Congenital atresia of pulmonary valve	C0242855		Approved			C0002335	11α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid
Alprostadil	Tricuspid Atresia	C0243002		Approved			C0002335	11α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid
Alprostadil	Aortic coarctation	C0003492		Approved			C0002335	11α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid
Alprostadil	Tetralogy of Fallot	C0039685		Approved			C0002335	11α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid
Alprostadil	Erectile dysfunction	C0242350		Approved			C0002335	11α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid
Clidinium	Irritable Bowel Syndrome	C0022104		Approved			C0055877	3-hydroxy-1-methylquinuclidinium benzilate ester
Clidinium	Enterocolitis	C0014356		Approved			C0055877	3-hydroxy-1-methylquinuclidinium benzilate ester
Malathion	Pediculus capitis infestation	C0030757		Approved			C0024547	diethyl (dimethoxyphosphinothioylthio)succinate
Etoposide	Small cell carcinoma of lung	C0149925		Approved			C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Hydroflumethiazide	Hypertensive disease	C0020538		Approved			C0020273	Hydroflumethiazidum
Hydroflumethiazide	Edema	C0013604		Approved			C0020273	Hydroflumethiazidum
Tirofiban	Non-Q wave myocardial infarction	C0542269		Approved			C0247025	(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
Tirofiban	Acute Coronary Syndrome	C0948089		Approved			C0247025	(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
Oxcarbazepine	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0069751	Oxcarbazepinum
Oxcarbazepine	Epilepsies, Partial	C0014547		Approved			C0069751	Oxcarbazepinum
Oxcarbazepine	Simple Partial Seizures	C0234974		Approved			C0069751	Oxcarbazepinum
Phenelzine	Depressive disorder	C0011581		Approved			C0031392	Fenelzina
Polymyxin B Sulfate	Infective blepharitis	C0729587		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Blepharoconjunctivitis	C0005743		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Uveitis	C0042164		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Corneal abrasion	C0010032		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Urinary tract infection	C0042029		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Bacterial conjunctivitis	C0009768		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Otitis Externa	C0029878		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Keratitis	C0022568		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Bacterial keratitis	C0854211		Approved			C0032535	Polymyxin B
Polymyxin B Sulfate	Bacterial sepsis	C0684256		Approved			C0032535	Polymyxin B
Propantheline	Peptic Ulcer	C0030920		Approved			C0033447	Propantheline
Estradiol	Carcinoma breast stage IV	C0278488		Approved			C0014912	17β-oestradiol
Estradiol	Atrophic Vaginitis	C0221392		Approved			C0014912	17β-oestradiol
Estradiol	Urethral atrophy	C0520577		Approved			C0014912	17β-oestradiol
Estradiol	Premenstrual Dysphoric Disorder	C0520676		Approved			C0014912	17β-oestradiol
Estradiol	Acne Vulgaris	C0001144		Approved			C0014912	17β-oestradiol
Estradiol	Atrophy of vulva	C0156393		Approved			C0014912	17β-oestradiol
Estradiol	Female hypogonadism syndrome	C0271578		Approved			C0014912	17β-oestradiol
Estradiol	Hot flushes	C0600142		Approved			C0014912	17β-oestradiol
Estradiol	Metastatic Prostate Carcinoma	C0936223		Approved			C0014912	17β-oestradiol
Mefenamic acid	Dysmenorrhea	C0013390		Approved			C0025152	N-2,3-xylylanthranilic acid
Mefenamic acid	Pain	C0030193		Approved			C0025152	N-2,3-xylylanthranilic acid
Aciclovir	Chickenpox	C0008049		Approved			C0001367	Aciclovir
Aciclovir	Herpes simplex infection of skin	C0349719		Approved			C0001367	Aciclovir
Aciclovir	Recurrent genital herpes simplex	C1274323		Approved			C0001367	Aciclovir
Aciclovir	Herpes Labialis	C0019345		Approved			C0001367	Aciclovir
Aciclovir	Herpes zoster disease	C0019360		Approved			C0001367	Aciclovir
Aciclovir	Herpes encephalitis	C0276226		Approved			C0001367	Aciclovir
Aciclovir	Herpes Simplex Infections	C0019348		Approved			C0001367	Aciclovir
Aciclovir	Genital Herpes	C0019342		Approved			C0001367	Aciclovir
Aciclovir	Recurrent herpes simplex labialis	C1274321		Approved			C0001367	Aciclovir
Naproxen	Arthralgia	C0003862		Approved			C0027396	Naproxenum
Naproxen	Rheumatoid Arthritis	C0003873		Approved			C0027396	Naproxenum
Naproxen	Sinus headache	C0037195		Approved			C0027396	Naproxenum
Naproxen	Dysmenorrhea	C0013390		Approved			C0027396	Naproxenum
Naproxen	Rhinorrhea	C1260880		Approved			C0027396	Naproxenum
Naproxen	Headache Disorders	C0393735		Approved			C0027396	Naproxenum
Naproxen	Migraine Disorders	C0149931		Approved			C0027396	Naproxenum
Naproxen	Degenerative polyarthritis	C0029408		Approved			C0027396	Naproxenum
Naproxen	Fever	C0015967		Approved			C0027396	Naproxenum
Naproxen	Bursitis	C0006444		Approved			C0027396	Naproxenum
Naproxen	Myalgia	C0231528		Approved			C0027396	Naproxenum
Naproxen	Pain	C0030193		Approved			C0027396	Naproxenum
Naproxen	Gout	C0018099		Approved			C0027396	Naproxenum
Naproxen	Tendinitis	C0039503		Approved			C0027396	Naproxenum
Naproxen	Ankylosing spondylitis	C0038013		Approved			C0027396	Naproxenum
Naproxen	Toothache	C0040460		Approved			C0027396	Naproxenum
Perindopril	Hypertensive disease	C0020538		Approved			C0136123	(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
Uracil mustard	Lymphoma, Non-Hodgkin	C0024305		Approved			C0041920	5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione
Uracil mustard	Polycythemia Vera	C0032463		Approved			C0041920	5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione
Uracil mustard	Myeloid Leukemia, Chronic	C0023473		Approved			C0041920	5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione
Uracil mustard	Chronic Lymphocytic Leukemia	C0023434		Approved			C0041920	5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione
Tripelennamine	Pruritus	C0033774		Approved			C0041090	Tripelennamina
Tripelennamine	Symptomatic dermographism	C0343065		Approved			C0041090	Tripelennamina
Tripelennamine	Allergic rhinitis (disorder)	C2607914		Approved			C0041090	Tripelennamina
Tripelennamine	Rhinorrhea	C1260880		Approved			C0041090	Tripelennamina
Tripelennamine	Urticaria	C0042109		Approved			C0041090	Tripelennamina
Tripelennamine	Rhinitis, Vasomotor	C0035460		Approved			C0041090	Tripelennamina
Tripelennamine	Nasal congestion (finding)	C0027424		Approved			C0041090	Tripelennamina
Tripelennamine	Sneezing	C0037383		Approved			C0041090	Tripelennamina
Tripelennamine	Allergic Conjunctivitis	C0009766		Approved			C0041090	Tripelennamina
Haloprogin	Tinea cruris	C1384589		Approved			C0062106	Haloproginum
Haloprogin	Tinea corporis (disorder)	C0040252		Approved			C0062106	Haloproginum
Haloprogin	Tinea Pedis	C0040259		Approved			C0062106	Haloproginum
Primidone	Simple Partial Seizures	C0234974		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Primidone	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Primidone	Bipolar disorder in remission	C0270425		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Primidone	Epilepsy	C0014544		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Primidone	Tonic - clonic seizures	C0494475		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Primidone	Tonic-Clonic Epilepsy	C0014549		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Primidone	Lennox-Gastaut syndrome	C0238111		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Primidone	Epilepsies, Partial	C0014547		Approved			C0033148	5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione
Sulfasalazine	Rheumatoid Arthritis	C0003873		Approved			C0036078	5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid
Sulfasalazine	Ulcerative Colitis	C0009324		Approved			C0036078	5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid
Candesartan	Hypertensive disease	C0020538		Approved			C0527379	Candesartan cilexetil
Candesartan	Chronic heart failure	C0264716		Approved			C0527379	Candesartan cilexetil
Tolazoline	Cerebrovascular Disorders	C0007820		Approved			C0040373	Benzazoline
Tolazoline	Persistent Fetal Circulation Syndrome	C0031190		Approved			C0040373	Benzazoline
Tolazoline	Vascular Diseases	C0042373		Approved			C0040373	Benzazoline
Gentamicin	Pneumonia due to Escherichia coli	C0276089		Approved			C3854019	Gentamicina
Gentamicin	Sepsis due to Gram negative bacteria	C3163829		Approved			C3854019	Gentamicina
Gentamicin	Pseudomonas aeruginosa meningitis	C3665869		Approved			C3854019	Gentamicina
Gentamicin	Meningitis, Bacterial	C0085437		Approved			C3854019	Gentamicina
Gentamicin	Serratia sepsis	C0152973		Approved			C3854019	Gentamicina
Gentamicin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C3854019	Gentamicina
Gentamicin	Serratia Infections	C0085394		Approved			C3854019	Gentamicina
Gentamicin	Pneumonia due to Pseudomonas	C0155860		Approved			C3854019	Gentamicina
Gentamicin	Infection of bone	C2242472		Approved			C3854019	Gentamicina
Gentamicin	Enterobacter pneumonia	C1096258		Approved			C3854019	Gentamicina
Gentamicin	Bacterial sepsis	C0684256		Approved			C3854019	Gentamicina
Gentamicin	Bacterial conjunctivitis	C0009768		Approved			C3854019	Gentamicina
Gentamicin	Cholangitis	C0008311		Approved			C3854019	Gentamicina
Gentamicin	Bacterial keratitis	C0854211		Approved			C3854019	Gentamicina
Gentamicin	Rhinoscleroma	C0035468		Approved			C3854019	Gentamicina
Gentamicin	Pneumonia, Bacterial	C0004626		Approved			C3854019	Gentamicina
Gentamicin	Escherichia coli septicemia	C0276088		Approved			C3854019	Gentamicina
Gentamicin	Dacryocystitis	C0010930		Approved			C3854019	Gentamicina
Gentamicin	Folliculitis	C0016436		Approved			C3854019	Gentamicina
Gentamicin	Blepharoconjunctivitis	C0005743		Approved			C3854019	Gentamicina
Gentamicin	Meibomianitis	C0549398		Approved			C3854019	Gentamicina
Gentamicin	Sepsis due to Pseudomonas	C2887096		Approved			C3854019	Gentamicina
Gentamicin	Peritonitis	C0031154		Approved			C3854019	Gentamicina
Gentamicin	Neonatal meningitis	C0456107		Approved			C3854019	Gentamicina
Gentamicin	Citrobacter sepsis	C1096254		Approved			C3854019	Gentamicina
Gentamicin	Escherichia coli Infections	C0014836		Approved			C3854019	Gentamicina
Gentamicin	Enterobacteriaceae Infections	C0014347		Approved			C3854019	Gentamicina
Gentamicin	Infection due to Pseudomonas aeruginosa	C0276075		Approved			C3854019	Gentamicina
Gentamicin	Neonatal pneumonia	C0339968		Approved			C3854019	Gentamicina
Gentamicin	Arthropathy associated with infection	C0157749		Approved			C3854019	Gentamicina
Gentamicin	Intraabdominal Infections	C1112209		Approved			C3854019	Gentamicina
Gentamicin	Paronychia Inflammation	C0030578		Approved			C3854019	Gentamicina
Gentamicin	Sepsis of the newborn	C0456103		Approved			C3854019	Gentamicina
Gentamicin	Proteus septicemia	C0577690		Approved			C3854019	Gentamicina
Gentamicin	Infective blepharitis	C0729587		Approved			C3854019	Gentamicina
Gentamicin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C3854019	Gentamicina
Gentamicin	Proteus pneumonia	C1260917		Approved			C3854019	Gentamicina
Gentamicin	Klebsiella sepsis	C0745528		Approved			C3854019	Gentamicina
Gentamicin	Furunculosis	C0016867		Approved			C3854019	Gentamicina
Tazarotene	Acne Vulgaris	C0001144		Approved			C0288792	Tazaroteno
Tazarotene	Psoriasis	C0033860		Approved			C0288792	Tazaroteno
Tazarotene	Facial hyperpigmentation	C2677857		Approved			C0288792	Tazaroteno
Fenoldopam	Hypertensive urgency	C0745138		Approved			C0060180	Fénoldopam
Fenoldopam	Malignant essential hypertension	C0024588		Approved			C0060180	Fénoldopam
Halazepam	Anxiety	C0003467		Approved			C0062092	Halazépam
Colistin	Pseudomonas aeruginosa infection	C0854135		Approved			C0009316	Colistinum
Colistin	Infection caused by Enterobacter	C0948205		Approved			C0009316	Colistinum
Colistin	Klebsiella Infections	C0022729		Approved			C0009316	Colistinum
Colistin	Otitis Externa	C0029878		Approved			C0009316	Colistinum
Dicyclomine	Irritable Bowel Syndrome	C0022104		Approved			C0012125	2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate
Pentoxifylline	Peripheral Vascular Diseases	C0085096		Approved			C0030899	Pentoxifilina
Indapamide	Hypertensive disease	C0020538		Approved			C0021186	Indapamida
Indapamide	Edema	C0013604		Approved			C0021186	Indapamida
Tropicamide	Mydriasis	C0026961		Approved			C0041190	Tropicamida
Tropicamide	Cycloplegia	C0235238		Approved			C0041190	Tropicamida
Biperiden	Extrapyramidal Disorders	C0015371		Approved			C0005578	alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
Biperiden	Parkinsonian Disorders	C0242422		Approved			C0005578	alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
Biperiden	Parkinson Disease	C0030567		Approved			C0005578	alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
Biperiden	Parkinson Disease, Postencephalitic	C0030568		Approved			C0005578	alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
Ribavirin	Hepatitis C, Chronic	C0524910		Approved			C0035525	Ribavirinum
Ribavirin	Respiratory Syncytial Virus Infections	C0035235		Approved			C0035525	Ribavirinum
Fentanyl	Acute postoperative pain	C2215257		Approved			C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Fentanyl	Pain	C0030193		Approved			C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Meloxicam	Rheumatoid Arthritis	C0003873		Approved			C0083381	Méloxicam
Meloxicam	Degenerative polyarthritis	C0029408		Approved			C0083381	Méloxicam
Orciprenaline	Bronchitis	C0006277		Approved			C0029193	Orciprenalina
Orciprenaline	Pulmonary Emphysema	C0034067		Approved			C0029193	Orciprenalina
Orciprenaline	Asthma attack	C0347950		Approved			C0029193	Orciprenalina
Orciprenaline	Asthma	C0004096		Approved			C0029193	Orciprenalina
Acetazolamide	Malignant glaucoma	C0271152		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Acetazolamide	Absence Epilepsy	C0014553		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Acetazolamide	Glaucoma, Open-Angle	C0017612		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Acetazolamide	Peripheral edema	C0085649		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Acetazolamide	Secondary glaucoma	C0149893		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Acetazolamide	Edema	C0013604		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Acetazolamide	Angle Closure Glaucoma	C0017605		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Acetazolamide	Altitude Sickness	C0002351		Approved			C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Tadalafil	Pulmonary Hypertension	C0020542		Approved			C1176316	(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
Tadalafil	Erectile dysfunction	C0242350		Approved			C1176316	(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
Tadalafil	Prostatic Hypertrophy	C1739363		Approved			C1176316	(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
Disulfiram	Alcoholic Intoxication, Chronic	C0001973		Approved			C0012772	Tetraethylthiuram disulphide
Menthol	Tinea Versicolor	C0040262		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Skin irritation	C0152030		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Pruritus	C0033774		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Scurfiness of scalp	C0423775		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Sprains and Strains	C0038048		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Arthritic pains	C0857177		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Mouth irritation	C0235339		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Diaper Rash	C0011974		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Back Pain	C0004604		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Menthol	Seborrheic dermatitis	C0036508		Approved			C0771655	(-)-(1R,3R,4S)-menthol
Natamycin	Fungal conjunctivitis	C0339170		Approved			C0027444	Natamicina
Natamycin	Fungal keratitis	C1262117		Approved			C0027444	Natamicina
Cinoxacin	Urinary tract infection	C0042029		Approved			C0008806	1-ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid
Fosfomycin	Escherichia coli urinary tract infection	C0577708		Approved			C0016610	L-cis-1,2-epoxypropylphosphonic acid
Fosfomycin	Urinary tract infection	C0042029		Approved			C0016610	L-cis-1,2-epoxypropylphosphonic acid
Fosfomycin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0016610	L-cis-1,2-epoxypropylphosphonic acid
Diazepam	Alcohol Withdrawal Delirium	C0001957		Approved			C0012010	Methyl diazepinone
Diazepam	Status Epilepticus	C0038220		Approved			C0012010	Methyl diazepinone
Diazepam	Anxiety	C0003467		Approved			C0012010	Methyl diazepinone
Diazepam	Alcohol withdrawal syndrome	C0236663		Approved			C0012010	Methyl diazepinone
Diazepam	Muscle Spasticity	C0026838		Approved			C0012010	Methyl diazepinone
Diazepam	Tetanus	C0039614		Approved			C0012010	Methyl diazepinone
Phenmetrazine	Obesity	C0028754		Approved			C0031411	2-phenyl-3-methylmorpholine
Trifluoperazine	Schizophrenia	C0036341		Approved			C0040979	10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
Trifluoperazine	Anxiety	C0003467		Approved			C0040979	10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
Phensuximide	Epilepsy	C0014544		Approved			C0070592	Fensuximida
Phensuximide	Absence Epilepsy	C0014553		Approved			C0070592	Fensuximida
Cefaclor	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0007537	Céfeaclor
Cefaclor	Tonsillitis	C0040425		Approved			C0007537	Céfeaclor
Cefaclor	Streptococcal tonsillitis	C0275804		Approved			C0007537	Céfeaclor
Cefaclor	Upper Respiratory Infections	C0041912		Approved			C0007537	Céfeaclor
Cefaclor	Haemophilus influenzae pneumonia	C0276026		Approved			C0007537	Céfeaclor
Cefaclor	Pneumonia	C0032285		Approved			C0007537	Céfeaclor
Cefaclor	Lower respiratory tract infection	C0149725		Approved			C0007537	Céfeaclor
Cefaclor	Urinary tract infection	C0042029		Approved			C0007537	Céfeaclor
Cefaclor	Pharyngitis	C0031350		Approved			C0007537	Céfeaclor
Cefaclor	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007537	Céfeaclor
Cefaclor	Staphylococcus aureus infection	C1318973		Approved			C0007537	Céfeaclor
Cefaclor	Infective otitis media	C0729586		Approved			C0007537	Céfeaclor
Mifepristone	Unspecified Abortion	C0156543		Approved			C0026088	Mifepristonum
Brompheniramine	Allergic Conjunctivitis	C0009766		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Influenza-like symptoms	C0392171		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Allergic rhinitis (disorder)	C2607914		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Hay fever	C0018621		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Urticaria	C0042109		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Pruritus	C0033774		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Symptomatic dermographism	C0343065		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Rhinorrhea	C1260880		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Brompheniramine	Rhinitis, Vasomotor	C0035460		Approved			C0006246	1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Loperamide	Traveler's diarrhea	C0277528		Approved			C0023992	Loperamidum
Loperamide	Diarrhea	C0011991		Approved			C0023992	Loperamidum
Clocortolone	Scalp psoriasis	C0406326		Approved			C0055899	Clocortolona
Clocortolone	Seborrheic dermatitis	C0036508		Approved			C0055899	Clocortolona
Clocortolone	Pruritus Ani	C0033775		Approved			C0055899	Clocortolona
Clocortolone	Lichen Simplex Chronicus	C0149922		Approved			C0055899	Clocortolona
Clocortolone	Contact Dermatitis	C0011616		Approved			C0055899	Clocortolona
Clocortolone	Chronic small plaque psoriasis	C0406317		Approved			C0055899	Clocortolona
Clocortolone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0055899	Clocortolona
Clocortolone	Pruritus of genital organs	C0033777		Approved			C0055899	Clocortolona
Clocortolone	Lupus Erythematosus, Discoid	C0024138		Approved			C0055899	Clocortolona
Clocortolone	Exanthema	C0015230		Approved			C0055899	Clocortolona
Clocortolone	Granuloma Annulare	C0085074		Approved			C0055899	Clocortolona
Tolazamide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0040372	N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea
Dobutamine	Shock, Cardiogenic	C0036980		Approved			C0012963	rac-dobutamine
Dobutamine	Decompensated cardiac failure	C0581377		Approved			C0012963	rac-dobutamine
Dobutamine	Heart Decompensation	C1961112		Approved			C0012963	rac-dobutamine
Oxazepam	Anxiety	C0003467		Approved			C0029997	(RS)-Oxazepam
Oxazepam	Alcohol Withdrawal Delirium	C0001957		Approved			C0029997	(RS)-Oxazepam
Donepezil	Alzheimer's Disease	C0002395		Approved			C0527316	Donepezilo
Nalbuphine	Pain	C0030193		Approved			C0027348	N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriol
Nalbuphine	Labor Pain	C0474368		Approved			C0027348	N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriol
Clofazimine	Dapsone resistant mycobacterium leprae disease	C1563054		Approved			C0008996	Clofazimina
Clofazimine	Pyoderma Gangrenosum	C0085652		Approved			C0008996	Clofazimina
Clofazimine	Erythema nodosum leprosum	C0343467		Approved			C0008996	Clofazimina
Clofazimine	Leprosy	C0023343		Approved			C0008996	Clofazimina
Clofazimine	Leprosy, Multibacillary	C1562585		Approved			C0008996	Clofazimina
Flurandrenolide	Lupus Erythematosus, Discoid	C0024138		Approved			C0016374	Fludroxycortide
Flurandrenolide	Pruritus of genital organs	C0033777		Approved			C0016374	Fludroxycortide
Flurandrenolide	Chronic small plaque psoriasis	C0406317		Approved			C0016374	Fludroxycortide
Flurandrenolide	Scalp psoriasis	C0406326		Approved			C0016374	Fludroxycortide
Flurandrenolide	Exanthema	C0015230		Approved			C0016374	Fludroxycortide
Flurandrenolide	Contact Dermatitis	C0011616		Approved			C0016374	Fludroxycortide
Flurandrenolide	Granuloma Annulare	C0085074		Approved			C0016374	Fludroxycortide
Flurandrenolide	Lichen Simplex Chronicus	C0149922		Approved			C0016374	Fludroxycortide
Flurandrenolide	Seborrheic dermatitis	C0036508		Approved			C0016374	Fludroxycortide
Flurandrenolide	Pruritus Ani	C0033775		Approved			C0016374	Fludroxycortide
Flurandrenolide	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0016374	Fludroxycortide
Flurandrenolide	Dermatitis, Atopic	C0011615		Approved			C0016374	Fludroxycortide
Cysteamine	Nephropathic cystinosis	C2931187		Approved			C0010648	Mercaptaminum
Methylphenobarbital	apprehension	C0233485		Approved			C0025382	5-ethyl-1-methyl-5-phenylbarbituric acid
Methylphenobarbital	Tonic-Clonic Epilepsy	C0014549		Approved			C0025382	5-ethyl-1-methyl-5-phenylbarbituric acid
Methylphenobarbital	Tension	C0233494		Approved			C0025382	5-ethyl-1-methyl-5-phenylbarbituric acid
Methylphenobarbital	Epilepsy	C0014544		Approved			C0025382	5-ethyl-1-methyl-5-phenylbarbituric acid
Methylphenobarbital	Anxiety	C0003467		Approved			C0025382	5-ethyl-1-methyl-5-phenylbarbituric acid
Perphenazine	Nausea and vomiting	C0027498		Approved			C0031184	Perphenazinum
Perphenazine	Schizophrenia	C0036341		Approved			C0031184	Perphenazinum
Perphenazine	Mixed anxiety and depressive disorder	C0338908		Approved			C0031184	Perphenazinum
Dacarbazine	Hodgkin Disease	C0019829		Approved			C0010927	DTIC
Dacarbazine	Malignant melanoma, metastatic	C0860594		Approved			C0010927	DTIC
Pseudoephedrine	Headache Disorders	C0393735		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Nasal congestion (finding)	C0027424		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Rhinorrhea	C1260880		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Allergic Conjunctivitis	C0009766		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Hay fever	C0018621		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Rhinitis, Vasomotor	C0035460		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Allergic rhinitis (disorder)	C2607914		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Influenza-like symptoms	C0392171		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Sinus headache	C0037195		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Rhinitis	C0035455		Approved			C0033798	Pseudoephedrine D-form
Pseudoephedrine	Common Cold	C0009443		Approved			C0033798	Pseudoephedrine D-form
Temozolomide	Anaplastic astrocytoma	C0334579		Approved			C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Temozolomide	Glioblastoma multiforme of brain	C0349543		Approved			C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Levorphanol	Pain	C0030193		Approved			C0023586	Levorphanolum
Aminolevulinic acid	Actinic keratosis	C0022602		Approved			C0002563	ácido 5-aminolevulínico
Chlorphenesin	Muscle Spasticity	C0026838		Approved			C0008280	glycerol α-p-chlorophenyl ether
Terbinafine	Onychomycosis	C0040261		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafine	Tinea Pedis	C0040259		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafine	Tinea Versicolor	C0040262		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafine	Onychomycosis of toenails	C1274470		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafine	Tinea Capitis	C0040250		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafine	Tinea cruris	C1384589		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafine	Onychomycosis of fingernails	C1274469		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafine	Tinea corporis (disorder)	C0040252		Approved			C0076110	(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Drostanolone	Corneal Ulcer	C0010043		Approved			C0058753	Drostanolonum
Drostanolone	Iritis	C0022081		Approved			C0058753	Drostanolonum
Drostanolone	Rosacea	C0035854		Approved			C0058753	Drostanolonum
Drostanolone	Anemia, Diamond-Blackfan	C1260899		Approved			C0058753	Drostanolonum
Drostanolone	Uveitis	C0042164		Approved			C0058753	Drostanolonum
Drostanolone	Aplastic Anemia	C0002874		Approved			C0058753	Drostanolonum
Drostanolone	Punctate keratopathy	C0423234		Approved			C0058753	Drostanolonum
Drostanolone	Iridocyclitis	C0022073		Approved			C0058753	Drostanolonum
Drostanolone	Allergic Conjunctivitis	C0009766		Approved			C0058753	Drostanolonum
Drostanolone	Herpes zoster keratitis	C1275687		Approved			C0058753	Drostanolonum
Drostanolone	Corneal abrasion	C0010032		Approved			C0058753	Drostanolonum
Drostanolone	Cyclitis	C0010543		Approved			C0058753	Drostanolonum
Drostanolone	Hypoplastic anemia	C0178416		Approved			C0058753	Drostanolonum
Penicillamine	Rheumatoid Arthritis	C0003873		Approved			C0030817	penicilamina
Penicillamine	Hepatolenticular Degeneration	C0019202		Approved			C0030817	penicilamina
Penicillamine	Cystinuria	C0010691		Approved			C0030817	penicilamina
Prednisolone	Bacterial conjunctivitis	C0009768		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Blepharoconjunctivitis	C0005743		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Iridocyclitis	C0022073		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Infective blepharitis	C0729587		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Dermatitis, Atopic	C0011615		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Pruritus of genital organs	C0033777		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Pruritus Ani	C0033775		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Lupus Erythematosus, Discoid	C0024138		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Lichen Simplex Chronicus	C0149922		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Contact Dermatitis	C0011616		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Granuloma Annulare	C0085074		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Exanthema	C0015230		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Scalp psoriasis	C0406326		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Seborrheic dermatitis	C0036508		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Chronic small plaque psoriasis	C0406317		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Ophthalmia, Sympathetic	C0029077		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Mycosis Fungoides	C0026948		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Ulcerative Colitis	C0009324		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Eosinophilic Pneumonia	C1527407		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Addison Disease	C0001403		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Musculoskeletal Diseases	C0026857		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Arthritis, Gouty	C0003868		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Addisonian crisis	C0151467		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Disorder of eye	C0015397		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Synovitis	C0039103		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Bacterial keratitis	C0854211		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Serum Sickness	C0036830		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Multiple Sclerosis	C0026769		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Sjogren's Syndrome	C1527336		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Nephrotic Syndrome	C0027726		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Exacerbation of asthma	C0349790		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Arthritis, Psoriatic	C0003872		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Stevens-Johnson Syndrome	C0038325		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Rheumatic Heart Disease	C0035439		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Cyclitis	C0010543		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Lymphoma, Follicular	C0024301		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Inflammatory Bowel Diseases	C0021390		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Keratitis	C0022568		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Ankylosing spondylitis	C0038013		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Punctate keratopathy	C0423234		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Crohn Disease	C0010346		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Cooley's anemia	C0002875		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Psoriasis	C0033860		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Status Asthmaticus	C0038218		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Simple Pulmonary Eosinophilia	C0242459		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Corneal abrasion	C0010032		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Uveitis	C0042164		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Lymphoma, Non-Hodgkin	C0024305		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Acute lymphocytic leukemia	C0023449		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Erythema Multiforme	C0014742		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Lupus Erythematosus, Systemic	C0024141		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Adrenal cortical hypofunction	C0405580		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Adrenogenital disorder	C0701163		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Exfoliative dermatitis	C0011606		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Pemphigus	C0030807		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Ocular Rosacea	C0406486		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Berylliosis	C0005138		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Anemia, Diamond-Blackfan	C1260899		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Bursitis	C0006444		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Epicondylitis	C0014488		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Meibomianitis	C0549398		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Acquired thrombocytopenia	C0154301		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Giant Cell Arteritis	C0039483		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Herpes zoster keratitis	C1275687		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Sarcoidosis	C0036202		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Aspergillosis, Allergic Bronchopulmonary	C0004031		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Post traumatic osteoarthritis	C2894027		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Transplanted organ rejection	C0345468		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Autoimmune Diseases	C0004364		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Asthma	C0004096		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Corneal Ulcer	C0010043		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Rosacea	C0035854		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Extrinsic allergic alveolitis	C0002390		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Thyroiditis	C0040147		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Dermatitis Herpetiformis	C0011608		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Polymyalgia Rheumatica	C0032533		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Dacryocystitis	C0010930		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Rheumatoid Arthritis	C0003873		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Angioedema	C0002994		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Autoimmune hemolytic anemia	C0002880		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Dermatologic disorders	C0037274		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Congenital adrenal hyperplasia	C0001627		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Tenosynovitis	C0039520		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Iritis	C0022081		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Cerebral Edema	C0006114		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Allergic rhinitis (disorder)	C2607914		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Tuberculosis, Miliary	C0041321		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Tendinitis	C0039503		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Hodgkin Disease	C0019829		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Pulmonary Fibrosis	C0034069		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Allergic Conjunctivitis	C0009766		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Aspiration pneumonitis	C1761609		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Prednisolone	Laryngeal Edema	C0023052		Approved			C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Diflunisal	Degenerative polyarthritis	C0029408		Approved			C0012228	2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid
Diflunisal	Rheumatoid Arthritis	C0003873		Approved			C0012228	2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid
Diflunisal	Pain	C0030193		Approved			C0012228	2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid
Diflunisal	Chronic pain	C0150055		Approved			C0012228	2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid
Vardenafil	Erectile dysfunction	C0242350		Approved			C0971579	Vardenafilo
Ranitidine	Erosive esophagitis	C0267055		Approved			C0034665	Ranitidinum
Ranitidine	Duodenal Ulcer	C0013295		Approved			C0034665	Ranitidinum
Ranitidine	Zollinger-Ellison syndrome	C0043515		Approved			C0034665	Ranitidinum
Ranitidine	Dyspepsia	C0013395		Approved			C0034665	Ranitidinum
Ranitidine	Gastroesophageal reflux disease	C0017168		Approved			C0034665	Ranitidinum
Ranitidine	Heartburn	C0018834		Approved			C0034665	Ranitidinum
Ranitidine	Gastric ulcer	C0038358		Approved			C0034665	Ranitidinum
Tacrolimus	Transplanted organ rejection	C0345468		Approved			C0771204	Tacrolimus anhydrous
Tacrolimus	Renal transplant rejection	C0238217		Approved			C0771204	Tacrolimus anhydrous
Tacrolimus	Liver transplant rejection	C0400968		Approved			C0771204	Tacrolimus anhydrous
Benzphetamine	Obesity	C0028754		Approved			C0005096	Benzfetamina
Ritodrine	Premature Obstetric Labor	C0022876		Approved			C0035661	p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol
Benzonatate	Coughing	C0010200		Approved			C0053229	nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate
Dorzolamide	Glaucoma, Open-Angle	C0017612		Approved			C0165590	4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
Dorzolamide	Ocular Hypertension	C0028840		Approved			C0165590	4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
Terbutaline	Pulmonary Emphysema	C0034067		Approved			C0039542	Terbutalina
Terbutaline	Pruritus	C0033774		Approved			C0039542	Terbutalina
Terbutaline	Dry Eye Syndromes	C0013238		Approved			C0039542	Terbutalina
Terbutaline	Asthma	C0004096		Approved			C0039542	Terbutalina
Terbutaline	Skin irritation	C0152030		Approved			C0039542	Terbutalina
Terbutaline	Bronchitis	C0006277		Approved			C0039542	Terbutalina
Terbutaline	Asthma attack	C0347950		Approved			C0039542	Terbutalina
Conivaptan	Hyponatremia	C0020625		Approved			C0966107	4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
Loteprednol	Iritis	C0022081		Approved			C0772364	Loteprednol
Loteprednol	Herpes zoster keratoconjunctivitis	C0153027		Approved			C0772364	Loteprednol
Loteprednol	Corneal abrasion	C0010032		Approved			C0772364	Loteprednol
Loteprednol	Corneal Perforation	C0339293		Approved			C0772364	Loteprednol
Loteprednol	Punctate keratitis	C0259799		Approved			C0772364	Loteprednol
Loteprednol	Rosacea	C0035854		Approved			C0772364	Loteprednol
Loteprednol	Herpes zoster keratitis	C1275687		Approved			C0772364	Loteprednol
Loteprednol	Iridocyclitis	C0022073		Approved			C0772364	Loteprednol
Loteprednol	Anterior uveitis	C0042165		Approved			C0772364	Loteprednol
Loteprednol	Ocular Rosacea	C0406486		Approved			C0772364	Loteprednol
Loteprednol	Allergic Conjunctivitis	C0009766		Approved			C0772364	Loteprednol
Guaifenesin	Headache Disorders	C0393735		Approved			C0018305	Guaifenesina
Guaifenesin	Fever	C0015967		Approved			C0018305	Guaifenesina
Guaifenesin	Rhinitis	C0035455		Approved			C0018305	Guaifenesina
Guaifenesin	Common Cold	C0009443		Approved			C0018305	Guaifenesina
Guaifenesin	Influenza-like symptoms	C0392171		Approved			C0018305	Guaifenesina
Guaifenesin	Allergic rhinitis (disorder)	C2607914		Approved			C0018305	Guaifenesina
Guaifenesin	Nasal congestion (finding)	C0027424		Approved			C0018305	Guaifenesina
Guaifenesin	Rhinorrhea	C1260880		Approved			C0018305	Guaifenesina
Guaifenesin	Sinus headache	C0037195		Approved			C0018305	Guaifenesina
Guaifenesin	Coughing	C0010200		Approved			C0018305	Guaifenesina
Flupentixol	Schizophrenia	C0036341		Approved			C0016367	Flupentixolum
Eprosartan	Hypertensive disease	C0020538		Approved			C0287041	(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
Sirolimus	Renal Cell Carcinoma	C0007134		Approved			C0072980	Sirolimús
Sirolimus	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634		Approved			C0072980	Sirolimús
Sirolimus	Pulmonary lymphangioleiomyomatosis	C0349649		Approved			C0072980	Sirolimús
Chlorhexidine	Gingivitis	C0017574		Approved			C0008196	N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
Emtricitabine	HIV Infections	C0019693		Approved			C0909839	5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
Chlorothiazide	Edema	C0013604		Approved			C0008273	Clorotiazida
Chlorothiazide	Hypertensive urgency	C0745138		Approved			C0008273	Clorotiazida
Chlorothiazide	Hypertensive disease	C0020538		Approved			C0008273	Clorotiazida
Chlorothiazide	Chronic heart failure	C0264716		Approved			C0008273	Clorotiazida
Quinapril	Hypertensive disease	C0020538		Approved			C0072857	Quinaprilum
Quinapril	Chronic heart failure	C0264716		Approved			C0072857	Quinaprilum
Clomifene	Female infertility	C0021361		Approved			C0009008	2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine
Isosorbide Dinitrate	Chronic heart failure	C0264716		Approved			C0022252	Isosorbidi dinitras
Isosorbide Dinitrate	Angina Pectoris	C0002962		Approved			C0022252	Isosorbidi dinitras
Risedronate	Osteitis Deformans	C0029401		Approved			C0140610	Risedronic acid
Risedronate	Osteoporosis, Postmenopausal	C0029458		Approved			C0140610	Risedronic acid
Risedronate	Osteoporosis	C0029456		Approved			C0140610	Risedronic acid
Pemirolast	Allergic Conjunctivitis	C0009766		Approved			C0053881	Pemirolastum
Pemirolast	Asthma	C0004096		Approved			C0053881	Pemirolastum
Pemirolast	Allergic rhinitis (disorder)	C2607914		Approved			C0053881	Pemirolastum
Bumetanide	Renal disease with edema NOS	C0866125		Approved			C0006376	3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid
Bumetanide	Edema	C0013604		Approved			C0006376	3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid
Mechlorethamine	Hodgkin Disease	C0019829		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Malignant neoplasm of lung	C0242379		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Lymphoma, Non-Hodgkin	C0024305		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Malignant pericardial effusion	C0220655		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Chronic Lymphocytic Leukemia	C0023434		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Myeloid Leukemia, Chronic	C0023473		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Pleural Effusion, Malignant	C0080032		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Malignant ascites	C0220656		Approved			C0025033	methylbis(β-chloroethyl)amine
Mechlorethamine	Mycosis Fungoides	C0026948		Approved			C0025033	methylbis(β-chloroethyl)amine
Granisetron	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C0061863	Granisétron
Dienestrol	Dyspareunia	C1384606		Approved			C0012145	4,4'-Hydroxy-γ,δ-diphenyl-β,δ-hexadiene
Dienestrol	Atrophy of vulva	C0156393		Approved			C0012145	4,4'-Hydroxy-γ,δ-diphenyl-β,δ-hexadiene
Dienestrol	Atrophic Vaginitis	C0221392		Approved			C0012145	4,4'-Hydroxy-γ,δ-diphenyl-β,δ-hexadiene
Sulfapyridine	Dermatitis Herpetiformis	C0011608		Approved			C0038710	2-(p-Aminobenzenesulphonamido)pyridine
Testolactone	Malignant epithelial neoplasm of female breast	C3163805		Approved			C0039600	Δ1-testololactone
Rimexolone	Uveitis	C0042164		Approved			C0140594	Rimexolona
Triazolam	Sleeplessness	C0917801		Approved			C0040879	Triazolamum
Remifentanil	Acute postoperative pain	C2215257		Approved			C0246631	Remifentanilo
Didanosine	HIV Infections	C0019693		Approved			C0012133	9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
Methdilazine	Pruritus	C0033774		Approved			C0066101	Methdilazinum
Methdilazine	Allergic rhinitis (disorder)	C2607914		Approved			C0066101	Methdilazinum
Methdilazine	Nasal congestion (finding)	C0027424		Approved			C0066101	Methdilazinum
Methdilazine	Angioedema	C0002994		Approved			C0066101	Methdilazinum
Methdilazine	Symptomatic dermographism	C0343065		Approved			C0066101	Methdilazinum
Methdilazine	Rhinorrhea	C1260880		Approved			C0066101	Methdilazinum
Methdilazine	Urticaria	C0042109		Approved			C0066101	Methdilazinum
Methdilazine	Allergic Conjunctivitis	C0009766		Approved			C0066101	Methdilazinum
Methdilazine	Sneezing	C0037383		Approved			C0066101	Methdilazinum
Etacrynic acid	Edema	C0013604		Approved			C0014963	Acidum etacrynicum
Ondansetron	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C0061851	Ondansetron
Bimatoprost	Glaucoma, Open-Angle	C0017612		Approved			C0937917	(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
Bimatoprost	Ocular Hypertension	C0028840		Approved			C0937917	(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
Bimatoprost	Hypertrichosis of eyelid	C0155213		Approved			C0937917	(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
Tiagabine	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0068897	Tiagabinum
Tiagabine	Simple Partial Seizures	C0234974		Approved			C0068897	Tiagabinum
Quinidine	Pseudobulbar affect	C2316460		Approved			C0034414	Quinidina
Tinidazole	Acute amebiasis	C0152499		Approved			C0040263	Tinidazol
Tinidazole	Trichomonas Infections	C0040921		Approved			C0040263	Tinidazol
Tinidazole	Bacterial Vaginosis	C0085166		Approved			C0040263	Tinidazol
Tinidazole	Liver Abscess, Amebic	C0023886		Approved			C0040263	Tinidazol
Tinidazole	Giardiasis	C0017536		Approved			C0040263	Tinidazol
Repaglinide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0246689	Repaglinida
Amantadine	Extrapyramidal Disorders	C0015371		Approved			C0002403	Amantadinum
Amantadine	Parkinson Disease	C0030567		Approved			C0002403	Amantadinum
Amantadine	Parkinsonian Disorders	C0242422		Approved			C0002403	Amantadinum
Amantadine	Influenza due to Influenza A virus	C2711180		Approved			C0002403	Amantadinum
Amantadine	Parkinson Disease, Postencephalitic	C0030568		Approved			C0002403	Amantadinum
Metronidazole	Liver Abscess, Amebic	C0023886		Approved			C0025872	Metronidazol
Metronidazole	Bacteroides empyema	C2062454		Approved			C0025872	Metronidazol
Metronidazole	Infection due to anaerobic bacteria	C0854328		Approved			C0025872	Metronidazol
Metronidazole	Bacterial sepsis	C0684256		Approved			C0025872	Metronidazol
Metronidazole	Acute amebiasis	C0152499		Approved			C0025872	Metronidazol
Metronidazole	Female genital tract infection	C1263758		Approved			C0025872	Metronidazol
Metronidazole	Arthropathy associated with infection	C0157749		Approved			C0025872	Metronidazol
Metronidazole	Trichomonas Infections	C0040921		Approved			C0025872	Metronidazol
Metronidazole	Liver Abscess	C0023885		Approved			C0025872	Metronidazol
Metronidazole	Lower respiratory tract infection	C0149725		Approved			C0025872	Metronidazol
Metronidazole	Tubo-ovarian abscess	C0041343		Approved			C0025872	Metronidazol
Metronidazole	Intraabdominal Infections	C1112209		Approved			C0025872	Metronidazol
Metronidazole	Peritonitis	C0031154		Approved			C0025872	Metronidazol
Metronidazole	Bacterial Vaginosis	C0085166		Approved			C0025872	Metronidazol
Metronidazole	Infection of bone	C2242472		Approved			C0025872	Metronidazol
Metronidazole	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0025872	Metronidazol
Metronidazole	Giardiasis	C0017536		Approved			C0025872	Metronidazol
Metronidazole	Brain Abscess	C0006105		Approved			C0025872	Metronidazol
Metronidazole	Meningitis due to Bacteroides	C0865436		Approved			C0025872	Metronidazol
Metronidazole	Septicemia due to Bacteroides	C0276064		Approved			C0025872	Metronidazol
Metronidazole	Abdominal Abscess	C0243001		Approved			C0025872	Metronidazol
Metronidazole	Endometritis	C0014179		Approved			C0025872	Metronidazol
Dinoprostone	Hydatidiform mole, benign	C0549315		Approved			C0012472	(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
Dinoprostone	Unspecified Abortion	C0156543		Approved			C0012472	(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
Dinoprostone	Incomplete spontaneous abortion	C0000810		Approved			C0012472	(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
Almotriptan	Migraine Disorders	C0149931		Approved			C0914729	1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
Spectinomycin	GONOCOCCAL INFECTION DISSEMINATED	C0744451		Approved			C0001268	Spectinomicina
Spectinomycin	Gonorrhea of rectum	C0275665		Approved			C0001268	Spectinomicina
Spectinomycin	Gonorrhea	C0018081		Approved			C0001268	Spectinomicina
Spectinomycin	Acute gonococcal cervicitis	C0153195		Approved			C0001268	Spectinomicina
Spectinomycin	Acute gonococcal urethritis	C0275652		Approved			C0001268	Spectinomicina
Ketotifen	Allergic Conjunctivitis	C0009766		Approved			C0022642	Ketotifene
Buprenorphine	Opiate Addiction	C0524662		Approved			C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Buprenorphine	Chronic pain	C0150055		Approved			C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Buprenorphine	Acute postoperative pain	C2215257		Approved			C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Buprenorphine	Severe pain	C0278140		Approved			C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Levosimendan	Congestive heart failure	C0018802		Approved			C0246904	Lévosimendan
Cyclobenzaprine	Muscle Spasticity	C0026838		Approved			C0056732	Cyclobenzaprinum
Phenoxybenzamine	Pheochromocytoma	C0031511		Approved			C0031441	Fenoxibenzamina
Famotidine	Peptic Esophagitis	C0014869		Approved			C0015620	Famotidina
Famotidine	Duodenal Ulcer	C0013295		Approved			C0015620	Famotidina
Famotidine	Zollinger-Ellison syndrome	C0043515		Approved			C0015620	Famotidina
Famotidine	Dyspepsia	C0013395		Approved			C0015620	Famotidina
Famotidine	Heartburn	C0018834		Approved			C0015620	Famotidina
Famotidine	Erosive esophagitis	C0267055		Approved			C0015620	Famotidina
Famotidine	Gastric ulcer	C0038358		Approved			C0015620	Famotidina
Famotidine	Gastroesophageal reflux disease	C0017168		Approved			C0015620	Famotidina
Misoprostol	Postpartum Hemorrhage	C0032797		Approved			C0085174	Misoprostolum
Colesevelam	Hypercholesterolemia	C0020443		Approved			C0541155	Colesevelam
Methacycline	Bacterial enteritis	C0152516		Approved			C0025603	Methacycline
Tipranavir	HIV Infections	C0019693		Approved			C0663733	Tipranavir
Mesoridazine	Schizophrenia	C0036341		Approved			C2354526	Thioridazine 2-sulfoxide
Maprotiline	Mixed anxiety and depressive disorder	C0338908		Approved			C0024778	Maprotilina
Maprotiline	Depressive disorder	C0011581		Approved			C0024778	Maprotilina
Oxymetazoline	Rhinorrhea	C1260880		Approved			C0030071	Oxymétazoline
Oxymetazoline	Nasal congestion (finding)	C0027424		Approved			C0030071	Oxymétazoline
Oxymetazoline	Redness of eye	C0235267		Approved			C0030071	Oxymétazoline
Salicylic acid	Allergic rhinitis (disorder)	C2607914		Approved			C0036079	ácido salicílico
Salicylic acid	Degenerative polyarthritis	C0029408		Approved			C0036079	ácido salicílico
Salicylic acid	Hyperkeratosis	C0870082		Approved			C0036079	ácido salicílico
Salicylic acid	Fever	C0015967		Approved			C0036079	ácido salicílico
Salicylic acid	Seborrheic dermatitis	C0036508		Approved			C0036079	ácido salicílico
Salicylic acid	Scurfiness of scalp	C0423775		Approved			C0036079	ácido salicílico
Salicylic acid	Common Cold	C0009443		Approved			C0036079	ácido salicílico
Salicylic acid	Plantar wart	C0042548		Approved			C0036079	ácido salicílico
Salicylic acid	Acne Vulgaris	C0001144		Approved			C0036079	ácido salicílico
Salicylic acid	Tinea Pedis	C0040259		Approved			C0036079	ácido salicílico
Salicylic acid	Rheumatoid Arthritis	C0003873		Approved			C0036079	ácido salicílico
Salicylic acid	Pain	C0030193		Approved			C0036079	ácido salicílico
Salicylic acid	Tinea corporis (disorder)	C0040252		Approved			C0036079	ácido salicílico
Salicylic acid	Greasy skin	C0234925		Approved			C0036079	ácido salicílico
Salicylic acid	Synovitis	C0039103		Approved			C0036079	ácido salicílico
Salicylic acid	Disorder of keratinization	C0475811		Approved			C0036079	ácido salicílico
Salicylic acid	Corns and callus	C0157726		Approved			C0036079	ácido salicílico
Salicylic acid	Influenza-like symptoms	C0392171		Approved			C0036079	ácido salicílico
Salicylic acid	Migraine Disorders	C0149931		Approved			C0036079	ácido salicílico
Salicylic acid	Back Pain	C0004604		Approved			C0036079	ácido salicílico
Salicylic acid	Headache Disorders	C0393735		Approved			C0036079	ácido salicílico
Salicylic acid	Sinus headache	C0037195		Approved			C0036079	ácido salicílico
Salicylic acid	Toothache	C0040460		Approved			C0036079	ácido salicílico
Salicylic acid	Myocardial Infarction	C0027051		Approved			C0036079	ácido salicílico
Salicylic acid	Arthralgia	C0003862		Approved			C0036079	ácido salicílico
Salicylic acid	Arthritic pains	C0857177		Approved			C0036079	ácido salicílico
Diethylpropion	Obesity	C0028754		Approved			C0012201	2-(diethylamino)-1-phenyl-1-propanone
Salmeterol	Intrinsic asthma	C0155880		Approved			C0073992	Salmeterolum
Salmeterol	Pulmonary Emphysema	C0034067		Approved			C0073992	Salmeterolum
Salmeterol	Allergic asthma	C0155877		Approved			C0073992	Salmeterolum
Meclofenamic acid	Degenerative polyarthritis	C0029408		Approved			C0025042	ácido meclofenámico
Meclofenamic acid	Rheumatoid Arthritis	C0003873		Approved			C0025042	ácido meclofenámico
Meclofenamic acid	Menorrhagia	C0025323		Approved			C0025042	ácido meclofenámico
Meclofenamic acid	Dysmenorrhea	C0013390		Approved			C0025042	ácido meclofenámico
Meclofenamic acid	Pain	C0030193		Approved			C0025042	ácido meclofenámico
Methantheline	Peptic Ulcer	C0030920		Approved			C0025624	Methantheline ion
Methantheline	Gastric ulcer	C0038358		Approved			C0025624	Methantheline ion
Methantheline	Urinary Incontinence	C0042024		Approved			C0025624	Methantheline ion
Cycrimine	Parkinson Disease	C0030567		Approved			C0056835	alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol
Zalcitabine	HIV Infections	C0019693		Approved			C0012132	4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
Acetylsalicylic acid	Rheumatoid Arthritis	C0003873		Approved			C0004057	Aspirina
Acetylsalicylic acid	Influenza-like symptoms	C0392171		Approved			C0004057	Aspirina
Acetylsalicylic acid	Migraine Disorders	C0149931		Approved			C0004057	Aspirina
Acetylsalicylic acid	Back Pain	C0004604		Approved			C0004057	Aspirina
Acetylsalicylic acid	Degenerative polyarthritis	C0029408		Approved			C0004057	Aspirina
Acetylsalicylic acid	Headache Disorders	C0393735		Approved			C0004057	Aspirina
Acetylsalicylic acid	Common Cold	C0009443		Approved			C0004057	Aspirina
Acetylsalicylic acid	Pain	C0030193		Approved			C0004057	Aspirina
Acetylsalicylic acid	Sinus headache	C0037195		Approved			C0004057	Aspirina
Acetylsalicylic acid	Toothache	C0040460		Approved			C0004057	Aspirina
Acetylsalicylic acid	Myocardial Infarction	C0027051		Approved			C0004057	Aspirina
Acetylsalicylic acid	Arthralgia	C0003862		Approved			C0004057	Aspirina
Acetylsalicylic acid	Arthritic pains	C0857177		Approved			C0004057	Aspirina
Phenprocoumon	Thrombosis	C0040053		Approved			C0031444	Fenprocumon
Phenprocoumon	Myocardial Infarction	C0027051		Approved			C0031444	Fenprocumon
Phenprocoumon	Thromboembolism	C0040038		Approved			C0031444	Fenprocumon
Mezlocillin	Bacterial sepsis	C0684256		Approved			C0025893	Mezlocillinum
Mezlocillin	Urinary tract infection	C0042029		Approved			C0025893	Mezlocillinum
Mezlocillin	Intraabdominal Infections	C1112209		Approved			C0025893	Mezlocillinum
Mezlocillin	Pneumonia due to Pseudomonas	C0155860		Approved			C0025893	Mezlocillinum
Mezlocillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0025893	Mezlocillinum
Mezlocillin	Enterobacter pneumonia	C1096258		Approved			C0025893	Mezlocillinum
Mezlocillin	Genitourinary tract infection	C1279247		Approved			C0025893	Mezlocillinum
Mezlocillin	Serratia Infections	C0085394		Approved			C0025893	Mezlocillinum
Mezlocillin	Aspiration Pneumonia	C0032290		Approved			C0025893	Mezlocillinum
Mezlocillin	Haemophilus influenzae pneumonia	C0276026		Approved			C0025893	Mezlocillinum
Mezlocillin	Pneumonia due to Escherichia coli	C0276089		Approved			C0025893	Mezlocillinum
Mezlocillin	Acute gonococcal endometritis	C0153196		Approved			C0025893	Mezlocillinum
Mezlocillin	Gonorrhea	C0018081		Approved			C0025893	Mezlocillinum
Mezlocillin	Acute gonococcal cervicitis	C0153195		Approved			C0025893	Mezlocillinum
Mezlocillin	Acute gonococcal urethritis	C0275652		Approved			C0025893	Mezlocillinum
Mezlocillin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0025893	Mezlocillinum
Felbamate	Simple Partial Seizures	C0234974		Approved			C0060135	2-phenyl-1,3-propanediol dicarbamate
Felbamate	Lennox-Gastaut syndrome	C0238111		Approved			C0060135	2-phenyl-1,3-propanediol dicarbamate
Felbamate	Epilepsy	C0014544		Approved			C0060135	2-phenyl-1,3-propanediol dicarbamate
Fexofenadine	Chronic idiopathic urticaria	C0578870		Approved			C0296800	Fexofenadina
Fexofenadine	Hay fever	C0018621		Approved			C0296800	Fexofenadina
Fexofenadine	Allergic Conjunctivitis	C0009766		Approved			C0296800	Fexofenadina
Fexofenadine	Allergic rhinitis (disorder)	C2607914		Approved			C0296800	Fexofenadina
Fexofenadine	Sneezing	C0037383		Approved			C0296800	Fexofenadina
Isoniazid	Acute tuberculosis	C0275959		Approved			C0022209	Isoniazida
Isoniazid	Tuberculosis, Pulmonary	C0041327		Approved			C0022209	Isoniazida
Naratriptan	Migraine Disorders	C0149931		Approved			C0540623	Naratriptán
Rizatriptan	Migraine Disorders	C0149931		Approved			C0297635	Rizatriptanum
Dirithromycin	Staphylococcus aureus infection	C1318973		Approved			C0058445	Dirithromycin
Dirithromycin	Pharyngitis	C0031350		Approved			C0058445	Dirithromycin
Dirithromycin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0058445	Dirithromycin
Dirithromycin	Legionella pneumophila pneumonia	C0857846		Approved			C0058445	Dirithromycin
Dirithromycin	Streptococcal tonsillitis	C0275804		Approved			C0058445	Dirithromycin
Dirithromycin	Bronchitis	C0006277		Approved			C0058445	Dirithromycin
Dirithromycin	Tonsillitis	C0040425		Approved			C0058445	Dirithromycin
Dirithromycin	Streptococcus pyogenes infection	C0554628		Approved			C0058445	Dirithromycin
Dirithromycin	Pneumonia	C0032285		Approved			C0058445	Dirithromycin
Dirithromycin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0058445	Dirithromycin
Dirithromycin	Mycoplasma pneumonia	C0032302		Approved			C0058445	Dirithromycin
Hydrocodone	Rhinorrhea	C1260880		Approved			C0020264	Hidrocodona
Hydrocodone	Nasal congestion (finding)	C0027424		Approved			C0020264	Hidrocodona
Hydrocodone	Coughing	C0010200		Approved			C0020264	Hidrocodona
Hydrocodone	Rhinitis	C0035455		Approved			C0020264	Hidrocodona
Hydrocodone	Pain	C0030193		Approved			C0020264	Hidrocodona
Hydrocodone	Allergic rhinitis (disorder)	C2607914		Approved			C0020264	Hidrocodona
Hydrocodone	Common Cold	C0009443		Approved			C0020264	Hidrocodona
Norgestimate	Acne Vulgaris	C0001144		Approved			C0068992	(17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
Norgestimate	Atrophic Vaginitis	C0221392		Approved			C0068992	(17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
Norgestimate	Atrophy of vulva	C0156393		Approved			C0068992	(17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
Norgestimate	Hot flushes	C0600142		Approved			C0068992	(17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
Carboplatin	Malignant neoplasm of ovary	C1140680		Approved			C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Methylprednisolone	Mycosis Fungoides	C0026948		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Asthma	C0004096		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Rheumatoid Arthritis	C0003873		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Rheumatic Heart Disease	C0035439		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Pruritus Ani	C0033775		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Laryngeal Edema	C0023052		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Congenital adrenal hyperplasia	C0001627		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Dermatologic disorders	C0037274		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Arthritis, Psoriatic	C0003872		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Addison Disease	C0001403		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Exacerbation of asthma	C0349790		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Epicondylitis	C0014488		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Exfoliative dermatitis	C0011606		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Multiple Sclerosis	C0026769		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Lichen Simplex Chronicus	C0149922		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Arthritis, Gouty	C0003868		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Thyroiditis	C0040147		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Autoimmune hemolytic anemia	C0002880		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Chronic small plaque psoriasis	C0406317		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Hodgkin Disease	C0019829		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Dermatitis Herpetiformis	C0011608		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Cerebral Edema	C0006114		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Lymphoma, Follicular	C0024301		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Berylliosis	C0005138		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Lymphoma, Non-Hodgkin	C0024305		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Erythema Multiforme	C0014742		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Exanthema	C0015230		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Granuloma Annulare	C0085074		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Pruritus of genital organs	C0033777		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Acute lymphocytic leukemia	C0023449		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Synovitis	C0039103		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Tendinitis	C0039503		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Adrenogenital disorder	C0701163		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Angioedema	C0002994		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Serum Sickness	C0036830		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Post traumatic osteoarthritis	C2894027		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Scalp psoriasis	C0406326		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Lupus Erythematosus, Discoid	C0024138		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Transplanted organ rejection	C0345468		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Allergic rhinitis (disorder)	C2607914		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Acquired thrombocytopenia	C0154301		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Lupus Erythematosus, Systemic	C0024141		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Tenosynovitis	C0039520		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Seborrheic dermatitis	C0036508		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Musculoskeletal Diseases	C0026857		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Pemphigus	C0030807		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Sarcoidosis	C0036202		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Status Asthmaticus	C0038218		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Simple Pulmonary Eosinophilia	C0242459		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Contact Dermatitis	C0011616		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Trichinellosis	C0040896		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Anemia, Diamond-Blackfan	C1260899		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Adrenal cortical hypofunction	C0405580		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Nephrotic Syndrome	C0027726		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Ankylosing spondylitis	C0038013		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Bursitis	C0006444		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Crohn Disease	C0010346		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Autoimmune Diseases	C0004364		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Psoriasis	C0033860		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Tuberculosis, Miliary	C0041321		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Addisonian crisis	C0151467		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Disorder of eye	C0015397		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Inflammatory Bowel Diseases	C0021390		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Cooley's anemia	C0002875		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Aspiration pneumonitis	C1761609		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Dermatitis, Atopic	C0011615		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Hay fever	C0018621		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Methylprednisolone	Rhinitis, Allergic, Perennial	C0035457		Approved			C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Pindolol	Hypertensive disease	C0020538		Approved			C0031937	1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol
Zaleplon	Initial insomnia	C0393760		Approved			C0251504	3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
Zaleplon	Sleep Initiation and Maintenance Disorders	C0021603		Approved			C0251504	3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
Bromfenac	Pain	C0030193		Approved			C0054094	Bromfenaco
Apraclonidine	Cerebrovascular Occlusion	C0596298		Approved			C0048038	Apraclonidina
Apraclonidine	Glaucoma, Open-Angle	C0017612		Approved			C0048038	Apraclonidina
Telmisartan	Hypertensive disease	C0020538		Approved			C0248719	4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
Telmisartan	Cerebrovascular accident	C0038454		Approved			C0248719	4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
Desloratadine	Chronic idiopathic urticaria	C0578870		Approved			C0908935	Desloratadina
Desloratadine	Rhinitis, Vasomotor	C0035460		Approved			C0908935	Desloratadina
Desloratadine	Hay fever	C0018621		Approved			C0908935	Desloratadina
Desloratadine	Sneezing	C0037383		Approved			C0908935	Desloratadina
Desloratadine	Allergic Conjunctivitis	C0009766		Approved			C0908935	Desloratadina
Desloratadine	Common Cold	C0009443		Approved			C0908935	Desloratadina
Desloratadine	Nasal congestion (finding)	C0027424		Approved			C0908935	Desloratadina
Desloratadine	Rhinorrhea	C1260880		Approved			C0908935	Desloratadina
Desloratadine	Allergic rhinitis (disorder)	C2607914		Approved			C0908935	Desloratadina
Desloratadine	Allergic urticaria	C0149526		Approved			C0908935	Desloratadina
Methyldopa	Hypertensive disease	C0020538		Approved			C0025741	metildopa
Alosetron	Irritable bowel syndrome with diarrhea	C0348898		Approved			C0291772	2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one
Alosetron	Diarrhoea predominant irritable bowel syndrome	C1262211		Approved			C0291772	2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one
Dactinomycin	Gestational Trophoblastic Neoplasms	C1135868		Approved			C0010934	Actinomycin IV
Dactinomycin	Nephroblastoma	C0027708		Approved			C0010934	Actinomycin IV
Dactinomycin	Rhabdomyosarcoma	C0035412		Approved			C0010934	Actinomycin IV
Dactinomycin	Ewings sarcoma	C0553580		Approved			C0010934	Actinomycin IV
Selenium Sulfide	Seborrheic dermatitis	C0036508		Approved			C0074281	Selenii disulfidum
Selenium Sulfide	Scurfiness of scalp	C0423775		Approved			C0074281	Selenii disulfidum
Selenium Sulfide	Tinea Versicolor	C0040262		Approved			C0074281	Selenii disulfidum
Azelastine	Allergic rhinitis (disorder)	C2607914		Approved			C0052762	Azélastine
Azelastine	Allergic Conjunctivitis	C0009766		Approved			C0052762	Azélastine
Azelastine	Rhinitis, Vasomotor	C0035460		Approved			C0052762	Azélastine
Azelastine	Hay fever	C0018621		Approved			C0052762	Azélastine
Ezetimibe	Hyperlipidemia, Familial Combined	C0020474		Approved			C1142985	Ezetimiba
Ezetimibe	Familial hypercholesterolemia - homozygous	C0342881		Approved			C1142985	Ezetimiba
Ezetimibe	Hypercholesterolemia	C0020443		Approved			C1142985	Ezetimiba
Ezetimibe	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C1142985	Ezetimiba
Ezetimibe	Hyperlipidemia	C0020473		Approved			C1142985	Ezetimiba
Ezetimibe	Sitosterolemia	C0342907		Approved			C1142985	Ezetimiba
Edetic Acid	Accidental poisoning by lead and its compounds and fumes	C0261486		Approved			C0013618	Acide ethylenediaminetetracetique
Edetic Acid	Hypercalcemia	C0020437		Approved			C0013618	Acide ethylenediaminetetracetique
Dipyridamole	Chronic heart failure	C0264716		Approved			C0012582	Dipyridamolum
Dipyridamole	Atrial Fibrillation	C0004238		Approved			C0012582	Dipyridamolum
Dipyridamole	Platelet aggregation inhibition	C0919737		Approved			C0012582	Dipyridamolum
Telithromycin	Haemophilus influenzae pneumonia	C0276026		Approved			C0907410	telitromicina
Telithromycin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0907410	telitromicina
Telithromycin	Mycoplasma pneumonia	C0032302		Approved			C0907410	telitromicina
Telithromycin	Chlamydial pneumonia	C0339959		Approved			C0907410	telitromicina
Telithromycin	Streptococcal pneumonia	C0155862		Approved			C0907410	telitromicina
Ethinyl Estradiol	Premenstrual Dysphoric Disorder	C0520676		Approved			C0015011	Ethinylestradiol
Ethinyl Estradiol	Atrophy of vulva	C0156393		Approved			C0015011	Ethinylestradiol
Ethinyl Estradiol	Hot flushes	C0600142		Approved			C0015011	Ethinylestradiol
Ethinyl Estradiol	Acne Vulgaris	C0001144		Approved			C0015011	Ethinylestradiol
Ethinyl Estradiol	Atrophic Vaginitis	C0221392		Approved			C0015011	Ethinylestradiol
Lomefloxacin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0065162	(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Lomefloxacin	Cystitis escherichia	C0853852		Approved			C0065162	(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Lomefloxacin	Urinary tract infection	C0042029		Approved			C0065162	(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Lomefloxacin	Bronchitis	C0006277		Approved			C0065162	(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Lomefloxacin	Lower respiratory tract infection	C0149725		Approved			C0065162	(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Cyclopentolate	Cycloplegia	C0235238		Approved			C0010582	β-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate
Cyclopentolate	Mydriasis	C0026961		Approved			C0010582	β-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate
Ramelteon	Initial insomnia	C0393760		Approved			C1565316	Ramelteon
Physostigmine	anticholinergic toxicity	C0237996		Approved			C0031849	Physostigmine
Physostigmine	Glaucoma, Open-Angle	C0017612		Approved			C0031849	Physostigmine
Isotretinoin	Hypertensive disease	C0020538		Approved			C0022265	Isotrétinoine
Formoterol	Intrinsic asthma	C0155880		Approved			C0060657	N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide
Formoterol	Pulmonary Emphysema	C0034067		Approved			C0060657	N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide
Formoterol	Allergic asthma	C0155877		Approved			C0060657	N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide
Dimenhydrinate	Vomiting	C0042963		Approved			C0012381	β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Dimenhydrinate	Motion Sickness	C0026603		Approved			C0012381	β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Dimenhydrinate	Nausea	C0027497		Approved			C0012381	β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Dimenhydrinate	Vertigo	C0042571		Approved			C0012381	β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Dimenhydrinate	Nausea and vomiting	C0027498		Approved			C0012381	β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Glycopyrronium	Peptic Ulcer	C0030920		Approved			C3814772	Glicopirronio
Glycopyrronium	Sialorrhea	C0037036		Approved			C3814772	Glicopirronio
Glycopyrronium	Chronic Obstructive Airway Disease	C0024117		Approved			C3814772	Glicopirronio
Cytarabine	Meningeal Leukemia	C0948840		Approved			C0010711	Cytarabinum
Cytarabine	Metastatic Malignant Neoplasm to the Leptomeninges	C1704231		Approved			C0010711	Cytarabinum
Cytarabine	Acute Promyelocytic Leukemia	C0023487		Approved			C0010711	Cytarabinum
Cytarabine	Leukemia, Myelocytic, Acute	C0023467		Approved			C0010711	Cytarabinum
Cytarabine	Acute lymphocytic leukemia	C0023449		Approved			C0010711	Cytarabinum
Dopamine	Low Cardiac Output Syndrome	C0600177		Approved			C0013030	Dopamina
Dopamine	Hypotension	C0020649		Approved			C0013030	Dopamina
Dopamine	Decompensated cardiac failure	C0581377		Approved			C0013030	Dopamina
Dopamine	Parkinson Disease, Postencephalitic	C0030568		Approved			C0013030	Dopamina
Dopamine	Parkinsonian Disorders	C0242422		Approved			C0013030	Dopamina
Dopamine	Parkinson Disease	C0030567		Approved			C0013030	Dopamina
Rivastigmine	Alzheimer's Disease	C0002395		Approved			C0649350	Rivastigmina
Rivastigmine	Dementia associated with Parkinson's Disease	C1828079		Approved			C0649350	Rivastigmina
Oxaprozin	Degenerative polyarthritis	C0029408		Approved			C0069739	Oxaprozinum
Oxaprozin	Rheumatoid Arthritis	C0003873		Approved			C0069739	Oxaprozinum
Azathioprine	Rheumatoid Arthritis	C0003873		Approved			C0004482	Azamun
Neomycin	Urinary tract infection	C0042029		Approved			C0027603	Neomicina
Neomycin	Otitis Externa	C0029878		Approved			C0027603	Neomicina
Neomycin	Blepharoconjunctivitis	C0005743		Approved			C0027603	Neomicina
Neomycin	Hepatic Encephalopathy	C0019151		Approved			C0027603	Neomicina
Neomycin	Hepatic Coma	C0019147		Approved			C0027603	Neomicina
Neomycin	Keratitis	C0022568		Approved			C0027603	Neomicina
Neomycin	Uveitis	C0042164		Approved			C0027603	Neomicina
Neomycin	Infective blepharitis	C0729587		Approved			C0027603	Neomicina
Neomycin	Corneal abrasion	C0010032		Approved			C0027603	Neomicina
Neomycin	Bacterial keratitis	C0854211		Approved			C0027603	Neomicina
Auranofin	Rheumatoid Arthritis	C0003873		Approved			C0004320	Auranofinum
Gabapentin	Postherpetic neuralgia	C0032768		Approved			C0060926	Gabapentina
Gabapentin	Restless Legs Syndrome	C0035258		Approved			C0060926	Gabapentina
Doxorubicin	Hodgkin Disease	C0019829		Approved			C0013089	Doxorubicine
Doxorubicin	Carcinoma breast stage IV	C0278488		Approved			C0013089	Doxorubicine
Doxorubicin	Malignant epithelial neoplasm of female breast	C3163805		Approved			C0013089	Doxorubicine
Doxorubicin	Multiple Myeloma	C0026764		Approved			C0013089	Doxorubicine
Doxorubicin	Osteosarcoma of bone	C0585442		Approved			C0013089	Doxorubicine
Doxorubicin	AIDS with Kaposi's sarcoma	C0276535		Approved			C0013089	Doxorubicine
Doxorubicin	Diffuse Large B-Cell Lymphoma	C0079744		Approved			C0013089	Doxorubicine
Doxorubicin	Lymphoma, Follicular	C0024301		Approved			C0013089	Doxorubicine
Doxorubicin	Leukemia, Myelocytic, Acute	C0023467		Approved			C0013089	Doxorubicine
Doxorubicin	Nephroblastoma	C0027708		Approved			C0013089	Doxorubicine
Doxorubicin	Lymphoma, Non-Hodgkin	C0024305		Approved			C0013089	Doxorubicine
Doxorubicin	Breast Carcinoma	C0678222		Approved			C0013089	Doxorubicine
Doxorubicin	Malignant neoplasm of lung	C0242379		Approved			C0013089	Doxorubicine
Doxorubicin	Small cell carcinoma of lung	C0149925		Approved			C0013089	Doxorubicine
Doxorubicin	Acute lymphocytic leukemia	C0023449		Approved			C0013089	Doxorubicine
Doxorubicin	Burkitt Lymphoma	C0006413		Approved			C0013089	Doxorubicine
Doxorubicin	Malignant neoplasm of stomach stage IV	C0278498		Approved			C0013089	Doxorubicine
Doxorubicin	Malignant neoplasm of thyroid	C0007115		Approved			C0013089	Doxorubicine
Doxorubicin	Kaposi Sarcoma	C0036220		Approved			C0013089	Doxorubicine
Doxorubicin	Neuroblastoma	C0027819		Approved			C0013089	Doxorubicine
Doxorubicin	Malignant neoplasm of ovary	C1140680		Approved			C0013089	Doxorubicine
Frovatriptan	Migraine Disorders	C0149931		Approved			C0754647	Frovatriptan
Hydrochlorothiazide	Hypertensive urgency	C0745138		Approved			C0020261	hidroclorotiazida
Hydrochlorothiazide	Hypertensive disease	C0020538		Approved			C0020261	hidroclorotiazida
Hydrochlorothiazide	Edema	C0013604		Approved			C0020261	hidroclorotiazida
Hydrochlorothiazide	Chronic heart failure	C0264716		Approved			C0020261	hidroclorotiazida
Cyclacillin	Pharyngitis	C0031350		Approved			C0010523	6-(1-aminocyclohexanecarboxamido)penicillanic acid
Cyclacillin	Urinary tract infection	C0042029		Approved			C0010523	6-(1-aminocyclohexanecarboxamido)penicillanic acid
Cyclacillin	Bronchitis	C0006277		Approved			C0010523	6-(1-aminocyclohexanecarboxamido)penicillanic acid
Cyclacillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0010523	6-(1-aminocyclohexanecarboxamido)penicillanic acid
Cyclacillin	Infective otitis media	C0729586		Approved			C0010523	6-(1-aminocyclohexanecarboxamido)penicillanic acid
Salbutamol	Bronchial Spasm	C0006266		Approved			C0001927	Salbutamol
Salbutamol	Asthma attack	C0347950		Approved			C0001927	Salbutamol
Cromoglicic acid	Asthma	C0004096		Approved			C0086073	Cromoglycic acid
Cromoglicic acid	Allergic rhinitis (disorder)	C2607914		Approved			C0086073	Cromoglycic acid
Cromoglicic acid	Conjunctivitis, Giant Papillary	C0009769		Approved			C0086073	Cromoglycic acid
Cromoglicic acid	Allergic Conjunctivitis	C0009766		Approved			C0086073	Cromoglycic acid
Cromoglicic acid	Conjunctivitis, Vernal	C0009773		Approved			C0086073	Cromoglycic acid
Cromoglicic acid	Allergic keratoconjunctivitis	C1112631		Approved			C0086073	Cromoglycic acid
Cromoglicic acid	Keratoconjunctivitis, Vernal	C0022577		Approved			C0086073	Cromoglycic acid
Cromoglicic acid	Mastocytosis, Systemic	C0221013		Approved			C0086073	Cromoglycic acid
Ganciclovir	Keratitis, Dendritic	C0022570		Approved			C0017066	2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
Ganciclovir	Paroxysmal supraventricular tachycardia	C0030590		Approved			C0017066	2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
Ganciclovir	Cytomegalovirus Retinitis	C0206178		Approved			C0017066	2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
Hydroxyurea	Cancer of Head and Neck	C0278996		Approved			C0020402	Hydroxycarbamid
Hydroxyurea	Hemoglobin SS disease with crisis	C0238425		Approved			C0020402	Hydroxycarbamid
Hydroxyurea	Myeloid Leukemia, Chronic	C0023473		Approved			C0020402	Hydroxycarbamid
Hydroxyurea	Malignant neoplasm of ovary	C1140680		Approved			C0020402	Hydroxycarbamid
Hydroxyurea	Anemia, Sickle Cell	C0002895		Approved			C0020402	Hydroxycarbamid
Hydroxyurea	melanoma	C0025202		Approved			C0020402	Hydroxycarbamid
Tioconazole	Candidiasis, Vulvovaginal	C0700345		Approved			C0076705	Tioconazolum
Busulfan	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			C0006463	Busulfano
Ketoprofen	Degenerative polyarthritis	C0029408		Approved			C0022635	L'acide (benzoyl-3-phenyl)-2-propionique
Ketoprofen	Pain	C0030193		Approved			C0022635	L'acide (benzoyl-3-phenyl)-2-propionique
Ketoprofen	Dysmenorrhea	C0013390		Approved			C0022635	L'acide (benzoyl-3-phenyl)-2-propionique
Ketoprofen	Rheumatoid Arthritis	C0003873		Approved			C0022635	L'acide (benzoyl-3-phenyl)-2-propionique
Clobetasol propionate	Seborrheic dermatitis	C0036508		Approved			C0055895	Clobetasol propionate E
Clobetasol propionate	Contact Dermatitis	C0011616		Approved			C0055895	Clobetasol propionate E
Clobetasol propionate	Scalp psoriasis	C0406326		Approved			C0055895	Clobetasol propionate E
Clobetasol propionate	Inflammatory dermatosis	C3875321		Approved			C0055895	Clobetasol propionate E
Clobetasol propionate	Scalp Dermatoses	C0036271		Approved			C0055895	Clobetasol propionate E
Clobetasol propionate	Nummular eczema	C0085656		Approved			C0055895	Clobetasol propionate E
Clobetasol propionate	Chronic small plaque psoriasis	C0406317		Approved			C0055895	Clobetasol propionate E
Balsalazide	Ulcerative Colitis	C0009324		Approved			C0052940	(E)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid
Sulfamethoxazole	Shigella Infections	C0013371		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Infective otitis media	C0729586		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Toxoplasmosis	C0040558		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Klebsiella cystitis	C0520775		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Proteus urinary tract infection	C0577709		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Nocardia Infections	C0028242		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Bacterial urinary infection	C0729524		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Acute otitis media	C0271429		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Inclusion conjunctivitis	C0009770		Approved			C0038689	Sulphamethoxazole
Sulfamethoxazole	Escherichia coli urinary tract infection	C0577708		Approved			C0038689	Sulphamethoxazole
Glyburide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0017628	1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea
Minocycline	Bronchitis	C0006277		Approved			C0026187	Minociclinum
Minocycline	Infection by Campylobacter fetus	C0275979		Approved			C0026187	Minociclinum
Minocycline	TYPHUS	C0041471		Approved			C0026187	Minociclinum
Minocycline	Listeriosis	C0023860		Approved			C0026187	Minociclinum
Minocycline	Plague	C0032064		Approved			C0026187	Minociclinum
Minocycline	Cholera	C0008354		Approved			C0026187	Minociclinum
Minocycline	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0026187	Minociclinum
Minocycline	Acute gonococcal endometritis	C0153196		Approved			C0026187	Minociclinum
Minocycline	Gonorrhea of pharynx	C0149966		Approved			C0026187	Minociclinum
Minocycline	Relapsing Fever	C0035021		Approved			C0026187	Minociclinum
Minocycline	Meningococcus carrier	C0421162		Approved			C0026187	Minociclinum
Minocycline	Psittacosis	C0029291		Approved			C0026187	Minociclinum
Minocycline	Acne Vulgaris	C0001144		Approved			C0026187	Minociclinum
Minocycline	Actinomycosis	C0001261		Approved			C0026187	Minociclinum
Minocycline	Syphilis	C0039128		Approved			C0026187	Minociclinum
Minocycline	Infective otitis media	C0729586		Approved			C0026187	Minociclinum
Minocycline	Brucellosis	C0006309		Approved			C0026187	Minociclinum
Minocycline	Lymphogranuloma Venereum	C0024286		Approved			C0026187	Minociclinum
Minocycline	Periodontitis	C0031099		Approved			C0026187	Minociclinum
Minocycline	Granuloma Inguinale	C0018190		Approved			C0026187	Minociclinum
Minocycline	Sinusitis	C0037199		Approved			C0026187	Minociclinum
Minocycline	Chlamydia trachomatis infection of genital structure	C1997322		Approved			C0026187	Minociclinum
Minocycline	Gonorrhea of rectum	C0275665		Approved			C0026187	Minociclinum
Minocycline	Acute gonococcal urethritis	C0275652		Approved			C0026187	Minociclinum
Minocycline	Gonorrhea	C0018081		Approved			C0026187	Minociclinum
Minocycline	Fusospirochetal pharyngitis	C1318559		Approved			C0026187	Minociclinum
Minocycline	Rocky Mountain Spotted Fever	C0035793		Approved			C0026187	Minociclinum
Minocycline	Chancroids	C0007947		Approved			C0026187	Minociclinum
Minocycline	Trachoma	C0040592		Approved			C0026187	Minociclinum
Minocycline	Tularemia	C0041351		Approved			C0026187	Minociclinum
Minocycline	Pharyngitis	C0031350		Approved			C0026187	Minociclinum
Minocycline	Gingivostomatitis	C0149704		Approved			C0026187	Minociclinum
Minocycline	Q Fever	C0034362		Approved			C0026187	Minociclinum
Minocycline	Acute gonococcal cervicitis	C0153195		Approved			C0026187	Minociclinum
Minocycline	Urinary tract infection	C0042029		Approved			C0026187	Minociclinum
Minocycline	Bartonella Infections	C0004771		Approved			C0026187	Minociclinum
Minocycline	Yaws	C0043388		Approved			C0026187	Minociclinum
Minocycline	Rickettsialpox	C0035597		Approved			C0026187	Minociclinum
Minocycline	Pneumonia	C0032285		Approved			C0026187	Minociclinum
Guanfacine	Hypertensive disease	C0020538		Approved			C0079466	Guanfacinum
Guanfacine	Attention deficit hyperactivity disorder	C1263846		Approved			C0079466	Guanfacinum
Bethanechol	Urinary Retention	C0080274		Approved			C0053526	(2-hydroxypropyl)trimethylammonium carbamate
Isosorbide Mononitrate	Angina Pectoris	C0002962		Approved			C0064079	mononitrate d'isosorbide
Trichlormethiazide	Hypertensive disease	C0020538		Approved			C0040899	triclormetiazida
Phylloquinone	Hypocalcemia	C0020598		Approved			C0031862	Phyllochinon
Phylloquinone	Osteoporosis	C0029456		Approved			C0031862	Phyllochinon
Phylloquinone	Factor II deficiency	C3203356		Approved			C0031862	Phyllochinon
Felodipine	Hypertensive disease	C0020538		Approved			C0015772	Felodipino
Amlexanox	Aphthous Stomatitis	C0038363		Approved			C0103049	Amlexanoxo
Ketoconazole	Oral candidiasis	C0006849		Approved			C0022625	Ketoconazol
Ketoconazole	Scurfiness of scalp	C0423775		Approved			C0022625	Ketoconazol
Ketoconazole	Seborrheic dermatitis	C0036508		Approved			C0022625	Ketoconazol
Ketoconazole	Coccidioidomycosis	C0009186		Approved			C0022625	Ketoconazol
Ketoconazole	Chromoblastomycosis	C0008582		Approved			C0022625	Ketoconazol
Ketoconazole	Histoplasmosis	C0019655		Approved			C0022625	Ketoconazol
Ketoconazole	Tinea Versicolor	C0040262		Approved			C0022625	Ketoconazol
Ketoconazole	Paracoccidioidomycosis	C0030409		Approved			C0022625	Ketoconazol
Ketoconazole	Systemic candidiasis	C0153252		Approved			C0022625	Ketoconazol
Ketoconazole	Tinea cruris	C1384589		Approved			C0022625	Ketoconazol
Ketoconazole	Cutaneous Candidiasis	C0006846		Approved			C0022625	Ketoconazol
Ketoconazole	Tinea corporis (disorder)	C0040252		Approved			C0022625	Ketoconazol
Ketoconazole	Blastomycosis	C0005716		Approved			C0022625	Ketoconazol
Ketoconazole	Tinea Pedis	C0040259		Approved			C0022625	Ketoconazol
Ketoconazole	Adrenal Gland Hyperfunction	C0001622		Approved			C0022625	Ketoconazol
Irbesartan	Hypertensive disease	C0020538		Approved			C0288171	2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
Irbesartan	Diabetic Nephropathy	C0011881		Approved			C0288171	2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
Topotecan	Malignant neoplasm of ovary	C1140680		Approved			C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Topotecan	Small cell carcinoma of lung	C0149925		Approved			C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Topotecan	Malignant tumor of cervix	C0007847		Approved			C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Ethinamate	Sleeplessness	C0917801		Approved			C0059714	1-ethynylcyclohexanol carbamate
Probenecid	Acute gonococcal endometritis	C0153196		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Probenecid	Arthritis, Gouty	C0003868		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Probenecid	Acute gonococcal urethritis	C0275652		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Probenecid	Acute gonococcal cervicitis	C0153195		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Probenecid	Gonorrhea	C0018081		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Probenecid	Chronic gouty arthritis	C0268108		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Probenecid	Hyperuricemia	C0740394		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Probenecid	Gonorrhea of rectum	C0275665		Approved			C0033209	p-(Dipropylsulfamoyl)benzoic acid
Mercaptopurine	Acute Promyelocytic Leukemia	C0023487		Approved			C1881785	Mercaptopurine anhydrous
Mercaptopurine	Acute lymphocytic leukemia	C0023449		Approved			C1881785	Mercaptopurine anhydrous
Tolterodine	Increased frequency of micturition	C0042023		Approved			C0388753	Tolterodina
Tolterodine	Urge Incontinence	C0150045		Approved			C0388753	Tolterodina
Tolterodine	Urgency of micturition	C0085606		Approved			C0388753	Tolterodina
Tolterodine	Bladder muscle dysfunction - overactive	C0403643		Approved			C0388753	Tolterodina
Selegiline	Major Depressive Disorder	C1269683		Approved			C0036579	Selegilinum
Selegiline	Parkinson Disease	C0030567		Approved			C0036579	Selegilinum
Fenofibrate	Hypercholesterolemia	C0020443		Approved			C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Fenofibrate	Hyperlipidemia	C0020473		Approved			C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Fenofibrate	Hypertriglyceridemia	C0020557		Approved			C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Fenofibrate	Hyperlipidemia, Familial Combined	C0020474		Approved			C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Fenofibrate	Hypoalphalipoproteinemias	C0473527		Approved			C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Fenofibrate	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Thalidomide	Multiple Myeloma	C0026764		Approved			C0039736	Thalidomidum
Thalidomide	Erythema nodosum leprosum	C0343467		Approved			C0039736	Thalidomidum
Melphalan	Malignant neoplasm of ovary	C1140680		Approved			C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Melphalan	Multiple Myeloma	C0026764		Approved			C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Gatifloxacin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Bacterial conjunctivitis	C0009768		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Legionella pneumophila pneumonia	C0857846		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Escherichia coli urinary tract infection	C0577708		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Streptococcal pneumonia	C0155862		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Chlamydial pneumonia	C0339959		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Acute gonococcal urethritis	C0275652		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Staphylococcal Pneumonia	C0032308		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Gonorrhea of rectum	C0275665		Approved			C0753645	Gatifloxacinum
Gatifloxacin	PYELONEPHRITIS E COLI	C0748196		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Staphylococcus aureus infection	C1318973		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Acute gonococcal cervicitis	C0153195		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Pneumonia, Bacterial	C0004626		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Mycoplasma pneumonia	C0032302		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Klebsiella cystitis	C0520775		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0753645	Gatifloxacinum
Gatifloxacin	Proteus urinary tract infection	C0577709		Approved			C0753645	Gatifloxacinum
Rifampicin	Acute tuberculosis	C0275959		Approved			C0035608	Rifampicine
Rifampicin	Meningococcus carrier	C0421162		Approved			C0035608	Rifampicine
Rifampicin	Tuberculosis, Pulmonary	C0041327		Approved			C0035608	Rifampicine
Lubiprostone	Chronic idiopathic constipation	C0267509		Approved			C1684405	Lubiprostone
Lubiprostone	Irritable bowel syndrome characterized by constipation	C1868889		Approved			C1684405	Lubiprostone
Fluocinonide	Lichen Simplex Chronicus	C0149922		Approved			C0016299	Fluocinonida
Fluocinonide	Seborrheic dermatitis	C0036508		Approved			C0016299	Fluocinonida
Fluocinonide	Scalp psoriasis	C0406326		Approved			C0016299	Fluocinonida
Fluocinonide	Contact Dermatitis	C0011616		Approved			C0016299	Fluocinonida
Fluocinonide	Chronic small plaque psoriasis	C0406317		Approved			C0016299	Fluocinonida
Fluocinonide	Pruritus of genital organs	C0033777		Approved			C0016299	Fluocinonida
Fluocinonide	Inflammatory dermatosis	C3875321		Approved			C0016299	Fluocinonida
Fluocinonide	Granuloma Annulare	C0085074		Approved			C0016299	Fluocinonida
Fluocinonide	Exanthema	C0015230		Approved			C0016299	Fluocinonida
Fluocinonide	Pruritus Ani	C0033775		Approved			C0016299	Fluocinonida
Fluocinonide	Lupus Erythematosus, Discoid	C0024138		Approved			C0016299	Fluocinonida
Fluocinonide	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0016299	Fluocinonida
Abacavir	HIV Infections	C0019693		Approved			C0663655	{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
Ergoloid mesylate	Dementia	C0497327		Approved			C0014708	Ergoloid Mesilates
Ibuprofen	Influenza-like symptoms	C0392171		Approved			C0020740	Ibuprofenum
Ibuprofen	Severe pain	C0278140		Approved			C0020740	Ibuprofenum
Ibuprofen	Rheumatoid Arthritis	C0003873		Approved			C0020740	Ibuprofenum
Ibuprofen	Acute postoperative pain	C2215257		Approved			C0020740	Ibuprofenum
Ibuprofen	Pain	C0030193		Approved			C0020740	Ibuprofenum
Ibuprofen	Fever	C0015967		Approved			C0020740	Ibuprofenum
Ibuprofen	Headache Disorders	C0393735		Approved			C0020740	Ibuprofenum
Ibuprofen	Dysmenorrhea	C0013390		Approved			C0020740	Ibuprofenum
Ibuprofen	Degenerative polyarthritis	C0029408		Approved			C0020740	Ibuprofenum
Ibuprofen	Sinus headache	C0037195		Approved			C0020740	Ibuprofenum
Benzylpenicillin	Septicemia due to enterococcus	C0588233		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Streptococcal toxic shock syndrome	C0343532		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Botulism	C0006057		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Gonococcal joint infection	C0153216		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Syphilis, Congenital	C0039131		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Neurosyphilis	C0027927		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Neonatal meningitis	C0456107		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Syphilis, secondary	C0149985		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Pasteurella Infections	C0030636		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Yaws	C0043388		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Infection by Pasteurella multocida	C1260911		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Gingivostomatitis	C0149704		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Abdominal actinomycosis	C0001263		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Latent yaws	C0153240		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Tetanus	C0039614		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Infection due to Erysipelothrix rhusiopathiae (disorder)	C1276801		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Acute otitis media	C0271429		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Cutaneous anthrax	C0003177		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Late latent syphilis	C1260915		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Meningococcal meningitis	C0025294		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Listerial endocarditis	C0348868		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Rat-Bite Fever	C0034686		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Streptococcal meningitis	C0154639		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Syphilis, Latent	C0039133		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Granulomatosis infantiseptica	C1535478		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Pulmonary actinomycosis	C0275566		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Upper Respiratory Infections	C0041912		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Meningitis, Pneumococcal	C0025295		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Anthrax sepsis	C0152946		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Pinta	C0031946		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Streptococcal Infections	C0038395		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Streptococcal pneumonia	C0155862		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Bejel	C0004945		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Pneumonia, Necrotizing	C0264515		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Cervicofacial actinomycosis	C0001264		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Lung Abscess	C0024110		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Syphilis	C0039128		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Infective otitis media	C0729586		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Syphilis, tertiary	C0153188		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Streptococcal tonsillitis	C0275804		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Erysipelas	C0014733		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Streptococcus pyogenes infection	C0554628		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Primary genital syphilis	C0017418		Approved			C0030827	bensylpenicillin
Benzylpenicillin	GONOCOCCAL INFECTION DISSEMINATED	C0744451		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Anthrax disease	C0003175		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Sepsis of the newborn	C0456103		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Early latent syphilis, positive serology, negative cerebrospinal fluid, less than 2 years after infection	C0275842		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Fusospirochetal pharyngitis	C1318559		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Bacterial Endocarditis	C0014121		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Gas gangrene caused by clostridium perfringens	C0343500		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Scarlet Fever	C0036285		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Neonatal pneumonia	C0339968		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Meningitis, Listeria	C0025293		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Gastrointestinal anthrax	C0152945		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Streptococcal endocarditis	C3665800		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Tertiary lesion of yaws	C0343833		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Inhalational anthrax	C0155866		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Pharyngitis	C0031350		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Staphylococcus aureus infection	C1318973		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Actinomycosis	C0001261		Approved			C0030827	bensylpenicillin
Benzylpenicillin	Meningococcemia	C0025306		Approved			C0030827	bensylpenicillin
Tocainide	Ventricular arrhythmia	C0085612		Approved			C0085237	2-Amino-N-(2,6-dimethylphenyl)propionamid
Echothiophate	Glaucoma	C0017601		Approved			C0301366	Ecothiopatum
Echothiophate	Glaucoma, Open-Angle	C0017612		Approved			C0301366	Ecothiopatum
Echothiophate	Esotropia	C0014877		Approved			C0301366	Ecothiopatum
Echothiophate	Stargardt's disease	C0271093		Approved			C0301366	Ecothiopatum
Praziquantel	Opisthorchiasis	C0029106		Approved			C0032911	Praziquantel
Praziquantel	Schistosomiasis	C0036323		Approved			C0032911	Praziquantel
Norfloxacin	Pneumonia due to Pseudomonas	C0155860		Approved			C0028365	Norfloxacine
Norfloxacin	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			C0028365	Norfloxacine
Norfloxacin	Enterobacter pneumonia	C1096258		Approved			C0028365	Norfloxacine
Norfloxacin	Streptococcal pneumonia	C0155862		Approved			C0028365	Norfloxacine
Norfloxacin	Streptococcus pyogenes infection	C0554628		Approved			C0028365	Norfloxacine
Norfloxacin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0028365	Norfloxacine
Norfloxacin	Female pelvic cellulitis	C0349734		Approved			C0028365	Norfloxacine
Norfloxacin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0028365	Norfloxacine
Norfloxacin	Miscarriage with sepsis	C0269398		Approved			C0028365	Norfloxacine
Norfloxacin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0028365	Norfloxacine
Norfloxacin	Shigella Infections	C0013371		Approved			C0028365	Norfloxacine
Norfloxacin	prostatitis	C0033581		Approved			C0028365	Norfloxacine
Norfloxacin	Pneumonia due to Escherichia coli	C0276089		Approved			C0028365	Norfloxacine
Norfloxacin	Legionella pneumophila pneumonia	C0857846		Approved			C0028365	Norfloxacine
Norfloxacin	Cystitis escherichia	C0853852		Approved			C0028365	Norfloxacine
Norfloxacin	Lower respiratory tract infection	C0149725		Approved			C0028365	Norfloxacine
Norfloxacin	Escherichia coli septicemia	C0276088		Approved			C0028365	Norfloxacine
Norfloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0028365	Norfloxacine
Norfloxacin	Staphylococcal Pneumonia	C0032308		Approved			C0028365	Norfloxacine
Norfloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0028365	Norfloxacine
Norfloxacin	Pneumonia, Bacterial	C0004626		Approved			C0028365	Norfloxacine
Norfloxacin	Postnatal infection	C1278797		Approved			C0028365	Norfloxacine
Norfloxacin	Proteus pneumonia	C1260917		Approved			C0028365	Norfloxacine
Norfloxacin	Acute gonococcal endometritis	C0153196		Approved			C0028365	Norfloxacine
Norfloxacin	Acute osteomyelitis	C0158371		Approved			C0028365	Norfloxacine
Norfloxacin	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			C0028365	Norfloxacine
Norfloxacin	Peritonitis	C0031154		Approved			C0028365	Norfloxacine
Norfloxacin	Acute maxillary sinusitis	C0155804		Approved			C0028365	Norfloxacine
Norfloxacin	Proteus urinary tract infection	C0577709		Approved			C0028365	Norfloxacine
Norfloxacin	Otitis Externa	C0029878		Approved			C0028365	Norfloxacine
Norfloxacin	Urinary tract infection	C0042029		Approved			C0028365	Norfloxacine
Norfloxacin	Rhinoscleroma	C0035468		Approved			C0028365	Norfloxacine
Norfloxacin	Chlamydial pelvic inflammatory disease	C0520777		Approved			C0028365	Norfloxacine
Norfloxacin	Anthrax disease	C0003175		Approved			C0028365	Norfloxacine
Norfloxacin	Arthropathy associated with infection	C0157749		Approved			C0028365	Norfloxacine
Norfloxacin	Bacterial urinary infection	C0729524		Approved			C0028365	Norfloxacine
Norfloxacin	Traveler's diarrhea	C0277528		Approved			C0028365	Norfloxacine
Norfloxacin	Bronchitis	C0006277		Approved			C0028365	Norfloxacine
Norfloxacin	Bacterial conjunctivitis	C0009768		Approved			C0028365	Norfloxacine
Norfloxacin	Female genital tract infection	C1263758		Approved			C0028365	Norfloxacine
Norfloxacin	PYELONEPHRITIS E COLI	C0748196		Approved			C0028365	Norfloxacine
Norfloxacin	Chancroids	C0007947		Approved			C0028365	Norfloxacine
Norfloxacin	Chlamydial cervicitis	C0341834		Approved			C0028365	Norfloxacine
Norfloxacin	Acute bacterial bronchitis	C0339933		Approved			C0028365	Norfloxacine
Norfloxacin	Chlamydial pneumonia	C0339959		Approved			C0028365	Norfloxacine
Norfloxacin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0028365	Norfloxacine
Norfloxacin	Pyelonephritis	C0034186		Approved			C0028365	Norfloxacine
Norfloxacin	Endomyometritis	C0269050		Approved			C0028365	Norfloxacine
Norfloxacin	Typhoid Fever	C0041466		Approved			C0028365	Norfloxacine
Norfloxacin	Infective otitis externa	C0021355		Approved			C0028365	Norfloxacine
Norfloxacin	Gonorrhea of rectum	C0275665		Approved			C0028365	Norfloxacine
Norfloxacin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0028365	Norfloxacine
Norfloxacin	Mycoplasma pneumonia	C0032302		Approved			C0028365	Norfloxacine
Norfloxacin	Intraabdominal Infections	C1112209		Approved			C0028365	Norfloxacine
Norfloxacin	Chronic Bacterial Prostatitis	C1720797		Approved			C0028365	Norfloxacine
Norfloxacin	Enterobacteriaceae Infections	C0014347		Approved			C0028365	Norfloxacine
Norfloxacin	Chlamydial urethritis	C1278807		Approved			C0028365	Norfloxacine
Norfloxacin	Acute gonococcal cervicitis	C0153195		Approved			C0028365	Norfloxacine
Norfloxacin	non-gonococcal urethritis (NGU)	C1112709		Approved			C0028365	Norfloxacine
Norfloxacin	Pneumonia	C0032285		Approved			C0028365	Norfloxacine
Norfloxacin	Klebsiella cystitis	C0520775		Approved			C0028365	Norfloxacine
Norfloxacin	Infection of bone	C2242472		Approved			C0028365	Norfloxacine
Norfloxacin	URINARY TRACT INFECTION CITROBACTER	C0749955		Approved			C0028365	Norfloxacine
Norfloxacin	Abdominal Abscess	C0243001		Approved			C0028365	Norfloxacine
Norfloxacin	Cystitis	C0010692		Approved			C0028365	Norfloxacine
Norfloxacin	Postoperative infection	C0392618		Approved			C0028365	Norfloxacine
Norfloxacin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0028365	Norfloxacine
Norfloxacin	Acute gonococcal urethritis	C0275652		Approved			C0028365	Norfloxacine
Norfloxacin	Staphylococcus aureus infection	C1318973		Approved			C0028365	Norfloxacine
Norfloxacin	Gonorrhea	C0018081		Approved			C0028365	Norfloxacine
Norfloxacin	Escherichia coli Infections	C0014836		Approved			C0028365	Norfloxacine
Norfloxacin	Enteric campylobacteriosis	C0275982		Approved			C0028365	Norfloxacine
Norfloxacin	Infective cystitis	C0600041		Approved			C0028365	Norfloxacine
Norfloxacin	Escherichia coli urinary tract infection	C0577708		Approved			C0028365	Norfloxacine
Norfloxacin	Acute bacterial sinusitis	C0275556		Approved			C0028365	Norfloxacine
Norfloxacin	Nosocomial pneumonia	C0949083		Approved			C0028365	Norfloxacine
Norfloxacin	Chronic tubotympanic suppurative otitis media	C0155440		Approved			C0028365	Norfloxacine
Amoxicillin	Haemophilus influenzae pneumonia	C0276026		Approved			C0002645	Amoxicilline
Amoxicillin	Acute otitis media	C0271429		Approved			C0002645	Amoxicilline
Amoxicillin	pharyngitis due to Haemophilus influenzae	C2062475		Approved			C0002645	Amoxicilline
Amoxicillin	Pneumonia, Bacterial	C0004626		Approved			C0002645	Amoxicilline
Amoxicillin	Lower respiratory tract infection	C0149725		Approved			C0002645	Amoxicilline
Amoxicillin	Genitourinary tract infection	C1279247		Approved			C0002645	Amoxicilline
Amoxicillin	Pneumonia due to Staphylococcus aureus	C2349530		Approved			C0002645	Amoxicilline
Amoxicillin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0002645	Amoxicilline
Amoxicillin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0002645	Amoxicilline
Amoxicillin	Bacterial urinary infection	C0729524		Approved			C0002645	Amoxicilline
Amoxicillin	Pharyngitis	C0031350		Approved			C0002645	Amoxicilline
Amoxicillin	Rhinoscleroma	C0035468		Approved			C0002645	Amoxicilline
Amoxicillin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0002645	Amoxicilline
Amoxicillin	Streptococcal pneumonia	C0155862		Approved			C0002645	Amoxicilline
Amoxicillin	Escherichia coli urinary tract infection	C0577708		Approved			C0002645	Amoxicilline
Amoxicillin	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			C0002645	Amoxicilline
Amoxicillin	Staphylococcus aureus infection	C1318973		Approved			C0002645	Amoxicilline
Amoxicillin	Staphylococcal pharyngitis	C0275794		Approved			C0002645	Amoxicilline
Amoxicillin	Streptococcal tonsillitis	C0275804		Approved			C0002645	Amoxicilline
Amoxicillin	Helicobacter-associated gastritis	C0343378		Approved			C0002645	Amoxicilline
Amoxicillin	Staphylococcal tonsillitis	C0275793		Approved			C0002645	Amoxicilline
Amoxicillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0002645	Amoxicilline
Amoxicillin	Escherichia coli Infections	C0014836		Approved			C0002645	Amoxicilline
Amoxicillin	Klebsiella cystitis	C0520775		Approved			C0002645	Amoxicilline
Amoxicillin	Acute bacterial sinusitis	C0275556		Approved			C0002645	Amoxicilline
Amoxicillin	Urinary tract infection	C0042029		Approved			C0002645	Amoxicilline
Amoxicillin	Infective otitis media	C0729586		Approved			C0002645	Amoxicilline
Azlocillin	Aspiration Pneumonia	C0032290		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Enterobacter pneumonia	C1096258		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Serratia Infections	C0085394		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Pneumonia due to Pseudomonas	C0155860		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Pneumonia due to Escherichia coli	C0276089		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Urinary tract infection	C0042029		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Bacterial sepsis	C0684256		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Infection of bone	C2242472		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Arthropathy associated with infection	C0157749		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Haemophilus influenzae pneumonia	C0276026		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Azlocillin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0004499	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Oxybutynin	Increased frequency of micturition	C0042023		Approved			C0069805	Oxibutinina
Oxybutynin	Urgency of micturition	C0085606		Approved			C0069805	Oxibutinina
Oxybutynin	Urge Incontinence	C0150045		Approved			C0069805	Oxibutinina
Oxybutynin	Bladder muscle dysfunction - overactive	C0403643		Approved			C0069805	Oxibutinina
Oxybutynin	Neurogenic Urinary Bladder	C0005697		Approved			C0069805	Oxibutinina
Acetophenazine	Psychotic Disorders	C0033975		Approved			C0050458	Acetophenazinum
Isoprenaline	Common Cold	C0009443		Approved			C0022245	3,4-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol
Isoprenaline	Low Cardiac Output Syndrome	C0600177		Approved			C0022245	3,4-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol
Isoprenaline	Atrioventricular Block	C0004245		Approved			C0022245	3,4-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol
Isoprenaline	Hypovolemic Shock	C0020683		Approved			C0022245	3,4-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol
Isoprenaline	Cardiac Arrest	C0018790		Approved			C0022245	3,4-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol
Melatonin	Sleep Initiation and Maintenance Disorders	C0021603		Approved			C0025219	Mélatonine
Cefditoren	Streptococcal tonsillitis	C0275804		Approved			C0287573	Cefditoreno
Cefditoren	Streptococcus pyogenes infection	C0554628		Approved			C0287573	Cefditoreno
Cefditoren	Pneumonia, Bacterial	C0004626		Approved			C0287573	Cefditoreno
Cefditoren	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0287573	Cefditoreno
Cefditoren	Streptococcal pneumonia	C0155862		Approved			C0287573	Cefditoreno
Cefditoren	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0287573	Cefditoreno
Cefditoren	Staphylococcus aureus infection	C1318973		Approved			C0287573	Cefditoreno
Cefditoren	Haemophilus influenzae pneumonia	C0276026		Approved			C0287573	Cefditoreno
Cefditoren	Moraxella catarrhalis pneumonia	C0857831		Approved			C0287573	Cefditoreno
Glipizide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0017642	1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea
Clonazepam	Epileptic drop attack	C0270846		Approved			C0009011	1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
Clonazepam	Panic Disorder	C0030319		Approved			C0009011	1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
Clonazepam	Absence Epilepsy	C0014553		Approved			C0009011	1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
Clonazepam	Lennox-Gastaut syndrome	C0238111		Approved			C0009011	1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
Clonazepam	Epilepsies, Myoclonic	C0014550		Approved			C0009011	1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
Promethazine	Hay fever	C0018621		Approved			C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Promethazine	Nausea and vomiting	C0027498		Approved			C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Promethazine	Rhinitis, Vasomotor	C0035460		Approved			C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Promethazine	Urticaria	C0042109		Approved			C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Promethazine	Allergic Conjunctivitis	C0009766		Approved			C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Dihydrotachysterol	Hypocalcemia	C0020598		Approved			C0012319	Dihidrotaquisterol
Dihydrotachysterol	Tetany	C0039621		Approved			C0012319	Dihidrotaquisterol
Dihydrotachysterol	Hypoparathyroidism	C0020626		Approved			C0012319	Dihidrotaquisterol
Dihydrotachysterol	Rickets	C0035579		Approved			C0012319	Dihidrotaquisterol
Dihydrotachysterol	Hypophosphatemia	C0085682		Approved			C0012319	Dihidrotaquisterol
Atazanavir	HIV Infections	C0019693		Approved			C1145759	Atazanavirum
Diphenhydramine	Allergic Conjunctivitis	C0009766		Approved			C0012522	β-dimethylaminoethanol diphenylmethyl ether
Diphenhydramine	Rhinitis, Vasomotor	C0035460		Approved			C0012522	β-dimethylaminoethanol diphenylmethyl ether
Diphenhydramine	Hay fever	C0018621		Approved			C0012522	β-dimethylaminoethanol diphenylmethyl ether
Diphenhydramine	Sleeplessness	C0917801		Approved			C0012522	β-dimethylaminoethanol diphenylmethyl ether
Atorvastatin	Angina Pectoris	C0002962		Approved			C0286651	atorvastatine
Atorvastatin	Hypercholesterolemia	C0020443		Approved			C0286651	atorvastatine
Atorvastatin	Hypertensive disease	C0020538		Approved			C0286651	atorvastatine
Atorvastatin	Cerebrovascular accident	C0038454		Approved			C0286651	atorvastatine
Atorvastatin	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0286651	atorvastatine
Atorvastatin	Hyperlipidemia, Familial Combined	C0020474		Approved			C0286651	atorvastatine
Atorvastatin	Arteriosclerosis	C0003850		Approved			C0286651	atorvastatine
Atorvastatin	Hyperlipoproteinemia Type III	C0020479		Approved			C0286651	atorvastatine
Atorvastatin	Familial hypercholesterolemia - homozygous	C0342881		Approved			C0286651	atorvastatine
Atorvastatin	Angina Pectoris, Variant	C0002963		Approved			C0286651	atorvastatine
Atorvastatin	Hypertriglyceridemia	C0020557		Approved			C0286651	atorvastatine
Etidronic acid	Osteitis Deformans	C0029401		Approved			C0015121	acidum etidronicum
Etidronic acid	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0015121	acidum etidronicum
Etidronic acid	Heterotopic Ossification	C0029396		Approved			C0015121	acidum etidronicum
Vigabatrin	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0048044	Vigabatrina
Vigabatrin	West Syndrome	C0037769		Approved			C0048044	Vigabatrina
Diphenoxylate	Diarrhea	C0011991		Approved			C0012525	Difenossilato
Streptomycin	Plague	C0032064		Approved			C0038425	Streptomyzin
Streptomycin	Escherichia coli urinary tract infection	C0577708		Approved			C0038425	Streptomyzin
Streptomycin	Haemophilus influenzae pneumonia	C0276026		Approved			C0038425	Streptomyzin
Streptomycin	Proteus urinary tract infection	C0577709		Approved			C0038425	Streptomyzin
Streptomycin	Chancroids	C0007947		Approved			C0038425	Streptomyzin
Streptomycin	Endocarditis haemophilus	C0854528		Approved			C0038425	Streptomyzin
Streptomycin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0038425	Streptomyzin
Streptomycin	Klebsiella cystitis	C0520775		Approved			C0038425	Streptomyzin
Streptomycin	Brucellosis	C0006309		Approved			C0038425	Streptomyzin
Streptomycin	Acute tuberculosis	C0275959		Approved			C0038425	Streptomyzin
Streptomycin	Granuloma Inguinale	C0018190		Approved			C0038425	Streptomyzin
Streptomycin	Bacterial urinary infection	C0729524		Approved			C0038425	Streptomyzin
Streptomycin	Tularemia	C0041351		Approved			C0038425	Streptomyzin
Streptomycin	Tuberculosis, Pulmonary	C0041327		Approved			C0038425	Streptomyzin
Orlistat	Obesity	C0028754		Approved			C0076275	Orlipastatum
Emedastine	Allergic Conjunctivitis	C0009766		Approved			C0064263	1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole
Emedastine	Urticaria	C0042109		Approved			C0064263	1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole
Emedastine	Pruritus	C0033774		Approved			C0064263	1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole
Pilocarpine	Xerostomia	C0043352		Approved			C0031923	Pilocarpina
Pilocarpine	Glaucoma, Open-Angle	C0017612		Approved			C0031923	Pilocarpina
Pilocarpine	Ocular Hypertension	C0028840		Approved			C0031923	Pilocarpina
Benzocaine	Skin irritation	C0152030		Approved			C0005059	Ethyl aminobenzoate
Benzocaine	Coughing	C0010200		Approved			C0005059	Ethyl aminobenzoate
Benzocaine	Sore Throat	C0242429		Approved			C0005059	Ethyl aminobenzoate
Benzocaine	Pruritus	C0033774		Approved			C0005059	Ethyl aminobenzoate
Benzocaine	Mouth irritation	C0235339		Approved			C0005059	Ethyl aminobenzoate
Benzocaine	Tinea	C0040247		Approved			C0005059	Ethyl aminobenzoate
Benzocaine	Tinea corporis (disorder)	C0040252		Approved			C0005059	Ethyl aminobenzoate
Benzocaine	Tinea Pedis	C0040259		Approved			C0005059	Ethyl aminobenzoate
Primaquine	Malaria, Vivax	C0024537		Approved			C0033126	Primachinum
Iloprost	Pulmonary arterial hypertension	C2973725		Approved			C0079594	Iloprost
Butenafine	Tinea corporis (disorder)	C0040252		Approved			C0107497	N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine
Butenafine	Tinea Versicolor	C0040262		Approved			C0107497	N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine
Butenafine	Tinea Pedis	C0040259		Approved			C0107497	N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine
Butenafine	Tinea cruris	C1384589		Approved			C0107497	N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine
Dimethyl sulfoxide	Interstitial Cystitis	C0282488		Approved			C0012403	Dimethylsulfoxid
Fluvastatin	Hyperlipidemia, Familial Combined	C0020474		Approved			C0082608	fluvastatinum
Fluvastatin	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0082608	fluvastatinum
Fluvastatin	Hypercholesterolemia	C0020443		Approved			C0082608	fluvastatinum
Fluvastatin	Arteriosclerosis	C0003850		Approved			C0082608	fluvastatinum
Oxamniquine	Schistosomiasis	C0036323		Approved			C0029994	Oxamniquine
Leflunomide	Rheumatoid Arthritis	C0003873		Approved			C0063041	alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
Leflunomide	Arthritis, Psoriatic	C0003872		Approved			C0063041	alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
Rosuvastatin	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C0965129	Rosuvastatina
Rosuvastatin	Cerebrovascular accident	C0038454		Approved			C0965129	Rosuvastatina
Rosuvastatin	Hyperlipidemia, Familial Combined	C0020474		Approved			C0965129	Rosuvastatina
Rosuvastatin	Familial hypercholesterolemia - homozygous	C0342881		Approved			C0965129	Rosuvastatina
Rosuvastatin	Arteriosclerosis	C0003850		Approved			C0965129	Rosuvastatina
Rosuvastatin	Hypercholesterolemia	C0020443		Approved			C0965129	Rosuvastatina
Rosuvastatin	Hypertriglyceridemia	C0020557		Approved			C0965129	Rosuvastatina
Rosuvastatin	Hyperlipoproteinemia Type III	C0020479		Approved			C0965129	Rosuvastatina
Pimozide	Gilles de la Tourette syndrome	C0040517		Approved			C0031935	Pimozidum
Capecitabine	Metastasis from malignant tumor of colon	C1282500		Approved			C0671970	Capecitabin
Capecitabine	Malignant neoplasm of stomach	C0024623		Approved			C0671970	Capecitabin
Capecitabine	Carcinoma breast stage IV	C0278488		Approved			C0671970	Capecitabin
Quinacrine	Giardiasis	C0017536		Approved			C0034403	3-chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine
Sertraline	Premenstrual Dysphoric Disorder	C0520676		Approved			C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Sertraline	Depressive disorder	C0011581		Approved			C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Sertraline	Phobia, Social	C0031572		Approved			C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Sertraline	Obsessive-Compulsive Disorder	C0028768		Approved			C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Sertraline	Panic Disorder	C0030319		Approved			C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Sertraline	Post-Traumatic Stress Disorder	C0038436		Approved			C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Sibutramine	Obesity	C0028754		Approved			C0074493	Sibutramina
Levocabastine	Allergic Conjunctivitis	C0009766		Approved			C0064870	Levocabastinum
Methyprylon	Sleeplessness	C0917801		Approved			C0025840	Metiprilona
Trilostane	Adrenal Gland Hyperfunction	C0001622		Approved			C0077144	Trilostanum
Heparin	Deep Vein Thrombosis	C0149871		Approved			C0019134	Heparina
Heparin	Non-Q wave myocardial infarction	C0542269		Approved			C0019134	Heparina
Heparin	Disseminated Intravascular Coagulation	C0012739		Approved			C0019134	Heparina
Heparin	Peripheral arterial embolism	C0564750		Approved			C0019134	Heparina
Miconazole	Diaper Rash	C0011974		Approved			C0025942	Miconazol
Miconazole	Tinea Pedis	C0040259		Approved			C0025942	Miconazol
Miconazole	Candidiasis, Vulvovaginal	C0700345		Approved			C0025942	Miconazol
Miconazole	Tinea Versicolor	C0040262		Approved			C0025942	Miconazol
Miconazole	Tinea corporis (disorder)	C0040252		Approved			C0025942	Miconazol
Miconazole	Tinea cruris	C1384589		Approved			C0025942	Miconazol
Miconazole	Cutaneous Candidiasis	C0006846		Approved			C0025942	Miconazol
Miconazole	Oropharyngeal candidiasis	C0919659		Approved			C0025942	Miconazol
Miconazole	Onychomycosis	C0040261		Approved			C0025942	Miconazol
Colistimethate	Infection caused by Enterobacter	C0948205		Approved			C0009315	Colistimethate
Colistimethate	Pseudomonas aeruginosa infection	C0854135		Approved			C0009315	Colistimethate
Colistimethate	Klebsiella Infections	C0022729		Approved			C0009315	Colistimethate
Cefuroxime	Klebsiella cystitis	C0520775		Approved			C0007562	Cefuroxima
Cefuroxime	Acute maxillary sinusitis	C0155804		Approved			C0007562	Cefuroxima
Cefuroxime	Haemophilus influenzae pneumonia	C0276026		Approved			C0007562	Cefuroxima
Cefuroxime	Staphylococcal bacteraemia	C0152965		Approved			C0007562	Cefuroxima
Cefuroxime	Haemophilus sepsis	C0854324		Approved			C0007562	Cefuroxima
Cefuroxime	GONOCOCCAL INFECTION DISSEMINATED	C0744451		Approved			C0007562	Cefuroxima
Cefuroxime	Gonorrhea of rectum	C0275665		Approved			C0007562	Cefuroxima
Cefuroxime	Escherichia coli Infections	C0014836		Approved			C0007562	Cefuroxima
Cefuroxime	Staphylococcus aureus infection	C1318973		Approved			C0007562	Cefuroxima
Cefuroxime	Streptococcus pyogenes infection	C0554628		Approved			C0007562	Cefuroxima
Cefuroxime	Bacterial sepsis	C0684256		Approved			C0007562	Cefuroxima
Cefuroxime	Acute otitis media	C0271429		Approved			C0007562	Cefuroxima
Cefuroxime	Streptococcal tonsillitis	C0275804		Approved			C0007562	Cefuroxima
Cefuroxime	Lower respiratory tract infection	C0149725		Approved			C0007562	Cefuroxima
Cefuroxime	Impetigo	C0021099		Approved			C0007562	Cefuroxima
Cefuroxime	Escherichia coli septicemia	C0276088		Approved			C0007562	Cefuroxima
Cefuroxime	Infective otitis media	C0729586		Approved			C0007562	Cefuroxima
Cefuroxime	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007562	Cefuroxima
Cefuroxime	Pneumonia, Bacterial	C0004626		Approved			C0007562	Cefuroxima
Cefuroxime	Infection of bone	C2242472		Approved			C0007562	Cefuroxima
Cefuroxime	Gonorrhea	C0018081		Approved			C0007562	Cefuroxima
Cefuroxime	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007562	Cefuroxima
Cefuroxime	Lyme Disease	C0024198		Approved			C0007562	Cefuroxima
Cefuroxime	Staphylococcal Pneumonia	C0032308		Approved			C0007562	Cefuroxima
Cefuroxime	Enterobacteriaceae Infections	C0014347		Approved			C0007562	Cefuroxima
Cefuroxime	Escherichia coli urinary tract infection	C0577708		Approved			C0007562	Cefuroxima
Cefuroxime	Acute gonococcal endometritis	C0153196		Approved			C0007562	Cefuroxima
Cefuroxime	Acute gonococcal cervicitis	C0153195		Approved			C0007562	Cefuroxima
Cefuroxime	Meningitis, Bacterial	C0085437		Approved			C0007562	Cefuroxima
Cefuroxime	Gonorrhea of pharynx	C0149966		Approved			C0007562	Cefuroxima
Cefuroxime	Rhinoscleroma	C0035468		Approved			C0007562	Cefuroxima
Cefuroxime	Pneumonia due to Escherichia coli	C0276089		Approved			C0007562	Cefuroxima
Cefuroxime	Acute gonococcal urethritis	C0275652		Approved			C0007562	Cefuroxima
Cefuroxime	Streptococcal sepsis	C0152964		Approved			C0007562	Cefuroxima
Cefuroxime	Arthropathy associated with infection	C0157749		Approved			C0007562	Cefuroxima
Cefuroxime	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007562	Cefuroxima
Cefuroxime	Staphylococcal meningitis	C0154640		Approved			C0007562	Cefuroxima
Cefuroxime	Streptococcal meningitis	C0154639		Approved			C0007562	Cefuroxima
Cefuroxime	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0007562	Cefuroxima
Papaverine	Peripheral Vascular Diseases	C0085096		Approved			C0030350	Papaverina
Papaverine	Cerebral Ischemia	C0917798		Approved			C0030350	Papaverina
Chlorphenamine	Urticaria	C0042109		Approved			C0008281	Clorfenamina
Chlorphenamine	Symptomatic dermographism	C0343065		Approved			C0008281	Clorfenamina
Chlorphenamine	Nasal congestion (finding)	C0027424		Approved			C0008281	Clorfenamina
Chlorphenamine	Rhinitis, Vasomotor	C0035460		Approved			C0008281	Clorfenamina
Chlorphenamine	Influenza-like symptoms	C0392171		Approved			C0008281	Clorfenamina
Chlorphenamine	Rhinorrhea	C1260880		Approved			C0008281	Clorfenamina
Chlorphenamine	Allergic Conjunctivitis	C0009766		Approved			C0008281	Clorfenamina
Chlorphenamine	Sneezing	C0037383		Approved			C0008281	Clorfenamina
Chlorphenamine	Hay fever	C0018621		Approved			C0008281	Clorfenamina
Chlorphenamine	Allergic rhinitis (disorder)	C2607914		Approved			C0008281	Clorfenamina
Chlorphenamine	Common Cold	C0009443		Approved			C0008281	Clorfenamina
Chlorphenamine	Pruritus	C0033774		Approved			C0008281	Clorfenamina
Nifedipine	Angina Pectoris, Variant	C0002963		Approved			C0028066	Nifedipinum
Nifedipine	Hypertensive disease	C0020538		Approved			C0028066	Nifedipinum
Nifedipine	Angina Pectoris	C0002962		Approved			C0028066	Nifedipinum
Trimethaphan	Hypertensive emergency	C0745136		Approved			C0041040	Trimetaphan
Trimethaphan	Pulmonary Edema	C0034063		Approved			C0041040	Trimetaphan
Atovaquone	Malaria, Falciparum	C0024535		Approved			C0165603	Atovacuona
Amiodarone	Ventricular Fibrillation	C0042510		Approved			C0002598	2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
Diazoxide	Hyperinsulinism	C0020459		Approved			C0012022	Diazoxidum
Diazoxide	insulinoma	C0021670		Approved			C0012022	Diazoxidum
Diazoxide	Nesidioblastosis	C0027773		Approved			C0012022	Diazoxidum
Diazoxide	Hypertensive urgency	C0745138		Approved			C0012022	Diazoxidum
Diazoxide	Hypertensive emergency	C0745136		Approved			C0012022	Diazoxidum
Gliclazide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0017631	1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea
Phenacemide	Epilepsy	C0014544		Approved			C0070525	Phenacemide
Phenacemide	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0070525	Phenacemide
Ambenonium	Myasthenia Gravis	C0026896		Approved			C0002412	Ambenonum
Tolbutamide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0040374	N-Butyl-N'-(4-methylphenylsulfonyl)urea
Dutasteride	Prostatic Hypertrophy	C1739363		Approved			C0754659	α,α,α,α',α',α'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide
Econazole	Cutaneous Candidiasis	C0006846		Approved			C0013547	Econazol
Econazole	Tinea Pedis	C0040259		Approved			C0013547	Econazol
Econazole	Tinea Versicolor	C0040262		Approved			C0013547	Econazol
Econazole	Tinea cruris	C1384589		Approved			C0013547	Econazol
Econazole	Tinea corporis (disorder)	C0040252		Approved			C0013547	Econazol
Bicalutamide	Metastatic Prostate Carcinoma	C0936223		Approved			C0285590	Bicalutamida
Rabeprazole	Multiple Endocrine Neoplasia	C0027662		Approved			C0378482	Rabeprazole
Rabeprazole	Zollinger-Ellison syndrome	C0043515		Approved			C0378482	Rabeprazole
Rabeprazole	Mastocytosis, Systemic	C0221013		Approved			C0378482	Rabeprazole
Rabeprazole	Gastroesophageal reflux disease	C0017168		Approved			C0378482	Rabeprazole
Rabeprazole	Duodenal Ulcer	C0013295		Approved			C0378482	Rabeprazole
Rabeprazole	Peptic Ulcer	C0030920		Approved			C0378482	Rabeprazole
Prednicarbate	Dermatitis, Atopic	C0011615		Approved			C0071836	Prednicarbato
Prednicarbate	Pruritus of genital organs	C0033777		Approved			C0071836	Prednicarbato
Prednicarbate	Pruritus Ani	C0033775		Approved			C0071836	Prednicarbato
Prednicarbate	Lupus Erythematosus, Discoid	C0024138		Approved			C0071836	Prednicarbato
Prednicarbate	Lichen Simplex Chronicus	C0149922		Approved			C0071836	Prednicarbato
Prednicarbate	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0071836	Prednicarbato
Prednicarbate	Contact Dermatitis	C0011616		Approved			C0071836	Prednicarbato
Prednicarbate	Granuloma Annulare	C0085074		Approved			C0071836	Prednicarbato
Prednicarbate	Exanthema	C0015230		Approved			C0071836	Prednicarbato
Prednicarbate	Scalp psoriasis	C0406326		Approved			C0071836	Prednicarbato
Prednicarbate	Seborrheic dermatitis	C0036508		Approved			C0071836	Prednicarbato
Prednicarbate	Chronic small plaque psoriasis	C0406317		Approved			C0071836	Prednicarbato
Proguanil	Malaria, Falciparum	C0024535		Approved			C0008241	1-(p-Chlorophenyl)-5-isopropylbiguanide
Pioglitazone	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0071097	(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
Tiludronate	Osteitis Deformans	C0029401		Approved			C0043611	Tiludronic acid
Carvedilol	Chronic heart failure	C0264716		Approved			C0054836	(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
Carvedilol	Hypertensive disease	C0020538		Approved			C0054836	(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
Levofloxacin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Staphylococcus aureus infection	C1318973		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Escherichia coli urinary tract infection	C0577708		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Streptococcus pyogenes infection	C0554628		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Acute maxillary sinusitis	C0155804		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Chlamydial pneumonia	C0339959		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Streptococcal pneumonia	C0155862		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Klebsiella cystitis	C0520775		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Legionella pneumophila pneumonia	C0857846		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	PYELONEPHRITIS E COLI	C0748196		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Anthrax disease	C0003175		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Pyelonephritis	C0034186		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Pneumonia, Bacterial	C0004626		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Bacterial conjunctivitis	C0009768		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Mycoplasma pneumonia	C0032302		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Bacterial urinary infection	C0729524		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Staphylococcal Pneumonia	C0032308		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Proteus urinary tract infection	C0577709		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Levofloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Sulfinpyrazone	Hyperuricemia	C0740394		Approved			C0038742	Sulphinpyrazone
Sulfinpyrazone	Chronic gouty arthritis	C0268108		Approved			C0038742	Sulphinpyrazone
Cefapirin	Staphylococcal endocarditis	C0520767		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Staphylococcal bacteraemia	C0152965		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Streptococcus pyogenes infection	C0554628		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Streptococcal endocarditis	C3665800		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Pneumonia	C0032285		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Staphylococcal Pneumonia	C0032308		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Proteus urinary tract infection	C0577709		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Urinary tract infection	C0042029		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Staphylococcus aureus infection	C1318973		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Bacterial sepsis	C0684256		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Escherichia coli Infections	C0014836		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Escherichia coli septicemia	C0276088		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Arthropathy associated with infection	C0157749		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Streptococcal sepsis	C0152964		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Klebsiella cystitis	C0520775		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Haemophilus influenzae pneumonia	C0276026		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Rhinoscleroma	C0035468		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Infection of bone	C2242472		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Lower respiratory tract infection	C0149725		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefapirin	Escherichia coli urinary tract infection	C0577708		Approved			C0007737	(6R,7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefadroxil	Urinary tract infection	C0042029		Approved			C0007538	Cefadroxilo
Cefadroxil	Streptococcus pyogenes infection	C0554628		Approved			C0007538	Cefadroxilo
Cefadroxil	Proteus urinary tract infection	C0577709		Approved			C0007538	Cefadroxilo
Cefadroxil	Klebsiella cystitis	C0520775		Approved			C0007538	Cefadroxilo
Cefadroxil	Escherichia coli urinary tract infection	C0577708		Approved			C0007538	Cefadroxilo
Cefadroxil	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007538	Cefadroxilo
Cefadroxil	Tonsillitis	C0040425		Approved			C0007538	Cefadroxilo
Cefadroxil	Streptococcal tonsillitis	C0275804		Approved			C0007538	Cefadroxilo
Cefadroxil	Staphylococcus aureus infection	C1318973		Approved			C0007538	Cefadroxilo
Micafungin	Candidemia	C0877445		Approved			C1120386	Micafungina
Micafungin	Systemic candidiasis	C0153252		Approved			C1120386	Micafungina
Micafungin	Septicemia candida	C0349009		Approved			C1120386	Micafungina
Micafungin	Candidiasis of the esophagus	C0239295		Approved			C1120386	Micafungina
Micafungin	candidal peritonitis	C2062982		Approved			C1120386	Micafungina
Doxepin	Depression, Bipolar	C0005587		Approved			C0013085	Doxepinum
Doxepin	Severe major depression with psychotic features	C0270458		Approved			C0013085	Doxepinum
Doxepin	Anxiety	C0003467		Approved			C0013085	Doxepinum
Doxepin	Depressive disorder	C0011581		Approved			C0013085	Doxepinum
Doxepin	Sleeplessness	C0917801		Approved			C0013085	Doxepinum
Doxepin	Pruritus	C0033774		Approved			C0013085	Doxepinum
Doxepin	Lichen Simplex Chronicus	C0149922		Approved			C0013085	Doxepinum
Diclofenamide	Glaucoma, Open-Angle	C0017612		Approved			C0012086	4,5-dichlorobenzene-1,3-disulfonamide
Diclofenamide	Angle Closure Glaucoma	C0017605		Approved			C0012086	4,5-dichlorobenzene-1,3-disulfonamide
Diclofenamide	Secondary glaucoma	C0149893		Approved			C0012086	4,5-dichlorobenzene-1,3-disulfonamide
Diphenylpyraline	Nasal congestion (finding)	C0027424		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Rhinitis, Vasomotor	C0035460		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Allergic Conjunctivitis	C0009766		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Allergic rhinitis (disorder)	C2607914		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Urticaria	C0042109		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Pruritus	C0033774		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Symptomatic dermographism	C0343065		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Sneezing	C0037383		Approved			C0058389	Difenilpiralina
Diphenylpyraline	Rhinorrhea	C1260880		Approved			C0058389	Difenilpiralina
Cloxacillin	Staphylococcal meningitis	C0154640		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Cloxacillin	Staphylococcal Pneumonia	C0032308		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Cloxacillin	Pharyngitis	C0031350		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Cloxacillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Cloxacillin	Staphylococcal bacteraemia	C0152965		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Cloxacillin	Lower respiratory tract infection	C0149725		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Cloxacillin	Staphylococcus aureus infection	C1318973		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Cloxacillin	Sinusitis	C0037199		Approved			C0009077	6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
Flavoxate	Urgency of micturition	C0085606		Approved			C0016225	2-piperidinoethyl 3-methylflavone-8-carboxylate
Flavoxate	Nocturia	C0028734		Approved			C0016225	2-piperidinoethyl 3-methylflavone-8-carboxylate
Flavoxate	Urinary Incontinence	C0042024		Approved			C0016225	2-piperidinoethyl 3-methylflavone-8-carboxylate
Flavoxate	Suprapubic pain	C0241310		Approved			C0016225	2-piperidinoethyl 3-methylflavone-8-carboxylate
Flavoxate	Increased frequency of micturition	C0042023		Approved			C0016225	2-piperidinoethyl 3-methylflavone-8-carboxylate
Flavoxate	Dysuria	C0013428		Approved			C0016225	2-piperidinoethyl 3-methylflavone-8-carboxylate
Nefazodone	Major Depressive Disorder	C1269683		Approved			C0068485	Nefazodonum
Cefprozil	Acute otitis media	C0271429		Approved			C0053882	Cefprozilum
Cefprozil	Upper Respiratory Infections	C0041912		Approved			C0053882	Cefprozilum
Cefprozil	Acute bacterial sinusitis	C0275556		Approved			C0053882	Cefprozilum
Cefprozil	Streptococcus pyogenes infection	C0554628		Approved			C0053882	Cefprozilum
Cefprozil	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0053882	Cefprozilum
Cefprozil	Streptococcal tonsillitis	C0275804		Approved			C0053882	Cefprozilum
Cefprozil	Infective otitis media	C0729586		Approved			C0053882	Cefprozilum
Cefprozil	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0053882	Cefprozilum
Cefprozil	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0053882	Cefprozilum
Cefprozil	Staphylococcus aureus infection	C1318973		Approved			C0053882	Cefprozilum
Cefprozil	Tonsillitis	C0040425		Approved			C0053882	Cefprozilum
Cefprozil	Bronchitis	C0006277		Approved			C0053882	Cefprozilum
Desipramine	Depressive disorder	C0011581		Approved			C0011685	Désipramine
Sertaconazole	Tinea Pedis	C0040259		Approved			C0074391	Sertaconazolum
Gemifloxacin	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			C0533545	Gemifloxacin
Gemifloxacin	Acute bacterial bronchitis	C0339933		Approved			C0533545	Gemifloxacin
Gemifloxacin	Mycoplasma pneumonia	C0032302		Approved			C0533545	Gemifloxacin
Gemifloxacin	Pneumonia, Bacterial	C0004626		Approved			C0533545	Gemifloxacin
Gemifloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0533545	Gemifloxacin
Gemifloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0533545	Gemifloxacin
Gemifloxacin	Chlamydial pneumonia	C0339959		Approved			C0533545	Gemifloxacin
Gemifloxacin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0533545	Gemifloxacin
Gemifloxacin	Streptococcal pneumonia	C0155862		Approved			C0533545	Gemifloxacin
Bupropion	Nicotine Dependence	C0028043		Approved			C0085208	Bupropion
Bupropion	Depressive disorder	C0011581		Approved			C0085208	Bupropion
Bupropion	Major Depressive Disorder	C1269683		Approved			C0085208	Bupropion
Bupropion	Seasonal Affective Disorder	C0085159		Approved			C0085208	Bupropion
Bupropion	Obesity	C0028754		Approved			C0085208	Bupropion
Bretylium	Ventricular Fibrillation	C0042510		Approved			C0054040	N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium
Bretylium	Ventricular arrhythmia	C0085612		Approved			C0054040	N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium
Dinoprost Tromethamine	Unspecified Abortion	C0156543		Approved			C0058310	Dinoprost tromethamine
Dinoprost Tromethamine	Hydatidiform mole, benign	C0549315		Approved			C0058310	Dinoprost tromethamine
Dinoprost Tromethamine	Incomplete spontaneous abortion	C0000810		Approved			C0058310	Dinoprost tromethamine
Terazosin	Prostatic Hypertrophy	C1739363		Approved			C0076107	Térazosine
Terazosin	Hypertensive disease	C0020538		Approved			C0076107	Térazosine
Calcium Chloride	Hypokalemia	C0020621		Approved			C0006686	Calcio cloruro
Calcium Chloride	Hypermagnesemia	C0151714		Approved			C0006686	Calcio cloruro
Calcium Chloride	Disorder of electrolytes	C1704431		Approved			C0006686	Calcio cloruro
Calcium Chloride	Cardiac Arrest	C0018790		Approved			C0006686	Calcio cloruro
Calcium Chloride	Hypocalcemic tetany	C0151940		Approved			C0006686	Calcio cloruro
Calcium Chloride	Hypocalcemia	C0020598		Approved			C0006686	Calcio cloruro
Calcium Chloride	Hyperkalemia	C0020461		Approved			C0006686	Calcio cloruro
Ofloxacin	Pyelonephritis	C0034186		Approved			C0028902	Ofloxacino
Ofloxacin	URINARY TRACT INFECTION CITROBACTER	C0749955		Approved			C0028902	Ofloxacino
Ofloxacin	Anthrax disease	C0003175		Approved			C0028902	Ofloxacino
Ofloxacin	Typhoid Fever	C0041466		Approved			C0028902	Ofloxacino
Ofloxacin	Proteus pneumonia	C1260917		Approved			C0028902	Ofloxacino
Ofloxacin	Escherichia coli urinary tract infection	C0577708		Approved			C0028902	Ofloxacino
Ofloxacin	Infective otitis externa	C0021355		Approved			C0028902	Ofloxacino
Ofloxacin	Escherichia coli septicemia	C0276088		Approved			C0028902	Ofloxacino
Ofloxacin	Shigella Infections	C0013371		Approved			C0028902	Ofloxacino
Ofloxacin	Chronic tubotympanic suppurative otitis media	C0155440		Approved			C0028902	Ofloxacino
Ofloxacin	Gonorrhea	C0018081		Approved			C0028902	Ofloxacino
Ofloxacin	Infective cystitis	C0600041		Approved			C0028902	Ofloxacino
Ofloxacin	Streptococcus pyogenes infection	C0554628		Approved			C0028902	Ofloxacino
Ofloxacin	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0028902	Ofloxacino
Ofloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0028902	Ofloxacino
Ofloxacin	Proteus urinary tract infection	C0577709		Approved			C0028902	Ofloxacino
Ofloxacin	Staphylococcal Pneumonia	C0032308		Approved			C0028902	Ofloxacino
Ofloxacin	Pneumonia due to Pseudomonas	C0155860		Approved			C0028902	Ofloxacino
Ofloxacin	Bacterial urinary infection	C0729524		Approved			C0028902	Ofloxacino
Ofloxacin	non-gonococcal urethritis (NGU)	C1112709		Approved			C0028902	Ofloxacino
Ofloxacin	Escherichia coli Infections	C0014836		Approved			C0028902	Ofloxacino
Ofloxacin	Arthropathy associated with infection	C0157749		Approved			C0028902	Ofloxacino
Ofloxacin	Chlamydial pneumonia	C0339959		Approved			C0028902	Ofloxacino
Ofloxacin	Klebsiella cystitis	C0520775		Approved			C0028902	Ofloxacino
Ofloxacin	Chancroids	C0007947		Approved			C0028902	Ofloxacino
Ofloxacin	Enterobacter pneumonia	C1096258		Approved			C0028902	Ofloxacino
Ofloxacin	Infection of bone	C2242472		Approved			C0028902	Ofloxacino
Ofloxacin	Chlamydial cervicitis	C0341834		Approved			C0028902	Ofloxacino
Ofloxacin	Acute maxillary sinusitis	C0155804		Approved			C0028902	Ofloxacino
Ofloxacin	Pneumonia due to Escherichia coli	C0276089		Approved			C0028902	Ofloxacino
Ofloxacin	Gonorrhea of rectum	C0275665		Approved			C0028902	Ofloxacino
Ofloxacin	Female genital tract infection	C1263758		Approved			C0028902	Ofloxacino
Ofloxacin	Acute gonococcal urethritis	C0275652		Approved			C0028902	Ofloxacino
Ofloxacin	Enteric campylobacteriosis	C0275982		Approved			C0028902	Ofloxacino
Ofloxacin	Staphylococcus aureus infection	C1318973		Approved			C0028902	Ofloxacino
Ofloxacin	Acute gonococcal cervicitis	C0153195		Approved			C0028902	Ofloxacino
Ofloxacin	Otitis Externa	C0029878		Approved			C0028902	Ofloxacino
Ofloxacin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0028902	Ofloxacino
Ofloxacin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0028902	Ofloxacino
Ofloxacin	Rhinoscleroma	C0035468		Approved			C0028902	Ofloxacino
Ofloxacin	Acute gonococcal endometritis	C0153196		Approved			C0028902	Ofloxacino
Ofloxacin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0028902	Ofloxacino
Ofloxacin	Pneumonia, Bacterial	C0004626		Approved			C0028902	Ofloxacino
Ofloxacin	Chronic Bacterial Prostatitis	C1720797		Approved			C0028902	Ofloxacino
Ofloxacin	Enterobacteriaceae Infections	C0014347		Approved			C0028902	Ofloxacino
Ofloxacin	Chlamydial pelvic inflammatory disease	C0520777		Approved			C0028902	Ofloxacino
Ofloxacin	Cystitis	C0010692		Approved			C0028902	Ofloxacino
Ofloxacin	Postoperative infection	C0392618		Approved			C0028902	Ofloxacino
Ofloxacin	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			C0028902	Ofloxacino
Ofloxacin	Urinary tract infection	C0042029		Approved			C0028902	Ofloxacino
Ofloxacin	Pneumonia	C0032285		Approved			C0028902	Ofloxacino
Ofloxacin	prostatitis	C0033581		Approved			C0028902	Ofloxacino
Ofloxacin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0028902	Ofloxacino
Ofloxacin	Streptococcal pneumonia	C0155862		Approved			C0028902	Ofloxacino
Ofloxacin	Intraabdominal Infections	C1112209		Approved			C0028902	Ofloxacino
Ofloxacin	Lower respiratory tract infection	C0149725		Approved			C0028902	Ofloxacino
Ofloxacin	Bronchitis	C0006277		Approved			C0028902	Ofloxacino
Ofloxacin	Traveler's diarrhea	C0277528		Approved			C0028902	Ofloxacino
Ofloxacin	Mycoplasma pneumonia	C0032302		Approved			C0028902	Ofloxacino
Ofloxacin	Legionella pneumophila pneumonia	C0857846		Approved			C0028902	Ofloxacino
Ofloxacin	Acute bacterial sinusitis	C0275556		Approved			C0028902	Ofloxacino
Ofloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0028902	Ofloxacino
Ofloxacin	Chlamydial urethritis	C1278807		Approved			C0028902	Ofloxacino
Ofloxacin	Acute osteomyelitis	C0158371		Approved			C0028902	Ofloxacino
Ofloxacin	PYELONEPHRITIS E COLI	C0748196		Approved			C0028902	Ofloxacino
Ofloxacin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0028902	Ofloxacino
Ofloxacin	Nosocomial pneumonia	C0949083		Approved			C0028902	Ofloxacino
Ofloxacin	Cystitis escherichia	C0853852		Approved			C0028902	Ofloxacino
Ofloxacin	Bacterial conjunctivitis	C0009768		Approved			C0028902	Ofloxacino
Ofloxacin	Abdominal Abscess	C0243001		Approved			C0028902	Ofloxacino
Cilostazol	Intermittent Claudication	C0021775		Approved			C0055729	6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
Itraconazole	Candidemia	C0877445		Approved			C0064113	Itraconazolum
Itraconazole	Onychomycosis of fingernails	C1274469		Approved			C0064113	Itraconazolum
Itraconazole	Systemic candidiasis	C0153252		Approved			C0064113	Itraconazolum
Itraconazole	Candidiasis of the esophagus	C0239295		Approved			C0064113	Itraconazolum
Itraconazole	Onychomycosis of toenails	C1274470		Approved			C0064113	Itraconazolum
Itraconazole	Fusariosis	C0276758		Approved			C0064113	Itraconazolum
Itraconazole	Aspergillosis	C0004030		Approved			C0064113	Itraconazolum
Itraconazole	Oropharyngeal candidiasis	C0919659		Approved			C0064113	Itraconazolum
Itraconazole	Invasive Pulmonary Aspergillosis	C0276653		Approved			C0064113	Itraconazolum
Itraconazole	Blastomycosis	C0005716		Approved			C0064113	Itraconazolum
Itraconazole	Histoplasmosis	C0019655		Approved			C0064113	Itraconazolum
Procarbazine	Hodgkin Disease	C0019829		Approved			C0033223	N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
Arsenic trioxide	Acute myelomonocytic leukemia	C0023479		Approved			C0052416	arsénico trióxido
Arsenic trioxide	Acute Promyelocytic Leukemia	C0023487		Approved			C0052416	arsénico trióxido
Guanethidine	Hypertensive disease	C0020538		Approved			C0018318	guanetidina
Moclobemide	Depressive disorder	C0011581		Approved			C0066673	Moclobemida
Kanamycin	Infection of bone	C2242472		Approved			C0022489	Kanamycin A
Kanamycin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0022489	Kanamycin A
Kanamycin	Pneumonia, Bacterial	C0004626		Approved			C0022489	Kanamycin A
Kanamycin	Meningitis	C0025289		Approved			C0022489	Kanamycin A
Kanamycin	Urinary tract infection	C0042029		Approved			C0022489	Kanamycin A
Kanamycin	Intraabdominal Infections	C1112209		Approved			C0022489	Kanamycin A
Kanamycin	Arthropathy associated with infection	C0157749		Approved			C0022489	Kanamycin A
Kanamycin	Bacterial sepsis	C0684256		Approved			C0022489	Kanamycin A
Kanamycin	Cholangitis	C0008311		Approved			C0022489	Kanamycin A
Orphenadrine	Muscle Spasticity	C0026838		Approved			C0029309	phenyl-o-tolylmethyl dimethyaminoethyl ether
Orphenadrine	Parkinsonian Disorders	C0242422		Approved			C0029309	phenyl-o-tolylmethyl dimethyaminoethyl ether
Phenobarbital	Simple Partial Seizures	C0234974		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Bipolar disorder in remission	C0270425		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Vascular Headaches	C0042376		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Lennox-Gastaut syndrome	C0238111		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Epilepsy	C0014544		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Tonic - clonic seizures	C0494475		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Cluster Headache	C0009088		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Migraine Disorders	C0149931		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Tonic-Clonic Epilepsy	C0014549		Approved			C0031412	Phenylethylbarbitursäure
Phenobarbital	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0031412	Phenylethylbarbitursäure
Escitalopram	Major Depressive Disorder	C1269683		Approved			C1099456	Escitalopramum
Escitalopram	Generalized Anxiety Disorder	C0270549		Approved			C1099456	Escitalopramum
Cyclizine	Coughing	C0010200		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Hay fever	C0018621		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Motion Sickness	C0026603		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Rhinorrhea	C1260880		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Allergic rhinitis (disorder)	C2607914		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Nasal congestion (finding)	C0027424		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Rhinitis, Vasomotor	C0035460		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Allergic Conjunctivitis	C0009766		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Common Cold	C0009443		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Cyclizine	Sneezing	C0037383		Approved			C0010547	(N-Benzhydryl)(N'-methyl)diethylenediamine
Idarubicin	Leukemia, Myelocytic, Acute	C0023467		Approved			C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Idarubicin	Acute Promyelocytic Leukemia	C0023487		Approved			C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Chlormezanone	Anxiety	C0003467		Approved			C0008223	Chlormezanona
Podofilox	Condylomata Acuminata	C0009663		Approved			C0032334	(-)-podophyllotoxin
Ifosfamide	Testicular Germ Cell Tumor	C1336708		Approved			C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Propafenone	Paroxysmal atrial fibrillation	C0235480		Approved			C0033429	2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone
Propafenone	Paroxysmal atrial flutter	C0741292		Approved			C0033429	2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone
Propafenone	Paroxysmal supraventricular tachycardia	C0030590		Approved			C0033429	2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone
Naloxone	Poisoning by opiate analgesic drug	C0412850		Approved			C0027358	Nalossone
Naloxone	Opiate Addiction	C0524662		Approved			C0027358	Nalossone
Naloxone	Pain	C0030193		Approved			C0027358	Nalossone
Naloxone	Drug-induced constipation	C0267511		Approved			C0027358	Nalossone
Domperidone	Nausea and vomiting	C0027498		Approved			C0013015	5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
Fluoxymesterone	Noonan Syndrome	C0028326		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone	Testicular hypogonadism	C0151721		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone	Cryptorchidism	C0010417		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone	Klinefelter Syndrome	C0022735		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone	Deficiency of testosterone biosynthesis	C0342527		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone	Delayed Puberty	C0034012		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone	Generalized Myotonia of Thomsen	C2936781		Approved			C0016366	9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one
Pergolide	Parkinsonian Disorders	C0242422		Approved			C0031007	Pergolidum
Ciclopirox	Scurfiness of scalp	C0423775		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopirox	Tinea corporis (disorder)	C0040252		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopirox	Onychomycosis	C0040261		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopirox	Tinea cruris	C1384589		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopirox	Tinea Versicolor	C0040262		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopirox	Tinea Pedis	C0040259		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopirox	Seborrheic dermatitis	C0036508		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopirox	Cutaneous Candidiasis	C0006846		Approved			C0055711	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Clindamycin	Streptococcal pneumonia	C0155862		Approved			C0008947	Clindamycine
Clindamycin	Streptococcal sepsis	C0152964		Approved			C0008947	Clindamycine
Clindamycin	Bacterial sepsis	C0684256		Approved			C0008947	Clindamycine
Clindamycin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0008947	Clindamycine
Clindamycin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0008947	Clindamycine
Clindamycin	Staphylococcal bacteraemia	C0152965		Approved			C0008947	Clindamycine
Clindamycin	Gas gangrene caused by clostridium perfringens	C0343500		Approved			C0008947	Clindamycine
Clindamycin	Arthropathy associated with infection	C0157749		Approved			C0008947	Clindamycine
Clindamycin	Aspiration Pneumonia	C0032290		Approved			C0008947	Clindamycine
Clindamycin	Intraabdominal Infections	C1112209		Approved			C0008947	Clindamycine
Clindamycin	Staphylococcal Pneumonia	C0032308		Approved			C0008947	Clindamycine
Clindamycin	Pelvic Inflammatory Disease	C0242172		Approved			C0008947	Clindamycine
Clindamycin	Streptococcus pyogenes infection	C0554628		Approved			C0008947	Clindamycine
Clindamycin	Staphylococcus aureus infection	C1318973		Approved			C0008947	Clindamycine
Clindamycin	Septicemia due to anaerobes	C0152967		Approved			C0008947	Clindamycine
Clindamycin	Infection of bone	C2242472		Approved			C0008947	Clindamycine
Clindamycin	Empyema, Pleural	C0014013		Approved			C0008947	Clindamycine
Clindamycin	Acne Vulgaris	C0001144		Approved			C0008947	Clindamycine
Clindamycin	Bacterial Vaginosis	C0085166		Approved			C0008947	Clindamycine
Dexfenfluramine	Obesity	C0028754		Approved			C0011786	(S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
Oxymorphone	Pain	C0030193		Approved			C0030073	Oximorfona
Oxymorphone	Chronic pain	C0150055		Approved			C0030073	Oximorfona
Oxymorphone	Severe pain	C0278140		Approved			C0030073	Oximorfona
Oxymorphone	Labor Pain	C0474368		Approved			C0030073	Oximorfona
Acebutolol	Hypertensive disease	C0020538		Approved			C0000946	N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide
Acebutolol	Premature ventricular contractions	C0151636		Approved			C0000946	N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide
Brinzolamide	Ocular Hypertension	C0028840		Approved			C0673966	Brinzolamida
Brinzolamide	Glaucoma, Open-Angle	C0017612		Approved			C0673966	Brinzolamida
Flecainide	Paroxysmal atrial flutter	C0741292		Approved			C0016229	Flécanide
Flecainide	Paroxysmal atrial fibrillation	C0235480		Approved			C0016229	Flécanide
Estramustine	Prostatic Neoplasms	C0033578		Approved			C0014921	Estramustina
Captopril	Chronic heart failure	C0264716		Approved			C0006938	(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Captopril	Hypertensive disease	C0020538		Approved			C0006938	(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Captopril	Diabetic Nephropathy	C0011881		Approved			C0006938	(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Zopiclone	Sleeplessness	C0917801		Approved			C0078847	Zopiclona
Bromocriptine	Parkinson Disease, Postencephalitic	C0030568		Approved			C0006230	Bromocriptinum
Bromocriptine	Acromegaly	C0001206		Approved			C0006230	Bromocriptinum
Bromocriptine	Parkinson Disease	C0030567		Approved			C0006230	Bromocriptinum
Bromocriptine	Hyperprolactinemia	C0020514		Approved			C0006230	Bromocriptinum
Rifapentine	Tuberculosis, Pulmonary	C0041327		Approved			C0073372	Rifapentin
Levetiracetam	Simple Partial Seizures	C0234974		Approved			C0377265	Levetiracetamum
Levetiracetam	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0377265	Levetiracetamum
Nadolol	Angina Pectoris	C0002962		Approved			C0027302	Nadolol
Nadolol	Hypertensive disease	C0020538		Approved			C0027302	Nadolol
Mitoxantrone	Leukemia, Myelocytic, Acute	C0023467		Approved			C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Mitoxantrone	Metastatic Prostate Carcinoma	C0936223		Approved			C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Mitoxantrone	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Lomustine	Hodgkin Disease	C0019829		Approved			C0023972	1-(2-chloroethyl)-3-cyclohexylnitrosourea
Lomustine	Brain Neoplasms	C0006118		Approved			C0023972	1-(2-chloroethyl)-3-cyclohexylnitrosourea
Sparfloxacin	Mycoplasma pneumonia	C0032302		Approved			C0052585	cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Sparfloxacin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0052585	cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Sparfloxacin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0052585	cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Sparfloxacin	Pneumonia	C0032285		Approved			C0052585	cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Sparfloxacin	Haemophilus influenzae pneumonia	C0276026		Approved			C0052585	cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Sparfloxacin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0052585	cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Sparfloxacin	Chlamydial pneumonia	C0339959		Approved			C0052585	cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Dezocine	Pain	C0030193		Approved			C0057626	(-)-13β-amino-5,6,7,8,9,10,11α,12-octahydro-5α-methyl-5,11-methanobenzocyclodecen-3-ol
Levobunolol	Ocular Hypertension	C0028840		Approved			C0006388	(S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone
Levobunolol	Glaucoma, Open-Angle	C0017612		Approved			C0006388	(S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone
Clarithromycin	Acute maxillary sinusitis	C0155804		Approved			C0055856	Clarithromycinum
Clarithromycin	Staphylococcus aureus infection	C1318973		Approved			C0055856	Clarithromycinum
Clarithromycin	Acute bacterial sinusitis	C0275556		Approved			C0055856	Clarithromycinum
Clarithromycin	Infective otitis media	C0729586		Approved			C0055856	Clarithromycinum
Clarithromycin	Pulmonary Mycobacterium avium complex infection	C2733595		Approved			C0055856	Clarithromycinum
Clarithromycin	Helicobacter-associated gastritis	C0343378		Approved			C0055856	Clarithromycinum
Clarithromycin	Chlamydial pneumonia	C0339959		Approved			C0055856	Clarithromycinum
Clarithromycin	Acute otitis media	C0271429		Approved			C0055856	Clarithromycinum
Clarithromycin	Mycoplasma pneumonia	C0032302		Approved			C0055856	Clarithromycinum
Clarithromycin	Pneumonia, Bacterial	C0004626		Approved			C0055856	Clarithromycinum
Clarithromycin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0055856	Clarithromycinum
Clarithromycin	Streptococcus pyogenes infection	C0554628		Approved			C0055856	Clarithromycinum
Clarithromycin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0055856	Clarithromycinum
Clarithromycin	Moraxella catarrhalis pneumonia	C0857831		Approved			C0055856	Clarithromycinum
Clarithromycin	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0055856	Clarithromycinum
Clarithromycin	Acute bacterial bronchitis	C0339933		Approved			C0055856	Clarithromycinum
Clarithromycin	Streptococcal pneumonia	C0155862		Approved			C0055856	Clarithromycinum
Clarithromycin	Streptococcal tonsillitis	C0275804		Approved			C0055856	Clarithromycinum
Clarithromycin	Haemophilus influenzae pneumonia	C0276026		Approved			C0055856	Clarithromycinum
Clarithromycin	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0055856	Clarithromycinum
Ceftriaxone	Serratia Infections	C0085394		Approved			C0035750	Rocephin
Ceftriaxone	Proteus pneumonia	C1260917		Approved			C0035750	Rocephin
Ceftriaxone	Pneumonia due to Escherichia coli	C0276089		Approved			C0035750	Rocephin
Ceftriaxone	GONOCOCCAL INFECTION DISSEMINATED	C0744451		Approved			C0035750	Rocephin
Ceftriaxone	Staphylococcal meningitis	C0154640		Approved			C0035750	Rocephin
Ceftriaxone	Chancroids	C0007947		Approved			C0035750	Rocephin
Ceftriaxone	Acute gonococcal cervicitis	C0153195		Approved			C0035750	Rocephin
Ceftriaxone	Gonococcal endocarditis	C0153227		Approved			C0035750	Rocephin
Ceftriaxone	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0035750	Rocephin
Ceftriaxone	Septic arthritis haemophilus	C0860048		Approved			C0035750	Rocephin
Ceftriaxone	Enterobacter pneumonia	C1096258		Approved			C0035750	Rocephin
Ceftriaxone	Arthropathy associated with infection	C0157749		Approved			C0035750	Rocephin
Ceftriaxone	Staphylococcal bacteraemia	C0152965		Approved			C0035750	Rocephin
Ceftriaxone	Meningitis due to Klebsiella mobilis	C1719906		Approved			C0035750	Rocephin
Ceftriaxone	Gonococcal meningitis	C0153225		Approved			C0035750	Rocephin
Ceftriaxone	Rhinoscleroma	C0035468		Approved			C0035750	Rocephin
Ceftriaxone	Escherichia coli septicemia	C0276088		Approved			C0035750	Rocephin
Ceftriaxone	Klebsiella cystitis	C0520775		Approved			C0035750	Rocephin
Ceftriaxone	Intraabdominal Infections	C1112209		Approved			C0035750	Rocephin
Ceftriaxone	Streptococcal meningitis	C0154639		Approved			C0035750	Rocephin
Ceftriaxone	Meningococcal meningitis	C0025294		Approved			C0035750	Rocephin
Ceftriaxone	Endometritis	C0014179		Approved			C0035750	Rocephin
Ceftriaxone	Arthritis, Bacterial	C1692886		Approved			C0035750	Rocephin
Ceftriaxone	Gonococcal joint infection	C0153216		Approved			C0035750	Rocephin
Ceftriaxone	Lower respiratory tract infection	C0149725		Approved			C0035750	Rocephin
Ceftriaxone	Escherichia coli urinary tract infection	C0577708		Approved			C0035750	Rocephin
Ceftriaxone	Salmonella sepsis	C0152486		Approved			C0035750	Rocephin
Ceftriaxone	Bacterial sepsis	C0684256		Approved			C0035750	Rocephin
Ceftriaxone	Meningitis, Escherichia coli	C0338395		Approved			C0035750	Rocephin
Ceftriaxone	Haemophilus influenzae pneumonia	C0276026		Approved			C0035750	Rocephin
Ceftriaxone	Staphylococcal Pneumonia	C0032308		Approved			C0035750	Rocephin
Ceftriaxone	Pelvic Inflammatory Disease	C0242172		Approved			C0035750	Rocephin
Ceftriaxone	Gonorrhea of pharynx	C0149966		Approved			C0035750	Rocephin
Ceftriaxone	Haemophilus parainfluenzae pneumonia	C0877633		Approved			C0035750	Rocephin
Ceftriaxone	Gonorrhea	C0018081		Approved			C0035750	Rocephin
Ceftriaxone	Female genital tract infection	C1263758		Approved			C0035750	Rocephin
Ceftriaxone	Streptococcus pyogenes infection	C0554628		Approved			C0035750	Rocephin
Ceftriaxone	Pneumonia, Bacterial	C0004626		Approved			C0035750	Rocephin
Ceftriaxone	Escherichia coli Infections	C0014836		Approved			C0035750	Rocephin
Ceftriaxone	Acute gonococcal urethritis	C0275652		Approved			C0035750	Rocephin
Ceftriaxone	Infection of bone	C2242472		Approved			C0035750	Rocephin
Ceftriaxone	Gonorrhea of rectum	C0275665		Approved			C0035750	Rocephin
Ceftriaxone	Streptococcal sepsis	C0152964		Approved			C0035750	Rocephin
Ceftriaxone	Acute gonococcal endometritis	C0153196		Approved			C0035750	Rocephin
Ceftriaxone	Haemophilus influenzae type b infection	C2028293		Approved			C0035750	Rocephin
Ceftriaxone	Meningitis, Pneumococcal	C0025295		Approved			C0035750	Rocephin
Ceftriaxone	Proteus urinary tract infection	C0577709		Approved			C0035750	Rocephin
Ceftriaxone	Haemophilus sepsis	C0854324		Approved			C0035750	Rocephin
Ceftriaxone	Meningitis, Bacterial	C0085437		Approved			C0035750	Rocephin
Ceftriaxone	Enterobacteriaceae Infections	C0014347		Approved			C0035750	Rocephin
Ceftriaxone	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0035750	Rocephin
Ceftriaxone	Infective otitis media	C0729586		Approved			C0035750	Rocephin
Fomepizole	Accidental poisoning by methyl alcohol	C0261439		Approved			C0048504	4-methylpyrazol
Fomepizole	Ethylene glycol poisoning (disorder)	C0413194		Approved			C0048504	4-methylpyrazol
Metipranolol	Glaucoma, Open-Angle	C0017612		Approved			C0041030	(±)-metipranolol
Metipranolol	Ocular Hypertension	C0028840		Approved			C0041030	(±)-metipranolol
Finasteride	Prostatic Hypertrophy	C1739363		Approved			C0060389	Finasterida
Finasteride	Alopecia, Male Pattern	C4083212		Approved			C0060389	Finasterida
Anastrozole	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Halofantrine	Malaria, Falciparum	C0024535		Approved			C0120726	Halofantrinum
Dantrolene	Malignant hyperpyrexia due to anesthesia	C0024591		Approved			C0010976	1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin
Dantrolene	Muscle Spasticity	C0026838		Approved			C0010976	1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin
Dantrolene	Muscle spasticity of spinal origin	C1562430		Approved			C0010976	1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin
Rifaximin	Hepatic Encephalopathy	C0019151		Approved			C0073374	Rifaximinun
Rifaximin	Irritable bowel syndrome with diarrhea	C0348898		Approved			C0073374	Rifaximinun
Rifaximin	Diarrhoea predominant irritable bowel syndrome	C1262211		Approved			C0073374	Rifaximinun
Budesonide	Crohn Disease	C0010346		Approved			C0054201	(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Budesonide	Asthma	C0004096		Approved			C0054201	(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Budesonide	Allergic rhinitis (disorder)	C2607914		Approved			C0054201	(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Budesonide	Crohn's disease in remission	C1960764		Approved			C0054201	(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Aminophylline	Lung diseases	C0024115		Approved			C0002575	Aminophyllinum
Aminophylline	Status Asthmaticus	C0038218		Approved			C0002575	Aminophyllinum
Aminophylline	Asthma night-time symptoms	C1273489		Approved			C0002575	Aminophyllinum
Aminophylline	Asthma	C0004096		Approved			C0002575	Aminophyllinum
Aminophylline	Bronchitis	C0006277		Approved			C0002575	Aminophyllinum
Aminophylline	Pulmonary Emphysema	C0034067		Approved			C0002575	Aminophyllinum
Aminophylline	Asthma-chronic obstructive pulmonary disease overlap syndrome	C4038730		Approved			C0002575	Aminophyllinum
Aminophylline	Bronchial Spasm	C0006266		Approved			C0002575	Aminophyllinum
Aminophylline	Asthma attack	C0347950		Approved			C0002575	Aminophyllinum
Quetiapine	Schizophrenia	C0036341		Approved			C0123091	Quetiapina
Quetiapine	Depression, Bipolar	C0005587		Approved			C0123091	Quetiapina
Quetiapine	Bipolar Disorder	C0005586		Approved			C0123091	Quetiapina
Quetiapine	Bipolar affective disorder, current episode manic	C0338873		Approved			C0123091	Quetiapina
Quetiapine	Bipolar disorder in remission	C0270425		Approved			C0123091	Quetiapina
Enoxaparin	Deep Vein Thrombosis	C0149871		Approved			C0206460	Enoxaparin
Levomethadyl Acetate	Opiate Addiction	C0524662		Approved			C3536876	Levacetylmethadol
Encainide	Premature ventricular contractions	C0151636		Approved			C0085251	4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide
Paclitaxel	Kaposi Sarcoma	C0036220		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Glaucoma, Open-Angle	C0017612		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Carcinoma breast stage IV	C0278488		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Malignant neoplasm of ovary	C1140680		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Ocular Hypertension	C0028840		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Non-Small Cell Lung Carcinoma	C0007131		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Hypertensive disease	C0020538		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Breast Carcinoma	C0678222		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	Secondary malignant neoplasm of pancreas	C0346976		Approved			C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Diphenidol	Vertigo	C0042571		Approved			C0058371	Difénidol
Saquinavir	HIV Infections	C0019693		Approved			C0286738	Saquinavir
Metoclopramide	Gastroesophageal reflux disease	C0017168		Approved			C0025853	4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
Metoclopramide	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C0025853	4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
Metoclopramide	Gastroparesis due to diabetes mellitus	C0267176		Approved			C0025853	4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
Dexamethasone	Keloid	C0022548		Approved			C0011777	Dexaméthasone
Dexamethasone	Allergic Conjunctivitis	C0009766		Approved			C0011777	Dexaméthasone
Dexamethasone	Branch retinal vein occlusion with macular edema	C0339507		Approved			C0011777	Dexaméthasone
Dexamethasone	Dermatitis Herpetiformis	C0011608		Approved			C0011777	Dexaméthasone
Dexamethasone	Blepharoconjunctivitis	C0005743		Approved			C0011777	Dexaméthasone
Dexamethasone	Corneal abrasion	C0010032		Approved			C0011777	Dexaméthasone
Dexamethasone	Exanthema	C0015230		Approved			C0011777	Dexaméthasone
Dexamethasone	Exacerbation of asthma	C0349790		Approved			C0011777	Dexaméthasone
Dexamethasone	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0011777	Dexaméthasone
Dexamethasone	Scalp psoriasis	C0406326		Approved			C0011777	Dexaméthasone
Dexamethasone	Asthma	C0004096		Approved			C0011777	Dexaméthasone
Dexamethasone	Autoimmune hemolytic anemia	C0002880		Approved			C0011777	Dexaméthasone
Dexamethasone	Allergic rhinitis (disorder)	C2607914		Approved			C0011777	Dexaméthasone
Dexamethasone	Transplanted organ rejection	C0345468		Approved			C0011777	Dexaméthasone
Dexamethasone	Angioedema	C0002994		Approved			C0011777	Dexaméthasone
Dexamethasone	Pruritus Ani	C0033775		Approved			C0011777	Dexaméthasone
Dexamethasone	Mycosis Fungoides	C0026948		Approved			C0011777	Dexaméthasone
Dexamethasone	Epicondylitis	C0014488		Approved			C0011777	Dexaméthasone
Dexamethasone	Punctate keratitis	C0259799		Approved			C0011777	Dexaméthasone
Dexamethasone	Tenosynovitis	C0039520		Approved			C0011777	Dexaméthasone
Dexamethasone	Rheumatic Heart Disease	C0035439		Approved			C0011777	Dexaméthasone
Dexamethasone	Addisonian crisis	C0151467		Approved			C0011777	Dexaméthasone
Dexamethasone	Inflammatory Bowel Diseases	C0021390		Approved			C0011777	Dexaméthasone
Dexamethasone	Disorder of eye	C0015397		Approved			C0011777	Dexaméthasone
Dexamethasone	Iridocyclitis	C0022073		Approved			C0011777	Dexaméthasone
Dexamethasone	Bacterial keratitis	C0854211		Approved			C0011777	Dexaméthasone
Dexamethasone	Ankylosing spondylitis	C0038013		Approved			C0011777	Dexaméthasone
Dexamethasone	Lupus Erythematosus, Discoid	C0024138		Approved			C0011777	Dexaméthasone
Dexamethasone	Acquired thrombocytopenia	C0154301		Approved			C0011777	Dexaméthasone
Dexamethasone	Lichen Simplex Chronicus	C0149922		Approved			C0011777	Dexaméthasone
Dexamethasone	Herpes zoster keratitis	C1275687		Approved			C0011777	Dexaméthasone
Dexamethasone	Crohn Disease	C0010346		Approved			C0011777	Dexaméthasone
Dexamethasone	Trichinellosis	C0040896		Approved			C0011777	Dexaméthasone
Dexamethasone	Cyclitis	C0010543		Approved			C0011777	Dexaméthasone
Dexamethasone	Addison Disease	C0001403		Approved			C0011777	Dexaméthasone
Dexamethasone	Erythema Multiforme	C0014742		Approved			C0011777	Dexaméthasone
Dexamethasone	Adrenogenital disorder	C0701163		Approved			C0011777	Dexaméthasone
Dexamethasone	Dermatitis, Atopic	C0011615		Approved			C0011777	Dexaméthasone
Dexamethasone	Corneal Ulcer	C0010043		Approved			C0011777	Dexaméthasone
Dexamethasone	Hodgkin Disease	C0019829		Approved			C0011777	Dexaméthasone
Dexamethasone	Tuberculosis, Miliary	C0041321		Approved			C0011777	Dexaméthasone
Dexamethasone	Serum Sickness	C0036830		Approved			C0011777	Dexaméthasone
Dexamethasone	Exfoliative dermatitis	C0011606		Approved			C0011777	Dexaméthasone
Dexamethasone	Psoriasis	C0033860		Approved			C0011777	Dexaméthasone
Dexamethasone	Cerebral Edema	C0006114		Approved			C0011777	Dexaméthasone
Dexamethasone	Granuloma Annulare	C0085074		Approved			C0011777	Dexaméthasone
Dexamethasone	Chronic small plaque psoriasis	C0406317		Approved			C0011777	Dexaméthasone
Dexamethasone	Pruritus of genital organs	C0033777		Approved			C0011777	Dexaméthasone
Dexamethasone	Seborrheic dermatitis	C0036508		Approved			C0011777	Dexaméthasone
Dexamethasone	Berylliosis	C0005138		Approved			C0011777	Dexaméthasone
Dexamethasone	Rheumatoid Arthritis	C0003873		Approved			C0011777	Dexaméthasone
Dexamethasone	Sarcoidosis	C0036202		Approved			C0011777	Dexaméthasone
Dexamethasone	Thyroiditis	C0040147		Approved			C0011777	Dexaméthasone
Dexamethasone	Multiple Myeloma	C0026764		Approved			C0011777	Dexaméthasone
Dexamethasone	Lymphoma, Follicular	C0024301		Approved			C0011777	Dexaméthasone
Dexamethasone	Contact Dermatitis	C0011616		Approved			C0011777	Dexaméthasone
Dexamethasone	Infective blepharitis	C0729587		Approved			C0011777	Dexaméthasone
Dexamethasone	Dermatologic disorders	C0037274		Approved			C0011777	Dexaméthasone
Dexamethasone	Lymphoma, Non-Hodgkin	C0024305		Approved			C0011777	Dexaméthasone
Dexamethasone	Pemphigus	C0030807		Approved			C0011777	Dexaméthasone
Dexamethasone	Iritis	C0022081		Approved			C0011777	Dexaméthasone
Dexamethasone	Simple Pulmonary Eosinophilia	C0242459		Approved			C0011777	Dexaméthasone
Dexamethasone	Acute lymphocytic leukemia	C0023449		Approved			C0011777	Dexaméthasone
Dexamethasone	Cooley's anemia	C0002875		Approved			C0011777	Dexaméthasone
Dexamethasone	Allergic otitis externa	C1320547		Approved			C0011777	Dexaméthasone
Dexamethasone	Keratitis	C0022568		Approved			C0011777	Dexaméthasone
Dexamethasone	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0011777	Dexaméthasone
Dexamethasone	Multiple Sclerosis	C0026769		Approved			C0011777	Dexaméthasone
Dexamethasone	Bursitis	C0006444		Approved			C0011777	Dexaméthasone
Dexamethasone	Otitis Externa	C0029878		Approved			C0011777	Dexaméthasone
Dexamethasone	Rosacea	C0035854		Approved			C0011777	Dexaméthasone
Dexamethasone	Lupus Erythematosus, Systemic	C0024141		Approved			C0011777	Dexaméthasone
Dexamethasone	Anemia, Diamond-Blackfan	C1260899		Approved			C0011777	Dexaméthasone
Dexamethasone	Musculoskeletal Diseases	C0026857		Approved			C0011777	Dexaméthasone
Dexamethasone	Arthritis, Gouty	C0003868		Approved			C0011777	Dexaméthasone
Dexamethasone	Nephrotic Syndrome	C0027726		Approved			C0011777	Dexaméthasone
Dexamethasone	Punctate keratopathy	C0423234		Approved			C0011777	Dexaméthasone
Dexamethasone	Laryngeal Edema	C0023052		Approved			C0011777	Dexaméthasone
Dexamethasone	Arthritis, Psoriatic	C0003872		Approved			C0011777	Dexaméthasone
Dexamethasone	Uveitis	C0042164		Approved			C0011777	Dexaméthasone
Dexamethasone	Diffuse Large B-Cell Lymphoma	C0079744		Approved			C0011777	Dexaméthasone
Dexamethasone	Anterior uveitis	C0042165		Approved			C0011777	Dexaméthasone
Dexamethasone	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			C0011777	Dexaméthasone
Dexamethasone	Burkitt Lymphoma	C0006413		Approved			C0011777	Dexaméthasone
Dexamethasone	Adrenal cortical hypofunction	C0405580		Approved			C0011777	Dexaméthasone
Dexamethasone	Corneal Perforation	C0339293		Approved			C0011777	Dexaméthasone
Dexamethasone	Central retinal vein occlusion with macular edema	C0339498		Approved			C0011777	Dexaméthasone
Levodopa	Parkinson Disease, Postencephalitic	C0030568		Approved			C0023570	Levodopum
Levodopa	Parkinsonian Disorders	C0242422		Approved			C0023570	Levodopum
Levodopa	Parkinson Disease	C0030567		Approved			C0023570	Levodopum
Bromodiphenhydramine	Rhinorrhea	C1260880		Approved			C0054120	2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamine
Bromodiphenhydramine	Coughing	C0010200		Approved			C0054120	2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamine
Bromodiphenhydramine	Common Cold	C0009443		Approved			C0054120	2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamine
Bromodiphenhydramine	Nasal congestion (finding)	C0027424		Approved			C0054120	2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamine
Aripiprazole	Bipolar disorder in remission	C0270425		Approved			C0299792	Aripiprazolum
Aripiprazole	Autistic Disorder	C0004352		Approved			C0299792	Aripiprazolum
Aripiprazole	Mixed bipolar I disorder	C0236780		Approved			C0299792	Aripiprazolum
Aripiprazole	Schizophrenia	C0036341		Approved			C0299792	Aripiprazolum
Aripiprazole	Bipolar affective disorder, current episode manic	C0338873		Approved			C0299792	Aripiprazolum
Chlorprothixene	Schizophrenia	C0036341		Approved			C0008290	Chlorprotixen
Epoprostenol	Pulmonary arterial hypertension	C2973725		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol	Pulmonary Hypertension	C0020542		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol	Rhinorrhea	C1260880		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol	Coughing	C0010200		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol	Nasal congestion (finding)	C0027424		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol	Allergic rhinitis (disorder)	C2607914		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol	Rhinitis	C0035455		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol	Common Cold	C0009443		Approved			C0033567	(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Gemfibrozil	Hypertriglyceridemia	C0020557		Approved			C0017245	2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure
Clomipramine	Obsessive-Compulsive Disorder	C0028768		Approved			C0009010	3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine
Chloroxine	Scurfiness of scalp	C0423775		Approved			C0055461	5,7-dichlor-8-hydroxychinolin
Chloroxine	Seborrheic dermatitis	C0036508		Approved			C0055461	5,7-dichlor-8-hydroxychinolin
Bepridil	Angina Pectoris	C0002962		Approved			C0206026	Bepadin
Alimemazine	Sneezing	C0037383		Approved			C0041031	Alimemazinum
Alimemazine	Rhinorrhea	C1260880		Approved			C0041031	Alimemazinum
Alimemazine	Allergic rhinitis (disorder)	C2607914		Approved			C0041031	Alimemazinum
Alimemazine	Allergic Conjunctivitis	C0009766		Approved			C0041031	Alimemazinum
Alimemazine	Angioedema	C0002994		Approved			C0041031	Alimemazinum
Alimemazine	Nasal congestion (finding)	C0027424		Approved			C0041031	Alimemazinum
Alimemazine	Symptomatic dermographism	C0343065		Approved			C0041031	Alimemazinum
Alimemazine	Urticaria	C0042109		Approved			C0041031	Alimemazinum
Alimemazine	Pruritus	C0033774		Approved			C0041031	Alimemazinum
Isocarboxazid	Major Depressive Disorder	C1269683		Approved			C0022154	Isocarboxazidum
Docetaxel	Cancer of Head and Neck	C0278996		Approved			C0246415	Docetaxel
Docetaxel	Breast Carcinoma	C0678222		Approved			C0246415	Docetaxel
Docetaxel	Non-Small Cell Lung Carcinoma	C0007131		Approved			C0246415	Docetaxel
Docetaxel	Carcinoma breast stage IV	C0278488		Approved			C0246415	Docetaxel
Docetaxel	Malignant neoplasm of stomach	C0024623		Approved			C0246415	Docetaxel
Docetaxel	Malignant neoplasm of prostate	C0376358		Approved			C0246415	Docetaxel
Olsalazine	Ulcerative colitis in remission	C3697010		Approved			C0069454	Olsalazine
Gliquidone	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0061328	Gliquidonum
Mitiglinide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0906166	Mitiglinide
Ergonovine	Postpartum Hemorrhage	C0032797		Approved			C0014704	Ergometrine
Dasatinib	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			C2699562	Dasatinib anhydrous
Dasatinib	Philadelphia chromosome-positive acute lymphoblastic leukemia	C1960397		Approved			C2699562	Dasatinib anhydrous
Dasatinib	Blast Phase	C0005699		Approved			C2699562	Dasatinib anhydrous
Dasatinib	Leukemia, Myeloid, Chronic-Phase	C0023474		Approved			C2699562	Dasatinib anhydrous
Dasatinib	Leukemia, Myeloid, Accelerated Phase	C0023472		Approved			C2699562	Dasatinib anhydrous
Lisdexamfetamine	Attention deficit hyperactivity disorder	C1263846		Approved			C1873633	Lisdexamfetamine
Lisdexamfetamine	Binge eating disorder	C0596170		Approved			C1873633	Lisdexamfetamine
Retapamulin	Impetigo	C0021099		Approved			C1703334	Retapamulina
Retapamulin	Superficial bacterial infection of skin	C0342985		Approved			C1703334	Retapamulina
Eculizumab	Paroxysmal nocturnal hemoglobinuria	C0024790		Approved			C1541483	Eculizumab
Eculizumab	Congenital hemolytic uremic syndrome	C2919522		Approved			C1541483	Eculizumab
Desonide	Chronic small plaque psoriasis	C0406317		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Seborrheic dermatitis	C0036508		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Crohn Disease	C0010346		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Otitis Externa	C0029878		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Granuloma Annulare	C0085074		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Pruritus of genital organs	C0033777		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Allergic rhinitis (disorder)	C2607914		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Crohn's disease in remission	C1960764		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Exanthema	C0015230		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Pruritus Ani	C0033775		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Lupus Erythematosus, Discoid	C0024138		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Lichen Simplex Chronicus	C0149922		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Scalp psoriasis	C0406326		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Contact Dermatitis	C0011616		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Desonide	Asthma	C0004096		Approved			C0011705	16α-hydroxyprednisole-16,17-acetonide
Sitagliptin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C1565750	Sitagliptinum
Decitabine	Leukemia, Myelocytic, Acute	C0023467		Approved			C0049065	5-azadeoxycytidine
Posaconazole	Aspergillosis	C0004030		Approved			C0936148	Posaconazole
Posaconazole	Fusariosis	C0276758		Approved			C0936148	Posaconazole
Posaconazole	Chromoblastomycosis	C0008582		Approved			C0936148	Posaconazole
Posaconazole	Mycetoma	C0024449		Approved			C0936148	Posaconazole
Posaconazole	Coccidioidomycosis	C0009186		Approved			C0936148	Posaconazole
Posaconazole	Candidiasis	C0006840		Approved			C0936148	Posaconazole
Darunavir	HIV Infections	C0019693		Approved			C1435444	(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
Telbivudine	Hepatitis B, Chronic	C0524909		Approved			C1453933	β-L-2'-deoxythymidine
Sinecatechins	Condylomata Acuminata	C0009663		Approved			C1816270	Kunecatechins
Sinecatechins	Perianal warts	C0343730		Approved			C1816270	Kunecatechins
Paliperidone	Schizoaffective Disorder	C0036337		Approved			C0753678	Paliperidona
Paliperidone	Schizophrenia	C0036341		Approved			C0753678	Paliperidona
Paliperidone	Psychotic Disorders	C0033975		Approved			C0753678	Paliperidona
Sunitinib	Gastrointestinal Stromal Tumors	C0238198		Approved			C1176020	Sunitinibum
Sunitinib	Renal Cell Carcinoma	C0007134		Approved			C1176020	Sunitinibum
Panitumumab	Secondary malignant neoplasm of colon	C0346974		Approved			C0879427	ABX-EGF
Ranibizumab	Exudative age-related macular degeneration	C0271084		Approved			C1566537	rhuFab V2
Ranibizumab	Central retinal vein occlusion with macular edema	C0339498		Approved			C1566537	rhuFab V2
Ranibizumab	Branch retinal vein occlusion with macular edema	C0339507		Approved			C1566537	rhuFab V2
Ranibizumab	Diabetic macular edema	C0730285		Approved			C1566537	rhuFab V2
Ranibizumab	Diabetic Retinopathy	C0011884		Approved			C1566537	rhuFab V2
Idursulfase	Mucopolysaccharidosis II	C0026705		Approved			C1739462	Idursulfasa
Alglucosidase alfa	Generalized glycogen storage disease of infants	C0342751		Approved			C1695579	Alglucosidasa alfa
Arformoterol	Chronic Obstructive Airway Disease	C0024117		Approved			C0969589	(-)-formoterol
Arformoterol	Bronchitis, Chronic	C0008677		Approved			C0969589	(-)-formoterol
Arformoterol	Pulmonary Emphysema	C0034067		Approved			C0969589	(-)-formoterol
Hydralazine	Chronic heart failure	C0264716		Approved			C0020223	Hidralazina
Hydralazine	Hypertensive disease	C0020538		Approved			C0020223	Hidralazina
Mecasermin	Laron Syndrome	C0271568		Approved			C0021665	Human somatomedin C
Galsulfase	Mucopolysaccharidosis VI	C0026709		Approved			C1615657	Galsulfase (genetical recombination)
Nelarabine	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	C1961099		Approved			C0907349	Nelarabina
Nelarabine	Precursor T-cell lymphoblastic lymphoma	C1292758		Approved			C0907349	Nelarabina
Abatacept	Rheumatoid Arthritis	C0003873		Approved			C1619966	Abatacept recombinant
Abatacept	Juvenile arthritis	C3495559		Approved			C1619966	Abatacept recombinant
Carbetocin	Prader-Willi Syndrome	C0032897		Approved			C0054670	deamino-2-O-methyltyrosine-1-carbaoxytocin
Carbetocin	Uterine Inertia	C0042135		Approved			C0054670	deamino-2-O-methyltyrosine-1-carbaoxytocin
Lumiracoxib	Degenerative polyarthritis	C0029408		Approved			C1176415	lumiracoxib
Corticotropin	West Syndrome	C0037769		Approved			C4255705	Cortigel
Corticotropin	Exacerbation of multiple sclerosis	C0581392		Approved			C4255705	Cortigel
Corticotropin	Stevens-Johnson Syndrome	C0038325		Approved			C4255705	Cortigel
Glisoxepide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0061330	Glisoxepide
Pirbuterol	Lung diseases	C0024115		Approved			C0071129	(+/-)-pirbuterol
Pirbuterol	Bronchiectasis	C0006267		Approved			C0071129	(+/-)-pirbuterol
Pirbuterol	Pulmonary Emphysema	C0034067		Approved			C0071129	(+/-)-pirbuterol
Pirbuterol	Asthma	C0004096		Approved			C0071129	(+/-)-pirbuterol
Pirbuterol	Bronchitis	C0006277		Approved			C0071129	(+/-)-pirbuterol
Pirbuterol	Asthma attack	C0347950		Approved			C0071129	(+/-)-pirbuterol
Bismuth Subsalicylate	Dyspepsia	C0013395		Approved			C0053792	Bismuth subsalicylate
Bismuth Subsalicylate	Diarrhea	C0011991		Approved			C0053792	Bismuth subsalicylate
Insulin Aspart	Diabetes Mellitus	C0011849		Approved			C0123677	Insulina asparta
Insulin Detemir	Diabetes Mellitus	C0011849		Approved			C0537270	Insulina detemir
Insulin Glulisine	Diabetes Mellitus	C0011849		Approved			C1313386	Insulina glulisina
Fosamprenavir	HIV Infections	C0019693		Approved			C1176315	FOS-APV
Fosphenytoin	Status Epilepticus	C0038220		Approved			C0244656	Fosphenytoinum
Fosphenytoin	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			C0244656	Fosphenytoinum
Fosphenytoin	Epilepsy	C0014544		Approved			C0244656	Fosphenytoinum
Polythiazide	Hypertensive disease	C0020538		Approved			C0032613	Polythiazide
Cefamandole	Bacterial peritonitis	C0341503		Approved			C0007541	Cefamandolum
Cefamandole	Proteus pneumonia	C1260917		Approved			C0007541	Cefamandolum
Cefamandole	Urinary tract infection	C0042029		Approved			C0007541	Cefamandolum
Cefamandole	Escherichia coli septicemia	C0276088		Approved			C0007541	Cefamandolum
Cefamandole	Arthropathy associated with infection	C0157749		Approved			C0007541	Cefamandolum
Cefamandole	Haemophilus sepsis	C0854324		Approved			C0007541	Cefamandolum
Cefamandole	Bacterial sepsis	C0684256		Approved			C0007541	Cefamandolum
Cefamandole	Pneumonia	C0032285		Approved			C0007541	Cefamandolum
Cefamandole	Infection of bone	C2242472		Approved			C0007541	Cefamandolum
Cefamandole	Staphylococcal Pneumonia	C0032308		Approved			C0007541	Cefamandolum
Cefamandole	Peritonitis	C0031154		Approved			C0007541	Cefamandolum
Cefamandole	Escherichia coli Infections	C0014836		Approved			C0007541	Cefamandolum
Cefamandole	Bacterial urinary infection	C0729524		Approved			C0007541	Cefamandolum
Cefamandole	Lower respiratory tract infection	C0149725		Approved			C0007541	Cefamandolum
Cefamandole	Staphylococcus aureus infection	C1318973		Approved			C0007541	Cefamandolum
Cefamandole	Pneumonia due to Escherichia coli	C0276089		Approved			C0007541	Cefamandolum
Cefamandole	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007541	Cefamandolum
Cefamandole	Haemophilus influenzae pneumonia	C0276026		Approved			C0007541	Cefamandolum
Cefamandole	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007541	Cefamandolum
Cefamandole	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007541	Cefamandolum
Cefamandole	Streptococcus pyogenes infection	C0554628		Approved			C0007541	Cefamandolum
Cefamandole	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0007541	Cefamandolum
Cefamandole	Enterobacteriaceae Infections	C0014347		Approved			C0007541	Cefamandolum
Cefamandole	Klebsiella cystitis	C0520775		Approved			C0007541	Cefamandolum
Cefamandole	Proteus urinary tract infection	C0577709		Approved			C0007541	Cefamandolum
Cefamandole	Staphylococcal bacteraemia	C0152965		Approved			C0007541	Cefamandolum
Cefamandole	Escherichia coli urinary tract infection	C0577708		Approved			C0007541	Cefamandolum
Cefamandole	Intraabdominal Infections	C1112209		Approved			C0007541	Cefamandolum
Cefamandole	Streptococcal sepsis	C0152964		Approved			C0007541	Cefamandolum
Cefazolin	Arthropathy associated with infection	C0157749		Approved			C0007546	Cefazolinum
Cefazolin	Lower respiratory tract infection	C0149725		Approved			C0007546	Cefazolinum
Cefazolin	Staphylococcal Pneumonia	C0032308		Approved			C0007546	Cefazolinum
Cefazolin	Genitourinary tract infection	C1279247		Approved			C0007546	Cefazolinum
Cefazolin	Infection of bone	C2242472		Approved			C0007546	Cefazolinum
Cefazolin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007546	Cefazolinum
Cefazolin	Bacterial sepsis	C0684256		Approved			C0007546	Cefazolinum
Cefazolin	Pneumonia, Bacterial	C0004626		Approved			C0007546	Cefazolinum
Cefazolin	Cholangitis	C0008311		Approved			C0007546	Cefazolinum
Cefonicid	Klebsiella cystitis	C0520775		Approved			C0007551	Cefonicidum
Cefonicid	Urinary tract infection	C0042029		Approved			C0007551	Cefonicidum
Cefonicid	Escherichia coli septicemia	C0276088		Approved			C0007551	Cefonicidum
Cefonicid	Staphylococcus aureus infection	C1318973		Approved			C0007551	Cefonicidum
Cefonicid	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007551	Cefonicidum
Cefonicid	Lower respiratory tract infection	C0149725		Approved			C0007551	Cefonicidum
Cefonicid	Proteus urinary tract infection	C0577709		Approved			C0007551	Cefonicidum
Cefonicid	Haemophilus influenzae pneumonia	C0276026		Approved			C0007551	Cefonicidum
Cefonicid	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007551	Cefonicidum
Cefonicid	Pneumonia due to Escherichia coli	C0276089		Approved			C0007551	Cefonicidum
Cefonicid	Escherichia coli urinary tract infection	C0577708		Approved			C0007551	Cefonicidum
Cefonicid	Streptococcal sepsis	C0152964		Approved			C0007551	Cefonicidum
Cefonicid	Bacterial sepsis	C0684256		Approved			C0007551	Cefonicidum
Cefonicid	Streptococcus pyogenes infection	C0554628		Approved			C0007551	Cefonicidum
Cefonicid	Arthropathy associated with infection	C0157749		Approved			C0007551	Cefonicidum
Cefonicid	Infection of bone	C2242472		Approved			C0007551	Cefonicidum
Cefonicid	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007551	Cefonicidum
Cefonicid	Pneumonia	C0032285		Approved			C0007551	Cefonicidum
Cefotetan	Proteus urinary tract infection	C0577709		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Female genital tract infection	C1263758		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Intraabdominal Infections	C1112209		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Haemophilus influenzae pneumonia	C0276026		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Pneumonia, Bacterial	C0004626		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Pneumonia due to Escherichia coli	C0276089		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Staphylococcal Pneumonia	C0032308		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Staphylococcus aureus infection	C1318973		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Bacterial sepsis	C0684256		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Escherichia coli Infections	C0014836		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Endometritis	C0014179		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Lower respiratory tract infection	C0149725		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Klebsiella cystitis	C0520775		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Pelvic Inflammatory Disease	C0242172		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Proteus pneumonia	C1260917		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Escherichia coli urinary tract infection	C0577708		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Streptococcus pyogenes infection	C0554628		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefotetan	Acute gonococcal endometritis	C0153196		Approved			C0007555	(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
Cefoxitin	Bacterial sepsis	C0684256		Approved			C0007557	Cefoxitine
Cefoxitin	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0007557	Cefoxitine
Cefoxitin	Abdominal Abscess	C0243001		Approved			C0007557	Cefoxitine
Cefoxitin	Postoperative infection	C0392618		Approved			C0007557	Cefoxitine
Cefoxitin	Staphylococcal Pneumonia	C0032308		Approved			C0007557	Cefoxitine
Cefoxitin	Endometritis	C0014179		Approved			C0007557	Cefoxitine
Cefoxitin	Female genital tract infection	C1263758		Approved			C0007557	Cefoxitine
Cefoxitin	Rhinoscleroma	C0035468		Approved			C0007557	Cefoxitine
Cefoxitin	Acute gonococcal endometritis	C0153196		Approved			C0007557	Cefoxitine
Cefoxitin	Klebsiella cystitis	C0520775		Approved			C0007557	Cefoxitine
Cefoxitin	Peritonitis	C0031154		Approved			C0007557	Cefoxitine
Cefoxitin	Intraabdominal Infections	C1112209		Approved			C0007557	Cefoxitine
Cefoxitin	Pelvic Inflammatory Disease	C0242172		Approved			C0007557	Cefoxitine
Cefoxitin	Arthropathy associated with infection	C0157749		Approved			C0007557	Cefoxitine
Cefoxitin	Streptococcus pyogenes infection	C0554628		Approved			C0007557	Cefoxitine
Cefoxitin	Escherichia coli septicemia	C0276088		Approved			C0007557	Cefoxitine
Cefoxitin	Pneumonia due to Escherichia coli	C0276089		Approved			C0007557	Cefoxitine
Cefoxitin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007557	Cefoxitine
Cefoxitin	Proteus urinary tract infection	C0577709		Approved			C0007557	Cefoxitine
Cefoxitin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007557	Cefoxitine
Cefoxitin	Female pelvic cellulitis	C0349734		Approved			C0007557	Cefoxitine
Cefoxitin	Pneumonia, Bacterial	C0004626		Approved			C0007557	Cefoxitine
Cefoxitin	Lung Abscess	C0024110		Approved			C0007557	Cefoxitine
Cefoxitin	Septicemia due to Bacteroides	C0276064		Approved			C0007557	Cefoxitine
Cefoxitin	Staphylococcus aureus infection	C1318973		Approved			C0007557	Cefoxitine
Cefoxitin	Escherichia coli Infections	C0014836		Approved			C0007557	Cefoxitine
Cefoxitin	Streptococcal sepsis	C0152964		Approved			C0007557	Cefoxitine
Cefoxitin	Gonorrhea	C0018081		Approved			C0007557	Cefoxitine
Cefoxitin	Infection of bone	C2242472		Approved			C0007557	Cefoxitine
Cefoxitin	Acute gonococcal cervicitis	C0153195		Approved			C0007557	Cefoxitine
Cefoxitin	Haemophilus influenzae pneumonia	C0276026		Approved			C0007557	Cefoxitine
Cefoxitin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007557	Cefoxitine
Cefoxitin	Escherichia coli urinary tract infection	C0577708		Approved			C0007557	Cefoxitine
Ceftizoxime	Streptococcus pyogenes infection	C0554628		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Proteus urinary tract infection	C0577709		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Gonorrhea of rectum	C0275665		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Escherichia coli urinary tract infection	C0577708		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Rhinoscleroma	C0035468		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Streptococcal sepsis	C0152964		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Pneumonia due to Escherichia coli	C0276089		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Escherichia coli Infections	C0014836		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Serratia Infections	C0085394		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Urinary tract infection	C0042029		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Pneumonia	C0032285		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Meningitis	C0025289		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Serratia sepsis	C0152973		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Arthropathy associated with infection	C0157749		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Enterobacter pneumonia	C1096258		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Acute gonococcal cervicitis	C0153195		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Bacterial sepsis	C0684256		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Infection of bone	C2242472		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Acute gonococcal urethritis	C0275652		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Klebsiella cystitis	C0520775		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Staphylococcal Pneumonia	C0032308		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Proteus pneumonia	C1260917		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Acute gonococcal endometritis	C0153196		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Lower respiratory tract infection	C0149725		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Bacterial urinary infection	C0729524		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Enterobacteriaceae Infections	C0014347		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Streptococcal meningitis	C0154639		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Gonorrhea	C0018081		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Intraabdominal Infections	C1112209		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Haemophilus influenzae pneumonia	C0276026		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Staphylococcus aureus infection	C1318973		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Bacterial peritonitis	C0341503		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Septicemia due to Bacteroides	C0276064		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Ceftizoxime	Escherichia coli septicemia	C0276088		Approved			C0007560	syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
Cefradine	Infection of bone	C2242472		Approved			C0007738	Cefradinum
Cefradine	Urinary tract infection	C0042029		Approved			C0007738	Cefradinum
Cefradine	Haemophilus influenzae pneumonia	C0276026		Approved			C0007738	Cefradinum
Cefradine	Upper Respiratory Infections	C0041912		Approved			C0007738	Cefradinum
Cefradine	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0007738	Cefradinum
Cefradine	Escherichia coli urinary tract infection	C0577708		Approved			C0007738	Cefradinum
Cefradine	Streptococcus pyogenes infection	C0554628		Approved			C0007738	Cefradinum
Cefradine	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0007738	Cefradinum
Cefradine	Streptococcal tonsillitis	C0275804		Approved			C0007738	Cefradinum
Cefradine	prostatitis	C0033581		Approved			C0007738	Cefradinum
Cefradine	Arthropathy associated with infection	C0157749		Approved			C0007738	Cefradinum
Cefradine	Tonsillitis	C0040425		Approved			C0007738	Cefradinum
Cefradine	Staphylococcal Pneumonia	C0032308		Approved			C0007738	Cefradinum
Cefradine	Pharyngitis	C0031350		Approved			C0007738	Cefradinum
Cefradine	Staphylococcus aureus infection	C1318973		Approved			C0007738	Cefradinum
Cefradine	Infective otitis media	C0729586		Approved			C0007738	Cefradinum
Cefradine	Pneumonia	C0032285		Approved			C0007738	Cefradinum
Cefradine	URINARY TRACT INFECTION ENTEROCOCCUS	C0749958		Approved			C0007738	Cefradinum
Cefradine	Proteus urinary tract infection	C0577709		Approved			C0007738	Cefradinum
Cefradine	Lower respiratory tract infection	C0149725		Approved			C0007738	Cefradinum
Cefradine	Klebsiella cystitis	C0520775		Approved			C0007738	Cefradinum
Cefradine	Acute otitis media	C0271429		Approved			C0007738	Cefradinum
Cilazapril	Hypertensive disease	C0020538		Approved			C0055723	Cilazaprilum
Polystyrene sulfonate	Hyperkalemia	C0020461		Approved			C0379624	Tolevamer
Spirapril	Hypertensive disease	C0020538		Approved			C0075007	Espirapril
Tasosartan	Hypertensive disease	C0020538		Approved			CUI-less-DB01349	T
Amobarbital	Epilepsy	C0014544		Approved			C0002640	5-ethyl-5-isoamylbarbituric acid
Amobarbital	Sleeplessness	C0917801		Approved			C0002640	5-ethyl-5-isoamylbarbituric acid
Amobarbital	Status Epilepticus	C0038220		Approved			C0002640	5-ethyl-5-isoamylbarbituric acid
Amobarbital	Severe anxiety (panic)	C0231403		Approved			C0002640	5-ethyl-5-isoamylbarbituric acid
Aprobarbital	Severe anxiety (panic)	C0231403		Approved			C0051241	5-allyl-5-isopropylbarbituric acid
Aprobarbital	Sleeplessness	C0917801		Approved			C0051241	5-allyl-5-isopropylbarbituric acid
Butethal	Sleeplessness	C0917801		Approved			C0054249	Butobarbital
Butethal	Severe anxiety (panic)	C0231403		Approved			C0054249	Butobarbital
Lithium	Bipolar Disorder	C0005586		Approved			C0023870	Lithium
Lithium	Bipolar affective disorder, current episode manic	C0338873		Approved			C0023870	Lithium
Lithium	Bipolar disorder in remission	C0270425		Approved			C0023870	Lithium
Lithium	Headache Disorders	C0393735		Approved			C0023870	Lithium
Lithium	Pain	C0030193		Approved			C0023870	Lithium
Lithium	Fever	C0015967		Approved			C0023870	Lithium
Lithium	Degenerative polyarthritis	C0029408		Approved			C0023870	Lithium
Lithium	Rheumatoid Arthritis	C0003873		Approved			C0023870	Lithium
Lithium	Dysmenorrhea	C0013390		Approved			C0023870	Lithium
Mestranol	Menorrhagia	C0025323		Approved			C0025506	Mestranol
Mestranol	Endometriosis	C0014175		Approved			C0025506	Mestranol
Mestranol	Female hypogonadism syndrome	C0271578		Approved			C0025506	Mestranol
Penbutolol	Hypertensive disease	C0020538		Approved			C0030812	Penbutololum
Troleandomycin	Streptococcal pneumonia	C0155862		Approved			CUI-less-DB01361	T
Ephedrine	Sinus headache	C0037195		Approved			C0014479	Efedrina
Ephedrine	Bronchitis	C0006277		Approved			C0014479	Efedrina
Ephedrine	Headache Disorders	C0393735		Approved			C0014479	Efedrina
Ephedrine	Allergic Conjunctivitis	C0009766		Approved			C0014479	Efedrina
Ephedrine	Rhinorrhea	C1260880		Approved			C0014479	Efedrina
Ephedrine	Influenza-like symptoms	C0392171		Approved			C0014479	Efedrina
Ephedrine	Allergic rhinitis (disorder)	C2607914		Approved			C0014479	Efedrina
Ephedrine	Hay fever	C0018621		Approved			C0014479	Efedrina
Ephedrine	Bronchial Spasm	C0006266		Approved			C0014479	Efedrina
Ephedrine	Rhinitis, Vasomotor	C0035460		Approved			C0014479	Efedrina
Ephedrine	Hypotension	C0020649		Approved			C0014479	Efedrina
Ephedrine	Rhinitis	C0035455		Approved			C0014479	Efedrina
Ephedrine	Nasal congestion (finding)	C0027424		Approved			C0014479	Efedrina
Ephedrine	Sneezing	C0037383		Approved			C0014479	Efedrina
Ephedrine	Common Cold	C0009443		Approved			C0014479	Efedrina
Mephentermine	Hypotension	C0020649		Approved			C0025380	Mefentermina
Rasagiline	Parkinson Disease	C0030567		Approved			C0525678	(R)-indan-1-yl-prop-2-ynyl-amine
Quinupristin	Streptococcus pyogenes infection	C0554628		Approved			C0756081	Quinupristin
Magnesium oxide	Incomplete passage of stool	C0426639		Approved			C0024477	Magnesia
Magnesium oxide	Hypocalcemia	C0020598		Approved			C0024477	Magnesia
Magnesium oxide	Constipation	C0009806		Approved			C0024477	Magnesia
Magnesium oxide	Osteoporosis	C0029456		Approved			C0024477	Magnesia
Magnesium oxide	Dyspepsia	C0013395		Approved			C0024477	Magnesia
Magnesium oxide	Hypomagnesemia	C0151723		Approved			C0024477	Magnesia
Cortisone acetate	Punctate keratopathy	C0423234		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Herpes zoster keratitis	C1275687		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Granuloma Annulare	C0085074		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Addisonian crisis	C0151467		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Pemphigus	C0030807		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Asthma	C0004096		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Anemia, Diamond-Blackfan	C1260899		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Bursitis	C0006444		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Sarcoidosis	C0036202		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Lupus Erythematosus, Systemic	C0024141		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Recurrent herpes simplex labialis	C1274321		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Rosacea	C0035854		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Exanthema	C0015230		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Allergic Conjunctivitis	C0009766		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Autoimmune hemolytic anemia	C0002880		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Tinea Pedis	C0040259		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Lymphoma, Follicular	C0024301		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Serum Sickness	C0036830		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Otitis Externa	C0029878		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Mycosis Fungoides	C0026948		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Inflammatory Bowel Diseases	C0021390		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Congenital adrenal hyperplasia	C0001627		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Post traumatic osteoarthritis	C2894027		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Tendinitis	C0039503		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Proctitis	C0033246		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Pruritus Ani	C0033775		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Pruritus of genital organs	C0033777		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Dermatitis Herpetiformis	C0011608		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Scalp psoriasis	C0406326		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Seborrheic dermatitis	C0036508		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Uveitis	C0042164		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Arthritis, Gouty	C0003868		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Synovitis	C0039103		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Hemorrhoids	C0019112		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Addison Disease	C0001403		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Cerebral Edema	C0006114		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Erythema Multiforme	C0014742		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Corneal abrasion	C0010032		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Dermatologic disorders	C0037274		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Corneal Ulcer	C0010043		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Gingival Diseases	C0017563		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Disorder of eye	C0015397		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Musculoskeletal Diseases	C0026857		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Exfoliative dermatitis	C0011606		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Keratitis	C0022568		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Epicondylitis	C0014488		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Nephrotic Syndrome	C0027726		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Bacterial keratitis	C0854211		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Iridocyclitis	C0022073		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Lichen Simplex Chronicus	C0149922		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Cooley's anemia	C0002875		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Hodgkin Disease	C0019829		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Thyroiditis	C0040147		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Laryngeal Edema	C0023052		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Transplanted organ rejection	C0345468		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Tenosynovitis	C0039520		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Acute lymphocytic leukemia	C0023449		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Berylliosis	C0005138		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Chronic small plaque psoriasis	C0406317		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Infective blepharitis	C0729587		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Adrenogenital disorder	C0701163		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Ankylosing spondylitis	C0038013		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Tinea corporis (disorder)	C0040252		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Blepharoconjunctivitis	C0005743		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Lupus Erythematosus, Discoid	C0024138		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Simple Pulmonary Eosinophilia	C0242459		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Acquired thrombocytopenia	C0154301		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Psoriasis	C0033860		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Adrenal cortical hypofunction	C0405580		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Trichinellosis	C0040896		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Chronic ulcerative proctitis	C2937222		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Contact Dermatitis	C0011616		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Tinea cruris	C1384589		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Itching of ear	C0849907		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Rheumatoid Arthritis	C0003873		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Allergic rhinitis (disorder)	C2607914		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Tuberculosis, Miliary	C0041321		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Lymphoma, Non-Hodgkin	C0024305		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Acne Vulgaris	C0001144		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Multiple Sclerosis	C0026769		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Iritis	C0022081		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Ulcerative Colitis	C0009324		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Autoimmune Diseases	C0004364		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Inflammatory dermatosis	C3875321		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Rheumatic Heart Disease	C0035439		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Crohn Disease	C0010346		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Arthritis, Psoriatic	C0003872		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Status Asthmaticus	C0038218		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Cyclitis	C0010543		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Aphthous Stomatitis	C0038363		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Angioedema	C0002994		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Aspiration pneumonitis	C1761609		Approved			C0056391	Cortisone 21-acetate
Cortisone acetate	Infective otitis externa	C0021355		Approved			C0056391	Cortisone 21-acetate
Glycodiazine	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0351000	Glycodiazine
Bezafibrate	Hyperlipidemia	C0020473		Approved			C0005330	2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
Bezafibrate	Hypercholesterolemia	C0020443		Approved			C0005330	2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
Colchicine	Familial Mediterranean Fever	C0031069		Approved			C0009262	Colchicinum
Colchicine	Gout	C0018099		Approved			C0009262	Colchicinum
Colchicine	Chronic gouty arthritis	C0268108		Approved			C0009262	Colchicinum
Drospirenone	Atrophic Vaginitis	C0221392		Approved			C0043822	Drospirénone
Drospirenone	Hot flushes	C0600142		Approved			C0043822	Drospirénone
Drospirenone	Premenstrual Dysphoric Disorder	C0520676		Approved			C0043822	Drospirénone
Drospirenone	Acne Vulgaris	C0001144		Approved			C0043822	Drospirénone
Drospirenone	Atrophy of vulva	C0156393		Approved			C0043822	Drospirénone
Magnesium salicylate	Back Pain	C0004604		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Rheumatoid Arthritis	C0003873		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Fever	C0015967		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Shoulder tendinitis	C0262633		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Pain	C0030193		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Degenerative polyarthritis	C0029408		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Dysmenorrhea	C0013390		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Synovitis	C0039103		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Arthralgia	C0003862		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Bursitis	C0006444		Approved			C0126789	Magnesium salicylate
Magnesium salicylate	Headache Disorders	C0393735		Approved			C0126789	Magnesium salicylate
Salsalate	Rheumatoid Arthritis	C0003873		Approved			C0073983	o-Salicylsalicylic acid
Salsalate	Degenerative polyarthritis	C0029408		Approved			C0073983	o-Salicylsalicylic acid
Neostigmine	Myasthenia Gravis	C0026896		Approved			C0027679	Neostigmina
Neostigmine	Urinary Retention	C0080274		Approved			C0027679	Neostigmina
Danazol	Endometriosis	C0014175		Approved			C0010961	Danazolum
Danazol	Breast Fibrocystic Disease	C0016034		Approved			C0010961	Danazolum
Tiotropium	Bronchitis, Chronic	C0008677		Approved			C0213771	Tiotropium
Tiotropium	Pulmonary Emphysema	C0034067		Approved			C0213771	Tiotropium
Tiotropium	Asthma	C0004096		Approved			C0213771	Tiotropium
Ciclesonide	Asthma	C0004096		Approved			C0907850	Ciclesonida
Ciclesonide	Hay fever	C0018621		Approved			C0907850	Ciclesonida
Ciclesonide	Allergic rhinitis (disorder)	C2607914		Approved			C0907850	Ciclesonida
Pranlukast	Allergic rhinitis (disorder)	C2607914		Approved			C0526058	Pranlukast
Pranlukast	Asthma	C0004096		Approved			C0526058	Pranlukast
Cefepime	PYELONEPHRITIS E COLI	C0748196		Approved			C0055003	Cefepimum
Cefepime	Klebsiella cystitis	C0520775		Approved			C0055003	Cefepimum
Cefepime	Staphylococcus aureus infection	C1318973		Approved			C0055003	Cefepimum
Cefepime	Pneumonia due to Pseudomonas	C0155860		Approved			C0055003	Cefepimum
Cefepime	Intraabdominal Infections	C1112209		Approved			C0055003	Cefepimum
Cefepime	Pneumonia, Bacterial	C0004626		Approved			C0055003	Cefepimum
Cefepime	Streptococcus pyogenes infection	C0554628		Approved			C0055003	Cefepimum
Cefepime	Escherichia coli urinary tract infection	C0577708		Approved			C0055003	Cefepimum
Cefepime	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0055003	Cefepimum
Cefepime	Proteus urinary tract infection	C0577709		Approved			C0055003	Cefepimum
Cefepime	Enterobacter pneumonia	C1096258		Approved			C0055003	Cefepimum
Cefepime	Streptococcal pneumonia	C0155862		Approved			C0055003	Cefepimum
Ceftibuten	Tonsillitis	C0040425		Approved			C0055014	Ceftibutenum
Ceftibuten	Acute otitis media	C0271429		Approved			C0055014	Ceftibutenum
Ceftibuten	Infective otitis media	C0729586		Approved			C0055014	Ceftibutenum
Ceftibuten	Streptococcal tonsillitis	C0275804		Approved			C0055014	Ceftibutenum
Cefpodoxime	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0055011	Cefpodoximum
Cefpodoxime	Infective otitis media	C0729586		Approved			C0055011	Cefpodoximum
Cefpodoxime	Acute gonococcal cervicitis	C0153195		Approved			C0055011	Cefpodoximum
Cefpodoxime	Streptococcal tonsillitis	C0275804		Approved			C0055011	Cefpodoximum
Cefpodoxime	Haemophilus influenzae pneumonia	C0276026		Approved			C0055011	Cefpodoximum
Cefpodoxime	Streptococcal pneumonia	C0155862		Approved			C0055011	Cefpodoximum
Cefpodoxime	Acute maxillary sinusitis	C0155804		Approved			C0055011	Cefpodoximum
Cefpodoxime	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			C0055011	Cefpodoximum
Cefpodoxime	Klebsiella cystitis	C0520775		Approved			C0055011	Cefpodoximum
Cefpodoxime	Gonorrhea of rectum	C0275665		Approved			C0055011	Cefpodoximum
Cefpodoxime	Pneumonia, Bacterial	C0004626		Approved			C0055011	Cefpodoximum
Cefpodoxime	Tonsillitis	C0040425		Approved			C0055011	Cefpodoximum
Cefpodoxime	Proteus urinary tract infection	C0577709		Approved			C0055011	Cefpodoximum
Cefpodoxime	Escherichia coli urinary tract infection	C0577708		Approved			C0055011	Cefpodoximum
Cefpodoxime	Gonorrhea	C0018081		Approved			C0055011	Cefpodoximum
Cefpodoxime	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0055011	Cefpodoximum
Cefpodoxime	Acute otitis media	C0271429		Approved			C0055011	Cefpodoximum
Cefpodoxime	Staphylococcus aureus infection	C1318973		Approved			C0055011	Cefpodoximum
Cefpodoxime	Pharyngitis	C0031350		Approved			C0055011	Cefpodoximum
Cefpodoxime	Acute gonococcal urethritis	C0275652		Approved			C0055011	Cefpodoximum
Cefpodoxime	Streptococcus pyogenes infection	C0554628		Approved			C0055011	Cefpodoximum
Testosterone Propionate	Cryptorchidism	C0010417		Approved			C0039607	Testosterone propionate
Testosterone Propionate	Klinefelter Syndrome	C0022735		Approved			C0039607	Testosterone propionate
Testosterone Propionate	Delayed Puberty	C0034012		Approved			C0039607	Testosterone propionate
Testosterone Propionate	Testicular hypogonadism	C0151721		Approved			C0039607	Testosterone propionate
Testosterone Propionate	Deficiency of testosterone biosynthesis	C0342527		Approved			C0039607	Testosterone propionate
Testosterone Propionate	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0039607	Testosterone propionate
Paromomycin	Chronic intestinal amebiasis	C0002440		Approved			C0030576	Paromomicina
Paromomycin	Hepatic Coma	C0019147		Approved			C0030576	Paromomicina
Amrinone	Decompensated cardiac failure	C0581377		Approved			C0002697	Amrinona
Aprindine	Supraventricular arrhythmia	C0428974		Approved			C0003639	Aprindine
Aprindine	Ventricular arrhythmia	C0085612		Approved			C0003639	Aprindine
Almitrine	Chronic Obstructive Airway Disease	C0024117		Approved			C0002164	2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
Cholestyramine	Hyperlipidemia	C0020473		Approved			C0008402	Colestiramina
Cholestyramine	Hypercholesterolemia	C0020443		Approved			C0008402	Colestiramina
Methadyl Acetate	Opiate Addiction	C0524662		Approved			C0025607	Methadyl acetate
Antipyrine	Infective otitis media	C0729586		Approved			C0003420	Fenazon
Alfacalcidol	Renal Osteodystrophy	C0035086		Approved			C0044410	1α-hydroxy-vitamin D3
Alfacalcidol	Hyperparathyroidism	C0020502		Approved			C0044410	1α-hydroxy-vitamin D3
Alfacalcidol	Hypoparathyroidism	C0020626		Approved			C0044410	1α-hydroxy-vitamin D3
Alfacalcidol	Neonatal hypocalcemia	C0342634		Approved			C0044410	1α-hydroxy-vitamin D3
Glutethimide	Sleeplessness	C0917801		Approved			C0017845	Glutetimida
Phenazopyridine	Dysuria	C0013428		Approved			C0031379	Phénazopyridine
Gamma Hydroxybutyric Acid	Narcolepsy-Cataplexy Syndrome	C0751362		Approved			C0673093	gamma-Hydroxybutyric acid
Gamma Hydroxybutyric Acid	Narcolepsy	C0027404		Approved			C0673093	gamma-Hydroxybutyric acid
Heroin	Severe pain	C0278140		Approved			C0011892	Diamorphine
Difenoxin	Diarrhea	C0011991		Approved			C0057981	1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid
Ethyl loflazepate	Anxiety	C0003467		Approved			C0059772	Loflazepato de etilo
Ethyl loflazepate	Depressive disorder	C0011581		Approved			C0059772	Loflazepato de etilo
Fenproporex	Obesity	C0028754		Approved			C0060194	Femproporex
Dihydrocodeine	Allergic rhinitis (disorder)	C2607914		Approved			C0058056	Dihydrocodeine
Dihydrocodeine	Rhinitis	C0035455		Approved			C0058056	Dihydrocodeine
Dihydrocodeine	Common Cold	C0009443		Approved			C0058056	Dihydrocodeine
Dihydrocodeine	Rhinorrhea	C1260880		Approved			C0058056	Dihydrocodeine
Dihydrocodeine	Nasal congestion (finding)	C0027424		Approved			C0058056	Dihydrocodeine
Dihydrocodeine	Pain	C0030193		Approved			C0058056	Dihydrocodeine
Dihydrocodeine	Coughing	C0010200		Approved			C0058056	Dihydrocodeine
Chloral hydrate	Sleeplessness	C0917801		Approved			C0008161	1,1,1-trichloro-2,2-dihydroxyethane
Dextroamphetamine	Narcolepsy	C0027404		Approved			C0011812	Desamfetamina
Dextroamphetamine	Attention deficit hyperactivity disorder	C1263846		Approved			C0011812	Desamfetamina
Methamphetamine	Attention deficit hyperactivity disorder	C1263846		Approved			C0025611	Metamfetamine
Methamphetamine	Obesity	C0028754		Approved			C0025611	Metamfetamine
Phendimetrazine	Obesity	C0028754		Approved			C0070549	Phendimetrazine
Oxprenolol	Hypertensive disease	C0020538		Approved			C0030040	Oxprenololum
Oxprenolol	Ventricular arrhythmia	C0085612		Approved			C0030040	Oxprenololum
Oxprenolol	Anxiety	C0003467		Approved			C0030040	Oxprenololum
Ursodeoxycholic acid	Cholelithiasis	C0008350		Approved			C0042105	Acidum ursodeoxycholicum
Ursodeoxycholic acid	Primary biliary cirrhosis	C0008312		Approved			C0042105	Acidum ursodeoxycholicum
Prazepam	Anxiety	C0003467		Approved			C0032910	Prazepamum
Prazepam	Sleeplessness	C0917801		Approved			C0032910	Prazepamum
Quazepam	Sleeplessness	C0917801		Approved			C0072828	Quazepamum
Everolimus	Renal Cell Carcinoma	C0007134		Approved			C0541315	évérolimus
Everolimus	Breast Carcinoma	C0678222		Approved			C0541315	évérolimus
Everolimus	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0541315	évérolimus
Everolimus	Angiomyolipoma of kidney	C0241961		Approved			C0541315	évérolimus
Everolimus	Tuberous Sclerosis	C0041341		Approved			C0541315	évérolimus
Solifenacin	Bladder muscle dysfunction - overactive	C0403643		Approved			C1099677	Solifenacina
Solifenacin	Urgency of micturition	C0085606		Approved			C1099677	Solifenacina
Solifenacin	Increased frequency of micturition	C0042023		Approved			C1099677	Solifenacina
Solifenacin	Urge Incontinence	C0150045		Approved			C1099677	Solifenacina
Iron	Iron deficiency anemia	C0162316		Approved			C0302583	fer
Iron	Anemia of prematurity	C0158996		Approved			C0302583	fer
Iron	Megaloblastic anemia due to folate deficiency	C0151482		Approved			C0302583	fer
Nitrazepam	Sleeplessness	C0917801		Approved			C0028126	7-nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
Nitrazepam	Epilepsies, Myoclonic	C0014550		Approved			C0028126	7-nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
Cilastatin	Pneumonia, Bacterial	C0004626		Approved			C0008777	Cilastatinum
Cilastatin	Intraabdominal Infections	C1112209		Approved			C0008777	Cilastatinum
Cilastatin	Peritonitis	C0031154		Approved			C0008777	Cilastatinum
Cilastatin	Pneumonia due to Escherichia coli	C0276089		Approved			C0008777	Cilastatinum
Cilastatin	Haemophilus influenzae pneumonia	C0276026		Approved			C0008777	Cilastatinum
Cilastatin	Female genital tract infection	C1263758		Approved			C0008777	Cilastatinum
Cilastatin	Abdominal Abscess	C0243001		Approved			C0008777	Cilastatinum
Cilastatin	Enterobacter pneumonia	C1096258		Approved			C0008777	Cilastatinum
Cilastatin	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0008777	Cilastatinum
Cilastatin	Bacterial sepsis	C0684256		Approved			C0008777	Cilastatinum
Cilastatin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0008777	Cilastatinum
Cilastatin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0008777	Cilastatinum
Cilastatin	Lower respiratory tract infection	C0149725		Approved			C0008777	Cilastatinum
Cilastatin	Infection of bone	C2242472		Approved			C0008777	Cilastatinum
Cilastatin	Pelvic Inflammatory Disease	C0242172		Approved			C0008777	Cilastatinum
Cilastatin	Endometritis	C0014179		Approved			C0008777	Cilastatinum
Cilastatin	Arthropathy associated with infection	C0157749		Approved			C0008777	Cilastatinum
Cilastatin	Diabetic foot infection	C0744130		Approved			C0008777	Cilastatinum
Imipenem	Pneumonia due to Escherichia coli	C0276089		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Endometritis	C0014179		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Diabetic foot infection	C0744130		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Intraabdominal Infections	C1112209		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Arthropathy associated with infection	C0157749		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Abdominal Abscess	C0243001		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Lower respiratory tract infection	C0149725		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Enterobacter pneumonia	C1096258		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Female genital tract infection	C1263758		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Pneumonia, Bacterial	C0004626		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Bacterial sepsis	C0684256		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Infection of bone	C2242472		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Haemophilus influenzae pneumonia	C0276026		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Peritonitis	C0031154		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Pelvic Inflammatory Disease	C0242172		Approved			C0020933	N-formimidoyl thienamycin
Imipenem	Acute exacerbation of chronic bronchitis	C0856695		Approved			C0020933	N-formimidoyl thienamycin
Probucol	Hypercholesterolemia	C0020443		Approved			C0033215	Probucolum
Probucol	Hyperlipidemia	C0020473		Approved			C0033215	Probucolum
Tiaprofenic acid	Degenerative polyarthritis	C0029408		Approved			C0076653	2-(5-Benzyl-2-thienyl)propionsäure
Tiaprofenic acid	Pain	C0030193		Approved			C0076653	2-(5-Benzyl-2-thienyl)propionsäure
Tiaprofenic acid	Rheumatoid Arthritis	C0003873		Approved			C0076653	2-(5-Benzyl-2-thienyl)propionsäure
Lopinavir	HIV Infections	C0019693		Approved			C0674432	Lopinavir
Bacampicillin	Gonorrhea	C0018081		Approved			C0052865	Bacampicilina
Bacampicillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0052865	Bacampicilina
Bacampicillin	Urinary tract infection	C0042029		Approved			C0052865	Bacampicilina
Bacampicillin	Pharyngitis	C0031350		Approved			C0052865	Bacampicilina
Bacampicillin	Sinusitis	C0037199		Approved			C0052865	Bacampicilina
Bacampicillin	Haemophilus influenzae pneumonia	C0276026		Approved			C0052865	Bacampicilina
Bacampicillin	Infective otitis media	C0729586		Approved			C0052865	Bacampicilina
Meticillin	Bacterial sepsis	C0684256		Approved			C0025643	6β-(2,6-dimethoxybenzamido)penicillanic acid
Meticillin	Staphylococcal Pneumonia	C0032308		Approved			C0025643	6β-(2,6-dimethoxybenzamido)penicillanic acid
Meticillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0025643	6β-(2,6-dimethoxybenzamido)penicillanic acid
Meticillin	Sinusitis	C0037199		Approved			C0025643	6β-(2,6-dimethoxybenzamido)penicillanic acid
Tazobactam	Pelvic Inflammatory Disease	C0242172		Approved			C0075870	Tazobactamum
Tazobactam	Diabetic foot infection	C0744130		Approved			C0075870	Tazobactamum
Tazobactam	Appendicitis	C0003615		Approved			C0075870	Tazobactamum
Tazobactam	Pneumonia, Bacterial	C0004626		Approved			C0075870	Tazobactamum
Tazobactam	Nosocomial pneumonia	C0949083		Approved			C0075870	Tazobactamum
Tazobactam	Peritonitis	C0031154		Approved			C0075870	Tazobactamum
Tazobactam	Abdominal Abscess	C0243001		Approved			C0075870	Tazobactamum
Tazobactam	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0075870	Tazobactamum
Tazobactam	Haemophilus influenzae pneumonia	C0276026		Approved			C0075870	Tazobactamum
Tazobactam	Staphylococcus aureus infection	C1318973		Approved			C0075870	Tazobactamum
Ticarcillin	Enterobacter pneumonia	C1096258		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Pneumonia due to Escherichia coli	C0276089		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Lung Abscess	C0024110		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Salpingitis	C0036130		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Klebsiella cystitis	C0520775		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Escherichia coli urinary tract infection	C0577708		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Pneumonia due to Pseudomonas	C0155860		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Serratia Infections	C0085394		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Enterobacteriaceae Infections	C0014347		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Sepsis due to Pseudomonas	C2887096		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Empyema, Pleural	C0014013		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Rhinoscleroma	C0035468		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Proteus pneumonia	C1260917		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Urinary tract infection	C0042029		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Intraabdominal Infections	C1112209		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Pneumonia, Bacterial	C0004626		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Bacterial sepsis	C0684256		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Sepsis due to Gram negative bacteria	C3163829		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Haemophilus influenzae pneumonia	C0276026		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Escherichia coli Infections	C0014836		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Pelvic Inflammatory Disease	C0242172		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Staphylococcus aureus infection	C1318973		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Escherichia coli septicemia	C0276088		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Pelvic abscess	C0030785		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Bacterial urinary infection	C0729524		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Genitourinary tract infection	C1279247		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	URINARY TRACT INFECTION CITROBACTER	C0749955		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Staphylococcal Pneumonia	C0032308		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Aspiration Pneumonia	C0032290		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Proteus septicemia	C0577690		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Ticarcillin	Sepsis due to Staphylococcus aureus	C2887088		Approved			C0040193	α-carboxy-3-thienylmethylpenicillin
Deferasirox	Chronic iron overload	C1739382		Approved			C1619629	Deferasiroxum
Deferasirox	beta Thalassemia	C0005283		Approved			C1619629	Deferasiroxum
Hydroxychloroquine	Malaria, Vivax	C0024537		Approved			C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Hydroxychloroquine	Lupus Erythematosus, Systemic	C0024141		Approved			C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Hydroxychloroquine	Ovale malaria	C0152072		Approved			C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Hydroxychloroquine	Rheumatoid Arthritis	C0003873		Approved			C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Hydroxychloroquine	Lupus Erythematosus, Discoid	C0024138		Approved			C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Hydroxychloroquine	Quartan malaria	C0024536		Approved			C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Hydroxychloroquine	Malaria, Falciparum	C0024535		Approved			C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Amyl Nitrite	Toxic effect of cyanide	C0238080		Approved			C0002711	1-nitropentane
Aceprometazine	Sleeplessness	C0917801		Approved			CUI-less-DB01615	A
Molindone	Schizophrenia	C0036341		Approved			C0026388	(+/-)-molindone
Phenindamine	Allergic Conjunctivitis	C0009766		Approved			C0070563	Fenindamina
Phenindamine	Pruritus	C0033774		Approved			C0070563	Fenindamina
Phenindamine	Rhinorrhea	C1260880		Approved			C0070563	Fenindamina
Phenindamine	Symptomatic dermographism	C0343065		Approved			C0070563	Fenindamina
Phenindamine	Rhinitis, Vasomotor	C0035460		Approved			C0070563	Fenindamina
Phenindamine	Urticaria	C0042109		Approved			C0070563	Fenindamina
Phenindamine	Nasal congestion (finding)	C0027424		Approved			C0070563	Fenindamina
Phenindamine	Sneezing	C0037383		Approved			C0070563	Fenindamina
Phenindamine	Allergic rhinitis (disorder)	C2607914		Approved			C0070563	Fenindamina
Pheniramine	Allergic rhinitis (disorder)	C2607914		Approved			C0031408	Pheniraminum
Pheniramine	Symptomatic dermographism	C0343065		Approved			C0031408	Pheniraminum
Pheniramine	Redness of eye	C0235267		Approved			C0031408	Pheniraminum
Pheniramine	Fever	C0015967		Approved			C0031408	Pheniraminum
Pheniramine	Hay fever	C0018621		Approved			C0031408	Pheniraminum
Pheniramine	Itching of eye	C0022281		Approved			C0031408	Pheniraminum
Pheniramine	Rhinorrhea	C1260880		Approved			C0031408	Pheniraminum
Pheniramine	Urticaria	C0042109		Approved			C0031408	Pheniraminum
Pheniramine	Influenza-like symptoms	C0392171		Approved			C0031408	Pheniraminum
Pheniramine	Sore Throat	C0242429		Approved			C0031408	Pheniraminum
Pheniramine	Sneezing	C0037383		Approved			C0031408	Pheniraminum
Pheniramine	Sinus headache	C0037195		Approved			C0031408	Pheniraminum
Pheniramine	Headache Disorders	C0393735		Approved			C0031408	Pheniraminum
Pheniramine	Common Cold	C0009443		Approved			C0031408	Pheniraminum
Pheniramine	Allergic Conjunctivitis	C0009766		Approved			C0031408	Pheniraminum
Pheniramine	Nasal congestion (finding)	C0027424		Approved			C0031408	Pheniraminum
Pheniramine	Coughing	C0010200		Approved			C0031408	Pheniraminum
Pheniramine	Rhinitis, Vasomotor	C0035460		Approved			C0031408	Pheniraminum
Pheniramine	Pruritus	C0033774		Approved			C0031408	Pheniraminum
Pipotiazine	Schizophrenia	C0036341		Approved			C0031968	Pipotiazina
Thiothixene	Schizophrenia	C0036341		Approved			C0039955	Tiotixenum
Isopropamide	Peptic Ulcer	C0030920		Approved			C0301373	Isopropamide
Pargyline	Hypertensive disease	C0020538		Approved			C0030557	Pargylinum
Lincomycin	Pneumococcal Infections	C0032269		Approved			C0023726	Lincomycine
Lincomycin	Streptococcal Infections	C0038395		Approved			C0023726	Lincomycine
Roflumilast	Severe chronic obstructive pulmonary disease	C0730607		Approved			C0965618	Roflumilastum
Camphor	Sprains and Strains	C0038048		Approved			C2948081	Camphor (natural)
Camphor	Back Pain	C0004604		Approved			C2948081	Camphor (natural)
Camphor	Arthritic pains	C0857177		Approved			C2948081	Camphor (natural)
Dalfopristin	Streptococcus pyogenes infection	C0554628		Approved			C0756085	Dalfopristina
Calcipotriol	Scalp psoriasis	C0406326		Approved			C0065767	Calcipotriol
Calcipotriol	Chronic small plaque psoriasis	C0406317		Approved			C0065767	Calcipotriol
Vorinostat	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0672708	Vorinostatum
Cholic Acid	Biliary Tract Diseases	C0005424		Approved			C0055568	Cholic Acid
Cholic Acid	Cholelithiasis	C0008350		Approved			C0055568	Cholic Acid
Cholic Acid	Constipation	C0009806		Approved			C0055568	Cholic Acid
Cholic Acid	Incomplete passage of stool	C0426639		Approved			C0055568	Cholic Acid
Cholic Acid	3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency	C0342826		Approved			C0055568	Cholic Acid
Cholic Acid	Delta-4-3-oxosteroid-5-beta-reductase deficiency	C0342827		Approved			C0055568	Cholic Acid
Cholic Acid	Xanthomatosis, Cerebrotendinous	C0238052		Approved			C0055568	Cholic Acid
Nicotinamide	Acne Vulgaris	C0001144		Approved			C0028027	3-pyridinecarboxamide
Nicotinamide	Pellagra	C0030783		Approved			C0028027	3-pyridinecarboxamide
Fusidic Acid	Pneumonia due to Escherichia coli	C0276089		Approved			C0016875	Fusidic acid
Fusidic Acid	Furunculosis	C0016867		Approved			C0016875	Fusidic acid
Fusidic Acid	Bacterial keratitis	C0854211		Approved			C0016875	Fusidic acid
Fusidic Acid	Gingivostomatitis	C0149704		Approved			C0016875	Fusidic acid
Fusidic Acid	Endemic Flea-Borne Typhus	C0041472		Approved			C0016875	Fusidic acid
Fusidic Acid	Pharyngitis	C0031350		Approved			C0016875	Fusidic acid
Fusidic Acid	Rosacea	C0035854		Approved			C0016875	Fusidic acid
Fusidic Acid	Keratoconjunctivitis	C0022573		Approved			C0016875	Fusidic acid
Fusidic Acid	Acute gonococcal endometritis	C0153196		Approved			C0016875	Fusidic acid
Fusidic Acid	Herpes zoster keratitis	C1275687		Approved			C0016875	Fusidic acid
Fusidic Acid	Escherichia coli septicemia	C0276088		Approved			C0016875	Fusidic acid
Fusidic Acid	Anthrax disease	C0003175		Approved			C0016875	Fusidic acid
Fusidic Acid	Peritonitis	C0031154		Approved			C0016875	Fusidic acid
Fusidic Acid	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			C0016875	Fusidic acid
Fusidic Acid	Tularemia	C0041351		Approved			C0016875	Fusidic acid
Fusidic Acid	Infection of bone	C2242472		Approved			C0016875	Fusidic acid
Fusidic Acid	Brucellosis	C0006309		Approved			C0016875	Fusidic acid
Fusidic Acid	Staphylococcal Pneumonia	C0032308		Approved			C0016875	Fusidic acid
Fusidic Acid	Acute gonococcal urethritis	C0275652		Approved			C0016875	Fusidic acid
Fusidic Acid	non-gonococcal urethritis (NGU)	C1112709		Approved			C0016875	Fusidic acid
Fusidic Acid	Intraabdominal Infections	C1112209		Approved			C0016875	Fusidic acid
Fusidic Acid	Sinusitis	C0037199		Approved			C0016875	Fusidic acid
Fusidic Acid	Gonorrhea	C0018081		Approved			C0016875	Fusidic acid
Fusidic Acid	Actinomycosis	C0001261		Approved			C0016875	Fusidic acid
Fusidic Acid	Sepsis due to Pseudomonas	C2887096		Approved			C0016875	Fusidic acid
Fusidic Acid	Pneumonia due to Pseudomonas	C0155860		Approved			C0016875	Fusidic acid
Fusidic Acid	Granuloma Inguinale	C0018190		Approved			C0016875	Fusidic acid
Fusidic Acid	Rickettsia Infections	C0035585		Approved			C0016875	Fusidic acid
Fusidic Acid	Yaws	C0043388		Approved			C0016875	Fusidic acid
Fusidic Acid	Boutonneuse Fever	C0006060		Approved			C0016875	Fusidic acid
Fusidic Acid	Corneal Perforation	C0339293		Approved			C0016875	Fusidic acid
Fusidic Acid	Serratia sepsis	C0152973		Approved			C0016875	Fusidic acid
Fusidic Acid	Citrobacter sepsis	C1096254		Approved			C0016875	Fusidic acid
Fusidic Acid	Q Fever	C0034362		Approved			C0016875	Fusidic acid
Fusidic Acid	Bacterial sepsis	C0684256		Approved			C0016875	Fusidic acid
Fusidic Acid	Q fever endocarditis	C0340354		Approved			C0016875	Fusidic acid
Fusidic Acid	Pneumococcal Infections	C0032269		Approved			C0016875	Fusidic acid
Fusidic Acid	Meningitis, Bacterial	C0085437		Approved			C0016875	Fusidic acid
Fusidic Acid	Sepsis of the newborn	C0456103		Approved			C0016875	Fusidic acid
Fusidic Acid	Mycoplasma pneumonia	C0032302		Approved			C0016875	Fusidic acid
Fusidic Acid	Inhalational anthrax	C0155866		Approved			C0016875	Fusidic acid
Fusidic Acid	Dacryocystitis	C0010930		Approved			C0016875	Fusidic acid
Fusidic Acid	Rhinoscleroma	C0035468		Approved			C0016875	Fusidic acid
Fusidic Acid	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C0016875	Fusidic acid
Fusidic Acid	Urinary tract infection	C0042029		Approved			C0016875	Fusidic acid
Fusidic Acid	Sepsis due to Gram negative bacteria	C3163829		Approved			C0016875	Fusidic acid
Fusidic Acid	Gonorrhea of pharynx	C0149966		Approved			C0016875	Fusidic acid
Fusidic Acid	Listeriosis	C0023860		Approved			C0016875	Fusidic acid
Fusidic Acid	Cholangitis	C0008311		Approved			C0016875	Fusidic acid
Fusidic Acid	Allergic Conjunctivitis	C0009766		Approved			C0016875	Fusidic acid
Fusidic Acid	Anterior uveitis	C0042165		Approved			C0016875	Fusidic acid
Fusidic Acid	Relapsing Fever	C0035021		Approved			C0016875	Fusidic acid
Fusidic Acid	Bacterial conjunctivitis	C0009768		Approved			C0016875	Fusidic acid
Fusidic Acid	Acne Vulgaris	C0001144		Approved			C0016875	Fusidic acid
Fusidic Acid	Cutaneous anthrax	C0003177		Approved			C0016875	Fusidic acid
Fusidic Acid	Infective otitis media	C0729586		Approved			C0016875	Fusidic acid
Fusidic Acid	Meibomianitis	C0549398		Approved			C0016875	Fusidic acid
Fusidic Acid	Trachoma	C0040592		Approved			C0016875	Fusidic acid
Fusidic Acid	Rocky Mountain Spotted Fever	C0035793		Approved			C0016875	Fusidic acid
Fusidic Acid	Gonorrhea of rectum	C0275665		Approved			C0016875	Fusidic acid
Fusidic Acid	Paronychia Inflammation	C0030578		Approved			C0016875	Fusidic acid
Fusidic Acid	Folliculitis	C0016436		Approved			C0016875	Fusidic acid
Fusidic Acid	Chancroids	C0007947		Approved			C0016875	Fusidic acid
Fusidic Acid	Escherichia coli Infections	C0014836		Approved			C0016875	Fusidic acid
Fusidic Acid	Brill-Zinsser Disease	C0006181		Approved			C0016875	Fusidic acid
Fusidic Acid	Infection due to Pseudomonas aeruginosa	C0276075		Approved			C0016875	Fusidic acid
Fusidic Acid	Neonatal meningitis	C0456107		Approved			C0016875	Fusidic acid
Fusidic Acid	Cholera	C0008354		Approved			C0016875	Fusidic acid
Fusidic Acid	Bacterial peritonitis	C0341503		Approved			C0016875	Fusidic acid
Fusidic Acid	Neonatal pneumonia	C0339968		Approved			C0016875	Fusidic acid
Fusidic Acid	Typhus, Epidemic Louse-Borne	C0041473		Approved			C0016875	Fusidic acid
Fusidic Acid	Pseudomonas aeruginosa meningitis	C3665869		Approved			C0016875	Fusidic acid
Fusidic Acid	Enterobacteriaceae Infections	C0014347		Approved			C0016875	Fusidic acid
Fusidic Acid	Bronchitis	C0006277		Approved			C0016875	Fusidic acid
Fusidic Acid	Acute gonococcal cervicitis	C0153195		Approved			C0016875	Fusidic acid
Fusidic Acid	Acute gonococcal epididymo-orchitis	C0153193		Approved			C0016875	Fusidic acid
Fusidic Acid	Klebsiella sepsis	C0745528		Approved			C0016875	Fusidic acid
Fusidic Acid	Syphilis	C0039128		Approved			C0016875	Fusidic acid
Fusidic Acid	Psittacosis	C0029291		Approved			C0016875	Fusidic acid
Fusidic Acid	TYPHUS	C0041471		Approved			C0016875	Fusidic acid
Fusidic Acid	Blepharoconjunctivitis	C0005743		Approved			C0016875	Fusidic acid
Fusidic Acid	Enterobacter pneumonia	C1096258		Approved			C0016875	Fusidic acid
Fusidic Acid	Lymphogranuloma Venereum	C0024286		Approved			C0016875	Fusidic acid
Fusidic Acid	Chlamydia Infections	C0008149		Approved			C0016875	Fusidic acid
Fusidic Acid	Gastrointestinal anthrax	C0152945		Approved			C0016875	Fusidic acid
Fusidic Acid	Proteus pneumonia	C1260917		Approved			C0016875	Fusidic acid
Fusidic Acid	Arthropathy associated with infection	C0157749		Approved			C0016875	Fusidic acid
Fusidic Acid	Chlamydia trachomatis infection of genital structure	C1997322		Approved			C0016875	Fusidic acid
Fusidic Acid	Rickettsialpox	C0035597		Approved			C0016875	Fusidic acid
Fusidic Acid	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0016875	Fusidic acid
Fusidic Acid	Pneumonia, Bacterial	C0004626		Approved			C0016875	Fusidic acid
Fusidic Acid	Infective blepharitis	C0729587		Approved			C0016875	Fusidic acid
Fusidic Acid	Nosocomial pneumonia	C0949083		Approved			C0016875	Fusidic acid
Fusidic Acid	Proteus septicemia	C0577690		Approved			C0016875	Fusidic acid
Fusidic Acid	Punctate keratitis	C0259799		Approved			C0016875	Fusidic acid
Fusidic Acid	Streptococcal Infections	C0038395		Approved			C0016875	Fusidic acid
Fusidic Acid	Bartonella Infections	C0004771		Approved			C0016875	Fusidic acid
Fusidic Acid	Pneumonia	C0032285		Approved			C0016875	Fusidic acid
Fusidic Acid	Scrub Typhus	C0036472		Approved			C0016875	Fusidic acid
Fusidic Acid	Staphylococcus aureus infection	C1318973		Approved			C0016875	Fusidic acid
Fusidic Acid	Serratia Infections	C0085394		Approved			C0016875	Fusidic acid
Fusidic Acid	Corneal abrasion	C0010032		Approved			C0016875	Fusidic acid
Fusidic Acid	GONOCOCCAL INFECTION DISSEMINATED	C0744451		Approved			C0016875	Fusidic acid
Acetic acid	Otitis Externa	C0029878		Approved			C0000983	ácido acético
Oteracil	Malignant neoplasm of stomach	C0024623		Approved			C0030032	5-azaorotic acid
Phenol	Skin irritation	C0152030		Approved			C0070570	Carbolsäure
Phenol	Mouth irritation	C0235339		Approved			C0070570	Carbolsäure
Phenol	Pruritus	C0033774		Approved			C0070570	Carbolsäure
Hemin	Acute intermittent porphyria	C0162565		Approved			C0018988	Hemina
Deoxycholic Acid	Excess subcutaneous fat	C0424620		Approved			C0011479	Desoxycholsäure
Benzoic Acid	Dermatomyositis	C0011633		Approved			C0053225	Benzoic Acid
Benzoic Acid	Scleroderma	C0011644		Approved			C0053225	Benzoic Acid
Benzoic Acid	Morphea	C1527383		Approved			C0053225	Benzoic Acid
Benzoic Acid	Peyronie Disease	C0030848		Approved			C0053225	Benzoic Acid
Benzoic Acid	Pemphigus	C0030807		Approved			C0053225	Benzoic Acid
Benzoic Acid	Hyperammonemia	C0220994		Approved			C0053225	Benzoic Acid
Formaldehyde	Influenza	C0021400		Approved			C0016564	Formaldehyd
Urea	Impacted cerumen	C0021092		Approved			C0041942	Carbonyldiamide
Urea	Exanthema	C0015230		Approved			C0041942	Carbonyldiamide
Urea	Contact Dermatitis	C0011616		Approved			C0041942	Carbonyldiamide
Urea	Scurfiness of scalp	C0423775		Approved			C0041942	Carbonyldiamide
Urea	Seborrheic dermatitis	C0036508		Approved			C0041942	Carbonyldiamide
Urea	Tinea Versicolor	C0040262		Approved			C0041942	Carbonyldiamide
Lactic Acid	Pruritus	C0033774		Approved			C0064582	Lactic acid
Lactose	Lactose Intolerance	C0022951		Approved			C0022949	Lactose
Trioxsalen	Photosensitivity of skin	C0349506		Approved			C0041086	Trioxysalenum
Trioxsalen	Vitiligo	C0042900		Approved			C0041086	Trioxysalenum
Thiotepa	Hodgkin Disease	C0019829		Approved			C0039871	Thiotepa
Thiotepa	Pleural Effusion, Malignant	C0080032		Approved			C0039871	Thiotepa
Thiotepa	Malignant neoplasm of ovary	C1140680		Approved			C0039871	Thiotepa
Thiotepa	Lymphoma, Non-Hodgkin	C0024305		Approved			C0039871	Thiotepa
Thiotepa	Malignant epithelial neoplasm of female breast	C3163805		Approved			C0039871	Thiotepa
Thiotepa	Malignant ascites	C0220656		Approved			C0039871	Thiotepa
Thiotepa	Malignant pericardial effusion	C0220655		Approved			C0039871	Thiotepa
Thiotepa	Malignant neoplasm of urinary bladder	C0005684		Approved			C0039871	Thiotepa
Estrone sulfate	Atrophic Vaginitis	C0221392		Approved			C0059668	Estrone bisulfate
Quinestrol	Female hypogonadism syndrome	C0271578		Approved			C0034410	Quinestrolo
Quinestrol	Hot flushes	C0600142		Approved			C0034410	Quinestrolo
Quinestrol	Atrophic Vaginitis	C0221392		Approved			C0034410	Quinestrolo
Suramin	African Trypanosomiasis	C0041228		Approved			C0038880	Suramin
Clofedanol	Coughing	C0010200		Approved			C0055904	Clofedanolum
Clofedanol	Common Cold	C0009443		Approved			C0055904	Clofedanolum
Clofedanol	Allergic rhinitis (disorder)	C2607914		Approved			C0055904	Clofedanolum
Clofedanol	Rhinitis, Vasomotor	C0035460		Approved			C0055904	Clofedanolum
Clofedanol	Rhinorrhea	C1260880		Approved			C0055904	Clofedanolum
Clofedanol	Nasal congestion (finding)	C0027424		Approved			C0055904	Clofedanolum
Clofedanol	Rhinitis	C0035455		Approved			C0055904	Clofedanolum
Fluspirilene	Schizophrenia	C0036341		Approved			C0016383	Fluspirileno
Mepenzolate	Gastric ulcer	C0038358		Approved			C0360172	Mepenzolate
Mepenzolate	Peptic Ulcer	C0030920		Approved			C0360172	Mepenzolate
Ixabepilone	Breast Carcinoma	C0678222		Approved			C1135132	Aza-epothilone B
Ixabepilone	Carcinoma breast stage IV	C0278488		Approved			C1135132	Aza-epothilone B
Celiprolol	Hypertensive disease	C0020538		Approved			C0055021	RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
Febuxostat	Hyperuricemia	C0740394		Approved			C0249529	Fébuxostat
Dronedarone	Paroxysmal atrial fibrillation	C0235480		Approved			C0766326	N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
Nebivolol	Hypertensive disease	C0020538		Approved			C0068475	Nebivololum
Homoharringtonine	Myeloid Leukemia, Chronic	C0023473		Approved			C0062941	mepesuccinato de omacetaxina
Nilotinib	Leukemia, Myeloid, Accelerated Phase	C0023472		Approved			C1721377	Nilotinibum
Nilotinib	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			C1721377	Nilotinibum
Nilotinib	Leukemia, Myeloid, Chronic-Phase	C0023474		Approved			C1721377	Nilotinibum
Lorcaserin	Obesity	C0028754		Approved			C4255624	Lorqess
Vildagliptin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C1570906	Vildagliptina
Voglibose	Gaucher Disease	C0017205		Approved			C0532578	Voglibosa
Voglibose	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C0532578	Voglibosa
Bepotastine	Allergic Conjunctivitis	C0009766		Approved			C2698371	bepotastina
Pegaptanib	Exudative age-related macular degeneration	C0271084		Approved			C1576729	Pegaptanib sodium
Milnacipran	Fibromyalgia	C0016053		Approved			C1533126	(+-)-Milnacipran
Lucinactant	Respiratory Distress Syndrome, Newborn	C0035220		Approved			C0385603	ATI-02
Nesiritide	Decompensated chronic heart failure	C1827266		Approved			C0054015	Human brain natriuretic factor-32
Nesiritide	Decompensated cardiac failure	C0581377		Approved			C0054015	Human brain natriuretic factor-32
Flibanserin	Hypoactive Sexual Desire Disorder	C0020594		Approved			C0754280	Flibanserin
Oritavancin	Skin Diseases, Bacterial	C0162627		Approved			C1144403	Chlorobiphenyl-chloroeremomycin
Oritavancin	Staphylococcal Skin Infections	C0038166		Approved			C1144403	Chlorobiphenyl-chloroeremomycin
Oritavancin	Streptococcal infection of skin	C1274355		Approved			C1144403	Chlorobiphenyl-chloroeremomycin
Clevidipine	Hypertensive disease	C0020538		Approved			C0766108	Clevidipino
Permethrin	Scabies <infestation>	C0036262		Approved			C0070455	(3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
Permethrin	Pediculus capitis infestation	C0030757		Approved			C0070455	(3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
Permethrin	Infestation by Phthirus pubis	C0030759		Approved			C0070455	(3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
Permethrin	Body louse infestation	C0030758		Approved			C0070455	(3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
Afamelanotide	Erythropoietic Protoporphyria	C0162568		Approved			C2607750	Afamelanotide
Defibrotide	Hepatic Veno-Occlusive Disease	C0019156		Approved			C4703922	Defibrotide free acid (porcine)
Ospemifene	Dyspareunia	C1384606		Approved			C1313616	2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol
Crofelemer	Non-infective diarrhea	C0267436		Approved			C2744960	Crofelemer
Tamibarotene	Acute Promyelocytic Leukemia	C0023487		Approved			C1567753	retinobenzoic acid
Iloperidone	Schizophrenia	C0036341		Approved			C0247194	4'-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
Lofexidine	Opioid withdrawal	C0029104		Approved			C0065152	Lofexidina
Ingenol Mebutate	Actinic keratosis	C0022602		Approved			C1452152	3-Angeloylingenol
Belinostat	Peripheral T-Cell Lymphoma	C0079774		Approved			C1948068	Belinostat
Ataluren	Muscular Dystrophy, Duchenne	C0013264		Approved			C2930764	3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
Trabectedin	Malignant neoplasm of ovary	C1140680		Approved			C1311070	Trabectedina
Trabectedin	liposarcoma	C0023827		Approved			C1311070	Trabectedina
Trabectedin	leiomyosarcoma	C0023269		Approved			C1311070	Trabectedina
Cobimetinib	Malignant melanoma, metastatic	C0860594		Approved			C4049146	Cobimetinib
Silver sulfadiazine	Skin Ulcer	C0037299		Approved			C0037134	Sulfadiazine silver
Methsuximide	Absence Epilepsy	C0014553		Approved			C0109002	alpha-Methyl-alpha-phenyl N-methyl succinimide
Methsuximide	Epilepsy	C0014544		Approved			C0109002	alpha-Methyl-alpha-phenyl N-methyl succinimide
Glatiramer Acetate	Multiple Sclerosis	C0026769		Approved			C0717787	COP 1
Ecabet	Peptic Ulcer	C0030920		Approved			C0209315	Ecabetum
Ibudilast	Asthma	C0004096		Approved			C0123047	Ibudilastum
Rotigotine	Restless Legs Syndrome	C0035258		Approved			C1700683	Rotigotina
Rotigotine	Parkinson Disease	C0030567		Approved			C1700683	Rotigotina
Vandetanib	Malignant epithelial neoplasm of thyroid	C3163939		Approved			C1121849	N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
Ecallantide	Angioedemas, Hereditary	C0019243		Approved			C1722685	Ecallantide
Romiplostim	Chronic idiopathic thrombocytopenic purpura	C0272293		Approved			C2364481	Romiplostim
Obiltoxaximab	Inhalational anthrax	C0155866		Approved			C4224790	Obiltoxaximab
Telaprevir	Hepatitis C, Chronic	C0524910		Approved			C1876229	(1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide
Mipomersen	Familial hypercholesterolemia - homozygous	C0342881		Approved			C2604635	Mipomersen
Ramucirumab	Gastric Adenocarcinoma	C0278701		Approved			C2742502	Ramucirumab
Ramucirumab	Non-Small Cell Lung Carcinoma	C0007131		Approved			C2742502	Ramucirumab
Sodium stibogluconate	Leishmaniasis	C0023281		Approved			C0030895	Stibogluconate de sodium
Apremilast	Arthritis, Psoriatic	C0003872		Approved			C1678805	Aprémilast
Apremilast	Chronic small plaque psoriasis	C0406317		Approved			C1678805	Aprémilast
Ustekinumab	Psoriasis	C0033860		Approved			C4292395	Stelera
Ustekinumab	Arthritis, Psoriatic	C0003872		Approved			C4292395	Stelera
Trastuzumab emtansine	HER2-positive carcinoma of breast	C1960398		Approved			C2935436	Trastuzumab emtansine
Abiraterone	Malignant neoplasm of prostate	C0376358		Approved			C0754011	Abiraterona
Parathyroid hormone	Hypoparathyroidism	C0020626		Approved			C0030520	Parathyroid hormone (rDNA)
Cariprazine	Schizophrenia	C0036341		Approved			C2936870	Cariprazine
Cariprazine	Mixed bipolar I disorder	C0236780		Approved			C2936870	Cariprazine
Cariprazine	Bipolar affective disorder, current episode manic	C0338873		Approved			C2936870	Cariprazine
Sertindole	Schizophrenia	C0036341		Approved			C0084528	1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one
Sulfathiazole	Vulvovaginitis	C0042998		Approved			C0038722	Sulfathiazol
Mianserin	Major Depressive Disorder	C1269683		Approved			C0025912	1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine
Acetylcysteine	Poisoning by acetaminophen	C0237963		Approved			C0001047	NAC
Acetylcysteine	Bronchiectasis	C0006267		Approved			C0001047	NAC
Acetylcysteine	Bronchitis	C0006277		Approved			C0001047	NAC
Acetylcysteine	Amyloidosis	C0002726		Approved			C0001047	NAC
Acetylcysteine	Pulmonary Cystic Fibrosis	C0392164		Approved			C0001047	NAC
Rimonabant	Obesity	C0028754		Approved			C1142933	Rimonabant
Canakinumab	Cryopyrin-Associated Periodic Syndromes	C2316212		Approved			C2718773	Canakinumab
Canakinumab	Systemic onset juvenile chronic arthritis	C1384600		Approved			C2718773	Canakinumab
Canakinumab	Arthritis, Gouty	C0003868		Approved			C2718773	Canakinumab
Canakinumab	Deficiency of mevalonate kinase	C0342731		Approved			C2718773	Canakinumab
Canakinumab	Familial Mediterranean Fever	C0031069		Approved			C2718773	Canakinumab
Canakinumab	TNF receptor-associated periodic fever syndrome (TRAPS)	C1275126		Approved			C2718773	Canakinumab
Romidepsin	Peripheral T-Cell Lymphoma	C0079774		Approved			C1527027	Romidepsine
Romidepsin	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C1527027	Romidepsine
Ipilimumab	Malignant melanoma, metastatic	C0860594		Approved			C1691227	MDX-CTLA-4
Icatibant	Angioedemas, Hereditary	C0019243		Approved			C0246269	Icatibant
Rufinamide	Lennox-Gastaut syndrome	C0238111		Approved			C0213404	Rufinamida
Alogliptin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C1958126	Alogliptina
Tapentadol	Pain	C0030193		Approved			C2001271	Tapentadol
Silodosin	Prostatic Hypertrophy	C1739363		Approved			C1870115	Silodosina
Prasugrel	Acute Coronary Syndrome	C0948089		Approved			C1620287	Prasugrel
Eltrombopag	Chronic idiopathic thrombocytopenic purpura	C0272293		Approved			C1831905	Eltrombopag
Doripenem	Pyelonephritis	C0034186		Approved			C0389169	Doripenem
Doripenem	Intraabdominal Infections	C1112209		Approved			C0389169	Doripenem
Doripenem	Complicated appendicitis	C1632842		Approved			C0389169	Doripenem
Doripenem	Cholecystitis	C0008325		Approved			C0389169	Doripenem
Doripenem	Abdominal Abscess	C0243001		Approved			C0389169	Doripenem
Tolvaptan	Inappropriate ADH Syndrome	C0021141		Approved			C1176308	Tolvaptan
Tolvaptan	Hyponatremia	C0020625		Approved			C1176308	Tolvaptan
Tolvaptan	Polycystic Kidney, Autosomal Dominant	C0085413		Approved			C1176308	Tolvaptan
Asenapine	Schizophrenia	C0036341		Approved			C2000088	asenapina
Asenapine	Mixed bipolar I disorder	C0236780		Approved			C2000088	asenapina
Asenapine	Bipolar affective disorder, current episode manic	C0338873		Approved			C2000088	asenapina
Dalbavancin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C1172636	Dalbavancina
Dalbavancin	Staphylococcal Skin Infections	C0038166		Approved			C1172636	Dalbavancina
Dalbavancin	Skin Diseases, Bacterial	C0162627		Approved			C1172636	Dalbavancina
Avanafil	Erectile dysfunction	C0242350		Approved			C2698280	Avanafilo
Eflornithine	African Trypanosomiasis	C0041228		Approved			C0002260	alpha-difluoromethylornithine
Incadronic acid	Osteoporosis	C0029456		Approved			CUI-less-DB06255	I
Droxidopa	Parkinson Disease	C0030567		Approved			C0000378	L-Dihydroxyphenylserine
Udenafil	Erectile dysfunction	C0242350		Approved			C1742789	Udenafil
Sitaxentan	Pulmonary arterial hypertension	C2973725		Approved			C1704271	Sitaxsentan
Tocilizumab	Rheumatoid Arthritis	C0003873		Approved			C1609165	Atlizumab
Tocilizumab	Angiolymphoid hyperplasia	C0017531		Approved			C1609165	Atlizumab
Alvimopan	Postoperative ileus	C0400877		Approved			C1508750	Alvimopan
Levocetirizine	Hay fever	C0018621		Approved			C1174893	Levocetirizina
Levocetirizine	Allergic rhinitis (disorder)	C2607914		Approved			C1174893	Levocetirizina
Levocetirizine	Chronic idiopathic urticaria	C0578870		Approved			C1174893	Levocetirizina
Ziconotide	Chronic pain	C0150055		Approved			C0211011	Ziconotida
Ziconotide	Severe pain	C0278140		Approved			C0211011	Ziconotida
Ziconotide	Pain in spine	C0423673		Approved			C0211011	Ziconotida
Teriparatide	Osteoporosis, Postmenopausal	C0029458		Approved			C0070093	Teriparatida
Temsirolimus	Renal Cell Carcinoma	C0007134		Approved			C1707080	Temsirolimus
Temsirolimus	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634		Approved			C1707080	Temsirolimus
Amisulpride	Chronic schizophrenia	C0221765		Approved			C0103045	Amisulprida
Simeprevir	Hepatitis C, Chronic	C0524910		Approved			C2605855	Simeprevir
Dapagliflozin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C2353951	Dapagliflozina
Elotuzumab	Multiple Myeloma	C0026764		Approved			C4521041	Immunoglobulin G1, anti-(human SLAM family member 7 (CD2-like receptor activating cytotoxic cells, CD319 antigen)), humanized mouse monoclonal HuLuc63 gamma-1 heavy chain (222-214')-disulfide with humanized mouse monoclonal HuLuc63 kappa light chain (228-228'';231-231'')-bisdisulfide dimer
Saxagliptin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C1611934	Saxagliptina
Pertuzumab	HER2-positive carcinoma of breast	C1960398		Approved			C1434409	rhuMAb-2C4
Rilonacept	Cryopyrin-Associated Periodic Syndromes	C2316212		Approved			C2343589	interleukin-1 (IL-1) trap
Bazedoxifene	Osteoporosis, Postmenopausal	C0029458		Approved			C2346970	Bazedoxifeno
Bazedoxifene	Hot flushes	C0600142		Approved			C2346970	Bazedoxifeno
Telavancin	Pneumonia due to Staphylococcus aureus	C2349530		Approved			C1453642	Telavancina
Telavancin	Pneumonia, Bacterial	C0004626		Approved			C1453642	Telavancina
Ambrisentan	Pulmonary arterial hypertension	C2973725		Approved			C1176329	Ambrisentan
Oxymetholone	Aplastic Anemia	C0002874		Approved			C0030072	Oxymétholone
Oxymetholone	Hypoplastic anemia	C0178416		Approved			C0030072	Oxymétholone
Oxymetholone	Anemia, Diamond-Blackfan	C1260899		Approved			C0030072	Oxymétholone
Armodafinil	Narcolepsy	C0027404		Approved			C1701455	Armodafinilo
Etravirine	HIV Infections	C0019693		Approved			C1456409	Etravirina
Calfactant	Respiratory Distress Syndrome, Newborn	C0035220		Approved			C0763530	Bovactant
Tyloxapol	Respiratory Distress Syndrome, Newborn	C0035220		Approved			C0077539	Tyloxapol
Prucalopride	Constipation	C0009806		Approved			C0913506	Prucaloprida
Pazopanib	Renal Cell Carcinoma	C0007134		Approved			C1831796	Pazopanibum
Pazopanib	Sarcoma	C1261473		Approved			C1831796	Pazopanibum
Ceftaroline fosamil	Streptococcus pyogenes infection	C0554628		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Escherichia coli Infections	C0014836		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Pneumonia due to Staphylococcus aureus	C2349530		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Rhinoscleroma	C0035468		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Haemophilus influenzae pneumonia	C0276026		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Staphylococcus aureus infection	C1318973		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Streptococcal pneumonia	C0155862		Approved			C2001525	Ceftarolina fosamilo
Ceftaroline fosamil	Pneumonia due to Escherichia coli	C0276089		Approved			C2001525	Ceftarolina fosamilo
Agomelatine	Major Depressive Disorder	C1269683		Approved			C0971637	Agomelatina
Panobinostat	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C1998098	(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Panobinostat	Multiple Myeloma	C0026764		Approved			C1998098	(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Apixaban	Arterial embolus and thrombosis	C0155749		Approved			C1831808	apixabán
Mepolizumab	Eosinophilic Pneumonia	C1527407		Approved			C0969324	Mepolizumab
Peramivir	Influenza	C0021400		Approved			C3872016	Peramivir anhydrous
Bosutinib	Leukemia, Myeloid, Accelerated Phase	C0023472		Approved			C1099259	4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile
Bosutinib	Blast Phase	C0005699		Approved			C1099259	4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile
Axitinib	Renal Cell Carcinoma	C0007134		Approved			C1700874	Axitinibum
Isavuconazonium	Mucormycosis	C0026718		Approved			C4018471	Isavuconazonium
Isavuconazonium	Aspergillosis	C0004030		Approved			C4018471	Isavuconazonium
Dalfampridine	Multiple Sclerosis	C0026769		Approved			C0000477	γ-Aminopyridine
Denosumab	Osteoporosis, Postmenopausal	C0029458		Approved			C1690432	Denosumab
Denosumab	Osteoporosis	C0029456		Approved			C1690432	Denosumab
Denosumab	Drug-induced osteoporosis	C0264115		Approved			C1690432	Denosumab
Ofatumumab	Chronic Lymphocytic Leukemia	C0023434		Approved			C1832027	Ofatumumabum
Liraglutide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C1456408	Liraglutida
Pasireotide	Adrenal Gland Hyperfunction	C0001622		Approved			C1872203	cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
golimumab	Rheumatoid Arthritis	C0003873		Approved			C2353893	Golimumab
golimumab	Arthritis, Psoriatic	C0003872		Approved			C2353893	Golimumab
golimumab	Ankylosing spondylitis	C0038013		Approved			C2353893	Golimumab
golimumab	Ulcerative Colitis	C0009324		Approved			C2353893	Golimumab
Belatacept	Renal transplant rejection	C0238217		Approved			C1619962	Belatacept
Vilazodone	Major Depressive Disorder	C1269683		Approved			C1530072	Vilazodona
Mepyramine	Sneezing	C0037383		Approved			C0034282	Mepiramina
Mepyramine	Pruritus	C0033774		Approved			C0034282	Mepiramina
Mepyramine	Common Cold	C0009443		Approved			C0034282	Mepiramina
Mepyramine	Influenza-like symptoms	C0392171		Approved			C0034282	Mepiramina
Mepyramine	Rhinorrhea	C1260880		Approved			C0034282	Mepiramina
Mepyramine	Allergic Conjunctivitis	C0009766		Approved			C0034282	Mepiramina
Mepyramine	Hay fever	C0018621		Approved			C0034282	Mepiramina
Mepyramine	Allergic rhinitis (disorder)	C2607914		Approved			C0034282	Mepiramina
Mepyramine	Rhinitis, Vasomotor	C0035460		Approved			C0034282	Mepiramina
Mepyramine	Urticaria	C0042109		Approved			C0034282	Mepiramina
Mepyramine	Symptomatic dermographism	C0343065		Approved			C0034282	Mepiramina
Mepyramine	Nasal congestion (finding)	C0027424		Approved			C0034282	Mepiramina
Mepyramine	Sinus headache	C0037195		Approved			C0034282	Mepiramina
Mepyramine	Dysmenorrhea	C0013390		Approved			C0034282	Mepiramina
Aprotinin	Hemorrhage	C0019080		Approved			C0003641	Aprotinina
Xylometazoline	Rhinorrhea	C1260880		Approved			C0078643	Xylometazolinum
Xylometazoline	Nasal congestion (finding)	C0027424		Approved			C0078643	Xylometazolinum
Betahistine	Meniere Disease	C0025281		Approved			C0005301	Betahistinum
Desvenlafaxine	Major Depressive Disorder	C1269683		Approved			C1880288	Desvenlafaxina
Dexmethylphenidate	Attention deficit hyperactivity disorder	C1263846		Approved			C1169997	Dexmethylphenidatum
Fesoterodine	Increased frequency of micturition	C0042023		Approved			C2343853	Fesoterodina
Fesoterodine	Bladder muscle dysfunction - overactive	C0403643		Approved			C2343853	Fesoterodina
Fesoterodine	Urge Incontinence	C0150045		Approved			C2343853	Fesoterodina
Fesoterodine	Urgency of micturition	C0085606		Approved			C2343853	Fesoterodina
Lumefantrine	Malaria, Falciparum	C0024535		Approved			C0531104	(±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
Methyltestosterone	Testicular hypogonadism	C0151721		Approved			C0025826	Methyltestosteronum
Methyltestosterone	Deficiency of testosterone biosynthesis	C0342527		Approved			C0025826	Methyltestosteronum
Methyltestosterone	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			C0025826	Methyltestosteronum
Methyltestosterone	Hot flushes	C0600142		Approved			C0025826	Methyltestosteronum
Methyltestosterone	Delayed Puberty	C0034012		Approved			C0025826	Methyltestosteronum
Naphazoline	Itching of eye	C0022281		Approved			C0027373	Nafazolina
Naphazoline	Redness of eye	C0235267		Approved			C0027373	Nafazolina
Potassium Iodide	Coughing	C0010200		Approved			C0032831	Potasio ioduro
Potassium Iodide	Common Cold	C0009443		Approved			C0032831	Potasio ioduro
Potassium Iodide	Nasal congestion (finding)	C0027424		Approved			C0032831	Potasio ioduro
Potassium Iodide	Rhinorrhea	C1260880		Approved			C0032831	Potasio ioduro
Potassium Iodide	Allergic rhinitis (disorder)	C2607914		Approved			C0032831	Potasio ioduro
Fosaprepitant	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C2349941	Fosaprépitant
Stanozolol	Angioedemas, Hereditary	C0019243		Approved			C0038149	estanozolol
Velaglucerase alfa	Gaucher Disease	C0017205		Approved			C2919267	Velaglucerasa alfa
Velaglucerase alfa	Gaucher Disease, Type 1	C1961835		Approved			C2919267	Velaglucerasa alfa
Aluminum hydroxide	Gastric ulcer	C0038358		Approved			C0002371	Aluminio hidróxido
Aluminum hydroxide	Heartburn	C0018834		Approved			C0002371	Aluminio hidróxido
Aluminum hydroxide	Peptic Ulcer	C0030920		Approved			C0002371	Aluminio hidróxido
Aluminum hydroxide	Dyspepsia	C0013395		Approved			C0002371	Aluminio hidróxido
Aluminum hydroxide	Duodenal Ulcer	C0013295		Approved			C0002371	Aluminio hidróxido
Aluminum hydroxide	Gastroesophageal reflux disease	C0017168		Approved			C0002371	Aluminio hidróxido
Calcium carbonate	Hypocalcemia	C0020598		Approved			C0006681	Calcio carbonato
Calcium carbonate	Dyspepsia	C0013395		Approved			C0006681	Calcio carbonato
Lornoxicam	Pain	C0030193		Approved			C0055477	lornoxicam
Ambroxol	Sore Throat	C0242429		Approved			C0002421	Ambroxolum
Glycine betaine	Homocystinuria	C0019880		Approved			C0005304	betaína anhidra
Glycine betaine	Klebsiella cystitis	C0520775		Approved			C0005304	betaína anhidra
Glycine betaine	Escherichia coli urinary tract infection	C0577708		Approved			C0005304	betaína anhidra
Glycine betaine	Infective cystitis	C0600041		Approved			C0005304	betaína anhidra
Glycine betaine	Cystitis	C0010692		Approved			C0005304	betaína anhidra
Glycine betaine	PYELONEPHRITIS E COLI	C0748196		Approved			C0005304	betaína anhidra
Sacrosidase	Sucrase-isomaltase deficiency, congenital	C1283620		Approved			C0718043	Sacrosidase
Beractant	Respiratory Distress Syndrome, Newborn	C0035220		Approved			C0105750	Beractant
Tetryzoline	Rhinorrhea	C1260880		Approved			C0076286	4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole
Tetryzoline	Redness of eye	C0235267		Approved			C0076286	4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole
Tetryzoline	Nasal congestion (finding)	C0027424		Approved			C0076286	4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole
Alcaftadine	Allergic Conjunctivitis	C0009766		Approved			C2348241	Alcaftadinum
Ammonium chloride	Coughing	C0010200		Approved			C0002615	Ammonium chloride
Ammonium chloride	Nasal congestion (finding)	C0027424		Approved			C0002615	Ammonium chloride
Ammonium chloride	Common Cold	C0009443		Approved			C0002615	Ammonium chloride
Ammonium chloride	Rhinorrhea	C1260880		Approved			C0002615	Ammonium chloride
Ammonium lactate	Seborrheic dermatitis	C0036508		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Exanthema	C0015230		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Dry skin	C0151908		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Pruritus Ani	C0033775		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Contact Dermatitis	C0011616		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Pruritus	C0033774		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Pruritus of genital organs	C0033777		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Dermatitis, Atopic	C0011615		Approved			C0718495	Lactic acid ammonium salt
Ammonium lactate	Granuloma Annulare	C0085074		Approved			C0718495	Lactic acid ammonium salt
Bendamustine	Lymphoma, Follicular	C0024301		Approved			C0525079	Bendamustina
Bendamustine	Chronic Lymphocytic Leukemia	C0023434		Approved			C0525079	Bendamustina
Benzyl alcohol	Skin irritation	C0152030		Approved			C0005100	Alcool benzylique
Benzyl alcohol	Pruritus	C0033774		Approved			C0005100	Alcool benzylique
Besifloxacin	Bacterial conjunctivitis	C0009768		Approved			C2351042	Besifloxacin
Cabazitaxel	Metastatic Prostate Carcinoma	C0936223		Approved			C2830183	Cabazitaxelum
Capsaicin	Postherpetic neuralgia	C0032768		Approved			C0006931	Capsaicina
Capsaicin	Arthritic pains	C0857177		Approved			C0006931	Capsaicina
Capsaicin	Sprains and Strains	C0038048		Approved			C0006931	Capsaicina
Capsaicin	Neuralgia	C0027796		Approved			C0006931	Capsaicina
Capsaicin	Back Pain	C0004604		Approved			C0006931	Capsaicina
Chenodeoxycholic acid	Cholelithiasis	C0008350		Approved			C0008024	Acidum chenodeoxycholicum
Dimercaprol	Arsenic Poisoning	C0311375		Approved			C0012383	2,3-dimercaptol-1-propanol
Dimercaprol	Accidental poisoning by lead and its compounds and fumes	C0261486		Approved			C0012383	2,3-dimercaptol-1-propanol
Prussian blue	Thallium poisoning	C0238452		Approved			C0060234	Ferrocin
Halcinonide	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			C0018513	Halcinonid
Halcinonide	Lupus Erythematosus, Discoid	C0024138		Approved			C0018513	Halcinonid
Halcinonide	Lichen Simplex Chronicus	C0149922		Approved			C0018513	Halcinonid
Halcinonide	Seborrheic dermatitis	C0036508		Approved			C0018513	Halcinonid
Halcinonide	Exanthema	C0015230		Approved			C0018513	Halcinonid
Halcinonide	Contact Dermatitis	C0011616		Approved			C0018513	Halcinonid
Halcinonide	Pruritus Ani	C0033775		Approved			C0018513	Halcinonid
Halcinonide	Pruritus of genital organs	C0033777		Approved			C0018513	Halcinonid
Halcinonide	Dermatitis, Atopic	C0011615		Approved			C0018513	Halcinonid
Halcinonide	Granuloma Annulare	C0085074		Approved			C0018513	Halcinonid
Halcinonide	Chronic small plaque psoriasis	C0406317		Approved			C0018513	Halcinonid
Halcinonide	Scalp psoriasis	C0406326		Approved			C0018513	Halcinonid
Histrelin	Precocious Puberty	C0034013		Approved			C0121902	histrelinum
Lanreotide	Acromegaly	C0001206		Approved			C0209211	Lanreotida
Lanreotide	Hypersomatotropic gigantism	C0001207		Approved			C0209211	Lanreotida
Lodoxamide	Conjunctivitis, Vernal	C0009773		Approved			C0126120	Lodoxamida
Lodoxamide	Keratoconjunctivitis, Vernal	C0022577		Approved			C0126120	Lodoxamida
Hexamethylenetetramine	Urinary tract infection	C0042029		Approved			C0025638	Methenamine
Methylnaltrexone	Drug-induced constipation	C0267511		Approved			C0066411	MNTX
Niclosamide	Teniasis	C0039254		Approved			C0028017	Niclosamide
Niclosamide	Diphyllobothriasis	C0012561		Approved			C0028017	Niclosamide
Plerixafor	Multiple Myeloma	C0026764		Approved			C1955474	Plerixafor
Polidocanol	Varicosity	C0042345		Approved			C0071330	Polyoxyl 9 lauryl ether
Pralatrexate	Peripheral T-Cell Lymphoma	C0079774		Approved			C1721300	Pralatrexato
Raltegravir	HIV Infections	C0019693		Approved			C1871526	Raltegravir
Sodium phenylbutyrate	Carbamoyl-Phosphate Synthase I Deficiency Disease	C0751753		Approved			C0170531	γ-phenylbutyric acid
Sodium phenylbutyrate	Citrullinemia	C0175683		Approved			C0170531	γ-phenylbutyric acid
Sodium phenylbutyrate	Urea Cycle Disorders, Inborn	C0154246		Approved			C0170531	γ-phenylbutyric acid
Sulconazole	Tinea corporis (disorder)	C0040252		Approved			C0075503	Sulconazole
Sulconazole	Tinea Versicolor	C0040262		Approved			C0075503	Sulconazole
Sulconazole	Tinea Pedis	C0040259		Approved			C0075503	Sulconazole
Sulconazole	Tinea cruris	C1384589		Approved			C0075503	Sulconazole
Tiopronin	Cystinuria	C0010691		Approved			C0025405	Tioproninum
Triethylenetetramine	Renal Cell Carcinoma	C0007134		Approved			C0040976	Trientine
Triethylenetetramine	Hepatolenticular Degeneration	C0019202		Approved			C0040976	Trientine
Triethylenetetramine	Scalp psoriasis	C0406326		Approved			C0040976	Trientine
Triethylenetetramine	Chronic small plaque psoriasis	C0406317		Approved			C0040976	Trientine
Unoprostone	Ocular Hypertension	C0028840		Approved			C0772319	Unoprostone
Unoprostone	Glaucoma, Open-Angle	C0017612		Approved			C0772319	Unoprostone
Tranilast	Asthma	C0004096		Approved			C0146337	Tranilastum
Tranilast	Allergic rhinitis (disorder)	C2607914		Approved			C0146337	Tranilastum
Tranilast	Keloid	C0022548		Approved			C0146337	Tranilastum
Tranilast	Cicatrix, Hypertrophic	C0162810		Approved			C0146337	Tranilastum
Parecoxib	Acute postoperative pain	C2215257		Approved			C0915142	N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide
Diloxanide	Amebiasis	C0002438		Approved			CUI-less-DB08792	D
Azidocillin	Respiratory Tract Infections	C0035243		Approved			CUI-less-DB08795	A
Salicylamide	Back Pain	C0004604		Approved			C0036071	Salicilamida
Salicylamide	Headache Disorders	C0393735		Approved			C0036071	Salicilamida
Salicylamide	Arthralgia	C0003862		Approved			C0036071	Salicilamida
Salicylamide	Fever	C0015967		Approved			C0036071	Salicilamida
Salicylamide	Pain	C0030193		Approved			C0036071	Salicilamida
Antazoline	Rhinitis, Vasomotor	C0035460		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Symptomatic dermographism	C0343065		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Nasal congestion (finding)	C0027424		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Pruritus	C0033774		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Itching of eye	C0022281		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Sneezing	C0037383		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Rhinorrhea	C1260880		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Allergic Conjunctivitis	C0009766		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Redness of eye	C0235267		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Urticaria	C0042109		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Antazoline	Allergic rhinitis (disorder)	C2607914		Approved			C0003143	2-(N-Phenyl-N-benzylaminomethyl)imidazoline
Nandrolone decanoate	Anemia in chronic kidney disease	C1561828		Approved			C0068395	Nandrolone 17β-decanoate
Roxatidine acetate	Gastric ulcer	C0038358		Approved			C0073601	Roxatidine acetate
Roxatidine acetate	Gastroesophageal reflux disease	C0017168		Approved			C0073601	Roxatidine acetate
Roxatidine acetate	Zollinger-Ellison syndrome	C0043515		Approved			C0073601	Roxatidine acetate
Bupranolol	Glaucoma	C0017601		Approved			C0006403	Bupranolol
Bupranolol	Hypertensive disease	C0020538		Approved			C0006403	Bupranolol
Lurasidone	Schizophrenia	C0036341		Approved			C2003424	Lurasidonum
Lurasidone	Depression, Bipolar	C0005587		Approved			C2003424	Lurasidonum
Ticagrelor	Acute Coronary Syndrome	C0948089		Approved			C1999375	(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Ticagrelor	Peripheral Vascular Diseases	C0085096		Approved			C1999375	(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Tafluprost	Ocular Hypertension	C0028840		Approved			C1451502	Tafluprost
Tafluprost	Glaucoma, Open-Angle	C0017612		Approved			C1451502	Tafluprost
Ivacaftor	Pulmonary Cystic Fibrosis	C0392164		Approved			C3264621	Ivacaftorum
Azilsartan medoxomil	Hypertensive disease	C0020538		Approved			C2698291	Azilsartán medoxomilo
Spinosad	Pediculus capitis infestation	C0030757		Approved			C0961781	Spinosad
Deferiprone	beta Thalassemia	C0005283		Approved			C0043832	Deferiprona
Deferiprone	Iron Overload	C0282193		Approved			C0043832	Deferiprona
Lomitapide	Familial hypercholesterolemia - homozygous	C0342881		Approved			C2827241	Lomitapida
Vismodegib	Basal cell carcinoma	C0007117		Approved			C2987716	Vismodégib
Pitavastatin	Hyperlipidemia, Familial Combined	C0020474		Approved			C1101838	Pitavastatina
Pitavastatin	Hypercholesterolemia	C0020443		Approved			C1101838	Pitavastatina
Rilpivirine	HIV Infections	C0019693		Approved			C1566826	Rilpivirina
Ulipristal	Uterine Fibroids	C0042133		Approved			C0300205	Ulipristal
Fingolimod	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C1699926	Fingolimodum
Tesamorelin	Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy	C3854116		Approved			C1876200	N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet)
Brentuximab vedotin	Hodgkin Disease	C0019829		Approved			C2973446	Brentuximab vedotina
Brentuximab vedotin	Anaplastic large T-cell systemic malignant lymphoma	C1275317		Approved			C2973446	Brentuximab vedotina
Eribulin	Carcinoma breast stage IV	C0278488		Approved			C2350866	Eribulina
Eribulin	liposarcoma	C0023827		Approved			C2350866	Eribulina
gabapentin enacarbil	Postherpetic neuralgia	C0032768		Approved			C2700226	Gabapentine enacarbil
gabapentin enacarbil	Restless Legs Syndrome	C0035258		Approved			C2700226	Gabapentine enacarbil
Boceprevir	Hepatitis C, Chronic	C0524910		Approved			C1738934	Boceprevir
Fidaxomicin	Enterocolitis, Pseudomembranous	C0014358		Approved			C0065023	Fidaxomicina
Fidaxomicin	Clostridium difficile infection	C0343386		Approved			C0065023	Fidaxomicina
Fidaxomicin	Clostridium Infections	C0009062		Approved			C0065023	Fidaxomicina
Cabozantinib	Medullary carcinoma of thyroid	C0238462		Approved			C3181682	Cabozantinib
Cabozantinib	Renal Cell Carcinoma	C0007134		Approved			C3181682	Cabozantinib
Ruxolitinib	Myeloproliferative disease	C0027022		Approved			C2931926	Ruxolitinib
Ruxolitinib	Myelofibrosis	C0026987		Approved			C2931926	Ruxolitinib
Belimumab	Lupus Erythematosus, Systemic	C0024141		Approved			C1723401	Belimumab
Teriflunomide	Rheumatoid Arthritis	C0003873		Approved			C1718383	Teriflunomidum
Teriflunomide	Arthritis, Psoriatic	C0003872		Approved			C1718383	Teriflunomidum
Teriflunomide	Multiple Sclerosis	C0026769		Approved			C1718383	Teriflunomidum
Linagliptin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C2746078	(R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Aflibercept	Exudative age-related macular degeneration	C0271084		Approved			C1134659	Aflibercept (genetical recombination)
Aflibercept	Central retinal vein occlusion with macular edema	C0339498		Approved			C1134659	Aflibercept (genetical recombination)
Aflibercept	Branch retinal vein occlusion with macular edema	C0339507		Approved			C1134659	Aflibercept (genetical recombination)
Aflibercept	Diabetic macular edema	C0730285		Approved			C1134659	Aflibercept (genetical recombination)
Aflibercept	Metastasis from malignant tumor of colon	C1282500		Approved			C1134659	Aflibercept (genetical recombination)
Icosapent ethyl	Hypertriglyceridemia	C0020557		Approved			C1565135	ethyl-eicosapentaenoic acid
Ocriplasmin	Vitreomacular traction syndrome	C0730274		Approved			C0066522	Ocriplasmina
Carfilzomib	Multiple Myeloma	C0026764		Approved			C2001856	Carfilzomib
Linaclotide	Irritable bowel syndrome characterized by constipation	C1868889		Approved			C2000261	Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (disulfide bridge: 1-6; 2-10; 5-13)
Linaclotide	Chronic idiopathic constipation	C0267509		Approved			C2000261	Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (disulfide bridge: 1-6; 2-10; 5-13)
Linaclotide	Irritable Bowel Syndrome	C0022104		Approved			C2000261	Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (disulfide bridge: 1-6; 2-10; 5-13)
Mirabegron	Bladder muscle dysfunction - overactive	C0403643		Approved			C2983812	Mirabegron
Peginesatide	Anemia in chronic kidney disease	C1561828		Approved			C1710272	Hematide
Tofacitinib	Rheumatoid Arthritis	C0003873		Approved			C2930696	Tofacitinibum
Regorafenib	Metastasis from malignant tumor of colon	C1282500		Approved			C2980094	Régorafénib
Regorafenib	Gastrointestinal Stromal Tumors	C0238198		Approved			C2980094	Régorafénib
Aclidinium	Chronic Obstructive Airway Disease	C0024117		Approved			C2699757	Aclidinio
Enzalutamide	Malignant neoplasm of prostate	C0376358		Approved			C3496793	Enzalutamida
Teduglutide	Short Bowel Syndrome	C0036992		Approved			C1530889	Teduglutida
Ponatinib	Myeloid Leukemia, Chronic	C0023473		Approved			C2987417	Ponatinibum
Ponatinib	Philadelphia chromosome-positive acute lymphoblastic leukemia	C1960397		Approved			C2987417	Ponatinibum
Raxibacumab	Inhalational anthrax	C0155866		Approved			C4305879	PA mAb
Bedaquiline	Tuberculosis, Pulmonary	C0041327		Approved			C1664205	Bédaquiline
Bedaquiline	Tuberculosis, Drug-Resistant	C0206525		Approved			C1664205	Bédaquiline
Certolizumab pegol	Crohn Disease	C0010346		Approved			C1872109	Certolizumab pegol
Certolizumab pegol	Rheumatoid Arthritis	C0003873		Approved			C1872109	Certolizumab pegol
Certolizumab pegol	Arthritis, Psoriatic	C0003872		Approved			C1872109	Certolizumab pegol
Certolizumab pegol	Ankylosing spondylitis	C0038013		Approved			C1872109	Certolizumab pegol
Formestane	Malignant epithelial neoplasm of female breast	C3163805		Approved			C0048306	Formestano
Fluticasone furoate	Allergic rhinitis (disorder)	C2607914		Approved			C1948374	Furoate de fluticasone
Fluticasone furoate	Asthma	C0004096		Approved			C1948374	Furoate de fluticasone
Canagliflozin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C2974540	Canagliflozina
Dimethyl fumarate	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C0058218	1,2-bis(methoxycarbonyl)-trans-ethylene
Glycerol Phenylbutyrate	Urea Cycle Disorders, Inborn	C0154246		Approved			C3490329	Glycerol phenylbutyrate
Pomalidomide	Multiple Myeloma	C0026764		Approved			C2347624	Pomalidomida
Trametinib	Malignant melanoma, metastatic	C0860594		Approved			C2697961	Tramétinib
Dabrafenib	Malignant melanoma, metastatic	C0860594		Approved			C3467876	Dabrafenib
Radium Ra 223 Dichloride	Malignant neoplasm of prostate	C0376358		Approved			C3541342	Radium chloride Ra-223
Afatinib	Epidermal growth factor receptor positive non-small cell lung cancer	C1960925		Approved			C2987648	Afatinibum
Ferric Carboxymaltose	Iron deficiency anemia	C0162316		Approved			C2001867	Ferric carboxymaltose
Levomilnacipran	Major Depressive Disorder	C1269683		Approved			C3541367	(1S,2R)-milnacipran
Perospirone	Schizophrenia	C0036341		Approved			CUI-less-DB08922	P
Epoetin Zeta	Anemia in chronic kidney disease	C1561828		Approved			CUI-less-DB08923	E
Dolutegravir	HIV Infections	C0019693		Approved			C3253985	Dolutegravir
Riociguat	Chronic thromboembolic pulmonary hypertension	C2363973		Approved			C2717561	Riociguatum
Riociguat	Pulmonary arterial hypertension	C2973725		Approved			C2717561	Riociguatum
Macitentan	Pulmonary arterial hypertension	C2973725		Approved			C2606556	Macitentán
Luliconazole	Tinea Pedis	C0040259		Approved			C1956280	Luliconazole
Luliconazole	Tinea cruris	C1384589		Approved			C1956280	Luliconazole
Luliconazole	Tinea corporis (disorder)	C0040252		Approved			C1956280	Luliconazole
Sofosbuvir	Hepatitis C, Chronic	C0524910		Approved			C2976303	S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate
Obinutuzumab	Chronic Lymphocytic Leukemia	C0023434		Approved			C2742503	Afutuzumab
Chlorcyclizine	Common Cold	C0009443		Approved			C0008183	Clorciclicina
Chlorcyclizine	Hay fever	C0018621		Approved			C0008183	Clorciclicina
Chlorcyclizine	Rhinorrhea	C1260880		Approved			C0008183	Clorciclicina
Chlorcyclizine	Allergic Conjunctivitis	C0009766		Approved			C0008183	Clorciclicina
Chlorcyclizine	Allergic rhinitis (disorder)	C2607914		Approved			C0008183	Clorciclicina
Chlorcyclizine	Sneezing	C0037383		Approved			C0008183	Clorciclicina
Chlorcyclizine	Nasal congestion (finding)	C0027424		Approved			C0008183	Clorciclicina
Chlorcyclizine	Coughing	C0010200		Approved			C0008183	Clorciclicina
Chlorcyclizine	Rhinitis, Vasomotor	C0035460		Approved			C0008183	Clorciclicina
Isoxsuprine	Vascular Diseases	C0042373		Approved			C0022267	Isoxsuprine
Isoxsuprine	Cerebrovascular Disorders	C0007820		Approved			C0022267	Isoxsuprine
Isoxsuprine	Raynaud Disease	C0034734		Approved			C0022267	Isoxsuprine
Floctafenine	Acute onset pain	C0184567		Approved			C0016245	Floctafenine
Etofenamate	Degenerative polyarthritis	C0029408		Approved			CUI-less-DB08984	E
Enviomycin	Tuberculosis, Pulmonary	C0041327		Approved			CUI-less-DB08993	E
Demexiptiline	Depressive disorder	C0011581		Approved			CUI-less-DB08998	D
Captodiame	Anxiety Disorders	C0003469		Approved			CUI-less-DB09014	C
Butriptyline	Depressive disorder	C0011581		Approved			C0054270	(±)-3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)-N,N,2-trimethylpropan-1-amine
Bisacodyl	Incomplete passage of stool	C0426639		Approved			C0005632	Bisacodyle
Bisacodyl	Constipation	C0009806		Approved			C0005632	Bisacodyle
Aliskiren	Hypertensive disease	C0020538		Approved			C1120110	Aliskireno
Ledipasvir	Hepatitis C, Chronic	C0524910		Approved			C3851350	methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate
Secukinumab	Chronic small plaque psoriasis	C0406317		Approved			C3179547	Secukinumab
Vorapaxar	Cerebrovascular accident	C0038454		Approved			C2974521	[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle
Miltefosine	Leishmaniasis, Visceral	C0023290		Approved			C0068006	Miltefosina
Miltefosine	Leishmaniasis, Cutaneous	C0023283		Approved			C0068006	Miltefosina
Miltefosine	Mucocutaneous leishmaniasis	C1328252		Approved			C0068006	Miltefosina
Vedolizumab	Ulcerative Colitis	C0009324		Approved			C2742797	Vedolizumab
Vedolizumab	Crohn Disease	C0010346		Approved			C2742797	Vedolizumab
Suvorexant	Sleeplessness	C0917801		Approved			C3179535	Suvorexant
Nivolumab	Malignant melanoma, metastatic	C0860594		Approved			C3657270	Nivolumab
Nivolumab	Squamous cell carcinoma of lung	C0149782		Approved			C3657270	Nivolumab
Nivolumab	Non-Small Cell Lung Carcinoma	C0007131		Approved			C3657270	Nivolumab
Nivolumab	Metastatic Renal Cell Cancer	C0278678		Approved			C3657270	Nivolumab
Siltuximab	Angiolymphoid hyperplasia	C0017531		Approved			C1609931	Siltuximab
Pembrolizumab	Malignant melanoma, metastatic	C0860594		Approved			C3658706	Lambrolizumab
Pembrolizumab	Non-Small Cell Lung Carcinoma	C0007131		Approved			C3658706	Lambrolizumab
Empagliflozin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C3490348	Empagliflozina
Eliglustat	Gaucher Disease	C0017205		Approved			C3272698	N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide
Efinaconazole	Onychomycosis of toenails	C1274470		Approved			C3273754	efinaconazol
Efinaconazole	Onychomycosis due to Trichophyton mentagrophytes	C0276755		Approved			C3273754	efinaconazol
Efinaconazole	Onychomycosis	C0040261		Approved			C3273754	efinaconazol
Tavaborole	Onychomycosis of toenails	C1274470		Approved			C3642427	5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
Tavaborole	Onychomycosis due to Trichophyton mentagrophytes	C0276755		Approved			C3642427	5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
Tavaborole	Onychomycosis due to Trichophyton rubrum	C0276754		Approved			C3642427	5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
Tedizolid Phosphate	Staphylococcal Skin Infections	C0038166		Approved			C2930762	Tedizolid phosphate
Tedizolid Phosphate	Skin Diseases, Bacterial	C0162627		Approved			C2930762	Tedizolid phosphate
Tedizolid Phosphate	Streptococcal infection of skin	C1274355		Approved			C2930762	Tedizolid phosphate
Albiglutide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C2607479	Albiglutida
Dulaglutide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C3179549	Dulaglutida
Metreleptin	Familial generalized lipodystrophy	C0221032		Approved			C0961965	Métréleptine
Metreleptin	Acquired generalized lipodystrophy	C0271693		Approved			C0961965	Métréleptine
Metreleptin	Acquired partial lipodystrophy	C0220989		Approved			C0961965	Métréleptine
Finafloxacin	Acute otitis externa	C0149948		Approved			C2825286	Finafloxacin
Netupitant	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C1700730	2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide
Naloxegol	Drug-induced constipation	C0267511		Approved			C3700399	Naloxegol
Ceftolozane	Urinary tract infection	C0042029		Approved			C3852726	ceftolozano
Ceftolozane	Intraabdominal Infections	C1112209		Approved			C3852726	ceftolozano
Elosulfase alfa	Mucopolysaccharidosis, MPS-IV-A	C0086651		Approved			C0700083	N-acetylgalactosamine-6-sulfatase
Blinatumomab	Pre B-cell acute lymphoblastic leukemia	C0349636		Approved			C3853839	Blinatumomab
Ibrutinib	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634		Approved			C3501358	Ibrutinib
Ibrutinib	Chronic Lymphocytic Leukemia	C0023434		Approved			C3501358	Ibrutinib
Ibrutinib	Waldenstrom Macroglobulinemia	C0024419		Approved			C3501358	Ibrutinib
Idelalisib	Chronic Lymphocytic Leukemia	C0023434		Approved			C2698692	Idelalisib
Idelalisib	Lymphoma, Follicular	C0024301		Approved			C2698692	Idelalisib
Idelalisib	Small Lymphocytic Lymphoma	C0855095		Approved			C2698692	Idelalisib
Avibactam	Pyelonephritis	C0034186		Approved			C3489748	Avibactam
Avibactam	Intraabdominal Infections	C1112209		Approved			C3489748	Avibactam
Cobicistat	HIV Infections	C0019693		Approved			C3177235	Cobicistat
Vortioxetine	Major Depressive Disorder	C1269683		Approved			C3661282	Vortioxétine
Tasimelteon	Non-24 hour sleep-wake cycle	C0393772		Approved			C1313052	tasimeltéon
Sodium oxybate	Narcolepsy-Cataplexy Syndrome	C0751362		Approved			C0037537	Oxybate sodium
Sodium oxybate	Narcolepsy	C0027404		Approved			C0037537	Oxybate sodium
Palbociclib	Human epidermal growth factor 2 negative carcinoma of breast	C2316304		Approved			C3853822	Palbociclib
Olaparib	Malignant tumor of peritoneum	C0153467		Approved			C2316164	Olaparib
Olaparib	Malignant neoplasm of ovary	C1140680		Approved			C2316164	Olaparib
Olaparib	Epithelial tumor of ovary	C0341823		Approved			C2316164	Olaparib
Edoxaban	Pulmonary Embolism	C0034065		Approved			C2975435	Edoxaban
Edoxaban	Embolism	C0013922		Approved			C2975435	Edoxaban
Umeclidinium	Chronic Obstructive Airway Disease	C0024117		Approved			C3661274	Umeclidinium
Dinutuximab	Neuroblastoma	C0027819		Approved			C4722567	Dinutuximab beta
Lenvatinib	Follicular thyroid carcinoma	C0206682		Approved			C2986924	Lenvatinib
Lenvatinib	Papillary thyroid carcinoma	C0238463		Approved			C2986924	Lenvatinib
Nintedanib	Hamman-Rich syndrome	C0085786		Approved			C2930789	Nintedanib
Nintedanib	Non-Small Cell Lung Carcinoma	C0007131		Approved			C2930789	Nintedanib
Olodaterol	Chronic Obstructive Airway Disease	C0024117		Approved			C2934193	Olodaterol
Idebenone	Optic Atrophy, Hereditary, Leber	C0917796		Approved			C0123163	idebenona
Vilanterol	Bronchitis, Chronic	C0008677		Approved			C2935023	Vilanterolum
Vilanterol	Pulmonary Emphysema	C0034067		Approved			C2935023	Vilanterolum
Vilanterol	Chronic Obstructive Airway Disease	C0024117		Approved			C2935023	Vilanterolum
Vilanterol	Asthma	C0004096		Approved			C2935023	Vilanterolum
Ivabradine	Chronic heart failure	C0264716		Approved			C0257190	Ivabradinum
Benzydamine	Pain	C0030193		Approved			C0005099	bencidamina
Tetracaine	Pruritus	C0033774		Approved			C0039629	Tétracane
Tetracaine	Skin irritation	C0152030		Approved			C0039629	Tétracane
Potassium alum	Heartburn	C0018834		Approved			C0725101	Burnt potassium alum
Potassium alum	Dyspepsia	C0013395		Approved			C0725101	Burnt potassium alum
Potassium alum	Peptic Ulcer	C0030920		Approved			C0725101	Burnt potassium alum
Potassium alum	Gastroesophageal reflux disease	C0017168		Approved			C0725101	Burnt potassium alum
Chlortetracycline	Ophthalmia Neonatorum	C0029076		Approved			C0008293	clortetraciclina
Chlortetracycline	Trachoma	C0040592		Approved			C0008293	clortetraciclina
Benzoyl peroxide	Seborrheic dermatitis	C0036508		Approved			C0005088	Peróxido de benzoilo
Benzoyl peroxide	Acne Vulgaris	C0001144		Approved			C0005088	Peróxido de benzoilo
Benzoyl peroxide	Exanthema	C0015230		Approved			C0005088	Peróxido de benzoilo
Benzoyl peroxide	Granuloma Annulare	C0085074		Approved			C0005088	Peróxido de benzoilo
Benzoyl peroxide	Pruritus of genital organs	C0033777		Approved			C0005088	Peróxido de benzoilo
Benzoyl peroxide	Contact Dermatitis	C0011616		Approved			C0005088	Peróxido de benzoilo
Benzoyl peroxide	Pruritus Ani	C0033775		Approved			C0005088	Peróxido de benzoilo
Elvitegravir	HIV Infections	C0019693		Approved			C1700388	GS 9137
Daclatasvir	Hepatitis C, Chronic	C0524910		Approved			C2933824	BMS-790052
Magnesium hydroxide	Constipation	C0009806		Approved			C0024476	Magnesio hidróxido
Magnesium hydroxide	Incomplete passage of stool	C0426639		Approved			C0024476	Magnesio hidróxido
Magnesium hydroxide	Peptic Ulcer	C0030920		Approved			C0024476	Magnesio hidróxido
Magnesium hydroxide	Dyspepsia	C0013395		Approved			C0024476	Magnesio hidróxido
Magnesium hydroxide	Gastroesophageal reflux disease	C0017168		Approved			C0024476	Magnesio hidróxido
Magnesium hydroxide	Heartburn	C0018834		Approved			C0024476	Magnesio hidróxido
Asfotase Alfa	Hypophosphatasia	C0020630		Approved			C3490795	Asfotase alfa
Methoxy polyethylene glycol-epoetin beta	Anemia in chronic kidney disease	C1561828		Approved			C1328071	Pegzerepoetin alfa
Turoctocog alfa	Hemophilia A	C0019069		Approved			C3529563	Turoctocog alfa
Mesna	Testicular Germ Cell Tumor	C1336708		Approved			C0206008	reduced CoM
Sodium Nitrite	Toxic effect of cyanide	C0238080		Approved			C0028214	nitrosyl hydroxide
Poractant alfa	Respiratory Distress Syndrome, Newborn	C0035220		Approved			C0771648	Poractant alfa
Colfosceril palmitate	Respiratory Distress Syndrome, Newborn	C0035220		Approved			C0216971	Palmitato de colfoscerilo
Diiodohydroxyquinoline	Amebiasis	C0002438		Approved			C4292381	Ioquin
Stiripentol	Epilepsies, Myoclonic	C0014550		Approved			C0075262	Stiripentolum
Stiripentol	Infantile Severe Myoclonic Epilepsy	C0751122		Approved			C0075262	Stiripentolum
Peginterferon beta-1a	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			C3848580	Peginterferon beta-1a
Potassium Citrate	Hypokalemia	C0020621		Approved			C0137996	tripotassium citrate
Potassium Citrate	Calcium renal calculus	C1959799		Approved			C0137996	tripotassium citrate
Potassium Citrate	Renal tubular acidosis	C0001126		Approved			C0137996	tripotassium citrate
Potassium Citrate	RENAL CALCULUS CALCIUM OXALATE	C0748267		Approved			C0137996	tripotassium citrate
Potassium Citrate	Uric acid renal calculus	C0558595		Approved			C0137996	tripotassium citrate
Disodium phosphate	Constipation	C0009806		Approved			CUI-less-DB09127	D
Brexpiprazole	Schizophrenia	C0036341		Approved			C3885614	Brexpiprazole
Brexpiprazole	Major Depressive Disorder	C1269683		Approved			C3885614	Brexpiprazole
Protamine sulfate	Heparin overdose	C0573789		Approved			C0033602	Protamine sulfate
Sonidegib	Basal cell carcinoma	C0007117		Approved			C3886731	Sonidegib
Uridine triacetate	Hereditary orotic aciduria	C0220987		Approved			C0281351	2',3',5'-Triacetyluridine
Uridine triacetate	Antimetabolite overdose	C0572583		Approved			C0281351	2',3',5'-Triacetyluridine
Sucroferric Oxyhydroxide	Hyperphosphatemia (disorder)	C0085681		Approved			C0060241	Iron(III) hydroxide sucrose complex
Nitrogen	Persistent Fetal Circulation Syndrome	C0031190		Approved			C0028158	Nitrogen
Sodium Citrate	Common Cold	C0009443		Approved			C0142825	Sodium citrate
Sodium Citrate	Peptic Ulcer	C0030920		Approved			C0142825	Sodium citrate
Sodium Citrate	Gastroesophageal reflux disease	C0017168		Approved			C0142825	Sodium citrate
Sodium Citrate	Dyspepsia	C0013395		Approved			C0142825	Sodium citrate
Sodium Citrate	Coughing	C0010200		Approved			C0142825	Sodium citrate
Sodium Citrate	Rhinitis	C0035455		Approved			C0142825	Sodium citrate
Sodium Citrate	Heartburn	C0018834		Approved			C0142825	Sodium citrate
Sodium Citrate	Nasal congestion (finding)	C0027424		Approved			C0142825	Sodium citrate
Sodium Citrate	Rhinorrhea	C1260880		Approved			C0142825	Sodium citrate
Ferric Citrate	Hyperphosphatemia (disorder)	C0085681		Approved			CUI-less-DB09162	F
Etizolam	Anxiety	C0003467		Approved			CUI-less-DB09166	E
Dosulepin	Major Depressive Disorder	C1269683		Approved			C0013065	Dosulépine
Dasabuvir	Hepatitis C, Chronic	C0524910		Approved			C3852512	Sodium 3-(3-tert-butyl-4-methoxy-5-{6- [(methylsulfonyl)amino]naphthalene-2-yl}phenyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-ide hydrate (1:1:1)
Viloxazine	Narcolepsy-Cataplexy Syndrome	C0751362		Approved			C0042665	Viloxazinum
Lobeglitazone	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CUI-less-DB09198	L
Moxisylyte	Erectile dysfunction	C0242350		Approved			C0040108	Moxisylyte
Moxisylyte	Raynaud Disease	C0034734		Approved			C0040108	Moxisylyte
Loxoprofen	Rheumatoid Arthritis	C0003873		Approved			C0065199	loxoprofeno
Dexibuprofen	Headache Disorders	C0393735		Approved			C2714681	Dexibuprofeno
Dexibuprofen	Pain	C0030193		Approved			C2714681	Dexibuprofeno
Dexibuprofen	Fever	C0015967		Approved			C2714681	Dexibuprofeno
Dexibuprofen	Degenerative polyarthritis	C0029408		Approved			C2714681	Dexibuprofeno
Dexibuprofen	Rheumatoid Arthritis	C0003873		Approved			C2714681	Dexibuprofeno
Dexibuprofen	Dysmenorrhea	C0013390		Approved			C2714681	Dexibuprofeno
Polaprezinc	Peptic Ulcer	C0030920		Approved			CUI-less-DB09221	P
Blonanserin	Schizophrenia	C0036341		Approved			C0287983	Blonanserin
Conestat alfa	Hereditary C1 esterase inhibitor deficiency - deficient factor	C0398775		Approved			C3195420	Recombinant human C1 inhibitor
Aranidipine	Hypertensive disease	C0020538		Approved			CUI-less-DB09229	A
Azelnidipine	Hypertensive disease	C0020538		Approved			C0753287	Azelnidipine
Efonidipine	Hypertensive disease	C0020538		Approved			CUI-less-DB09235	E
Pirlindole	Depressive disorder	C0011581		Approved			CUI-less-DB09244	P
Toloxatone	Depressive disorder	C0011581		Approved			CUI-less-DB09245	T
Tegafur	Malignant neoplasm of stomach	C0024623		Approved			C0016778	1-(2-Tetrahydrofuryl)-5-fluorouracil
Gimeracil	Malignant neoplasm of stomach	C0024623		Approved			C0535459	5-Chloro-4-hydroxy-2-pyridone
Bemiparin	Pulmonary Embolism	C0034065		Approved			C0916062	Bemiparin
Bemiparin	Deep Vein Thrombosis	C0149871		Approved			C0916062	Bemiparin
Imidafenacin	Bladder muscle dysfunction - overactive	C0403643		Approved			C1876226	Imidafenacin
Patiromer	Hyperkalemia	C0020461		Approved			C4045522	Patiromer FOS
Idarucizumab	Drug-induced coagulation inhibitor disorder	C0272373		Approved			C3885063	aDabi-Fab
Lixisenatide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			C2973895	L-histidylglycyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysinamide
Strontium ranelate	Osteoporosis, Postmenopausal	C0029458		Approved			C0936139	Strontium ranelate
Phenylacetic acid	Hyperammonemia	C0220994		Approved			C0070620	ω-phenylacetic acid
Eluxadoline	Irritable bowel syndrome with diarrhea	C0348898		Approved			C3712232	5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
Eluxadoline	Diarrhoea predominant irritable bowel syndrome	C1262211		Approved			C3712232	5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
Artesunate	Malaria, Falciparum	C0024535		Approved			C0052432	artesunato
Sodium aurothiomalate	Rheumatoid Arthritis	C0003873		Approved			C0018034	Natrii aurothiomalas
Fimasartan	Hypertensive disease	C0020538		Approved			C2825622	Fimasartan
Magnesium Trisilicate	Dyspepsia	C0013395		Approved			C0065533	Magnesium trisilicate
Magnesium Trisilicate	Peptic Ulcer	C0030920		Approved			C0065533	Magnesium trisilicate
Magnesium Trisilicate	Gastroesophageal reflux disease	C0017168		Approved			C0065533	Magnesium trisilicate
Magnesium Trisilicate	Heartburn	C0018834		Approved			C0065533	Magnesium trisilicate
Polyethylene glycol	Incomplete passage of stool	C0426639		Approved			C0032483	Polyethylene glycol
Polyethylene glycol	Dry Eye Syndromes	C0013238		Approved			C0032483	Polyethylene glycol
Polyethylene glycol	Redness of eye	C0235267		Approved			C0032483	Polyethylene glycol
Polyethylene glycol	Constipation	C0009806		Approved			C0032483	Polyethylene glycol
Ramosetron	Irritable bowel syndrome with diarrhea	C0348898		Approved			C0526950	Ramosetron
Ramosetron	Diarrhoea predominant irritable bowel syndrome	C1262211		Approved			C0526950	Ramosetron
Rolapitant	Chemotherapy-induced nausea and vomiting	C0401160		Approved			C3273719	Rolapitant
Sacubitril	Chronic heart failure	C0264716		Approved			C4033447	Sacubitrilo
Sodium Iodide I-131	Hyperthyroidism	C0020550		Approved			C0303029	iodine I-131
Ombitasvir	Hepatitis C, Chronic	C0524910		Approved			C3852670	dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
Paritaprevir	Hepatitis C, Chronic	C0524910		Approved			C3864824	(2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
Tenofovir alafenamide	HIV Infections	C0019693		Approved			C3713958	Tenofovir alafenamide
Scopolamine butylbromide	Gastric spasm (disorder)	C0581358		Approved			C2827093	butilescopolamina
Alirocumab	Hypercholesterolemia	C0020443		Approved			C3491162	Alirocumab
Alirocumab	Complex dyslipidemia	C3875286		Approved			C3491162	Alirocumab
Alirocumab	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C3491162	Alirocumab
Alirocumab	Atherosclerosis	C0004153		Approved			C3491162	Alirocumab
Evolocumab	Hypercholesterolemia	C0020443		Approved			C3529352	Evolocumab
Evolocumab	Complex dyslipidemia	C3875286		Approved			C3529352	Evolocumab
Evolocumab	Familial hypercholesterolemia - heterozygous	C0342882		Approved			C3529352	Evolocumab
Evolocumab	Familial hypercholesterolemia - homozygous	C0342881		Approved			C3529352	Evolocumab
Coagulation Factor XIII A-Subunit (Recombinant)	Hereditary factor XIII A subunit deficiency	C2584877		Approved			C3709760	Catridecacog
Procaine benzylpenicillin	Gingivostomatitis	C0149704		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Streptococcal tonsillitis	C0275804		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Syphilis, tertiary	C0153188		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Pharyngitis	C0031350		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Syphilis, secondary	C0149985		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Acute otitis media	C0271429		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Streptococcal Infections	C0038395		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Fusospirochetal pharyngitis	C1318559		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Syphilis, Latent	C0039133		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Streptococcal endocarditis	C3665800		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Scarlet Fever	C0036285		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Neurosyphilis	C0027927		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Bejel	C0004945		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Streptococcus pyogenes infection	C0554628		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Streptococcal pneumonia	C0155862		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Primary genital syphilis	C0017418		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Rat-Bite Fever	C0034686		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Anthrax disease	C0003175		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Syphilis, Congenital	C0039131		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Pinta	C0031946		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Yaws	C0043388		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Erysipelas	C0014733		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Syphilis	C0039128		Approved			C0030830	Bencilpenicilina procaína
Procaine benzylpenicillin	Staphylococcus aureus infection	C1318973		Approved			C0030830	Bencilpenicilina procaína
Zinc oxide	Exanthema	C0015230		Approved			C0043491	Zinc óxido
Zinc oxide	Tinea Versicolor	C0040262		Approved			C0043491	Zinc óxido
Zinc oxide	Skin irritation	C0152030		Approved			C0043491	Zinc óxido
Zinc oxide	Arthropod bite wound	C1444173		Approved			C0043491	Zinc óxido
Zinc oxide	Tinea cruris	C1384589		Approved			C0043491	Zinc óxido
Zinc oxide	Tinea corporis (disorder)	C0040252		Approved			C0043491	Zinc óxido
Zinc oxide	Cutaneous Candidiasis	C0006846		Approved			C0043491	Zinc óxido
Zinc oxide	Pruritus	C0033774		Approved			C0043491	Zinc óxido
Zinc oxide	Pruritus Ani	C0033775		Approved			C0043491	Zinc óxido
Zinc oxide	Burn injury	C0006434		Approved			C0043491	Zinc óxido
Zinc oxide	Hemorrhoids	C0019112		Approved			C0043491	Zinc óxido
Zinc oxide	Diaper Rash	C0011974		Approved			C0043491	Zinc óxido
Zinc oxide	Injury wounds	C0043250		Approved			C0043491	Zinc óxido
Zinc oxide	Proctitis	C0033246		Approved			C0043491	Zinc óxido
Zinc oxide	Rectal pain	C0034886		Approved			C0043491	Zinc óxido
Zinc oxide	Tinea Pedis	C0040259		Approved			C0043491	Zinc óxido
Zinc sulfate	Redness of eye	C0235267		Approved			C2700331	Zinc sulfate anhydrous
Zinc sulfate	Zinc deficiency	C0235950		Approved			C2700331	Zinc sulfate anhydrous
Benzathine benzylpenicillin	Erysipelas	C0014733		Approved			CUI-less-DB09323	Benzathine benzylpenicillin
Benzathine benzylpenicillin	Scarlet Fever	C0036285		Approved			CUI-less-DB09323	Benzathine benzylpenicillin
Benzathine benzylpenicillin	Streptococcal pneumonia	C0155862		Approved			CUI-less-DB09323	Benzathine benzylpenicillin
Benzathine benzylpenicillin	Streptococcus pyogenes infection	C0554628		Approved			CUI-less-DB09323	Benzathine benzylpenicillin
Benzathine benzylpenicillin	Streptococcal Infections	C0038395		Approved			CUI-less-DB09323	Benzathine benzylpenicillin
Sulbactam	Intraabdominal Infections	C1112209		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Rhinoscleroma	C0035468		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Infection of skin AND/OR subcutaneous tissue	C0178299		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Female genital tract infection	C1263758		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Staphylococcus aureus infection	C1318973		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Bacterial peritonitis	C0341503		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Cholangitis	C0008311		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Pelvic Inflammatory Disease	C0242172		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Enterobacteriaceae Infections	C0014347		Approved			C0038665	Penicillanic acid sulfone
Sulbactam	Escherichia coli Infections	C0014836		Approved			C0038665	Penicillanic acid sulfone
Sodium fluoride	Vitamin Deficiency	C1510471		Approved			C0037508	Sodium fluoride
Osimertinib	Epidermal growth factor receptor positive non-small cell lung cancer	C1960925		Approved			C4058811	Osimertinibum
Daratumumab	Multiple Myeloma	C0026764		Approved			C2346801	Daratumumab
Kappadione	Jaundice, Obstructive	C0022354		Approved			C0127514	Menadiol sodium diphosphate
Tipiracil	Malignant tumor of colon	C0007102		Approved			C4056441	Tipiracilo
Pramocaine	Pruritus	C0033774		Approved			C0071810	Pramocaína
Pramocaine	Skin irritation	C0152030		Approved			C0071810	Pramocaína
Pramocaine	Tinea cruris	C1384589		Approved			C0071810	Pramocaína
Pramocaine	Proctitis	C0033246		Approved			C0071810	Pramocaína
Pramocaine	Injury wounds	C0043250		Approved			C0071810	Pramocaína
Pramocaine	Rectal pain	C0034886		Approved			C0071810	Pramocaína
Pramocaine	Arthropod bite wound	C1444173		Approved			C0071810	Pramocaína
Pramocaine	Otitis Externa	C0029878		Approved			C0071810	Pramocaína
Pramocaine	Tinea Pedis	C0040259		Approved			C0071810	Pramocaína
Pramocaine	Pruritus Ani	C0033775		Approved			C0071810	Pramocaína
Pramocaine	Exanthema	C0015230		Approved			C0071810	Pramocaína
Pramocaine	Dry skin	C0151908		Approved			C0071810	Pramocaína
Pramocaine	Tinea corporis (disorder)	C0040252		Approved			C0071810	Pramocaína
Pramocaine	Burn injury	C0006434		Approved			C0071810	Pramocaína
Pramocaine	Hemorrhoids	C0019112		Approved			C0071810	Pramocaína
Pramocaine	Itching of ear	C0849907		Approved			C0071810	Pramocaína
Pramocaine	Inflammatory dermatosis	C3875321		Approved			C0071810	Pramocaína
Pramocaine	Allergic otitis externa	C1320547		Approved			C0071810	Pramocaína
Piperonyl butoxide	Pediculus capitis infestation	C0030757		Approved			C0031962	Piperonyl butoxide
Piperonyl butoxide	Infestation by Phthirus pubis	C0030759		Approved			C0031962	Piperonyl butoxide
Piperonyl butoxide	Body louse infestation	C0030758		Approved			C0031962	Piperonyl butoxide
Levobetaxolol	Glaucoma, Open-Angle	C0017612		Approved			C1171274	levobetaxolol
Levobetaxolol	Ocular Hypertension	C0028840		Approved			C1171274	levobetaxolol
Hydroxyamphetamine hydrobromide	Mydriasis	C0026961		Approved			C0030140	Hydroxyamphetamine
Sulfur	Necrotizing Ulcerative Gingivitis	C0017575		Approved			C4731450	Octasulfur
Sulfur	Acne Vulgaris	C0001144		Approved			C4731450	Octasulfur
Sulfur	Acneiform Eruptions	C0175167		Approved			C4731450	Octasulfur
Sulfur	Greasy skin	C0234925		Approved			C4731450	Octasulfur
Sulfur	Aphthous Stomatitis	C0038363		Approved			C4731450	Octasulfur
Sulfur	Seborrheic dermatitis	C0036508		Approved			C4731450	Octasulfur
Sulfur	Scurfiness of scalp	C0423775		Approved			C4731450	Octasulfur
Dexpanthenol	Dermatologic disorders	C0037274		Approved			C0057610	Dexpantenol
Dexpanthenol	Diaper Rash	C0011974		Approved			C0057610	Dexpantenol
Dexpanthenol	Gastroparesis	C0152020		Approved			C0057610	Dexpantenol
Dexpanthenol	Paralytic Ileus	C0030446		Approved			C0057610	Dexpantenol
Dexpanthenol	Contact dermatitis due to Rhus diversiloba	C0263283		Approved			C0057610	Dexpantenol
Dexpanthenol	Eczema	C0013595		Approved			C0057610	Dexpantenol
Dexpanthenol	Arthropod bite wound	C1444173		Approved			C0057610	Dexpantenol
Norgestrel	Menorrhagia	C0025323		Approved			C0028368	Norgestrelum
Norgestrel	Hot flushes	C0600142		Approved			C0028368	Norgestrelum
Propoxyphene napsylate	Pain	C0030193		Approved			CUI-less-DB09396	P
Magnesium chloride	Hypomagnesemia	C0151723		Approved			C2698003	Magnesium chloride anhydrous
Sodium phosphate	Constipation	C0009806		Approved			C0770578	Sodium phosphate, monobasic
Glycerin	Constipation	C0009806		Approved			C0017861	glycérine
Sodium phosphate, dibasic, heptahydrate	Constipation	C0009806		Approved			CUI-less-DB09468	S
Sodium phosphate, monobasic, anhydrous	Constipation	C0009806		Approved			CUI-less-DB09469	S
Sodium sulfate	Incomplete passage of stool	C0426639		Approved			C0771797	Anhydrous sodium sulfate
Enalaprilat	Asymptomatic left ventricular systolic dysfunction	C3698411		Approved			C0886809	Enalaprilat anhydrous
Enalaprilat	Hypertensive disease	C0020538		Approved			C0886809	Enalaprilat anhydrous
Enalaprilat	Congestive heart failure	C0018802		Approved			C0886809	Enalaprilat anhydrous
Magnesium carbonate	Gastroesophageal reflux disease	C0017168		Approved			C0065517	Magnesio carbonato
Magnesium carbonate	Hypomagnesemia	C0151723		Approved			C0065517	Magnesio carbonato
Magnesium carbonate	Heartburn	C0018834		Approved			C0065517	Magnesio carbonato
Magnesium carbonate	Peptic Ulcer	C0030920		Approved			C0065517	Magnesio carbonato
Magnesium carbonate	Incomplete passage of stool	C0426639		Approved			C0065517	Magnesio carbonato
Magnesium carbonate	Dyspepsia	C0013395		Approved			C0065517	Magnesio carbonato
Magnesium carbonate	Constipation	C0009806		Approved			C0065517	Magnesio carbonato
Cysteine hydrochloride	Bronchitis	C0006277		Approved			C0724565	Cysteine hydrochloride
Cysteine hydrochloride	Poisoning by acetaminophen	C0237963		Approved			C0724565	Cysteine hydrochloride
Cysteine hydrochloride	Amyloidosis	C0002726		Approved			C0724565	Cysteine hydrochloride
Cysteine hydrochloride	Pulmonary Cystic Fibrosis	C0392164		Approved			C0724565	Cysteine hydrochloride
Cysteine hydrochloride	Bronchiectasis	C0006267		Approved			C0724565	Cysteine hydrochloride
Acrivastine	Hay fever	C0018621		Approved			C0054340	acrivastina
Acrivastine	Rhinitis, Vasomotor	C0035460		Approved			C0054340	acrivastina
Acrivastine	Nasal congestion (finding)	C0027424		Approved			C0054340	acrivastina
Acrivastine	Rhinorrhea	C1260880		Approved			C0054340	acrivastina
Acrivastine	Allergic Conjunctivitis	C0009766		Approved			C0054340	acrivastina
Acrivastine	Sneezing	C0037383		Approved			C0054340	acrivastina
Acrivastine	Common Cold	C0009443		Approved			C0054340	acrivastina
Acrivastine	Allergic rhinitis (disorder)	C2607914		Approved			C0054340	acrivastina
Octinoxate	Chloasma	C0025218		Approved			C4477116	parsol
Octinoxate	Discoloration of skin	C0151907		Approved			C4477116	parsol
Sodium thiosulfate	Toxic effect of cyanide	C0238080		Approved			C0302967	Thiosulfuric acid
Simethicone	Diaper Rash	C0011974		Approved			C0037138	Simeticona
Sodium ferric gluconate complex	Iron deficiency anemia	C0162316		Approved			C0875947	Ferric sodium gluconate complex
Sodium ferric gluconate complex	Anemia of prematurity	C0158996		Approved			C0875947	Ferric sodium gluconate complex
Sodium phosphate, monobasic, monohydrate	Urinary tract infection	C0042029		Approved			CUI-less-DB09525	Sodium phosphate, monobasic, monohydrate
Sodium phosphate, monobasic, monohydrate	Calcium renal calculus	C1959799		Approved			CUI-less-DB09525	Sodium phosphate, monobasic, monohydrate
Sodium phosphate, monobasic, monohydrate	Incomplete passage of stool	C0426639		Approved			CUI-less-DB09525	Sodium phosphate, monobasic, monohydrate
Sodium phosphate, monobasic, monohydrate	Hypophosphatemia	C0085682		Approved			CUI-less-DB09525	Sodium phosphate, monobasic, monohydrate
Hydroquinone	Facial hyperpigmentation	C2677857		Approved			C0020306	Quinol
Hydroquinone	Discoloration of skin	C0151907		Approved			C0020306	Quinol
Hydroquinone	Chloasma	C0025218		Approved			C0020306	Quinol
Methyl salicylate	Back Pain	C0004604		Approved			C1804800	Teaberry oil
Methyl salicylate	Sprains and Strains	C0038048		Approved			C1804800	Teaberry oil
Methyl salicylate	Arthritic pains	C0857177		Approved			C1804800	Teaberry oil
Thonzonium bromide	Otitis Externa	C0029878		Approved			C0772395	Tonzonium
Dexchlorpheniramine maleate	Symptomatic dermographism	C0343065		Approved			C0137440	Dexchlorpheniramine maleate
Dexchlorpheniramine maleate	Allergic Conjunctivitis	C0009766		Approved			C0137440	Dexchlorpheniramine maleate
Dexchlorpheniramine maleate	Urticaria	C0042109		Approved			C0137440	Dexchlorpheniramine maleate
Dexchlorpheniramine maleate	Pruritus	C0033774		Approved			C0137440	Dexchlorpheniramine maleate
Dexchlorpheniramine maleate	Hay fever	C0018621		Approved			C0137440	Dexchlorpheniramine maleate
Dexchlorpheniramine maleate	Allergic rhinitis (disorder)	C2607914		Approved			C0137440	Dexchlorpheniramine maleate
Dexchlorpheniramine maleate	Rhinitis, Vasomotor	C0035460		Approved			C0137440	Dexchlorpheniramine maleate
Necitumumab	Non-Small Cell Lung Carcinoma	C0007131		Approved			C2352806	Necitumumab
Filgrastim-sndz	Chemotherapy-induced neutropenia	C1827687		Approved			C3892863	Filgrastim-sndz
Filgrastim-sndz	Congenital neutropenia	C0340970		Approved			C3892863	Filgrastim-sndz
Filgrastim-sndz	Cyclic neutropenia	C0221023		Approved			C3892863	Filgrastim-sndz
Filgrastim-sndz	Chronic idiopathic neutropenia	C2267231		Approved			C3892863	Filgrastim-sndz
Insulin Degludec	Diabetes Mellitus	C0011849		Approved			C3491971	Insulina degludec
Omega-3-carboxylic acids	Hypertriglyceridemia	C0020557		Approved			C3832882	Omega-3-carboxylic acids
Ixazomib	Multiple Myeloma	C0026764		Approved			C3273711	Ixazomib
Levomethamphetamine	Nasal congestion (finding)	C0027424		Approved			C0724614	Levmetamfetamine
Histamine	Degenerative polyarthritis	C0029408		Approved			CUI-less-DB11320	H
Selexipag	Pulmonary arterial hypertension	C2973725		Approved			C2000145	Selexipag
Alectinib	Non-Small Cell Lung Carcinoma	C0007131		Approved			C3853921	9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
Senna glycoside	Constipation	C0009806		Approved			C3489575	Sennosides
Lesinurad	Hyperuricemia	C0740394		Approved			C3886073	{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
Sebelipase alfa	Wolman Disease	C0043208		Approved			C4050579	Sebelipasa alfa
Ixekizumab	Chronic small plaque psoriasis	C0406317		Approved			C3489764	Ixekizumab
Elbasvir	Hepatitis C, Chronic	C0524910		Approved			C4080052	Elbasvir
Grazoprevir	Hepatitis C, Chronic	C0524910		Approved			C4080053	(1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide
Venetoclax	Chronic Lymphocytic Leukemia	C0023434		Approved			C4079830	4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
Thiocolchicoside	Muscle Spasticity	C0026838		Approved			CUI-less-DB11582	T
Bilastine	Urticaria	C0042109		Approved			C1101148	Bilastina
Bilastine	Allergic rhinitis (disorder)	C2607914		Approved			C1101148	Bilastina
Atezolizumab	Carcinoma, Transitional Cell	C0007138		Approved			C4055433	Atezolizumab
Levoleucovorin	Poisoning by sulfadiazine	C0274462		Approved			C2721771	ácido levofolínico
Levoleucovorin	Methotrexate poisoning	C0568062		Approved			C2721771	ácido levofolínico
Levoleucovorin	Poisoning by pyrimethamine	C0274478		Approved			C2721771	ácido levofolínico
Levoleucovorin	Anemia, Megaloblastic	C0002888		Approved			C2721771	ácido levofolínico
Levoleucovorin	Folic Acid Deficiency	C0016412		Approved			C2721771	ácido levofolínico
Susoctocog alfa	Factor 8 deficiency, acquired	C0272325		Approved			C3859426	Susoctocog alfa
Eftrenonacog alfa	Hemophilia B	C0008533		Approved			C3818700	Eftrenonacog alfa
Buprenorphine	Heroin Dependence	C0019337	NCT00000330	Terminated	Phase 2		C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Buprenorphine	Opioid-Related Disorders	C0027412	NCT00000330	Terminated	Phase 2		C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Dextroamphetamine	Cocaine-Related Disorders	C0236736	NCT00000305	Terminated	Phase 1	Original P.I. left the institution	C0011812	Desamfetamina
Buprenorphine	Heroin Dependence	C0019337	NCT00000331	Terminated	Phase 2		C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Buprenorphine	Opioid-Related Disorders	C0027412	NCT00000331	Terminated	Phase 2		C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Methotrexate	Sensorineural Hearing Loss (disorder)	C0018784	NCT00000361	Terminated	Phase 3		C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Glycine	Schizophrenia	C0036341	NCT00000372	Withdrawn	Phase 3	Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients    with Schizophrenia, so the study was suspended.	C0017890	Glicina
Cycloserine	Schizophrenia	C0036341	NCT00000372	Withdrawn	Phase 3	Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients    with Schizophrenia, so the study was suspended.	C0010590	(+)-4-amino-3-isoxazolidinone
Clozapine	Schizophrenia	C0036341	NCT00000372	Withdrawn	Phase 3	Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients    with Schizophrenia, so the study was suspended.	C0009079	Clozapina
Alendronic acid	Osteopenia	C0029453	NCT00000430	Terminated	Phase 3		C0771311	Acide Alendronique
Alendronic acid	Osteoporosis	C0029456	NCT00000430	Terminated	Phase 3		C0771311	Acide Alendronique
Zidovudine	Kidney Diseases	C0022658	NCT00000685	Withdrawn	Phase 1		C0043474	Zidovudinum
Foscarnet	Cytomegalovirus Retinitis	C0206178	NCT00000697	Withdrawn	Phase 2		C0376236	Phosphonoformate
Trimethoprim	Pneumocystis jiroveci pneumonia	C1535939	NCT00000730	Terminated	Phase 3		C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Pentamidine	Pneumocystis jiroveci pneumonia	C1535939	NCT00000730	Terminated	Phase 3		C0030863	1,5-bis(4-amidinophenoxy)pentane
Prednisolone	Pneumocystis jiroveci pneumonia	C1535939	NCT00000730	Terminated	Phase 3		C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Pneumocystis jiroveci pneumonia	C1535939	NCT00000730	Terminated	Phase 3		C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Sulfamethoxazole	Pneumocystis jiroveci pneumonia	C1535939	NCT00000730	Terminated	Phase 3		C0038689	Sulphamethoxazole
Trimetrexate	Pneumocystis jiroveci pneumonia	C1535939	NCT00000730	Terminated	Phase 3		C0085176	Trimetrexatum
Levoleucovorin	Pneumocystis jiroveci pneumonia	C1535939	NCT00000730	Terminated	Phase 3		C2721771	ácido levofolínico
Vitamin E	Carotid Artery Diseases	C0007273	NCT00000600	Terminated	Phase 2		C0969677	alpha-tocopherol
Vitamin E	Intracranial Arteriosclerosis	C0007771	NCT00000600	Terminated	Phase 2		C0969677	alpha-tocopherol
Vitamin E	Heart Diseases	C0018799	NCT00000600	Terminated	Phase 2		C0969677	alpha-tocopherol
Vitamin E	Atherosclerosis	C0004153	NCT00000600	Terminated	Phase 2		C0969677	alpha-tocopherol
Foscarnet	Radiculitis	C0034544	NCT00000856	Withdrawn	Phase 1		C0376236	Phosphonoformate
Ganciclovir	Radiculitis	C0034544	NCT00000856	Withdrawn	Phase 1		C0017066	2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
Pseudoephedrine	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		C0033798	Pseudoephedrine D-form
Cefuroxime	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		C0007562	Cefuroxima
Ephedrine	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		C0014479	Efedrina
Prednisolone	Pneumocystis jiroveci pneumonia	C1535939	NCT00000741	Withdrawn	Phase 3		C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Pneumocystis jiroveci pneumonia	C1535939	NCT00000741	Withdrawn	Phase 3		C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Cidofovir	Cytomegalovirus Infections	C0010823	NCT00000881	Withdrawn	Phase 1		C0286079	Cidofovirum
Cidofovir	Cytomegalovirus Retinitis	C0206178	NCT00000881	Withdrawn	Phase 1		C0286079	Cidofovirum
Calcitriol	Rickets	C0035579	NCT00001151	Terminated	Phase 2	Terminated because of lack of drug supply	C0006674	Calcitriolum
Daclizumab	Aplastic Anemia	C0002874	NCT00001962	Terminated	Phase 2	DSMB recommended closing the study and publishing the results	C0663182	Daclizumab beta
Daclizumab	Pure Red-Cell Aplasia	C0034902	NCT00001962	Terminated	Phase 2	DSMB recommended closing the study and publishing the results	C0663182	Daclizumab beta
Cyclosporine	leukemia	C0023418	NCT00003056	Terminated	Phase 3	Interim analysis indicated study should be terminated	C0010592	Cyclosporine
Methotrexate	leukemia	C0023418	NCT00003056	Terminated	Phase 3	Interim analysis indicated study should be terminated	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Pegfilgrastim	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Pegfilgrastim	Monocytoid B-cell lymphoma	C0855139	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	Monocytoid B-cell lymphoma	C0855139	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	Monocytoid B-cell lymphoma	C0855139	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Pegfilgrastim	recurrent grade 1 follicular lymphoma	C0280182	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	recurrent grade 1 follicular lymphoma	C0280182	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	recurrent grade 1 follicular lymphoma	C0280182	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Pegfilgrastim	recurrent grade 2 follicular lymphoma	C0280183	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	recurrent grade 2 follicular lymphoma	C0280183	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	recurrent grade 2 follicular lymphoma	C0280183	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Pegfilgrastim	recurrent grade 3 follicular lymphoma	C0280185	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	recurrent grade 3 follicular lymphoma	C0280185	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	recurrent grade 3 follicular lymphoma	C0280185	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Pegfilgrastim	Marginal zone lymphoma recurrent	C1541273	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	Marginal zone lymphoma recurrent	C1541273	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	Marginal zone lymphoma recurrent	C1541273	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Pegfilgrastim	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Pegfilgrastim	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C4735048	pegfilgrastim-cbqv
Oprelvekin	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C0537670	Recombinant interleukin-11
Rituximab	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00012298	Terminated	Phase 1/Phase 2	Trial completed prematurely.	C5195655	rituximab-pvvr
Cisplatin	Malignant neoplasm of lung	C0242379	NCT00014196	Terminated	Phase 2	This study was closed early due to poor accrual.	C0008838	cisplatino
Docetaxel	Malignant neoplasm of lung	C0242379	NCT00014196	Terminated	Phase 2	This study was closed early due to poor accrual.	C0246415	Docetaxel
Metronidazole	unspecified adult solid tumor, protocol specific	C0279004	NCT00009958	Terminated	Phase 1		C0025872	Metronidazol
Cisplatin	unspecified adult solid tumor, protocol specific	C0279004	NCT00012194	Terminated	Phase 1		C0008838	cisplatino
Nitric Oxide	Pneumonia	C0032285	NCT00016523	Terminated	Phase 3	Preliminary results showed increased intraventricular hemorrhage (IVH) in experimental arm	C0028128	óxido nítrico
Nitric Oxide	Infant, Small for Gestational Age	C0021296	NCT00016523	Terminated	Phase 3	Preliminary results showed increased intraventricular hemorrhage (IVH) in experimental arm	C0028128	óxido nítrico
Betamethasone	Pregnancy Complications	C0032962	NCT00015002	Terminated	Phase 3	Concerns regarding neonatal data	C0005308	Bétaméthasone
Trastuzumab	Cardiotoxicity	C0876994	NCT00016276	Terminated	Phase 3	Administratively complete.	C5187552	trastuzumab-anns
Dexrazoxane	Cardiotoxicity	C0876994	NCT00016276	Terminated	Phase 3	Administratively complete.	C0086444	Dexrazoxanum
Cyclophosphamide	Cardiotoxicity	C0876994	NCT00016276	Terminated	Phase 3	Administratively complete.	C0010583	Cyclophosphamidum
Tamoxifen	Cardiotoxicity	C0876994	NCT00016276	Terminated	Phase 3	Administratively complete.	C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Doxorubicin	Cardiotoxicity	C0876994	NCT00016276	Terminated	Phase 3	Administratively complete.	C0013089	Doxorubicine
Paclitaxel	Cardiotoxicity	C0876994	NCT00016276	Terminated	Phase 3	Administratively complete.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Trastuzumab	Inflammatory Breast Carcinoma	C0278601	NCT00016276	Terminated	Phase 3	Administratively complete.	C5187552	trastuzumab-anns
Dexrazoxane	Inflammatory Breast Carcinoma	C0278601	NCT00016276	Terminated	Phase 3	Administratively complete.	C0086444	Dexrazoxanum
Cyclophosphamide	Inflammatory Breast Carcinoma	C0278601	NCT00016276	Terminated	Phase 3	Administratively complete.	C0010583	Cyclophosphamidum
Tamoxifen	Inflammatory Breast Carcinoma	C0278601	NCT00016276	Terminated	Phase 3	Administratively complete.	C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Doxorubicin	Inflammatory Breast Carcinoma	C0278601	NCT00016276	Terminated	Phase 3	Administratively complete.	C0013089	Doxorubicine
Paclitaxel	Inflammatory Breast Carcinoma	C0278601	NCT00016276	Terminated	Phase 3	Administratively complete.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Vincristine	leukemia	C0023418	NCT00019409	Withdrawn	Phase 3		C0042679	Vincristina
Daunorubicin	leukemia	C0023418	NCT00019409	Withdrawn	Phase 3		C0011015	(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Hydrocortisone	leukemia	C0023418	NCT00019409	Withdrawn	Phase 3		C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Cytarabine	leukemia	C0023418	NCT00019409	Withdrawn	Phase 3		C0010711	Cytarabinum
Doxorubicin	stage III adult soft tissue sarcoma	C0278663	NCT00017160	Withdrawn	Phase 2		C0013089	Doxorubicine
Ifosfamide	stage III adult soft tissue sarcoma	C0278663	NCT00017160	Withdrawn	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Doxorubicin	recurrent adult soft tissue sarcoma	C0278665	NCT00017160	Withdrawn	Phase 2		C0013089	Doxorubicine
Ifosfamide	recurrent adult soft tissue sarcoma	C0278665	NCT00017160	Withdrawn	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Doxorubicin	soft tissue sarcoma, adult, stage IVA	C0279771	NCT00017160	Withdrawn	Phase 2		C0013089	Doxorubicine
Ifosfamide	soft tissue sarcoma, adult, stage IVA	C0279771	NCT00017160	Withdrawn	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Doxorubicin	soft tissue sarcoma, adult, stage IIB	C0796438	NCT00017160	Withdrawn	Phase 2		C0013089	Doxorubicine
Ifosfamide	soft tissue sarcoma, adult, stage IIB	C0796438	NCT00017160	Withdrawn	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Doxorubicin	soft tissue sarcoma, adult, stage IIC	C0796439	NCT00017160	Withdrawn	Phase 2		C0013089	Doxorubicine
Ifosfamide	soft tissue sarcoma, adult, stage IIC	C0796439	NCT00017160	Withdrawn	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Temozolomide	Cutaneous Melanoma	C0151779	NCT00020839	Terminated	Phase 3	low accrual	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Imatinib	leukemia	C0023418	NCT00015847	Terminated	Phase 2		C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Thalidomide	Malignant tumor of colon	C0007102	NCT00019747	Terminated	Phase 2	DSMB recommended closure of the protocol due to slow accrual.	C0039736	Thalidomidum
Dexrazoxane	Cardiotoxicity	C0876994	NCT00019864	Terminated	Phase 2		C0086444	Dexrazoxanum
Doxorubicin	Cardiotoxicity	C0876994	NCT00019864	Terminated	Phase 2		C0013089	Doxorubicine
Levoleucovorin	Cardiotoxicity	C0876994	NCT00019864	Terminated	Phase 2		C2721771	ácido levofolínico
Alendronic acid	Secondary malignant neoplasm of bone	C0153690	NCT00019695	Terminated	Phase 2		C0771311	Acide Alendronique
Ketoconazole	Secondary malignant neoplasm of bone	C0153690	NCT00019695	Terminated	Phase 2		C0022625	Ketoconazol
Alendronic acid	Adenocarcinoma of prostate	C0007112	NCT00019695	Terminated	Phase 2		C0771311	Acide Alendronique
Ketoconazole	Adenocarcinoma of prostate	C0007112	NCT00019695	Terminated	Phase 2		C0022625	Ketoconazol
Alendronic acid	Prostate cancer recurrent	C0278838	NCT00019695	Terminated	Phase 2		C0771311	Acide Alendronique
Ketoconazole	Prostate cancer recurrent	C0278838	NCT00019695	Terminated	Phase 2		C0022625	Ketoconazol
Paclitaxel	Neoplasm Metastasis	C0027627	NCT00023166	Terminated	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Renal Pelvis and Ureter Urothelial Carcinoma	C0220648	NCT00022633	Terminated	Phase 2	Permanently Closed Due to Poor Accrual	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Renal Pelvis and Ureter Urothelial Carcinoma	C0220648	NCT00022633	Terminated	Phase 2	Permanently Closed Due to Poor Accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Urethral Carcinoma	C0700101	NCT00022633	Terminated	Phase 2	Permanently Closed Due to Poor Accrual	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Urethral Carcinoma	C0700101	NCT00022633	Terminated	Phase 2	Permanently Closed Due to Poor Accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Imatinib	leukemia	C0023418	NCT00022490	Terminated	Phase 2		C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Cytarabine	leukemia	C0023418	NCT00022490	Terminated	Phase 2		C0010711	Cytarabinum
Amifostine	Oral Complication	C3898092	NCT00025298	Terminated	Phase 2	low accrual	C3537278	Amifostine anhydrous
Amifostine	Radiation Sickness	C1510432	NCT00025298	Terminated	Phase 2	low accrual	C3537278	Amifostine anhydrous
Carboplatin	unspecified adult solid tumor, protocol specific	C0279004	NCT00028561	Terminated	Phase 1	Administratively complete.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Celecoxib	Precancerous Conditions	C0032927	NCT00027976	Withdrawn	Phase 2/Phase 3		C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Doxorubicin	Primary Systemic Amyloidosis	C0281479	NCT00030381	Terminated	Phase 1	Administratively complete.	C0013089	Doxorubicine
Homoharringtonine	leukemia	C0023418	NCT00030355	Withdrawn	Phase 1/Phase 2		C0062941	mepesuccinato de omacetaxina
Metronidazole	unspecified adult solid tumor, protocol specific	C0279004	NCT00030693	Terminated	Phase 1	Administratively complete.	C0025872	Metronidazol
Pentostatin	Acute GVH disease	C0856825	NCT00032773	Terminated	Phase 1/Phase 2		C0030896	Pentostatine
Nicotine	Malignant neoplasm of lung	C0242379	NCT00032084	Terminated	Phase 3	This study was closed early due to poor accrual	C0028040	Nikotin
Bupropion	Malignant neoplasm of lung	C0242379	NCT00032084	Terminated	Phase 3	This study was closed early due to poor accrual	C0085208	Bupropion
Sertraline	Epilepsy	C0014544	NCT00026637	Terminated	Phase 3	The PI left Columbia in 2008. No research related activity has taken place since then.	C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Methylphenidate	cognitive/functional effects	C0935657	NCT00031798	Terminated	Phase 3	low accrual; loss of funding	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Methylphenidate	Depressive disorder	C0011581	NCT00031798	Terminated	Phase 3	low accrual; loss of funding	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Cisplatin	Central Nervous System Neoplasms	C0085136	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0008838	cisplatino
Cyclophosphamide	Central Nervous System Neoplasms	C0085136	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0010583	Cyclophosphamidum
Vincristine	Central Nervous System Neoplasms	C0085136	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0042679	Vincristina
Lomustine	Central Nervous System Neoplasms	C0085136	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0023972	1-(2-chloroethyl)-3-cyclohexylnitrosourea
Cisplatin	Medulloblastoma	C0025149	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0008838	cisplatino
Cyclophosphamide	Medulloblastoma	C0025149	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0010583	Cyclophosphamidum
Vincristine	Medulloblastoma	C0025149	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0042679	Vincristina
Lomustine	Medulloblastoma	C0025149	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0023972	1-(2-chloroethyl)-3-cyclohexylnitrosourea
Cisplatin	Neuroectodermal Tumor, Primitive	C0206663	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0008838	cisplatino
Cyclophosphamide	Neuroectodermal Tumor, Primitive	C0206663	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0010583	Cyclophosphamidum
Vincristine	Neuroectodermal Tumor, Primitive	C0206663	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0042679	Vincristina
Lomustine	Neuroectodermal Tumor, Primitive	C0206663	NCT00031590	Terminated	Phase 2	The study was terminated prematurely due to slow accrual.	C0023972	1-(2-chloroethyl)-3-cyclohexylnitrosourea
Irinotecan	Malignant tumor of colon	C0007102	NCT00033306	Terminated	Phase 2		C0123931	(+)-Irinotecan
Gefitinib	Squamous cell carcinoma of the hypopharynx stage III	C0280390	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	Squamous cell carcinoma of the hypopharynx stage III	C0280390	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Gefitinib	Laryngeal squamous cell carcinoma stage III	C0280397	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	Laryngeal squamous cell carcinoma stage III	C0280397	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Gefitinib	stage III squamous cell carcinoma of the lip and oral cavity	C0280353	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	stage III squamous cell carcinoma of the lip and oral cavity	C0280353	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Gefitinib	Oropharyngeal squamous cell carcinoma stage III	C0280372	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	Oropharyngeal squamous cell carcinoma stage III	C0280372	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Gefitinib	Squamous cell carcinoma of the hypopharynx stage IV	C0280391	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	Squamous cell carcinoma of the hypopharynx stage IV	C0280391	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Gefitinib	Laryngeal squamous cell carcinoma stage IV	C0280399	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	Laryngeal squamous cell carcinoma stage IV	C0280399	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Gefitinib	stage IV squamous cell carcinoma of the lip and oral cavity	C0280358	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	stage IV squamous cell carcinoma of the lip and oral cavity	C0280358	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Gefitinib	stage IV squamous cell carcinoma of the oropharynx	C0280374	NCT00033449	Terminated	Phase 1	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Cisplatin	stage IV squamous cell carcinoma of the oropharynx	C0280374	NCT00033449	Terminated	Phase 1	Administratively complete.	C0008838	cisplatino
Celecoxib	Malignant tumor of colon	C0007102	NCT00033371	Terminated	Phase 2	Slow recruitment.	C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Eflornithine	Malignant tumor of colon	C0007102	NCT00033371	Terminated	Phase 2	Slow recruitment.	C0002260	alpha-difluoromethylornithine
Celecoxib	Adenomatous Polyposis Coli	C0032580	NCT00033371	Terminated	Phase 2	Slow recruitment.	C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Eflornithine	Adenomatous Polyposis Coli	C0032580	NCT00033371	Terminated	Phase 2	Slow recruitment.	C0002260	alpha-difluoromethylornithine
Dexrazoxane	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	C0086444	Dexrazoxanum
Cyclophosphamide	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	C0010583	Cyclophosphamidum
Vincristine	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	C0042679	Vincristina
Doxorubicin	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	C0013089	Doxorubicine
Celecoxib	Neoplasm Metastasis	C0027627	NCT00037180	Terminated	Phase 2		C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Celecoxib	Colorectal Neoplasms	C0009404	NCT00037180	Terminated	Phase 2		C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Abatacept	Multiple Sclerosis	C0026769	NCT00035529	Terminated	Phase 2		C1619966	Abatacept recombinant
Irinotecan	Colorectal Neoplasms	C0009404	NCT00040391	Terminated	Phase 2		C0123931	(+)-Irinotecan
Irinotecan	Diarrhea	C0011991	NCT00040391	Terminated	Phase 2		C0123931	(+)-Irinotecan
Pegfilgrastim	Hemoglobinopathies	C0019045	NCT00040417	Terminated	Phase 2		C4735048	pegfilgrastim-cbqv
Pegfilgrastim	Thalassemia	C0039730	NCT00040417	Terminated	Phase 2		C4735048	pegfilgrastim-cbqv
Trastuzumab	Breast cancer recurrent	C0278493	NCT00039455	Terminated	Phase 1	Administratively complete.	C5187552	trastuzumab-anns
Oprelvekin	Ulcerative Colitis	C0009324	NCT00038922	Terminated	Phase 1		C0537670	Recombinant interleukin-11
Oprelvekin	Inflammatory Bowel Diseases	C0021390	NCT00038922	Terminated	Phase 1		C0537670	Recombinant interleukin-11
Isotretinoin	T-Cell Lymphoma	C0079772	NCT00038376	Terminated	Phase 2		C0022265	Isotrétinoine
Isotretinoin	Mycosis Fungoides	C0026948	NCT00038376	Terminated	Phase 2		C0022265	Isotrétinoine
Isotretinoin	Hematologic Neoplasms	C0376545	NCT00038376	Terminated	Phase 2		C0022265	Isotrétinoine
Bevacizumab	Malignant tumor of colon	C0007102	NCT00043004	Terminated	Phase 2	low accrual	C0796392	Anti-VEGF monoclonal antibody
Levoleucovorin	Malignant tumor of colon	C0007102	NCT00043004	Terminated	Phase 2	low accrual	C2721771	ácido levofolínico
Carboplatin	Non-small cell lung cancer stage IIIB	C0278984	NCT00042302	Terminated	Phase 3		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Non-small cell lung cancer stage IIIB	C0278984	NCT00042302	Terminated	Phase 3		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Carboplatin	Non-small cell lung cancer metastatic	C0278987	NCT00042302	Terminated	Phase 3		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Non-small cell lung cancer metastatic	C0278987	NCT00042302	Terminated	Phase 3		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Vinorelbine	Non-small cell lung cancer stage IIIB	C0278984	NCT00042315	Terminated	Phase 3		C0078257	Vinorelbinum
Vinblastine	Non-small cell lung cancer stage IIIB	C0278984	NCT00042315	Terminated	Phase 3		C0042670	Vinblastina
Vinorelbine	Non-small cell lung cancer metastatic	C0278987	NCT00042315	Terminated	Phase 3		C0078257	Vinorelbinum
Vinblastine	Non-small cell lung cancer metastatic	C0278987	NCT00042315	Terminated	Phase 3		C0042670	Vinblastina
Docetaxel	thorax/respiratory cancer	C0279170	NCT00041171	Withdrawn	Phase 3	The study was not activated.	C0246415	Docetaxel
Docetaxel	adult solid tumor	C0280099	NCT00041171	Withdrawn	Phase 3	The study was not activated.	C0246415	Docetaxel
Docetaxel	kidney/urinary cancer	C0279521	NCT00041171	Withdrawn	Phase 3	The study was not activated.	C0246415	Docetaxel
Docetaxel	male reproductive cancer	C0699888	NCT00041171	Withdrawn	Phase 3	The study was not activated.	C0246415	Docetaxel
Nitric Oxide	Hypoxemia	C0700292	NCT00041548	Terminated	Phase 1/Phase 2	slow enrollment	C0028128	óxido nítrico
Nitric Oxide	Acidosis, Respiratory	C0001127	NCT00041548	Terminated	Phase 1/Phase 2	slow enrollment	C0028128	óxido nítrico
Cyclophosphamide	Scleroderma	C0011644	NCT00040651	Terminated	Phase 1		C0010583	Cyclophosphamidum
Cyclophosphamide	Systemic Scleroderma	C0036421	NCT00040651	Terminated	Phase 1		C0010583	Cyclophosphamidum
Nitric Oxide	Anoxemia	C0003129	NCT00041561	Terminated	Phase 3	Study stopped due to poor enrollment	C0028128	óxido nítrico
Cisplatin	Malignant neoplasm of lung	C0242379	NCT00045617	Terminated	Phase 2	Closed due to lack of drug availability.	C0008838	cisplatino
Etoposide	Malignant neoplasm of lung	C0242379	NCT00045617	Terminated	Phase 2	Closed due to lack of drug availability.	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Fluorouracil	Solid tumour	C0280100	NCT00044785	Terminated	Phase 1		C0016360	Fluorouracilum
Bortezomib	Non-small cell lung cancer metastatic	C0278987	NCT00040768	Terminated	Phase 2	Administratively complete.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Non-small cell lung cancer recurrent	C0278517	NCT00040768	Terminated	Phase 2	Administratively complete.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Micafungin	Aspergillosis	C0004030	NCT00047827	Terminated	Phase 2	Inadequate enrollment	C1120386	Micafungina
Decitabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	C1292772	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	de novo myelodysplastic syndromes	C0280451	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	C1328061	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	previously treated myelodysplastic syndromes	C0280744	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	recurrent adult acute myeloid leukemia	C0278780	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	secondary acute myeloid leukemia	C0280449	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	secondary myelodysplastic syndromes	C0280745	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Decitabine	untreated adult acute myeloid leukemia	C0279089	NCT00049582	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Alemtuzumab	Graft failure	C1262018	NCT00048399	Terminated	Phase 1/Phase 2		C0383429	Alemtuzumab
Erlotinib	adult primary hepatocellular carcinoma	C0279607	NCT00047333	Terminated	Phase 2	Administratively complete.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	advanced adult primary liver cancer	C0278774	NCT00047333	Terminated	Phase 2	Administratively complete.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	localized unresectable adult primary liver cancer	C0278773	NCT00047333	Terminated	Phase 2	Administratively complete.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Oxaliplatin	Colorectal Neoplasms	C0009404	NCT00051688	Terminated	Phase 2		C0069717	oxaliplatine
Micafungin	Invasive Fungal Infections	C1262313	NCT00048750	Terminated	Phase 3	Inadequate enrollment	C1120386	Micafungina
Verteporfin	Basal Cell Nevus Syndrome	C0004779	NCT00049959	Terminated	Phase 3		C0387288	Verteporfinum
Bevacizumab	unspecified adult solid tumor, protocol specific	C0279004	NCT00049088	Terminated	Phase 1	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Docetaxel	unspecified adult solid tumor, protocol specific	C0279004	NCT00049088	Terminated	Phase 1	Administratively complete.	C0246415	Docetaxel
Aldesleukin	childhood chronic myelogenous leukemia	C1327920	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	Childhood myelodysplastic syndrome	C2347761	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	recurrent adult acute myeloid leukemia	C0278780	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	recurrent childhood acute myeloid leukemia	C0278776	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	chronic myelogenous leukemia in relapse	C0278787	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	secondary acute myeloid leukemia	C0280449	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Aldesleukin	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT00052598	Terminated	Phase 1/Phase 2		C0218986	Aldesleukina
Gemcitabine	Malignant tumor of colon	C0007102	NCT00049608	Terminated	Phase 1	Principal investigator [PI] has left institution.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Malignant neoplasm of lung	C0242379	NCT00049608	Terminated	Phase 1	Principal investigator [PI] has left institution.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gefitinib	Adenocarcinoma of colon	C0338106	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	Adenocarcinoma of colon	C0338106	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	Adenocarcinoma of colon	C0338106	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Adenocarcinoma of colon	C0338106	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Gefitinib	Adenocarcinoma of rectum	C0149978	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	Adenocarcinoma of rectum	C0149978	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	Adenocarcinoma of rectum	C0149978	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Adenocarcinoma of rectum	C0149978	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Gefitinib	Mucinous adenocarcinoma of colon	C0279639	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	Mucinous adenocarcinoma of colon	C0279639	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	Mucinous adenocarcinoma of colon	C0279639	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Mucinous adenocarcinoma of colon	C0279639	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Gefitinib	mucinous adenocarcinoma of rectum	C0279652	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	mucinous adenocarcinoma of rectum	C0279652	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	mucinous adenocarcinoma of rectum	C0279652	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	mucinous adenocarcinoma of rectum	C0279652	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Gefitinib	Colon cancer recurrent	C0278553	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	Colon cancer recurrent	C0278553	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	Colon cancer recurrent	C0278553	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Colon cancer recurrent	C0278553	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Gefitinib	Recurrent Rectal Cancer	C0278554	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	Recurrent Rectal Cancer	C0278554	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	Recurrent Rectal Cancer	C0278554	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Recurrent Rectal Cancer	C0278554	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Gefitinib	signet ring adenocarcinoma of the colon	C0279640	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	signet ring adenocarcinoma of the colon	C0279640	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	signet ring adenocarcinoma of the colon	C0279640	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	signet ring adenocarcinoma of the colon	C0279640	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Gefitinib	signet ring adenocarcinoma of the rectum	C0279654	NCT00052585	Terminated	Phase 2	Administratively complete.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Fluorouracil	signet ring adenocarcinoma of the rectum	C0279654	NCT00052585	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Irinotecan	signet ring adenocarcinoma of the rectum	C0279654	NCT00052585	Terminated	Phase 2	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	signet ring adenocarcinoma of the rectum	C0279654	NCT00052585	Terminated	Phase 2	Administratively complete.	C2721771	ácido levofolínico
Aldesleukin	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Cutaneous T-cell lymphoma recurrent	C0278580	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Cutaneous T-cell lymphoma stage I	C0278566	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Mycosis fungoides/Sezary syndrome stage I	C0862211	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Cutaneous T-cell lymphoma stage II	C0278568	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Mycosis fungoides/Sezary syndrome stage II	C0862216	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Cutaneous T-cell lymphoma stage III	C0278570	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Mycosis fungoides/Sezary syndrome stage III	C0862221	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Cutaneous T-cell lymphoma stage IV	C0278572	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Aldesleukin	Mycosis fungoides/Sezary syndrome stage IV	C0862226	NCT00052377	Terminated	Phase 1/Phase 2	Administratively complete.	C0218986	Aldesleukina
Gemcitabine	ovarian neoplasm	C0919267	NCT00051584	Terminated	Phase 2		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Doxorubicin	ovarian neoplasm	C0919267	NCT00051584	Terminated	Phase 2		C0013089	Doxorubicine
Azathioprine	Pulmonary Fibrosis	C0034069	NCT00052039	Terminated	Phase 3	Study design changes were needed based on GIPF-001 results	C0004482	Azamun
Cyclosporine	leukemia	C0023418	NCT00053014	Terminated	Phase 2	Poor accrual	C0010592	Cyclosporine
Mycophenolate mofetil	leukemia	C0023418	NCT00053014	Terminated	Phase 2	Poor accrual	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	leukemia	C0023418	NCT00053014	Terminated	Phase 2	Poor accrual	C0026933	Mycophenolsäure
Aldesleukin	Neuroblastoma recurrent	C0278695	NCT00054405	Terminated	Phase 1	Administratively complete.	C0218986	Aldesleukina
Gemcitabine	Malignant neoplasm of lung	C0242379	NCT00054392	Withdrawn	Phase 3	Not opened at Fox Chase Cancer Center	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00054392	Withdrawn	Phase 3	Not opened at Fox Chase Cancer Center	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Trastuzumab	Breast cancer recurrent	C0278493	NCT00053339	Withdrawn	Phase 3	The study was not activated.	C5187552	trastuzumab-anns
Tamoxifen	Breast cancer recurrent	C0278493	NCT00053339	Withdrawn	Phase 3	The study was not activated.	C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Vinorelbine	Malignant neoplasm of lung	C0242379	NCT00055887	Withdrawn	Phase 3	Study never started. No patients were enrolled.	C0078257	Vinorelbinum
Gemcitabine	Malignant neoplasm of lung	C0242379	NCT00055887	Withdrawn	Phase 3	Study never started. No patients were enrolled.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Fondaparinux sodium	Myocardial Infarction	C0027051	NCT00060554	Withdrawn	Phase 2	Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have    data.	C1098510	Natural heparin pentasaccharide
Gemcitabine	stage IV adult Hodgkin's lymphoma	C0278473	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV adult immunoblastic large cell lymphoma	C0280177	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV adult lymphoblastic lymphoma	C0280178	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Adult T-cell lymphoma/leukaemia stage IV	C0280426	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Cutaneous T-cell lymphoma stage IV	C0278572	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV adult diffuse small cleaved cell lymphoma	C0280173	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent grade 3 follicular lymphoma	C0280185	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent grade 1 follicular lymphoma	C0280182	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent grade 2 follicular lymphoma	C0280183	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Mantle cell lymphoma recurrent	C0677725	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Marginal zone lymphoma recurrent	C1541273	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV adult Burkitt's lymphoma	C0280179	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV adult diffuse large cell lymphoma	C0280175	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV adult diffuse mixed cell lymphoma	C0280174	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV grade 1 follicular lymphoma	C0280169	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV grade 2 follicular lymphoma	C0280170	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	stage IV grade 3 follicular lymphoma	C0280172	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Mantle cell lymphoma stage IV	C0677721	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Marginal zone lymphoma stage IV	C1541270	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	B-cell small lymphocytic lymphoma stage IV	C0855101	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	unspecified adult solid tumor, protocol specific	C0279004	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Monocytoid B-cell lymphoma	C0855139	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent adult Burkitt's lymphoma	C0280192	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent adult diffuse large cell lymphoma	C0280188	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent adult Hodgkin's lymphoma	C0278530	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	recurrent adult lymphoblastic lymphoma	C0280191	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabine	Cutaneous T-cell lymphoma recurrent	C0278580	NCT00060112	Terminated	Phase 1	Administratively complete.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Rituximab	Lymphoma, Mixed-Cell, Follicular	C0079758	NCT00060671	Terminated	Phase 3		C5195655	rituximab-pvvr
Arsenic trioxide	Adenocarcinoma Of Esophagus	C0279628	NCT00061958	Terminated	Phase 2	Administratively complete.	C0052416	arsénico trióxido
Arsenic trioxide	Esophageal neoplasm metastatic	C0278562	NCT00061958	Terminated	Phase 2	Administratively complete.	C0052416	arsénico trióxido
Nitric Oxide	Reperfusion Injury	C0035126	NCT00060450	Terminated	Phase 3	Slow Enrollment	C0028128	óxido nítrico
Treprostinil	Critical limb ischemia	C1142264	NCT00060996	Terminated	Phase 3		C1145760	Tréprostinil
Treprostinil	Peripheral Vascular Diseases	C0085096	NCT00060996	Terminated	Phase 3		C1145760	Tréprostinil
Treprostinil	Foot Ulcer	C0085119	NCT00060996	Terminated	Phase 3		C1145760	Tréprostinil
Sulindac	Malignant tumor of colon	C0007102	NCT00062023	Terminated	Phase 2	Study closed by the NCI.	C0038792	Sulindacum
Salicylic acid	Malignant tumor of colon	C0007102	NCT00062023	Terminated	Phase 2	Study closed by the NCI.	C0036079	ácido salicílico
Acetylsalicylic acid	Malignant tumor of colon	C0007102	NCT00062023	Terminated	Phase 2	Study closed by the NCI.	C0004057	Aspirina
Ursodeoxycholic acid	Malignant tumor of colon	C0007102	NCT00062023	Terminated	Phase 2	Study closed by the NCI.	C0042105	Acidum ursodeoxycholicum
Alfuzosin	Benign Prostatic Hyperplasia	C1704272	NCT00064649	Terminated	Phase 3	Inability to recruit required sample size.	C0051150	Alfuzosina
Finasteride	Benign Prostatic Hyperplasia	C1704272	NCT00064649	Terminated	Phase 3	Inability to recruit required sample size.	C0060389	Finasterida
Cisplatin	Adenocarcinoma Of Esophagus	C0279628	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	Adenocarcinoma Of Esophagus	C0279628	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	Adenocarcinoma of the gastroesophageal junction	C1332166	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	Adenocarcinoma of the gastroesophageal junction	C1332166	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	diffuse adenocarcinoma of the stomach	C0279635	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	diffuse adenocarcinoma of the stomach	C0279635	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	intestinal adenocarcinoma of the stomach	C0279633	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	intestinal adenocarcinoma of the stomach	C0279633	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	mixed adenocarcinoma of the stomach	C0279638	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	mixed adenocarcinoma of the stomach	C0279638	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	Oesophageal carcinoma recurrent	C0854761	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	Oesophageal carcinoma recurrent	C0854761	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	recurrent gastric cancer	C0278502	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	recurrent gastric cancer	C0278502	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	Squamous cell carcinoma of esophagus	C0279626	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	Squamous cell carcinoma of esophagus	C0279626	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	Stage IIIC Gastric Cancer	C2981365	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	Stage IIIC Gastric Cancer	C2981365	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Cisplatin	Esophageal neoplasm metastatic	C0278562	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0008838	cisplatino
Fluorouracil	Esophageal neoplasm metastatic	C0278562	NCT00064259	Terminated	Phase 1/Phase 2	Discontinued development of G3139 (oblimersen)	C0016360	Fluorouracilum
Erlotinib	Malignant neoplasm of lung	C0242379	NCT00063258	Terminated	Phase 2	Low accrual rate	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00063258	Terminated	Phase 2	Low accrual rate	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Malignant neoplasm of lung	C0242379	NCT00063258	Terminated	Phase 2	Low accrual rate	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Lamotrigine	Bipolar Disorder	C0005586	NCT00063362	Terminated	Phase 3	Funding Expiration	C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Prednisolone	Chronic myeloproliferative disorder	C1292778	NCT00066417	Terminated	Phase 2	Trial was withdrawn for drug availability issues.	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Chronic myeloproliferative disorder	C1292778	NCT00066417	Terminated	Phase 2	Trial was withdrawn for drug availability issues.	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Fludarabine	Chronic myeloproliferative disorder	C1292778	NCT00066417	Terminated	Phase 2	Trial was withdrawn for drug availability issues.	C0059985	Fludarabinum
Prednisolone	leukemia	C0023418	NCT00066417	Terminated	Phase 2	Trial was withdrawn for drug availability issues.	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	leukemia	C0023418	NCT00066417	Terminated	Phase 2	Trial was withdrawn for drug availability issues.	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Fludarabine	leukemia	C0023418	NCT00066417	Terminated	Phase 2	Trial was withdrawn for drug availability issues.	C0059985	Fludarabinum
Bortezomib	unspecified adult solid tumor, protocol specific	C0279004	NCT00066625	Terminated	Phase 1	Administratively complete.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Oxaliplatin	unspecified adult solid tumor, protocol specific	C0279004	NCT00066625	Terminated	Phase 1	Administratively complete.	C0069717	oxaliplatine
Oxaliplatin	Colorectal Neoplasms	C0009404	NCT00065117	Terminated	Phase 2		C0069717	oxaliplatine
Fluorouracil	Colorectal Neoplasms	C0009404	NCT00065117	Terminated	Phase 2		C0016360	Fluorouracilum
Modafinil	Postpoliomyelitis Syndrome	C0080040	NCT00067496	Terminated	Phase 3		C0066677	2-((diphenylmethyl)sulfinyl)acetamide
Armodafinil	Postpoliomyelitis Syndrome	C0080040	NCT00067496	Terminated	Phase 3		C1701455	Armodafinilo
Treprostinil	Peripheral Vascular Diseases	C0085096	NCT00067041	Terminated	Phase 2/Phase 3		C1145760	Tréprostinil
Oxaliplatin	Recurrent Rectal Cancer	C0278554	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Recurrent Rectal Cancer	C0278554	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Recurrent Rectal Cancer	C0278554	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Recurrent Rectal Cancer	C0278554	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Recurrent Rectal Cancer	C0278554	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	signet ring adenocarcinoma of the rectum	C0279654	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	signet ring adenocarcinoma of the rectum	C0279654	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	signet ring adenocarcinoma of the rectum	C0279654	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	signet ring adenocarcinoma of the rectum	C0279654	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	signet ring adenocarcinoma of the rectum	C0279654	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IIA Rectal Cancer	C3897537	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IIA Rectal Cancer	C3897537	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IIA Rectal Cancer	C3897537	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IIA Rectal Cancer	C3897537	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IIA Rectal Cancer	C3897537	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IIB Rectal Cancer	C3897536	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IIB Rectal Cancer	C3897536	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IIB Rectal Cancer	C3897536	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IIB Rectal Cancer	C3897536	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IIB Rectal Cancer	C3897536	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IIC Rectal Cancer	C3897535	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IIC Rectal Cancer	C3897535	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IIC Rectal Cancer	C3897535	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IIC Rectal Cancer	C3897535	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IIC Rectal Cancer	C3897535	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IIIA Rectal Cancer	C3897531	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IIIA Rectal Cancer	C3897531	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IIIA Rectal Cancer	C3897531	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IIIA Rectal Cancer	C3897531	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IIIA Rectal Cancer	C3897531	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IIIB Rectal Cancer	C3897528	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IIIB Rectal Cancer	C3897528	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IIIB Rectal Cancer	C3897528	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IIIB Rectal Cancer	C3897528	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IIIB Rectal Cancer	C3897528	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IIIC Rectal Cancer	C3897525	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IIIC Rectal Cancer	C3897525	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IIIC Rectal Cancer	C3897525	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IIIC Rectal Cancer	C3897525	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IIIC Rectal Cancer	C3897525	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IVA Rectal Cancer	C3897520	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IVA Rectal Cancer	C3897520	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IVA Rectal Cancer	C3897520	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IVA Rectal Cancer	C3897520	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IVA Rectal Cancer	C3897520	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Stage IVB Rectal Cancer	C3897513	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Stage IVB Rectal Cancer	C3897513	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Stage IVB Rectal Cancer	C3897513	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	Stage IVB Rectal Cancer	C3897513	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IVB Rectal Cancer	C3897513	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	mucinous adenocarcinoma of rectum	C0279652	NCT00068692	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	mucinous adenocarcinoma of rectum	C0279652	NCT00068692	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	mucinous adenocarcinoma of rectum	C0279652	NCT00068692	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Irinotecan	mucinous adenocarcinoma of rectum	C0279652	NCT00068692	Terminated	Phase 3	Administratively complete.	C0123931	(+)-Irinotecan
Levoleucovorin	mucinous adenocarcinoma of rectum	C0279652	NCT00068692	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Metronidazole	Breast cancer recurrent	C0278493	NCT00071942	Terminated	Phase 1		C0025872	Metronidazol
Chlorhexidine	Dental caries	C0011334	NCT00067340	Terminated	Phase 3	Unable to recruit sufficient number of subjects	C0008196	N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
Sirolimus	leukemia	C0023418	NCT00068302	Terminated	Phase 1	Recruiting/enrolling participants halted prematurely but potentially will resume	C0072980	Sirolimús
Everolimus	leukemia	C0023418	NCT00068302	Terminated	Phase 1	Recruiting/enrolling participants halted prematurely but potentially will resume	C0541315	évérolimus
Gefitinib	Malignant tumor of colon	C0007102	NCT00087334	Terminated	Phase 1/Phase 2	Withdrawn due to poor/low accrual	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Oxaliplatin	Malignant tumor of colon	C0007102	NCT00087334	Terminated	Phase 1/Phase 2	Withdrawn due to poor/low accrual	C0069717	oxaliplatine
Capecitabine	Malignant tumor of colon	C0007102	NCT00087334	Terminated	Phase 1/Phase 2	Withdrawn due to poor/low accrual	C0671970	Capecitabin
Amphetamine	Depressive disorder	C0011581	NCT00069927	Terminated	Phase 2	Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility	C0002658	Amfetaminum
Methylphenidate	Depressive disorder	C0011581	NCT00069927	Terminated	Phase 2	Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Amphetamine	Neurotoxicity Syndromes	C0235032	NCT00069927	Terminated	Phase 2	Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility	C0002658	Amfetaminum
Methylphenidate	Neurotoxicity Syndromes	C0235032	NCT00069927	Terminated	Phase 2	Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Amphetamine	unspecified childhood solid tumor, protocol specific	C0279002	NCT00069927	Terminated	Phase 2	Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility	C0002658	Amfetaminum
Methylphenidate	unspecified childhood solid tumor, protocol specific	C0279002	NCT00069927	Terminated	Phase 2	Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Alemtuzumab	Chronic myeloproliferative disorder	C1292778	NCT00069992	Terminated	Phase 2	Closed due to competing protocols	C0383429	Alemtuzumab
Fludarabine	Chronic myeloproliferative disorder	C1292778	NCT00069992	Terminated	Phase 2	Closed due to competing protocols	C0059985	Fludarabinum
Alemtuzumab	leukemia	C0023418	NCT00069992	Terminated	Phase 2	Closed due to competing protocols	C0383429	Alemtuzumab
Fludarabine	leukemia	C0023418	NCT00069992	Terminated	Phase 2	Closed due to competing protocols	C0059985	Fludarabinum
Romidepsin	Renal Pelvis and Ureter Urothelial Carcinoma	C0220648	NCT00087295	Terminated	Phase 2	Permanently Closed Due to Poor Accrual	C1527027	Romidepsine
Romidepsin	Urethral Carcinoma	C0700101	NCT00087295	Terminated	Phase 2	Permanently Closed Due to Poor Accrual	C1527027	Romidepsine
Erlotinib	Stage IA Non-Small Cell Lung Carcinoma	C1336119	NCT00087269	Terminated	Phase 2		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	Stage IB Non-Small Cell Lung Carcinoma	C1336139	NCT00087269	Terminated	Phase 2		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	Stage IIA Non-Small Cell Lung Carcinoma	C1336167	NCT00087269	Terminated	Phase 2		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	Stage IIB Non-Small Cell Lung Carcinoma	C1336190	NCT00087269	Terminated	Phase 2		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	Non-small cell lung cancer stage IIIA	C0278983	NCT00087269	Terminated	Phase 2		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Bevacizumab	Adenocarcinoma of colon	C0338106	NCT00070122	Terminated	Phase 3	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Adenocarcinoma of colon	C0338106	NCT00070122	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Adenocarcinoma of colon	C0338106	NCT00070122	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Adenocarcinoma of colon	C0338106	NCT00070122	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Capecitabine	Adenocarcinoma of colon	C0338106	NCT00070122	Terminated	Phase 3	Administratively complete.	C0671970	Capecitabin
Levoleucovorin	Adenocarcinoma of colon	C0338106	NCT00070122	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Bevacizumab	Adenocarcinoma of rectum	C0149978	NCT00070122	Terminated	Phase 3	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Adenocarcinoma of rectum	C0149978	NCT00070122	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Adenocarcinoma of rectum	C0149978	NCT00070122	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Adenocarcinoma of rectum	C0149978	NCT00070122	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Capecitabine	Adenocarcinoma of rectum	C0149978	NCT00070122	Terminated	Phase 3	Administratively complete.	C0671970	Capecitabin
Levoleucovorin	Adenocarcinoma of rectum	C0149978	NCT00070122	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Bevacizumab	Colon cancer recurrent	C0278553	NCT00070122	Terminated	Phase 3	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Colon cancer recurrent	C0278553	NCT00070122	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Colon cancer recurrent	C0278553	NCT00070122	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Colon cancer recurrent	C0278553	NCT00070122	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Capecitabine	Colon cancer recurrent	C0278553	NCT00070122	Terminated	Phase 3	Administratively complete.	C0671970	Capecitabin
Levoleucovorin	Colon cancer recurrent	C0278553	NCT00070122	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Bevacizumab	Recurrent Rectal Cancer	C0278554	NCT00070122	Terminated	Phase 3	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Recurrent Rectal Cancer	C0278554	NCT00070122	Terminated	Phase 3	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Recurrent Rectal Cancer	C0278554	NCT00070122	Terminated	Phase 3	Administratively complete.	C0016360	Fluorouracilum
Leucovorin	Recurrent Rectal Cancer	C0278554	NCT00070122	Terminated	Phase 3	Administratively complete.	C0023413	Folinate
Capecitabine	Recurrent Rectal Cancer	C0278554	NCT00070122	Terminated	Phase 3	Administratively complete.	C0671970	Capecitabin
Levoleucovorin	Recurrent Rectal Cancer	C0278554	NCT00070122	Terminated	Phase 3	Administratively complete.	C2721771	ácido levofolínico
Oxaliplatin	Secondary malignant neoplasm of liver	C0494165	NCT00070265	Terminated	Phase 2	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Secondary malignant neoplasm of liver	C0494165	NCT00070265	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Capecitabine	Secondary malignant neoplasm of liver	C0494165	NCT00070265	Terminated	Phase 2	Administratively complete.	C0671970	Capecitabin
Oxaliplatin	Colon cancer recurrent	C0278553	NCT00070265	Terminated	Phase 2	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Colon cancer recurrent	C0278553	NCT00070265	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Capecitabine	Colon cancer recurrent	C0278553	NCT00070265	Terminated	Phase 2	Administratively complete.	C0671970	Capecitabin
Oxaliplatin	Recurrent Rectal Cancer	C0278554	NCT00070265	Terminated	Phase 2	Administratively complete.	C0069717	oxaliplatine
Fluorouracil	Recurrent Rectal Cancer	C0278554	NCT00070265	Terminated	Phase 2	Administratively complete.	C0016360	Fluorouracilum
Capecitabine	Recurrent Rectal Cancer	C0278554	NCT00070265	Terminated	Phase 2	Administratively complete.	C0671970	Capecitabin
Oxaliplatin	Malignant tumor of colon	C0007102	NCT00070434	Withdrawn	Phase 2	poor accrual	C0069717	oxaliplatine
Irinotecan	Malignant tumor of colon	C0007102	NCT00070434	Withdrawn	Phase 2	poor accrual	C0123931	(+)-Irinotecan
Levoleucovorin	Malignant tumor of colon	C0007102	NCT00070434	Withdrawn	Phase 2	poor accrual	C2721771	ácido levofolínico
Gefitinib	Malignant neoplasm of lung	C0242379	NCT00091156	Terminated	Phase 3	low accrual	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Triptorelin	Drug toxicity	C0013221	NCT00090844	Terminated	Phase 2	Early closure due to low accrual	C0077275	triptorelinum
Fluorouracil	Biliary Tract Cancer	C0750952	NCT00090025	Terminated	Phase 3	Futility reasons after Independent Data Monitoring Committee interim analysis	C0016360	Fluorouracilum
Celecoxib	Malignant tumor of colon	C0007102	NCT00087256	Terminated	Phase 3	For scientific, logistic, and administrative reasons.	C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Capsaicin	Peripheral Neuropathy	C0031117	NCT00085761	Terminated	Phase 3	Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes	C0006931	Capsaicina
Capsaicin	Pain	C0030193	NCT00085761	Terminated	Phase 3	Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes	C0006931	Capsaicina
Gefitinib	Recurrent Head and Neck Carcinoma	C1335703	NCT00088907	Terminated	Phase 3	It was unlikely that the primary endpoint would be reached based on the fifth interim analysis    results.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Docetaxel	Recurrent Head and Neck Carcinoma	C1335703	NCT00088907	Terminated	Phase 3	It was unlikely that the primary endpoint would be reached based on the fifth interim analysis    results.	C0246415	Docetaxel
Gefitinib	Head and neck cancer metastatic	C0744619	NCT00088907	Terminated	Phase 3	It was unlikely that the primary endpoint would be reached based on the fifth interim analysis    results.	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Docetaxel	Head and neck cancer metastatic	C0744619	NCT00088907	Terminated	Phase 3	It was unlikely that the primary endpoint would be reached based on the fifth interim analysis    results.	C0246415	Docetaxel
Metronidazole	Small cell lung cancer extensive stage	C0278726	NCT00088933	Terminated	Phase 1		C0025872	Metronidazol
Docetaxel	Small cell lung cancer extensive stage	C0278726	NCT00088933	Terminated	Phase 1		C0246415	Docetaxel
Metronidazole	Colon cancer recurrent	C0278553	NCT00088933	Terminated	Phase 1		C0025872	Metronidazol
Docetaxel	Colon cancer recurrent	C0278553	NCT00088933	Terminated	Phase 1		C0246415	Docetaxel
Metronidazole	Non-small cell lung cancer recurrent	C0278517	NCT00088933	Terminated	Phase 1		C0025872	Metronidazol
Docetaxel	Non-small cell lung cancer recurrent	C0278517	NCT00088933	Terminated	Phase 1		C0246415	Docetaxel
Metronidazole	Recurrent Rectal Cancer	C0278554	NCT00088933	Terminated	Phase 1		C0025872	Metronidazol
Docetaxel	Recurrent Rectal Cancer	C0278554	NCT00088933	Terminated	Phase 1		C0246415	Docetaxel
Metronidazole	Small cell lung cancer recurrent	C0278727	NCT00088933	Terminated	Phase 1		C0025872	Metronidazol
Docetaxel	Small cell lung cancer recurrent	C0278727	NCT00088933	Terminated	Phase 1		C0246415	Docetaxel
Metronidazole	Non-small cell lung cancer metastatic	C0278987	NCT00088933	Terminated	Phase 1		C0025872	Metronidazol
Docetaxel	Non-small cell lung cancer metastatic	C0278987	NCT00088933	Terminated	Phase 1		C0246415	Docetaxel
Romidepsin	Ovarian epithelial cancer recurrent	C0278689	NCT00091195	Terminated	Phase 2	Administratively complete.	C1527027	Romidepsine
Romidepsin	Gastrinoma	C0017150	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	Glucagonoma	C0017689	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	insulinoma	C0021670	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	pancreatic polypeptide tumor	C1882278	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	Carcinoid tumor of lung	C0280089	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	recurrent gastrointestinal carcinoid tumor	C0278750	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	recurrent islet cell carcinoma	C0278843	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	regional gastrointestinal carcinoid tumor	C0278748	NCT00084461	Terminated	Phase 2		C1527027	Romidepsine
Valsartan	Kidney Diseases	C0022658	NCT00089518	Withdrawn	Phase 3		C0216784	N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Capsaicin	Diabetic Neuropathies	C0011882	NCT00089557	Terminated	Phase 2		C0006931	Capsaicina
Capsaicin	Diabetes Mellitus	C0011849	NCT00089557	Terminated	Phase 2		C0006931	Capsaicina
Capsaicin	Polyneuropathy	C0152025	NCT00089557	Terminated	Phase 2		C0006931	Capsaicina
Capsaicin	Herpes zoster disease	C0019360	NCT00089557	Terminated	Phase 2		C0006931	Capsaicina
Capsaicin	Pain	C0030193	NCT00089557	Terminated	Phase 2		C0006931	Capsaicina
Capsaicin	Peripheral Neuropathy	C0031117	NCT00089557	Terminated	Phase 2		C0006931	Capsaicina
Metronidazole	Melanoma recurrent	C0278884	NCT00087373	Terminated	Phase 2		C0025872	Metronidazol
Doxorubicin	recurrent adult soft tissue sarcoma	C0278665	NCT00089544	Terminated	Phase 2		C0013089	Doxorubicine
Thalidomide	recurrent adult soft tissue sarcoma	C0278665	NCT00089544	Terminated	Phase 2		C0039736	Thalidomidum
Ifosfamide	recurrent adult soft tissue sarcoma	C0278665	NCT00089544	Terminated	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Doxorubicin	stage I adult soft tissue sarcoma	C0278661	NCT00089544	Terminated	Phase 2		C0013089	Doxorubicine
Thalidomide	stage I adult soft tissue sarcoma	C0278661	NCT00089544	Terminated	Phase 2		C0039736	Thalidomidum
Ifosfamide	stage I adult soft tissue sarcoma	C0278661	NCT00089544	Terminated	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Doxorubicin	stage II adult soft tissue sarcoma	C0278662	NCT00089544	Terminated	Phase 2		C0013089	Doxorubicine
Thalidomide	stage II adult soft tissue sarcoma	C0278662	NCT00089544	Terminated	Phase 2		C0039736	Thalidomidum
Ifosfamide	stage II adult soft tissue sarcoma	C0278662	NCT00089544	Terminated	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Doxorubicin	stage III adult soft tissue sarcoma	C0278663	NCT00089544	Terminated	Phase 2		C0013089	Doxorubicine
Thalidomide	stage III adult soft tissue sarcoma	C0278663	NCT00089544	Terminated	Phase 2		C0039736	Thalidomidum
Ifosfamide	stage III adult soft tissue sarcoma	C0278663	NCT00089544	Terminated	Phase 2		C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Rituximab	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00088881	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00088881	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00088881	Terminated	Phase 2		C0042679	Vincristina
Doxorubicin	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00088881	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00088881	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00088881	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00088881	Terminated	Phase 2		C0042679	Vincristina
Doxorubicin	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00088881	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	Monocytoid B-cell lymphoma	C0855139	NCT00088881	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	Monocytoid B-cell lymphoma	C0855139	NCT00088881	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	Monocytoid B-cell lymphoma	C0855139	NCT00088881	Terminated	Phase 2		C0042679	Vincristina
Doxorubicin	Monocytoid B-cell lymphoma	C0855139	NCT00088881	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00088881	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00088881	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00088881	Terminated	Phase 2		C0042679	Vincristina
Doxorubicin	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00088881	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00088881	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00088881	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00088881	Terminated	Phase 2		C0042679	Vincristina
Doxorubicin	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT00088881	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	stage I adult diffuse large cell lymphoma	C0279960	NCT00088881	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	stage I adult diffuse large cell lymphoma	C0279960	NCT00088881	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	stage I adult diffuse large cell lymphoma	C0279960	NCT00088881	Terminated	Phase 2		C0042679	Vincristina
Doxorubicin	stage I adult diffuse large cell lymphoma	C0279960	NCT00088881	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	Malignant lymphoma of testis	C0349644	NCT00088881	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	Malignant lymphoma of testis	C0349644	NCT00088881	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	Malignant lymphoma of testis	C0349644	NCT00088881	Terminated	Phase 2		C0042679	Vincristina
Doxorubicin	Malignant lymphoma of testis	C0349644	NCT00088881	Terminated	Phase 2		C0013089	Doxorubicine
Ifosfamide	unspecified adult solid tumor, protocol specific	C0279004	NCT00086970	Terminated	Phase 1	Administratively complete.	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Vitamin C	refractory plasma cell neoplasm	C0278620	NCT00085345	Withdrawn	Phase 2		C0003968	Acidum ascorbicum
Melphalan	refractory plasma cell neoplasm	C0278620	NCT00085345	Withdrawn	Phase 2		C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Arsenic trioxide	refractory plasma cell neoplasm	C0278620	NCT00085345	Withdrawn	Phase 2		C0052416	arsénico trióxido
Oxaliplatin	unspecified adult solid tumor, protocol specific	C0279004	NCT00086983	Terminated	Phase 1		C0069717	oxaliplatine
Rituximab	leukemia	C0023418	NCT00087009	Terminated	Phase 1	Lack of Accrual	C5195655	rituximab-pvvr
Rituximab	Lymphoproliferative Disorders	C0024314	NCT00087009	Terminated	Phase 1	Lack of Accrual	C5195655	rituximab-pvvr
Topotecan	Malignant neoplasm of lung	C0242379	NCT00087048	Terminated	Phase 2	Slow accrual	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Sirolimus	Rheumatoid Arthritis	C0003873	NCT00076206	Terminated	Phase 2		C0072980	Sirolimús
Everolimus	Rheumatoid Arthritis	C0003873	NCT00076206	Terminated	Phase 2		C0541315	évérolimus
Pegfilgrastim	Central Nervous System Neoplasms	C0085136	NCT00107471	Terminated	Phase 1/Phase 2	The unpromising experience of the French group with topotecan given at a dosage of 0.4    mg/m2/day over 30 mins w/in 1 hr of radiation (Cancer 2005; 104: 2792).	C4735048	pegfilgrastim-cbqv
Topotecan	Central Nervous System Neoplasms	C0085136	NCT00107471	Terminated	Phase 1/Phase 2	The unpromising experience of the French group with topotecan given at a dosage of 0.4    mg/m2/day over 30 mins w/in 1 hr of radiation (Cancer 2005; 104: 2792).	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Vancomycin	Bacteremia	C0004610	NCT00108433	Terminated	Phase 3	See Detailed Description	C0042313	Vancomycine
Linezolid	Bacteremia	C0004610	NCT00108433	Terminated	Phase 3	See Detailed Description	C0663241	Linezolidum
Cefazolin	Bacteremia	C0004610	NCT00108433	Terminated	Phase 3	See Detailed Description	C0007546	Cefazolinum
Vancomycin	Gram-Positive Bacterial Infections	C0085426	NCT00108433	Terminated	Phase 3	See Detailed Description	C0042313	Vancomycine
Linezolid	Gram-Positive Bacterial Infections	C0085426	NCT00108433	Terminated	Phase 3	See Detailed Description	C0663241	Linezolidum
Cefazolin	Gram-Positive Bacterial Infections	C0085426	NCT00108433	Terminated	Phase 3	See Detailed Description	C0007546	Cefazolinum
Niacin	Kidney Failure, Chronic	C0022661	NCT00108485	Terminated	Phase 3	Unable to recruit sufficient study subjects	C0027996	anti-pellagra vitamin
Sorafenib	Conventional (Clear Cell) Renal Cell Carcinoma	C0279702	NCT00098618	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	Conventional (Clear Cell) Renal Cell Carcinoma	C0279702	NCT00098618	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Rituximab	recurrent grade 1 follicular lymphoma	C0280182	NCT00079443	Terminated	Phase 2		C5195655	rituximab-pvvr
Fludarabine	recurrent grade 1 follicular lymphoma	C0280182	NCT00079443	Terminated	Phase 2		C0059985	Fludarabinum
Romidepsin	recurrent grade 1 follicular lymphoma	C0280182	NCT00079443	Terminated	Phase 2		C1527027	Romidepsine
Rituximab	recurrent grade 2 follicular lymphoma	C0280183	NCT00079443	Terminated	Phase 2		C5195655	rituximab-pvvr
Fludarabine	recurrent grade 2 follicular lymphoma	C0280183	NCT00079443	Terminated	Phase 2		C0059985	Fludarabinum
Romidepsin	recurrent grade 2 follicular lymphoma	C0280183	NCT00079443	Terminated	Phase 2		C1527027	Romidepsine
Rituximab	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00079443	Terminated	Phase 2		C5195655	rituximab-pvvr
Fludarabine	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00079443	Terminated	Phase 2		C0059985	Fludarabinum
Romidepsin	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00079443	Terminated	Phase 2		C1527027	Romidepsine
Infliximab	Berylliosis	C0005138	NCT00111917	Terminated	Phase 1/Phase 2	Not enough patients meeting criteria to enroll in the time period	C4490035	Infliximab-abda
Vorinostat	Multiple Myeloma	C0026764	NCT00109109	Terminated	Phase 1		C0672708	Vorinostatum
Trimethoprim	HIV Infections	C0019693	NCT00080119	Terminated	Phase 2/Phase 3	Data Safety Monitoring Board (DSMB) recommended stopping study due to futility	C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Isoniazid	HIV Infections	C0019693	NCT00080119	Terminated	Phase 2/Phase 3	Data Safety Monitoring Board (DSMB) recommended stopping study due to futility	C0022209	Isoniazida
Sulfamethoxazole	HIV Infections	C0019693	NCT00080119	Terminated	Phase 2/Phase 3	Data Safety Monitoring Board (DSMB) recommended stopping study due to futility	C0038689	Sulphamethoxazole
Trimethoprim	Tuberculosis	C0041296	NCT00080119	Terminated	Phase 2/Phase 3	Data Safety Monitoring Board (DSMB) recommended stopping study due to futility	C0041041	2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Isoniazid	Tuberculosis	C0041296	NCT00080119	Terminated	Phase 2/Phase 3	Data Safety Monitoring Board (DSMB) recommended stopping study due to futility	C0022209	Isoniazida
Sulfamethoxazole	Tuberculosis	C0041296	NCT00080119	Terminated	Phase 2/Phase 3	Data Safety Monitoring Board (DSMB) recommended stopping study due to futility	C0038689	Sulphamethoxazole
Exemestane	Breast cancer stage II	C0278486	NCT00080613	Withdrawn	Phase 2		C0851344	6-methyleneandrosta-1,4-diene-3,17-dione
Lenalidomide	Reflex Sympathetic Dystrophy	C0034931	NCT00109772	Terminated	Phase 2	Interim analysis showed the primary outcome was not reached	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Reflex Sympathetic Dystrophy	C0034931	NCT00109772	Terminated	Phase 2	Interim analysis showed the primary outcome was not reached	C0039736	Thalidomidum
Alemtuzumab	Lymphoma, Non-Hodgkin	C0024305	NCT00077961	Terminated	Phase 1/Phase 2		C0383429	Alemtuzumab
Trastuzumab	Breast cancer recurrent	C0278493	NCT00079326	Terminated	Phase 2	Slow accrual.	C5187552	trastuzumab-anns
Imatinib	chronic myelogenous leukemia in relapse	C0278787	NCT00101088	Terminated	Phase 1		C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Sirolimus	chronic myelogenous leukemia in relapse	C0278787	NCT00101088	Terminated	Phase 1		C0072980	Sirolimús
Everolimus	chronic myelogenous leukemia in relapse	C0278787	NCT00101088	Terminated	Phase 1		C0541315	évérolimus
Lopinavir	Human immunodeficiency virus I infection	C0276500	NCT00102778	Terminated	Phase 2		C0674432	Lopinavir
Rituximab	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00080847	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00080847	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00080847	Terminated	Phase 2		C0042679	Vincristina
Prednisone	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00080847	Terminated	Phase 2		C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Doxorubicin	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT00080847	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00080847	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00080847	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00080847	Terminated	Phase 2		C0042679	Vincristina
Prednisone	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00080847	Terminated	Phase 2		C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Doxorubicin	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT00080847	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	stage III adult diffuse large cell lymphoma	C0280162	NCT00080847	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	stage III adult diffuse large cell lymphoma	C0280162	NCT00080847	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	stage III adult diffuse large cell lymphoma	C0280162	NCT00080847	Terminated	Phase 2		C0042679	Vincristina
Prednisone	stage III adult diffuse large cell lymphoma	C0280162	NCT00080847	Terminated	Phase 2		C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Doxorubicin	stage III adult diffuse large cell lymphoma	C0280162	NCT00080847	Terminated	Phase 2		C0013089	Doxorubicine
Rituximab	stage IV adult diffuse large cell lymphoma	C0280175	NCT00080847	Terminated	Phase 2		C5195655	rituximab-pvvr
Cyclophosphamide	stage IV adult diffuse large cell lymphoma	C0280175	NCT00080847	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	stage IV adult diffuse large cell lymphoma	C0280175	NCT00080847	Terminated	Phase 2		C0042679	Vincristina
Prednisone	stage IV adult diffuse large cell lymphoma	C0280175	NCT00080847	Terminated	Phase 2		C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Doxorubicin	stage IV adult diffuse large cell lymphoma	C0280175	NCT00080847	Terminated	Phase 2		C0013089	Doxorubicine
Bevacizumab	Colorectal Neoplasms	C0009404	NCT00106054	Terminated	Phase 2	After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could    be performed.	C0796392	Anti-VEGF monoclonal antibody
Irinotecan	Colorectal Neoplasms	C0009404	NCT00106054	Terminated	Phase 2	After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could    be performed.	C0123931	(+)-Irinotecan
Bevacizumab	Liver neoplasms	C0023903	NCT00106054	Terminated	Phase 2	After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could    be performed.	C0796392	Anti-VEGF monoclonal antibody
Irinotecan	Liver neoplasms	C0023903	NCT00106054	Terminated	Phase 2	After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could    be performed.	C0123931	(+)-Irinotecan
Ezetimibe	Lipid Metabolism, Inborn Errors	C0023772	NCT00092833	Terminated	Phase 3		C1142985	Ezetimiba
Clofarabine	leukemia	C0023418	NCT00081887	Terminated	Phase 1	low accrual	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Sirolimus	Multiple Sclerosis	C0026769	NCT00095329	Terminated	Phase 1/Phase 2		C0072980	Sirolimús
Everolimus	Multiple Sclerosis	C0026769	NCT00095329	Terminated	Phase 1/Phase 2		C0541315	évérolimus
Erlotinib	Metastatic malignant neoplasm to brain	C0220650	NCT00096265	Terminated	Phase 3		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Temozolomide	Metastatic malignant neoplasm to brain	C0220650	NCT00096265	Terminated	Phase 3		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Erlotinib	Non-small cell lung cancer recurrent	C0278517	NCT00096265	Terminated	Phase 3		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Temozolomide	Non-small cell lung cancer recurrent	C0278517	NCT00096265	Terminated	Phase 3		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Erlotinib	Non-small cell lung cancer metastatic	C0278987	NCT00096265	Terminated	Phase 3		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Temozolomide	Non-small cell lung cancer metastatic	C0278987	NCT00096265	Terminated	Phase 3		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Bortezomib	adult grade III lymphomatoid granulomatosis	C1541468	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Angioimmunoblastic Lymphadenopathy	C0020981	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Monocytoid B-cell lymphoma	C0855139	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult Burkitt's lymphoma	C0280192	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult diffuse large cell lymphoma	C0280188	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Cutaneous T-cell lymphoma recurrent	C0278580	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent grade 1 follicular lymphoma	C0280182	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent grade 2 follicular lymphoma	C0280183	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent grade 3 follicular lymphoma	C0280185	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mantle cell lymphoma recurrent	C0677725	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Marginal zone lymphoma recurrent	C1541273	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III adult Burkitt's lymphoma	C0280166	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III adult diffuse large cell lymphoma	C0280162	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III adult diffuse mixed cell lymphoma	C0280161	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III adult diffuse small cleaved cell lymphoma	C0280160	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III adult Hodgkin's lymphoma	C0278472	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III adult immunoblastic large cell lymphoma	C0280164	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III adult lymphoblastic lymphoma	C0280165	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Adult T-cell lymphoma/leukaemia stage III	C0280425	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Cutaneous T-cell lymphoma stage III	C0278570	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III grade 1 follicular lymphoma	C0280156	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III grade 2 follicular lymphoma	C0280157	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage III grade 3 follicular lymphoma	C0280159	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mantle cell lymphoma stage III	C0677714	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Marginal zone lymphoma stage III	C1541269	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mycosis fungoides/Sezary syndrome stage III	C0862221	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	B-cell small lymphocytic lymphoma stage III	C0855100	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV adult Burkitt's lymphoma	C0280179	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV adult diffuse large cell lymphoma	C0280175	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV adult diffuse mixed cell lymphoma	C0280174	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV adult diffuse small cleaved cell lymphoma	C0280173	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV adult Hodgkin's lymphoma	C0278473	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV adult immunoblastic large cell lymphoma	C0280177	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV adult lymphoblastic lymphoma	C0280178	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Adult T-cell lymphoma/leukaemia stage IV	C0280426	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Cutaneous T-cell lymphoma stage IV	C0278572	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	AIDS-related peripheral/systemic lymphoma	C0281240	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV grade 1 follicular lymphoma	C0280169	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV grade 2 follicular lymphoma	C0280170	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	stage IV grade 3 follicular lymphoma	C0280172	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mantle cell lymphoma stage IV	C0677721	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Marginal zone lymphoma stage IV	C1541270	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mycosis fungoides/Sezary syndrome stage IV	C0862226	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	B-cell small lymphocytic lymphoma stage IV	C0855101	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	unspecified adult solid tumor, protocol specific	C0279004	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult Hodgkin's lymphoma	C0278530	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent adult lymphoblastic lymphoma	C0280191	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT00096005	Terminated	Phase 1		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Sorafenib	Anaplastic thyroid carcinoma	C0238461	NCT00095693	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	Anaplastic thyroid carcinoma	C0238461	NCT00095693	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sorafenib	insular thyroid cancer	C1134506	NCT00095693	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	insular thyroid cancer	C1134506	NCT00095693	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sorafenib	Recurrent Thyroid Carcinoma	C0278861	NCT00095693	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	Recurrent Thyroid Carcinoma	C0278861	NCT00095693	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sorafenib	stage III follicular thyroid cancer	C0279178	NCT00095693	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	stage III follicular thyroid cancer	C0279178	NCT00095693	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sorafenib	stage III papillary thyroid cancer	C0279179	NCT00095693	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	stage III papillary thyroid cancer	C0279179	NCT00095693	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sorafenib	stage IV follicular thyroid cancer	C0278854	NCT00095693	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	stage IV follicular thyroid cancer	C0278854	NCT00095693	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sorafenib	Metastatic papillary thyroid carcinoma	C0278851	NCT00095693	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	Metastatic papillary thyroid carcinoma	C0278851	NCT00095693	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sirolimus	recurrent adult diffuse large cell lymphoma	C0280188	NCT00086840	Terminated	Phase 2	Administratively complete.	C0072980	Sirolimús
Everolimus	recurrent adult diffuse large cell lymphoma	C0280188	NCT00086840	Terminated	Phase 2	Administratively complete.	C0541315	évérolimus
Sirolimus	recurrent adult Hodgkin's lymphoma	C0278530	NCT00086840	Terminated	Phase 2	Administratively complete.	C0072980	Sirolimús
Everolimus	recurrent adult Hodgkin's lymphoma	C0278530	NCT00086840	Terminated	Phase 2	Administratively complete.	C0541315	évérolimus
Sirolimus	Chronic lymphocytic leukaemia refractory	C0278791	NCT00086840	Terminated	Phase 2	Administratively complete.	C0072980	Sirolimús
Everolimus	Chronic lymphocytic leukaemia refractory	C0278791	NCT00086840	Terminated	Phase 2	Administratively complete.	C0541315	évérolimus
Romidepsin	melanoma	C0025202	NCT00104884	Terminated	Phase 2	The study was terminated on May 17, 2006 due to slow accrual.	C1527027	Romidepsine
Ciprofloxacin	Fever	C0015967	NCT00107081	Terminated	Phase 3	Accrual goal for interventional part not achievable	C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Bortezomib	Malignant neoplasm of stomach	C0024623	NCT00103103	Terminated	Phase 2		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Levoleucovorin	Malignant neoplasm of stomach	C0024623	NCT00103103	Terminated	Phase 2		C2721771	ácido levofolínico
Venlafaxine	Anxiety Disorders	C0003469	NCT00083980	Terminated	Phase 2	European reports of liver toxicity from kava meant that the study had to stop	C0078569	Venlafaxinum
Metronidazole	Bladder Adenocarcinoma	C0279682	NCT00072137	Terminated	Phase 1		C0025872	Metronidazol
Metronidazole	Bladder Squamous Cell Carcinoma	C0279681	NCT00072137	Terminated	Phase 1		C0025872	Metronidazol
Metronidazole	Transitional cell carcinoma of bladder	C0279680	NCT00072137	Terminated	Phase 1		C0025872	Metronidazol
Metronidazole	Bladder cancer recurrent	C0278827	NCT00072137	Terminated	Phase 1		C0025872	Metronidazol
Metronidazole	Bladder cancer stage II	C0278823	NCT00072137	Terminated	Phase 1		C0025872	Metronidazol
Metronidazole	Bladder cancer stage III	C0278824	NCT00072137	Terminated	Phase 1		C0025872	Metronidazol
Infliximab	Giant Cell Arteritis	C0039483	NCT00076726	Terminated	Phase 2	Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative    glucocorticosteroid dosage	C4490035	Infliximab-abda
Sirolimus	Neoplasm Metastasis	C0027627	NCT00083993	Terminated	Phase 3		C0072980	Sirolimús
Letrozole	Neoplasm Metastasis	C0027627	NCT00083993	Terminated	Phase 3		C0246421	Letrozol
Everolimus	Neoplasm Metastasis	C0027627	NCT00083993	Terminated	Phase 3		C0541315	évérolimus
Gemcitabine	Meningitis	C0025289	NCT00074607	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Abciximab	Brain Ischemia	C0007786	NCT00073372	Terminated	Phase 3	Based on the data and observed benefit-risk profile, the trial's independent oversight    committee recommended that enrollment not resume.	C0288672	c7E3
Abciximab	Acute Disease	C0001314	NCT00073372	Terminated	Phase 3	Based on the data and observed benefit-risk profile, the trial's independent oversight    committee recommended that enrollment not resume.	C0288672	c7E3
Cisplatin	extragonadal germ cell tumor	C0262963	NCT00072215	Terminated	Phase 3	poor accrual	C0008838	cisplatino
Vinblastine	extragonadal germ cell tumor	C0262963	NCT00072215	Terminated	Phase 3	poor accrual	C0042670	Vinblastina
Ifosfamide	extragonadal germ cell tumor	C0262963	NCT00072215	Terminated	Phase 3	poor accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Paclitaxel	extragonadal germ cell tumor	C0262963	NCT00072215	Terminated	Phase 3	poor accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Vinblastine	Testicular Germ Cell Tumor	C1336708	NCT00072215	Terminated	Phase 3	poor accrual	C0042670	Vinblastina
Paclitaxel	Testicular Germ Cell Tumor	C1336708	NCT00072215	Terminated	Phase 3	poor accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Celecoxib	High-Grade Squamous Intraepithelial Lesions	C0333875	NCT00072540	Withdrawn	Phase 2	drug issues	C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Gemcitabine	unspecified adult solid tumor, protocol specific	C0279004	NCT00072228	Withdrawn	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Thalidomide	Stomatitis	C0038362	NCT00075023	Terminated	Phase 2	unable to enroll adequate subjects	C0039736	Thalidomidum
Sorafenib	Anaplastic thyroid carcinoma	C0238461	NCT00126568	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	Anaplastic thyroid carcinoma	C0238461	NCT00126568	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Sorafenib	Recurrent Thyroid Carcinoma	C0278861	NCT00126568	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	Recurrent Thyroid Carcinoma	C0278861	NCT00126568	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Cyclophosphamide	Leukemia, Myelocytic, Acute	C0023467	NCT00125606	Terminated	Phase 3	insufficient patient recruitement	C0010583	Cyclophosphamidum
Fludarabine	Leukemia, Myelocytic, Acute	C0023467	NCT00125606	Terminated	Phase 3	insufficient patient recruitement	C0059985	Fludarabinum
Bortezomib	Bronchioloalveolar Adenocarcinoma	C0007120	NCT00117351	Terminated	Phase 2	insufficient efficacy	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Rituximab	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C5195655	rituximab-pvvr
Cyclophosphamide	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C0010583	Cyclophosphamidum
Vincristine	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C0042679	Vincristina
Methotrexate	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Etoposide	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Cytarabine	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C0010711	Cytarabinum
Doxorubicin	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C0013089	Doxorubicine
Ifosfamide	Atypical Burkitt's lymphoma	C1629504	NCT00126191	Terminated	Phase 2	closed due to slow accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Tacrolimus	Graft-vs-Host Disease	C0018133	NCT00117702	Terminated	Phase 2/Phase 3	safety reasons	C0771204	Tacrolimus anhydrous
Sirolimus	Graft-vs-Host Disease	C0018133	NCT00117702	Terminated	Phase 2/Phase 3	safety reasons	C0072980	Sirolimús
Everolimus	Graft-vs-Host Disease	C0018133	NCT00117702	Terminated	Phase 2/Phase 3	safety reasons	C0541315	évérolimus
Sorafenib	Conventional (Clear Cell) Renal Cell Carcinoma	C0279702	NCT00126659	Terminated	Phase 2		C1516119	Sorafenibum
Nicotinamide	Conventional (Clear Cell) Renal Cell Carcinoma	C0279702	NCT00126659	Terminated	Phase 2		C0028027	3-pyridinecarboxamide
Bevacizumab	Adenocarcinoma	C0001418	NCT00127036	Terminated	Phase 2	drug now on market	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Adenocarcinoma	C0001418	NCT00127036	Terminated	Phase 2	drug now on market	C0069717	oxaliplatine
Fluorouracil	Adenocarcinoma	C0001418	NCT00127036	Terminated	Phase 2	drug now on market	C0016360	Fluorouracilum
Irinotecan	Adenocarcinoma	C0001418	NCT00127036	Terminated	Phase 2	drug now on market	C0123931	(+)-Irinotecan
Capecitabine	Adenocarcinoma	C0001418	NCT00127036	Terminated	Phase 2	drug now on market	C0671970	Capecitabin
Bevacizumab	adult acute basophilic leukemia	C0279631	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute basophilic leukemia	C0279631	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute basophilic leukemia	C0279631	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute eosinophilic leukemia	C0279630	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute eosinophilic leukemia	C0279630	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute eosinophilic leukemia	C0279630	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute monoblastic leukemia (M5a)	C0279629	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute monoblastic leukemia (M5a)	C0279629	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute monoblastic leukemia (M5a)	C0279629	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute monocytic leukemia (M5b)	C0280634	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute monocytic leukemia (M5b)	C0280634	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute monocytic leukemia (M5b)	C0280634	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult acute myelomonocytic leukemia (M4)	C0279627	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult acute myelomonocytic leukemia (M4)	C0279627	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult acute myelomonocytic leukemia (M4)	C0279627	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult erythroleukemia (M6a)	C1541339	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult erythroleukemia (M6a)	C1541339	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult erythroleukemia (M6a)	C1541339	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	adult pure erythroid leukemia (M6b)	C1541340	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	adult pure erythroid leukemia (M6b)	C1541340	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	adult pure erythroid leukemia (M6b)	C1541340	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	childhood acute basophilic leukemia	C0279649	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	childhood acute basophilic leukemia	C0279649	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	childhood acute basophilic leukemia	C0279649	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	childhood acute eosinophilic leukemia	C0279648	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	childhood acute eosinophilic leukemia	C0279648	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	childhood acute eosinophilic leukemia	C0279648	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	childhood acute erythroleukemia (M6)	C0279647	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	childhood acute erythroleukemia (M6)	C0279647	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	childhood acute erythroleukemia (M6)	C0279647	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	childhood acute megakaryocytic leukemia (M7)	C0279650	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	childhood acute megakaryocytic leukemia (M7)	C0279650	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	childhood acute megakaryocytic leukemia (M7)	C0279650	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	childhood acute myeloblastic leukemia with maturation (M2)	C0279636	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	childhood acute myeloblastic leukemia with maturation (M2)	C0279636	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	childhood acute myeloblastic leukemia with maturation (M2)	C0279636	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	childhood acute myeloblastic leukemia without maturation (M1)	C0279634	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	childhood acute myeloblastic leukemia without maturation (M1)	C0279634	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	childhood acute myeloblastic leukemia without maturation (M1)	C0279634	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	childhood acute myelomonocytic leukemia (M4)	C0279644	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	childhood acute myelomonocytic leukemia (M4)	C0279644	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	childhood acute myelomonocytic leukemia (M4)	C0279644	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	secondary acute myeloid leukemia	C0280449	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	secondary acute myeloid leukemia	C0280449	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	secondary acute myeloid leukemia	C0280449	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	untreated adult acute myeloid leukemia	C0279089	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	untreated adult acute myeloid leukemia	C0279089	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	untreated adult acute myeloid leukemia	C0279089	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Bevacizumab	untreated childhood acute myeloid leukemia and other myeloid malignancies	C0279090	NCT00096148	Terminated	Phase 2	Administratively complete.	C0796392	Anti-VEGF monoclonal antibody
Cytarabine	untreated childhood acute myeloid leukemia and other myeloid malignancies	C0279090	NCT00096148	Terminated	Phase 2	Administratively complete.	C0010711	Cytarabinum
Idarubicin	untreated childhood acute myeloid leukemia and other myeloid malignancies	C0279090	NCT00096148	Terminated	Phase 2	Administratively complete.	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Cidofovir	BK virus nephropathy	C1697878	NCT00138424	Terminated	Phase 1/Phase 2		C0286079	Cidofovirum
Sildenafil	Pre-Eclampsia	C0032914	NCT00141310	Terminated	Phase 2	Study prematurely discont’d 20-Apr-2006 after interim analysis suggested sample size could be    reduced without losing power. No safety concerns led to decision.	C0529793	Sildenafilo
Alefacept	Lichen Planus	C0023646	NCT00135733	Terminated	Phase 2	Pharmaceutical sponsor withdrew financial support.	C0962603	Alefacept
Rituximab	Waldenstrom Macroglobulinemia	C0024419	NCT00142168	Terminated	Phase 2	Toxicity	C5195655	rituximab-pvvr
Lenalidomide	Waldenstrom Macroglobulinemia	C0024419	NCT00142168	Terminated	Phase 2	Toxicity	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Waldenstrom Macroglobulinemia	C0024419	NCT00142168	Terminated	Phase 2	Toxicity	C0039736	Thalidomidum
Amlodipine	Chronic heart failure	C0264716	NCT00151619	Suspended	Phase 2		C0051696	Amlodipinum
Memantine	Schizophrenia	C0036341	NCT00148590	Terminated	Phase 3		C0025242	Memantina
Pioglitazone	HIV-Associated Lipodystrophy Syndrome	C1136321	NCT00148850	Terminated	Phase 3		C0071097	(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
Memantine	Chronic schizophrenia	C0221765	NCT00148616	Terminated	Phase 3		C0025242	Memantina
Mycophenolate mofetil	Evidence of liver transplantation	C0940823	NCT00151632	Terminated	Phase 3	insufficient enrollment	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Evidence of liver transplantation	C0940823	NCT00151632	Terminated	Phase 3	insufficient enrollment	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Evidence of liver transplantation	C0940823	NCT00151632	Terminated	Phase 3	insufficient enrollment	C0026933	Mycophenolsäure
Cyclophosphamide	Leukemia, Myelocytic, Acute	C0023467	NCT00150878	Terminated	Phase 3	Insurance coverage reached	C0010583	Cyclophosphamidum
Clonidine	Treatment related secondary malignancy	C0877578	NCT00166686	Withdrawn	Phase 1/Phase 2	Study was never initiated	C0009014	2-((2,6-Dichlorophenyl)imino)imidazolidine
Octreotide	Proliferative diabetic retinopathy	C0154830	NCT00170742	Terminated	Phase 3	trial stopped on Sept 24, 2007	C0028833	Octreotida
Oxaliplatin	Colonic Neoplasms	C0009375	NCT00180960	Terminated	Phase 2		C0069717	oxaliplatine
Irinotecan	Colonic Neoplasms	C0009375	NCT00180960	Terminated	Phase 2		C0123931	(+)-Irinotecan
Oxaliplatin	Rectal Neoplasms	C0034885	NCT00180960	Terminated	Phase 2		C0069717	oxaliplatine
Irinotecan	Rectal Neoplasms	C0034885	NCT00180960	Terminated	Phase 2		C0123931	(+)-Irinotecan
Oxaliplatin	Appendiceal Neoplasms	C0003614	NCT00180960	Terminated	Phase 2		C0069717	oxaliplatine
Irinotecan	Appendiceal Neoplasms	C0003614	NCT00180960	Terminated	Phase 2		C0123931	(+)-Irinotecan
Oxaliplatin	Peritoneal Neoplasms	C0031149	NCT00180960	Terminated	Phase 2		C0069717	oxaliplatine
Irinotecan	Peritoneal Neoplasms	C0031149	NCT00180960	Terminated	Phase 2		C0123931	(+)-Irinotecan
Oxaliplatin	Endocrine Gland Neoplasms	C0014132	NCT00180960	Terminated	Phase 2		C0069717	oxaliplatine
Irinotecan	Endocrine Gland Neoplasms	C0014132	NCT00180960	Terminated	Phase 2		C0123931	(+)-Irinotecan
Estradiol	Malignant epithelial neoplasm of female breast	C3163805	NCT00183963	Terminated	Phase 2	Insufficient accrual	C0014912	17β-oestradiol
Fulvestrant	Malignant epithelial neoplasm of female breast	C3163805	NCT00183963	Terminated	Phase 2	Insufficient accrual	C0935916	(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
Rituximab	Primary Effusion Lymphoma	C1292753	NCT00183976	Terminated	Phase 2	Insufficient Accrual	C5195655	rituximab-pvvr
Doxorubicin	Primary Effusion Lymphoma	C1292753	NCT00183976	Terminated	Phase 2	Insufficient Accrual	C0013089	Doxorubicine
Rituximab	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634	NCT00183989	Terminated	Phase 2	Insufficient accrual	C5195655	rituximab-pvvr
Fludarabine	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634	NCT00183989	Terminated	Phase 2	Insufficient accrual	C0059985	Fludarabinum
Mitoxantrone	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634	NCT00183989	Terminated	Phase 2	Insufficient accrual	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Gemcitabine	Carcinoma of unknown primary	C0220647	NCT00148135	Terminated	Phase 2	recruitment goals met	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Fluorouracil	Carcinoma of unknown primary	C0220647	NCT00148135	Terminated	Phase 2	recruitment goals met	C0016360	Fluorouracilum
Carboplatin	Carcinoma of unknown primary	C0220647	NCT00148135	Terminated	Phase 2	recruitment goals met	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Capecitabine	Carcinoma of unknown primary	C0220647	NCT00148135	Terminated	Phase 2	recruitment goals met	C0671970	Capecitabin
Cisplatin	Esophageal Neoplasms	C0014859	NCT00190554	Terminated	Phase 3		C0008838	cisplatino
Methotrexate	Urticaria	C0042109	NCT00189878	Terminated	Phase 2	unable to recruit	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Donepezil	Schizophrenia	C0036341	NCT00206947	Terminated	Phase 2	No more funding	C0527316	Donepezilo
Alemtuzumab	Leukemia, Myelocytic, Acute	C0023467	NCT00226512	Withdrawn	Phase 3	the PI is no longer work at Hadassah	C0383429	Alemtuzumab
Simvastatin	Depressive disorder	C0011581	NCT00208117	Terminated	Phase 1	Unable to enroll subjects	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Simvastatin	Coronary Artery Disease	C1956346	NCT00208117	Terminated	Phase 1	Unable to enroll subjects	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Sertraline	Coronary Artery Disease	C1956346	NCT00208117	Terminated	Phase 1	Unable to enroll subjects	C0074393	(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
Omeprazole	Nausea	C0027497	NCT00206440	Terminated	Phase 3	Accrual was not optimized	C0028978	Omeprazolum
Esomeprazole	Nausea	C0027497	NCT00206440	Terminated	Phase 3	Accrual was not optimized	C0937846	Ésoméprazole
Erythropoietin	Malignant neoplasm of gastrointestinal tract	C0685938	NCT00254436	Terminated	Phase 3		C0357126	Epoetina alfa
Pentoxifylline	Hepatitis, Alcoholic	C0019187	NCT00205049	Terminated	Phase 1	lack of funding	C0030899	Pentoxifilina
Dexamethasone	Malignant neoplasm of lung	C0242379	NCT00215748	Terminated	Phase 2	slow accrual	C0011777	Dexaméthasone
Salicylic acid	Adenomatous polyp of colon	C0850572	NCT00224679	Terminated	Phase 3		C0036079	ácido salicílico
Acetylsalicylic acid	Adenomatous polyp of colon	C0850572	NCT00224679	Terminated	Phase 3		C0004057	Aspirina
Testosterone	Hypogonadism	C0020619	NCT00254553	Terminated	Phase 2	Recruitment issues	C0039601	Testostérone
Methyltestosterone	Hypogonadism	C0020619	NCT00254553	Terminated	Phase 2	Recruitment issues	C0025826	Methyltestosteronum
Ciprofloxacin	Crohn Disease	C0010346	NCT00257699	Terminated	Phase 2	Inadequate recruitment to meet completion date	C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Metronidazole	Crohn Disease	C0010346	NCT00257699	Terminated	Phase 2	Inadequate recruitment to meet completion date	C0025872	Metronidazol
Bevacizumab	Pancreatic carcinoma recurrent	C0854777	NCT00253526	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Gemcitabine	Pancreatic carcinoma recurrent	C0854777	NCT00253526	Withdrawn	Phase 2		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Bevacizumab	Pancreatic carcinoma stage I	C1167720	NCT00253526	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Gemcitabine	Pancreatic carcinoma stage I	C1167720	NCT00253526	Withdrawn	Phase 2		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Bevacizumab	Pancreatic carcinoma stage II	C1167721	NCT00253526	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Gemcitabine	Pancreatic carcinoma stage II	C1167721	NCT00253526	Withdrawn	Phase 2		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Bevacizumab	Pancreatic carcinoma stage III	C1167722	NCT00253526	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Gemcitabine	Pancreatic carcinoma stage III	C1167722	NCT00253526	Withdrawn	Phase 2		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Trioxsalen	cholangiocarcinoma of the extrahepatic bile duct	C0280533	NCT00253617	Withdrawn	Phase 3		C0041086	Trioxysalenum
Trioxsalen	cholangiocarcinoma of the gallbladder	C0280532	NCT00253617	Withdrawn	Phase 3		C0041086	Trioxysalenum
Trioxsalen	unresectable extrahepatic bile duct cancer	C0278811	NCT00253617	Withdrawn	Phase 3		C0041086	Trioxysalenum
Trioxsalen	unresectable gallbladder cancer	C0278807	NCT00253617	Withdrawn	Phase 3		C0041086	Trioxysalenum
Trioxsalen	recurrent extrahepatic bile duct cancer	C0278812	NCT00253617	Withdrawn	Phase 3		C0041086	Trioxysalenum
Octreotide	Diabetic Retinopathy	C0011884	NCT00248131	Terminated	Phase 3		C0028833	Octreotida
Imiquimod	Morphea	C1527383	NCT00230373	Withdrawn	Phase 3	Study never started.	C0165032	1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
Rituximab	Purpura, Thrombotic Thrombocytopenic	C0034155	NCT00251277	Withdrawn	Phase 1/Phase 2		C5195655	rituximab-pvvr
Atorvastatin	Inflammation	C0021368	NCT00252967	Terminated	Phase 3	Insufficient power to show therapy difference at interim analysis.	C0286651	atorvastatine
Levofloxacin	Lymphoma, Non-Hodgkin	C0024305	NCT00250718	Terminated	Phase 2	Low rate of accrual	C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Ofloxacin	Lymphoma, Non-Hodgkin	C0024305	NCT00250718	Terminated	Phase 2	Low rate of accrual	C0028902	Ofloxacino
Capecitabine	Malignant tumor of colon	C0007102	NCT00251186	Terminated	Phase 2	Funding unavailable	C0671970	Capecitabin
Tenecteplase	Pulmonary Embolism	C0034065	NCT00222651	Terminated	Phase 2	competitor study about to start	C0872913	Tenecteplasa
Nandrolone phenpropionate	Malnutrition	C0162429	NCT00242463	Terminated	Phase 2	drug no longer available in canada	C0068397	Nandrolone phenylpropionate
Nandrolone decanoate	Malnutrition	C0162429	NCT00242463	Terminated	Phase 2	drug no longer available in canada	C0068395	Nandrolone 17β-decanoate
Nandrolone phenpropionate	Critical Illness	C0010340	NCT00242463	Terminated	Phase 2	drug no longer available in canada	C0068397	Nandrolone phenylpropionate
Nandrolone decanoate	Critical Illness	C0010340	NCT00242463	Terminated	Phase 2	drug no longer available in canada	C0068395	Nandrolone 17β-decanoate
Azacitidine	leukemia	C0023418	NCT00234000	Terminated	Phase 1	The study was closed due to poor enrollment	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Arsenic trioxide	leukemia	C0023418	NCT00234000	Terminated	Phase 1	The study was closed due to poor enrollment	C0052416	arsénico trióxido
Topiramate	Obesity	C0028754	NCT00231634	Terminated	Phase 3	Program discontinued	C0076829	Topiramato
Topiramate	Obesity	C0028754	NCT00231621	Terminated	Phase 3	The study was terminated prior to completion to focus on the development of a controlled    release formulation.	C0076829	Topiramato
Topiramate	Hyperlipidemia	C0020473	NCT00231621	Terminated	Phase 3	The study was terminated prior to completion to focus on the development of a controlled    release formulation.	C0076829	Topiramato
Topiramate	Hypertriglyceridemia	C0020557	NCT00231621	Terminated	Phase 3	The study was terminated prior to completion to focus on the development of a controlled    release formulation.	C0076829	Topiramato
Belinostat	Lymphoma, T-Cell, Cutaneous	C0079773	NCT00274651	Terminated	Phase 2	Enrollment stopped prior to reaching expected number of patients, study had accumulated    sufficient data to allow a registration study in PTCL (PXD101-CLN-19)	C1948068	Belinostat
Belinostat	Lymphoma, Non-Hodgkin	C0024305	NCT00274651	Terminated	Phase 2	Enrollment stopped prior to reaching expected number of patients, study had accumulated    sufficient data to allow a registration study in PTCL (PXD101-CLN-19)	C1948068	Belinostat
Rituximab	Immune thrombocytopenic purpura	C0398650	NCT00225875	Terminated	Phase 2		C5195655	rituximab-pvvr
Methylphenidate	Asthenia	C0004093	NCT00273741	Terminated	Phase 3	difficulty of recrutement	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Arsenic trioxide	MYELODYSPLASTIC SYNDROME	C3463824	NCT00225992	Terminated	Phase 2	terminated due to lack of accrual.	C0052416	arsénico trióxido
Pemetrexed	Malignant neoplasm of lung	C0242379	NCT00265785	Terminated	Phase 2	Closed due to poor accrual	C0210657	Pemetrexed
Simvastatin	Dyslipidemias	C0242339	NCT00267280	Terminated	Phase 3		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Atorvastatin	Dyslipidemias	C0242339	NCT00267280	Terminated	Phase 3		C0286651	atorvastatine
Simvastatin	Hyperlipidemia	C0020473	NCT00267280	Terminated	Phase 3		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Atorvastatin	Hyperlipidemia	C0020473	NCT00267280	Terminated	Phase 3		C0286651	atorvastatine
Simvastatin	Hyperlipidemia	C0020473	NCT00267267	Terminated	Phase 3		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Atorvastatin	Hyperlipidemia	C0020473	NCT00267267	Terminated	Phase 3		C0286651	atorvastatine
Simvastatin	Dyslipidemias	C0242339	NCT00267267	Terminated	Phase 3		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Ezetimibe	Dyslipidemias	C0242339	NCT00267267	Terminated	Phase 3		C1142985	Ezetimiba
Atorvastatin	Dyslipidemias	C0242339	NCT00267267	Terminated	Phase 3		C0286651	atorvastatine
Erythropoietin	Chemotherapy-induced peripheral neuropathy	C3873567	NCT00267007	Terminated	Phase 2	Slow enrollment	C0357126	Epoetina alfa
Diclofenac	Non-cyclical mastalgia	C0405473	NCT00276419	Terminated	Phase 2/Phase 3	Lack of funds; FDA approved a topical form of diclofenac during study, no need to continue    study of pharmacy-compounded drug.	C0012091	Diclofenac acid
Octreotide	Diabetic Retinopathy	C0011884	NCT00248157	Terminated	Phase 3	Inconsistent treatment benefit	C0028833	Octreotida
Bupropion	Tobacco Dependence	C0040332	NCT00248118	Terminated	Phase 2/Phase 3	PI left NIH	C0085208	Bupropion
Imatinib	Chronic myeloproliferative disorder	C1292778	NCT00245128	Terminated	Phase 2	Per PI, results from another similar study were published prior to study analysis. Negative    study results were published therefore analysis was not completed	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Floxuridine	Malignant tumor of colon	C0007102	NCT00268463	Terminated	Phase 3	The study was terminated due to low accrual.	C0016343	Fluoruridine deoxyribose
Oxaliplatin	Malignant tumor of colon	C0007102	NCT00268463	Terminated	Phase 3	The study was terminated due to low accrual.	C0069717	oxaliplatine
Capecitabine	Malignant tumor of colon	C0007102	NCT00268463	Terminated	Phase 3	The study was terminated due to low accrual.	C0671970	Capecitabin
Aldesleukin	Lymphoma, Non-Hodgkin	C0024305	NCT00250861	Terminated	Phase 2	Study terminated due to lack of enrollment.	C0218986	Aldesleukina
Mitomycin	Malignant tumor of colon	C0007102	NCT00271011	Terminated	Phase 2	The study was discontinued due to the death of a co-investigator and a second co-investigator    leaving the institution.	C0702050	Ametycine
Irinotecan	Malignant tumor of colon	C0007102	NCT00271011	Terminated	Phase 2	The study was discontinued due to the death of a co-investigator and a second co-investigator    leaving the institution.	C0123931	(+)-Irinotecan
Ganciclovir	Cytomegalovirus Infections	C0010823	NCT00241345	Terminated	Phase 3	Due to low accrual	C0017066	2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
Valganciclovir	Cytomegalovirus Infections	C0010823	NCT00241345	Terminated	Phase 3	Due to low accrual	C0909381	Valganciclovir
Toremifene	Neoplasms, Hormone-Dependent	C0027661	NCT00267553	Terminated	Phase 3	This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint	C0076836	Toremifeno
Letrozole	Neoplasms, Hormone-Dependent	C0027661	NCT00267553	Terminated	Phase 3	This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint	C0246421	Letrozol
Clofarabine	Multiple Myeloma	C0026764	NCT00241371	Terminated	Phase 2	No response seen in patients	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Rituximab	leukemia	C0023418	NCT00265915	Terminated	Phase 2		C5195655	rituximab-pvvr
Ritonavir	HIV-1 infection	C2363741	NCT00242879	Terminated	Phase 2		C0292818	Ritonavirum
Pemetrexed	Lung Neoplasms	C0024121	NCT00290017	Terminated	Phase 3	FDA Hold May 2007	C0210657	Pemetrexed
Pemetrexed	Malignant neoplasm of lung	C0242379	NCT00290017	Terminated	Phase 3	FDA Hold May 2007	C0210657	Pemetrexed
Etodolac	Multiple Myeloma	C0026764	NCT00293111	Terminated	Phase 2		C0059865	1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
Labetalol	Pregnancy associated hypertension	C0852036	NCT00293735	Suspended	Phase 2/Phase 3	Lack of funding	C0022860	Labétalol
Magnesium Sulfate	Pregnancy associated hypertension	C0852036	NCT00293735	Suspended	Phase 2/Phase 3	Lack of funding	C0024480	Magnesium sulfate
Labetalol	hypertension chronic	C0745114	NCT00293735	Suspended	Phase 2/Phase 3	Lack of funding	C0022860	Labétalol
Magnesium Sulfate	hypertension chronic	C0745114	NCT00293735	Suspended	Phase 2/Phase 3	Lack of funding	C0024480	Magnesium sulfate
Topiramate	Metabolic Syndrome X	C0524620	NCT00243984	Suspended	Phase 3	Study was discontinued because of high drop out rate.	C0076829	Topiramato
Cisplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT00291850	Terminated	Phase 2	no patient recruitment	C0008838	cisplatino
Hydroxocobalamin	Cerebral Edema	C0006114	NCT00243022	Terminated	Phase 2	Slow accrual	C0020316	OH-Cbl
Bevacizumab	Malignant neoplasm of lung	C0242379	NCT00293332	Terminated	Phase 2	Terminated due to low subject accrual	C0796392	Anti-VEGF monoclonal antibody
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00293332	Terminated	Phase 2	Terminated due to low subject accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Docetaxel	Malignant neoplasm of lung	C0242379	NCT00293332	Terminated	Phase 2	Terminated due to low subject accrual	C0246415	Docetaxel
Methamphetamine	Depressive disorder	C0011581	NCT00252434	Terminated	Phase 1	Slow enrollment	C0025611	Metamfetamine
Methamphetamine	Sexually Transmitted Diseases	C0036916	NCT00252434	Terminated	Phase 1	Slow enrollment	C0025611	Metamfetamine
Topotecan	Malignant neoplasm of lung	C0242379	NCT00253461	Terminated	Phase 0	Drugs unavailable:unable to make radioactive topotecan	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Topotecan	unspecified adult solid tumor, protocol specific	C0279004	NCT00253461	Terminated	Phase 0	Drugs unavailable:unable to make radioactive topotecan	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00290537	Terminated	Phase 2	Accrual was suboptimal and increasing the number of patients was not feasible.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Malignant neoplasm of lung	C0242379	NCT00290537	Terminated	Phase 2	Accrual was suboptimal and increasing the number of patients was not feasible.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Modafinil	Pain	C0030193	NCT00267332	Terminated	Phase 3	Low accrual	C0066677	2-((diphenylmethyl)sulfinyl)acetamide
Armodafinil	Pain	C0030193	NCT00267332	Terminated	Phase 3	Low accrual	C1701455	Armodafinilo
Gemcitabine	leukemia	C0023418	NCT00268242	Terminated	Phase 2	If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients    (21%) of 24 enrolled patients had a CR so the study was terminated.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Mitoxantrone	leukemia	C0023418	NCT00268242	Terminated	Phase 2	If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients    (21%) of 24 enrolled patients had a CR so the study was terminated.	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Leuprolide	Multiple Myeloma	C0026764	NCT00275262	Terminated	Phase 2		C0085272	Leuprorelinum
Leuprolide	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634	NCT00275262	Terminated	Phase 2		C0085272	Leuprorelinum
Lidocaine	Carpal Tunnel Syndrome	C0007286	NCT00266214	Terminated	Phase 3	Sponsor decision	C0023660	Lidocaína
Cyclosporine	Leukemia, Large Granular Lymphocytic	C1522378	NCT00363779	Terminated	Phase 2	Study terminated due to low accrual and the investigator left the NIH.	C0010592	Cyclosporine
Darbepoetin alfa	Chronic Kidney Diseases	C1561643	NCT00364845	Terminated	Phase 3	The reason for the discontinuation of the study is difficulty with recruitment and timely    enrolment and is not related to safety concerns	C0937950	Darbepoetina alfa
Dacarbazine	Glioblastoma	C0017636	NCT00365222	Terminated	Phase 2	IRB Study Closure	C0010927	DTIC
Temozolomide	Glioblastoma	C0017636	NCT00365222	Terminated	Phase 2	IRB Study Closure	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dacarbazine	gliosarcoma	C0206726	NCT00365222	Terminated	Phase 2	IRB Study Closure	C0010927	DTIC
Temozolomide	gliosarcoma	C0206726	NCT00365222	Terminated	Phase 2	IRB Study Closure	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Micafungin	Invasive aspergillosis	C0238013	NCT00376337	Terminated	Phase 2	Study was stopped due to difficulties in recruitment and changes in standard care for invasive    aspergillosis	C1120386	Micafungina
Pregabalin	Epilepsy	C0014544	NCT00372528	Terminated	Phase 3	This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug.    No efficacy or safety concerns factored into this decision.	C0657912	(S)-3-Isobutyl GABA
Fenofibrate	Obesity	C0028754	NCT00376285	Withdrawn	Phase 1		C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Cyclosporine	Hepatitis C, Chronic	C0524910	NCT00375895	Terminated	Phase 3	Insufficient enrollment	C0010592	Cyclosporine
Cyclosporine	Evidence of liver transplantation	C0940823	NCT00375895	Terminated	Phase 3	Insufficient enrollment	C0010592	Cyclosporine
Erlotinib	Malignant neoplasm of lung	C0242379	NCT00385398	Withdrawn	Phase 2	lack of funding and drug supply	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Temozolomide	Malignant neoplasm of lung	C0242379	NCT00385398	Withdrawn	Phase 2	lack of funding and drug supply	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Clopidogrel	Atherosclerosis	C0004153	NCT00385138	Terminated	Phase 3	Insufficient evidence of the clinical effectiveness of cangrelor	C0070166	Clopidogrelum
Cangrelor	Atherosclerosis	C0004153	NCT00385138	Terminated	Phase 3	Insufficient evidence of the clinical effectiveness of cangrelor	C1121991	Cangrelor
Cyclophosphamide	Myelofibrosis due to another disorder	C0242006	NCT00376519	Terminated	Phase 1	Slow accrual	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Myelofibrosis due to another disorder	C0242006	NCT00376519	Terminated	Phase 1	Slow accrual	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Myelofibrosis due to another disorder	C0242006	NCT00376519	Terminated	Phase 1	Slow accrual	C0026933	Mycophenolsäure
Fludarabine	Myelofibrosis due to another disorder	C0242006	NCT00376519	Terminated	Phase 1	Slow accrual	C0059985	Fludarabinum
Cyclophosphamide	leukemia	C0023418	NCT00376519	Terminated	Phase 1	Slow accrual	C0010583	Cyclophosphamidum
Mycophenolate mofetil	leukemia	C0023418	NCT00376519	Terminated	Phase 1	Slow accrual	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	leukemia	C0023418	NCT00376519	Terminated	Phase 1	Slow accrual	C0026933	Mycophenolsäure
Fludarabine	leukemia	C0023418	NCT00376519	Terminated	Phase 1	Slow accrual	C0059985	Fludarabinum
Infliximab	Toxic Epidermal Necrolysis	C0014518	NCT00372723	Withdrawn	Phase 2	slow enrollment	C4490035	Infliximab-abda
Trastuzumab	Neoplasm Metastasis	C0027627	NCT00377780	Terminated	Phase 2	wothdrawal of sponsor	C5187552	trastuzumab-anns
Doxorubicin	Neoplasm Metastasis	C0027627	NCT00377780	Terminated	Phase 2	wothdrawal of sponsor	C0013089	Doxorubicine
Docetaxel	Neoplasm Metastasis	C0027627	NCT00377780	Terminated	Phase 2	wothdrawal of sponsor	C0246415	Docetaxel
Peginterferon alfa-2b	Liver Cirrhosis	C0023890	NCT00381017	Withdrawn	Phase 3	Non-protocol feasibility	C0796545	Peginterferon alfa-2b
Cyclosporine	Psoriasis	C0033860	NCT00377325	Withdrawn	Phase 2	Study terminated by the DSMB due to low recruitment	C0010592	Cyclosporine
Salmon Calcitonin	Degenerative polyarthritis	C0029408	NCT00376311	Terminated	Phase 2		C0073994	Calcitonina salmón sintética
Methadone	Pain	C0030193	NCT00351637	Terminated	Phase 2	Study suspended due to low accrual	C0025605	Methadonum
Imatinib	leukemia	C0023418	NCT00362466	Terminated	Phase 3	Insufficient Enrollment	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Dasatinib	leukemia	C0023418	NCT00362466	Terminated	Phase 3	Insufficient Enrollment	C2699562	Dasatinib anhydrous
Pentoxifylline	Glomerulonephritis	C0017658	NCT00354198	Terminated	Phase 3	short of participants	C0030899	Pentoxifilina
Prednisolone	Glomerulonephritis	C0017658	NCT00354198	Terminated	Phase 3	short of participants	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Glomerulonephritis	C0017658	NCT00354198	Terminated	Phase 3	short of participants	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Doxorubicin	ovarian neoplasm	C0919267	NCT00350948	Terminated	Phase 3	Business reasons	C0013089	Doxorubicine
Methadone	Pain	C0030193	NCT00351715	Terminated	Phase 2	Study stopped due to low accrual	C0025605	Methadonum
Reboxetine	Pain	C0030193	NCT00353808	Terminated	Phase 2	This study has been terminated early as the esreboxetine development program is being    discontinued. There are no safety or efficacy concerns.	C0168388	Reboxetina
Irinotecan	Astrocytoma	C0004114	NCT00360828	Terminated	Phase 2	Principal Investigator left Moffitt and study had low accrual.	C0123931	(+)-Irinotecan
Sirolimus	Non-Small Cell Lung Carcinoma	C0007131	NCT00352950	Withdrawn	Phase 1		C0072980	Sirolimús
Donepezil	Advanced cancer	C0877373	NCT00352664	Terminated	Phase 3	Low patient accrual	C0527316	Donepezilo
Pregabalin	Herpes zoster disease	C0019360	NCT00352651	Terminated	Phase 2	This study should be terminated as the study has been closed for years and the investigator    has since retired. No records are available.    Thank you, Marlene	C0657912	(S)-3-Isobutyl GABA
Pemetrexed	Esophageal Neoplasms	C0014859	NCT00383266	Terminated	Phase 2	Low accrual	C0210657	Pemetrexed
Carboplatin	Esophageal Neoplasms	C0014859	NCT00383266	Terminated	Phase 2	Low accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Romidepsin	recurrent adult diffuse large cell lymphoma	C0280188	NCT00383565	Terminated	Phase 2		C1527027	Romidepsine
Romidepsin	Mantle cell lymphoma recurrent	C0677725	NCT00383565	Terminated	Phase 2		C1527027	Romidepsine
Infliximab	Lupus Nephritis	C0024143	NCT00368264	Terminated	Phase 2/Phase 3	Failure to recruit patients with membranous lupus nephritis not previously treated with    azathioprine .	C4490035	Infliximab-abda
Azathioprine	Lupus Nephritis	C0024143	NCT00368264	Terminated	Phase 2/Phase 3	Failure to recruit patients with membranous lupus nephritis not previously treated with    azathioprine .	C0004482	Azamun
Bevacizumab	Colorectal Neoplasms	C0009404	NCT00385021	Terminated	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Azacitidine	Chronic myeloproliferative disorder	C1292778	NCT00381693	Terminated	Phase 2	Due to lack of accrual and trial has demonstrated too little clinical benefit	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Azacitidine	Myelofibrosis due to another disorder	C0242006	NCT00381693	Terminated	Phase 2	Due to lack of accrual and trial has demonstrated too little clinical benefit	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Nitazoxanide	Clostridium difficile infection	C0343386	NCT00384527	Terminated	Phase 3	Study was terminated early due to slow recruitment.	C0068788	Nitazoxanida
Vancomycin	Clostridium difficile infection	C0343386	NCT00384527	Terminated	Phase 3	Study was terminated early due to slow recruitment.	C0042313	Vancomycine
Nitazoxanide	Clostridium Infections	C0009062	NCT00384527	Terminated	Phase 3	Study was terminated early due to slow recruitment.	C0068788	Nitazoxanida
Vancomycin	Clostridium Infections	C0009062	NCT00384527	Terminated	Phase 3	Study was terminated early due to slow recruitment.	C0042313	Vancomycine
Hydroxyurea	Pulmonary Hypertension	C0020542	NCT00350844	Terminated	Phase 1/Phase 2	Low subject accrual	C0020402	Hydroxycarbamid
Mitomycin	Urinary Bladder Diseases	C0005686	NCT00384891	Terminated	Phase 3	slow accrual	C0702050	Ametycine
Mitomycin	Bladder Neoplasm	C0005695	NCT00384891	Terminated	Phase 3	slow accrual	C0702050	Ametycine
Mitomycin	Malignant neoplasm of urinary bladder	C0005684	NCT00384891	Terminated	Phase 3	slow accrual	C0702050	Ametycine
Mitomycin	Urologic Diseases	C0042075	NCT00384891	Terminated	Phase 3	slow accrual	C0702050	Ametycine
Mitomycin	Urologic Neoplasms	C0042076	NCT00384891	Terminated	Phase 3	slow accrual	C0702050	Ametycine
Everolimus	Malignant tumor of colon	C0007102	NCT00390364	Terminated	Phase 2	Withdrawn due to low accrual	C0541315	évérolimus
Teriparatide	Myelofibrosis	C0026987	NCT00393380	Terminated	Phase 2	Study stopped because of toxicity concerns.	C0070093	Teriparatida
Cisplatin	untreated childhood medulloblastoma	C0338341	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0008838	cisplatino
Cyclophosphamide	untreated childhood medulloblastoma	C0338341	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0010583	Cyclophosphamidum
Vincristine	untreated childhood medulloblastoma	C0338341	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Carboplatin	untreated childhood medulloblastoma	C0338341	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Isotretinoin	untreated childhood medulloblastoma	C0338341	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0022265	Isotrétinoine
Cisplatin	untreated childhood supratentorial primitive neuroectodermal tumors	C0338333	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0008838	cisplatino
Cyclophosphamide	untreated childhood supratentorial primitive neuroectodermal tumors	C0338333	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0010583	Cyclophosphamidum
Vincristine	untreated childhood supratentorial primitive neuroectodermal tumors	C0338333	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Carboplatin	untreated childhood supratentorial primitive neuroectodermal tumors	C0338333	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Isotretinoin	untreated childhood supratentorial primitive neuroectodermal tumors	C0338333	NCT00392327	Suspended	Phase 3	Temporarily stopped for assessment	C0022265	Isotrétinoine
Cisplatin	Malignant neoplasm of lung	C0242379	NCT00389688	Terminated	Phase 2	low accrual	C0008838	cisplatino
Pemetrexed	Malignant neoplasm of lung	C0242379	NCT00389688	Terminated	Phase 2	low accrual	C0210657	Pemetrexed
Bevacizumab	Malignant tumor of colon	C0007102	NCT00394992	Terminated	Phase 3	Data from the C08 study and Avant study	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Malignant tumor of colon	C0007102	NCT00394992	Terminated	Phase 3	Data from the C08 study and Avant study	C0069717	oxaliplatine
Capecitabine	Malignant tumor of colon	C0007102	NCT00394992	Terminated	Phase 3	Data from the C08 study and Avant study	C0671970	Capecitabin
Bevacizumab	Secondary malignant neoplasm of liver	C0494165	NCT00394992	Terminated	Phase 3	Data from the C08 study and Avant study	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Secondary malignant neoplasm of liver	C0494165	NCT00394992	Terminated	Phase 3	Data from the C08 study and Avant study	C0069717	oxaliplatine
Fluorouracil	Secondary malignant neoplasm of liver	C0494165	NCT00394992	Terminated	Phase 3	Data from the C08 study and Avant study	C0016360	Fluorouracilum
Capecitabine	Secondary malignant neoplasm of liver	C0494165	NCT00394992	Terminated	Phase 3	Data from the C08 study and Avant study	C0671970	Capecitabin
Simvastatin	Diabetes Mellitus	C0011849	NCT00395603	Terminated	Phase 3	This study was terminated early due to poor recruitment.	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Ezetimibe	Diabetes Mellitus	C0011849	NCT00395603	Terminated	Phase 3	This study was terminated early due to poor recruitment.	C1142985	Ezetimiba
Atorvastatin	Diabetes Mellitus	C0011849	NCT00395603	Terminated	Phase 3	This study was terminated early due to poor recruitment.	C0286651	atorvastatine
Trastuzumab	cognitive/functional effects	C0935657	NCT00397501	Withdrawn	Phase 1/Phase 2	after original approval, IRB closed enrollment; major revisions required to re-open.	C5187552	trastuzumab-anns
Methotrexate	cognitive/functional effects	C0935657	NCT00397501	Withdrawn	Phase 1/Phase 2	after original approval, IRB closed enrollment; major revisions required to re-open.	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Carboplatin	cognitive/functional effects	C0935657	NCT00397501	Withdrawn	Phase 1/Phase 2	after original approval, IRB closed enrollment; major revisions required to re-open.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Sodium thiosulfate	cognitive/functional effects	C0935657	NCT00397501	Withdrawn	Phase 1/Phase 2	after original approval, IRB closed enrollment; major revisions required to re-open.	C0302967	Thiosulfuric acid
Valproic Acid	Locally advanced breast cancer	C3495949	NCT00395655	Terminated	Phase 2		C0042291	acidum valproicum
Hydralazine	Locally advanced breast cancer	C3495949	NCT00395655	Terminated	Phase 2		C0020223	Hidralazina
Heparin	Diabetic Angiopathies	C0011875	NCT00399425	Terminated	Phase 2/Phase 3		C0019134	Heparina
Pegfilgrastim	Multiple Myeloma	C0026764	NCT00395967	Terminated	Phase 2	Enrollment terminated in 2005 to focus on Phase 3 study enrollment.	C4735048	pegfilgrastim-cbqv
Cocaine	Cocaine Dependence	C0600427	NCT00373581	Terminated	Phase 2	Funding ran out	C0009170	[1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
Vigabatrin	Cocaine Dependence	C0600427	NCT00373581	Terminated	Phase 2	Funding ran out	C0048044	Vigabatrina
Cetuximab	Multiple Myeloma	C0026764	NCT00368121	Terminated	Phase 2	Lack of recruitable patients	C0995188	Cétuximab
Scopolamine	Unipolar Depression	C0041696	NCT00369915	Terminated	Phase 2		C0036442	alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Fluorouracil	Esophageal Neoplasms	C0014859	NCT00368329	Terminated	Phase 1	low accrual	C0016360	Fluorouracilum
Carboplatin	Esophageal Neoplasms	C0014859	NCT00368329	Terminated	Phase 1	low accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Capecitabine	Esophageal Neoplasms	C0014859	NCT00368329	Terminated	Phase 1	low accrual	C0671970	Capecitabin
Fluorouracil	Adenocarcinoma	C0001418	NCT00368329	Terminated	Phase 1	low accrual	C0016360	Fluorouracilum
Carboplatin	Adenocarcinoma	C0001418	NCT00368329	Terminated	Phase 1	low accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Capecitabine	Adenocarcinoma	C0001418	NCT00368329	Terminated	Phase 1	low accrual	C0671970	Capecitabin
Bevacizumab	Adenocarcinoma of lung (disorder)	C0152013	NCT00369551	Terminated	Phase 1		C0796392	Anti-VEGF monoclonal antibody
Carboplatin	Adenocarcinoma of lung (disorder)	C0152013	NCT00369551	Terminated	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Adenocarcinoma of lung (disorder)	C0152013	NCT00369551	Terminated	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Bevacizumab	Large cell carcinoma of lung	C0345958	NCT00369551	Terminated	Phase 1		C0796392	Anti-VEGF monoclonal antibody
Carboplatin	Large cell carcinoma of lung	C0345958	NCT00369551	Terminated	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Large cell carcinoma of lung	C0345958	NCT00369551	Terminated	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Bevacizumab	Non-small cell lung cancer stage II	C0278505	NCT00369551	Terminated	Phase 1		C0796392	Anti-VEGF monoclonal antibody
Carboplatin	Non-small cell lung cancer stage II	C0278505	NCT00369551	Terminated	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Non-small cell lung cancer stage II	C0278505	NCT00369551	Terminated	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Bevacizumab	Non-small cell lung cancer stage IIIA	C0278983	NCT00369551	Terminated	Phase 1		C0796392	Anti-VEGF monoclonal antibody
Carboplatin	Non-small cell lung cancer stage IIIA	C0278983	NCT00369551	Terminated	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Non-small cell lung cancer stage IIIA	C0278983	NCT00369551	Terminated	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Imatinib	Choroidal retinal neovascularization	C0271066	NCT00403156	Withdrawn	Phase 1	Lack of recruitment	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Imatinib	Choroidal Neovascularization	C0600518	NCT00403156	Withdrawn	Phase 1	Lack of recruitment	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Bevacizumab	Malignant neoplasm of lung	C0242379	NCT00402883	Terminated	Phase 2	Terminated due to bevacizumab and chemoradiotherapy toxicity	C0796392	Anti-VEGF monoclonal antibody
Folic Acid	Malignant neoplasm of lung	C0242379	NCT00402883	Terminated	Phase 2	Terminated due to bevacizumab and chemoradiotherapy toxicity	C0016410	Folic acid
Hydroxocobalamin	Malignant neoplasm of lung	C0242379	NCT00402883	Terminated	Phase 2	Terminated due to bevacizumab and chemoradiotherapy toxicity	C0020316	OH-Cbl
Pemetrexed	Malignant neoplasm of lung	C0242379	NCT00402883	Terminated	Phase 2	Terminated due to bevacizumab and chemoradiotherapy toxicity	C0210657	Pemetrexed
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00402883	Terminated	Phase 2	Terminated due to bevacizumab and chemoradiotherapy toxicity	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Cisplatin	Squamous cell carcinoma	C0007137	NCT00400205	Terminated	Phase 2	Safety reasons	C0008838	cisplatino
Fluorouracil	Squamous cell carcinoma	C0007137	NCT00400205	Terminated	Phase 2	Safety reasons	C0016360	Fluorouracilum
Docetaxel	Squamous cell carcinoma	C0007137	NCT00400205	Terminated	Phase 2	Safety reasons	C0246415	Docetaxel
Imatinib	Metastatic melanoma	C0278883	NCT00402662	Terminated	Phase 2	unexpected level of toxicity	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Sirolimus	Metastatic melanoma	C0278883	NCT00402662	Terminated	Phase 2	unexpected level of toxicity	C0072980	Sirolimús
Everolimus	Metastatic melanoma	C0278883	NCT00402662	Terminated	Phase 2	unexpected level of toxicity	C0541315	évérolimus
Metoprolol	Cardiac Arrest	C0018790	NCT00401882	Terminated	Phase 2	Difficult accrual	C0025859	DL-metoprolol
Metoprolol	Sudden Cardiac Death	C0085298	NCT00401882	Terminated	Phase 2	Difficult accrual	C0025859	DL-metoprolol
Metoprolol	Ventricular Fibrillation	C0042510	NCT00401882	Terminated	Phase 2	Difficult accrual	C0025859	DL-metoprolol
Cetuximab	Colorectal Neoplasms	C0009404	NCT00403052	Terminated	Phase 1	Administrative reasons	C0995188	Cétuximab
Irinotecan	Colorectal Neoplasms	C0009404	NCT00403052	Terminated	Phase 1	Administrative reasons	C0123931	(+)-Irinotecan
Minocycline	Carotid Stenosis	C0007282	NCT00401921	Terminated	Phase 2	PI moved to a new facility	C0026187	Minociclinum
Lithium	Major Depressive Disorder	C1269683	NCT00400088	Terminated	Phase 3	Recruitment difficulties	C0023870	Lithium
Azacitidine	Multiple Myeloma	C0026764	NCT00412919	Terminated	Phase 2	Lack of efficacy	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Salbutamol	Status Asthmaticus	C0038218	NCT00410150	Terminated	Phase 2	Study was stopped after interim analysis and slow enrollment.	C0001927	Salbutamol
Aminosalicylic Acid	Crohn Disease	C0010346	NCT00417690	Terminated	Phase 2	Efforts at recruitment have halted as recruitment was poor.	C0030125	4-amino-2-hydroxybenzoic acid
Alemtuzumab	leukemia	C0023418	NCT00416884	Terminated	Phase 2	Low enrollment	C0383429	Alemtuzumab
Fludarabine	leukemia	C0023418	NCT00416884	Terminated	Phase 2	Low enrollment	C0059985	Fludarabinum
Bevacizumab	Malignant neoplasm of lung	C0242379	NCT00411593	Withdrawn	Phase 1/Phase 2	Lack of Patient Accrual	C0796392	Anti-VEGF monoclonal antibody
Bortezomib	Malignant neoplasm of lung	C0242379	NCT00411593	Withdrawn	Phase 1/Phase 2	Lack of Patient Accrual	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Rituximab	B-Cell Lymphomas	C0079731	NCT00413959	Terminated	Phase 2		C5195655	rituximab-pvvr
Bortezomib	B-Cell Lymphomas	C0079731	NCT00413959	Terminated	Phase 2		C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Cyclophosphamide	B-Cell Lymphomas	C0079731	NCT00413959	Terminated	Phase 2		C0010583	Cyclophosphamidum
Dexamethasone	B-Cell Lymphomas	C0079731	NCT00413959	Terminated	Phase 2		C0011777	Dexaméthasone
Cytarabine	leukemia	C0023418	NCT00411281	Withdrawn	Phase 3	Per Group Chair: This study will not move forward.	C0010711	Cytarabinum
Prednisone	Multiple Myeloma	C0026764	NCT00406978	Terminated	Phase 1/Phase 2	difficulties in enrolling patients	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Defibrotide	Multiple Myeloma	C0026764	NCT00406978	Terminated	Phase 1/Phase 2	difficulties in enrolling patients	C4703922	Defibrotide free acid (porcine)
Peginterferon alfa-2b	leukemia	C0023418	NCT00415857	Terminated	Phase 2	Vaccine sponsor ceased operations.	C0796545	Peginterferon alfa-2b
Imatinib	leukemia	C0023418	NCT00415857	Terminated	Phase 2	Vaccine sponsor ceased operations.	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Azacitidine	leukemia	C0023418	NCT00413478	Terminated	Phase 2	Slow accrual.	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Sorafenib	Non-Small Cell Lung Carcinoma	C0007131	NCT00417248	Terminated	Phase 1/Phase 2	Negative sorafenib results from ESCAPE trial and safety concerns of regimen	C1516119	Sorafenibum
Cisplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT00417248	Terminated	Phase 1/Phase 2	Negative sorafenib results from ESCAPE trial and safety concerns of regimen	C0008838	cisplatino
Etoposide	Non-Small Cell Lung Carcinoma	C0007131	NCT00417248	Terminated	Phase 1/Phase 2	Negative sorafenib results from ESCAPE trial and safety concerns of regimen	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Gabapentin	Chronic intractable pain	C0476481	NCT00414466	Terminated	Phase 2	Study closed and subject follow-up completed following analysis of blinded study data.	C0060926	Gabapentina
Abatacept	Crohn Disease	C0010346	NCT00406653	Terminated	Phase 3	Sponsor Decision	C1619966	Abatacept recombinant
Sirolimus	Malignant neoplasm of lung	C0242379	NCT00406276	Terminated	Phase 1/Phase 2	data analysis showed insufficient drug efficacy	C0072980	Sirolimús
Docetaxel	Malignant neoplasm of lung	C0242379	NCT00406276	Terminated	Phase 1/Phase 2	data analysis showed insufficient drug efficacy	C0246415	Docetaxel
Everolimus	Malignant neoplasm of lung	C0242379	NCT00406276	Terminated	Phase 1/Phase 2	data analysis showed insufficient drug efficacy	C0541315	évérolimus
Rituximab	Lupus Nephritis	C0024143	NCT00404157	Withdrawn	Phase 3		C5195655	rituximab-pvvr
Bevacizumab	Non-Small Cell Lung Carcinoma	C0007131	NCT00404703	Terminated	Phase 2	Primary (safety) endpoint reached	C0796392	Anti-VEGF monoclonal antibody
Erlotinib	adult brain tumor	C0220624	NCT00387894	Terminated	Phase 2	Insufficient accrual of population likely to benefit; progression in 6 patients	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Topotecan	Neuroblastoma	C0027819	NCT00389766	Withdrawn	Phase 2	Withdrawn because protocol has been discontinued. It was never opened.	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Fentanyl	Chronic pain	C0150055	NCT00387010	Terminated	Phase 3	The sponsor felt enough information was available for the exploratory assessment of the effect    of treatment with FBT on pain anxiety	C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Fentanyl	Breakthrough Pain	C1135120	NCT00387010	Terminated	Phase 3	The sponsor felt enough information was available for the exploratory assessment of the effect    of treatment with FBT on pain anxiety	C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Citalopram	Malignant tumor of colon	C0007102	NCT00387348	Terminated	Phase 3	DSMB stopped study because placebo arm had more adverse events	C0008845	Citalopramum
Citalopram	Malignant neoplasm of stomach	C0024623	NCT00387348	Terminated	Phase 3	DSMB stopped study because placebo arm had more adverse events	C0008845	Citalopramum
Citalopram	Malignant neoplasm of lung	C0242379	NCT00387348	Terminated	Phase 3	DSMB stopped study because placebo arm had more adverse events	C0008845	Citalopramum
Dacarbazine	Astrocytoma	C0004114	NCT00389090	Terminated	Phase 2	AOI Pharma terminated the license agreement. IND Transferred to NCI	C0010927	DTIC
Temozolomide	Astrocytoma	C0004114	NCT00389090	Terminated	Phase 2	AOI Pharma terminated the license agreement. IND Transferred to NCI	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dacarbazine	Mixed Oligodendroglioma-Astrocytoma	C0280793	NCT00389090	Terminated	Phase 2	AOI Pharma terminated the license agreement. IND Transferred to NCI	C0010927	DTIC
Temozolomide	Mixed Oligodendroglioma-Astrocytoma	C0280793	NCT00389090	Terminated	Phase 2	AOI Pharma terminated the license agreement. IND Transferred to NCI	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Sunitinib	Acute Undifferentiated Leukemia	C0280141	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	adult acute lymphoblastic leukemia in remission	C0279095	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	adult acute myeloid leukemia in remission	C0279094	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	C1292772	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Leukemia, Mast-Cell	C0023461	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	meningeal chronic myelogenous leukemia	C0279083	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Primary Myelofibrosis	C0001815	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	progressive hairy cell leukemia, initial treatment	C0279779	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Prolymphocytic Leukemia	C0023486	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	recurrent adult acute lymphoblastic leukemia	C0278785	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	recurrent adult acute myeloid leukemia	C0278780	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Chronic lymphocytic leukaemia refractory	C0278791	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Hairy cell leukaemia recurrent	C0279780	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	chronic myelogenous leukemia in relapse	C0278787	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	secondary acute myeloid leukemia	C0280449	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Chronic lymphocytic leukaemia stage 1	C0278767	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Chronic lymphocytic leukaemia stage 2	C0854803	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Chronic lymphocytic leukaemia stage 3	C0278769	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	Chronic lymphocytic leukaemia stage 4	C0854804	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	untreated adult acute lymphoblastic leukemia	C0279088	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	untreated adult acute myeloid leukemia	C0279089	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Sunitinib	untreated hairy cell leukemia	C0279778	NCT00387426	Terminated	Phase 2		C1176020	Sunitinibum
Phenylephrine	Fecal Incontinence	C0015732	NCT00420797	Withdrawn	Phase 3	Terminated, new protocol to be developed	C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Oxymetazoline	Fecal Incontinence	C0015732	NCT00420797	Withdrawn	Phase 3	Terminated, new protocol to be developed	C0030071	Oxymétazoline
Losartan	Prehypertension	C1696708	NCT00388388	Terminated	Phase 2	Few subjects recruited, sponsor withdrew support.	C0126174	2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Hydrochlorothiazide	Prehypertension	C1696708	NCT00388388	Terminated	Phase 2	Few subjects recruited, sponsor withdrew support.	C0020261	hidroclorotiazida
Losartan	Prediabetes syndrome	C0362046	NCT00388388	Terminated	Phase 2	Few subjects recruited, sponsor withdrew support.	C0126174	2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Hydrochlorothiazide	Prediabetes syndrome	C0362046	NCT00388388	Terminated	Phase 2	Few subjects recruited, sponsor withdrew support.	C0020261	hidroclorotiazida
Gemcitabine	cervical cancer	C4048328	NCT00421096	Terminated	Phase 2	Problems of recruitment	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Lidocaine	Overactive Bladder	C0878773	NCT00427648	Terminated	Phase 3	Data collection complete; analysis to take place	C0023660	Lidocaína
Bevacizumab	Non-Small Cell Lung Carcinoma	C0007131	NCT00434226	Terminated	Phase 2	Based on data collected, the combination appeared to be poorly tolearated.	C0796392	Anti-VEGF monoclonal antibody
Carboplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT00434226	Terminated	Phase 2	Based on data collected, the combination appeared to be poorly tolearated.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Sunitinib	Non-Small Cell Lung Carcinoma	C0007131	NCT00434226	Terminated	Phase 2	Based on data collected, the combination appeared to be poorly tolearated.	C1176020	Sunitinibum
Ketoprofen	Tendinitis	C0039503	NCT00426985	Terminated	Phase 3	Sufficient number of subjects accrued to conduct analysis	C0022635	L'acide (benzoyl-3-phenyl)-2-propionique
Ketoprofen	Bursitis	C0006444	NCT00426985	Terminated	Phase 3	Sufficient number of subjects accrued to conduct analysis	C0022635	L'acide (benzoyl-3-phenyl)-2-propionique
Flucloxacillin	Chronic Kidney Diseases	C1561643	NCT00433342	Suspended	Phase 1		C0016267	Flucloxacillinum
Salbutamol	Respiratory Distress Syndrome, Adult	C0035222	NCT00434993	Terminated	Phase 2/Phase 3	Stopped for futility by DSMB	C0001927	Salbutamol
Sunitinib	Pancreatic Endocrine Carcinoma	C1328479	NCT00428597	Terminated	Phase 3	Refer to Detailed Description.	C1176020	Sunitinibum
Sunitinib	Pancreatic carcinoma	C0235974	NCT00428597	Terminated	Phase 3	Refer to Detailed Description.	C1176020	Sunitinibum
Dutasteride	Benign Prostatic Hyperplasia	C1704272	NCT00431626	Terminated	Phase 3	Low enrollment	C0754659	α,α,α,α',α',α'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide
Imatinib	Malignant Peripheral Nerve Sheath Tumor	C0751690	NCT00427583	Terminated	Phase 2/Phase 3	stopped due to slow recruitment and no effect	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Lorazepam	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0024002	Loracepam
Ondansetron	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0061851	Ondansetron
Promethazine	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Diphenhydramine	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0012522	β-dimethylaminoethanol diphenylmethyl ether
Dexamethasone	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0011777	Dexaméthasone
Lorazepam	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0024002	Loracepam
Ondansetron	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0061851	Ondansetron
Promethazine	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Diphenhydramine	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0012522	β-dimethylaminoethanol diphenylmethyl ether
Dexamethasone	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0011777	Dexaméthasone
Lorazepam	unspecified childhood solid tumor, protocol specific	C0279002	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0024002	Loracepam
Ondansetron	unspecified childhood solid tumor, protocol specific	C0279002	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0061851	Ondansetron
Promethazine	unspecified childhood solid tumor, protocol specific	C0279002	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Diphenhydramine	unspecified childhood solid tumor, protocol specific	C0279002	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0012522	β-dimethylaminoethanol diphenylmethyl ether
Dexamethasone	unspecified childhood solid tumor, protocol specific	C0279002	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	C0011777	Dexaméthasone
Benzylpenicillin	Psoriasis	C0033860	NCT00427609	Terminated	Phase 2	Not enough enrollees to obtain a valid conclusion	C0030827	bensylpenicillin
Procaine benzylpenicillin	Psoriasis	C0033860	NCT00427609	Terminated	Phase 2	Not enough enrollees to obtain a valid conclusion	C0030830	Bencilpenicilina procaína
Benzathine benzylpenicillin	Psoriasis	C0033860	NCT00427609	Terminated	Phase 2	Not enough enrollees to obtain a valid conclusion	CUI-less-DB09323	Benzathine benzylpenicillin
Cyclophosphamide	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Prednisolone	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Azathioprine	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	C0004482	Azamun
Mycophenolic acid	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	C0026933	Mycophenolsäure
Cisplatin	Squamous cell carcinoma	C0007137	NCT00427102	Terminated	Phase 1	No subjects enrolled and PI went to another facility	C0008838	cisplatino
Bevacizumab	Cholangiocarcinoma	C0206698	NCT00426829	Terminated	Phase 1	Low Accural	C0796392	Anti-VEGF monoclonal antibody
Mometasone	Sinusitis	C0037199	NCT00423176	Terminated	Phase 3	Based on business priorities. Not related to any safety or efficacy issue & took place before    data were unblinded or analyzed	C0360564	Mometason
Clavulanate	Sinusitis	C0037199	NCT00423176	Terminated	Phase 3	Based on business priorities. Not related to any safety or efficacy issue & took place before    data were unblinded or analyzed	C0110038	Clavulanate
Amoxicillin	Sinusitis	C0037199	NCT00423176	Terminated	Phase 3	Based on business priorities. Not related to any safety or efficacy issue & took place before    data were unblinded or analyzed	C0002645	Amoxicilline
Rituximab	Churg-Strauss Syndrome	C0008728	NCT00424749	Terminated	Phase 2	Company providing study drug terminated study due to lack of funds	C5195655	rituximab-pvvr
Carboplatin	Fallopian Tube Neoplasms	C0015558	NCT00407407	Terminated	Phase 1	MTD not determined	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Fallopian Tube Neoplasms	C0015558	NCT00407407	Terminated	Phase 1	MTD not determined	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Carboplatin	ovarian neoplasm	C0919267	NCT00407407	Terminated	Phase 1	MTD not determined	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	ovarian neoplasm	C0919267	NCT00407407	Terminated	Phase 1	MTD not determined	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Sunitinib	Recurrent disease	C0277556	NCT00408252	Terminated	Phase 2	Too frequent grade 3-4 toxicities	C1176020	Sunitinibum
Folic Acid	Infertility	C0021359	NCT00406874	Terminated	Phase 2	reports indicating that increased folic acid intake may increase colin cancer	C0016410	Folic acid
Anastrozole	Obesity	C0028754	NCT00440180	Terminated	Phase 3	Not able meet target enrollment.	C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Sorafenib	unspecified adult solid tumor, protocol specific	C0279004	NCT00436579	Terminated	Phase 1		C1516119	Sorafenibum
Nicotinamide	unspecified adult solid tumor, protocol specific	C0279004	NCT00436579	Terminated	Phase 1		C0028027	3-pyridinecarboxamide
Sodium phenylbutyrate	Muscular Atrophy, Spinal, Type II	C0393538	NCT00439569	Terminated	Phase 1/Phase 2	Due to poor compliance with study drug administration.	C0170531	γ-phenylbutyric acid
Sodium phenylbutyrate	Juvenile Spinal Muscular Atrophy	C0152109	NCT00439569	Terminated	Phase 1/Phase 2	Due to poor compliance with study drug administration.	C0170531	γ-phenylbutyric acid
Asparaginase	recurrent childhood acute lymphoblastic leukemia	C0278519	NCT00439296	Terminated	Phase 1	The study was stopped due to poor accrual and lack of funding.	C0003993	Colaspase
Pegaspargase	recurrent childhood acute lymphoblastic leukemia	C0278519	NCT00439296	Terminated	Phase 1	The study was stopped due to poor accrual and lack of funding.	C0071568	Pegaspargasa
Doxorubicin	recurrent childhood acute lymphoblastic leukemia	C0278519	NCT00439296	Terminated	Phase 1	The study was stopped due to poor accrual and lack of funding.	C0013089	Doxorubicine
Dexamethasone	recurrent childhood acute lymphoblastic leukemia	C0278519	NCT00439296	Terminated	Phase 1	The study was stopped due to poor accrual and lack of funding.	C0011777	Dexaméthasone
Carboplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT00437749	Terminated	Phase 3	slow accrual rate; interim accrual objective met	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Olanzapine	Schizoaffective Disorder	C0036337	NCT00440843	Withdrawn	Phase 3		C0171023	Olanzapinum
Daptomycin	Skin Diseases, Infectious	C0037278	NCT00430937	Terminated	Phase 3		C0057144	daptomicina
Vancomycin	Skin Diseases, Infectious	C0037278	NCT00430937	Terminated	Phase 3		C0042313	Vancomycine
Teicoplanin	Skin Diseases, Infectious	C0037278	NCT00430937	Terminated	Phase 3		C0145106	teicoplaninum
Daptomycin	Soft Tissue Infections	C0149778	NCT00430937	Terminated	Phase 3		C0057144	daptomicina
Vancomycin	Soft Tissue Infections	C0149778	NCT00430937	Terminated	Phase 3		C0042313	Vancomycine
Teicoplanin	Soft Tissue Infections	C0149778	NCT00430937	Terminated	Phase 3		C0145106	teicoplaninum
Atorvastatin	Venous Thromboembolism	C1861172	NCT00437892	Terminated	Phase 2	Competitive trials and slow recruitment rate	C0286651	atorvastatine
Ropivacaine	Phantom Limb Syndrome	C0031315	NCT00427947	Terminated	Phase 3	lack of patients	C0073571	Ropivacainum
Darbepoetin alfa	Chronic Kidney Diseases	C1561643	NCT00436748	Terminated	Phase 3	Study Terminated; Commitment met per Regulatory Authorities.	C0937950	Darbepoetina alfa
Darbepoetin alfa	Kidney Diseases	C0022658	NCT00436748	Terminated	Phase 3	Study Terminated; Commitment met per Regulatory Authorities.	C0937950	Darbepoetina alfa
Mycophenolate mofetil	Interstitial Cystitis	C0282488	NCT00451867	Terminated	Phase 3	The major and primary reason for the study termination is the observed reduced efficacy of    CellCept compared to placebo.	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Interstitial Cystitis	C0282488	NCT00451867	Terminated	Phase 3	The major and primary reason for the study termination is the observed reduced efficacy of    CellCept compared to placebo.	C0026933	Mycophenolsäure
Mycophenolate mofetil	Painful Bladder Syndrome	C1720830	NCT00451867	Terminated	Phase 3	The major and primary reason for the study termination is the observed reduced efficacy of    CellCept compared to placebo.	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Painful Bladder Syndrome	C1720830	NCT00451867	Terminated	Phase 3	The major and primary reason for the study termination is the observed reduced efficacy of    CellCept compared to placebo.	C0026933	Mycophenolsäure
Dapsone	Pemphigus Vulgaris	C0030809	NCT00429533	Terminated	Phase 2		C0010980	4-aminophenyl sulfone
Mycophenolate mofetil	Lupus Erythematosus, Systemic	C0024141	NCT00430677	Terminated	Phase 2/Phase 3	Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Lupus Erythematosus, Systemic	C0024141	NCT00430677	Terminated	Phase 2/Phase 3	Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period	C0026933	Mycophenolsäure
Abatacept	Lupus Erythematosus, Systemic	C0024141	NCT00430677	Terminated	Phase 2/Phase 3	Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period	C1619966	Abatacept recombinant
Ciprofloxacin	Inflammation	C0021368	NCT00431028	Terminated	Phase 1/Phase 2	Terminated	C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Triamcinolone	Inflammation	C0021368	NCT00431028	Terminated	Phase 1/Phase 2	Terminated	C0040864	Triamcinolonum
Ciprofloxacin	Bacterial Infections	C0004623	NCT00431028	Terminated	Phase 1/Phase 2	Terminated	C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Triamcinolone	Bacterial Infections	C0004623	NCT00431028	Terminated	Phase 1/Phase 2	Terminated	C0040864	Triamcinolonum
Belinostat	Multiple Myeloma	C0026764	NCT00431340	Terminated	Phase 2	Terminated due to dose limiting toxicity	C1948068	Belinostat
Hydroxyprogesterone caproate	Premature Birth	C0151526	NCT00439374	Terminated	Phase 3	Halted by NICHD after recommendation by DSMC to stop for futility	C0044971	Caproate d'hydroxyprogesterone
Hydroxyprogesterone caproate	transvaginal ultrasound: length of cervix	C2145605	NCT00439374	Terminated	Phase 3	Halted by NICHD after recommendation by DSMC to stop for futility	C0044971	Caproate d'hydroxyprogesterone
Lidocaine	Vulvar Vestibulitis	C0269084	NCT00450242	Terminated	Phase 2	lack of funding	C0023660	Lidocaína
Chloroquine	Malaria	C0024530	NCT00442403	Suspended	Phase 3	At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line    therapy for of uncomplicated malaria.	C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Erythropoietin	Kidney Failure	C0035078	NCT00450333	Terminated	Phase 3	The termination of the study is not linked to a product recall or result of any safety signal.    Rather it was sponsor's commercial decision to withdraw the MA	C0357126	Epoetina alfa
Alemtuzumab	leukemia	C0023418	NCT00453193	Terminated	Phase 2	Slow accrual.	C0383429	Alemtuzumab
Pentostatin	leukemia	C0023418	NCT00453193	Terminated	Phase 2	Slow accrual.	C0030896	Pentostatine
Rosiglitazone	Chronic Kidney Diseases	C1561643	NCT00452166	Terminated	Phase 3	it was not possible to recruit new patients anymore	C0289313	Rosiglitazona
Alfuzosin	Urinary Retention	C0080274	NCT00453908	Terminated	Phase 3	The study was early terminated due to slow and difficult recruitment	C0051150	Alfuzosina
Omeprazole	Solid tumour	C0280100	NCT00442741	Withdrawn	Phase 1	pts. will be captured in core	C0028978	Omeprazolum
Midazolam	Solid tumour	C0280100	NCT00442741	Withdrawn	Phase 1	pts. will be captured in core	C0026056	Midazolamum
Bevacizumab	Esophageal Neoplasms	C0014859	NCT00442507	Terminated	Phase 2	Slow accrual	C0796392	Anti-VEGF monoclonal antibody
Erlotinib	Esophageal Neoplasms	C0014859	NCT00442507	Terminated	Phase 2	Slow accrual	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Bevacizumab	Esophageal Diseases	C0014852	NCT00442507	Terminated	Phase 2	Slow accrual	C0796392	Anti-VEGF monoclonal antibody
Erlotinib	Esophageal Diseases	C0014852	NCT00442507	Terminated	Phase 2	Slow accrual	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Flibanserin	Psychosexual Disorders	C0033953	NCT00441558	Terminated	Phase 3	terminated for administrative reasons	C0754280	Flibanserin
Vincristine	Multiple Myeloma	C0026764	NCT00441168	Terminated	Phase 2	TRIAL STOPPED due to a change in standard of care and the required patient numbers could no    longer be achieved	C0042679	Vincristina
Methamphetamine	Anxiety	C0003467	NCT00442923	Withdrawn	Phase 2	This study was withdrawn for lack of progress. No subjects were recruited.	C0025611	Metamfetamine
Methamphetamine	Substance Dependence	C0038580	NCT00442923	Withdrawn	Phase 2	This study was withdrawn for lack of progress. No subjects were recruited.	C0025611	Metamfetamine
Sildenafil	Coronary Artery Vasospasm	C0010073	NCT00454714	Suspended	Phase 3	Patient study insurance expired	C0529793	Sildenafilo
Tolterodine	Overactive Bladder	C0878773	NCT00439192	Terminated	Phase 2	side effect profile did not match expectations	C0388753	Tolterodina
Tolterodine	Urinary Incontinence	C0042024	NCT00439192	Terminated	Phase 2	side effect profile did not match expectations	C0388753	Tolterodina
Sodium phenylbutyrate	HMN (Hereditary Motor Neuropathy) Proximal Type I	C0043116	NCT00439218	Terminated	Phase 1/Phase 2	Extremely slow enrollment	C0170531	γ-phenylbutyric acid
Rituximab	B-Cell Lymphomas	C0079731	NCT00455897	Terminated	Phase 2	Accrual was too slow. Trial terminated	C5195655	rituximab-pvvr
Rituximab	Lymphoma, Diffuse	C3714542	NCT00455897	Terminated	Phase 2	Accrual was too slow. Trial terminated	C5195655	rituximab-pvvr
Rimonabant	Microalbuminuria	C0730345	NCT00458081	Terminated	Phase 3	Company decision has been taken in light of recent demands by certain national health    authorities	C1142933	Rimonabant
Rimonabant	Dyslipidemias	C0242339	NCT00458081	Terminated	Phase 3	Company decision has been taken in light of recent demands by certain national health    authorities	C1142933	Rimonabant
Gemcitabine	Unknown Primary Tumors	C0087135	NCT00458315	Withdrawn	Phase 2	never been started	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Unknown Primary Tumors	C0087135	NCT00458315	Withdrawn	Phase 2	never been started	C0008838	cisplatino
Paclitaxel	Unknown Primary Tumors	C0087135	NCT00458315	Withdrawn	Phase 2	never been started	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Cyclosporine	Corneal Diseases	C0010034	NCT00447187	Terminated	Phase 3	The primary efficacy endpoint was not met	C0010592	Cyclosporine
Carboplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT00460317	Terminated	Phase 3	Amgen discontinued the development of AMG706 because 20050201 did not meet its primary    objective.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Mycophenolate mofetil	Lupus Nephritis	C0024143	NCT00447265	Terminated	Phase 2	The perceived risk-benefit ratio for individuals with early active RA	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Lupus Nephritis	C0024143	NCT00447265	Terminated	Phase 2	The perceived risk-benefit ratio for individuals with early active RA	C0026933	Mycophenolsäure
Oxaliplatin	Malignant neoplasm of stomach	C0024623	NCT00568529	Suspended	Phase 2	There are not enough patients enrolled.	C0069717	oxaliplatine
Tretinoin	Neuroblastoma	C0027819	NCT00533169	Terminated	Phase 1	Lack of enrollment.	C0040845	Tretin M
Isotretinoin	Neuroblastoma	C0027819	NCT00533169	Terminated	Phase 1	Lack of enrollment.	C0022265	Isotrétinoine
Piracetam	Epilepsy, Post-Traumatic	C0014557	NCT00566046	Terminated	Phase 3	Sponsor decision because of to small enrollment	C0031977	Piracetam
Levonorgestrel	Hereditary Nonpolyposis Colorectal Cancer	C1333990	NCT00566644	Terminated	Phase 3	Withdrawn due to poor accrual	C0023566	Lèvonorgestrel
Norgestrel	Hereditary Nonpolyposis Colorectal Cancer	C1333990	NCT00566644	Terminated	Phase 3	Withdrawn due to poor accrual	C0028368	Norgestrelum
Quetiapine	Methamphetamine dependence	C1533217	NCT00567866	Terminated	Phase 0	Study was terminated due to insufficient funds	C0123091	Quetiapina
Methamphetamine	Methamphetamine dependence	C1533217	NCT00567866	Terminated	Phase 0	Study was terminated due to insufficient funds	C0025611	Metamfetamine
Ticlopidine	Acute Coronary Syndrome	C0948089	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	C0040207	Ticlopidina
Salicylic acid	Acute Coronary Syndrome	C0948089	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	C0036079	ácido salicílico
Acetylsalicylic acid	Acute Coronary Syndrome	C0948089	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	C0004057	Aspirina
Ticlopidine	Myocardial Infarction	C0027051	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	C0040207	Ticlopidina
Clopidogrel	Myocardial Infarction	C0027051	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	C0070166	Clopidogrelum
Gemcitabine	Carcinoma	C0007097	NCT00557596	Terminated	Phase 1/Phase 2		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Bexarotene	Schizophrenia	C0036341	NCT00534898	Withdrawn	Phase 3	The study withdrawn due to lack financial support	C0765273	p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
Bexarotene	Schizoaffective Disorder	C0036337	NCT00534898	Withdrawn	Phase 3	The study withdrawn due to lack financial support	C0765273	p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
Methadone	Pain	C0030193	NCT00558870	Terminated	Phase 2	Low Accrual.	C0025605	Methadonum
Cyclosporine	Myeloid Leukemia	C0023470	NCT00568633	Terminated	Phase 3	Poor accrual	C0010592	Cyclosporine
Mycophenolate mofetil	Myeloid Leukemia	C0023470	NCT00568633	Terminated	Phase 3	Poor accrual	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Myeloid Leukemia	C0023470	NCT00568633	Terminated	Phase 3	Poor accrual	C0026933	Mycophenolsäure
Cyclosporine	leukemia	C0023418	NCT00568633	Terminated	Phase 3	Poor accrual	C0010592	Cyclosporine
Mycophenolate mofetil	leukemia	C0023418	NCT00568633	Terminated	Phase 3	Poor accrual	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	leukemia	C0023418	NCT00568633	Terminated	Phase 3	Poor accrual	C0026933	Mycophenolsäure
Omeprazole	Laryngeal Diseases	C0023051	NCT00567658	Withdrawn	Phase 3	The decision of terminate the study was reached due to difficulties surrounding recruitment    and enrollment of subjects since the inception of the study.	C0028978	Omeprazolum
Esomeprazole	Laryngeal Diseases	C0023051	NCT00567658	Withdrawn	Phase 3	The decision of terminate the study was reached due to difficulties surrounding recruitment    and enrollment of subjects since the inception of the study.	C0937846	Ésoméprazole
Finasteride	Benign Prostatic Hyperplasia	C1704272	NCT00564460	Withdrawn	Phase 3	Change of practice pattern. Green light laser	C0060389	Finasterida
Cisplatin	Malignant neoplasm of stomach	C0024623	NCT00568971	Terminated	Phase 2	The study has finished.	C0008838	cisplatino
Alemtuzumab	leukemia	C0023418	NCT00555048	Terminated	Phase 1/Phase 2	Low accrual	C0383429	Alemtuzumab
Cyclophosphamide	leukemia	C0023418	NCT00555048	Terminated	Phase 1/Phase 2	Low accrual	C0010583	Cyclophosphamidum
Busulfan	leukemia	C0023418	NCT00555048	Terminated	Phase 1/Phase 2	Low accrual	C0006463	Busulfano
Bevacizumab	Renal Cell Carcinoma	C0007134	NCT00556205	Withdrawn	Phase 2	Toxicity of combination from other trials	C0796392	Anti-VEGF monoclonal antibody
Temozolomide	Cutaneous Melanoma	C0151779	NCT00568451	Terminated	Phase 2	Slow accrual.	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Carboplatin	Cutaneous Melanoma	C0151779	NCT00568451	Terminated	Phase 2	Slow accrual.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Cutaneous Melanoma	C0151779	NCT00568451	Terminated	Phase 2	Slow accrual.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Ketamine	Traumatic Brain Injury	C0876926	NCT00556387	Withdrawn	Phase 2	This study has been withdraw from the IRB. The PI has transferred to another university. The    IND was transferred.	C0022614	Kétamine
Rituximab	Chronic rejection of renal transplant	C0403592	NCT00568477	Terminated	Phase 2	lacking recruitment	C5195655	rituximab-pvvr
Celecoxib	Malignant neoplasm of lung	C0242379	NCT00520845	Terminated	Phase 2	slow accrual	C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pemetrexed	Malignant neoplasm of lung	C0242379	NCT00520845	Terminated	Phase 2	slow accrual	C0210657	Pemetrexed
Docetaxel	Malignant neoplasm of lung	C0242379	NCT00520845	Terminated	Phase 2	slow accrual	C0246415	Docetaxel
Sunitinib	Kaposi's sarcoma classical type	C0279084	NCT00521092	Withdrawn	Phase 2	No participants enrolled.	C1176020	Sunitinibum
Ethanol	Pancreatic Cyst	C0030283	NCT00550108	Terminated	Phase 3	Inability to enroll subjects.	C0001962	Spiritus vini
Bevacizumab	Malignant tumor of colon	C0007102	NCT00537823	Terminated	Phase 2	Poor accrual.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Malignant tumor of colon	C0007102	NCT00537823	Terminated	Phase 2	Poor accrual.	C0069717	oxaliplatine
Trastuzumab	Advanced breast cancer	C3495917	NCT00522457	Terminated	Phase 2	change in development plan, not due to safety concerns.	C5187552	trastuzumab-anns
Etoposide	Neuroblastoma	C0027819	NCT00539500	Terminated	Phase 2/Phase 3	Slow Accrual.	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Carboplatin	Neuroblastoma	C0027819	NCT00539500	Terminated	Phase 2/Phase 3	Slow Accrual.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Melphalan	Neuroblastoma	C0027819	NCT00539500	Terminated	Phase 2/Phase 3	Slow Accrual.	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Prednisolone	Lupus Nephritis	C0024143	NCT00539799	Withdrawn	Phase 3	Local pharmacy unwilling to comply with study protocol	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Lupus Nephritis	C0024143	NCT00539799	Withdrawn	Phase 3	Local pharmacy unwilling to comply with study protocol	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Nicotine	Postoperative Nausea and Vomiting	C0520909	NCT00553709	Terminated	Phase 2	Unexpected difficult recruitment. Study drug expired	C0028040	Nikotin
Sirolimus	Hepatitis C recurrent	C2938989	NCT00582738	Terminated	Phase 2		C0072980	Sirolimús
Everolimus	Hepatitis C recurrent	C2938989	NCT00582738	Terminated	Phase 2		C0541315	évérolimus
Penicillamine	Lead Poisoning	C0023176	NCT00552630	Withdrawn	Phase 2/Phase 3		C0030817	penicilamina
Imatinib	Pulmonary Hypertension	C0020542	NCT00583115	Terminated	Phase 2	Unable to enroll subjects	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Topiramate	Epilepsy	C0014544	NCT00563459	Terminated	Phase 3	Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this    indication were terminated.	C0076829	Topiramato
Piracetam	Epilepsy	C0014544	NCT00563459	Terminated	Phase 3	Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this    indication were terminated.	C0031977	Piracetam
Erlotinib	Malignant neoplasm of lung	C0242379	NCT00554775	Terminated	Phase 2	IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was    not met.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Methadone	Pain	C0030193	NCT00573937	Terminated	Phase 2	Slow accrual.	C0025605	Methadonum
Cisplatin	Primary peritoneal carcinoma	C1514428	NCT00582205	Terminated	Phase 2	Study completed per investigator.	C0008838	cisplatino
Paclitaxel	Primary peritoneal carcinoma	C1514428	NCT00582205	Terminated	Phase 2	Study completed per investigator.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Quetiapine	Anorexia Nervosa	C0003125	NCT00584688	Terminated	Phase 2	Lack of Enrollment	C0123091	Quetiapina
Gemcitabine	Pancreatic Neoplasm	C0030297	NCT00574275	Terminated	Phase 3	Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to    gemcitabine would be unable to demonstrate improved survival	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Belimumab	Rheumatoid Arthritis	C0003873	NCT00583557	Terminated	Phase 2	Sponsor decision - not related to safety	C1723401	Belimumab
Clofarabine	leukemia	C0023418	NCT00577694	Terminated	Phase 1	funding unavailable	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Bevacizumab	Malignant tumor of colon	C0007102	NCT00577109	Terminated	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Vidarabine	Lymphoma, Non-Hodgkin	C0024305	NCT00577161	Terminated	Phase 3	closed to enrollment	C0042646	Vidarabinum
Fludarabine	Lymphoma, Non-Hodgkin	C0024305	NCT00577161	Terminated	Phase 3	closed to enrollment	C0059985	Fludarabinum
Peginterferon alfa-2b	Solid tumour	C0280100	NCT00585221	Terminated	Phase 2	PI terminated at the recommendation of DSMC & IRB	C0796545	Peginterferon alfa-2b
Imatinib	Solid tumour	C0280100	NCT00585221	Terminated	Phase 2	PI terminated at the recommendation of DSMC & IRB	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Docetaxel	Malignant neoplasm of lung	C0242379	NCT00539968	Terminated	Phase 1/Phase 2		C0246415	Docetaxel
Paclitaxel	Mammary Carcinoma, Human	C1257930	NCT00558545	Terminated	Phase 1/Phase 2	Avastin approved for first-in-line treatment.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Capecitabine	Malignant tumor of colon	C0007102	NCT00538291	Terminated	Phase 2	Study was terminated early due to lack of efficacy.	C0671970	Capecitabin
Vancomycin	Pneumonia, Ventilator-Associated	C1701940	NCT00543608	Terminated	Phase 2	Trial terminated due to financial resource limitations	C0042313	Vancomycine
Milrinone	Congenital Heart Defects	C0018798	NCT00543309	Terminated	Phase 2	DSMB recommended termination based on interim outcomes analysis	C0128513	Milrinonum
Sorafenib	Malignant neoplasm of lung	C0242379	NCT00543335	Terminated	Phase 1	Lack of Accrual.	C1516119	Sorafenibum
Nitric Oxide	Varicose Ulcer	C0042344	NCT00545298	Terminated	Phase 2	Strategic direction of the sponsor changed	C0028128	óxido nítrico
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00544648	Terminated	Phase 1/Phase 2	Ph I completed. Funding became unavailable causing Ph II to cease after two patients were    enrolled.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Malignant neoplasm of lung	C0242379	NCT00544648	Terminated	Phase 1/Phase 2	Ph I completed. Funding became unavailable causing Ph II to cease after two patients were    enrolled.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Cisplatin	Esophageal Neoplasms	C0014859	NCT00559351	Terminated	Phase 3	difficulty in recruitment	C0008838	cisplatino
Fluorouracil	Esophageal Neoplasms	C0014859	NCT00559351	Terminated	Phase 3	difficulty in recruitment	C0016360	Fluorouracilum
Progesterone	Premature Birth	C0151526	NCT00536003	Terminated	Phase 3		C0033308	Gelbkörperhormon
Tadalafil	Priapism	C0033117	NCT00538564	Terminated	Phase 2		C1176316	(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
Cisplatin	Adenocarcinoma Of Esophagus	C0279628	NCT00573131	Terminated	Phase 2	OncoGel did not show any impact on overall tumor response	C0008838	cisplatino
Cisplatin	Squamous cell carcinoma	C0007137	NCT00573131	Terminated	Phase 2	OncoGel did not show any impact on overall tumor response	C0008838	cisplatino
Dasatinib	Multiple Myeloma	C0026764	NCT00560352	Terminated	Phase 1		C2699562	Dasatinib anhydrous
Mycophenolate mofetil	Lupus Nephritis	C0024143	NCT00573157	Terminated	Phase 2/Phase 3	The study was terminated due to unanticipated safety issues	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Lupus Nephritis	C0024143	NCT00573157	Terminated	Phase 2/Phase 3	The study was terminated due to unanticipated safety issues	C0026933	Mycophenolsäure
Aminolevulinic acid	Leukoplakia, Oral	C0023532	NCT00571558	Terminated	Phase 1		C0002563	ácido 5-aminolevulínico
Dacarbazine	Adenocarcinoma	C0001418	NCT00632203	Terminated	Phase 2		C0010927	DTIC
Temozolomide	Adenocarcinoma	C0001418	NCT00632203	Terminated	Phase 2		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dacarbazine	Carcinoma, Large Cell	C0206704	NCT00632203	Terminated	Phase 2		C0010927	DTIC
Temozolomide	Carcinoma, Large Cell	C0206704	NCT00632203	Terminated	Phase 2		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Alprostadil	Pulmonary Hypertension	C0020542	NCT00598429	Withdrawn	Phase 2	Withdrawn due to lack of recruitment	C0002335	11α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid
Erythropoietin	Brain Injuries	C0270611	NCT00589953	Terminated	Phase 2		C0357126	Epoetina alfa
Erythropoietin	Ventricular hemorrhage	C0240059	NCT00589953	Terminated	Phase 2		C0357126	Epoetina alfa
Erythropoietin	Leukomalacia, Periventricular	C0023529	NCT00589953	Terminated	Phase 2		C0357126	Epoetina alfa
Prednisone	Adenocarcinoma of prostate	C0007112	NCT00598858	Withdrawn	Phase 2	Halted due to zero accrual and lack of funding	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Docetaxel	Adenocarcinoma of prostate	C0007112	NCT00598858	Withdrawn	Phase 2	Halted due to zero accrual and lack of funding	C0246415	Docetaxel
Phenylacetic acid	Hepatic Encephalopathy	C0019151	NCT00597909	Terminated	Phase 2	Study was terminated due to lack of enrollment and business decisions.	C0070620	ω-phenylacetic acid
Fluticasone Propionate	Bronchiolitis	C0006271	NCT00656916	Terminated	Phase 2	Terminated due to slow accrual.	C0117996	Fluticasone propionate
Teriparatide	Osteopenia	C0029453	NCT00624481	Withdrawn	Phase 2		C0070093	Teriparatida
Teriparatide	Osteoporosis	C0029456	NCT00624481	Withdrawn	Phase 2		C0070093	Teriparatida
Fondaparinux sodium	Malignant neoplasm of ovary	C1140680	NCT00659399	Withdrawn	Phase 1	Low accrual	C1098510	Natural heparin pentasaccharide
Busulfan	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	C0006463	Busulfano
Ifosfamide	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Lithium	Canavan Disease	C0206307	NCT00657748	Withdrawn	Phase 2		C0023870	Lithium
Parecoxib	Pain	C0030193	NCT00651300	Terminated	Phase 3	See Detailed Description field.	C0915142	N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide
Etoposide	Leukemia, Myelocytic, Acute	C0023467	NCT00660036	Terminated	Phase 1	due to new safety information	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Nelfinavir	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There    were no safety concerns that led to the decision to terminate.	C0525005	Nelfinavir
Zidovudine	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There    were no safety concerns that led to the decision to terminate.	C0043474	Zidovudinum
Lamivudine	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There    were no safety concerns that led to the decision to terminate.	C0209738	Lamivudina
Calcium carbonate	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There    were no safety concerns that led to the decision to terminate.	C0006681	Calcio carbonato
Simvastatin	Atherosclerosis	C0004153	NCT00651391	Terminated	Phase 3	Slow enrollment	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Ezetimibe	Atherosclerosis	C0004153	NCT00651391	Terminated	Phase 3	Slow enrollment	C1142985	Ezetimiba
Doxorubicin	ovarian neoplasm	C0919267	NCT00653952	Terminated	Phase 3	Poor accrual	C0013089	Doxorubicine
Paclitaxel	ovarian neoplasm	C0919267	NCT00653952	Terminated	Phase 3	Poor accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Vorinostat	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute monoblastic leukemia (M5a)	C0279629	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute monocytic leukemia (M5b)	C0280634	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult acute myelomonocytic leukemia (M4)	C0279627	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult erythroleukemia (M6a)	C1541339	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	adult pure erythroid leukemia (M6b)	C1541340	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Vorinostat	untreated adult acute myeloid leukemia	C0279089	NCT00673153	Terminated	Phase 2		C0672708	Vorinostatum
Morphine	Advanced cancer	C0877373	NCT00634010	Terminated	Phase 3	Slow Accrual	C0026549	Morfina
Methadone	Advanced cancer	C0877373	NCT00634010	Terminated	Phase 3	Slow Accrual	C0025605	Methadonum
Morphine	Solid tumour	C0280100	NCT00634010	Terminated	Phase 3	Slow Accrual	C0026549	Morfina
Methadone	Solid tumour	C0280100	NCT00634010	Terminated	Phase 3	Slow Accrual	C0025605	Methadonum
Aldesleukin	leukemia	C0023418	NCT00625729	Terminated	Phase 1/Phase 2	No patients exhibited natural killer cell expansion (primary endpoint).	C0218986	Aldesleukina
Rituximab	leukemia	C0023418	NCT00625729	Terminated	Phase 1/Phase 2	No patients exhibited natural killer cell expansion (primary endpoint).	C5195655	rituximab-pvvr
Fludarabine	leukemia	C0023418	NCT00625729	Terminated	Phase 1/Phase 2	No patients exhibited natural killer cell expansion (primary endpoint).	C0059985	Fludarabinum
Teriparatide	Hypocalcemia	C0020598	NCT00623974	Terminated	Phase 2	Terminated due to slow accrual.	C0070093	Teriparatida
Cyclophosphamide	leukemia	C0023418	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision	C0010583	Cyclophosphamidum
Clofarabine	leukemia	C0023418	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cyclophosphamide	Hodgkin Disease	C0019829	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision	C0010583	Cyclophosphamidum
Clofarabine	Hodgkin Disease	C0019829	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Clofarabine	Multiple Myeloma	C0026764	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Reboxetine	Diabetic Neuropathies	C0011882	NCT00625833	Terminated	Phase 2	Study was terminated for futility following the planned interim analysis.	C0168388	Reboxetina
Irinotecan	Malignant tumor of colon	C0007102	NCT00677924	Terminated	Phase 1/Phase 2	Due to changes in portfolio review	C0123931	(+)-Irinotecan
Oxaliplatin	Malignant tumor of colon	C0007102	NCT00625183	Terminated	Phase 2	Withdrawn due to poor/low accrual	C0069717	oxaliplatine
Capecitabine	Malignant tumor of colon	C0007102	NCT00625183	Terminated	Phase 2	Withdrawn due to poor/low accrual	C0671970	Capecitabin
Iloprost	Systemic Scleroderma	C0036421	NCT00622687	Terminated	Phase 2	sufficient number to reach the primary endpoint and as planned	C0079594	Iloprost
Cetuximab	Esophageal carcinoma	C0152018	NCT00636298	Withdrawn	Phase 2	lack of funding	C0995188	Cétuximab
Bevacizumab	Esophageal carcinoma	C0152018	NCT00636298	Withdrawn	Phase 2	lack of funding	C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Renal Cell Carcinoma	C0007134	NCT00684996	Terminated	Phase 1/Phase 2		C0796392	Anti-VEGF monoclonal antibody
Zonisamide	Epilepsy	C0014544	NCT00693017	Terminated	Phase 3	Sponsor's decision	C0078844	Benzo[d]isoxazol-3-yl-methanesulfonamide
Mesalazine	Diverticulitis	C0012813	NCT00695643	Terminated	Phase 3		C0253787	p-Aminosalicylsaeure
Lenalidomide	Advanced cancer	C0877373	NCT00684242	Terminated	Phase 2	Low accrual.	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Advanced cancer	C0877373	NCT00684242	Terminated	Phase 2	Low accrual.	C0039736	Thalidomidum
Lenalidomide	Pain	C0030193	NCT00684242	Terminated	Phase 2	Low accrual.	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Pain	C0030193	NCT00684242	Terminated	Phase 2	Low accrual.	C0039736	Thalidomidum
Alemtuzumab	Lupus Erythematosus, Systemic	C0024141	NCT00684255	Terminated	Phase 1	inactive	C0383429	Alemtuzumab
Busulfan	Lupus Erythematosus, Systemic	C0024141	NCT00684255	Terminated	Phase 1	inactive	C0006463	Busulfano
Fludarabine	Lupus Erythematosus, Systemic	C0024141	NCT00684255	Terminated	Phase 1	inactive	C0059985	Fludarabinum
Alemtuzumab	Systemic Scleroderma	C0036421	NCT00684255	Terminated	Phase 1	inactive	C0383429	Alemtuzumab
Busulfan	Systemic Scleroderma	C0036421	NCT00684255	Terminated	Phase 1	inactive	C0006463	Busulfano
Fludarabine	Systemic Scleroderma	C0036421	NCT00684255	Terminated	Phase 1	inactive	C0059985	Fludarabinum
Adalimumab	Sarcoidosis	C0036202	NCT00690911	Withdrawn	Phase 2	Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the    study started.	C5195654	adalimumab-bwwd
Propranolol	Cocaine Dependence	C0600427	NCT00688805	Terminated	Phase 1		C0033497	Propranololum
Lovastatin	Severe persistent asthma	C1960048	NCT00689806	Withdrawn	Phase 1/Phase 2	Study never opened	C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Pramipexole	Fibromyalgia	C0016053	NCT00689052	Terminated	Phase 2		C0074710	Pramipexolum
Nitroprusside	Sarcopenia	C0872084	NCT00690534	Terminated	Phase 1		C0028193	Nitroprusside
Adalimumab	Pyoderma Gangrenosum	C0085652	NCT00690846	Withdrawn	Phase 2	Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the    study started.	C5195654	adalimumab-bwwd
Alfuzosin	Multiple Sclerosis	C0026769	NCT00688948	Terminated	Phase 2/Phase 3	Lack of funding	C0051150	Alfuzosina
Alfuzosin	Bladder dysfunction	C0232841	NCT00688948	Terminated	Phase 2/Phase 3	Lack of funding	C0051150	Alfuzosina
Pioglitazone	Amyotrophic Lateral Sclerosis	C0002736	NCT00690118	Terminated	Phase 2	The interim analysis showed no tendency in favour of the verum group. Therefore it was decided    to stop the study prematurely.	C0071097	(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
Zonisamide	Epilepsy	C0014544	NCT00692003	Terminated	Phase 3	Sponsor's decision	C0078844	Benzo[d]isoxazol-3-yl-methanesulfonamide
Ziprasidone	Schizoaffective Disorder	C0036337	NCT00645229	Terminated	Phase 3	Please see Detailed Description for termination reason.	C0380393	Ziprasidonum
Citalopram	Sleeplessness	C0917801	NCT00642694	Terminated	Phase 3	Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor	C0008845	Citalopramum
Bevacizumab	Malignant tumor of colon	C0007102	NCT00642603	Terminated	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Malignant tumor of colon	C0007102	NCT00642603	Terminated	Phase 2		C0069717	oxaliplatine
Irinotecan	Malignant tumor of colon	C0007102	NCT00642603	Terminated	Phase 2		C0123931	(+)-Irinotecan
Capecitabine	Malignant tumor of colon	C0007102	NCT00642603	Terminated	Phase 2		C0671970	Capecitabin
Pyrimethamine	Malaria, antepartum	C0747820	NCT00711906	Terminated	Phase 3	Malaria prev. fell in the study area, so we cannot evaluate the primary endpoint	C0034283	Pyrimethaminum
Sulfadoxine	Malaria, antepartum	C0747820	NCT00711906	Terminated	Phase 3	Malaria prev. fell in the study area, so we cannot evaluate the primary endpoint	C0038679	Sulfadoxina
Treprostinil	Hamman-Rich syndrome	C0085786	NCT00703339	Terminated	Phase 2	Lack of enrollment to the trial. Very difficult population to recruit.	C1145760	Tréprostinil
Treprostinil	Pulmonary Hypertension	C0020542	NCT00703339	Terminated	Phase 2	Lack of enrollment to the trial. Very difficult population to recruit.	C1145760	Tréprostinil
Pemetrexed	Primary central nervous system lymphoma	C0280803	NCT00712062	Withdrawn	Phase 2	Lack of accrual	C0210657	Pemetrexed
Lenalidomide	Adult T-Cell Lymphoma/Leukemia	C0023493	NCT00704691	Terminated	Phase 0	Closed due to futility with only 1 patient accrued	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Adult T-Cell Lymphoma/Leukemia	C0023493	NCT00704691	Terminated	Phase 0	Closed due to futility with only 1 patient accrued	C0039736	Thalidomidum
Lenalidomide	Angioimmunoblastic Lymphadenopathy	C0020981	NCT00704691	Terminated	Phase 0	Closed due to futility with only 1 patient accrued	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Angioimmunoblastic Lymphadenopathy	C0020981	NCT00704691	Terminated	Phase 0	Closed due to futility with only 1 patient accrued	C0039736	Thalidomidum
Lenalidomide	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT00704691	Terminated	Phase 0	Closed due to futility with only 1 patient accrued	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT00704691	Terminated	Phase 0	Closed due to futility with only 1 patient accrued	C0039736	Thalidomidum
Salmon Calcitonin	Degenerative polyarthritis	C0029408	NCT00704847	Terminated	Phase 3	Male subjects were terminated due to an imbalance in prostate cancer events	C0073994	Calcitonina salmón sintética
Testosterone	Hypogonadism	C0020619	NCT00705796	Withdrawn	Phase 1	financial constraints	C0039601	Testostérone
Methyltestosterone	Hypogonadism	C0020619	NCT00705796	Withdrawn	Phase 1	financial constraints	C0025826	Methyltestosteronum
Aldesleukin	Cutaneous Melanoma	C0151779	NCT00704938	Terminated	Phase 2	Terminated due to withdrawal of support from our collaborator.	C0218986	Aldesleukina
Fludarabine	Cutaneous Melanoma	C0151779	NCT00704938	Terminated	Phase 2	Terminated due to withdrawal of support from our collaborator.	C0059985	Fludarabinum
Aldesleukin	unspecified adult solid tumor, protocol specific	C0279004	NCT00704938	Terminated	Phase 2	Terminated due to withdrawal of support from our collaborator.	C0218986	Aldesleukina
Fludarabine	unspecified adult solid tumor, protocol specific	C0279004	NCT00704938	Terminated	Phase 2	Terminated due to withdrawal of support from our collaborator.	C0059985	Fludarabinum
Temozolomide	Glioblastoma	C0017636	NCT00703859	Withdrawn	Phase 1		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Aminolevulinic acid	Cervical Intraepithelial Neoplasia	C0206708	NCT00708942	Terminated	Phase 2	Slow recruitment, study stopped with only 13 of 70 patients included in second part of the    study	C0002563	ácido 5-aminolevulínico
Riboflavin	progressive keratoconus	C2114756	NCT00679666	Withdrawn	Phase 2/Phase 3	Investigator no longer at university	C4550958	Vitamin Bi
Riboflavin	Corneal ectasia	C0155135	NCT00679666	Withdrawn	Phase 2/Phase 3	Investigator no longer at university	C4550958	Vitamin Bi
Peginterferon alfa-2b	unspecified adult solid tumor, protocol specific	C0279004	NCT00701298	Terminated	Phase 1		C0796545	Peginterferon alfa-2b
Decitabine	unspecified adult solid tumor, protocol specific	C0279004	NCT00701298	Terminated	Phase 1		C0049065	5-azadeoxycytidine
Heparin	Burn injury	C0006434	NCT00701623	Withdrawn	Phase 2/Phase 3		C0019134	Heparina
Bisoprolol	Chronic Obstructive Airway Disease	C0024117	NCT00702156	Terminated	Phase 2	Inadequate patient recruitment	C0053799	(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
Calfactant	Respiratory Distress Syndrome, Adult	C0035222	NCT00682500	Terminated	Phase 3	Expected mortality rates in placebo and treatment groups lower than predicted	C0763530	Bovactant
Exenatide	Diabetes Mellitus	C0011849	NCT00701935	Terminated	Phase 2	Enrollment was much slower than anticipated, leading to a decision to terminate the study    early for enrollment futility.	C0167117	Exenatida
Gemcitabine	Cholangiocarcinoma	C0206698	NCT00713687	Withdrawn	Phase 2	recruiting failed	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Oxaliplatin	Cholangiocarcinoma	C0206698	NCT00713687	Withdrawn	Phase 2	recruiting failed	C0069717	oxaliplatine
Bevacizumab	Colorectal Carcinoma	C0009402	NCT00735241	Withdrawn	Phase 2/Phase 3	Withdrawn by the study sponsor.	C0796392	Anti-VEGF monoclonal antibody
Folic Acid	Colorectal Carcinoma	C0009402	NCT00735241	Withdrawn	Phase 2/Phase 3	Withdrawn by the study sponsor.	C0016410	Folic acid
Levoleucovorin	Colorectal Carcinoma	C0009402	NCT00735241	Withdrawn	Phase 2/Phase 3	Withdrawn by the study sponsor.	C2721771	ácido levofolínico
Bevacizumab	Secondary malignant neoplasm of liver	C0494165	NCT00735241	Withdrawn	Phase 2/Phase 3	Withdrawn by the study sponsor.	C0796392	Anti-VEGF monoclonal antibody
Folic Acid	Secondary malignant neoplasm of liver	C0494165	NCT00735241	Withdrawn	Phase 2/Phase 3	Withdrawn by the study sponsor.	C0016410	Folic acid
Levoleucovorin	Secondary malignant neoplasm of liver	C0494165	NCT00735241	Withdrawn	Phase 2/Phase 3	Withdrawn by the study sponsor.	C2721771	ácido levofolínico
Ethanol	Pregnancy in Adolescence	C0032968	NCT00747630	Terminated	Phase 0	This project was not a clinical trial requiring registration	C0001962	Spiritus vini
Mefloquine	Leukoencephalopathy, Progressive Multifocal	C0023524	NCT00746941	Terminated	Phase 1/Phase 2	Primary endpoint not achieved	C0025153	Mefloquinum
Exemestane	Advanced breast cancer	C3495917	NCT00793546	Terminated	Phase 2	See termination reason in detailed description.	C0851344	6-methyleneandrosta-1,4-diene-3,17-dione
Tenofovir	Hepatitis B	C0019163	NCT00823342	Terminated	Phase 3		C0673857	Bis(POC)PMPA
Nitric Oxide	MRSA - Methicillin resistant Staphylococcus aureus infection	C0343401	NCT00790608	Terminated	Phase 2	Limited recruitment	C0028128	óxido nítrico
Alemtuzumab	leukemia	C0023418	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0383429	Alemtuzumab
Vidarabine	leukemia	C0023418	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0042646	Vidarabinum
Cyclophosphamide	leukemia	C0023418	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0010583	Cyclophosphamidum
Busulfan	leukemia	C0023418	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0006463	Busulfano
Fludarabine	leukemia	C0023418	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0059985	Fludarabinum
Thiotepa	leukemia	C0023418	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0039871	Thiotepa
Alemtuzumab	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0383429	Alemtuzumab
Vidarabine	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0042646	Vidarabinum
Busulfan	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0006463	Busulfano
Fludarabine	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0059985	Fludarabinum
Thiotepa	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0039871	Thiotepa
Alemtuzumab	Immunologic Deficiency Syndromes	C0021051	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0383429	Alemtuzumab
Vidarabine	Immunologic Deficiency Syndromes	C0021051	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0042646	Vidarabinum
Cyclophosphamide	Immunologic Deficiency Syndromes	C0021051	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0010583	Cyclophosphamidum
Busulfan	Immunologic Deficiency Syndromes	C0021051	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0006463	Busulfano
Fludarabine	Immunologic Deficiency Syndromes	C0021051	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0059985	Fludarabinum
Thiotepa	Immunologic Deficiency Syndromes	C0021051	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	C0039871	Thiotepa
Erlotinib	Malignant neoplasm of lung	C0242379	NCT00826449	Terminated	Phase 1/Phase 2	Closed early due to determination of futility/efficacy.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Dasatinib	Malignant neoplasm of lung	C0242379	NCT00826449	Terminated	Phase 1/Phase 2	Closed early due to determination of futility/efficacy.	C2699562	Dasatinib anhydrous
Dasatinib	Non-Small Cell Lung Carcinoma	C0007131	NCT00826449	Terminated	Phase 1/Phase 2	Closed early due to determination of futility/efficacy.	C2699562	Dasatinib anhydrous
Nitric Oxide	Chronic ulcer of lower extremity	C0263560	NCT00823095	Terminated	Phase 2	Subject recuitment halted and won't resume; subjects are no longer being treated.	C0028128	óxido nítrico
Budesonide	Inflammatory Bowel Diseases	C0021390	NCT00805285	Terminated	Phase 2	Study terminated due to insufficient enrollment	C0054201	(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Budesonide	Ulcerative Colitis	C0009324	NCT00805285	Terminated	Phase 2	Study terminated due to insufficient enrollment	C0054201	(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Anidulafungin	Fungemia	C0085082	NCT00806351	Terminated	Phase 3	The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not    terminate due to any safety issues or concerns.	C1142738	Anidulafungina
Caspofungin	Fungemia	C0085082	NCT00806351	Terminated	Phase 3	The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not    terminate due to any safety issues or concerns.	C0537894	(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
Anidulafungin	Candidiasis	C0006840	NCT00806351	Terminated	Phase 3	The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not    terminate due to any safety issues or concerns.	C1142738	Anidulafungina
Caspofungin	Candidiasis	C0006840	NCT00806351	Terminated	Phase 3	The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not    terminate due to any safety issues or concerns.	C0537894	(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
Vidarabine	Myeloproliferative disease	C0027022	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0042646	Vidarabinum
Mycophenolate mofetil	Myeloproliferative disease	C0027022	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Myeloproliferative disease	C0027022	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Myeloproliferative disease	C0027022	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0026933	Mycophenolsäure
Melphalan	Myeloproliferative disease	C0027022	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Fludarabine	Myeloproliferative disease	C0027022	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0059985	Fludarabinum
Vidarabine	leukemia	C0023418	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0042646	Vidarabinum
Mycophenolate mofetil	leukemia	C0023418	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	leukemia	C0023418	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0771204	Tacrolimus anhydrous
Mycophenolic acid	leukemia	C0023418	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0026933	Mycophenolsäure
Melphalan	leukemia	C0023418	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Fludarabine	leukemia	C0023418	NCT00827099	Terminated	Phase 2	Unacceptable morbidity & mortality	C0059985	Fludarabinum
Budesonide	Radiation proctitis	C0400827	NCT00828230	Terminated	Phase 2	Study was prematurely stopped due to slow recruitment after 17 of 32 anticipated patients were    recruited.	C0054201	(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Colchicine	Hepatitis C, Chronic	C0524910	NCT00840489	Terminated	Phase 2	Preliminary analysis	C0009262	Colchicinum
Pegfilgrastim	Non-Small Cell Lung Carcinoma	C0007131	NCT00862134	Terminated	Phase 2	Interim analysis indicated low probability of clinically significant result	C4735048	pegfilgrastim-cbqv
Erlotinib	Meningeal Carcinomatosis	C0220654	NCT00830245	Terminated	Phase 2	low accrual rate	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Cycloserine	Smoker	C0337664	NCT00827281	Withdrawn	Phase 2	Study was not funded and pilot work proved impractical.	C0010590	(+)-4-amino-3-isoxazolidinone
Clofarabine	adult acute myeloid leukemia in remission	C0279094	NCT00863434	Terminated	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	adult acute myeloid leukemia in remission	C0279094	NCT00863434	Terminated	Phase 2		C0010711	Cytarabinum
Clofarabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00863434	Terminated	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT00863434	Terminated	Phase 2		C0010711	Cytarabinum
Clofarabine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT00863434	Terminated	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT00863434	Terminated	Phase 2		C0010711	Cytarabinum
Clofarabine	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT00863434	Terminated	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT00863434	Terminated	Phase 2		C0010711	Cytarabinum
Clofarabine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT00863434	Terminated	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT00863434	Terminated	Phase 2		C0010711	Cytarabinum
Clofarabine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT00863434	Terminated	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT00863434	Terminated	Phase 2		C0010711	Cytarabinum
Clofarabine	recurrent adult acute myeloid leukemia	C0278780	NCT00863434	Terminated	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	recurrent adult acute myeloid leukemia	C0278780	NCT00863434	Terminated	Phase 2		C0010711	Cytarabinum
Topiramate	Alcoholic Intoxication, Chronic	C0001973	NCT00862563	Terminated	Phase 2	Recruitment goals could not be met before ending of funding for this project.	C0076829	Topiramato
Zonisamide	Alcoholic Intoxication, Chronic	C0001973	NCT00862563	Terminated	Phase 2	Recruitment goals could not be met before ending of funding for this project.	C0078844	Benzo[d]isoxazol-3-yl-methanesulfonamide
Piracetam	Alcoholic Intoxication, Chronic	C0001973	NCT00862563	Terminated	Phase 2	Recruitment goals could not be met before ending of funding for this project.	C0031977	Piracetam
Voriconazole	Invasive aspergillosis	C0238013	NCT00836875	Terminated	Phase 3	This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of    any safety issues or concerns.	C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Sevelamer	Chronic Kidney Diseases	C1561643	NCT00833768	Terminated	Phase 3	After an extensive review,the ASPIRE in CKD study was terminated because it was not possible    to complete the study in an appropriate time frame.	C0718050	Sévélamer
Sevelamer	Hyperphosphatemia (disorder)	C0085681	NCT00833768	Terminated	Phase 3	After an extensive review,the ASPIRE in CKD study was terminated because it was not possible    to complete the study in an appropriate time frame.	C0718050	Sévélamer
Busulfan	Refractory Brain Neoplasm	C2347923	NCT00836628	Withdrawn	Phase 1	slow accrual	C0006463	Busulfano
Rituximab	leukemia	C0023418	NCT00833534	Withdrawn	Phase 2	No patient enrolled on study. Did not get patients in timely fashion. All referrals for study    when assessed were not eligible.	C5195655	rituximab-pvvr
Lenalidomide	leukemia	C0023418	NCT00833534	Withdrawn	Phase 2	No patient enrolled on study. Did not get patients in timely fashion. All referrals for study    when assessed were not eligible.	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Paroxetine	Anxiety Disorders	C0003469	NCT00836069	Terminated	Phase 3	Pfizer has terminated the execution of this protocol	C0070122	Paroxetina
Floxuridine	Malignant neoplasm of stomach	C0024623	NCT00848783	Terminated	Phase 2	Due to slow accrual	C0016343	Fluoruridine deoxyribose
Cisplatin	Malignant neoplasm of stomach	C0024623	NCT00848783	Terminated	Phase 2	Due to slow accrual	C0008838	cisplatino
Irinotecan	Malignant neoplasm of stomach	C0024623	NCT00848783	Terminated	Phase 2	Due to slow accrual	C0123931	(+)-Irinotecan
Amphotericin B	Meningitis, Cryptococcal	C0085436	NCT00847678	Terminated	Phase 2		C1145701	Liposomal amphotericin B
Flucytosine	Meningitis, Cryptococcal	C0085436	NCT00847678	Terminated	Phase 2		C0016278	Flucytosinum
Glycine betaine	Hepatitis C, Chronic	C0524910	NCT00882193	Terminated	Phase 0	new medications with improved response released, nonaccrual	C0005304	betaína anhidra
Ampicillin	Chorioamnionitis	C0008495	NCT00879190	Suspended	Phase 2/Phase 3	We are currently performing and interim analysis for possible neonatal organism resistance to    antibiotic regimens.	C0724526	Ampicillin anhydrous
Sulbactam	Chorioamnionitis	C0008495	NCT00879190	Suspended	Phase 2/Phase 3	We are currently performing and interim analysis for possible neonatal organism resistance to    antibiotic regimens.	C0038665	Penicillanic acid sulfone
Valsartan	Oxidative Stress	C0242606	NCT00878969	Terminated	Phase 3	insufficient enrollment and retention	C0216784	N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Ramipril	Oxidative Stress	C0242606	NCT00878969	Terminated	Phase 3	insufficient enrollment and retention	C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Valsartan	Endothelial dysfunction	C0856169	NCT00878969	Terminated	Phase 3	insufficient enrollment and retention	C0216784	N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Ramipril	Endothelial dysfunction	C0856169	NCT00878969	Terminated	Phase 3	insufficient enrollment and retention	C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Bevacizumab	Biliary Tract Cancer	C0750952	NCT00881504	Terminated	Phase 2	It was not possible to get insurance companies to cover bevacizumab.	C0796392	Anti-VEGF monoclonal antibody
Pregabalin	Spinal Cord Injuries	C0037929	NCT00879021	Terminated	Phase 3	lack of funding and patients	C0657912	(S)-3-Isobutyl GABA
Pregabalin	Pain	C0030193	NCT00879021	Terminated	Phase 3	lack of funding and patients	C0657912	(S)-3-Isobutyl GABA
Prednisone	Adenocarcinoma of prostate	C0007112	NCT00879619	Terminated	Phase 1/Phase 2	Terminated due to slow accrual.	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Sunitinib	Adenocarcinoma of prostate	C0007112	NCT00879619	Terminated	Phase 1/Phase 2	Terminated due to slow accrual.	C1176020	Sunitinibum
Prednisone	Prostate cancer recurrent	C0278838	NCT00879619	Terminated	Phase 1/Phase 2	Terminated due to slow accrual.	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Sunitinib	Prostate cancer recurrent	C0278838	NCT00879619	Terminated	Phase 1/Phase 2	Terminated due to slow accrual.	C1176020	Sunitinibum
Pregabalin	Orofacial Pain	C0178782	NCT00852436	Terminated	Phase 2	difficulty to recruit patients	C0657912	(S)-3-Isobutyl GABA
Thiamine	Hyperemesis Gravidarum	C0020450	NCT00861523	Terminated	Phase 3	Difficulties in recruiting patients	C0039840	thiamine
Promethazine	Hyperemesis Gravidarum	C0020450	NCT00861523	Terminated	Phase 3	Difficulties in recruiting patients	C0033405	10-[2-(dimethylamino)propyl]phenothiazine
Diphenhydramine	Hyperemesis Gravidarum	C0020450	NCT00861523	Terminated	Phase 3	Difficulties in recruiting patients	C0012522	β-dimethylaminoethanol diphenylmethyl ether
Modafinil	Methamphetamine dependence	C1533217	NCT00859573	Terminated	Phase 2	Terminated due to lack of funding.	C0066677	2-((diphenylmethyl)sulfinyl)acetamide
Methamphetamine	Methamphetamine dependence	C1533217	NCT00859573	Terminated	Phase 2	Terminated due to lack of funding.	C0025611	Metamfetamine
Armodafinil	Methamphetamine dependence	C1533217	NCT00859573	Terminated	Phase 2	Terminated due to lack of funding.	C1701455	Armodafinilo
Dasatinib	Malignant neoplasm of lung	C0242379	NCT00858403	Terminated	Phase 2	Slow Accrual	C2699562	Dasatinib anhydrous
Risperidone	Schizoaffective Disorder	C0036337	NCT00857818	Terminated	Phase 3	Slow Accrual	C0073393	Rispéridone
Quetiapine	Schizoaffective Disorder	C0036337	NCT00857818	Terminated	Phase 3	Slow Accrual	C0123091	Quetiapina
Aripiprazole	Schizoaffective Disorder	C0036337	NCT00857818	Terminated	Phase 3	Slow Accrual	C0299792	Aripiprazolum
Risperidone	Bipolar I disorder	C0853193	NCT00857818	Terminated	Phase 3	Slow Accrual	C0073393	Rispéridone
Quetiapine	Bipolar I disorder	C0853193	NCT00857818	Terminated	Phase 3	Slow Accrual	C0123091	Quetiapina
Aripiprazole	Bipolar I disorder	C0853193	NCT00857818	Terminated	Phase 3	Slow Accrual	C0299792	Aripiprazolum
Pregabalin	Vulvodynia	C0406670	NCT00853229	Terminated	Phase 2	Not feasible due to low accrual	C0657912	(S)-3-Isobutyl GABA
Pregabalin	Vulvar Vestibulitis	C0269084	NCT00853229	Terminated	Phase 2	Not feasible due to low accrual	C0657912	(S)-3-Isobutyl GABA
Prednisone	Multiple Myeloma	C0026764	NCT00857324	Terminated	Phase 1/Phase 2	The Phase I of the study was completed, but Phase 2 has not been activated	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Vorinostat	Multiple Myeloma	C0026764	NCT00857324	Terminated	Phase 1/Phase 2	The Phase I of the study was completed, but Phase 2 has not been activated	C0672708	Vorinostatum
Zoledronic acid	Adenocarcinoma	C0001418	NCT00892242	Terminated	Phase 1	Principal Investigator decided to close the study early.	C0257685	ácido zoledrónico
Linezolid	Skin Diseases, Infectious	C0037278	NCT00865280	Terminated	Phase 3	Terminated	C0663241	Linezolidum
Quetiapine	Major Depressive Disorder	C1269683	NCT00868374	Terminated	Phase 3	Study terminated due to low enrollment	C0123091	Quetiapina
Quetiapine	Generalized Anxiety Disorder	C0270549	NCT00868374	Terminated	Phase 3	Study terminated due to low enrollment	C0123091	Quetiapina
Cisplatin	Epithelial ovarian cancer	C0677886	NCT00889733	Terminated	Phase 1/Phase 2	Poor recruitment	C0008838	cisplatino
Temozolomide	Mixed Oligodendroglioma-Astrocytoma	C0280793	NCT00897377	Terminated	Phase 3	Difficulty in recruiting patients	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Mifepristone	Affective Disorders, Psychotic	C0001723	NCT00867360	Terminated	Phase 3		C0026088	Mifepristonum
Rituximab	Lymphoproliferative Disorders	C0024314	NCT00869323	Terminated	Phase 2	Funding unavailable	C5195655	rituximab-pvvr
Bortezomib	Lymphoproliferative Disorders	C0024314	NCT00869323	Terminated	Phase 2	Funding unavailable	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Dacarbazine	Glioblastoma	C0017636	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C0010927	DTIC
Temozolomide	Glioblastoma	C0017636	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dasatinib	Glioblastoma	C0017636	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C2699562	Dasatinib anhydrous
Dacarbazine	CNS disorder	C0007682	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C0010927	DTIC
Temozolomide	CNS disorder	C0007682	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dasatinib	CNS disorder	C0007682	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C2699562	Dasatinib anhydrous
Dacarbazine	Brain Diseases	C0006111	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C0010927	DTIC
Temozolomide	Brain Diseases	C0006111	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dasatinib	Brain Diseases	C0006111	NCT00895960	Terminated	Phase 1	Sponsor withdrew support; Study did not progress to Phase II.	C2699562	Dasatinib anhydrous
Cetuximab	metastatic squamous neck cancer with occult primary squamous cell carcinoma	C0279696	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	metastatic squamous neck cancer with occult primary squamous cell carcinoma	C0279696	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	recurrent metastatic squamous neck cancer with occult primary	C0279100	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	recurrent metastatic squamous neck cancer with occult primary	C0279100	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Recurrent Salivary Gland Cancer	C0278993	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Recurrent Salivary Gland Cancer	C0278993	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Squamous cell carcinoma of the hypopharynx recurrent	C0280392	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Squamous cell carcinoma of the hypopharynx recurrent	C0280392	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Laryngeal squamous cell carcinoma recurrent	C0280401	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Laryngeal squamous cell carcinoma recurrent	C0280401	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	recurrent squamous cell carcinoma of the lip and oral cavity	C0280363	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	recurrent squamous cell carcinoma of the lip and oral cavity	C0280363	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Nasopharyngeal squamous cell carcinoma recurrent	C0280386	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Nasopharyngeal squamous cell carcinoma recurrent	C0280386	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Oropharyngeal squamous cell carcinoma recurrent	C0280376	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Oropharyngeal squamous cell carcinoma recurrent	C0280376	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280419	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280419	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Laryngeal verrucous carcinoma recurrent	C0280402	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Laryngeal verrucous carcinoma recurrent	C0280402	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Verrucous carcinoma of the oral cavity recurrent	C0280365	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Verrucous carcinoma of the oral cavity recurrent	C0280365	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	squamous cell carcinoma of salivary gland	C0279697	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	squamous cell carcinoma of salivary gland	C0279697	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Salivary gland cancer stage III	C0278991	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Salivary gland cancer stage III	C0278991	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Squamous cell carcinoma of the hypopharynx stage III	C0280390	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Squamous cell carcinoma of the hypopharynx stage III	C0280390	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Laryngeal squamous cell carcinoma stage III	C0280397	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Laryngeal squamous cell carcinoma stage III	C0280397	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	stage III squamous cell carcinoma of the lip and oral cavity	C0280353	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	stage III squamous cell carcinoma of the lip and oral cavity	C0280353	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Nasopharyngeal squamous cell carcinoma stage III	C0280382	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Nasopharyngeal squamous cell carcinoma stage III	C0280382	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Oropharyngeal squamous cell carcinoma stage III	C0280372	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Oropharyngeal squamous cell carcinoma stage III	C0280372	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	stage III squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280411	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	stage III squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280411	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Laryngeal verrucous carcinoma stage III	C0280398	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Laryngeal verrucous carcinoma stage III	C0280398	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Verrucous carcinoma of the oral cavity stage III	C0280355	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Verrucous carcinoma of the oral cavity stage III	C0280355	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Salivary gland cancer stage IV	C0278992	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Salivary gland cancer stage IV	C0278992	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Squamous cell carcinoma of the hypopharynx stage IV	C0280391	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Squamous cell carcinoma of the hypopharynx stage IV	C0280391	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Laryngeal squamous cell carcinoma stage IV	C0280399	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Laryngeal squamous cell carcinoma stage IV	C0280399	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	stage IV squamous cell carcinoma of the lip and oral cavity	C0280358	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	stage IV squamous cell carcinoma of the lip and oral cavity	C0280358	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Nasopharyngeal squamous cell carcinoma stage IV	C0280384	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Nasopharyngeal squamous cell carcinoma stage IV	C0280384	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	stage IV squamous cell carcinoma of the oropharynx	C0280374	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	stage IV squamous cell carcinoma of the oropharynx	C0280374	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280415	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280415	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Laryngeal verrucous carcinoma stage IV	C0280400	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Laryngeal verrucous carcinoma stage IV	C0280400	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	Verrucous carcinoma of the oral cavity stage IV	C0280360	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	Verrucous carcinoma of the oral cavity stage IV	C0280360	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Cetuximab	untreated metastatic squamous neck cancer with occult primary	C0279099	NCT00906360	Terminated	Phase 1		C0995188	Cétuximab
Sunitinib	untreated metastatic squamous neck cancer with occult primary	C0279099	NCT00906360	Terminated	Phase 1		C1176020	Sunitinibum
Sorafenib	Colorectal Neoplasms	C0009404	NCT00889343	Terminated	Phase 2		C1516119	Sorafenibum
Oxaliplatin	Colorectal Neoplasms	C0009404	NCT00889343	Terminated	Phase 2		C0069717	oxaliplatine
Irinotecan	Colorectal Neoplasms	C0009404	NCT00889343	Terminated	Phase 2		C0123931	(+)-Irinotecan
Oxytocin	Fetal Membranes, Premature Rupture	C0015944	NCT00890630	Terminated	Phase 2	Inadequate Patient Recruitment.	C0030095	Oxitocina
Lamotrigine	Bipolar Disorder	C0005586	NCT00907985	Terminated	Phase 1	Slow recruitment; trial unlikely to reach completion	C0064636	3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Zoledronic acid	Giant Cell Tumor of Bone	C0206638	NCT00889590	Terminated	Phase 2	low recruitment with registration denosumab	C0257685	ácido zoledrónico
Panobinostat	Non-Small Cell Lung Carcinoma	C0007131	NCT00907179	Terminated	Phase 1	Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..	C1998098	(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Cetuximab	Neoplasm Metastasis	C0027627	NCT00908024	Terminated	Phase 1/Phase 2		C0995188	Cétuximab
Sunitinib	cognitive/functional effects	C0935657	NCT00910039	Terminated	Phase 2	Slow Accrual	C1176020	Sunitinibum
Sunitinib	unspecified adult solid tumor, protocol specific	C0279004	NCT00910039	Terminated	Phase 2	Slow Accrual	C1176020	Sunitinibum
Cisplatin	Nausea and vomiting	C0027498	NCT00891761	Withdrawn	Phase 3	This study has been cancelled prior to enrollment.	C0008838	cisplatino
Ondansetron	Nausea and vomiting	C0027498	NCT00891761	Withdrawn	Phase 3	This study has been cancelled prior to enrollment.	C0061851	Ondansetron
Dexamethasone	Nausea and vomiting	C0027498	NCT00891761	Withdrawn	Phase 3	This study has been cancelled prior to enrollment.	C0011777	Dexaméthasone
Vincristine	Adult Kidney Wilms Tumor	C1332219	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	Adult Kidney Wilms Tumor	C1332219	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	Adult Kidney Wilms Tumor	C1332219	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	Adult Kidney Wilms Tumor	C1332219	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	Beckwith-Wiedemann Syndrome	C0004903	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	Beckwith-Wiedemann Syndrome	C0004903	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	Beckwith-Wiedemann Syndrome	C0004903	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	Beckwith-Wiedemann Syndrome	C0004903	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	Childhood Kidney Wilms Tumor	C1333015	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	Childhood Kidney Wilms Tumor	C1333015	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	Childhood Kidney Wilms Tumor	C1333015	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	Childhood Kidney Wilms Tumor	C1333015	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	Diffuse Hyperplastic Perilobar Nephroblastomatosis	C1880323	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	Diffuse Hyperplastic Perilobar Nephroblastomatosis	C1880323	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	Diffuse Hyperplastic Perilobar Nephroblastomatosis	C1880323	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	Diffuse Hyperplastic Perilobar Nephroblastomatosis	C1880323	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	Congenital hemihypertrophy	C0332890	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	Congenital hemihypertrophy	C0332890	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	Congenital hemihypertrophy	C0332890	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	Congenital hemihypertrophy	C0332890	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	stage I Wilms' tumor	C0278711	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	stage I Wilms' tumor	C0278711	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	stage I Wilms' tumor	C0278711	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	stage I Wilms' tumor	C0278711	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	stage II Wilms' tumor	C0278712	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	stage II Wilms' tumor	C0278712	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	stage II Wilms' tumor	C0278712	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	stage II Wilms' tumor	C0278712	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	stage III Wilms' tumor	C0278713	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	stage III Wilms' tumor	C0278713	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	stage III Wilms' tumor	C0278713	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	stage III Wilms' tumor	C0278713	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	stage IV Wilms' tumor	C0278714	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	stage IV Wilms' tumor	C0278714	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	stage IV Wilms' tumor	C0278714	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	stage IV Wilms' tumor	C0278714	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Vincristine	stage V Wilms' tumor	C0278715	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0042679	Vincristina
Etoposide	stage V Wilms' tumor	C0278715	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Dactinomycin	stage V Wilms' tumor	C0278715	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0010934	Actinomycin IV
Doxorubicin	stage V Wilms' tumor	C0278715	NCT00945009	Suspended	Phase 3	Temporarily stopped for assessment	C0013089	Doxorubicine
Gemcitabine	Malignant neoplasm of lung	C0242379	NCT00951444	Withdrawn	Phase 2	The study was not activated.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00951444	Withdrawn	Phase 2	The study was not activated.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Dexamethasone	Acute fungal otitis externa	C0728738	NCT00945646	Terminated	Phase 3		C0011777	Dexaméthasone
Haloperidol	Delirium	C0011206	NCT00954603	Terminated	Phase 3	few delirious patients were enrolled.	C0018546	4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
Quetiapine	Delirium	C0011206	NCT00954603	Terminated	Phase 3	few delirious patients were enrolled.	C0123091	Quetiapina
Cetuximab	Colorectal cancer metastatic	C0948380	NCT00954876	Withdrawn	Phase 2	Study has been terminated due to lack of accrual.	C0995188	Cétuximab
Fluorouracil	Colorectal cancer metastatic	C0948380	NCT00954876	Withdrawn	Phase 2	Study has been terminated due to lack of accrual.	C0016360	Fluorouracilum
Capecitabine	Colorectal cancer metastatic	C0948380	NCT00954876	Withdrawn	Phase 2	Study has been terminated due to lack of accrual.	C0671970	Capecitabin
Denileukin diftitox	Melanoma recurrent	C0278884	NCT00945269	Terminated	Phase 1/Phase 2	ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer    be supporting clinical trials that utilize this drug.	C0717670	Interleukin-2/diptheria toxin fusion protein
Aldesleukin	Melanoma recurrent	C0278884	NCT00945269	Terminated	Phase 1/Phase 2	ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer    be supporting clinical trials that utilize this drug.	C0218986	Aldesleukina
Denileukin diftitox	malignant melanoma of skin stage III	C0278882	NCT00945269	Terminated	Phase 1/Phase 2	ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer    be supporting clinical trials that utilize this drug.	C0717670	Interleukin-2/diptheria toxin fusion protein
Aldesleukin	malignant melanoma of skin stage III	C0278882	NCT00945269	Terminated	Phase 1/Phase 2	ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer    be supporting clinical trials that utilize this drug.	C0218986	Aldesleukina
Sunitinib	Malignant neoplasm of lung	C0242379	NCT00953459	Terminated	Phase 2	poorly recruiting	C1176020	Sunitinibum
Oxaliplatin	Colorectal Neoplasms	C0009404	NCT00950820	Terminated	Phase 2	Recruitment rate to low; changed environment made protocol in its current state obsolete	C0069717	oxaliplatine
Fluorouracil	Colorectal Neoplasms	C0009404	NCT00950820	Terminated	Phase 2	Recruitment rate to low; changed environment made protocol in its current state obsolete	C0016360	Fluorouracilum
Capecitabine	Colorectal Neoplasms	C0009404	NCT00950820	Terminated	Phase 2	Recruitment rate to low; changed environment made protocol in its current state obsolete	C0671970	Capecitabin
Midazolam	Pain	C0030193	NCT00942539	Terminated	Phase 2		C0026056	Midazolamum
Carboplatin	ovarian neoplasm	C0919267	NCT00919984	Terminated	Phase 2	This study stopped due to slow accrual.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	ovarian neoplasm	C0919267	NCT00919984	Terminated	Phase 2	This study stopped due to slow accrual.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Alemtuzumab	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00947388	Terminated	Phase 1	No more eligible patients	C0383429	Alemtuzumab
Bendamustine	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT00947388	Terminated	Phase 1	No more eligible patients	C0525079	Bendamustina
Alemtuzumab	Chronic lymphocytic leukaemia refractory	C0278791	NCT00947388	Terminated	Phase 1	No more eligible patients	C0383429	Alemtuzumab
Bendamustine	Chronic lymphocytic leukaemia refractory	C0278791	NCT00947388	Terminated	Phase 1	No more eligible patients	C0525079	Bendamustina
Alemtuzumab	Chronic lymphocytic leukaemia stage 3	C0278769	NCT00947388	Terminated	Phase 1	No more eligible patients	C0383429	Alemtuzumab
Bendamustine	Chronic lymphocytic leukaemia stage 3	C0278769	NCT00947388	Terminated	Phase 1	No more eligible patients	C0525079	Bendamustina
Alemtuzumab	B-cell small lymphocytic lymphoma stage III	C0855100	NCT00947388	Terminated	Phase 1	No more eligible patients	C0383429	Alemtuzumab
Bendamustine	B-cell small lymphocytic lymphoma stage III	C0855100	NCT00947388	Terminated	Phase 1	No more eligible patients	C0525079	Bendamustina
Alemtuzumab	Chronic lymphocytic leukaemia stage 4	C0854804	NCT00947388	Terminated	Phase 1	No more eligible patients	C0383429	Alemtuzumab
Bendamustine	Chronic lymphocytic leukaemia stage 4	C0854804	NCT00947388	Terminated	Phase 1	No more eligible patients	C0525079	Bendamustina
Alemtuzumab	B-cell small lymphocytic lymphoma stage IV	C0855101	NCT00947388	Terminated	Phase 1	No more eligible patients	C0383429	Alemtuzumab
Bendamustine	B-cell small lymphocytic lymphoma stage IV	C0855101	NCT00947388	Terminated	Phase 1	No more eligible patients	C0525079	Bendamustina
Cyproheptadine	leukemia	C0023418	NCT00949117	Terminated	Phase 2	study not feasible with low accrual. DSMB recommended closure	C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Malnutrition	C0162429	NCT00949117	Terminated	Phase 2	study not feasible with low accrual. DSMB recommended closure	C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	unspecified childhood solid tumor, protocol specific	C0279002	NCT00949117	Terminated	Phase 2	study not feasible with low accrual. DSMB recommended closure	C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Cyproheptadine	Body Weight Changes	C0005911	NCT00949117	Terminated	Phase 2	study not feasible with low accrual. DSMB recommended closure	C0010620	4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
Erlotinib	Neuroendocrine Tumors	C0206754	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Pertuzumab	Neuroendocrine Tumors	C0206754	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1434409	rhuMAb-2C4
Erlotinib	Adrenal Gland Neoplasms	C0001624	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Pertuzumab	Adrenal Gland Neoplasms	C0001624	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1434409	rhuMAb-2C4
Erlotinib	Neuroblastoma	C0027819	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Pertuzumab	Neuroblastoma	C0027819	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1434409	rhuMAb-2C4
Erlotinib	Multiple Endocrine Neoplasia	C0027662	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Pertuzumab	Multiple Endocrine Neoplasia	C0027662	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	C1434409	rhuMAb-2C4
Bevacizumab	Intracranial Meningioma	C0349604	NCT00972335	Terminated	Phase 2	Study terminated early due to slow accrual	C0796392	Anti-VEGF monoclonal antibody
Sirolimus	Intracranial Meningioma	C0349604	NCT00972335	Terminated	Phase 2	Study terminated early due to slow accrual	C0072980	Sirolimús
Everolimus	Intracranial Meningioma	C0349604	NCT00972335	Terminated	Phase 2	Study terminated early due to slow accrual	C0541315	évérolimus
Lovastatin	melanoma	C0025202	NCT00963664	Withdrawn	Phase 2	Modifications will be necessary before full IRB approval will be secured.	C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Darbepoetin alfa	Chronic Kidney Diseases	C1561643	NCT00968617	Terminated	Phase 2		C0937950	Darbepoetina alfa
Lenalidomide	Renal Cell Carcinoma	C0007134	NCT00975806	Terminated	Phase 1/Phase 2	MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Renal Cell Carcinoma	C0007134	NCT00975806	Terminated	Phase 1/Phase 2	MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.	C0039736	Thalidomidum
Palonosetron	Nausea	C0027497	NCT00982995	Terminated	Phase 2	site terminated due to lack of enrollment	C0220578	(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one
Palonosetron	Vomiting	C0042963	NCT00982995	Terminated	Phase 2	site terminated due to lack of enrollment	C0220578	(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one
Oxycodone	Degenerative polyarthritis	C0029408	NCT00985621	Terminated	Phase 3	See termination reason in detailed description.	C0030049	Oxycodonum
Norepinephrine	orthostatic; hypotension, neurogenic	C1400301	NCT00977171	Terminated	Phase 2	Enrollment issues.	C0028351	(-)-noradrenaline
Droxidopa	orthostatic; hypotension, neurogenic	C1400301	NCT00977171	Terminated	Phase 2	Enrollment issues.	C0000378	L-Dihydroxyphenylserine
Norepinephrine	Chronic Fatigue Syndrome	C0015674	NCT00977171	Terminated	Phase 2	Enrollment issues.	C0028351	(-)-noradrenaline
Droxidopa	Chronic Fatigue Syndrome	C0015674	NCT00977171	Terminated	Phase 2	Enrollment issues.	C0000378	L-Dihydroxyphenylserine
Tramadol	Premature Ejaculation	C0033038	NCT00983151	Terminated	Phase 3		C0040610	Tramadolum
Modafinil	Traumatic Brain Injury	C0876926	NCT00983437	Terminated	Phase 3	Study has been stopped by sponsor decision	C0066677	2-((diphenylmethyl)sulfinyl)acetamide
Armodafinil	Traumatic Brain Injury	C0876926	NCT00983437	Terminated	Phase 3	Study has been stopped by sponsor decision	C1701455	Armodafinilo
Tramadol	Premature Ejaculation	C0033038	NCT00983736	Terminated	Phase 3	This study was terminated because of recruitment difficulties.	C0040610	Tramadolum
Cyclophosphamide	Solid tumour	C0280100	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0010583	Cyclophosphamidum
Vincristine	Solid tumour	C0280100	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0042679	Vincristina
Irinotecan	Solid tumour	C0280100	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0123931	(+)-Irinotecan
Etoposide	Solid tumour	C0280100	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Temozolomide	Solid tumour	C0280100	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Doxorubicin	Solid tumour	C0280100	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0013089	Doxorubicine
Ifosfamide	Solid tumour	C0280100	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Cyclophosphamide	Kidney Neoplasm	C0022665	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0010583	Cyclophosphamidum
Vincristine	Kidney Neoplasm	C0022665	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0042679	Vincristina
Irinotecan	Kidney Neoplasm	C0022665	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0123931	(+)-Irinotecan
Etoposide	Kidney Neoplasm	C0022665	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Temozolomide	Kidney Neoplasm	C0022665	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Doxorubicin	Kidney Neoplasm	C0022665	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0013089	Doxorubicine
Ifosfamide	Kidney Neoplasm	C0022665	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Irinotecan	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0123931	(+)-Irinotecan
Etoposide	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Temozolomide	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Ifosfamide	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Clindamycin	Malaria	C0024530	NCT01002183	Withdrawn	Phase 2	Drug combination is no longer pursued	C0008947	Clindamycine
Vardenafil	Cystic Fibrosis	C0010674	NCT01002534	Suspended	Phase 2	not yet started	C0971579	Vardenafilo
Erlotinib	Psoriasis	C0033860	NCT01006096	Withdrawn	Phase 2	IND not obtained	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Bevacizumab	Non-Small Cell Lung Carcinoma	C0007131	NCT00998166	Terminated	Phase 2	Poor enrollment	C0796392	Anti-VEGF monoclonal antibody
Cisplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT00998166	Terminated	Phase 2	Poor enrollment	C0008838	cisplatino
Triptorelin	Infertility	C0021359	NCT01007851	Terminated	Phase 3	Lower than anticipated recruitment	C0077275	triptorelinum
Sorafenib	Liver cell carcinoma non-resectable	C1112459	NCT01009593	Terminated	Phase 3	See termination reason in detailed description	C1516119	Sorafenibum
Sorafenib	Hepatoma recurrent	C0861876	NCT01009593	Terminated	Phase 3	See termination reason in detailed description	C1516119	Sorafenibum
Sorafenib	Neoplasms by Histologic Type	C0027652	NCT01009593	Terminated	Phase 3	See termination reason in detailed description	C1516119	Sorafenibum
Sorafenib	Carcinoma	C0007097	NCT01009593	Terminated	Phase 3	See termination reason in detailed description	C1516119	Sorafenibum
Sorafenib	Liver neoplasms	C0023903	NCT01009593	Terminated	Phase 3	See termination reason in detailed description	C1516119	Sorafenibum
Sorafenib	Adenocarcinoma	C0001418	NCT01009593	Terminated	Phase 3	See termination reason in detailed description	C1516119	Sorafenibum
Sorafenib	Neoplasms, Glandular and Epithelial	C0027660	NCT01009593	Terminated	Phase 3	See termination reason in detailed description	C1516119	Sorafenibum
Cetuximab	Colorectal cancer metastatic	C0948380	NCT01008475	Terminated	Phase 1/Phase 2	The study is terminated prematurely as the sponsor decided to discontinue program with EMD    525797 in oncology.	C0995188	Cétuximab
Irinotecan	Colorectal cancer metastatic	C0948380	NCT01008475	Terminated	Phase 1/Phase 2	The study is terminated prematurely as the sponsor decided to discontinue program with EMD    525797 in oncology.	C0123931	(+)-Irinotecan
Carboplatin	Epithelial ovarian cancer	C0677886	NCT01000896	Withdrawn	Phase 1	AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical    studies will be initiated..	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Epithelial ovarian cancer	C0677886	NCT01000896	Withdrawn	Phase 1	AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical    studies will be initiated..	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Azacitidine	leukemia	C0023418	NCT00997243	Terminated	Phase 2	Drug no longer being supplied by sponsor	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Danazol	Dyskeratosis Congenita	C0265965	NCT01001598	Terminated	Phase 1/Phase 2	Study was terminated due to under enrollment	C0010961	Danazolum
Indomethacin	Gout acute	C2062908	NCT00997581	Withdrawn	Phase 2	Colaborator withdrew support.	C0021246	Indometacina
Apremilast	Gout acute	C2062908	NCT00997581	Withdrawn	Phase 2	Colaborator withdrew support.	C1678805	Aprémilast
Cetuximab	Malignant neoplasm of lung	C0242379	NCT00998101	Withdrawn	Phase 2	Study was withdrawn due issuses related to the science	C0995188	Cétuximab
Carboplatin	Malignant neoplasm of lung	C0242379	NCT00998101	Withdrawn	Phase 2	Study was withdrawn due issuses related to the science	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Ramipril	Low density lipoprotein increased	C0549399	NCT01004705	Terminated	Phase 2		C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Simvastatin	Low density lipoprotein increased	C0549399	NCT01004705	Terminated	Phase 2		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Salicylic acid	Low density lipoprotein increased	C0549399	NCT01004705	Terminated	Phase 2		C0036079	ácido salicílico
Acetylsalicylic acid	Low density lipoprotein increased	C0549399	NCT01004705	Terminated	Phase 2		C0004057	Aspirina
Simvastatin	Hypertensive disease	C0020538	NCT01005290	Terminated	Phase 2		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Salicylic acid	Hypertensive disease	C0020538	NCT01005290	Terminated	Phase 2		C0036079	ácido salicílico
Acetylsalicylic acid	Hypertensive disease	C0020538	NCT01005290	Terminated	Phase 2		C0004057	Aspirina
Magnesium Sulfate	Neuropathy	C0442874	NCT00998738	Terminated	Phase 3	lack of accrual	C0024480	Magnesium sulfate
Magnesium Sulfate	Pain	C0030193	NCT00998738	Terminated	Phase 3	lack of accrual	C0024480	Magnesium sulfate
Aminosalicylic Acid	Ulcerative Colitis	C0009324	NCT01004185	Terminated	Phase 3	Pediatric enrollment very slow.	C0030125	4-amino-2-hydroxybenzoic acid
Prednisone	Myasthenia Gravis, Ocular	C0751340	NCT00995722	Terminated	Phase 3	Slow recruitment rate	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Bevacizumab	Non-small cell lung cancer recurrent	C0278517	NCT00976677	Terminated	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Erlotinib	Non-small cell lung cancer recurrent	C0278517	NCT00976677	Terminated	Phase 2		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Carboplatin	Non-small cell lung cancer recurrent	C0278517	NCT00976677	Terminated	Phase 2		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Non-small cell lung cancer recurrent	C0278517	NCT00976677	Terminated	Phase 2		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Bevacizumab	Non-small cell lung cancer metastatic	C0278987	NCT00976677	Terminated	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Erlotinib	Non-small cell lung cancer metastatic	C0278987	NCT00976677	Terminated	Phase 2		C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Carboplatin	Non-small cell lung cancer metastatic	C0278987	NCT00976677	Terminated	Phase 2		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Non-small cell lung cancer metastatic	C0278987	NCT00976677	Terminated	Phase 2		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Carboplatin	ovarian neoplasm	C0919267	NCT00976183	Terminated	Phase 1/Phase 2	toxicities	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Vorinostat	ovarian neoplasm	C0919267	NCT00976183	Terminated	Phase 1/Phase 2	toxicities	C0672708	Vorinostatum
Hydroxyurea	Fibromatosis, Aggressive	C0079218	NCT00978146	Withdrawn	Phase 2	Study was administratively withdrawn by the IRB; no subjects were enrolled	C0020402	Hydroxycarbamid
Hydroxyurea	Fibromatosis	C0016048	NCT00978146	Withdrawn	Phase 2	Study was administratively withdrawn by the IRB; no subjects were enrolled	C0020402	Hydroxycarbamid
Cisplatin	Small cell carcinoma of lung	C0149925	NCT00977561	Terminated	Phase 2	See termination reason in detailed description.	C0008838	cisplatino
Carboplatin	Small cell carcinoma of lung	C0149925	NCT00977561	Terminated	Phase 2	See termination reason in detailed description.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Irinotecan	Malignant tumor of colon	C0007102	NCT01004159	Terminated	Phase 2	former PI left institute	C0123931	(+)-Irinotecan
Asparaginase	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0003993	Colaspase
Pegaspargase	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0071568	Pegaspargasa
Cyclophosphamide	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0010583	Cyclophosphamidum
Vincristine	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0042679	Vincristina
Methotrexate	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Imatinib	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Prednisolone	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Doxorubicin	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0013089	Doxorubicine
Dexamethasone	leukemia	C0023418	NCT01005914	Terminated	Phase 2	Increased rate of bacterial infections	C0011777	Dexaméthasone
Metoprolol	Obesity	C0028754	NCT00993421	Terminated	Phase 2	Clinical trial terminated due to results from recent nonclinical studies	C0025859	DL-metoprolol
Pregabalin	Chronic pain	C0150055	NCT00998816	Withdrawn	Phase 3	No funding	C0657912	(S)-3-Isobutyl GABA
Artesunate	Plasmodium falciparum infection	C0858318	NCT00988507	Terminated	Phase 2	Company decision to modify the ferroquine development strategy; discontinuation not due to    safety or activity unexpected findings	C0052432	artesunato
Darbepoetin alfa	Cancer anemia	C1536115	NCT00989092	Terminated	Phase 2	slow enrollment and change in product development strategy	C0937950	Darbepoetina alfa
Darbepoetin alfa	Carcinoma	C0007097	NCT00989092	Terminated	Phase 2	slow enrollment and change in product development strategy	C0937950	Darbepoetina alfa
Erlotinib	Squamous cell carcinoma	C0007137	NCT01009203	Terminated	Phase 2	High patient withdrawal rate	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	Squamous cell carcinoma	C0007137	NCT01009203	Terminated	Phase 2	High patient withdrawal rate	C0072980	Sirolimús
Everolimus	Squamous cell carcinoma	C0007137	NCT01009203	Terminated	Phase 2	High patient withdrawal rate	C0541315	évérolimus
Sitagliptin	Renal Insufficiency	C1565489	NCT00958269	Terminated	Phase 3	Technical/operational issues	C1565750	Sitagliptinum
Bevacizumab	Malignant tumor of colon	C0007102	NCT01006369	Suspended	Phase 2	Interim analysis	C0796392	Anti-VEGF monoclonal antibody
Hydroxychloroquine	Malignant tumor of colon	C0007102	NCT01006369	Suspended	Phase 2	Interim analysis	C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Warfarin	Hamman-Rich syndrome	C0085786	NCT00957242	Terminated	Phase 3	Excess of mortality in the treatment group created safety concerns.	C0043031	Warfarina
Riluzole	unspecified adult solid tumor, protocol specific	C0279004	NCT01018836	Terminated	Phase 1	Slow accrual	C0073379	Riluzolum
Bevacizumab	Hemangioblastoma	C0206734	NCT01015300	Terminated	Phase 0	Study terminated due to low accrual.	C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Von Hippel-Lindau Syndrome	C0019562	NCT01015300	Terminated	Phase 0	Study terminated due to low accrual.	C0796392	Anti-VEGF monoclonal antibody
Dopamine	Malignant Carcinoid Syndrome	C0024586	NCT01018953	Terminated	Phase 2	Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1	C0013030	Dopamina
Somatostatin	Malignant Carcinoid Syndrome	C0024586	NCT01018953	Terminated	Phase 2	Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1	C0037659	Somatostatina
Cytarabine	leukemia	C0023418	NCT01018069	Terminated	Phase 2	Failed to reach endpoints	C0010711	Cytarabinum
Idarubicin	leukemia	C0023418	NCT01018069	Terminated	Phase 2	Failed to reach endpoints	C0020789	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Cyclophosphamide	Lupus Nephritis	C0024143	NCT01015456	Terminated	Phase 3	Data Safety Monitoring Board concerning of the participants' safety	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Lupus Nephritis	C0024143	NCT01015456	Terminated	Phase 3	Data Safety Monitoring Board concerning of the participants' safety	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Lupus Nephritis	C0024143	NCT01015456	Terminated	Phase 3	Data Safety Monitoring Board concerning of the participants' safety	C0026933	Mycophenolsäure
Irinotecan	Malignant tumor of colon	C0007102	NCT01016860	Terminated	Phase 1	This study was discontinued due to a shown lack of efficacy in the investigational agent	C0123931	(+)-Irinotecan
Gemcitabine	Ovarian Diseases	C0029928	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Carboplatin	Ovarian Diseases	C0029928	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Doxorubicin	Ovarian Diseases	C0029928	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0013089	Doxorubicine
Gemcitabine	ovarian neoplasm	C0919267	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Carboplatin	ovarian neoplasm	C0919267	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Doxorubicin	ovarian neoplasm	C0919267	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0013089	Doxorubicine
Gemcitabine	Carcinoma	C0007097	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Carboplatin	Carcinoma	C0007097	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Doxorubicin	Carcinoma	C0007097	NCT01016054	Terminated	Phase 1	Trial was terminated to allow sponsors to evaluate the future development of the drug program	C0013089	Doxorubicine
Valproic Acid	High Grade Sarcoma	C1334008	NCT01010958	Terminated	Phase 1	Slow accrual	C0042291	acidum valproicum
Sirolimus	Hormone refractory prostate cancer	C1328504	NCT01020305	Terminated	Phase 1/Phase 2	Decision by funding sponsor due to poor accrual	C0072980	Sirolimús
Bicalutamide	Hormone refractory prostate cancer	C1328504	NCT01020305	Terminated	Phase 1/Phase 2	Decision by funding sponsor due to poor accrual	C0285590	Bicalutamida
Everolimus	Hormone refractory prostate cancer	C1328504	NCT01020305	Terminated	Phase 1/Phase 2	Decision by funding sponsor due to poor accrual	C0541315	évérolimus
Cisplatin	Cervical carcinoma stage IB	C0278582	NCT01019278	Withdrawn	Phase 2		C0008838	cisplatino
Cisplatin	Cervix carcinoma stage III	C0278577	NCT01019278	Withdrawn	Phase 2		C0008838	cisplatino
Atomoxetine	Methamphetamine dependence	C1533217	NCT01019707	Terminated	Phase 1	End in funding	C0076823	Atomoxetina
Methamphetamine	Methamphetamine dependence	C1533217	NCT01019707	Terminated	Phase 1	End in funding	C0025611	Metamfetamine
Atomoxetine	Methamphetamine abuse	C1456624	NCT01019707	Terminated	Phase 1	End in funding	C0076823	Atomoxetina
Methamphetamine	Methamphetamine abuse	C1456624	NCT01019707	Terminated	Phase 1	End in funding	C0025611	Metamfetamine
Hydrocortisone	Pneumonia, Viral	C0032310	NCT01014364	Terminated	Phase 3	the H1N1 pandemic is now over, and fewer cases than expected were observed	C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Choline	leukemia	C0023418	NCT01009931	Terminated	Phase 2	Study was terminated early due to lack of experimental medication (supply issues)	C0008405	Vitamin J
Dexamethasone	leukemia	C0023418	NCT01009931	Terminated	Phase 2	Study was terminated early due to lack of experimental medication (supply issues)	C0011777	Dexaméthasone
Sirolimus	Polycystic Kidney Diseases	C0022680	NCT01009957	Terminated	Phase 2/Phase 3	After primary completition date, experimental drug was no longer available	C0072980	Sirolimús
Everolimus	Polycystic Kidney Diseases	C0022680	NCT01009957	Terminated	Phase 2/Phase 3	After primary completition date, experimental drug was no longer available	C0541315	évérolimus
Carboplatin	Breast cancer recurrent	C0278493	NCT01009983	Terminated	Phase 2	Slow accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Breast cancer recurrent	C0278493	NCT01009983	Terminated	Phase 2	Slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Thalidomide	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634	NCT01021423	Terminated	Phase 3	Terminated by sponsor due to new unpublished data that rendered the current design of the    study no longer clinically relevant. There were no safety concerns.	C0039736	Thalidomidum
Lenalidomide	Lymphoma, Non-Hodgkin	C0024305	NCT01021423	Terminated	Phase 3	Terminated by sponsor due to new unpublished data that rendered the current design of the    study no longer clinically relevant. There were no safety concerns.	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Lymphoma, Non-Hodgkin	C0024305	NCT01021423	Terminated	Phase 3	Terminated by sponsor due to new unpublished data that rendered the current design of the    study no longer clinically relevant. There were no safety concerns.	C0039736	Thalidomidum
Rosuvastatin	Malignant tumor of colon	C0007102	NCT01011478	Terminated	Phase 3		C0965129	Rosuvastatina
Rosuvastatin	Precancerous Conditions	C0032927	NCT01011478	Terminated	Phase 3		C0965129	Rosuvastatina
Dopamine	Acromegaly	C0001206	NCT00994214	Terminated	Phase 2	Preliminary data from this study does not support expected inhibition of GH and IGF-1	C0013030	Dopamina
Somatostatin	Acromegaly	C0001206	NCT00994214	Terminated	Phase 2	Preliminary data from this study does not support expected inhibition of GH and IGF-1	C0037659	Somatostatina
Topotecan	Recurrent Primary Peritoneal Carcinoma	C3897731	NCT01012817	Suspended	Phase 1/Phase 2	Completion of dose escalation phase	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Irinotecan	Malignant glioma of brain	C0349541	NCT01017653	Terminated	Phase 2	study did not reach benchmark efficacy rule at 16 subjects	C0123931	(+)-Irinotecan
Pegfilgrastim	Lymphoma	C0024299	NCT01016795	Terminated	Phase 2	Study closed Nov 2000 by Amgen, who stopped drug delivery	C4735048	pegfilgrastim-cbqv
Cyclophosphamide	Non-Small Cell Lung Carcinoma	C0007131	NCT01015443	Terminated	Phase 3	The study is terminated prematurely as the sponsor decided to discontinue program with    Tecemotide in NSCLC.	C0010583	Cyclophosphamidum
Oxycodone	Constipation	C0009806	NCT01014559	Terminated	Phase 3	Lack of recruitment	C0030049	Oxycodonum
Naloxone	Constipation	C0009806	NCT01014559	Terminated	Phase 3	Lack of recruitment	C0027358	Nalossone
Oxycodone	Pain	C0030193	NCT01014559	Terminated	Phase 3	Lack of recruitment	C0030049	Oxycodonum
Dexmedetomidine	Traumatic Brain Injury	C0876926	NCT01007773	Withdrawn	Phase 2	Study will not be intiated	C0113293	(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
Fentanyl	Traumatic Brain Injury	C0876926	NCT01007773	Withdrawn	Phase 2	Study will not be intiated	C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Propofol	Traumatic Brain Injury	C0876926	NCT01007773	Withdrawn	Phase 2	Study will not be intiated	C0033487	2,6-bis(1-methylethyl)phenol
Acetaminophen	Cardiac Arrhythmia	C0003811	NCT01026961	Withdrawn	Phase 1/Phase 2	Study is no longer required by Brazil health authority.	C0000970	Acetaminofén
Phenylephrine	Cardiac Arrhythmia	C0003811	NCT01026961	Withdrawn	Phase 1/Phase 2	Study is no longer required by Brazil health authority.	C0031469	(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
Oxymetazoline	Cardiac Arrhythmia	C0003811	NCT01026961	Withdrawn	Phase 1/Phase 2	Study is no longer required by Brazil health authority.	C0030071	Oxymétazoline
Dimetindene	Cardiac Arrhythmia	C0003811	NCT01026961	Withdrawn	Phase 1/Phase 2	Study is no longer required by Brazil health authority.	C0012390	Dimetindeno
Acetylcysteine	Bulimia Nervosa	C2267227	NCT01033149	Terminated	Phase 3		C0001047	NAC
Warfarin	Pulmonary Hypertension	C0020542	NCT01036802	Terminated	Phase 2	Difficulty in accruing subjects	C0043031	Warfarina
Norepinephrine	Psychosexual Disorders	C0033953	NCT01040208	Terminated	Phase 3	Study terminated by Sponsor for administrative reasons prior to completion of all study visits	C0028351	(-)-noradrenaline
Flibanserin	Psychosexual Disorders	C0033953	NCT01040208	Terminated	Phase 3	Study terminated by Sponsor for administrative reasons prior to completion of all study visits	C0754280	Flibanserin
Norepinephrine	Depressive disorder	C0011581	NCT01040208	Terminated	Phase 3	Study terminated by Sponsor for administrative reasons prior to completion of all study visits	C0028351	(-)-noradrenaline
Flibanserin	Depressive disorder	C0011581	NCT01040208	Terminated	Phase 3	Study terminated by Sponsor for administrative reasons prior to completion of all study visits	C0754280	Flibanserin
Prednisolone	Clinically isolated syndrome	C2921627	NCT01039103	Suspended	Phase 2		C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Clinically isolated syndrome	C2921627	NCT01039103	Suspended	Phase 2		C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Lenalidomide	Malignant tumor of colon	C0007102	NCT01032291	Terminated	Phase 2	A business decision not to continue with Phase 2b based on non-safety observations during    proof of concept phase.	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Malignant tumor of colon	C0007102	NCT01032291	Terminated	Phase 2	A business decision not to continue with Phase 2b based on non-safety observations during    proof of concept phase.	C0039736	Thalidomidum
Mesalazine	Diverticulitis	C0012813	NCT01038739	Terminated	Phase 3	Stopped due to futility.	C0253787	p-Aminosalicylsaeure
Rituximab	Metastatic melanoma	C0278883	NCT01032122	Terminated	Phase 1	the only reason is that recruitment was not sufficient to meet the planned patient numbers,    because complete remissions are still infrequent.	C5195655	rituximab-pvvr
Prednisolone	Chronic graft-versus-host disease	C0867389	NCT01028313	Withdrawn	Phase 2	A decision was made to not move forward with the study. No participants were enrolled or    treated.	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Chronic graft-versus-host disease	C0867389	NCT01028313	Withdrawn	Phase 2	A decision was made to not move forward with the study. No participants were enrolled or    treated.	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Panobinostat	Chronic graft-versus-host disease	C0867389	NCT01028313	Withdrawn	Phase 2	A decision was made to not move forward with the study. No participants were enrolled or    treated.	C1998098	(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Propranolol	Recurrent respiratory papillomatosis	C1168198	NCT01058317	Withdrawn	Phase 2/Phase 3	No participants enrolled	C0033497	Propranololum
Simvastatin	Pneumonia	C0032285	NCT01057758	Terminated	Phase 3	stopped for futility	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Cefixime	Uterine Cervicitis	C0007860	NCT01072136	Terminated	Phase 3		C0060400	(-)-cefixim
Clofarabine	Leukemia, Myelocytic, Acute	C0023467	NCT01065545	Withdrawn	Phase 1	Due to funding issues.	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Tretinoin	Leukemia, Myelocytic, Acute	C0023467	NCT01067274	Withdrawn	Phase 3	Study abandoned	C0040845	Tretin M
Azacitidine	Leukemia, Myelocytic, Acute	C0023467	NCT01067274	Withdrawn	Phase 3	Study abandoned	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Paclitaxel	Pain	C0030193	NCT01096407	Terminated	Phase 1	slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Paclitaxel	unspecified adult solid tumor, protocol specific	C0279004	NCT01096407	Terminated	Phase 1	slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Dexmedetomidine	Respiratory Failure	C1145670	NCT01076816	Terminated	Phase 3	Poor inclusion rate.	C0113293	(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
Rituximab	Chronic lymphocytic leukaemia stage 4	C0854804	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	Chronic lymphocytic leukaemia stage 4	C0854804	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	B-cell small lymphocytic lymphoma stage IV	C0855101	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	B-cell small lymphocytic lymphoma stage IV	C0855101	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	Prolymphocytic Leukemia	C0023486	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	Prolymphocytic Leukemia	C0023486	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	Chronic lymphocytic leukaemia refractory	C0278791	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	Chronic lymphocytic leukaemia refractory	C0278791	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	Chronic lymphocytic leukaemia stage 1	C0278767	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	Chronic lymphocytic leukaemia stage 1	C0278767	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	B-cell small lymphocytic lymphoma stage I	C0855098	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	B-cell small lymphocytic lymphoma stage I	C0855098	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	Chronic lymphocytic leukaemia stage 2	C0854803	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	Chronic lymphocytic leukaemia stage 2	C0854803	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	B-cell small lymphocytic lymphoma stage II	C0855099	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	B-cell small lymphocytic lymphoma stage II	C0855099	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	Chronic lymphocytic leukaemia stage 3	C0278769	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	Chronic lymphocytic leukaemia stage 3	C0278769	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Rituximab	B-cell small lymphocytic lymphoma stage III	C0855100	NCT01076556	Terminated	Phase 1		C5195655	rituximab-pvvr
Cyclophosphamide	B-cell small lymphocytic lymphoma stage III	C0855100	NCT01076556	Terminated	Phase 1		C0010583	Cyclophosphamidum
Fenofibrate	Coronary Arteriosclerosis	C0010054	NCT01030328	Terminated	Phase 3	Lack of patient population	C0033228	Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Atorvastatin	Coronary Arteriosclerosis	C0010054	NCT01030328	Terminated	Phase 3	Lack of patient population	C0286651	atorvastatine
Rifampicin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT01068756	Terminated	Phase 1		C0035608	Rifampicine
Sildenafil	Persistent Fetal Circulation Syndrome	C0031190	NCT01069861	Terminated	Phase 2	See termination reason in detailed description.	C0529793	Sildenafilo
Sildenafil	Hypoxic respiratory failure	C3805211	NCT01069861	Terminated	Phase 2	See termination reason in detailed description.	C0529793	Sildenafilo
Ibuprofen	Patent ductus arteriosus	C0013274	NCT01070745	Withdrawn	Phase 2	Changes in approach to PDA therapy	C0020740	Ibuprofenum
Simvastatin	Cystic Fibrosis	C0010674	NCT01092572	Withdrawn	Phase 1/Phase 2	Lack of funding	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Voriconazole	Candidiasis	C0006840	NCT01092832	Terminated	Phase 3	This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of    any safety issues or concerns.	C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Venlafaxine	Depressive disorder	C0011581	NCT01114698	Terminated	Phase 2	Study was terminated due to sponsor portfolio decision.	C0078569	Venlafaxinum
Cisplatin	Carcinomatosis of peritoneal cavity	C0346990	NCT01116791	Terminated	Phase 2	Insufficient enrollment in Pancreatic & Biliary arm	C0008838	cisplatino
Cisplatin	Malignant neoplasm of gastrointestinal tract	C0685938	NCT01116791	Terminated	Phase 2	Insufficient enrollment in Pancreatic & Biliary arm	C0008838	cisplatino
Cisplatin	Mesothelioma malignant advanced	C0278752	NCT01105390	Withdrawn	Phase 2	withdrawn	C0008838	cisplatino
Pemetrexed	Mesothelioma malignant advanced	C0278752	NCT01105390	Withdrawn	Phase 2	withdrawn	C0210657	Pemetrexed
Cisplatin	Epithelioid mesothelioma, malignant	C0862312	NCT01105390	Withdrawn	Phase 2	withdrawn	C0008838	cisplatino
Pemetrexed	Epithelioid mesothelioma, malignant	C0862312	NCT01105390	Withdrawn	Phase 2	withdrawn	C0210657	Pemetrexed
Cisplatin	Mesothelioma malignant recurrent	C0278753	NCT01105390	Withdrawn	Phase 2	withdrawn	C0008838	cisplatino
Pemetrexed	Mesothelioma malignant recurrent	C0278753	NCT01105390	Withdrawn	Phase 2	withdrawn	C0210657	Pemetrexed
Cisplatin	Sarcomatoid Mesothelioma	C0334513	NCT01105390	Withdrawn	Phase 2	withdrawn	C0008838	cisplatino
Pemetrexed	Sarcomatoid Mesothelioma	C0334513	NCT01105390	Withdrawn	Phase 2	withdrawn	C0210657	Pemetrexed
Ziprasidone	Bipolar Disorder	C0005586	NCT01113541	Terminated	Phase 3	See termination reason in detailed description.	C0380393	Ziprasidonum
Lovastatin	Smith-Lemli-Opitz Syndrome	C0175694	NCT01110642	Withdrawn	Phase 2	Study was withdrawn due to lack of eligible population for study	C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Lovastatin	Chondrodysplasia punctata, X-linked dominant type	C0282102	NCT01110642	Withdrawn	Phase 2	Study was withdrawn due to lack of eligible population for study	C0024027	(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
Omeprazole	Infection caused by Helicobacter pylori	C0850666	NCT01109381	Terminated	Phase 1/Phase 2	Poor efficacy (2 of 31 completing participants with H.pylori eradication)	C0028978	Omeprazolum
Gemcitabine	Colorectal cancer metastatic	C0948380	NCT01109615	Terminated	Phase 2	Lacking effect of treatment	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Pemetrexed	Colorectal cancer metastatic	C0948380	NCT01109615	Terminated	Phase 2	Lacking effect of treatment	C0210657	Pemetrexed
Erythromycin	Gastroparesis	C0152020	NCT01117376	Terminated	Phase 2	The study was prematurely terminated because of unavailibility of Methylnaltrexone in the    region	C0014806	Erythromycinum
Naltrexone	Gastroparesis	C0152020	NCT01117376	Terminated	Phase 2	The study was prematurely terminated because of unavailibility of Methylnaltrexone in the    region	C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Methylnaltrexone	Gastroparesis	C0152020	NCT01117376	Terminated	Phase 2	The study was prematurely terminated because of unavailibility of Methylnaltrexone in the    region	C0066411	MNTX
Bevacizumab	Colorectal Carcinoma	C0009402	NCT01126866	Terminated	Phase 2	recruiting inadequate	C0796392	Anti-VEGF monoclonal antibody
Edetic Acid	Acetaminophen overdose	C0572025	NCT01118663	Terminated	Phase 3		C0013618	Acide ethylenediaminetetracetique
Acetylcysteine	Acetaminophen overdose	C0572025	NCT01118663	Terminated	Phase 3		C0001047	NAC
Lapatinib	Neoplasm Metastasis	C0027627	NCT01118975	Terminated	Phase 1/Phase 2	Lost sponsorship for study drug	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Vorinostat	Neoplasm Metastasis	C0027627	NCT01118975	Terminated	Phase 1/Phase 2	Lost sponsorship for study drug	C0672708	Vorinostatum
Goserelin	HER2/Neu Negative	C2348908	NCT01149356	Terminated	Phase 1	Manufacturer discontinued drug development.	C0120107	Goserelina
Exemestane	HER2/Neu Negative	C2348908	NCT01149356	Terminated	Phase 1	Manufacturer discontinued drug development.	C0851344	6-methyleneandrosta-1,4-diene-3,17-dione
Goserelin	Carcinoma of Male Breast	C0238033	NCT01149356	Terminated	Phase 1	Manufacturer discontinued drug development.	C0120107	Goserelina
Exemestane	Carcinoma of Male Breast	C0238033	NCT01149356	Terminated	Phase 1	Manufacturer discontinued drug development.	C0851344	6-methyleneandrosta-1,4-diene-3,17-dione
Dextroamphetamine	Depressive disorder	C0011581	NCT01131559	Terminated	Phase 3	Sponsor halted study.	C0011812	Desamfetamina
Carboplatin	Cholangiocarcinoma	C0206698	NCT01151761	Terminated	Phase 2	Poor accrual, lack of enthusiasm from referring physicians, unusual outcomes regarding 2    patients	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Carboplatin	Hepatobiliary neoplasm	C0854196	NCT01151761	Terminated	Phase 2	Poor accrual, lack of enthusiasm from referring physicians, unusual outcomes regarding 2    patients	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Amitriptyline	Transformed migraine	C1960870	NCT01151787	Terminated	Phase 3	Study was never initiated under new location/provider group. Contract to continue was never    signed between TEVA and Kennedy Headache Center	C0002600	5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
Cyclobenzaprine	Transformed migraine	C1960870	NCT01151787	Terminated	Phase 3	Study was never initiated under new location/provider group. Contract to continue was never    signed between TEVA and Kennedy Headache Center	C0056732	Cyclobenzaprinum
Aminolevulinic acid	adult anaplastic astrocytoma	C0280483	NCT01148966	Terminated	Phase 1/Phase 2		C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	adult anaplastic oligodendroglioma	C0280790	NCT01148966	Terminated	Phase 1/Phase 2		C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	adult giant cell glioblastoma	C1541316	NCT01148966	Terminated	Phase 1/Phase 2		C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	adult glioblastoma	C0278878	NCT01148966	Terminated	Phase 1/Phase 2		C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	adult gliosarcoma	C1541317	NCT01148966	Terminated	Phase 1/Phase 2		C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	Adult Mixed Glioma	C3900099	NCT01148966	Terminated	Phase 1/Phase 2		C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	recurrent adult brain tumor	C0278786	NCT01148966	Terminated	Phase 1/Phase 2		C0002563	ácido 5-aminolevulínico
Vitamin C	Adenocarcinoma	C0001418	NCT01125449	Suspended	Phase 2	Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche    (Ireland).	C0003968	Acidum ascorbicum
Vitamin C	Carcinoma	C0007097	NCT01125449	Suspended	Phase 2	Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche    (Ireland).	C0003968	Acidum ascorbicum
Vitamin C	Multiple Myeloma	C0026764	NCT01125449	Suspended	Phase 2	Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche    (Ireland).	C0003968	Acidum ascorbicum
Vitamin C	Desmoplastic Small Round Cell Tumor	C0281508	NCT01125449	Suspended	Phase 2	Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche    (Ireland).	C0003968	Acidum ascorbicum
Atorvastatin	Acute Coronary Syndrome	C0948089	NCT01187992	Terminated	Phase 3	Interim analysis showed significant effect in favour of full-dose atorvastatin.	C0286651	atorvastatine
Tolbutamide	Advanced cancer	C0877373	NCT01185548	Terminated	Phase 1	Terminated based on safety results from another trial	C0040374	N-Butyl-N'-(4-methylphenylsulfonyl)urea
Lidocaine	Pain	C0030193	NCT01155986	Terminated	Phase 2	Trial was stopped due to difficult enrolment	C0023660	Lidocaína
Lidocaine	Chronic pain	C0150055	NCT01155986	Terminated	Phase 2	Trial was stopped due to difficult enrolment	C0023660	Lidocaína
Peginterferon alfa-2a	Hepatitis C	C0019196	NCT01153919	Suspended	Phase 2	Interim analysis	C0391001	Pegylated interferon alpha-2a
Ribavirin	Hepatitis C	C0019196	NCT01153919	Suspended	Phase 2	Interim analysis	C0035525	Ribavirinum
Docetaxel	Urologic Neoplasms	C0042076	NCT01155791	Terminated	Phase 1		C0246415	Docetaxel
Anidulafungin	Aspergillosis	C0004030	NCT01188759	Withdrawn	Phase 3		C1142738	Anidulafungina
Voriconazole	Aspergillosis	C0004030	NCT01188759	Withdrawn	Phase 3		C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Anidulafungin	Invasive Pulmonary Aspergillosis	C0276653	NCT01188759	Withdrawn	Phase 3		C1142738	Anidulafungina
Anidulafungin	Neuroaspergillosis	C0752342	NCT01188759	Withdrawn	Phase 3		C1142738	Anidulafungina
Voriconazole	Neuroaspergillosis	C0752342	NCT01188759	Withdrawn	Phase 3		C0393080	(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
Cisplatin	Small cell carcinoma of lung	C0149925	NCT01187615	Terminated	Phase 1		C0008838	cisplatino
Pemetrexed	Small cell carcinoma of lung	C0149925	NCT01187615	Terminated	Phase 1		C0210657	Pemetrexed
Rasagiline	Progressive supranuclear palsy	C0038868	NCT01187888	Terminated	Phase 3	IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available    for the study(pre-treatm.with Rasagiline=exclusion criterion	C0525678	(R)-indan-1-yl-prop-2-ynyl-amine
Nicardipine	Cerebral Hemorrhage	C2937358	NCT01176565	Suspended	Phase 3	Pre-planned interim analysis.	C0028005	Nicardipinum
Celecoxib	Malignant neoplasm of ovary	C1140680	NCT01175772	Terminated	Phase 2	Due to change in the national policy of medications	C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Methotrexate	Malignant neoplasm of ovary	C1140680	NCT01175772	Terminated	Phase 2	Due to change in the national policy of medications	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Methotrexate	Neoplasm, Residual	C0242596	NCT01158885	Terminated	Phase 2	Study terminated for lack of accrual.	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Clofarabine	Neoplasm, Residual	C0242596	NCT01158885	Terminated	Phase 2	Study terminated for lack of accrual.	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cytarabine	Neoplasm, Residual	C0242596	NCT01158885	Terminated	Phase 2	Study terminated for lack of accrual.	C0010711	Cytarabinum
Cisplatin	Squamous cell carcinoma	C0007137	NCT01161498	Terminated	Phase 3	The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN).	C0008838	cisplatino
Cisplatin	Malignant neoplasm of lung	C0242379	NCT01160731	Withdrawn	Phase 1		C0008838	cisplatino
Etoposide	Malignant neoplasm of lung	C0242379	NCT01160731	Withdrawn	Phase 1		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Panobinostat	Malignant neoplasm of lung	C0242379	NCT01160731	Withdrawn	Phase 1		C1998098	(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Aldesleukin	Metastatic melanoma	C0278883	NCT01160445	Terminated	Phase 2	The study was terminated because we were not able to obtain the study drug.	C0218986	Aldesleukina
Aldesleukin	Renal cancer metastatic	C0919976	NCT01160445	Terminated	Phase 2	The study was terminated because we were not able to obtain the study drug.	C0218986	Aldesleukina
Pioglitazone	Endometriosis	C0014175	NCT01184144	Withdrawn	Phase 2/Phase 3		C0071097	(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
Pegaspargase	Leukemia, Lymphocytic, Acute, L1	C0023452	NCT01186328	Terminated	Phase 1	The company (Enzon Pharmaceuticals)providing the drug EZN-3042 decided to end its development    of EZN-3042.	C0071568	Pegaspargasa
Vincristine	Leukemia, Lymphocytic, Acute, L1	C0023452	NCT01186328	Terminated	Phase 1	The company (Enzon Pharmaceuticals)providing the drug EZN-3042 decided to end its development    of EZN-3042.	C0042679	Vincristina
Methotrexate	Leukemia, Lymphocytic, Acute, L1	C0023452	NCT01186328	Terminated	Phase 1	The company (Enzon Pharmaceuticals)providing the drug EZN-3042 decided to end its development    of EZN-3042.	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Prednisone	Leukemia, Lymphocytic, Acute, L1	C0023452	NCT01186328	Terminated	Phase 1	The company (Enzon Pharmaceuticals)providing the drug EZN-3042 decided to end its development    of EZN-3042.	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Alefacept	transplant; failure, kidney	C1404117	NCT01163799	Terminated	Phase 1	Noted increased risks, greater than expected for standard of care therapy.	C0962603	Alefacept
Sirolimus	Mucosal Melanoma	C3898222	NCT01166126	Terminated	Phase 2		C0072980	Sirolimús
Everolimus	Mucosal Melanoma	C3898222	NCT01166126	Terminated	Phase 2		C0541315	évérolimus
Sirolimus	Melanoma recurrent	C0278884	NCT01166126	Terminated	Phase 2		C0072980	Sirolimús
Everolimus	Melanoma recurrent	C0278884	NCT01166126	Terminated	Phase 2		C0541315	évérolimus
Zoledronic acid	Multiple Sclerosis	C0026769	NCT01166178	Terminated	Phase 3		C0257685	ácido zoledrónico
Oxaliplatin	Colorectal Carcinoma	C0009402	NCT01157039	Withdrawn	Phase 2	abandoned	C0069717	oxaliplatine
Oxaliplatin	Malignant tumor of colon	C0007102	NCT01157039	Withdrawn	Phase 2	abandoned	C0069717	oxaliplatine
Clomifene	Hypogonadotropic hypogonadism	C0271623	NCT01155518	Terminated	Phase 2	lack of funding	C0009008	2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine
Methyltestosterone	Hypogonadotropic hypogonadism	C0271623	NCT01155518	Terminated	Phase 2	lack of funding	C0025826	Methyltestosteronum
Pramlintide	Diabetes Mellitus	C0011849	NCT01165944	Withdrawn	Phase 1/Phase 2		C0537551	Pramlintide
Bortezomib	leukemia	C0023418	NCT01162031	Withdrawn	Phase 2	Low accrual	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Teriparatide	Post-surgical hypoparathyroidism	C0342341	NCT01171690	Terminated	Phase 2	Funding problems	C0070093	Teriparatida
Valproic Acid	unspecified childhood solid tumor, protocol specific	C0279002	NCT01204450	Terminated	Phase 1	Funding has become unavailable	C0042291	acidum valproicum
Sirolimus	unspecified childhood solid tumor, protocol specific	C0279002	NCT01204450	Terminated	Phase 1	Funding has become unavailable	C0072980	Sirolimús
Everolimus	unspecified childhood solid tumor, protocol specific	C0279002	NCT01204450	Terminated	Phase 1	Funding has become unavailable	C0541315	évérolimus
Valproic Acid	Neuroblastoma	C0027819	NCT01204450	Terminated	Phase 1	Funding has become unavailable	C0042291	acidum valproicum
Sirolimus	Neuroblastoma	C0027819	NCT01204450	Terminated	Phase 1	Funding has become unavailable	C0072980	Sirolimús
Everolimus	Neuroblastoma	C0027819	NCT01204450	Terminated	Phase 1	Funding has become unavailable	C0541315	évérolimus
Miltefosine	Chronic urticaria	C0263338	NCT01170949	Terminated	Phase 2	Study medication expired	C0068006	Miltefosina
Gemcitabine	Biliary Tract Cancer	C0750952	NCT01171755	Terminated	Phase 2	The objective response rate by more than two people are confirmed.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Arsenic trioxide	Endometrial Carcinoma	C0476089	NCT01184053	Terminated	Phase 2	Accrual was very low. No subject had been enrolled in a year.	C0052416	arsénico trióxido
Carboplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT01184287	Withdrawn	Phase 2	Program discontinued	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Latanoprost	Glaucoma, Primary Open Angle	C0339573	NCT01180062	Terminated	Phase 1	Study terminated early due to manufacturer not replenishing study site supply of inserts,    despite repeated requests for more inserts.	C0090306	propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Mesalazine	Proctitis	C0033246	NCT01172444	Terminated	Phase 3	Enrollment difficulties	C0253787	p-Aminosalicylsaeure
Sirolimus	Brain Stem Neoplasms	C0677866	NCT01182883	Withdrawn	Phase 1		C0072980	Sirolimús
Everolimus	Brain Stem Neoplasms	C0677866	NCT01182883	Withdrawn	Phase 1		C0541315	évérolimus
Cyclophosphamide	secondary acute myeloid leukemia	C0280449	NCT01203228	Terminated	Phase 3		C0010583	Cyclophosphamidum
Busulfan	secondary acute myeloid leukemia	C0280449	NCT01203228	Terminated	Phase 3		C0006463	Busulfano
Bevacizumab	adult anaplastic astrocytoma	C0280483	NCT01189240	Terminated	Phase 1/Phase 2	Company decided to stop development of drug - 7/31/12	C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	adult anaplastic oligodendroglioma	C0280790	NCT01189240	Terminated	Phase 1/Phase 2	Company decided to stop development of drug - 7/31/12	C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	adult giant cell glioblastoma	C1541316	NCT01189240	Terminated	Phase 1/Phase 2	Company decided to stop development of drug - 7/31/12	C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	adult glioblastoma	C0278878	NCT01189240	Terminated	Phase 1/Phase 2	Company decided to stop development of drug - 7/31/12	C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	adult gliosarcoma	C1541317	NCT01189240	Terminated	Phase 1/Phase 2	Company decided to stop development of drug - 7/31/12	C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	recurrent adult brain tumor	C0278786	NCT01189240	Terminated	Phase 1/Phase 2	Company decided to stop development of drug - 7/31/12	C0796392	Anti-VEGF monoclonal antibody
Sunitinib	Neuroendocrine Tumors	C0206754	NCT01215578	Terminated	Phase 2	lack of recruitement	C1176020	Sunitinibum
Sunitinib	advanced disease	C0679246	NCT01215578	Terminated	Phase 2	lack of recruitement	C1176020	Sunitinibum
Cisplatin	Malignant neoplasm of lung	C0242379	NCT01222572	Terminated	Phase 1/Phase 2	Slow accrual due to restrictive eligibility criteria	C0008838	cisplatino
Etoposide	Malignant neoplasm of lung	C0242379	NCT01222572	Terminated	Phase 1/Phase 2	Slow accrual due to restrictive eligibility criteria	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Aldesleukin	Malignant tumor of colon	C0007102	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0218986	Aldesleukina
Vidarabine	Malignant tumor of colon	C0007102	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0042646	Vidarabinum
Cyclophosphamide	Malignant tumor of colon	C0007102	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0010583	Cyclophosphamidum
Fludarabine	Malignant tumor of colon	C0007102	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0059985	Fludarabinum
Aldesleukin	Malignant neoplasm of stomach	C0024623	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0218986	Aldesleukina
Vidarabine	Malignant neoplasm of stomach	C0024623	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0042646	Vidarabinum
Cyclophosphamide	Malignant neoplasm of stomach	C0024623	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0010583	Cyclophosphamidum
Fludarabine	Malignant neoplasm of stomach	C0024623	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0059985	Fludarabinum
Aldesleukin	Malignant neoplasm of lung	C0242379	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0218986	Aldesleukina
Vidarabine	Malignant neoplasm of lung	C0242379	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0042646	Vidarabinum
Cyclophosphamide	Malignant neoplasm of lung	C0242379	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0010583	Cyclophosphamidum
Fludarabine	Malignant neoplasm of lung	C0242379	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0059985	Fludarabinum
Aldesleukin	unspecified adult solid tumor, protocol specific	C0279004	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0218986	Aldesleukina
Vidarabine	unspecified adult solid tumor, protocol specific	C0279004	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0042646	Vidarabinum
Cyclophosphamide	unspecified adult solid tumor, protocol specific	C0279004	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0010583	Cyclophosphamidum
Fludarabine	unspecified adult solid tumor, protocol specific	C0279004	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	C0059985	Fludarabinum
Duloxetine	Traumatic Brain Injury	C0876926	NCT01223001	Terminated	Phase 2	Most potential subjects had already been prescribed Cymbalta.	C0245561	Duloxetina
Duloxetine	Depressive disorder	C0011581	NCT01223001	Terminated	Phase 2	Most potential subjects had already been prescribed Cymbalta.	C0245561	Duloxetina
Doxorubicin	Hormone-Resistant Prostate Cancer	C3898877	NCT01240629	Suspended	Phase 1/Phase 2	Drug shortage	C0013089	Doxorubicine
Doxorubicin	Prostate cancer recurrent	C0278838	NCT01240629	Suspended	Phase 1/Phase 2	Drug shortage	C0013089	Doxorubicine
Cisplatin	Secondary malignant neoplasm of lung	C0153676	NCT01258634	Terminated	Phase 1	PI no longer affiliated with institution; only 2 subjects enrolled	C0008838	cisplatino
Etoposide	Secondary malignant neoplasm of lung	C0153676	NCT01258634	Terminated	Phase 1	PI no longer affiliated with institution; only 2 subjects enrolled	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Doxorubicin	Secondary malignant neoplasm of lung	C0153676	NCT01258634	Terminated	Phase 1	PI no longer affiliated with institution; only 2 subjects enrolled	C0013089	Doxorubicine
Ifosfamide	Secondary malignant neoplasm of lung	C0153676	NCT01258634	Terminated	Phase 1	PI no longer affiliated with institution; only 2 subjects enrolled	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Amlodipine	Cardiovascular event	C1320716	NCT01259297	Terminated	Phase 3	Terminated early in agreement with Health Authorities for feasibility reasons	C0051696	Amlodipinum
Hydrochlorothiazide	Cardiovascular event	C1320716	NCT01259297	Terminated	Phase 3	Terminated early in agreement with Health Authorities for feasibility reasons	C0020261	hidroclorotiazida
Aprepitant	Nausea	C0027497	NCT01249001	Suspended	Phase 2	lack of personnel resource and protocol amendment needed	C1176306	Aprépitant
Fosaprepitant	Nausea	C0027497	NCT01249001	Suspended	Phase 2	lack of personnel resource and protocol amendment needed	C2349941	Fosaprépitant
Aprepitant	Vomiting	C0042963	NCT01249001	Suspended	Phase 2	lack of personnel resource and protocol amendment needed	C1176306	Aprépitant
Fosaprepitant	Vomiting	C0042963	NCT01249001	Suspended	Phase 2	lack of personnel resource and protocol amendment needed	C2349941	Fosaprépitant
Erlotinib	Ependymoma	C0014474	NCT01247922	Terminated	Phase 2	In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety    concerns. As a result, the companion trial, OSI-774-206 has been stopped	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sitagliptin	Cystic Fibrosis	C0010674	NCT01257464	Terminated	Phase 2	Lack of recruitment	C1565750	Sitagliptinum
Etomidate	Hypertensive disease	C0020538	NCT01248234	Withdrawn	Phase 3	Did not begin	C0015131	Etomidatum
Propofol	Hypertensive disease	C0020538	NCT01248234	Withdrawn	Phase 3	Did not begin	C0033487	2,6-bis(1-methylethyl)phenol
Memantine	Glioblastoma	C0017636	NCT01260467	Terminated	Phase 2		C0025242	Memantina
Etoposide	adult acute basophilic leukemia	C0279631	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	adult acute basophilic leukemia	C0279631	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	adult acute basophilic leukemia	C0279631	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	adult acute eosinophilic leukemia	C0279630	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	adult acute eosinophilic leukemia	C0279630	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	adult acute eosinophilic leukemia	C0279630	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	adult acute myeloid leukemia in remission	C0279094	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	adult acute myeloid leukemia in remission	C0279094	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	adult acute myeloid leukemia in remission	C0279094	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11	C2825114	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11	C2825114	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11	C2825114	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	Adult Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1	C2347540	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	Adult Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1	C2347540	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	Adult Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1	C2347540	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	untreated adult acute myeloid leukemia	C0279089	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	untreated adult acute myeloid leukemia	C0279089	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	untreated adult acute myeloid leukemia	C0279089	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	Adult Erythroleukemia	C2347748	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	Adult Erythroleukemia	C2347748	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	Adult Erythroleukemia	C2347748	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	Adult Pure Erythroid Leukemia	C2347753	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	Adult Pure Erythroid Leukemia	C2347753	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	Adult Pure Erythroid Leukemia	C2347753	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	Alkylating Agent-Related Acute Myeloid Leukemia	C1332233	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	Alkylating Agent-Related Acute Myeloid Leukemia	C1332233	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	Alkylating Agent-Related Acute Myeloid Leukemia	C1332233	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	recurrent adult acute myeloid leukemia	C0278780	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	recurrent adult acute myeloid leukemia	C0278780	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	recurrent adult acute myeloid leukemia	C0278780	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Etoposide	secondary acute myeloid leukemia	C0280449	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Azacitidine	secondary acute myeloid leukemia	C0280449	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Mitoxantrone	secondary acute myeloid leukemia	C0280449	NCT01260714	Terminated	Phase 1	Inadequate accrual rate	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Amphotericin B	Lung transplant recipient	C2063401	NCT01254708	Suspended	Phase 2	Study has been placed on hold due to unavailability of funding.	C1145701	Liposomal amphotericin B
Ramipril	unspecified adult solid tumor, protocol specific	C0279004	NCT01234922	Terminated	Phase 2	slow accrual	C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Benazepril	unspecified adult solid tumor, protocol specific	C0279004	NCT01234922	Terminated	Phase 2	slow accrual	C0053091	Bénazépril
Losartan	unspecified adult solid tumor, protocol specific	C0279004	NCT01234922	Terminated	Phase 2	slow accrual	C0126174	2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Lisinopril	unspecified adult solid tumor, protocol specific	C0279004	NCT01234922	Terminated	Phase 2	slow accrual	C0065374	[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
Sirolimus	Multiple Myeloma	C0026764	NCT01234974	Withdrawn	Phase 2	Study never undertaken	C0072980	Sirolimús
Everolimus	Multiple Myeloma	C0026764	NCT01234974	Withdrawn	Phase 2	Study never undertaken	C0541315	évérolimus
Cyclophosphamide	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	C0393819	NCT01236456	Withdrawn	Phase 2	I am relocating to Johns Hopkins Medical Center	C0010583	Cyclophosphamidum
Denileukin diftitox	Multiple Myeloma	C0026764	NCT01251952	Terminated	Phase 1	Drug unavailable	C0717670	Interleukin-2/diptheria toxin fusion protein
Cyclophosphamide	Malignant neoplasm of skin	C0007114	NCT01236573	Terminated	Phase 1/Phase 2	Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.	C0010583	Cyclophosphamidum
Fludarabine	Malignant neoplasm of skin	C0007114	NCT01236573	Terminated	Phase 1/Phase 2	Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.	C0059985	Fludarabinum
Cyclophosphamide	Metastatic melanoma	C0278883	NCT01236573	Terminated	Phase 1/Phase 2	Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.	C0010583	Cyclophosphamidum
Fludarabine	Metastatic melanoma	C0278883	NCT01236573	Terminated	Phase 1/Phase 2	Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.	C0059985	Fludarabinum
Infliximab	Stevens-Johnson Syndrome	C0038325	NCT01256489	Withdrawn	Phase 1/Phase 2	Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (~3 in    1 million). No eligible subjects have been identified.	C4490035	Infliximab-abda
Norepinephrine	Septic Shock	C0036983	NCT01271114	Terminated	Phase 3	Low recruitment rate	C0028351	(-)-noradrenaline
Terlipressin	Septic Shock	C0036983	NCT01271114	Terminated	Phase 3	Low recruitment rate	C0145185	Terlipresina
Norepinephrine	Radiodermatitis	C0034561	NCT01263366	Terminated	Phase 1	Enrollment issues	C0028351	(-)-noradrenaline
Irinotecan	Secondary malignant neoplasm of liver	C0494165	NCT01285102	Terminated	Phase 2	This study was closed early by the DSMB due to increased toxicity.	C0123931	(+)-Irinotecan
Irinotecan	Mucinous adenocarcinoma of colon	C0279639	NCT01285102	Terminated	Phase 2	This study was closed early by the DSMB due to increased toxicity.	C0123931	(+)-Irinotecan
Irinotecan	mucinous adenocarcinoma of rectum	C0279652	NCT01285102	Terminated	Phase 2	This study was closed early by the DSMB due to increased toxicity.	C0123931	(+)-Irinotecan
Irinotecan	Colon cancer recurrent	C0278553	NCT01285102	Terminated	Phase 2	This study was closed early by the DSMB due to increased toxicity.	C0123931	(+)-Irinotecan
Irinotecan	Recurrent Rectal Cancer	C0278554	NCT01285102	Terminated	Phase 2	This study was closed early by the DSMB due to increased toxicity.	C0123931	(+)-Irinotecan
Irinotecan	signet ring adenocarcinoma of the colon	C0279640	NCT01285102	Terminated	Phase 2	This study was closed early by the DSMB due to increased toxicity.	C0123931	(+)-Irinotecan
Irinotecan	signet ring adenocarcinoma of the rectum	C0279654	NCT01285102	Terminated	Phase 2	This study was closed early by the DSMB due to increased toxicity.	C0123931	(+)-Irinotecan
Lapatinib	melanoma	C0025202	NCT01264081	Terminated	Phase 2	Protocol would not be able to reach stated accrual.	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Aldesleukin	Stage IV Skin Melanoma	C1321872	NCT01271907	Terminated	Phase 2	Study was terminated due to poor accrual.	C0218986	Aldesleukina
Cyclophosphamide	Stage IV Skin Melanoma	C1321872	NCT01271907	Terminated	Phase 2	Study was terminated due to poor accrual.	C0010583	Cyclophosphamidum
Fludarabine	Stage IV Skin Melanoma	C1321872	NCT01271907	Terminated	Phase 2	Study was terminated due to poor accrual.	C0059985	Fludarabinum
Lenalidomide	Chronic lymphocytic leukaemia stage 3	C0278769	NCT01271283	Withdrawn	Phase 2		C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Lenalidomide	Chronic lymphocytic leukaemia stage 4	C0854804	NCT01271283	Withdrawn	Phase 2		C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Cholecalciferol	Hyperlipidemia	C0020473	NCT01274104	Withdrawn	Phase 1	PI resigned.	C0008318	Colecalciferolum
Sirolimus	Liver neoplasms	C0023903	NCT01281943	Withdrawn	Phase 2	Doxil Shortage	C0072980	Sirolimús
Doxorubicin	Liver neoplasms	C0023903	NCT01281943	Withdrawn	Phase 2	Doxil Shortage	C0013089	Doxorubicine
Everolimus	Liver neoplasms	C0023903	NCT01281943	Withdrawn	Phase 2	Doxil Shortage	C0541315	évérolimus
Varenicline	Drug Dependence	C1510472	NCT01309685	Withdrawn	Phase 1		C1569608	vareniclina
Niacin	Primary hypercholesterolemia	C0342879	NCT01294683	Terminated	Phase 3		C0027996	anti-pellagra vitamin
Simvastatin	Primary hypercholesterolemia	C0342879	NCT01294683	Terminated	Phase 3		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Nicotinamide	Primary hypercholesterolemia	C0342879	NCT01294683	Terminated	Phase 3		C0028027	3-pyridinecarboxamide
Niacin	Dyslipidemias	C0242339	NCT01294683	Terminated	Phase 3		C0027996	anti-pellagra vitamin
Simvastatin	Dyslipidemias	C0242339	NCT01294683	Terminated	Phase 3		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Nicotinamide	Dyslipidemias	C0242339	NCT01294683	Terminated	Phase 3		C0028027	3-pyridinecarboxamide
Bevacizumab	Colorectal cancer metastatic	C0948380	NCT01293942	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Colorectal cancer metastatic	C0948380	NCT01293942	Withdrawn	Phase 2		C0069717	oxaliplatine
Fluorouracil	Colorectal cancer metastatic	C0948380	NCT01293942	Withdrawn	Phase 2		C0016360	Fluorouracilum
Irinotecan	Colorectal cancer metastatic	C0948380	NCT01293942	Withdrawn	Phase 2		C0123931	(+)-Irinotecan
Capecitabine	Colorectal cancer metastatic	C0948380	NCT01293942	Withdrawn	Phase 2		C0671970	Capecitabin
Ropivacaine	Other reconstructive surgery	C0418696	NCT01293149	Withdrawn	Phase 2		C0073571	Ropivacainum
Clonidine	Other reconstructive surgery	C0418696	NCT01293149	Withdrawn	Phase 2		C0009014	2-((2,6-Dichlorophenyl)imino)imidazolidine
Tacrolimus	function of renal transplant	C2170323	NCT01292525	Terminated	Phase 3	Difficulties of recruitment	C0771204	Tacrolimus anhydrous
Thalidomide	Rheumatoid Arthritis	C0003873	NCT01285310	Terminated	Phase 2	Study is terminated due to lack of efficacy	C0039736	Thalidomidum
Apremilast	Rheumatoid Arthritis	C0003873	NCT01285310	Terminated	Phase 2	Study is terminated due to lack of efficacy	C1678805	Aprémilast
Bupivacaine	Fracture of lower leg	C1542178	NCT01308047	Withdrawn	Phase 3	The Sponsor has no interest in continuing the study.	C0006400	Bupivacaina
Levobupivacaine	Fracture of lower leg	C1542178	NCT01308047	Withdrawn	Phase 3	The Sponsor has no interest in continuing the study.	C0873118	L-(-)-bupivacaine
Gemcitabine	advanced adult primary liver cancer	C0278774	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	advanced adult primary liver cancer	C0278774	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	localized unresectable adult primary liver cancer	C0278773	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	localized unresectable adult primary liver cancer	C0278773	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	Transitional cell cancer of renal pelvis and ureter metastatic	C0279937	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Transitional cell cancer of renal pelvis and ureter metastatic	C0279937	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	C0280281	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	C0280281	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	Bladder cancer stage III	C0278824	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Bladder cancer stage III	C0278824	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	Pancreatic carcinoma stage III	C1167722	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Pancreatic carcinoma stage III	C1167722	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	Non-small cell lung cancer stage IIIA	C0278983	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Non-small cell lung cancer stage IIIA	C0278983	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	Non-small cell lung cancer metastatic	C0278987	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Non-small cell lung cancer metastatic	C0278987	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	Stage IV Pancreatic Cancer	C1167725	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Stage IV Pancreatic Cancer	C1167725	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	unresectable extrahepatic bile duct cancer	C0278811	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	unresectable extrahepatic bile duct cancer	C0278811	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	unresectable gallbladder cancer	C0278807	NCT01282333	Terminated	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	unresectable gallbladder cancer	C0278807	NCT01282333	Terminated	Phase 1		C0008838	cisplatino
Gemcitabine	ovarian neoplasm	C0919267	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Carboplatin	ovarian neoplasm	C0919267	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Doxorubicin	ovarian neoplasm	C0919267	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0013089	Doxorubicine
Paclitaxel	ovarian neoplasm	C0919267	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Fallopian Tube Neoplasms	C0015558	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Carboplatin	Fallopian Tube Neoplasms	C0015558	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Doxorubicin	Fallopian Tube Neoplasms	C0015558	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0013089	Doxorubicine
Paclitaxel	Fallopian Tube Neoplasms	C0015558	NCT01279291	Terminated	Phase 1	The study was stopped due to the inability to determine an acceptable dose with the potential    for further study	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Tacrolimus	Lupus Nephritis	C0024143	NCT01288664	Withdrawn	Phase 3	sponsor withdraw from this study	C0771204	Tacrolimus anhydrous
Temozolomide	Melanoma recurrent	C0278884	NCT01328535	Suspended	Phase 2		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Carboplatin	ovarian neoplasm	C0919267	NCT01329549	Terminated	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Doxorubicin	ovarian neoplasm	C0919267	NCT01329549	Terminated	Phase 1		C0013089	Doxorubicine
Nintedanib	ovarian neoplasm	C0919267	NCT01329549	Terminated	Phase 1		C2930789	Nintedanib
Bortezomib	Relapse multiple myeloma	C2349261	NCT01329289	Withdrawn	Phase 2	Clinical trial being transferred to Columbia University with the Investigator.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Dexamethasone	Relapse multiple myeloma	C2349261	NCT01329289	Withdrawn	Phase 2	Clinical trial being transferred to Columbia University with the Investigator.	C0011777	Dexaméthasone
Milnacipran	Primary fibromyalgia syndrome	C0521517	NCT01328002	Terminated	Phase 2		C1533126	(+-)-Milnacipran
Cholecalciferol	Hyperparathyroidism, Primary	C0221002	NCT01329666	Withdrawn	Phase 2/Phase 3	Poor enrollment	C0008318	Colecalciferolum
Cholecalciferol	Hypercalcemia	C0020437	NCT01329666	Withdrawn	Phase 2/Phase 3	Poor enrollment	C0008318	Colecalciferolum
Cholecalciferol	Osteopenia	C0029453	NCT01329666	Withdrawn	Phase 2/Phase 3	Poor enrollment	C0008318	Colecalciferolum
Cyclophosphamide	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2		C0010583	Cyclophosphamidum
Vincristine	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2		C0042679	Vincristina
Irinotecan	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2		C0123931	(+)-Irinotecan
Temozolomide	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2		C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Doxorubicin	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2		C0013089	Doxorubicine
Cisplatin	Adenocarcinoma	C0001418	NCT01301612	Withdrawn	Phase 2	Regulatory requirement. A phase III study is being designed.	C0008838	cisplatino
Cisplatin	Carcinoma	C0007097	NCT01301612	Withdrawn	Phase 2	Regulatory requirement. A phase III study is being designed.	C0008838	cisplatino
Bortezomib	Lymphoma, Non-Hodgkin	C0024305	NCT01300793	Terminated	Phase 1	closed for low accrual and no data is available.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Etoposide	Lymphoma, Non-Hodgkin	C0024305	NCT01300793	Terminated	Phase 1	closed for low accrual and no data is available.	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Carboplatin	Lymphoma, Non-Hodgkin	C0024305	NCT01300793	Terminated	Phase 1	closed for low accrual and no data is available.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Ifosfamide	Lymphoma, Non-Hodgkin	C0024305	NCT01300793	Terminated	Phase 1	closed for low accrual and no data is available.	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Sirolimus	Pemphigus	C0030807	NCT01313923	Terminated	Phase 0	Lack of funding	C0072980	Sirolimús
Everolimus	Pemphigus	C0030807	NCT01313923	Terminated	Phase 0	Lack of funding	C0541315	évérolimus
Valrubicin	Carcinoma in Situ	C0007099	NCT01310803	Terminated	Phase 3		C0068314	Valrubicinum
Dexamethasone	Liver Cirrhosis	C0023890	NCT01311167	Terminated	Phase 3	Recruitment problems (not enough patients were found who met eligibility criteria)	C0011777	Dexaméthasone
Heparin	Coronary Artery Disease	C1956346	NCT01312935	Terminated	Phase 2	PolyMedix decided to stop enrollment in both clinical trials due to observations of reductions    in blood pressure.	C0019134	Heparina
Gefitinib	Glioblastoma	C0017636	NCT01310855	Terminated	Phase 2	closed to recruitment early due to AstraZeneca not developing cediranib further	C1122962	4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Bevacizumab	Secondary malignant neoplasm of liver	C0494165	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Secondary malignant neoplasm of liver	C0494165	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0069717	oxaliplatine
Fluorouracil	Secondary malignant neoplasm of liver	C0494165	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0016360	Fluorouracilum
Irinotecan	Secondary malignant neoplasm of liver	C0494165	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0123931	(+)-Irinotecan
Levoleucovorin	Secondary malignant neoplasm of liver	C0494165	NCT01320683	Terminated	Phase 2	This study will not be written up.	C2721771	ácido levofolínico
Bevacizumab	Colon cancer recurrent	C0278553	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Colon cancer recurrent	C0278553	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0069717	oxaliplatine
Fluorouracil	Colon cancer recurrent	C0278553	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0016360	Fluorouracilum
Irinotecan	Colon cancer recurrent	C0278553	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0123931	(+)-Irinotecan
Levoleucovorin	Colon cancer recurrent	C0278553	NCT01320683	Terminated	Phase 2	This study will not be written up.	C2721771	ácido levofolínico
Bevacizumab	Recurrent Rectal Cancer	C0278554	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Recurrent Rectal Cancer	C0278554	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0069717	oxaliplatine
Fluorouracil	Recurrent Rectal Cancer	C0278554	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0016360	Fluorouracilum
Irinotecan	Recurrent Rectal Cancer	C0278554	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0123931	(+)-Irinotecan
Levoleucovorin	Recurrent Rectal Cancer	C0278554	NCT01320683	Terminated	Phase 2	This study will not be written up.	C2721771	ácido levofolínico
Bevacizumab	Stage IVA Colon Cancer	C3897082	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Stage IVA Colon Cancer	C3897082	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0069717	oxaliplatine
Fluorouracil	Stage IVA Colon Cancer	C3897082	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0016360	Fluorouracilum
Irinotecan	Stage IVA Colon Cancer	C3897082	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IVA Colon Cancer	C3897082	NCT01320683	Terminated	Phase 2	This study will not be written up.	C2721771	ácido levofolínico
Bevacizumab	Stage IVA Rectal Cancer	C3897520	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Stage IVA Rectal Cancer	C3897520	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0069717	oxaliplatine
Fluorouracil	Stage IVA Rectal Cancer	C3897520	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0016360	Fluorouracilum
Irinotecan	Stage IVA Rectal Cancer	C3897520	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IVA Rectal Cancer	C3897520	NCT01320683	Terminated	Phase 2	This study will not be written up.	C2721771	ácido levofolínico
Bevacizumab	Stage IVB Colon Cancer	C3897517	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Stage IVB Colon Cancer	C3897517	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0069717	oxaliplatine
Fluorouracil	Stage IVB Colon Cancer	C3897517	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0016360	Fluorouracilum
Irinotecan	Stage IVB Colon Cancer	C3897517	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IVB Colon Cancer	C3897517	NCT01320683	Terminated	Phase 2	This study will not be written up.	C2721771	ácido levofolínico
Bevacizumab	Stage IVB Rectal Cancer	C3897513	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0796392	Anti-VEGF monoclonal antibody
Oxaliplatin	Stage IVB Rectal Cancer	C3897513	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0069717	oxaliplatine
Fluorouracil	Stage IVB Rectal Cancer	C3897513	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0016360	Fluorouracilum
Irinotecan	Stage IVB Rectal Cancer	C3897513	NCT01320683	Terminated	Phase 2	This study will not be written up.	C0123931	(+)-Irinotecan
Levoleucovorin	Stage IVB Rectal Cancer	C3897513	NCT01320683	Terminated	Phase 2	This study will not be written up.	C2721771	ácido levofolínico
Propofol	leukemia	C0023418	NCT01326078	Withdrawn	Phase 2/Phase 3	The Sponsor has no interest in continuing the study.	C0033487	2,6-bis(1-methylethyl)phenol
Erythromycin	Gastroparesis	C0152020	NCT01323582	Terminated	Phase 2	Original investigator left this institution, replacement investigator retired.	C0014806	Erythromycinum
Buprenorphine	Other acute postoperative pain	C1719392	NCT01324544	Withdrawn	Phase 3	Due to change in development plan.	C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Buprenorphine	INTUBATION ENDOTRACHEAL PROLONGED	C0745398	NCT01324544	Withdrawn	Phase 3	Due to change in development plan.	C0006405	2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
Cyclosporine	Lupus Nephritis	C0024143	NCT01299922	Withdrawn	Phase 3	IT was impossible to find patients	C0010592	Cyclosporine
Mycophenolate mofetil	Lupus Nephritis	C0024143	NCT01299922	Withdrawn	Phase 3	IT was impossible to find patients	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Lupus Nephritis	C0024143	NCT01299922	Withdrawn	Phase 3	IT was impossible to find patients	C0026933	Mycophenolsäure
Nicotine	Tobacco Dependence	C0040332	NCT01296698	Terminated	Phase 3	Study terminated due to a technical issue (randomization error).	C0028040	Nikotin
Fluvoxamine	Solid tumour	C0280100	NCT01299415	Terminated	Phase 1		C0085228	Fluvoxaminum
Methylphenidate	central nervous system tumor, pediatric	C1377665	NCT01348607	Terminated	Phase 2	Study only randomized 1 subject and was determined not feasible by DSMB	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Modafinil	central nervous system tumor, pediatric	C1377665	NCT01348607	Terminated	Phase 2	Study only randomized 1 subject and was determined not feasible by DSMB	C0066677	2-((diphenylmethyl)sulfinyl)acetamide
Armodafinil	central nervous system tumor, pediatric	C1377665	NCT01348607	Terminated	Phase 2	Study only randomized 1 subject and was determined not feasible by DSMB	C1701455	Armodafinilo
Ethanol	Alcohol problem	C0549393	NCT01348113	Terminated	Phase 3		C0001962	Spiritus vini
Ethanol	AOD misuse	C0678254	NCT01348113	Terminated	Phase 3		C0001962	Spiritus vini
Gemcitabine	Non-small cell lung cancer stage III	C0278506	NCT01336543	Withdrawn	Phase 2	Low accrual, small patient population at center.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Pemetrexed	Non-small cell lung cancer stage III	C0278506	NCT01336543	Withdrawn	Phase 2	Low accrual, small patient population at center.	C0210657	Pemetrexed
Etoposide	Non-small cell lung cancer stage III	C0278506	NCT01336543	Withdrawn	Phase 2	Low accrual, small patient population at center.	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Carboplatin	Non-small cell lung cancer metastatic	C0278987	NCT01337154	Terminated	Phase 2	Interim analysis showed that the primary endpoint would not be met.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Irinotecan	Advanced cancer	C0877373	NCT01347866	Terminated	Phase 1	Refer to Detailed Description for documentaion of Termination Statement.	C0123931	(+)-Irinotecan
Sirolimus	Advanced cancer	C0877373	NCT01347866	Terminated	Phase 1	Refer to Detailed Description for documentaion of Termination Statement.	C0072980	Sirolimús
Everolimus	Advanced cancer	C0877373	NCT01347866	Terminated	Phase 1	Refer to Detailed Description for documentaion of Termination Statement.	C0541315	évérolimus
Isotretinoin	Neuroblastoma	C0027819	NCT01319838	Withdrawn	Phase 1	no patient enrollment	C0022265	Isotrétinoine
Milnacipran	Fibromyalgia, Primary	C0751152	NCT01331109	Terminated	Phase 2		C1533126	(+-)-Milnacipran
Norepinephrine	Gait Disorders, Neurologic	C0751830	NCT01331122	Withdrawn	Phase 1/Phase 2	Never initiated. Withdrawn by sponsor.	C0028351	(-)-noradrenaline
Droxidopa	Gait Disorders, Neurologic	C0751830	NCT01331122	Withdrawn	Phase 1/Phase 2	Never initiated. Withdrawn by sponsor.	C0000378	L-Dihydroxyphenylserine
Amikacin	Cystic Fibrosis	C0010674	NCT01315691	Withdrawn	Phase 3		C0002499	1-N-(L(-)-γ-amino-α-hydroxybutyryl)kanamycin A
Nifedipine	Threatened premature labor	C0473390	NCT01314859	Withdrawn	Phase 3		C0028066	Nifedipinum
Gemcitabine	Bladder Neoplasm	C0005695	NCT01342172	Terminated	Phase 1/Phase 2	low accrual	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Lenalidomide	Bladder Neoplasm	C0005695	NCT01342172	Terminated	Phase 1/Phase 2	low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Cisplatin	Bladder Neoplasm	C0005695	NCT01342172	Terminated	Phase 1/Phase 2	low accrual	C0008838	cisplatino
Thalidomide	Bladder Neoplasm	C0005695	NCT01342172	Terminated	Phase 1/Phase 2	low accrual	C0039736	Thalidomidum
Atomoxetine	alcohol sensitivity	C0678306	NCT01343628	Terminated	Phase 1	Terminated due to lack of funding	C0076823	Atomoxetina
Heparin	Malignant Childhood Neoplasm	C0278704	NCT01343680	Terminated	Phase 3	Poor patient accrual	C0019134	Heparina
Heparin	Aplastic Anemia	C0002874	NCT01343680	Terminated	Phase 3	Poor patient accrual	C0019134	Heparina
Heparin	Metabolic Diseases	C0025517	NCT01343680	Terminated	Phase 3	Poor patient accrual	C0019134	Heparina
Cisplatin	Carcinoma	C0007097	NCT01345084	Withdrawn	Phase 3	change company strategy	C0008838	cisplatino
Tacrolimus	Lupus Nephritis	C0024143	NCT01342016	Terminated	Phase 3	Due to safety concern of active control drug	C0771204	Tacrolimus anhydrous
Leflunomide	Lupus Nephritis	C0024143	NCT01342016	Terminated	Phase 3	Due to safety concern of active control drug	C0063041	alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
Teriflunomide	Lupus Nephritis	C0024143	NCT01342016	Terminated	Phase 3	Due to safety concern of active control drug	C1718383	Teriflunomidum
Melatonin	Depressive disorder	C0011581	NCT01355523	Terminated	Phase 2/Phase 3	Inclusion rate not as expected. Not financially possible to involve other centres.	C0025219	Mélatonine
Prednisone	Polymyalgia Rheumatica	C0032533	NCT01364389	Terminated	Phase 2	Data did not show that the two biologic treatments impacted PMR disease activity to the same    degree as steroid treatment within a 2-week treatment period.	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Prednisone	Inflammatory disorder	C1290884	NCT01364389	Terminated	Phase 2	Data did not show that the two biologic treatments impacted PMR disease activity to the same    degree as steroid treatment within a 2-week treatment period.	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Bevacizumab	Malignant tumor of colon	C0007102	NCT01338558	Withdrawn	Phase 3		C0796392	Anti-VEGF monoclonal antibody
Irinotecan	Colorectal Neoplasms	C0009404	NCT01336985	Terminated	Phase 1		C0123931	(+)-Irinotecan
Cyclosporine	adult acute monocytic leukemia (M5b)	C0280634	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute monocytic leukemia (M5b)	C0280634	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute monocytic leukemia (M5b)	C0280634	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute monocytic leukemia (M5b)	C0280634	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute myelomonocytic leukemia (M4)	C0279627	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute myelomonocytic leukemia (M4)	C0279627	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute myelomonocytic leukemia (M4)	C0279627	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute myelomonocytic leukemia (M4)	C0279627	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult acute monoblastic leukemia (M5a)	C0279629	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult acute monoblastic leukemia (M5a)	C0279629	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult acute monoblastic leukemia (M5a)	C0279629	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult acute monoblastic leukemia (M5a)	C0279629	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult erythroleukemia (M6a)	C1541339	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult erythroleukemia (M6a)	C1541339	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult erythroleukemia (M6a)	C1541339	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult erythroleukemia (M6a)	C1541339	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	adult pure erythroid leukemia (M6b)	C1541340	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	adult pure erythroid leukemia (M6b)	C1541340	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	adult pure erythroid leukemia (M6b)	C1541340	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	adult pure erythroid leukemia (M6b)	C1541340	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Cyclosporine	recurrent adult acute myeloid leukemia	C0278780	NCT01342887	Terminated	Phase 1/Phase 2		C0010592	Cyclosporine
Pravastatin	recurrent adult acute myeloid leukemia	C0278780	NCT01342887	Terminated	Phase 1/Phase 2		C0085542	Pravastatine
Etoposide	recurrent adult acute myeloid leukemia	C0278780	NCT01342887	Terminated	Phase 1/Phase 2		C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Mitoxantrone	recurrent adult acute myeloid leukemia	C0278780	NCT01342887	Terminated	Phase 1/Phase 2		C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Clonidine	Neonatal Abstinence Syndrome	C0027609	NCT01360450	Terminated	Phase 2/Phase 3	The study was treminated because of low accural	C0009014	2-((2,6-Dichlorophenyl)imino)imidazolidine
Niacin	Primary hypercholesterolemia	C0342879	NCT01335997	Terminated	Phase 3		C0027996	anti-pellagra vitamin
Simvastatin	Primary hypercholesterolemia	C0342879	NCT01335997	Terminated	Phase 3		C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Nicotinamide	Primary hypercholesterolemia	C0342879	NCT01335997	Terminated	Phase 3		C0028027	3-pyridinecarboxamide
Erlotinib	recurrent metastatic squamous neck cancer with occult primary	C0279100	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	recurrent metastatic squamous neck cancer with occult primary	C0279100	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	recurrent metastatic squamous neck cancer with occult primary	C0279100	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	Recurrent Salivary Gland Cancer	C0278993	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	Recurrent Salivary Gland Cancer	C0278993	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	Recurrent Salivary Gland Cancer	C0278993	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	Squamous cell carcinoma of the hypopharynx recurrent	C0280392	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	Squamous cell carcinoma of the hypopharynx recurrent	C0280392	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	Squamous cell carcinoma of the hypopharynx recurrent	C0280392	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	Laryngeal squamous cell carcinoma recurrent	C0280401	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	Laryngeal squamous cell carcinoma recurrent	C0280401	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	Laryngeal squamous cell carcinoma recurrent	C0280401	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	recurrent squamous cell carcinoma of the lip and oral cavity	C0280363	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	recurrent squamous cell carcinoma of the lip and oral cavity	C0280363	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	recurrent squamous cell carcinoma of the lip and oral cavity	C0280363	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	Oropharyngeal squamous cell carcinoma recurrent	C0280376	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	Oropharyngeal squamous cell carcinoma recurrent	C0280376	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	Oropharyngeal squamous cell carcinoma recurrent	C0280376	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280419	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280419	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280419	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	Laryngeal verrucous carcinoma recurrent	C0280402	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	Laryngeal verrucous carcinoma recurrent	C0280402	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	Laryngeal verrucous carcinoma recurrent	C0280402	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	Verrucous carcinoma of the oral cavity recurrent	C0280365	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	Verrucous carcinoma of the oral cavity recurrent	C0280365	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	Verrucous carcinoma of the oral cavity recurrent	C0280365	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Erlotinib	squamous cell carcinoma of salivary gland	C0279697	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Sirolimus	squamous cell carcinoma of salivary gland	C0279697	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0072980	Sirolimús
Everolimus	squamous cell carcinoma of salivary gland	C0279697	NCT01332279	Withdrawn	Phase 1	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.	C0541315	évérolimus
Letrozole	HER-2 positive breast cancer	C1699634	NCT01361945	Withdrawn	Phase 1/Phase 2	Closed due to no enrollment	C0246421	Letrozol
Lapatinib	HER-2 positive breast cancer	C1699634	NCT01361945	Withdrawn	Phase 1/Phase 2	Closed due to no enrollment	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Ramipril	Low density lipoprotein increased	C0549399	NCT01362218	Terminated	Phase 2	Per sponsor's decision	C0072973	(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Simvastatin	Low density lipoprotein increased	C0549399	NCT01362218	Terminated	Phase 2	Per sponsor's decision	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Salicylic acid	Low density lipoprotein increased	C0549399	NCT01362218	Terminated	Phase 2	Per sponsor's decision	C0036079	ácido salicílico
Acetylsalicylic acid	Low density lipoprotein increased	C0549399	NCT01362218	Terminated	Phase 2	Per sponsor's decision	C0004057	Aspirina
Busulfan	Hematological Disease	C0018939	NCT01359254	Terminated	Phase 2	did not accrue enough patients.	C0006463	Busulfano
Melphalan	Hematological Disease	C0018939	NCT01359254	Terminated	Phase 2	did not accrue enough patients.	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Fludarabine	Hematological Disease	C0018939	NCT01359254	Terminated	Phase 2	did not accrue enough patients.	C0059985	Fludarabinum
Metformin	Squamous cell carcinoma	C0007137	NCT01333852	Terminated	Phase 2	Low accrual	C0025598	Metformina
Paclitaxel	Squamous cell carcinoma	C0007137	NCT01333852	Terminated	Phase 2	Low accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Aminolevulinic acid	Astrocytoma	C0004114	NCT01351519	Terminated	Phase 2	Limited staff available for enrollment and limited availability of drug	C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	Malignant Glioma	C0555198	NCT01351519	Terminated	Phase 2	Limited staff available for enrollment and limited availability of drug	C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	Glioblastoma	C0017636	NCT01351519	Terminated	Phase 2	Limited staff available for enrollment and limited availability of drug	C0002563	ácido 5-aminolevulínico
Magnesium Sulfate	Traumatic Brain Injury	C0876926	NCT01333488	Terminated	Phase 2	Low accrual	C0024480	Magnesium sulfate
Cyclosporine	Bronchiolitis Obliterans	C0006272	NCT01334892	Terminated	Phase 2/Phase 3	Interim analysis results revealed substantial increase of patient number, with unfeasible    study prolongation.	C0010592	Cyclosporine
Vitamin E	Nonalcoholic Steatohepatitis	C3241937	NCT01384578	Withdrawn	Phase 3	Lack of funds	C0969677	alpha-tocopherol
Pentoxifylline	Nonalcoholic Steatohepatitis	C3241937	NCT01384578	Withdrawn	Phase 3	Lack of funds	C0030899	Pentoxifilina
Vigabatrin	Alcoholic Intoxication, Chronic	C0001973	NCT01335867	Terminated	Phase 2		C0048044	Vigabatrina
Vigabatrin	Cocaine Dependence	C0600427	NCT01335867	Terminated	Phase 2		C0048044	Vigabatrina
Sirolimus	Non-small cell lung cancer recurrent	C0278517	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0072980	Sirolimús
Everolimus	Non-small cell lung cancer recurrent	C0278517	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0541315	évérolimus
Sodium aurothiomalate	Non-small cell lung cancer recurrent	C0278517	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0018034	Natrii aurothiomalas
Sirolimus	Non-small cell lung cancer stage IIIA	C0278983	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0072980	Sirolimús
Everolimus	Non-small cell lung cancer stage IIIA	C0278983	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0541315	évérolimus
Sodium aurothiomalate	Non-small cell lung cancer stage IIIA	C0278983	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0018034	Natrii aurothiomalas
Sirolimus	Non-small cell lung cancer metastatic	C0278987	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0072980	Sirolimús
Everolimus	Non-small cell lung cancer metastatic	C0278987	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0541315	évérolimus
Sodium aurothiomalate	Non-small cell lung cancer metastatic	C0278987	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0018034	Natrii aurothiomalas
Sirolimus	unspecified adult solid tumor, protocol specific	C0279004	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0072980	Sirolimús
Everolimus	unspecified adult solid tumor, protocol specific	C0279004	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0541315	évérolimus
Sodium aurothiomalate	unspecified adult solid tumor, protocol specific	C0279004	NCT01383668	Withdrawn	Phase 1	lack of access to study drug	C0018034	Natrii aurothiomalas
Imatinib	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01383447	Terminated	Phase 1/Phase 2	Administratively complete.	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Vorinostat	adult anaplastic astrocytoma	C0280483	NCT01378481	Terminated	Phase 1		C0672708	Vorinostatum
Vorinostat	adult anaplastic oligodendroglioma	C0280790	NCT01378481	Terminated	Phase 1		C0672708	Vorinostatum
Vorinostat	adult giant cell glioblastoma	C1541316	NCT01378481	Terminated	Phase 1		C0672708	Vorinostatum
Vorinostat	adult glioblastoma	C0278878	NCT01378481	Terminated	Phase 1		C0672708	Vorinostatum
Vorinostat	adult gliosarcoma	C1541317	NCT01378481	Terminated	Phase 1		C0672708	Vorinostatum
Vorinostat	Adult Mixed Glioma	C3900099	NCT01378481	Terminated	Phase 1		C0672708	Vorinostatum
Docetaxel	Bladder cancer stage III	C0278824	NCT01382706	Terminated	Phase 2	Trial not progressing toward scientific goals	C0246415	Docetaxel
Lapatinib	Bladder cancer stage III	C0278824	NCT01382706	Terminated	Phase 2	Trial not progressing toward scientific goals	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Sevoflurane	Brain Injuries	C0270611	NCT01374633	Terminated	Phase 2	Sponsor decision	C0074414	Sevoflurano
Tadalafil	Multiple Myeloma	C0026764	NCT01374217	Terminated	Phase 2	early stopping rule	C1176316	(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
Sildenafil	Persistent Fetal Circulation Syndrome	C0031190	NCT01360671	Withdrawn	Phase 2		C0529793	Sildenafilo
Melphalan	Hodgkin Disease	C0019829	NCT01350258	Terminated	Phase 1/Phase 2	Poor accrual	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Fludarabine	Hodgkin Disease	C0019829	NCT01350258	Terminated	Phase 1/Phase 2	Poor accrual	C0059985	Fludarabinum
Melphalan	Lymphoma, Non-Hodgkin	C0024305	NCT01350258	Terminated	Phase 1/Phase 2	Poor accrual	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Fludarabine	Lymphoma, Non-Hodgkin	C0024305	NCT01350258	Terminated	Phase 1/Phase 2	Poor accrual	C0059985	Fludarabinum
Bortezomib	Disorder of transplanted kidney	C1261281	NCT01349595	Terminated	Phase 2	Study halted due to lack of funding	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Domperidone	Gastroparesis	C0152020	NCT01378884	Withdrawn	Phase 3		C0013015	5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
Irinotecan	Malignant tumor of colon	C0007102	NCT01367275	Terminated	Phase 2	Sponsor closed study	C0123931	(+)-Irinotecan
Irinotecan	Adenocarcinoma of large intestine	C1319315	NCT01367275	Terminated	Phase 2	Sponsor closed study	C0123931	(+)-Irinotecan
Midazolam	Traumatic Brain Injury	C0876926	NCT01402596	Withdrawn	Phase 2	Institution decided on starting a new protocol of sedation, with another methods and that´s    why this study has not started.	C0026056	Midazolamum
Chloral hydrate	Traumatic Brain Injury	C0876926	NCT01402596	Withdrawn	Phase 2	Institution decided on starting a new protocol of sedation, with another methods and that´s    why this study has not started.	C0008161	1,1,1-trichloro-2,2-dihydroxyethane
Bosentan	Persistent Fetal Circulation Syndrome	C0031190	NCT01389856	Terminated	Phase 3	To be compliant with the timelines as agreed with Paediatric Committee (PC) within the    Paediatric Investigational Plan	C2825457	bosentan anhydrous
Formoterol	Chronic Obstructive Airway Disease	C0024117	NCT01351792	Terminated	Phase 3		C0060657	N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide
Peginterferon alfa-2a	leukemia	C0023418	NCT01392170	Terminated	Phase 2	Slow Accrual	C0391001	Pegylated interferon alpha-2a
Bortezomib	recurrent adult diffuse large cell lymphoma	C0280188	NCT01397591	Terminated	Phase 2	Study closed by PI due to lower than expected accrual.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent grade 1 follicular lymphoma	C0280182	NCT01397591	Terminated	Phase 2	Study closed by PI due to lower than expected accrual.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent grade 2 follicular lymphoma	C0280183	NCT01397591	Terminated	Phase 2	Study closed by PI due to lower than expected accrual.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	recurrent grade 3 follicular lymphoma	C0280185	NCT01397591	Terminated	Phase 2	Study closed by PI due to lower than expected accrual.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bortezomib	Mantle cell lymphoma recurrent	C0677725	NCT01397591	Terminated	Phase 2	Study closed by PI due to lower than expected accrual.	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Oxytocin	Dystocia	C0013418	NCT01397630	Terminated	Phase 3	Due to budgetary concerns, the TSC decided it best to adjust sample size as there was    sufficient data to assess feasibility. Recruitment was terminated early.	C0030095	Oxitocina
Sunitinib	Plexiform Neurofibroma	C0206728	NCT01402817	Suspended	Phase 2	1 patient died of uncertain cause but possibly related to drug. Regulatory currently reviewing	C1176020	Sunitinibum
Modafinil	Malignant Glioma	C0555198	NCT01400958	Terminated	Phase 2	Slow Accrual, Initiating Principal Investigator (PI) left Moffitt	C0066677	2-((diphenylmethyl)sulfinyl)acetamide
Temozolomide	Malignant Glioma	C0555198	NCT01400958	Terminated	Phase 2	Slow Accrual, Initiating Principal Investigator (PI) left Moffitt	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Armodafinil	Malignant Glioma	C0555198	NCT01400958	Terminated	Phase 2	Slow Accrual, Initiating Principal Investigator (PI) left Moffitt	C1701455	Armodafinilo
Bevacizumab	Malignant tumor of colon	C0007102	NCT01375816	Terminated	Phase 2	efficacy interim analysis as per protocol	C0796392	Anti-VEGF monoclonal antibody
Leucovorin	Malignant tumor of colon	C0007102	NCT01375816	Terminated	Phase 2	efficacy interim analysis as per protocol	C0023413	Folinate
Irinotecan	Malignant tumor of colon	C0007102	NCT01375816	Terminated	Phase 2	efficacy interim analysis as per protocol	C0123931	(+)-Irinotecan
Levoleucovorin	Malignant tumor of colon	C0007102	NCT01375816	Terminated	Phase 2	efficacy interim analysis as per protocol	C2721771	ácido levofolínico
Norepinephrine	Alopecia	C0002170	NCT01367990	Terminated	Phase 1	Study site has terminated the study due to the complexity of the study	C0028351	(-)-noradrenaline
Norepinephrine	Radiodermatitis	C0034561	NCT01367990	Terminated	Phase 1	Study site has terminated the study due to the complexity of the study	C0028351	(-)-noradrenaline
Testosterone	hormone deficiency	C0599750	NCT01397500	Terminated	Phase 2	Recruitment problems due to change of patient population at site.	C0039601	Testostérone
Methyltestosterone	hormone deficiency	C0599750	NCT01397500	Terminated	Phase 2	Recruitment problems due to change of patient population at site.	C0025826	Methyltestosteronum
Dutasteride	Adenocarcinoma of prostate	C0007112	NCT01368003	Withdrawn	Phase 2	Loss of funding.	C0754659	α,α,α,α',α',α'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide
Goserelin	Oestrogen receptor positive breast cancer	C2938924	NCT01368263	Terminated	Phase 2	Due to funding source and lack of accrual	C0120107	Goserelina
Letrozole	Oestrogen receptor positive breast cancer	C2938924	NCT01368263	Terminated	Phase 2	Due to funding source and lack of accrual	C0246421	Letrozol
Anastrozole	Oestrogen receptor positive breast cancer	C2938924	NCT01368263	Terminated	Phase 2	Due to funding source and lack of accrual	C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Goserelin	Breast cancer stage II	C0278486	NCT01368263	Terminated	Phase 2	Due to funding source and lack of accrual	C0120107	Goserelina
Letrozole	Breast cancer stage II	C0278486	NCT01368263	Terminated	Phase 2	Due to funding source and lack of accrual	C0246421	Letrozol
Anastrozole	Breast cancer stage II	C0278486	NCT01368263	Terminated	Phase 2	Due to funding source and lack of accrual	C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Niacin	Psoriasis	C0033860	NCT01368887	Suspended	Phase 2	Sponsor seeking additional financial support before starting the study	C0027996	anti-pellagra vitamin
Calcipotriol	Psoriasis	C0033860	NCT01368887	Suspended	Phase 2	Sponsor seeking additional financial support before starting the study	C0065767	Calcipotriol
Nicotinamide	Psoriasis	C0033860	NCT01368887	Suspended	Phase 2	Sponsor seeking additional financial support before starting the study	C0028027	3-pyridinecarboxamide
Riboflavin	Pathological Dilatation	C0012359	NCT01398839	Terminated	Phase 3		C4550958	Vitamin Bi
Gemcitabine	leiomyosarcoma	C0023269	NCT01418001	Terminated	Phase 1/Phase 2	Lack of accrual	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Docetaxel	leiomyosarcoma	C0023269	NCT01418001	Terminated	Phase 1/Phase 2	Lack of accrual	C0246415	Docetaxel
Lenalidomide	leukemia	C0023418	NCT01401322	Terminated	Phase 2	low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	leukemia	C0023418	NCT01401322	Terminated	Phase 2	low accrual	C0039736	Thalidomidum
Glycine	Cystic Fibrosis	C0010674	NCT01417481	Terminated	Phase 2	Some of the researchers finished their participation in the study.	C0017890	Glicina
Mycophenolate mofetil	Lupus Nephritis	C0024143	NCT01369628	Terminated	Phase 1	Please see Purpose Statement below	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Mycophenolic acid	Lupus Nephritis	C0024143	NCT01369628	Terminated	Phase 1	Please see Purpose Statement below	C0026933	Mycophenolsäure
Methylphenidate	Traumatic Brain Injury	C0876926	NCT01416948	Terminated	Phase 2	The funding agency, DoD, determined that the study could not meet its enrollment numbers by    the end of the grant.	C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Galantamine	Traumatic Brain Injury	C0876926	NCT01416948	Terminated	Phase 2	The funding agency, DoD, determined that the study could not meet its enrollment numbers by    the end of the grant.	C0016967	Galantamina
Cisplatin	Malignant neoplasm of lung	C0242379	NCT01416961	Withdrawn	Phase 1	Neutron therapy has become unavailable	C0008838	cisplatino
Etoposide	Malignant neoplasm of lung	C0242379	NCT01416961	Withdrawn	Phase 1	Neutron therapy has become unavailable	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Rituximab	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Hepatosplenic T-cell lymphoma	C1333984	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Hepatosplenic T-cell lymphoma	C1333984	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Hepatosplenic T-cell lymphoma	C1333984	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Monocytoid B-cell lymphoma	C0855139	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Monocytoid B-cell lymphoma	C0855139	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Monocytoid B-cell lymphoma	C0855139	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Peripheral T-Cell Lymphoma	C0079774	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Peripheral T-Cell Lymphoma	C0079774	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Peripheral T-Cell Lymphoma	C0079774	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Prolymphocytic Leukemia	C0023486	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Prolymphocytic Leukemia	C0023486	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Prolymphocytic Leukemia	C0023486	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent adult Burkitt's lymphoma	C0280192	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent adult Burkitt's lymphoma	C0280192	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent adult Burkitt's lymphoma	C0280192	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent adult diffuse large cell lymphoma	C0280188	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent adult diffuse large cell lymphoma	C0280188	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent adult diffuse large cell lymphoma	C0280188	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent grade 1 follicular lymphoma	C0280182	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent grade 1 follicular lymphoma	C0280182	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent grade 1 follicular lymphoma	C0280182	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent grade 2 follicular lymphoma	C0280183	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent grade 2 follicular lymphoma	C0280183	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent grade 2 follicular lymphoma	C0280183	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent grade 3 follicular lymphoma	C0280185	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent grade 3 follicular lymphoma	C0280185	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent grade 3 follicular lymphoma	C0280185	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Mantle cell lymphoma recurrent	C0677725	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Mantle cell lymphoma recurrent	C0677725	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Mantle cell lymphoma recurrent	C0677725	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Marginal zone lymphoma recurrent	C1541273	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Marginal zone lymphoma recurrent	C1541273	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Marginal zone lymphoma recurrent	C1541273	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Chronic lymphocytic leukaemia refractory	C0278791	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Chronic lymphocytic leukaemia refractory	C0278791	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Chronic lymphocytic leukaemia refractory	C0278791	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Hairy cell leukaemia recurrent	C0279780	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Hairy cell leukaemia recurrent	C0279780	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Hairy cell leukaemia recurrent	C0279780	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Small Intestinal Lymphoma	C0278805	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Small Intestinal Lymphoma	C0278805	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Small Intestinal Lymphoma	C0278805	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Malignant lymphoma of testis	C0349644	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Malignant lymphoma of testis	C0349644	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Malignant lymphoma of testis	C0349644	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	recurrent adult lymphoblastic lymphoma	C0280191	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	recurrent adult lymphoblastic lymphoma	C0280191	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	recurrent adult lymphoblastic lymphoma	C0280191	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Rituximab	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01419795	Terminated	Phase 2	Low accrual	C5195655	rituximab-pvvr
Lenalidomide	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01419795	Terminated	Phase 2	Low accrual	C1144149	1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Thalidomide	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01419795	Terminated	Phase 2	Low accrual	C0039736	Thalidomidum
Sildenafil	Respiratory Failure	C1145670	NCT01409031	Terminated	Phase 2		C0529793	Sildenafilo
Sildenafil	Persistent pulmonary hypertension	C1135361	NCT01409031	Terminated	Phase 2		C0529793	Sildenafilo
Prednisolone	Microscopic Polyarteritis	C2347126	NCT01408836	Terminated	Phase 2/Phase 3	Completed	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Microscopic Polyarteritis	C2347126	NCT01408836	Terminated	Phase 2/Phase 3	Completed	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Omeprazole	Dyspepsia	C0013395	NCT01408849	Suspended	Phase 2	Lack of adherence and huge loss of follow up.	C0028978	Omeprazolum
Atomoxetine	Craving for alcohol	C0556385	NCT01408589	Terminated	Phase 1		C0076823	Atomoxetina
Atomoxetine	Mood swings	C0085633	NCT01408589	Terminated	Phase 1		C0076823	Atomoxetina
Bevacizumab	Glioblastoma	C0017636	NCT01413438	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Bevacizumab	Brain Neoplasms	C0006118	NCT01413438	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Timolol	Strawberry nevus of skin	C0206733	NCT01408056	Withdrawn	Phase 2	Difficulty with recruitment	C0040233	Timololo
Mupirocin	Strawberry nevus of skin	C0206733	NCT01408056	Withdrawn	Phase 2	Difficulty with recruitment	C0085259	Mupirocina
Cisplatin	Non-small cell lung cancer recurrent	C0278517	NCT01411098	Terminated	Phase 1	Low accrual	C0008838	cisplatino
Etoposide	Non-small cell lung cancer recurrent	C0278517	NCT01411098	Terminated	Phase 1	Low accrual	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Cisplatin	Stage IIB Non-Small Cell Lung Carcinoma	C1336190	NCT01411098	Terminated	Phase 1	Low accrual	C0008838	cisplatino
Etoposide	Stage IIB Non-Small Cell Lung Carcinoma	C1336190	NCT01411098	Terminated	Phase 1	Low accrual	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Cisplatin	Non-small cell lung cancer stage IIIA	C0278983	NCT01411098	Terminated	Phase 1	Low accrual	C0008838	cisplatino
Etoposide	Non-small cell lung cancer stage IIIA	C0278983	NCT01411098	Terminated	Phase 1	Low accrual	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Alitretinoin	Lupus Erythematosus, Cutaneous	C0024137	NCT01407679	Terminated	Phase 2		C0281666	(7E,9Z,11E,13E)-retinoic acid
Tretinoin	Lupus Erythematosus, Cutaneous	C0024137	NCT01407679	Terminated	Phase 2		C0040845	Tretin M
Melphalan	Retinoblastoma	C0035335	NCT01393769	Terminated	Phase 2	Only 5 subjects could be enrolled. The sample of 25 subjects could not be achieved due to it    is a rare disease.	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Bevacizumab	Anaplastic astrocytoma	C0334579	NCT01386710	Suspended	Phase 1/Phase 2	In the process of transferring IRB to PI's current institution	C0796392	Anti-VEGF monoclonal antibody
Carboplatin	Anaplastic astrocytoma	C0334579	NCT01386710	Suspended	Phase 1/Phase 2	In the process of transferring IRB to PI's current institution	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Anastrozole	Oestrogen receptor positive breast cancer	C2938924	NCT01394211	Terminated	Phase 2	Slow accrual	C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrozole	Breast cancer recurrent	C0278493	NCT01394211	Terminated	Phase 2	Slow accrual	C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrozole	Breast cancer stage II	C0278486	NCT01394211	Terminated	Phase 2	Slow accrual	C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Verapamil	Classical phenylketonuria	C0751434	NCT01395394	Terminated	Phase 2	Difficulty with recruitment and agreed with Sponsor to report completed data as case reports	C0042523	Vérapamil
Carboplatin	Adenocarcinoma Of Esophagus	C0279628	NCT01395537	Terminated	Phase 1/Phase 2	Research Cancelled	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Adenocarcinoma Of Esophagus	C0279628	NCT01395537	Terminated	Phase 1/Phase 2	Research Cancelled	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Lapatinib	Adenocarcinoma Of Esophagus	C0279628	NCT01395537	Terminated	Phase 1/Phase 2	Research Cancelled	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Carboplatin	Adenocarcinoma of the gastroesophageal junction	C1332166	NCT01395537	Terminated	Phase 1/Phase 2	Research Cancelled	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Adenocarcinoma of the gastroesophageal junction	C1332166	NCT01395537	Terminated	Phase 1/Phase 2	Research Cancelled	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Lapatinib	Adenocarcinoma of the gastroesophageal junction	C1332166	NCT01395537	Terminated	Phase 1/Phase 2	Research Cancelled	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Doxycycline	Colorectal Carcinoma	C0009402	NCT01418742	Terminated	Phase 2	Recruitement did not meet expectations. Prev. differentiation of RAS-wild-type and mutated RAS    are not in accordance with the scientific rank anymore.	C2699808	Doxycycline anhydrous
Hydroxychloroquine	Secondary malignant neoplasm of bone	C0153690	NCT01417403	Terminated	Phase 1	Recently published data that has shown HCQ to be safe when combined with chemo and or    radiation at even higher doses than what is used in this study.	C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Hydroxychloroquine	unspecified adult solid tumor, protocol specific	C0279004	NCT01417403	Terminated	Phase 1	Recently published data that has shown HCQ to be safe when combined with chemo and or    radiation at even higher doses than what is used in this study.	C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Trastuzumab	HER-2 positive breast cancer	C1699634	NCT01388647	Terminated	Phase 1/Phase 2	Closed early due to increased hematologic toxicity and possible reduced efficacy	C5187552	trastuzumab-anns
Carboplatin	HER-2 positive breast cancer	C1699634	NCT01388647	Terminated	Phase 1/Phase 2	Closed early due to increased hematologic toxicity and possible reduced efficacy	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Oxaliplatin	Nasopharyngeal carcinoma	C2931822	NCT01403259	Terminated	Phase 2	poor accrual of eligible patients	C0069717	oxaliplatine
Cyclophosphamide	Glioblastoma	C0017636	NCT01403285	Terminated	Phase 1	Due to poor accrual. This decision was taken without any safety reasons. Since beginning of    the study (June 2011) only six patients were enrolled.	C0010583	Cyclophosphamidum
Imiquimod	Glioblastoma	C0017636	NCT01403285	Terminated	Phase 1	Due to poor accrual. This decision was taken without any safety reasons. Since beginning of    the study (June 2011) only six patients were enrolled.	C0165032	1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
Tigecycline	Dialysis Catheter Infection	C1400574	NCT01483872	Terminated	Phase 3	The study was stopped due to poor enrollment.	C1260298	(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Heparin	Dialysis Catheter Infection	C1400574	NCT01483872	Terminated	Phase 3	The study was stopped due to poor enrollment.	C0019134	Heparina
Milnacipran	Irritable Bowel Syndrome	C0022104	NCT01471379	Terminated	Phase 2	Due to recruitment difficulties the study is terminated.	C1533126	(+-)-Milnacipran
Doxorubicin	colon cancer liver metastasis	C0742558	NCT01464593	Terminated	Phase 2	trial design contingent on RFA optimization	C0013089	Doxorubicine
Lansoprazole	Eosinophilic esophagitis	C0341106	NCT01479231	Withdrawn	Phase 1/Phase 2	Souces of funding have been terminated	C0050940	Lansoprazolum
Lansoprazole	Deglutition Disorders	C0011168	NCT01479231	Withdrawn	Phase 1/Phase 2	Souces of funding have been terminated	C0050940	Lansoprazolum
Pregabalin	Neuralgia	C0027796	NCT01485094	Terminated	Phase 2	The trial was early terminated after it was concluded that there was no added benefit from    exposing further participants after an unblinded interim analysis.	C0657912	(S)-3-Isobutyl GABA
Tenofovir	HIV-1 infection	C2363741	NCT01489046	Terminated	Phase 2		C0673857	Bis(POC)PMPA
Efavirenz	HIV-1 infection	C2363741	NCT01489046	Terminated	Phase 2		C0674428	(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
Lamivudine	HIV-1 infection	C2363741	NCT01489046	Terminated	Phase 2		C0209738	Lamivudina
Tacrolimus	Acute leukemia in remission	C0686586	NCT01488253	Terminated	Phase 2	We could not receive the support from the national medical insurance owing to the changed    policy of the government for clincal trials.	C0771204	Tacrolimus anhydrous
Sirolimus	Acute leukemia in remission	C0686586	NCT01488253	Terminated	Phase 2	We could not receive the support from the national medical insurance owing to the changed    policy of the government for clincal trials.	C0072980	Sirolimús
Everolimus	Acute leukemia in remission	C0686586	NCT01488253	Terminated	Phase 2	We could not receive the support from the national medical insurance owing to the changed    policy of the government for clincal trials.	C0541315	évérolimus
Doxorubicin	Solid tumour	C0280100	NCT01490047	Withdrawn	Phase 1		C0013089	Doxorubicine
Diclofenac	Kidney Failure, Chronic	C0022661	NCT01481610	Terminated	Phase 2	Interim analysis shows harma to one of the study arms.	C0012091	Diclofenac acid
Lumiracoxib	Kidney Failure, Chronic	C0022661	NCT01481610	Terminated	Phase 2	Interim analysis shows harma to one of the study arms.	C1176415	lumiracoxib
Spironolactone	Type 2 diabetes mellitus with established diabetic nephropathy	C0837031	NCT01488877	Terminated	Phase 1	See termination reason in detailed description.	C0037982	Espironolactona
Paromomycin	Leishmaniasis, Cutaneous	C0023283	NCT01494350	Terminated	Phase 2	This study was closed prematurely due study team travel restrictions.	C0030576	Paromomicina
Citalopram	Anxiety	C0003467	NCT01522092	Withdrawn	Phase 3	Study was not given ethical approval- a alternative protocol required	C0008845	Citalopramum
Vorinostat	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	C0334634	NCT01500538	Terminated	Phase 2	Poor recruitment rate	C0672708	Vorinostatum
Ezogabine	Epilepsy	C0014544	NCT01494584	Terminated	Phase 2	Terminated after placing the study on hold at the request of the FDA	C0530684	ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate
Vorinostat	Multiple Myeloma	C0026764	NCT01501370	Withdrawn	Phase 2		C0672708	Vorinostatum
Ketamine	Bipolar Disorder	C0005586	NCT01504659	Suspended	Phase 2/Phase 3	Protocol Revisions	C0022614	Kétamine
Atorvastatin	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT01477853	Terminated	Phase 3		C0286651	atorvastatine
Bortezomib	Malignant tumor of colon	C0007102	NCT01504477	Terminated	Phase 1/Phase 2	Low accrual--unable to meet accrual goals	C1176309	[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
Bexarotene	Solid tumour	C0280100	NCT01504490	Terminated	Phase 1	Drug no longer available	C0765273	p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
Bexarotene	Multiple Myeloma	C0026764	NCT01504490	Terminated	Phase 1	Drug no longer available	C0765273	p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
Fludarabine	Leukemia, Myelocytic, Acute	C0023467	NCT01478074	Withdrawn	Phase 1	The treatment planned was determined to be of low feasibility as no subject was found eligible    and able to enroll after screening over 30 subjects	C0059985	Fludarabinum
Lidocaine	Interstitial Cystitis	C0282488	NCT01475253	Terminated	Phase 2	This study was not enrolled completely and was terminated.	C0023660	Lidocaína
Sirolimus	Endocrine Breast Diseases	C1449718	NCT01499160	Terminated	Phase 2	low accrual	C0072980	Sirolimús
Letrozole	Endocrine Breast Diseases	C1449718	NCT01499160	Terminated	Phase 2	low accrual	C0246421	Letrozol
Lapatinib	Endocrine Breast Diseases	C1449718	NCT01499160	Terminated	Phase 2	low accrual	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Everolimus	Endocrine Breast Diseases	C1449718	NCT01499160	Terminated	Phase 2	low accrual	C0541315	évérolimus
Sirolimus	Neoplasm Metastasis	C0027627	NCT01499160	Terminated	Phase 2	low accrual	C0072980	Sirolimús
Letrozole	Neoplasm Metastasis	C0027627	NCT01499160	Terminated	Phase 2	low accrual	C0246421	Letrozol
Lapatinib	Neoplasm Metastasis	C0027627	NCT01499160	Terminated	Phase 2	low accrual	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Everolimus	Neoplasm Metastasis	C0027627	NCT01499160	Terminated	Phase 2	low accrual	C0541315	évérolimus
Bevacizumab	Metastatic melanoma	C0278883	NCT01495988	Terminated	Phase 2	Slow accrual; toxicity; change in priorities	C0796392	Anti-VEGF monoclonal antibody
Pravastatin	HIV-1 infection	C2363741	NCT01515813	Withdrawn	Phase 2	On 05/08/12, team working on revising protocol and re-open study under version 2.0	C0085542	Pravastatine
Tenofovir	HIV-1 infection	C2363741	NCT01515813	Withdrawn	Phase 2	On 05/08/12, team working on revising protocol and re-open study under version 2.0	C0673857	Bis(POC)PMPA
Emtricitabine	HIV-1 infection	C2363741	NCT01515813	Withdrawn	Phase 2	On 05/08/12, team working on revising protocol and re-open study under version 2.0	C0909839	5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
Irinotecan	Neuroblastoma	C0027819	NCT01505608	Terminated	Phase 1/Phase 2	Lack of Enrollment	C0123931	(+)-Irinotecan
Dacarbazine	Neuroblastoma	C0027819	NCT01505608	Terminated	Phase 1/Phase 2	Lack of Enrollment	C0010927	DTIC
Temozolomide	Neuroblastoma	C0027819	NCT01505608	Terminated	Phase 1/Phase 2	Lack of Enrollment	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Bevacizumab	Secondary malignant neoplasm of liver	C0494165	NCT01508000	Terminated	Phase 2	Low or poor accrual	C0796392	Anti-VEGF monoclonal antibody
Cholecalciferol	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute myelomonocytic leukemia (M4)	C0279627	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult erythroleukemia (M6a)	C1541339	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult pure erythroid leukemia (M6b)	C1541340	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	untreated adult acute myeloid leukemia	C0279089	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute monoblastic leukemia (M5a)	C0279629	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute monocytic leukemia (M5b)	C0280634	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Cholecalciferol	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT01521936	Terminated	Phase 2	Lack of funding	C0008318	Colecalciferolum
Aripiprazole	Bipolar Disorder	C0005586	NCT01520350	Terminated	Phase 3	recruitment issues	C0299792	Aripiprazolum
Aripiprazole	Depressive episode, unspecified	C0349217	NCT01520350	Terminated	Phase 3	recruitment issues	C0299792	Aripiprazolum
Alemtuzumab	leukemia	C0023418	NCT01518153	Terminated	Phase 2	Objectives not met.	C0383429	Alemtuzumab
Methotrexate	leukemia	C0023418	NCT01518153	Terminated	Phase 2	Objectives not met.	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Tacrolimus	leukemia	C0023418	NCT01518153	Terminated	Phase 2	Objectives not met.	C0771204	Tacrolimus anhydrous
Melphalan	leukemia	C0023418	NCT01518153	Terminated	Phase 2	Objectives not met.	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Fludarabine	leukemia	C0023418	NCT01518153	Terminated	Phase 2	Objectives not met.	C0059985	Fludarabinum
Azacitidine	leukemia	C0023418	NCT01542684	Terminated	Phase 2	Slow Accrual	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Cyclophosphamide	Metastatic melanoma	C0278883	NCT01542255	Terminated	Phase 2	Low accrual not allowing to support statistical endpoints	C0010583	Cyclophosphamidum
Vinblastine	Metastatic melanoma	C0278883	NCT01542255	Terminated	Phase 2	Low accrual not allowing to support statistical endpoints	C0042670	Vinblastina
Vorinostat	Multiple Myeloma	C0026764	NCT01492881	Withdrawn	Phase 2	Doxil is currently unavailable	C0672708	Vorinostatum
Pioglitazone	Opioid-Related Disorders	C0027412	NCT01517165	Terminated	Phase 1		C0071097	(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
Testosterone	Multiple Sclerosis	C0026769	NCT01516554	Terminated	Phase 2	Poor recruitment	C0039601	Testostérone
Methyltestosterone	Multiple Sclerosis	C0026769	NCT01516554	Terminated	Phase 2	Poor recruitment	C0025826	Methyltestosteronum
Erlotinib	Non-small cell lung cancer recurrent	C0278517	NCT01515969	Suspended	Phase 1	Interim analysis of PK and toxicity data	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib	Non-small cell lung cancer metastatic	C0278987	NCT01515969	Suspended	Phase 1	Interim analysis of PK and toxicity data	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Pegfilgrastim	Multiple Myeloma	C0026764	NCT01537861	Terminated	Phase 0	Unexpected toxicity (2 early deaths)	C4735048	pegfilgrastim-cbqv
Hydroxychloroquine	Kidney Failure, Chronic	C0022661	NCT01537315	Terminated	Phase 2	lack of funding	C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Penciclovir	Meniere Disease	C0025281	NCT01526408	Terminated	Phase 3	HRI no longer conducting research.	C0164815	Penciclovirum
Famciclovir	Meniere Disease	C0025281	NCT01526408	Terminated	Phase 3	HRI no longer conducting research.	C0209227	9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
Vitamin C	Disorder of vitamin C	C1272557	NCT01537094	Withdrawn	Phase 2	Unable to obtain funding to initiate the study. No subjects were enrolled.	C0003968	Acidum ascorbicum
Vitamin C	Growth Hormone Secretion Abnormality	C3536718	NCT01537094	Withdrawn	Phase 2	Unable to obtain funding to initiate the study. No subjects were enrolled.	C0003968	Acidum ascorbicum
Sirolimus	Acinar cell carcinoma of pancreas	C0279661	NCT01537107	Suspended	Phase 1		C0072980	Sirolimús
Everolimus	Acinar cell carcinoma of pancreas	C0279661	NCT01537107	Suspended	Phase 1		C0541315	évérolimus
Sirolimus	duct cell adenocarcinoma of the pancreas	C0279176	NCT01537107	Suspended	Phase 1		C0072980	Sirolimús
Everolimus	duct cell adenocarcinoma of the pancreas	C0279176	NCT01537107	Suspended	Phase 1		C0541315	évérolimus
Sirolimus	Pancreatic carcinoma recurrent	C0854777	NCT01537107	Suspended	Phase 1		C0072980	Sirolimús
Everolimus	Pancreatic carcinoma recurrent	C0854777	NCT01537107	Suspended	Phase 1		C0541315	évérolimus
Sirolimus	Stage IV Pancreatic Cancer	C1167725	NCT01537107	Suspended	Phase 1		C0072980	Sirolimús
Everolimus	Stage IV Pancreatic Cancer	C1167725	NCT01537107	Suspended	Phase 1		C0541315	évérolimus
Sirolimus	unspecified adult solid tumor, protocol specific	C0279004	NCT01537107	Suspended	Phase 1		C0072980	Sirolimús
Everolimus	unspecified adult solid tumor, protocol specific	C0279004	NCT01537107	Suspended	Phase 1		C0541315	évérolimus
Bupivacaine	Shoulder Pain	C0037011	NCT01538459	Withdrawn	Phase 3		C0006400	Bupivacaina
Dexamethasone	Shoulder Pain	C0037011	NCT01538459	Withdrawn	Phase 3		C0011777	Dexaméthasone
Bupivacaine	Shoulder Injuries	C0149776	NCT01538459	Withdrawn	Phase 3		C0006400	Bupivacaina
Dexamethasone	Shoulder Injuries	C0149776	NCT01538459	Withdrawn	Phase 3		C0011777	Dexaméthasone
Bupivacaine	Disorder of shoulder	C1290859	NCT01538459	Withdrawn	Phase 3		C0006400	Bupivacaina
Dexamethasone	Disorder of shoulder	C1290859	NCT01538459	Withdrawn	Phase 3		C0011777	Dexaméthasone
Bupivacaine	Disorder of rotator cuff	C1532240	NCT01538459	Withdrawn	Phase 3		C0006400	Bupivacaina
Dexamethasone	Disorder of rotator cuff	C1532240	NCT01538459	Withdrawn	Phase 3		C0011777	Dexaméthasone
Bupivacaine	Disorder of tendon of biceps	C1996944	NCT01538459	Withdrawn	Phase 3		C0006400	Bupivacaina
Dexamethasone	Disorder of tendon of biceps	C1996944	NCT01538459	Withdrawn	Phase 3		C0011777	Dexaméthasone
L-Carnitine	Ulcerative Colitis	C0009324	NCT01538251	Terminated	Phase 3	Evidence of very low probability to success. No safety issues.	C0087163	Levocarnitine
Rituximab	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C5195655	rituximab-pvvr
Cyclophosphamide	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0010583	Cyclophosphamidum
Vincristine	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0042679	Vincristina
Doxorubicin	contiguous stage II adult diffuse large cell lymphoma	C0677695	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0013089	Doxorubicine
Rituximab	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C5195655	rituximab-pvvr
Cyclophosphamide	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0010583	Cyclophosphamidum
Vincristine	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0042679	Vincristina
Doxorubicin	noncontiguous stage II adult diffuse large cell lymphoma	C0677709	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0013089	Doxorubicine
Rituximab	stage I adult diffuse large cell lymphoma	C0279960	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C5195655	rituximab-pvvr
Cyclophosphamide	stage I adult diffuse large cell lymphoma	C0279960	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0010583	Cyclophosphamidum
Vincristine	stage I adult diffuse large cell lymphoma	C0279960	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0042679	Vincristina
Doxorubicin	stage I adult diffuse large cell lymphoma	C0279960	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0013089	Doxorubicine
Rituximab	stage III adult diffuse large cell lymphoma	C0280162	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C5195655	rituximab-pvvr
Cyclophosphamide	stage III adult diffuse large cell lymphoma	C0280162	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0010583	Cyclophosphamidum
Vincristine	stage III adult diffuse large cell lymphoma	C0280162	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0042679	Vincristina
Doxorubicin	stage III adult diffuse large cell lymphoma	C0280162	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0013089	Doxorubicine
Rituximab	stage IV adult diffuse large cell lymphoma	C0280175	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C5195655	rituximab-pvvr
Cyclophosphamide	stage IV adult diffuse large cell lymphoma	C0280175	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0010583	Cyclophosphamidum
Vincristine	stage IV adult diffuse large cell lymphoma	C0280175	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0042679	Vincristina
Doxorubicin	stage IV adult diffuse large cell lymphoma	C0280175	NCT01539174	Withdrawn	Phase 2	No Funding Source and Competing Trials	C0013089	Doxorubicine
Atorvastatin	Psoriasis	C0033860	NCT01527097	Withdrawn	Phase 3	We strongly feel that the ability to recruit the required number of patients is very low and    thus decided to stop the study.	C0286651	atorvastatine
Panobinostat	Malignant neoplasm of stomach stage IV	C0278498	NCT01528501	Terminated	Phase 2	medical/ethical reasons	C1998098	(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Bevacizumab	colon cancer liver metastasis	C0742558	NCT01540435	Withdrawn	Phase 2	insufficient recruitment	C0796392	Anti-VEGF monoclonal antibody
Imiquimod	melanoma	C0025202	NCT01543464	Terminated	Phase 2	Diminished rectruitment	C0165032	1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
Temozolomide	melanoma	C0025202	NCT01543464	Terminated	Phase 2	Diminished rectruitment	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Norepinephrine	Radiodermatitis	C0034561	NCT01544504	Withdrawn	Phase 1/Phase 2	The principal investigator withdrew from the study. The study was withdrawn because a    qualified replacement was not available.	C0028351	(-)-noradrenaline
Eptifibatide	Pneumonia	C0032285	NCT01532544	Suspended	Phase 2		C0253563	Eptifibatida
Heparin	Pneumonia	C0032285	NCT01532544	Suspended	Phase 2		C0019134	Heparina
Tamsulosin	Benign Prostatic Hyperplasia	C1704272	NCT01534351	Terminated	Phase 3	Business Reasons	C0257343	(-)-tamsulosin
Finasteride	Benign Prostatic Hyperplasia	C1704272	NCT01534351	Terminated	Phase 3	Business Reasons	C0060389	Finasterida
Cyclophosphamide	leukemia	C0023418	NCT01532635	Terminated	Phase 2	Slow accrual	C0010583	Cyclophosphamidum
Mycophenolate mofetil	leukemia	C0023418	NCT01532635	Terminated	Phase 2	Slow accrual	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	leukemia	C0023418	NCT01532635	Terminated	Phase 2	Slow accrual	C0771204	Tacrolimus anhydrous
Mycophenolic acid	leukemia	C0023418	NCT01532635	Terminated	Phase 2	Slow accrual	C0026933	Mycophenolsäure
Cyclophosphamide	Hodgkin Disease	C0019829	NCT01532635	Terminated	Phase 2	Slow accrual	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Hodgkin Disease	C0019829	NCT01532635	Terminated	Phase 2	Slow accrual	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Hodgkin Disease	C0019829	NCT01532635	Terminated	Phase 2	Slow accrual	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Hodgkin Disease	C0019829	NCT01532635	Terminated	Phase 2	Slow accrual	C0026933	Mycophenolsäure
Erythromycin	Preterm premature rupture of membranes (disorder)	C0729264	NCT01556334	Withdrawn	Phase 3	Terminated before starting due to need for IND determined by FDA.	C0014806	Erythromycinum
Cisplatin	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	C0008838	cisplatino
Etoposide	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Imatinib	Scleroderma	C0011644	NCT01545427	Terminated	Phase 2	Frequent adverse events occurred early in treatment with poor tolerability.	C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Paclitaxel	Solid tumour	C0280100	NCT01548924	Terminated	Phase 1	Drug toxicity	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Torasemide	Renal Insufficiency	C1565489	NCT01558674	Terminated	Phase 1		C0076840	Torasémide
Furosemide	Renal Insufficiency	C1565489	NCT01558674	Terminated	Phase 1		C0016860	Furosemidu
Varenicline	Nicotine Dependence	C0028043	NCT01560507	Terminated	Phase 2/Phase 3	Low Recruitment	C1569608	vareniclina
Alendronic acid	Osteoporosis	C0029456	NCT01552122	Withdrawn	Phase 3		C0771311	Acide Alendronique
Calcium carbonate	Osteoporosis	C0029456	NCT01552122	Withdrawn	Phase 3		C0006681	Calcio carbonato
Acetaminophen	Headache	C0018681	NCT01552798	Terminated	Phase 3		C0000970	Acetaminofén
Salicylic acid	Headache	C0018681	NCT01552798	Terminated	Phase 3		C0036079	ácido salicílico
Acetylsalicylic acid	Headache	C0018681	NCT01552798	Terminated	Phase 3		C0004057	Aspirina
Loperamide	Clostridium difficile diarrhea	C0235952	NCT01570634	Terminated	Phase 2	Study was stopped for slow enrollment - only 2 patients, no evaluable results	C0023992	Loperamidum
Exenatide	Septic Shock	C0036983	NCT01573806	Withdrawn	Phase 1/Phase 2	No funding	C0167117	Exenatida
Exenatide	Inflammation	C0021368	NCT01573806	Withdrawn	Phase 1/Phase 2	No funding	C0167117	Exenatida
Memantine	Asperger Syndrome	C0236792	NCT01592773	Terminated	Phase 2	Terminated because primary efficacy parameter failed to demonstrate statistically significant    difference between memantine and placebo in controlled trials	C0025242	Memantina
Fluconazole	CRYPTOCOCCAL INFECTION DISSEMINATED	C0742909	NCT01562132	Terminated	Phase 2	Stopped in accordance with pre-specified stopping rules for poor recruitment.	C0016277	Fluconazol
Flucytosine	CRYPTOCOCCAL INFECTION DISSEMINATED	C0742909	NCT01562132	Terminated	Phase 2	Stopped in accordance with pre-specified stopping rules for poor recruitment.	C0016278	Flucytosinum
Metformin	Prostate carcinoma	C0600139	NCT01561482	Withdrawn	Phase 2	Study closed due to slow/low enrollment; no subjects were enrolled.	C0025598	Metformina
Simvastatin	Prostate carcinoma	C0600139	NCT01561482	Withdrawn	Phase 2	Study closed due to slow/low enrollment; no subjects were enrolled.	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Dexmedetomidine	Subarachnoid Hemorrhage, Aneurysmal	C0751530	NCT01565590	Terminated	Phase 3	Slow enrollment along with new competing studies, investigators decided to stop study	C0113293	(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
Carboplatin	Malignant neoplasm of lung	C0242379	NCT01562301	Withdrawn	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Docetaxel	Malignant neoplasm of lung	C0242379	NCT01562301	Withdrawn	Phase 1		C0246415	Docetaxel
Carboplatin	Chemotherapeutic Agent Toxicity	C1707372	NCT01562301	Withdrawn	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Docetaxel	Chemotherapeutic Agent Toxicity	C1707372	NCT01562301	Withdrawn	Phase 1		C0246415	Docetaxel
Cisplatin	Non-Small Cell Lung Carcinoma	C0007131	NCT01565772	Terminated	Phase 1	Slow accrual	C0008838	cisplatino
Etoposide	Non-Small Cell Lung Carcinoma	C0007131	NCT01565772	Terminated	Phase 1	Slow accrual	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Rasburicase	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	contiguous stage II adult Burkitt's lymphoma	C0677696	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	contiguous stage II adult Burkitt's lymphoma	C0677696	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	de novo myelodysplastic syndromes	C0280451	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	de novo myelodysplastic syndromes	C0280451	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	noncontiguous stage II adult Burkitt's lymphoma	C0677710	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	noncontiguous stage II adult Burkitt's lymphoma	C0677710	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	previously treated myelodysplastic syndromes	C0280744	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	previously treated myelodysplastic syndromes	C0280744	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	recurrent adult acute myeloid leukemia	C0278780	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	recurrent adult acute myeloid leukemia	C0278780	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	recurrent adult Burkitt's lymphoma	C0280192	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	recurrent adult Burkitt's lymphoma	C0280192	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	stage I adult Burkitt's lymphoma	C0279963	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	stage I adult Burkitt's lymphoma	C0279963	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	stage III adult Burkitt's lymphoma	C0280166	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	stage III adult Burkitt's lymphoma	C0280166	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	stage IV adult Burkitt's lymphoma	C0280179	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	stage IV adult Burkitt's lymphoma	C0280179	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	untreated adult acute lymphoblastic leukemia	C0279088	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	untreated adult acute lymphoblastic leukemia	C0279088	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	untreated adult acute myeloid leukemia	C0279089	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	untreated adult acute myeloid leukemia	C0279089	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Rasburicase	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01564277	Terminated	Phase 2	low accrual	C0937932	Rasburicasa
Allopurinol	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01564277	Terminated	Phase 2	low accrual	C0002144	1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Ketoconazole	Granulosa cell tumor of the ovary	C1370419	NCT01584297	Terminated	Phase 2	Insufficient recruitment rate	C0022625	Ketoconazol
Bupivacaine	Chronic pain	C0150055	NCT01584947	Terminated	Phase 2	Because of a very slow patient recruitment.	C0006400	Bupivacaina
Adalimumab	Inflammatory disease of mucous membrane	C0333355	NCT01562951	Terminated	Phase 3	Not enough patient population according to selection criteria to complete the study	C5195654	adalimumab-bwwd
L-Carnitine	Ulcerative Colitis	C0009324	NCT01567956	Terminated	Phase 3	Evidence of very low probability to success. No safety issues	C0087163	Levocarnitine
Imatinib	Pulmonary Hypertension	C0020542	NCT01568645	Withdrawn	Phase 1		C0935989	α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
Carvedilol	Pulmonary Hypertension	C0020542	NCT01568645	Withdrawn	Phase 1		C0054836	(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
L-Carnitine	Postpoliomyelitis Syndrome	C0080040	NCT01549847	Withdrawn	Phase 3	Study was not approved by Health Surveillance Agency	C0087163	Levocarnitine
Aminolevulinic acid	adult giant cell glioblastoma	C1541316	NCT01575275	Terminated	Phase 2	Drugs unavailable	C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	adult glioblastoma	C0278878	NCT01575275	Terminated	Phase 2	Drugs unavailable	C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	adult gliosarcoma	C1541317	NCT01575275	Terminated	Phase 2	Drugs unavailable	C0002563	ácido 5-aminolevulínico
Aminolevulinic acid	recurrent adult brain tumor	C0278786	NCT01575275	Terminated	Phase 2	Drugs unavailable	C0002563	ácido 5-aminolevulínico
Ropivacaine	Appendicitis	C0003615	NCT01575028	Terminated	Phase 2	The study was allowed to expire due to changes in standard care for the patient population    within the NCH institution.	C0073571	Ropivacainum
Tobramycin	Pneumonia, Bacterial	C0004626	NCT01570192	Terminated	Phase 2	NIAID terminated the study due to low subject enrollment	C0040341	3'-Deoxykanamycin B
Meropenem	Pneumonia, Bacterial	C0004626	NCT01570192	Terminated	Phase 2	NIAID terminated the study due to low subject enrollment	C0066005	Meropenemum
Vitamin C	Shock	C0036974	NCT01587963	Terminated	Phase 2	PI's additional responsibilities and time commitments prevent him from completing this    clinical trial so he decided to close the study prematurely	C0003968	Acidum ascorbicum
Dipyridamole	Rheumatoid Arthritis	C0003873	NCT01612377	Terminated	Phase 2	missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg	C0012582	Dipyridamolum
Pentoxifylline	Diabetes Mellitus, Insulin-Dependent	C0011854	NCT01603121	Terminated	Phase 1/Phase 2	Unable to enroll sufficient number of subjects	C0030899	Pentoxifilina
Gemcitabine	unspecified adult solid tumor, protocol specific	C0279004	NCT01573780	Terminated	Phase 1	Sponsor did not have funds to continue study	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Hydrocortisone	Phobic anxiety disorder	C0349231	NCT01574014	Terminated	Phase 2	Recruiting problems	C0020268	(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
Glucagon recombinant	Short Bowel Syndrome	C0036992	NCT01573286	Terminated	Phase 1/Phase 2	GLP-2 Drug product stability concerns	C0017687	Glucagon
Zonisamide	alcohol use disorder	C0001956	NCT01566370	Terminated	Phase 2	recruitment infeasible	C0078844	Benzo[d]isoxazol-3-yl-methanesulfonamide
Zonisamide	Bipolar Disorder	C0005586	NCT01566370	Terminated	Phase 2	recruitment infeasible	C0078844	Benzo[d]isoxazol-3-yl-methanesulfonamide
Ganirelix	Infertility	C0021359	NCT01599494	Withdrawn	Phase 3		C0073629	Ganirelix
Rivaroxaban	Heparin-induced thrombocytopenia	C0272285	NCT01598168	Terminated	Phase 3	slow recruitment	C1739768	Rivaroxaban
Folic Acid	Pervasive Development Disorder	C0524528	NCT01602016	Terminated	Phase 2	Non-compliance	C0016410	Folic acid
Leucovorin	Pervasive Development Disorder	C0524528	NCT01602016	Terminated	Phase 2	Non-compliance	C0023413	Folinate
Levoleucovorin	Pervasive Development Disorder	C0524528	NCT01602016	Terminated	Phase 2	Non-compliance	C2721771	ácido levofolínico
Methamphetamine	Methamphetamine dependence	C1533217	NCT01601717	Withdrawn	Phase 1		C0025611	Metamfetamine
Methamphetamine	Methamphetamine abuse	C1456624	NCT01601717	Withdrawn	Phase 1		C0025611	Metamfetamine
Ertapenem	Endometritis	C0014179	NCT01587495	Terminated	Phase 1	study terminated due to low subject accrual	C1120106	(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
Finasteride	Retinal Diseases	C0035309	NCT01585441	Terminated	Phase 2	This study was terminated early due to lack of enrollment.	C0060389	Finasterida
Cetuximab	Malignant neoplasm of stomach	C0024623	NCT01611506	Terminated	Phase 1/Phase 2	Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in    advanced gastric cancer in the overall patient population)	C0995188	Cétuximab
Cisplatin	Malignant neoplasm of stomach	C0024623	NCT01611506	Terminated	Phase 1/Phase 2	Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in    advanced gastric cancer in the overall patient population)	C0008838	cisplatino
Capsaicin	Hyperalgesia	C0020429	NCT01615510	Terminated	Phase 1		C0006931	Capsaicina
Capsaicin	Allodynia	C0458247	NCT01615510	Terminated	Phase 1		C0006931	Capsaicina
Capsaicin	Pain	C0030193	NCT01615510	Terminated	Phase 1		C0006931	Capsaicina
Timolol	Optic Neuropathy, Ischemic	C0155305	NCT01607671	Withdrawn	Phase 1	Unable to recruit participants from recruiting sites.	C0040233	Timololo
Timolol	Anterior Ischemic Optic Neuropathy	C0751711	NCT01607671	Withdrawn	Phase 1	Unable to recruit participants from recruiting sites.	C0040233	Timololo
Letrozole	Medical abortion, complete or unspecified, without complication	C0495144	NCT01615211	Terminated	Phase 2	No access to study drug Trilostan. Company closed down	C0246421	Letrozol
Trilostane	Medical abortion, complete or unspecified, without complication	C0495144	NCT01615211	Terminated	Phase 2	No access to study drug Trilostan. Company closed down	C0077144	Trilostanum
Misoprostol	Missed abortion	C0000814	NCT01615224	Suspended	Phase 2/Phase 3	No funding	C0085174	Misoprostolum
Mefloquine	Malaria	C0024530	NCT01615822	Terminated	Phase 1	Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single    dose cure due to low probability of success	C0025153	Mefloquinum
Folic Acid	Secondary malignant neoplasm of liver	C0494165	NCT01646554	Withdrawn	Phase 2/Phase 3		C0016410	Folic acid
Oxaliplatin	Secondary malignant neoplasm of liver	C0494165	NCT01646554	Withdrawn	Phase 2/Phase 3		C0069717	oxaliplatine
Levoleucovorin	Secondary malignant neoplasm of liver	C0494165	NCT01646554	Withdrawn	Phase 2/Phase 3		C2721771	ácido levofolínico
Udenafil	Heart Failure, Systolic	C1135191	NCT01646515	Terminated	Phase 3	Substantial benefit was observed in the active treatment group	C1742789	Udenafil
Metformin	Polycystic Ovary Syndrome	C0032460	NCT01638988	Withdrawn	Phase 3	Previous studies have been done regarding same condition	C0025598	Metformina
Clomifene	Polycystic Ovary Syndrome	C0032460	NCT01638988	Withdrawn	Phase 3	Previous studies have been done regarding same condition	C0009008	2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine
Ezogabine	Epilepsy	C0014544	NCT01648101	Terminated	Phase 3	Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam	C0530684	ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate
Gemcitabine	anterior urethral cancer	C0279930	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	anterior urethral cancer	C0279930	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	anterior urethral cancer	C0279930	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	anterior urethral cancer	C0279930	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	anterior urethral cancer	C0279930	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Gemcitabine	Transitional cell cancer of the renal pelvis and ureter localised	C0280240	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Transitional cell cancer of the renal pelvis and ureter localised	C0280240	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	Transitional cell cancer of the renal pelvis and ureter localised	C0280240	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	Transitional cell cancer of the renal pelvis and ureter localised	C0280240	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	Transitional cell cancer of the renal pelvis and ureter localised	C0280240	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Gemcitabine	posterior urethral cancer	C0279931	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	posterior urethral cancer	C0279931	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	posterior urethral cancer	C0279931	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	posterior urethral cancer	C0279931	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	posterior urethral cancer	C0279931	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Gemcitabine	Recurrent Urethral Cancer	C0279912	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Recurrent Urethral Cancer	C0279912	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	Recurrent Urethral Cancer	C0279912	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	Recurrent Urethral Cancer	C0279912	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	Recurrent Urethral Cancer	C0279912	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Gemcitabine	Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	C0280281	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	C0280281	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	C0280281	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	C0280281	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	Regional Urothelial Carcinoma of the Renal Pelvis and Ureter	C0280281	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Gemcitabine	Bladder cancer stage III	C0278824	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Bladder cancer stage III	C0278824	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	Bladder cancer stage III	C0278824	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	Bladder cancer stage III	C0278824	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	Bladder cancer stage III	C0278824	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Gemcitabine	Malignant neoplasm of ureter	C0153619	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	Malignant neoplasm of ureter	C0153619	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	Malignant neoplasm of ureter	C0153619	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	Malignant neoplasm of ureter	C0153619	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	Malignant neoplasm of ureter	C0153619	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Gemcitabine	urethral carcinoma associated with invasive bladder cancer	C0279932	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Cisplatin	urethral carcinoma associated with invasive bladder cancer	C0279932	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0008838	cisplatino
Methotrexate	urethral carcinoma associated with invasive bladder cancer	C0279932	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Vinblastine	urethral carcinoma associated with invasive bladder cancer	C0279932	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0042670	Vinblastina
Doxorubicin	urethral carcinoma associated with invasive bladder cancer	C0279932	NCT01639521	Withdrawn	Phase 2	Lack of funding	C0013089	Doxorubicine
Sorafenib	Malignant neoplasm of lung	C0242379	NCT01636921	Withdrawn	Phase 2	Terminated with slow accrual in early phase of study.	C1516119	Sorafenibum
Vidarabine	previously treated myelodysplastic syndromes	C0280744	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	previously treated myelodysplastic syndromes	C0280744	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	previously treated myelodysplastic syndromes	C0280744	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	previously treated myelodysplastic syndromes	C0280744	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	previously treated myelodysplastic syndromes	C0280744	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	previously treated myelodysplastic syndromes	C0280744	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult acute lymphoblastic leukemia	C0278785	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult acute myeloid leukemia	C0278780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult acute myeloid leukemia	C0278780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult acute myeloid leukemia	C0278780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult acute myeloid leukemia	C0278780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult acute myeloid leukemia	C0278780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult acute myeloid leukemia	C0278780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult Burkitt's lymphoma	C0280192	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult Burkitt's lymphoma	C0280192	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult Burkitt's lymphoma	C0280192	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult Burkitt's lymphoma	C0280192	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult Burkitt's lymphoma	C0280192	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult Burkitt's lymphoma	C0280192	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult diffuse large cell lymphoma	C0280188	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult diffuse large cell lymphoma	C0280188	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult diffuse large cell lymphoma	C0280188	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult diffuse large cell lymphoma	C0280188	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult diffuse large cell lymphoma	C0280188	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult diffuse large cell lymphoma	C0280188	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult diffuse mixed cell lymphoma	C0280187	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult diffuse small cleaved cell lymphoma	C0280186	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult grade III lymphomatoid granulomatosis	C1541469	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult Hodgkin's lymphoma	C0278530	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult Hodgkin's lymphoma	C0278530	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult Hodgkin's lymphoma	C0278530	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult Hodgkin's lymphoma	C0278530	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult Hodgkin's lymphoma	C0278530	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult Hodgkin's lymphoma	C0278530	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult immunoblastic large cell lymphoma	C0280190	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent adult lymphoblastic lymphoma	C0280191	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent adult lymphoblastic lymphoma	C0280191	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent adult lymphoblastic lymphoma	C0280191	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent adult lymphoblastic lymphoma	C0280191	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent adult lymphoblastic lymphoma	C0280191	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent adult lymphoblastic lymphoma	C0280191	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Adult T-cell lymphoma/leukaemia recurrent	C0280427	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Cutaneous T-cell lymphoma recurrent	C0278580	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent grade 1 follicular lymphoma	C0280182	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent grade 1 follicular lymphoma	C0280182	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent grade 1 follicular lymphoma	C0280182	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent grade 1 follicular lymphoma	C0280182	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent grade 1 follicular lymphoma	C0280182	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent grade 1 follicular lymphoma	C0280182	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent grade 2 follicular lymphoma	C0280183	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent grade 2 follicular lymphoma	C0280183	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent grade 2 follicular lymphoma	C0280183	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent grade 2 follicular lymphoma	C0280183	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent grade 2 follicular lymphoma	C0280183	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent grade 2 follicular lymphoma	C0280183	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	recurrent grade 3 follicular lymphoma	C0280185	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	recurrent grade 3 follicular lymphoma	C0280185	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	recurrent grade 3 follicular lymphoma	C0280185	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	recurrent grade 3 follicular lymphoma	C0280185	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	recurrent grade 3 follicular lymphoma	C0280185	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	recurrent grade 3 follicular lymphoma	C0280185	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Mantle cell lymphoma recurrent	C0677725	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Mantle cell lymphoma recurrent	C0677725	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Mantle cell lymphoma recurrent	C0677725	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Mantle cell lymphoma recurrent	C0677725	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Mantle cell lymphoma recurrent	C0677725	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Mantle cell lymphoma recurrent	C0677725	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Marginal zone lymphoma recurrent	C1541273	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Marginal zone lymphoma recurrent	C1541273	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Marginal zone lymphoma recurrent	C1541273	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Marginal zone lymphoma recurrent	C1541273	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Marginal zone lymphoma recurrent	C1541273	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Marginal zone lymphoma recurrent	C1541273	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Mycosis fungoides/Sezary syndrome recurrent	C0862200	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	B-cell small lymphocytic lymphoma recurrent	C0855096	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Chronic lymphocytic leukaemia refractory	C0278791	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Chronic lymphocytic leukaemia refractory	C0278791	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Chronic lymphocytic leukaemia refractory	C0278791	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Chronic lymphocytic leukaemia refractory	C0278791	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Chronic lymphocytic leukaemia refractory	C0278791	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Chronic lymphocytic leukaemia refractory	C0278791	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Hairy cell leukaemia recurrent	C0279780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Hairy cell leukaemia recurrent	C0279780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Hairy cell leukaemia recurrent	C0279780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Hairy cell leukaemia recurrent	C0279780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Hairy cell leukaemia recurrent	C0279780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Hairy cell leukaemia recurrent	C0279780	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	chronic myelogenous leukemia in relapse	C0278787	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	chronic myelogenous leukemia in relapse	C0278787	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	chronic myelogenous leukemia in relapse	C0278787	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	chronic myelogenous leukemia in relapse	C0278787	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	chronic myelogenous leukemia in relapse	C0278787	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	chronic myelogenous leukemia in relapse	C0278787	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	secondary acute myeloid leukemia	C0280449	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	secondary acute myeloid leukemia	C0280449	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	secondary acute myeloid leukemia	C0280449	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	secondary acute myeloid leukemia	C0280449	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	secondary acute myeloid leukemia	C0280449	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	secondary acute myeloid leukemia	C0280449	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	secondary myelodysplastic syndromes	C0280745	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	secondary myelodysplastic syndromes	C0280745	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	secondary myelodysplastic syndromes	C0280745	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	secondary myelodysplastic syndromes	C0280745	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	secondary myelodysplastic syndromes	C0280745	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	secondary myelodysplastic syndromes	C0280745	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Small Intestinal Lymphoma	C0278805	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Small Intestinal Lymphoma	C0278805	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Small Intestinal Lymphoma	C0278805	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Small Intestinal Lymphoma	C0278805	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Small Intestinal Lymphoma	C0278805	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Small Intestinal Lymphoma	C0278805	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Splenic Marginal Zone B-Cell Lymphoma	C0349632	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	T-Cell Large Granular Lymphocyte Leukemia	C1955861	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Malignant lymphoma of testis	C0349644	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Malignant lymphoma of testis	C0349644	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Malignant lymphoma of testis	C0349644	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Malignant lymphoma of testis	C0349644	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Malignant lymphoma of testis	C0349644	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Malignant lymphoma of testis	C0349644	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult acute lymphoblastic leukemia in remission	C0279095	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult acute lymphoblastic leukemia in remission	C0279095	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult acute lymphoblastic leukemia in remission	C0279095	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult acute lymphoblastic leukemia in remission	C0279095	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult acute lymphoblastic leukemia in remission	C0279095	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult acute lymphoblastic leukemia in remission	C0279095	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult acute myeloid leukemia in remission	C0279094	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult acute myeloid leukemia in remission	C0279094	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult acute myeloid leukemia in remission	C0279094	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult acute myeloid leukemia in remission	C0279094	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult acute myeloid leukemia in remission	C0279094	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult acute myeloid leukemia in remission	C0279094	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult acute myeloid leukemia with t(15;17)(q22;q12)	C1541335	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	adult nasal type extranodal NK/T-cell lymphoma	C1879279	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Ki-1+ Anaplastic Large Cell Lymphoma	C0206180	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Angioimmunoblastic Lymphadenopathy	C0020981	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Cutaneous B-Cell Non-Hodgkin Lymphoma	C1511566	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	de novo myelodysplastic syndromes	C0280451	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	de novo myelodysplastic syndromes	C0280451	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	de novo myelodysplastic syndromes	C0280451	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	de novo myelodysplastic syndromes	C0280451	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	de novo myelodysplastic syndromes	C0280451	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	de novo myelodysplastic syndromes	C0280451	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Mucosa-Associated Lymphoid Tissue Lymphoma	C0242647	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Hepatosplenic T-cell lymphoma	C1333984	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Hepatosplenic T-cell lymphoma	C1333984	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Hepatosplenic T-cell lymphoma	C1333984	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Hepatosplenic T-cell lymphoma	C1333984	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Hepatosplenic T-cell lymphoma	C1333984	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Hepatosplenic T-cell lymphoma	C1333984	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	C1328061	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	C1328061	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	C1328061	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	C1328061	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	C1328061	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	C1328061	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Monocytoid B-cell lymphoma	C0855139	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Monocytoid B-cell lymphoma	C0855139	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Monocytoid B-cell lymphoma	C0855139	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Monocytoid B-cell lymphoma	C0855139	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Monocytoid B-cell lymphoma	C0855139	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Monocytoid B-cell lymphoma	C0855139	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Vidarabine	Post-transplant lymphoproliferative disorder	C0432487	NCT01652014	Suspended	Phase 2	Funding unavailable	C0042646	Vidarabinum
Cyclophosphamide	Post-transplant lymphoproliferative disorder	C0432487	NCT01652014	Suspended	Phase 2	Funding unavailable	C0010583	Cyclophosphamidum
Mycophenolate mofetil	Post-transplant lymphoproliferative disorder	C0432487	NCT01652014	Suspended	Phase 2	Funding unavailable	C0209368	2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Tacrolimus	Post-transplant lymphoproliferative disorder	C0432487	NCT01652014	Suspended	Phase 2	Funding unavailable	C0771204	Tacrolimus anhydrous
Mycophenolic acid	Post-transplant lymphoproliferative disorder	C0432487	NCT01652014	Suspended	Phase 2	Funding unavailable	C0026933	Mycophenolsäure
Fludarabine	Post-transplant lymphoproliferative disorder	C0432487	NCT01652014	Suspended	Phase 2	Funding unavailable	C0059985	Fludarabinum
Etoposide	Multiple Myeloma	C0026764	NCT01653418	Terminated	Phase 2	Due to the high rate of morbidity and mortality	C0015133	9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
Cytarabine	Multiple Myeloma	C0026764	NCT01653418	Terminated	Phase 2	Due to the high rate of morbidity and mortality	C0010711	Cytarabinum
Cisplatin	stage III squamous cell carcinoma of the lip and oral cavity	C0280353	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Nasopharyngeal squamous cell carcinoma stage III	C0280382	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Oropharyngeal squamous cell carcinoma stage III	C0280372	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	stage III squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280411	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Squamous cell carcinoma of the hypopharynx stage IV	C0280391	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Laryngeal squamous cell carcinoma stage IV	C0280399	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	stage IV squamous cell carcinoma of the lip and oral cavity	C0280358	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Chemotherapeutic Agent Toxicity	C1707372	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Radiation Sickness	C1510432	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Squamous cell carcinoma of the hypopharynx stage III	C0280390	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Laryngeal squamous cell carcinoma stage III	C0280397	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Nasopharyngeal squamous cell carcinoma stage IV	C0280384	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	stage IV squamous cell carcinoma of the oropharynx	C0280374	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280415	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Cisplatin	Xerostomia	C0043352	NCT01682031	Terminated	Phase 2	Due to a lack of funding	C0008838	cisplatino
Ketamine	Depressive disorder	C0011581	NCT01680172	Terminated	Phase 2	Slow enrollment	C0022614	Kétamine
Ketamine	Anxiety	C0003467	NCT01680172	Terminated	Phase 2	Slow enrollment	C0022614	Kétamine
Alemtuzumab	Multiple Sclerosis	C0026769	NCT01679041	Terminated	Phase 2	Insufficient accruals; PI leaving site	C0383429	Alemtuzumab
Cyclophosphamide	Multiple Sclerosis	C0026769	NCT01679041	Terminated	Phase 2	Insufficient accruals; PI leaving site	C0010583	Cyclophosphamidum
Fludarabine	Multiple Sclerosis	C0026769	NCT01679041	Terminated	Phase 2	Insufficient accruals; PI leaving site	C0059985	Fludarabinum
Trastuzumab	Malignant neoplasm of lung	C0242379	NCT01679743	Withdrawn	Phase 2		C5187552	trastuzumab-anns
Bevacizumab	Colorectal Neoplasms	C0009404	NCT01677884	Terminated	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Citalopram	Acute Coronary Syndrome	C0948089	NCT01667744	Withdrawn	Phase 1/Phase 2	unfunded	C0008845	Citalopramum
Cocaine	Cocaine Dependence	C0600427	NCT01715051	Withdrawn	Phase 2	Funding was not received	C0009170	[1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
Ezogabine	Epilepsy	C0014544	NCT01668654	Terminated	Phase 3	FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in    subjects; early termination allows for timely reporting of results.	C0530684	ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate
Dexmedetomidine	Sleep Apnea, Obstructive	C0520679	NCT01733043	Withdrawn	Phase 2/Phase 3	Failure to secure funding	C0113293	(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
Prednisolone	Ischemic reperfusion injury	C0349419	NCT01726465	Terminated	Phase 2	The first phase was completed	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Ischemic reperfusion injury	C0349419	NCT01726465	Terminated	Phase 2	The first phase was completed	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Acetylcysteine	Ischemic reperfusion injury	C0349419	NCT01726465	Terminated	Phase 2	The first phase was completed	C0001047	NAC
Prednisolone	insufficiency; hepatic, postoperative	C1401063	NCT01726465	Terminated	Phase 2	The first phase was completed	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	insufficiency; hepatic, postoperative	C1401063	NCT01726465	Terminated	Phase 2	The first phase was completed	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Acetylcysteine	insufficiency; hepatic, postoperative	C1401063	NCT01726465	Terminated	Phase 2	The first phase was completed	C0001047	NAC
Carboplatin	Small cell carcinoma of lung	C0149925	NCT01722292	Terminated	Phase 1/Phase 2	Change in clinical strategy.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Cisplatin	Squamous cell carcinoma of the hypopharynx recurrent	C0280392	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Laryngeal squamous cell carcinoma recurrent	C0280401	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	recurrent squamous cell carcinoma of the lip and oral cavity	C0280363	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Nasopharyngeal squamous cell carcinoma recurrent	C0280386	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Oropharyngeal squamous cell carcinoma recurrent	C0280376	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280419	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Laryngeal verrucous carcinoma recurrent	C0280402	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Verrucous carcinoma of the oral cavity recurrent	C0280365	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Squamous cell carcinoma of the hypopharynx stage III	C0280390	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Laryngeal squamous cell carcinoma stage III	C0280397	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	stage III squamous cell carcinoma of the lip and oral cavity	C0280353	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Nasopharyngeal squamous cell carcinoma stage III	C0280382	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Oropharyngeal squamous cell carcinoma stage III	C0280372	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	stage III squamous cell carcinoma of the paranasal sinus and nasal cavity	C0280411	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Laryngeal verrucous carcinoma stage III	C0280398	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Verrucous carcinoma of the oral cavity stage III	C0280355	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Squamous cell carcinoma of the hypopharynx stage IV	C0280391	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Nasopharyngeal squamous cell carcinoma stage IV	C0280384	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVA Laryngeal Squamous Cell Carcinoma	C1336343	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma	C3897523	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVA Oropharyngeal Squamous Cell Carcinoma	C1336356	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	C3897522	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVA Laryngeal Verrucous Carcinoma	C1336344	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVA Oral Cavity Verrucous Carcinoma	C1336354	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVB Laryngeal Squamous Cell Carcinoma	C1336374	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma	C3897516	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVB Oropharyngeal Squamous Cell Carcinoma	C1336387	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	C3897515	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVB Laryngeal Verrucous Carcinoma	C1336375	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVB Oral Cavity Verrucous Carcinoma	C1336385	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVC Laryngeal Squamous Cell Carcinoma	C1336395	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma	C3897510	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVC Oropharyngeal Squamous Cell Carcinoma	C1336407	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	C3897509	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVC Laryngeal Verrucous Carcinoma	C1336396	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Cisplatin	Stage IVC Oral Cavity Verrucous Carcinoma	C1336405	NCT01728480	Withdrawn	Phase 1	Financial Sponsor requested termination	C0008838	cisplatino
Naproxen	Headache	C0018681	NCT01726920	Withdrawn	Phase 3	Due to budget limitations, the company decided to withdraw this study.	C0027396	Naproxenum
Naratriptan	Headache	C0018681	NCT01726920	Withdrawn	Phase 3	Due to budget limitations, the company decided to withdraw this study.	C0540623	Naratriptán
Asenapine	Stuttering	C0038506	NCT01684657	Suspended	Phase 3	Study transferring to another facility	C2000088	asenapina
Haloperidol	Nausea	C0027497	NCT01684969	Withdrawn	Phase 0	lack of accrual and funding is about to expire.	C0018546	4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
Haloperidol	Vomiting	C0042963	NCT01684969	Withdrawn	Phase 0	lack of accrual and funding is about to expire.	C0018546	4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
Nitric Oxide	Bronchopulmonary Dysplasia	C0006287	NCT01748045	Terminated	Phase 2/Phase 3	Enrollenment has been suspended due to poor enrollment	C0028128	óxido nítrico
Tamsulosin	Urinary Retention	C0080274	NCT01747993	Terminated	Phase 3	low inclusion	C0257343	(-)-tamsulosin
Dextroamphetamine	Schizophrenia	C0036341	NCT01738698	Terminated	Phase 3	Study was discontinued due to non-safety related business prioritization decisions. No    subjects were randomized.	C0011812	Desamfetamina
Zinc sulfate	Acute gastroenteritis	C0267446	NCT01737086	Terminated	Phase 2/Phase 3	Terminated due to lack of eligible patients.	C2700331	Zinc sulfate anhydrous
Sorafenib	Medullary carcinoma of thyroid	C0238462	NCT01736878	Withdrawn	Phase 2	Study was withdrawn due to unanticipated hassle in patient recruitment.	C1516119	Sorafenibum
Cytarabine	acute leukemia in relapse	C2367453	NCT01701375	Terminated	Phase 1	Material sponsor withdrew support	C0010711	Cytarabinum
Mitoxantrone	acute leukemia in relapse	C2367453	NCT01701375	Terminated	Phase 1	Material sponsor withdrew support	C0026259	1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
Carboplatin	Anaplastic thyroid carcinoma	C0238461	NCT01701349	Withdrawn	Phase 3	Expected inability to recruit study participants in a reasonable amount of time.	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Anaplastic thyroid carcinoma	C0238461	NCT01701349	Withdrawn	Phase 3	Expected inability to recruit study participants in a reasonable amount of time.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Dextroamphetamine	Schizophrenia	C0036341	NCT01760889	Terminated	Phase 3	Study was discontinued due to non-safety related business prioritization decisions. No    subjects were randomized	C0011812	Desamfetamina
Estradiol	Atrophy of vagina	C0241616	NCT01753102	Terminated	Phase 3	Slow recruitment	C0014912	17β-oestradiol
Topiramate	heavy drinking	C0687132	NCT01764685	Terminated	Phase 2	We terminated the study due to problems recruiting alcoholic subjects with HIV.	C0076829	Topiramato
Leuprolide	Hypertensive disease	C0020538	NCT01763541	Withdrawn	Phase 0		C0085272	Leuprorelinum
Testosterone	Hypertensive disease	C0020538	NCT01763541	Withdrawn	Phase 0		C0039601	Testostérone
Estradiol	Hypertensive disease	C0020538	NCT01763541	Withdrawn	Phase 0		C0014912	17β-oestradiol
Anastrozole	Hypertensive disease	C0020538	NCT01763541	Withdrawn	Phase 0		C0290883	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Methyltestosterone	Hypertensive disease	C0020538	NCT01763541	Withdrawn	Phase 0		C0025826	Methyltestosteronum
Isoniazid	Latent Tuberculosis	C1609538	NCT01761201	Terminated	Phase 3	Recruitment rythm not sufficent to reach the simple size needed.	C0022209	Isoniazida
Levofloxacin	Latent Tuberculosis	C1609538	NCT01761201	Terminated	Phase 3	Recruitment rythm not sufficent to reach the simple size needed.	C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Ofloxacin	Latent Tuberculosis	C1609538	NCT01761201	Terminated	Phase 3	Recruitment rythm not sufficent to reach the simple size needed.	C0028902	Ofloxacino
Isoniazid	Infection in solid organ transplant recipients	C0857825	NCT01761201	Terminated	Phase 3	Recruitment rythm not sufficent to reach the simple size needed.	C0022209	Isoniazida
Levofloxacin	Infection in solid organ transplant recipients	C0857825	NCT01761201	Terminated	Phase 3	Recruitment rythm not sufficent to reach the simple size needed.	C0282386	(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
Ofloxacin	Infection in solid organ transplant recipients	C0857825	NCT01761201	Terminated	Phase 3	Recruitment rythm not sufficent to reach the simple size needed.	C0028902	Ofloxacino
Belimumab	Membranous glomerulonephritis	C0017665	NCT01762852	Withdrawn	Phase 2	Withdrawn due to difficulties in to recruiting due to competing studies, changing treatment    practices, unavailability of eligible study population	C1723401	Belimumab
Fluoxetine	Cerebral Hemorrhage	C2937358	NCT01737541	Terminated	Phase 3	Study recruitment was suspended due to lack of funding	C0016365	Fluoxetina
Rituximab	Lupus Nephritis	C0024143	NCT01765842	Terminated	Phase 3	The recruitment period has finished without reaching sample size	C5195655	rituximab-pvvr
Vancomycin	Surgical Wound Infection	C0038941	NCT01764750	Suspended	Phase 1	awaiting FDA approval for next dose group	C0042313	Vancomycine
Loteprednol	Keratitis	C0022568	NCT01721694	Withdrawn	Phase 3	withdrawn by industry	C0772364	Loteprednol
Bevacizumab	Malignant tumor of colon	C0007102	NCT01759238	Terminated	Phase 2	slow accrual	C0796392	Anti-VEGF monoclonal antibody
Capecitabine	Malignant tumor of colon	C0007102	NCT01759238	Terminated	Phase 2	slow accrual	C0671970	Capecitabin
Fluticasone Propionate	Chronic Obstructive Airway Disease	C0024117	NCT01757015	Withdrawn	Phase 3		C0117996	Fluticasone propionate
Salmeterol	Chronic Obstructive Airway Disease	C0024117	NCT01757015	Withdrawn	Phase 3		C0073992	Salmeterolum
Oxaliplatin	Gastric carcinoma stage IV	C0863191	NCT01748851	Terminated	Phase 3	Poor enrollment of patients	C0069717	oxaliplatine
Fluorouracil	Gastric carcinoma stage IV	C0863191	NCT01748851	Terminated	Phase 3	Poor enrollment of patients	C0016360	Fluorouracilum
Capecitabine	Gastric carcinoma stage IV	C0863191	NCT01748851	Terminated	Phase 3	Poor enrollment of patients	C0671970	Capecitabin
Omeprazole	Laryngomalacia	C0264303	NCT01782560	Withdrawn	Phase 1	Unable to recruit a sufficient amount of subjects	C0028978	Omeprazolum
Simvastatin	Rhinosinusitis	C0948780	NCT01771198	Terminated	Phase 2	Lack of efficacy with one month of treatement	C0074554	2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Denileukin diftitox	Epithelial ovarian cancer	C0677886	NCT01773889	Terminated	Phase 2	Lack of funding	C0717670	Interleukin-2/diptheria toxin fusion protein
Denileukin diftitox	Fallopian Tube Carcinoma	C0238122	NCT01773889	Terminated	Phase 2	Lack of funding	C0717670	Interleukin-2/diptheria toxin fusion protein
Unoprostone	Retinitis Pigmentosa	C0035334	NCT01786395	Terminated	Phase 3		C0772319	Unoprostone
Ketamine	Chronic pain	C0150055	NCT01755169	Terminated	Phase 2	Inability to enroll sufficient patients	C0022614	Kétamine
Chloroquine	Malaria	C0024530	NCT01785979	Withdrawn	Phase 3	Lack of funding	C0008269	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Prednisone	Malaria	C0024530	NCT01785979	Withdrawn	Phase 3	Lack of funding	C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Bevacizumab	Glioblastoma	C0017636	NCT01782976	Withdrawn	Phase 2		C0796392	Anti-VEGF monoclonal antibody
Heparin	Inhalation injury	C0745334	NCT01773083	Terminated	Phase 3	insufficient recruitment of patients and high costs associated with the purchase and blinding    of study medication	C0019134	Heparina
Nitrous oxide	Labor Pain	C0474368	NCT01738672	Suspended	Phase 2		C0028215	N2O
Ranolazine	Acute Coronary Syndrome	C0948089	NCT01767987	Terminated	Phase 2	Sponsor terminated study due to lack of enrollment	C0073633	Ranolazina
Rosuvastatin	Influenza due to Influenza A virus subtype H1N1	C2076600	NCT01798602	Terminated	Phase 2	H1N1 pandemic concluded	C0965129	Rosuvastatina
Azacitidine	Leukemia, Myelocytic, Acute	C0023467	NCT01794169	Terminated	Phase 2	Poor recruitment	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Theophylline	Non-Small Cell Lung Carcinoma	C0007131	NCT01799161	Withdrawn	Phase 1	Insufficient funding	C0039771	Teofilina
Aminophylline	Non-Small Cell Lung Carcinoma	C0007131	NCT01799161	Withdrawn	Phase 1	Insufficient funding	C0002575	Aminophyllinum
Theophylline	Malignant neoplasm of lung	C0242379	NCT01799161	Withdrawn	Phase 1	Insufficient funding	C0039771	Teofilina
Aminophylline	Malignant neoplasm of lung	C0242379	NCT01799161	Withdrawn	Phase 1	Insufficient funding	C0002575	Aminophyllinum
Estradiol	Infertility	C0021359	NCT01798836	Terminated	Phase 2/Phase 3	Obtained results were not good. Protocol was proved ineffective.	C0014912	17β-oestradiol
Triptorelin	Infertility	C0021359	NCT01798836	Terminated	Phase 2/Phase 3	Obtained results were not good. Protocol was proved ineffective.	C0077275	triptorelinum
Clofarabine	Histiocytosis, Langerhans-Cell	C0019621	NCT01796405	Withdrawn	Phase 2		C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Eplerenone	Ascites	C0003962	NCT01801228	Withdrawn	Phase 2	difficulties to include patients	C0961485	Eplerenona
Hydroxychloroquine	Antiphospholipid Syndrome	C0085278	NCT01784523	Terminated	Phase 3	low recruitment rate exacerbated by manufacturing shortage and price increase of    hydroxychloroquine.	C0020336	2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
Papaverine	Schizophrenia	C0036341	NCT01813955	Terminated	Phase 0	Patient recruitment insufficient	C0030350	Papaverina
Metformin	Colorectal Carcinoma	C0009402	NCT01816659	Terminated	Phase 1	Slow Accrual	C0025598	Metformina
Nicardipine	Cerebral Vasospasm	C0265110	NCT01810302	Terminated	Phase 2	Unable to secure drug.	C0028005	Nicardipinum
Ifosfamide	adult central nervous system germ cell tumor	C0280796	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Adult teratoma	C1368898	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Malignant Extragonadal Germ Cell Tumor	C1334581	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Malignant Extragonadal Non-Seminomatous Germ Cell Tumor	C1334582	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Extragonadal Seminoma	C1333502	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Testis cancer recurrent	C0278841	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	recurrent ovarian germ cell tumor	C0279975	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor	C1336415	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Stage IV Extragonadal Seminoma	C1336416	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamide	Ovarian germ cell cancer stage IV	C0279974	NCT01808534	Terminated	Phase 2	Due to Low Accrual	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Sirolimus	Eosinophilic gastroenteritis	C1262481	NCT01814059	Terminated	Phase 1		C0072980	Sirolimús
Everolimus	Eosinophilic gastroenteritis	C1262481	NCT01814059	Terminated	Phase 1		C0541315	évérolimus
Sirolimus	Eosinophilic esophagitis	C0341106	NCT01814059	Terminated	Phase 1		C0072980	Sirolimús
Everolimus	Eosinophilic esophagitis	C0341106	NCT01814059	Terminated	Phase 1		C0541315	évérolimus
Ponatinib	Thyroid Neoplasm	C0040136	NCT01838642	Terminated	Phase 2	Recruiting halted prematurely and will not resume. New study to open soon.	C2987417	Ponatinibum
Prednisone	Polymyalgia Rheumatica	C0032533	NCT01821040	Terminated	Phase 3		C0032952	1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Cyclophosphamide	Breast cancer stage II	C0278486	NCT01818063	Suspended	Phase 2	Lack of funding	C0010583	Cyclophosphamidum
Carboplatin	Breast cancer stage II	C0278486	NCT01818063	Suspended	Phase 2	Lack of funding	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Doxorubicin	Breast cancer stage II	C0278486	NCT01818063	Suspended	Phase 2	Lack of funding	C0013089	Doxorubicine
Paclitaxel	Breast cancer stage II	C0278486	NCT01818063	Suspended	Phase 2	Lack of funding	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Heparin	Bacteremia	C0004610	NCT01820962	Terminated	Phase 3	Because the inclusion rate was lower than expected.	C0019134	Heparina
Aluminum hydroxide	viral; infection, enterovirus	C1400756	NCT01812135	Withdrawn	Phase 2	Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was    elected to be used for the efficacy Phase III study.	C0002371	Aluminio hidróxido
Naltrexone	Inflammatory Bowel Diseases	C0021390	NCT01810185	Withdrawn	Phase 2	Low patient enrollment	C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Naltrexone	Crohn Disease	C0010346	NCT01810185	Withdrawn	Phase 2	Low patient enrollment	C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Naltrexone	Ulcerative Colitis	C0009324	NCT01810185	Withdrawn	Phase 2	Low patient enrollment	C0027360	17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Levoleucovorin	Non-Small Cell Lung Carcinoma	C0007131	NCT01820091	Withdrawn	Phase 1		C2721771	ácido levofolínico
Sulindac	Malignant tumor of colon	C0007102	NCT01856322	Terminated	Phase 2	The trial was prematurely closed due to lack of accrual.	C0038792	Sulindacum
Sulindac	Adenocarcinoma of large intestine	C1319315	NCT01856322	Terminated	Phase 2	The trial was prematurely closed due to lack of accrual.	C0038792	Sulindacum
Lidocaine	colorectal disorders	C2103078	NCT01836614	Withdrawn	Phase 1/Phase 2	Study was closed due to recommendations of performing a PK study first.	C0023660	Lidocaína
Cyclophosphamide	Metastatic melanoma	C0278883	NCT01833767	Withdrawn	Phase 2	No participants enrolled	C0010583	Cyclophosphamidum
Mechlorethamine	DS Stage I Plasma Cell Myeloma	C0278722	NCT01842308	Suspended	Phase 1/Phase 2	Accrual to dose level 3 (56 mg/m2 Carfilzomib; 100 mg/m2 Melphalan) has been met.	C0025033	methylbis(β-chloroethyl)amine
Melphalan	DS Stage I Plasma Cell Myeloma	C0278722	NCT01842308	Suspended	Phase 1/Phase 2	Accrual to dose level 3 (56 mg/m2 Carfilzomib; 100 mg/m2 Melphalan) has been met.	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Mechlorethamine	DS Stage II Plasma Cell Myeloma	C0278723	NCT01842308	Suspended	Phase 1/Phase 2	Accrual to dose level 3 (56 mg/m2 Carfilzomib; 100 mg/m2 Melphalan) has been met.	C0025033	methylbis(β-chloroethyl)amine
Melphalan	DS Stage II Plasma Cell Myeloma	C0278723	NCT01842308	Suspended	Phase 1/Phase 2	Accrual to dose level 3 (56 mg/m2 Carfilzomib; 100 mg/m2 Melphalan) has been met.	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Mechlorethamine	DS Stage III Plasma Cell Myeloma	C0278724	NCT01842308	Suspended	Phase 1/Phase 2	Accrual to dose level 3 (56 mg/m2 Carfilzomib; 100 mg/m2 Melphalan) has been met.	C0025033	methylbis(β-chloroethyl)amine
Melphalan	DS Stage III Plasma Cell Myeloma	C0278724	NCT01842308	Suspended	Phase 1/Phase 2	Accrual to dose level 3 (56 mg/m2 Carfilzomib; 100 mg/m2 Melphalan) has been met.	C0025241	L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Sulindac	Leukemia, Myelocytic, Acute	C0023467	NCT01843179	Withdrawn	Phase 2	Lack of Funding	C0038792	Sulindacum
Doxorubicin	Epithelial ovarian cancer	C0677886	NCT01840943	Terminated	Phase 3	the study was terminated due to medication supply issue from current manufacturer	C0013089	Doxorubicine
Topotecan	Epithelial ovarian cancer	C0677886	NCT01840943	Terminated	Phase 3	the study was terminated due to medication supply issue from current manufacturer	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Tacrolimus	Vitiligo	C0042900	NCT01841008	Terminated	Phase 2/Phase 3		C0771204	Tacrolimus anhydrous
Paroxetine	Hepatitis C	C0019196	NCT01841502	Terminated	Phase 2	Telaprevir will not be used in NL, no more inclusions are expected.	C0070122	Paroxetina
Lipoic Acid	Chronic Fatigue Syndrome	C0015674	NCT01872351	Withdrawn	Phase 1	PI left the institution	C0023791	Alpha lipoic acid
Acetylcarnitine	Chronic Fatigue Syndrome	C0015674	NCT01872351	Withdrawn	Phase 1	PI left the institution	C0001040	O-Acetylcarnitine
Ciprofloxacin	Urolithiasis	C0451641	NCT01873690	Terminated	Phase 3	Due to the low recruitment rate and the large number lost to follow-up	C0008809	1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Sorafenib	Melanoma recurrent	C0278884	NCT01851408	Withdrawn	Phase 2	No progression of Phase 1 trial to Phase 2.	C1516119	Sorafenibum
Sirolimus	Melanoma recurrent	C0278884	NCT01851408	Withdrawn	Phase 2	No progression of Phase 1 trial to Phase 2.	C0072980	Sirolimús
Everolimus	Melanoma recurrent	C0278884	NCT01851408	Withdrawn	Phase 2	No progression of Phase 1 trial to Phase 2.	C0541315	évérolimus
Sorafenib	malignant melanoma of skin stage III	C0278882	NCT01851408	Withdrawn	Phase 2	No progression of Phase 1 trial to Phase 2.	C1516119	Sorafenibum
Sirolimus	malignant melanoma of skin stage III	C0278882	NCT01851408	Withdrawn	Phase 2	No progression of Phase 1 trial to Phase 2.	C0072980	Sirolimús
Everolimus	malignant melanoma of skin stage III	C0278882	NCT01851408	Withdrawn	Phase 2	No progression of Phase 1 trial to Phase 2.	C0541315	évérolimus
Lapatinib	Breast cancer recurrent	C0278493	NCT01868503	Terminated	Phase 2	Protocol modification	C1506770	N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
Valproic Acid	childhood brain tumor	C0220603	NCT01861990	Withdrawn	Phase 1	Feasibility of the trial was proven to be absent.	C0042291	acidum valproicum
Valproic Acid	Anaplastic astrocytoma	C0334579	NCT01861990	Withdrawn	Phase 1	Feasibility of the trial was proven to be absent.	C0042291	acidum valproicum
Valproic Acid	Medulloblastoma	C0025149	NCT01861990	Withdrawn	Phase 1	Feasibility of the trial was proven to be absent.	C0042291	acidum valproicum
Valproic Acid	Glioblastoma	C0017636	NCT01861990	Withdrawn	Phase 1	Feasibility of the trial was proven to be absent.	C0042291	acidum valproicum
Warfarin	primary disorders	C0277554	NCT01868243	Terminated	Phase 2/Phase 3	because a significant decrease of viable candidates for the study.	C0043031	Warfarina
Melatonin	ENCEPHALOPATHY, HYPOXIC-ISCHEMIC, NEWBORN	C0149878	NCT01904786	Withdrawn	Phase 1	Lack of enrollment of suitable candidates	C0025219	Mélatonine
Trametinib	recurrent adult acute myeloid leukemia	C0278780	NCT01907815	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	untreated adult acute myeloid leukemia	C0279089	NCT01907815	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Lidocaine	Periodontitis	C0031099	NCT01878864	Terminated	Phase 2	Too slow patient inclusion and superior effect of the injection	C0023660	Lidocaína
Bupivacaine	Periodontitis	C0031099	NCT01878864	Terminated	Phase 2	Too slow patient inclusion and superior effect of the injection	C0006400	Bupivacaina
Epinephrine	Periodontitis	C0031099	NCT01878864	Terminated	Phase 2	Too slow patient inclusion and superior effect of the injection	C0014563	(-)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
Eslicarbazepine acetate	Epilepsy	C0014544	NCT01878578	Terminated	Phase 1	prematurely terminated due to impossibility of recruiting the planned number of patients by    the study centre.	C4255554	Stedesa
Asparaginase	T-cell lymphoma recurrent	C0854826	NCT01878708	Terminated	Phase 0	Slow accrual	C0003993	Colaspase
Pegaspargase	T-cell lymphoma recurrent	C0854826	NCT01878708	Terminated	Phase 0	Slow accrual	C0071568	Pegaspargasa
Dexamethasone	T-cell lymphoma recurrent	C0854826	NCT01878708	Terminated	Phase 0	Slow accrual	C0011777	Dexaméthasone
Asparaginase	T-cell lymphoma refractory	C0854827	NCT01878708	Terminated	Phase 0	Slow accrual	C0003993	Colaspase
Pegaspargase	T-cell lymphoma refractory	C0854827	NCT01878708	Terminated	Phase 0	Slow accrual	C0071568	Pegaspargasa
Dexamethasone	T-cell lymphoma refractory	C0854827	NCT01878708	Terminated	Phase 0	Slow accrual	C0011777	Dexaméthasone
Moxifloxacin	Tuberculosis	C0041296	NCT01874314	Withdrawn	Phase 1		C0536495	Moxifloxacino
Octreotide	Carcinoma, Neuroendocrine	C0206695	NCT01886287	Terminated	Phase 2	Slow accrual	C0028833	Octreotida
Gemcitabine	duct cell adenocarcinoma of the pancreas	C0279176	NCT01893294	Terminated	Phase 1	Funding discontinued; all patients off study	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Fluorouracil	duct cell adenocarcinoma of the pancreas	C0279176	NCT01893294	Terminated	Phase 1	Funding discontinued; all patients off study	C0016360	Fluorouracilum
Gemcitabine	Pancreatic carcinoma stage III	C1167722	NCT01893294	Terminated	Phase 1	Funding discontinued; all patients off study	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Fluorouracil	Pancreatic carcinoma stage III	C1167722	NCT01893294	Terminated	Phase 1	Funding discontinued; all patients off study	C0016360	Fluorouracilum
Gemcitabine	Stage IV Pancreatic Cancer	C1167725	NCT01893294	Terminated	Phase 1	Funding discontinued; all patients off study	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Fluorouracil	Stage IV Pancreatic Cancer	C1167725	NCT01893294	Terminated	Phase 1	Funding discontinued; all patients off study	C0016360	Fluorouracilum
Abatacept	Alopecia Areata	C0002171	NCT01917058	Withdrawn	Phase 2	Unfortunately we did not receive funding and therefore were not able to begin the trial.	C1619966	Abatacept recombinant
Mifepristone	Pituitary-dependent Cushing's disease	C0221406	NCT01925092	Withdrawn	Phase 3	Lack of enrollment	C0026088	Mifepristonum
Cetuximab	Colorectal cancer metastatic	C0948380	NCT01925274	Terminated	Phase 2	Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no    safety or efficacy issues that contributed to this decision.	C0995188	Cétuximab
Irinotecan	Colorectal cancer metastatic	C0948380	NCT01925274	Terminated	Phase 2	Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no    safety or efficacy issues that contributed to this decision.	C0123931	(+)-Irinotecan
Vitamin C	Blood Coagulation Disorders	C0005779	NCT01897792	Terminated	Phase 2	Study was terminated due to inability to recruit enough patients that meet inclusion criteria.    No analysis will be done.	C0003968	Acidum ascorbicum
Vitamin E	Blood Coagulation Disorders	C0005779	NCT01897792	Terminated	Phase 2	Study was terminated due to inability to recruit enough patients that meet inclusion criteria.    No analysis will be done.	C0969677	alpha-tocopherol
Vitamin C	Nosocomial pneumonia	C0949083	NCT01897792	Terminated	Phase 2	Study was terminated due to inability to recruit enough patients that meet inclusion criteria.    No analysis will be done.	C0003968	Acidum ascorbicum
Vitamin E	Nosocomial pneumonia	C0949083	NCT01897792	Terminated	Phase 2	Study was terminated due to inability to recruit enough patients that meet inclusion criteria.    No analysis will be done.	C0969677	alpha-tocopherol
Amitriptyline	Sleep Initiation and Maintenance Disorders	C0021603	NCT01921296	Terminated	Phase 2	Accrual terminated early because of poor accrual	C0002600	5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
Cyclobenzaprine	Sleep Initiation and Maintenance Disorders	C0021603	NCT01921296	Terminated	Phase 2	Accrual terminated early because of poor accrual	C0056732	Cyclobenzaprinum
Amitriptyline	Pain	C0030193	NCT01921296	Terminated	Phase 2	Accrual terminated early because of poor accrual	C0002600	5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
Cyclobenzaprine	Pain	C0030193	NCT01921296	Terminated	Phase 2	Accrual terminated early because of poor accrual	C0056732	Cyclobenzaprinum
Cisplatin	Breast cancer recurrent	C0278493	NCT01918306	Terminated	Phase 1/Phase 2	company stopped production of study drug due to excessive toxicities	C0008838	cisplatino
Trametinib	malignant neoplasm of large intestine stage IIIc	C2217039	NCT01902173	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics	C2697961	Tramétinib
Dabrafenib	malignant neoplasm of large intestine stage IIIc	C2217039	NCT01902173	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics	C3467876	Dabrafenib
Trametinib	Melanoma recurrent	C0278884	NCT01902173	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics	C2697961	Tramétinib
Dabrafenib	Melanoma recurrent	C0278884	NCT01902173	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics	C3467876	Dabrafenib
Trametinib	Stage IIIC Skin Melanoma	C2828036	NCT01902173	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics	C2697961	Tramétinib
Dabrafenib	Stage IIIC Skin Melanoma	C2828036	NCT01902173	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics	C3467876	Dabrafenib
Paclitaxel	Metastatic melanoma	C0278883	NCT01933061	Withdrawn	Phase 2	Strategic decision not to proceed with the opening of this study. There are no concerns over    the safety or quality of the investigational products involved.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Pegfilgrastim	Solid tumour	C0280100	NCT01940601	Withdrawn	Phase 2		C4735048	pegfilgrastim-cbqv
Megestrol acetate	Atypical Endometrial Hyperplasia	C0349579	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0065879	17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
Levonorgestrel	Atypical Endometrial Hyperplasia	C0349579	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0023566	Lèvonorgestrel
Norgestrel	Atypical Endometrial Hyperplasia	C0349579	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0028368	Norgestrelum
Megestrol acetate	Endometrial adenocarcinoma	C1153706	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0065879	17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
Levonorgestrel	Endometrial adenocarcinoma	C1153706	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0023566	Lèvonorgestrel
Norgestrel	Endometrial adenocarcinoma	C1153706	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0028368	Norgestrelum
Megestrol acetate	Recurrent Endometrial Cancer	C0278802	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0065879	17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
Levonorgestrel	Recurrent Endometrial Cancer	C0278802	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0023566	Lèvonorgestrel
Norgestrel	Recurrent Endometrial Cancer	C0278802	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0028368	Norgestrelum
Megestrol acetate	Endometrial cancer stage II	C0278799	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0065879	17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
Levonorgestrel	Endometrial cancer stage II	C0278799	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0023566	Lèvonorgestrel
Norgestrel	Endometrial cancer stage II	C0278799	NCT01943058	Withdrawn	Phase 2	Lack of funding	C0028368	Norgestrelum
Chlorhexidine	Cerebral Hemorrhage	C2937358	NCT01933230	Terminated	Phase 1	Closed study due to issues we have encountered with meeting our enrollment goals of this study    at our site.	C0008196	N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
Carboplatin	Solid tumour	C0280100	NCT01930292	Terminated	Phase 1	Part B was cancelled based on business decision	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Solid tumour	C0280100	NCT01930292	Terminated	Phase 1	Part B was cancelled based on business decision	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Doxycycline	Non-ischemic cardiomyopathy	C0877438	NCT01935622	Terminated	Phase 2	End of funding	C2699808	Doxycycline anhydrous
Sodium thiosulfate	Calcinosis cutis	C0006664	NCT01918904	Withdrawn	Phase 2		C0302967	Thiosulfuric acid
Isotretinoin	Neuroblastoma	C0027819	NCT01916187	Withdrawn	Phase 1	drug company withdrww support following a re-examination of the benefit-risk assessment for    the investigational use of imetelstat in this population	C0022265	Isotrétinoine
Ifosfamide	Liposarcoma, Dedifferentiated	C0205824	NCT01913652	Suspended	Phase 2	Major amendment - change in design	C0020823	3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Azacitidine	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01908387	Terminated	Phase 1	Due to Slow Accrual study was terminated.	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Azacitidine	Leukemia, Myelocytic, Acute	C0023467	NCT01908387	Terminated	Phase 1	Due to Slow Accrual study was terminated.	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Azacitidine	Multiple Myeloma	C0026764	NCT01908387	Terminated	Phase 1	Due to Slow Accrual study was terminated.	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Deferasirox	Iron Overload	C0282193	NCT01927913	Withdrawn	Phase 2	This study was withdrawn until the evaluation of the nonclinical rat findings is complete.	C1619629	Deferasiroxum
Deferasirox	Iron Metabolism Disorders	C0012715	NCT01927913	Withdrawn	Phase 2	This study was withdrawn until the evaluation of the nonclinical rat findings is complete.	C1619629	Deferasiroxum
Norepinephrine	Pure Autonomic Failure	C0393911	NCT01927055	Terminated	Phase 3	Due to potential competition with a post-marketing study requested by FDA	C0028351	(-)-noradrenaline
Droxidopa	Pure Autonomic Failure	C0393911	NCT01927055	Terminated	Phase 3	Due to potential competition with a post-marketing study requested by FDA	C0000378	L-Dihydroxyphenylserine
Norepinephrine	dopamine beta hydroxylase deficiency	C0342687	NCT01927055	Terminated	Phase 3	Due to potential competition with a post-marketing study requested by FDA	C0028351	(-)-noradrenaline
Droxidopa	dopamine beta hydroxylase deficiency	C0342687	NCT01927055	Terminated	Phase 3	Due to potential competition with a post-marketing study requested by FDA	C0000378	L-Dihydroxyphenylserine
Gemcitabine	Secondary malignant neoplasm of pancreas	C0346976	NCT01956812	Terminated	Phase 3	The DSMB conducted an interim analysis on overall survival, which showed that the treatment    arm did not demonstrate a sufficient improvement in OS vs. placebo.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Lidocaine	Pain	C0030193	NCT01930877	Withdrawn	Phase 2	Withdrawn by PI	C0023660	Lidocaína
Abciximab	Hb-SS disease with vasoocclusive pain	C2873760	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0288672	c7E3
Morphine	Hb-SS disease with vasoocclusive pain	C2873760	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0026549	Morfina
Hydromorphone	Hb-SS disease with vasoocclusive pain	C2873760	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Fentanyl	Hb-SS disease with vasoocclusive pain	C2873760	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Ibuprofen	Hb-SS disease with vasoocclusive pain	C2873760	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0020740	Ibuprofenum
Abciximab	Hemoglobin SS disease with vasoocclusive crisis	C2585715	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0288672	c7E3
Morphine	Hemoglobin SS disease with vasoocclusive crisis	C2585715	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0026549	Morfina
Hydromorphone	Hemoglobin SS disease with vasoocclusive crisis	C2585715	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Fentanyl	Hemoglobin SS disease with vasoocclusive crisis	C2585715	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Ibuprofen	Hemoglobin SS disease with vasoocclusive crisis	C2585715	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0020740	Ibuprofenum
Abciximab	Other sickle-cell disease with vaso-occlusive pain	C1260331	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0288672	c7E3
Morphine	Other sickle-cell disease with vaso-occlusive pain	C1260331	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0026549	Morfina
Hydromorphone	Other sickle-cell disease with vaso-occlusive pain	C1260331	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Fentanyl	Other sickle-cell disease with vaso-occlusive pain	C1260331	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0015846	N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
Ibuprofen	Other sickle-cell disease with vaso-occlusive pain	C1260331	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	C0020740	Ibuprofenum
Clofarabine	Leukemia, Myelocytic, Acute	C0023467	NCT01960387	Terminated	Phase 2	lack of accrual	C0092777	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
Cisplatin	Non-small cell lung cancer recurrent	C0278517	NCT01928160	Withdrawn	Phase 2	study not accruing	C0008838	cisplatino
Erlotinib	Non-small cell lung cancer recurrent	C0278517	NCT01928160	Withdrawn	Phase 2	study not accruing	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Pemetrexed	Non-small cell lung cancer recurrent	C0278517	NCT01928160	Withdrawn	Phase 2	study not accruing	C0210657	Pemetrexed
Carboplatin	Non-small cell lung cancer recurrent	C0278517	NCT01928160	Withdrawn	Phase 2	study not accruing	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Cisplatin	Non-small cell lung cancer metastatic	C0278987	NCT01928160	Withdrawn	Phase 2	study not accruing	C0008838	cisplatino
Erlotinib	Non-small cell lung cancer metastatic	C0278987	NCT01928160	Withdrawn	Phase 2	study not accruing	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Pemetrexed	Non-small cell lung cancer metastatic	C0278987	NCT01928160	Withdrawn	Phase 2	study not accruing	C0210657	Pemetrexed
Carboplatin	Non-small cell lung cancer metastatic	C0278987	NCT01928160	Withdrawn	Phase 2	study not accruing	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Cisplatin	Oropharyngeal squamous cell carcinoma stage III	C0280372	NCT01953952	Withdrawn	Phase 2	Slow accrual	C0008838	cisplatino
Cisplatin	Stage IVA Oropharyngeal Squamous Cell Carcinoma	C1336356	NCT01953952	Withdrawn	Phase 2	Slow accrual	C0008838	cisplatino
Metformin	Stage IA Pancreatic Cancer	C2981674	NCT01954732	Withdrawn	Phase 1	Slow accrual	C0025598	Metformina
Metformin	Stage IB Pancreatic Cancer	C2981675	NCT01954732	Withdrawn	Phase 1	Slow accrual	C0025598	Metformina
Metformin	Stage IIA Pancreatic Cancer	C2981676	NCT01954732	Withdrawn	Phase 1	Slow accrual	C0025598	Metformina
Metformin	Stage IIB Pancreatic Cancer	C2981677	NCT01954732	Withdrawn	Phase 1	Slow accrual	C0025598	Metformina
Hydroxyurea	Pulmonary Hypertension	C0020542	NCT01950585	Withdrawn	Phase 0		C0020402	Hydroxycarbamid
Fluconazole	Leishmaniasis, Cutaneous	C0023283	NCT01953744	Terminated	Phase 3	Low cure rate in the study (fluconazole) group	C0016277	Fluconazol
Granisetron	Malignant Glioma	C0555198	NCT01952886	Withdrawn	Phase 2	Lack of approval and funding from company	C0061863	Granisétron
Ondansetron	Malignant Glioma	C0555198	NCT01952886	Withdrawn	Phase 2	Lack of approval and funding from company	C0061851	Ondansetron
Mannitol	Acute Cerebrovascular Accidents	C0751956	NCT01954290	Withdrawn	Phase 2	Investigator is leaving the institution.	C0024730	(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Verapamil	Classical phenylketonuria	C0751434	NCT01977820	Terminated	Phase 2	Recruitment challenges	C0042523	Vérapamil
Omeprazole	Cystic Fibrosis	C0010674	NCT01983774	Terminated	Phase 2	Closed by sponsor of the study; PI has left the institution and Columbia is now the sponsor of    the record	C0028978	Omeprazolum
Esomeprazole	Cystic Fibrosis	C0010674	NCT01983774	Terminated	Phase 2	Closed by sponsor of the study; PI has left the institution and Columbia is now the sponsor of    the record	C0937846	Ésoméprazole
Hydromorphone	Back Pain	C0004604	NCT01986946	Terminated	Phase 3	Lack of recruitment.	C0012306	(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
Rituximab	Non-Hodgkin's lymphoma of central nervous system	C2213246	NCT01973062	Terminated	Phase 2	Funding Unavailable	C5195655	rituximab-pvvr
Trastuzumab	Malignant neoplasm of stomach	C0024623	NCT02005484	Terminated	Phase 2	Study terminated due to slow patient recruitment.	C5187552	trastuzumab-anns
Atomoxetine	Nicotine Dependence	C0028043	NCT02046551	Suspended	Phase 1/Phase 2	funding lost	C0076823	Atomoxetina
Trastuzumab	Cancer of Urinary Tract	C0751571	NCT02013765	Terminated	Phase 2	Trial was terminated prematurely because of recruitment difficulties.	C5187552	trastuzumab-anns
Exenatide	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT02020616	Terminated	Phase 1/Phase 2	Lack of Efficacy	C0167117	Exenatida
Cytarabine	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	C1332153	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute megakaryoblastic leukemia (M7)	C0279632	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute minimally differentiated myeloid leukemia (M0)	C0281641	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute monoblastic leukemia (M5a)	C0279629	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute monoblastic leukemia (M5a)	C0279629	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute monoblastic leukemia (M5a)	C0279629	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute monocytic leukemia (M5b)	C0280634	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute monocytic leukemia (M5b)	C0280634	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute monocytic leukemia (M5b)	C0280634	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute myeloblastic leukemia with maturation (M2)	C0279624	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	Adult Acute Myeloid Leukemia without Maturation	C0279623	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute myeloid leukemia with 11q23 (MLL) abnormalities	C1541334	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute myeloid leukemia with inv(16)(p13;q22)	C1541333	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute myeloid leukemia with t(16;16)(p13;q22)	C1541332	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute myeloid leukemia with t(8;21)(q22;q22)	C1541331	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult acute myelomonocytic leukemia (M4)	C0279627	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult acute myelomonocytic leukemia (M4)	C0279627	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult acute myelomonocytic leukemia (M4)	C0279627	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult erythroleukemia (M6a)	C1541339	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult erythroleukemia (M6a)	C1541339	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult erythroleukemia (M6a)	C1541339	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	adult pure erythroid leukemia (M6b)	C1541340	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	adult pure erythroid leukemia (M6b)	C1541340	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	adult pure erythroid leukemia (M6b)	C1541340	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	secondary acute myeloid leukemia	C0280449	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	secondary acute myeloid leukemia	C0280449	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	secondary acute myeloid leukemia	C0280449	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Cytarabine	untreated adult acute myeloid leukemia	C0279089	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0010711	Cytarabinum
Decitabine	untreated adult acute myeloid leukemia	C0279089	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0049065	5-azadeoxycytidine
Homoharringtonine	untreated adult acute myeloid leukemia	C0279089	NCT02029417	Terminated	Phase 2	Major revisions needed in study	C0062941	mepesuccinato de omacetaxina
Ondansetron	Vomiting	C0042963	NCT02028910	Terminated	Phase 3		C0061851	Ondansetron
Ondansetron	Gastroenteritis	C0017160	NCT02028910	Terminated	Phase 3		C0061851	Ondansetron
Folic Acid	Inflammation	C0021368	NCT02079948	Withdrawn	Phase 2	Potential participants had concerns about taking the study drug (methotrexate).	C0016410	Folic acid
Methotrexate	Inflammation	C0021368	NCT02079948	Withdrawn	Phase 2	Potential participants had concerns about taking the study drug (methotrexate).	C0025677	N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Trametinib	Colorectal cancer recurrent	C0854750	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Pancreatic carcinoma stage III	C1167722	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IIIA Colorectal Cancer	C2981401	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IIIB Colorectal Cancer	C2981402	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IIIC Colorectal Cancer	C2981403	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IV Pancreatic Cancer	C1167725	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVA Colorectal Cancer	C2981404	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVB Colorectal Cancer	C2981405	NCT02079740	Suspended	Phase 1/Phase 2	Drug supply issues	C2697961	Tramétinib
Irinotecan	adult anaplastic astrocytoma	C0280483	NCT02055196	Withdrawn	Phase 1	New study written	C0123931	(+)-Irinotecan
Irinotecan	adult anaplastic oligodendroglioma	C0280790	NCT02055196	Withdrawn	Phase 1	New study written	C0123931	(+)-Irinotecan
Irinotecan	adult giant cell glioblastoma	C1541316	NCT02055196	Withdrawn	Phase 1	New study written	C0123931	(+)-Irinotecan
Irinotecan	adult glioblastoma	C0278878	NCT02055196	Withdrawn	Phase 1	New study written	C0123931	(+)-Irinotecan
Irinotecan	adult gliosarcoma	C1541317	NCT02055196	Withdrawn	Phase 1	New study written	C0123931	(+)-Irinotecan
Irinotecan	recurrent adult brain tumor	C0278786	NCT02055196	Withdrawn	Phase 1	New study written	C0123931	(+)-Irinotecan
Celecoxib	Malignant neoplasm of lung	C0242379	NCT02054104	Suspended	Phase 1/Phase 2		C0538927	p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Cyclophosphamide	Malignant neoplasm of lung	C0242379	NCT02054104	Suspended	Phase 1/Phase 2		C0010583	Cyclophosphamidum
Paclitaxel	Squamous cell carcinoma of skin	C0553723	NCT02076243	Terminated	Phase 2	Closed by sponsor	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	duct cell adenocarcinoma of the pancreas	C0279176	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	duct cell adenocarcinoma of the pancreas	C0279176	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Pancreatic carcinoma recurrent	C0854777	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Pancreatic carcinoma recurrent	C0854777	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	unspecified adult solid tumor, protocol specific	C0279004	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	unspecified adult solid tumor, protocol specific	C0279004	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Pancreatic carcinoma stage III	C1167722	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Pancreatic carcinoma stage III	C1167722	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Stage IV Pancreatic Cancer	C1167725	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Stage IV Pancreatic Cancer	C1167725	NCT02048943	Withdrawn	Phase 1	Lack of funding	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Milrinone	Cardiomyopathies	C0878544	NCT02077010	Suspended	Phase 3	Drug reformulation	C0128513	Milrinonum
Linagliptin	Vascular inflammations	C0947751	NCT02077309	Terminated	Phase 3	bad recruitment of suitable participants, just 4 patients in one year	C2746078	(R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Prasugrel	ST segment elevation myocardial infarction	C1536220	NCT02075125	Terminated	Phase 3	Enrolling participants has halted prematurely and will not resume	C1620287	Prasugrel
Ticagrelor	ST segment elevation myocardial infarction	C1536220	NCT02075125	Terminated	Phase 3	Enrolling participants has halted prematurely and will not resume	C1999375	(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Bupivacaine	Anterior Cruciate Ligament Injuries	C1456574	NCT02075411	Terminated	Phase 3	Difficult to enroll, parents/subjects prefer to choose type of anesthetic block.	C0006400	Bupivacaina
Metformin	Ovarian epithelial cancer recurrent	C0278689	NCT02050009	Withdrawn	Phase 1		C0025598	Metformina
Carboplatin	Ovarian epithelial cancer recurrent	C0278689	NCT02050009	Withdrawn	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Ovarian epithelial cancer recurrent	C0278689	NCT02050009	Withdrawn	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Metformin	recurrent ovarian germ cell tumor	C0279975	NCT02050009	Withdrawn	Phase 1		C0025598	Metformina
Carboplatin	recurrent ovarian germ cell tumor	C0279975	NCT02050009	Withdrawn	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	recurrent ovarian germ cell tumor	C0279975	NCT02050009	Withdrawn	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Metformin	Serous cystadenocarcinoma ovary	C0279663	NCT02050009	Withdrawn	Phase 1		C0025598	Metformina
Carboplatin	Serous cystadenocarcinoma ovary	C0279663	NCT02050009	Withdrawn	Phase 1		C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Serous cystadenocarcinoma ovary	C0279663	NCT02050009	Withdrawn	Phase 1		C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Nitrendipine	Isolated systolic hypertension	C0745133	NCT02088450	Terminated	Phase 2		C0028127	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
Norepinephrine	Septic Shock	C0036983	NCT02069288	Withdrawn	Phase 3	Problems of drugs supply by the manufacturer	C0028351	(-)-noradrenaline
Trametinib	hepatic complications	C1832055	NCT02070549	Suspended	Phase 1	Drug supply issues	C2697961	Tramétinib
Sirolimus	Malignant neoplasm of prostate	C0376358	NCT02091531	Terminated	Phase 2	Slow accrual	C0072980	Sirolimús
Everolimus	Malignant neoplasm of prostate	C0376358	NCT02091531	Terminated	Phase 2	Slow accrual	C0541315	évérolimus
Gemcitabine	Gallbladder Carcinoma	C0235782	NCT02105350	Suspended	Phase 1		C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Oxaliplatin	Gallbladder Carcinoma	C0235782	NCT02105350	Suspended	Phase 1		C0069717	oxaliplatine
Bevacizumab	Hereditary hemorrhagic telangiectasia	C0039445	NCT02106520	Terminated	Phase 2/Phase 3	DSMB's decision following the first step analysis	C0796392	Anti-VEGF monoclonal antibody
Tamoxifen	Papillary serous cystadenocarcinoma	C0334359	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Doxorubicin	Papillary serous cystadenocarcinoma	C0334359	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0013089	Doxorubicine
Letrozole	Papillary serous cystadenocarcinoma	C0334359	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0246421	Letrozol
Topotecan	Papillary serous cystadenocarcinoma	C0334359	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Paclitaxel	Papillary serous cystadenocarcinoma	C0334359	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Trametinib	Papillary serous cystadenocarcinoma	C0334359	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C2697961	Tramétinib
Tamoxifen	Ovarian Serous Adenocarcinoma	C1335177	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Doxorubicin	Ovarian Serous Adenocarcinoma	C1335177	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0013089	Doxorubicine
Letrozole	Ovarian Serous Adenocarcinoma	C1335177	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0246421	Letrozol
Topotecan	Ovarian Serous Adenocarcinoma	C1335177	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Paclitaxel	Ovarian Serous Adenocarcinoma	C1335177	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Trametinib	Ovarian Serous Adenocarcinoma	C1335177	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C2697961	Tramétinib
Tamoxifen	Primary Peritoneal Serous Adenocarcinoma	C1514429	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Doxorubicin	Primary Peritoneal Serous Adenocarcinoma	C1514429	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0013089	Doxorubicine
Letrozole	Primary Peritoneal Serous Adenocarcinoma	C1514429	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0246421	Letrozol
Topotecan	Primary Peritoneal Serous Adenocarcinoma	C1514429	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Paclitaxel	Primary Peritoneal Serous Adenocarcinoma	C1514429	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Trametinib	Primary Peritoneal Serous Adenocarcinoma	C1514429	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C2697961	Tramétinib
Tamoxifen	Recurrent Primary Peritoneal Carcinoma	C3897731	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Doxorubicin	Recurrent Primary Peritoneal Carcinoma	C3897731	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0013089	Doxorubicine
Letrozole	Recurrent Primary Peritoneal Carcinoma	C3897731	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0246421	Letrozol
Topotecan	Recurrent Primary Peritoneal Carcinoma	C3897731	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0146224	9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Paclitaxel	Recurrent Primary Peritoneal Carcinoma	C3897731	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Trametinib	Recurrent Primary Peritoneal Carcinoma	C3897731	NCT02101788	Suspended	Phase 2/Phase 3	Drug supply issues	C2697961	Tramétinib
Azacitidine	MYELODYSPLASTIC SYNDROME	C3463824	NCT02147873	Terminated	Phase 2	Study terminated due to lack of efficacy	C0004475	4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
Sirolimus	Non-small cell lung cancer recurrent	C0278517	NCT02126527	Withdrawn	Phase 1	no participants enrolled	C0072980	Sirolimús
Auranofin	Non-small cell lung cancer recurrent	C0278517	NCT02126527	Withdrawn	Phase 1	no participants enrolled	C0004320	Auranofinum
Everolimus	Non-small cell lung cancer recurrent	C0278517	NCT02126527	Withdrawn	Phase 1	no participants enrolled	C0541315	évérolimus
Sirolimus	unspecified adult solid tumor, protocol specific	C0279004	NCT02126527	Withdrawn	Phase 1	no participants enrolled	C0072980	Sirolimús
Auranofin	unspecified adult solid tumor, protocol specific	C0279004	NCT02126527	Withdrawn	Phase 1	no participants enrolled	C0004320	Auranofinum
Everolimus	unspecified adult solid tumor, protocol specific	C0279004	NCT02126527	Withdrawn	Phase 1	no participants enrolled	C0541315	évérolimus
Oxytocin	Noninfiltrating Intraductal Carcinoma	C0007124	NCT02127073	Suspended	Phase 0	Enrollment on hold	C0030095	Oxitocina
Erlotinib	HIV Infections	C0019693	NCT02134886	Terminated	Phase 1	No Accrual	C1135135	[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erythropoietin	Traumatic Brain Injury	C0876926	NCT02148367	Withdrawn	Phase 2	Publication of recent trials showing no effect of EPO in TBI substantially reduced equipoise    about this study.	C0357126	Epoetina alfa
Esmolol	Septic Shock	C0036983	NCT02120404	Suspended	Phase 2		C0116569	(±)-esmolol
Cisplatin	Malignant neoplasm of stomach	C0024623	NCT02137343	Terminated	Phase 3	All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data    Monitoring Committee safety review of study 20070622.	C0008838	cisplatino
Nimodipine	Acute Cerebrovascular Accidents	C0751956	NCT02165644	Withdrawn	Phase 2	The PI is leaving the University of Florida.	C0028094	2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-methoxyethyl ester 5-isopropyl ester
Acetazolamide	Acute Cerebrovascular Accidents	C0751956	NCT02165644	Withdrawn	Phase 2	The PI is leaving the University of Florida.	C0000981	N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
Trametinib	Poorly Differentiated Thyroid Carcinoma	C1266050	NCT02152995	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVA Thyroid Gland Follicular Carcinoma	C3897519	NCT02152995	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVA Thyroid Gland Papillary Carcinoma	C3897518	NCT02152995	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVB Thyroid Gland Follicular Carcinoma	C3897512	NCT02152995	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVB Thyroid Gland Papillary Carcinoma	C3897511	NCT02152995	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVC Thyroid Gland Follicular Carcinoma	C3897507	NCT02152995	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Trametinib	Stage IVC Thyroid Gland Papillary Carcinoma	C3897506	NCT02152995	Suspended	Phase 2	Drug supply issues	C2697961	Tramétinib
Aldesleukin	Desmoplastic Small Round Cell Tumor	C0281508	NCT02173093	Suspended	Phase 1/Phase 2	Study on hold due to primary co-investigator leaving the institution.	C0218986	Aldesleukina
Aldesleukin	Metastatic osteosarcoma	C0278512	NCT02173093	Suspended	Phase 1/Phase 2	Study on hold due to primary co-investigator leaving the institution.	C0218986	Aldesleukina
Aldesleukin	Neuroblastoma recurrent	C0278695	NCT02173093	Suspended	Phase 1/Phase 2	Study on hold due to primary co-investigator leaving the institution.	C0218986	Aldesleukina
Aldesleukin	Osteosarcoma recurrent	C0278779	NCT02173093	Suspended	Phase 1/Phase 2	Study on hold due to primary co-investigator leaving the institution.	C0218986	Aldesleukina
Eslicarbazepine acetate	Epilepsy	C0014544	NCT02172755	Terminated	Phase 1	occurrence of a serious adverse event	C4255554	Stedesa
Cholecalciferol	Schizophrenia	C0036341	NCT02197286	Withdrawn	Phase 2	Personnel changes at study site.	C0008318	Colecalciferolum
Cholecalciferol	Schizoaffective Disorder	C0036337	NCT02197286	Withdrawn	Phase 2	Personnel changes at study site.	C0008318	Colecalciferolum
Gemcitabine	Pancreatic Ductal Adenocarcinoma	C1335302	NCT02194829	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Pancreatic Ductal Adenocarcinoma	C1335302	NCT02194829	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Pancreatic carcinoma stage III	C1167722	NCT02194829	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Pancreatic carcinoma stage III	C1167722	NCT02194829	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Gemcitabine	Stage IV Pancreatic Cancer	C1167725	NCT02194829	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment.	C0045093	4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Paclitaxel	Stage IV Pancreatic Cancer	C1167725	NCT02194829	Suspended	Phase 1/Phase 2	Temporarily stopped for assessment.	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Tiotropium	Chronic Obstructive Airway Disease	C0024117	NCT02203474	Withdrawn	Phase 2		C0213771	Tiotropium
Deferoxamine	Subarachnoid Hemorrhage	C0038525	NCT02216513	Terminated	Phase 0	Principle Investigator is moving to another institution and plans to restart this proctocol in    the new location.	C0011145	Deferrioxamine B
Trametinib	Melanoma recurrent	C0278884	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C2697961	Tramétinib
Dabrafenib	Melanoma recurrent	C0278884	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C3467876	Dabrafenib
Trametinib	Stage IIIA Skin Melanoma	C2828034	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C2697961	Tramétinib
Dabrafenib	Stage IIIA Skin Melanoma	C2828034	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C3467876	Dabrafenib
Trametinib	Stage IIIB Skin Melanoma	C2828035	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C2697961	Tramétinib
Dabrafenib	Stage IIIB Skin Melanoma	C2828035	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C3467876	Dabrafenib
Trametinib	Stage IIIC Skin Melanoma	C2828036	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C2697961	Tramétinib
Dabrafenib	Stage IIIC Skin Melanoma	C2828036	NCT02196181	Suspended	Phase 2	Drug Supply Issues	C3467876	Dabrafenib
Prednisolone	Fever	C0015967	NCT02212210	Terminated	Phase 0	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study    remains open; PI is currently editing the manuscript.	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Fever	C0015967	NCT02212210	Terminated	Phase 0	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study    remains open; PI is currently editing the manuscript.	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Prednisolone	Labor Pain	C0474368	NCT02212210	Terminated	Phase 0	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study    remains open; PI is currently editing the manuscript.	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Labor Pain	C0474368	NCT02212210	Terminated	Phase 0	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study    remains open; PI is currently editing the manuscript.	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Prednisolone	Complication of anesthesia during pregnancy, unspecified	C0495199	NCT02212210	Terminated	Phase 0	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study    remains open; PI is currently editing the manuscript.	C0032950	3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Methylprednisolone	Complication of anesthesia during pregnancy, unspecified	C0495199	NCT02212210	Terminated	Phase 0	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study    remains open; PI is currently editing the manuscript.	C0025815	6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
Ranolazine	Irritable bowel syndrome with diarrhea	C0348898	NCT02239926	Terminated	Phase 2/Phase 3	Difficulty in enrolling subjects	C0073633	Ranolazina
Ranolazine	Diarrhoea predominant irritable bowel syndrome	C1262211	NCT02239926	Terminated	Phase 2/Phase 3	Difficulty in enrolling subjects	C0073633	Ranolazina
Fluorouracil	Mucinous adenocarcinoma of colon	C0279639	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	Mucinous adenocarcinoma of colon	C0279639	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	Mucinous adenocarcinoma of colon	C0279639	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	mucinous adenocarcinoma of rectum	C0279652	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	mucinous adenocarcinoma of rectum	C0279652	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	mucinous adenocarcinoma of rectum	C0279652	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	Colon cancer recurrent	C0278553	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	Colon cancer recurrent	C0278553	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	Colon cancer recurrent	C0278553	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	Recurrent Rectal Cancer	C0278554	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	Recurrent Rectal Cancer	C0278554	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	Recurrent Rectal Cancer	C0278554	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	signet ring adenocarcinoma of the colon	C0279640	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	signet ring adenocarcinoma of the colon	C0279640	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	signet ring adenocarcinoma of the colon	C0279640	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	signet ring adenocarcinoma of the rectum	C0279654	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	signet ring adenocarcinoma of the rectum	C0279654	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	signet ring adenocarcinoma of the rectum	C0279654	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	Stage IVA Colon Cancer	C3897082	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	Stage IVA Colon Cancer	C3897082	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	Stage IVA Colon Cancer	C3897082	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	Stage IVA Rectal Cancer	C3897520	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	Stage IVA Rectal Cancer	C3897520	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	Stage IVA Rectal Cancer	C3897520	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	Stage IVB Colon Cancer	C3897517	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	Stage IVB Colon Cancer	C3897517	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	Stage IVB Colon Cancer	C3897517	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Fluorouracil	Stage IVB Rectal Cancer	C3897513	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0016360	Fluorouracilum
Leucovorin	Stage IVB Rectal Cancer	C3897513	NCT02235324	Withdrawn	Phase 2	Lack of funding	C0023413	Folinate
Levoleucovorin	Stage IVB Rectal Cancer	C3897513	NCT02235324	Withdrawn	Phase 2	Lack of funding	C2721771	ácido levofolínico
Oxycodone	Pain	C0030193	NCT02240602	Withdrawn	Phase 3	Lack of internal resources	C0030049	Oxycodonum
Tamoxifen	Postmenopausal state	C0232970	NCT02322853	Suspended	Phase 2		C0039286	1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Methylphenidate	Conduct Disorder	C0149654	NCT02247986	Withdrawn	Phase 1/Phase 2		C0025810	α-phenyl-2-piperidineacetic acid methyl ester
Ezetimibe	Non-alcoholic Fatty Liver Disease	C0400966	NCT02244944	Terminated	Phase 2	Failure to recruit	C1142985	Ezetimiba
Dimethyl fumarate	Multiple Sclerosis	C0026769	NCT02428231	Terminated	Phase 3	Sponsor decision	C0058218	1,2-bis(methoxycarbonyl)-trans-ethylene
Estradiol	Vaginal ulcer	C0566951	NCT02316249	Withdrawn	Phase 2	the study was not feasible	C0014912	17β-oestradiol
Caffeine	Dyspnea	C0013404	NCT02311088	Terminated	Phase 2	Too low enrolment rate	C0006644	Teína
Simeprevir	Renal Insufficiency	C1565489	NCT02397395	Withdrawn	Phase 2	Trial has been cancelled due to availability of new therapeutic options for patient population	C2605855	Simeprevir
Oxaliplatin	Stage IB Esophageal Adenocarcinoma	C2981371	NCT02392377	Terminated	Phase 2	Slow accrual	C0069717	oxaliplatine
Fluorouracil	Stage IB Esophageal Adenocarcinoma	C2981371	NCT02392377	Terminated	Phase 2	Slow accrual	C0016360	Fluorouracilum
Carboplatin	Stage IB Esophageal Adenocarcinoma	C2981371	NCT02392377	Terminated	Phase 2	Slow accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Stage IB Esophageal Adenocarcinoma	C2981371	NCT02392377	Terminated	Phase 2	Slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Levoleucovorin	Stage IB Esophageal Adenocarcinoma	C2981371	NCT02392377	Terminated	Phase 2	Slow accrual	C2721771	ácido levofolínico
Oxaliplatin	Stage IIA Esophageal Adenocarcinoma	C1336158	NCT02392377	Terminated	Phase 2	Slow accrual	C0069717	oxaliplatine
Fluorouracil	Stage IIA Esophageal Adenocarcinoma	C1336158	NCT02392377	Terminated	Phase 2	Slow accrual	C0016360	Fluorouracilum
Carboplatin	Stage IIA Esophageal Adenocarcinoma	C1336158	NCT02392377	Terminated	Phase 2	Slow accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Stage IIA Esophageal Adenocarcinoma	C1336158	NCT02392377	Terminated	Phase 2	Slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Levoleucovorin	Stage IIA Esophageal Adenocarcinoma	C1336158	NCT02392377	Terminated	Phase 2	Slow accrual	C2721771	ácido levofolínico
Oxaliplatin	Stage IIB Esophageal Adenocarcinoma	C1336180	NCT02392377	Terminated	Phase 2	Slow accrual	C0069717	oxaliplatine
Fluorouracil	Stage IIB Esophageal Adenocarcinoma	C1336180	NCT02392377	Terminated	Phase 2	Slow accrual	C0016360	Fluorouracilum
Carboplatin	Stage IIB Esophageal Adenocarcinoma	C1336180	NCT02392377	Terminated	Phase 2	Slow accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Stage IIB Esophageal Adenocarcinoma	C1336180	NCT02392377	Terminated	Phase 2	Slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Levoleucovorin	Stage IIB Esophageal Adenocarcinoma	C1336180	NCT02392377	Terminated	Phase 2	Slow accrual	C2721771	ácido levofolínico
Oxaliplatin	Stage IIIA Esophageal Adenocarcinoma	C2981372	NCT02392377	Terminated	Phase 2	Slow accrual	C0069717	oxaliplatine
Fluorouracil	Stage IIIA Esophageal Adenocarcinoma	C2981372	NCT02392377	Terminated	Phase 2	Slow accrual	C0016360	Fluorouracilum
Carboplatin	Stage IIIA Esophageal Adenocarcinoma	C2981372	NCT02392377	Terminated	Phase 2	Slow accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Stage IIIA Esophageal Adenocarcinoma	C2981372	NCT02392377	Terminated	Phase 2	Slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Levoleucovorin	Stage IIIA Esophageal Adenocarcinoma	C2981372	NCT02392377	Terminated	Phase 2	Slow accrual	C2721771	ácido levofolínico
Oxaliplatin	Stage IIIB Esophageal Adenocarcinoma	C2981373	NCT02392377	Terminated	Phase 2	Slow accrual	C0069717	oxaliplatine
Fluorouracil	Stage IIIB Esophageal Adenocarcinoma	C2981373	NCT02392377	Terminated	Phase 2	Slow accrual	C0016360	Fluorouracilum
Carboplatin	Stage IIIB Esophageal Adenocarcinoma	C2981373	NCT02392377	Terminated	Phase 2	Slow accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Stage IIIB Esophageal Adenocarcinoma	C2981373	NCT02392377	Terminated	Phase 2	Slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Levoleucovorin	Stage IIIB Esophageal Adenocarcinoma	C2981373	NCT02392377	Terminated	Phase 2	Slow accrual	C2721771	ácido levofolínico
Oxaliplatin	Stage IIIC Esophageal Adenocarcinoma	C2981374	NCT02392377	Terminated	Phase 2	Slow accrual	C0069717	oxaliplatine
Fluorouracil	Stage IIIC Esophageal Adenocarcinoma	C2981374	NCT02392377	Terminated	Phase 2	Slow accrual	C0016360	Fluorouracilum
Carboplatin	Stage IIIC Esophageal Adenocarcinoma	C2981374	NCT02392377	Terminated	Phase 2	Slow accrual	C0079083	cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Paclitaxel	Stage IIIC Esophageal Adenocarcinoma	C2981374	NCT02392377	Terminated	Phase 2	Slow accrual	C0144576	(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Levoleucovorin	Stage IIIC Esophageal Adenocarcinoma	C2981374	NCT02392377	Terminated	Phase 2	Slow accrual	C2721771	ácido levofolínico
Vitamin E	Hypercholesterolemia	C0020443	NCT02634606	Terminated	Phase 3	Unable to obtain supplement for this study. Unable to recruit.	C0969677	alpha-tocopherol
Dimethyl fumarate	Multiple Sclerosis, Secondary Progressive	C0751965	NCT02430532	Terminated	Phase 3	Sponsor Decision	C0058218	1,2-bis(methoxycarbonyl)-trans-ethylene
Ketamine	Acute depression	C1386135	NCT02378415	Terminated	Phase 1	Discrepancies in medication orders	C0022614	Kétamine
Succinylcholine	Multiple Myeloma	C0026764	NCT02605356	Withdrawn	Phase 1/Phase 2		C0038627	2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
Radium Ra 223 Dichloride	Multiple Myeloma	C0026764	NCT02605356	Withdrawn	Phase 1/Phase 2		C3541342	Radium chloride Ra-223
Iloprost	Chronic left ventricular failure	C1328381	NCT02482402	Withdrawn	Phase 2	Delay in recruitment	C0079594	Iloprost
Iloprost	Pulmonary Hypertension	C0020542	NCT02482402	Withdrawn	Phase 2	Delay in recruitment	C0079594	Iloprost
Docetaxel	Lung squamous cell carcinoma recurrent	C0854989	NCT02536495	Withdrawn	Phase 1/Phase 2	PI decision due to funding support	C0246415	Docetaxel
Docetaxel	Lung squamous cell carcinoma stage IV	C0854994	NCT02536495	Withdrawn	Phase 1/Phase 2	PI decision due to funding support	C0246415	Docetaxel
Morphine	Chronic Obstructive Airway Disease	C0024117	NCT02455362	Withdrawn	Phase 3	'Recruitment not possible given changes to trial criteria	C0026549	Morfina
Morphine	Dyspnea	C0013404	NCT02455362	Withdrawn	Phase 3	'Recruitment not possible given changes to trial criteria	C0026549	Morfina
Sodium thiosulfate	Calciphylaxis	C0006666	NCT02527213	Terminated	Phase 3	Company decision	C0302967	Thiosulfuric acid
Dacarbazine	Glioblastoma	C0017636	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C0010927	DTIC
Temozolomide	Glioblastoma	C0017636	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dasatinib	Glioblastoma	C0017636	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C2699562	Dasatinib anhydrous
Dacarbazine	CNS disorder	C0007682	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C0010927	DTIC
Temozolomide	CNS disorder	C0007682	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dasatinib	CNS disorder	C0007682	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C2699562	Dasatinib anhydrous
Dacarbazine	Brain Diseases	C0006111	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C0010927	DTIC
Temozolomide	Brain Diseases	C0006111	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C0076080	8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Dasatinib	Brain Diseases	C0006111	NCT02661113	Withdrawn	Phase 2	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)	C2699562	Dasatinib anhydrous
